-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Jta3UaulO++MIZ3NnPqSq5lm34xf+M3uLAg/2AfCfKzcazwApYAoRNevjAnzJ0d0
 2Q2YL+5MNo91AnXdTYA5DQ==

<SEC-DOCUMENT>0000730469-06-000027.txt : 20060316
<SEC-HEADER>0000730469-06-000027.hdr.sgml : 20060316
<ACCEPTANCE-DATETIME>20060316144308
ACCESSION NUMBER:		0000730469-06-000027
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		21
CONFORMED PERIOD OF REPORT:	20051231
FILED AS OF DATE:		20060316
DATE AS OF CHANGE:		20060316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALPHARMA INC
		CENTRAL INDEX KEY:			0000730469
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				222095212
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-08593
		FILM NUMBER:		06691387

	BUSINESS ADDRESS:	
		STREET 1:		ONE EXECUTIVE DR
		STREET 2:		P O BOX 1399
		CITY:			FORT LEE
		STATE:			NJ
		ZIP:			07024
		BUSINESS PHONE:		2019477774

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	A L PHARMA
		DATE OF NAME CHANGE:	19960513

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	A L LABORATORIES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>alo10k2005.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>_SECURITIES AND EXCHANGE COMMISSION</TITLE>
</HEAD>
<BODY LINK="#0000ff">

<TABLE BORDER CELLSPACING=1 CELLPADDING=7 WIDTH=638>
<TR><TD VALIGN="TOP" COLSPAN=9>
<FONT SIZE=2><P ALIGN="CENTER">SECURITIES AND EXCHANGE COMMISSION<BR>
WASHINGTON, D.C.  20549<BR>
FORM 10-K  <BR>
Annual Report Pursuant to Section 13 or 15 (d) of<BR>
the Securities Exchange Act of 1934<BR>
</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="34%" VALIGN="TOP" COLSPAN=3>
<FONT SIZE=2><P>For the fiscal year ended<BR>
December 31, 2005</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="42%" VALIGN="TOP" COLSPAN=3>
<FONT SIZE=2><P ALIGN="JUSTIFY">Commission File No.  <U>1-8593</U></FONT></TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>
<U><FONT SIZE=2><P ALIGN="CENTER">ALPHARMA INC.</U><BR>
(Exact name of registrant as specified in its charter)<BR>
</FONT></TD>
</TR>
<TR><TD WIDTH="22%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="CENTER">Delaware</U></FONT></TD>
<TD WIDTH="45%" VALIGN="TOP" COLSPAN=6>&nbsp;</TD>
<TD WIDTH="33%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="JUSTIFY">22-2095212</U></FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="TOP" COLSPAN=3>
<FONT SIZE=2><P ALIGN="JUSTIFY">(State of Incorporation)</FONT></TD>
<TD WIDTH="25%" VALIGN="TOP" COLSPAN=3>&nbsp;</TD>
<TD WIDTH="42%" VALIGN="TOP" COLSPAN=3>
<FONT SIZE=2><P ALIGN="JUSTIFY">(I.R.S. Employer Identification No.)</FONT></TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>
<U><FONT SIZE=2><P ALIGN="CENTER">One Executive Drive, Fort Lee, New Jersey</U>    <U>07024</U><BR>
(Address of principal executive offices)    zip code<BR>
</FONT></TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>
<U><FONT SIZE=2><P ALIGN="CENTER">(201) 947-7774</U><BR>
(Registrant's Telephone Number Including Area Code)<BR>
</FONT></TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>
<FONT SIZE=2><P>Securities registered pursuant to Section 12(b) of the Act:<BR>
</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP" COLSPAN=7>
<U><FONT SIZE=2><P><BR>
Title of each Class</U></FONT></TD>
<TD WIDTH="40%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="CENTER">Name of each Exchange on<BR>
<U>which Registered</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP" COLSPAN=7>&nbsp;</TD>
<TD WIDTH="40%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP" COLSPAN=7>
<FONT SIZE=2><P ALIGN="JUSTIFY">Class A Common Stock, $.20 par value</FONT></TD>
<TD WIDTH="40%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="CENTER">New York Stock Exchange</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP" COLSPAN=7>&nbsp;</TD>
<TD WIDTH="40%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>
<FONT SIZE=2><P>Securities registered pursuant to Section 12 (g) of the Act:  None</FONT></TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>&nbsp;</TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>
<FONT SIZE=2><P>Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act of 1933.  YES X  NO ___ </FONT></TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>&nbsp;</TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>
<FONT SIZE=2><P>Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934.  YES [  ] NO [X]  Indicate by check mark whether the Registrant (1) has filed all reports to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  YES<U>  X  </U>  NO<U>     . </U><BR>
</FONT></TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>
<FONT SIZE=2><P>Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  (    )</FONT></TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>&nbsp;</TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>
<FONT SIZE=2><P>Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.   See definition of or "accelerated filer and large accelerated filer" in Rule 12b-2 of the Securities Exchange Act of 1934.</FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="TOP" COLSPAN=3>&nbsp;</TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=5>&nbsp;</TD>
<TD WIDTH="33%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="TOP" COLSPAN=3>
<FONT SIZE=2><P>Large Accelerated Filer  [X]</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=5>
<FONT SIZE=2><P>Accelerated Filer [__]</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP">
<FONT SIZE=2><P>Non-accelerated Filer [__]</FONT></TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>&nbsp;</TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>
<FONT SIZE=2><P>Indicate by check mark whether the Registrant is a shell company (as defined by Rule 12b-2 of the Securities Exchange Act of 1934)  YES [__]  NO [X]   <BR>
</FONT></TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>&nbsp;</TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>
<FONT SIZE=2><P>The aggregate market value of the voting stock of the Registrant (Class A Common Stock, $.20 par value) as of June 30, 2005 was $771,032,000 and as of March 1, 2006<B> </B>was $1,676,978,000.<BR>
</FONT></TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>
<FONT SIZE=2><P>The number of shares outstanding of each of the Registrant's classes of common stock as of March 1, 2006 was:</FONT></TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>&nbsp;</TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>
<FONT SIZE=2><P ALIGN="CENTER">Class A Common Stock, $.20 par value - 42,433,400 shares; <BR>
Class B Common Stock, $.20 par value -11,872,897 shares.<BR>
</FONT></TD>
</TR>
<TR><TD VALIGN="TOP" COLSPAN=9>
<FONT SIZE=2><P ALIGN="CENTER">DOCUMENTS INCORPORATED BY REFERENCE:<BR>
</FONT><FONT SIZE=3>Portions of the Proxy Statement relating to the Annual Meeting of Shareholders to be held on May 23, 2006 are incorporated by reference into Part III of this report.  Other documents incorporated by reference are listed in the Exhibit index.</FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P ALIGN="CENTER"></P>
<B><P>Trademarks</P>
</FONT><P ALIGN="JUSTIFY"><A NAME="_DV_M16"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT SIZE=3>The following are trademarks and service marks belonging to, licensed to, or otherwise used by us throughout this Form 10-K:  Albac&reg;, Aureomycin&reg;, Avatec&reg;, Bio-Cox&reg;, BMD&reg;, Betolvex&reg; Bovatec&reg;, ChlorMax&reg;, Cygro&reg;, Deccox&reg;,  Histostat&reg;, KADIAN&reg;, Reporcin&reg;,  Robenz&reg;, Rofenaid&reg;, Zoamix&reg; and 3-Nitro&reg;. </P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY"><A NAME="_DV_M17"><A NAME="_DV_M18"><A NAME="_DV_M22"></A></A></A>Forward-Looking Statements</P>
</B><P ALIGN="JUSTIFY"><A NAME="_DV_M23"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This annual report contains "forward-looking statements," or statements that are based on current expectations, estimates, and projections rather than historical facts.  The Company offers forward-looking statements in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements may prove, in hindsight, to have been inaccurate because of risks and uncertainties that are difficult to predict.  Many of the risks and uncertainties that the Company faces are included under the caption "Risk Factors". </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
</FONT><B><FONT FACE="CG Times (W1),Times New Roman" SIZE=3><P ALIGN="CENTER"><A NAME="_DV_M24"></A>PART I</P>
</FONT><FONT SIZE=3><P ALIGN="JUSTIFY"><A NAME="_DV_M25"></A>Item 1. Business</P>
</B>
<B><U><P><A NAME="_DV_M26"></A>GENERAL</P>
</B></U><P ALIGN="JUSTIFY"><A NAME="_DV_M27"></A><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alpharma is a global specialty pharmaceutical company that develops, manufactures and markets pharmaceutical products for humans and animals.  The Company markets one branded pharmaceutical prescription product that is contract manufactured by a third party, a pain medication sold under the trademark KADIAN, in the U.S.  Alpharma manufactures and markets a line of fermentation-based active pharmaceutical ingredients ("APIs") that are used primarily by third parties in the manufacturing of generic and branded pharmaceutical products.  The Company manufactures and markets animal health products in over 80 formulations and dosage forms.  In addition, the Company has a distribution business which utilizes telemarketing to sell generic pharmaceutical products manufactured by third parties (See "Discontinued Operations" below).  The Company presently conducts business in more than 60 countries and has approximately 1,400 employees in over 19 countries.  For the year ended December 31,
 2005, the Company generated revenue of approximately $1,423.8 million including $801.3 million related to its generic pharmaceutical business, which it sold on December 19, 2005 and $68.9 million related to its generic pharmaceutical telemarketing distribution business which is under contract for sale (See "Discontinued Operations" below).  </P>
<B><P ALIGN="JUSTIFY"><A NAME="_DV_M29"></A>Formation</P>
</B><P ALIGN="JUSTIFY"><A NAME="_DV_M30"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is incorporated in Delaware.  The Company was originally organized as A.L. Laboratories, Inc., a wholly owned subsidiary of Apothekernes Laboratorium A.S., a Norwegian healthcare company (the predecessor company to A.L. Industrier ASA; Alpharma's controlling stockholder).  In 1994, the Company acquired the complementary human pharmaceutical and animal health business of its parent company and subsequently changed its name to Alpharma Inc. to operate worldwide as one corporate entity</FONT><B>.   </P>
<FONT SIZE=3><P ALIGN="JUSTIFY"><A NAME="_DV_M31"></A>Controlling Stockholder</P>
</B><P ALIGN="JUSTIFY"><A NAME="_DV_M32"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.L. Industrier ASA ("Industrier") beneficially owns all of the outstanding shares of the Company's Class B common stock, or approximately 22% of the Company's total common stock outstanding at December 31, 2005.   The Class B common stock currently bears the right to elect more than a majority of the Company's Board of Directors and to cast a majority of the votes in any vote of the Company's stockholders.  Mr. Einar W. Sissener, Chairman of the Board of the Company and a controlling stockholder of Industrier, and members of his immediate family, also beneficially own 373,667 shares of the Company's Class A Common Stock.  As a result of the ownership of the Class B shares, Industrier, and ultimately Mr. Sissener, can control the Company.</P>
<B><P ALIGN="JUSTIFY">Discontinued Operations</P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December 19, 2005, the Company sold its world-wide human generic pharmaceutical business (the "Generics Business"), excluding ParMed Pharmaceuticals Inc. ("ParMed"), its generic pharmaceutical telemarketing distribution unit to Actavis Group hf  ("Actavis") for cash in the amount of $810 million (computed on a cash and debt free basis).  The form of this transaction included the sale of all of the Company's subsidiaries which were, as of the closing of the transaction, engaged solely in the human generic business and a transfer of the assets and liabilities related to the Generics Business from those subsidiaries of the Company that, as of the closing of the transaction, engaged in both the Generics Business and other businesses of the Company.</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result of the transaction substantially all of the material liabilities (including without limitation, claims, lawsuits and other contingent liabilities) of the Generics Business were transferred to Actavis or entities owned by Actavis.   The Company made certain representations and warranties to Actavis regarding the Generics Business as a part of the transaction, and subject to certain limitations, agreed to indemnify Actavis to the extent that such representations and warranties were incorrect.  In addition, the Company retained liability for certain specified liabilities which the Company believes are not, in the aggregate, material to the Company and may be held responsible for certain liabilities of the Generic Business transferred to Actavis in the event that Actavis fails to or is unable to satisfy such liabilities.  As a result, except as specifically stated, all references to the Generics Business including claims, lawsuits and other contingent 
liabilities related thereto are excluded from this Report and the financial statements contained in this Report. The financial statements contained in this Report treat the Generics Business as a discontinued operation. </P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;More than half of the proceeds of the transaction that were received as consideration for the non-US assets of the Generics Business were repatriated to the United States under the American Jobs Creation Act of 2004.  Beginning in the first quarter of 2005, and through to January 23, 2006, the Company repaid substantially all of its outstanding debt. </P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, the sale of ParMed is currently under contract. ParMed is being reported in the financial statements contained in this Report, as a discontinued operation.</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As such, throughout this Report, Discontinued Operations refers to the Generic Business and ParMed.  For further information on the Discontinued Operations see Note 3 to the Notes to the Consolidated Financial Statements included in Item 8 of this Report.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_DV_M33"></A>Management and Financial Reporting Structure</P>
</B><P ALIGN="JUSTIFY"><A NAME="_DV_M53"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company operates in the human and animal pharmaceuticals industries.  After giving effect to the Discontinued Operations, for financial reporting purposes it has three businesses within these industries:  Branded Pharmaceutical Products ("BP"), Active Pharmaceutical Ingredients ("API"), and Animal Health ("AH").  The Discontinued Operations were the US Generic Pharmaceutical and International Generic Pharmaceutical business and ParMed.  In addition, prior to the sale of the US and International Generics operations, ParMed was reported as a part of the US Generic Pharmaceutical business.  </P>
<P ALIGN="JUSTIFY"></P>
<P><A NAME="_DV_M56"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table shows the revenues and operating income or loss of each of the Company's business segments and Discontinued Operations for the past three years:</P>
</FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=624>
<TR><TD WIDTH="40%" VALIGN="TOP" HEIGHT=14><P></P></TD>
<TD WIDTH="30%" VALIGN="TOP" COLSPAN=3 HEIGHT=14>
<B><FONT SIZE=2><P ALIGN="CENTER">Revenues</B></FONT></TD>
<TD WIDTH="30%" VALIGN="TOP" COLSPAN=3 HEIGHT=14>
<B><FONT SIZE=2><P ALIGN="CENTER">Operating Income (loss)</B></FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP" HEIGHT=14><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=14>
<B><FONT SIZE=2><P ALIGN="CENTER">2005</B></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<B><FONT SIZE=2><P ALIGN="CENTER">2004</B></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<B><FONT SIZE=2><P ALIGN="CENTER">2003</B></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<B><FONT SIZE=2><P ALIGN="CENTER">2005</B></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<B><FONT SIZE=2><P ALIGN="CENTER">2004</B></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=14>
<B><FONT SIZE=2><P ALIGN="CENTER">2003</B></FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP" HEIGHT=14><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=14><P></P></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14><P></P></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14><P></P></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14><P></P></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=14><P></P></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Branded Pharmaceuticals </FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">$101.6</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">$62.4</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">$65.3</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">$23.6</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">$6.5</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">$22.0</FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Active Pharmaceutical Ingredients </FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">138.4</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">143.2</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">124.5</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">52.4</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">72.8</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">65.7</FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Animal Health (a)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">325.1</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">314.6</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">295.7</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">66.3</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">24.8</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">20.1</FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P>          </FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=14><P></P></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14><P></P></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14><P></P></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14><P></P></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=14><P></P></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unallocated and eliminations</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">(11.5)</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">(6.9)</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">(6.0)</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">(47.4)</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">(41.0)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">(39.0)</FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discontinued Operations</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=14>
<U><FONT SIZE=2><P ALIGN="RIGHT">870.2</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<U><FONT SIZE=2><P ALIGN="RIGHT">826.2</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<U><FONT SIZE=2><P ALIGN="RIGHT">817.8</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<U><FONT SIZE=2><P ALIGN="RIGHT">44.6</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<U><FONT SIZE=2><P ALIGN="RIGHT">(286.2)</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=14>
<U><FONT SIZE=2><P ALIGN="RIGHT">30.7</U></FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P>        Total</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=14>
<U><FONT SIZE=2><P ALIGN="RIGHT">$1,423.8</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<U><FONT SIZE=2><P ALIGN="RIGHT">$1,339.5</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<U><FONT SIZE=2><P ALIGN="RIGHT">$1,297.3</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<U><FONT SIZE=2><P ALIGN="RIGHT">$139.5</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=14>
<U><FONT SIZE=2><P ALIGN="RIGHT">$(223.1)</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=14>
<U><FONT SIZE=2><P ALIGN="RIGHT">$99.5</U></FONT></TD>
</TR>
</TABLE>
<DIR>

<FONT SIZE=3><P ALIGN="JUSTIFY"><A NAME="_DV_M57"><A NAME="_DV_M58"><A NAME="_DV_M59"><A NAME="_DV_M60"><A NAME="_DV_M61"><A NAME="_DV_M62"><A NAME="_DV_M64"></A></A></A></A></A></A></A></P>
<P ALIGN="JUSTIFY">(a)  Animal Health 2004 results include a $10.0 million charge to write down the carrying value of Aquatics assets to fair value.</P>
<P ALIGN="JUSTIFY"></P></DIR>

<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For additional financial information concerning the Company's business segments see Note 21 of the Notes to the Consolidated Financial Statements included in Item 8 of this Report. </P>
<B><P ALIGN="JUSTIFY"><BR>
Internet Website</P>
</B><P ALIGN="JUSTIFY"><A NAME="_DV_M65"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains an Internet website at www.alpharma.com.  The Company makes available free of charge on its website its annual report on Form 10-K, its quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) of the Securities Exchange Act of 1934 as soon as practicable after the Company electronically files such material with, or furnishes it to, the Securities and Exchange Commission.</P>
<B><U><P><A NAME="_DV_M66"></A>NARRATIVE DESCRIPTION OF BUSINESS</P>
</B></U><P ALIGN="JUSTIFY"><A NAME="_DV_M67"></A> <B>BRANDED PHARMACEUTICALS ("BP")</P>
</B></FONT><I><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I><FONT SIZE=3>Branded Pharmaceuticals ("BP") markets one branded pharmaceutical prescription product, a pain medication sold under the trademark KADIAN, in the U.S. that is contract manufactured by a third party.  BP is currently focused on the pain management market in the United States.  For the year ended December 31, 2005, BP had product sales of approximately $101.6 million and operating income of approximately $23.6 million.</P>
</FONT><I><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT SIZE=3>Product Lines.</I>  KADIAN is an extended release morphine product which F.H. Faulding &amp; Co. Limited (now a wholly-owned subsidiary of Mayne Nickless Limited) licenses to BP pursuant to a perpetual, royalty-free license.  The Company's BP business is actively working on the development of a next-generation pain product which, if successful, would include an abuse deterrent technology. A major focus of the Company is to expand and enhance its BP product portfolio by actively seeking to purchase marketing rights to other pain-related products (either in the development or commercial stages) and identify and enter into co-development and co-promotion opportunities with other pharmaceutical companies. See Risk Factors - "The Company depends on development, manufacture and marketing of new products for its future success" and "The Company could have difficulties in developing and integrating strategic alliances, co-development opportuniti
es and other relationships".</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2005, the Company terminated an arrangement for a third party's promotion of KADIAN to oncology healthcare professionals in the United States and a second arrangement for the Company's sales force to promote a product manufactured and marketed by a third party. Neither arrangement provided revenues or operating income material to BP.</P>
<I><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Facilities.  </I>BP's one product is manufactured under a toll manufacturing agreement with Purepac Pharmaceutical Co. ("Purepac"); the former subsidiary of the Company purchased by Actavis as a part of the Company's sale of the Generic Business.  Purepac is the sole source of supply for KADIAN.   BP's headquarters are located in Piscataway, New Jersey.  </P>
<I><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competition. </I>BP operates in a highly competitive, price sensitive market.  The Company's BP products compete with pain management products manufactured by generic pharmaceutical manufacturers and worldwide research-based brand drug companies.  As the Company expands its BP portfolio product line, it expects to encounter continued competition.</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BP's principal competitors, all of which are believed to have higher shares of the pain management market, are: Ligand Pharmaceuticals, Janssen Pharmaceutica and Purdue Pharma.</P>
<I><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales, Distribution and Customers.</I>  The Company has a sales organization for BP's branded pharmaceutical products.  BP has an authorized sales force of 195 sales representatives (although the actual number of representatives will vary from time to time based upon resignations and other normal personnel actions) which was an expansion from an authorized force of  140 representatives as of January 1, 2005. BP focuses its sales and marketing efforts on the pain specialists who are likely to be the most active writers of prescriptions for KADIAN.   BP predominately sells pharmaceutical products to the warehousing and non-warehousing chains, as well as mail order companies.  The Company has no long-term agreements with any of these accounts.  Any cessation or material reduction of certain customers' purchases would likely have a material effect on the Company's sales and profitability.</P>
<B><P ALIGN="JUSTIFY">ACTIVE PHARMACEUTICAL INGREDIENTS ("API")</P>
</B><P ALIGN="JUSTIFY"><A NAME="_DV_M91"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's Active Pharmaceutical Ingredients ("API") business develops, manufactures and markets a range of antibiotic fermentation based active pharmaceutical ingredients that are used, primarily by third parties, in the manufacture of finished dose pharmaceutical products. For the year ended December 31, 2005, API had product sales of approximately $138.4 million and operating income of approximately $52.4 million.  The Company's API business benefits from over four decades of experience in the use and development of fermentation and purification technology. Additionally, the Company's API business' fermentation expertise in the production of bulk antibiotics has a direct technological application to the manufacture of products for the Company's Animal Health business.<A NAME="_DV_M92"></A></P>
<I><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product Lines.  </I>The Company's API business markets and sells primarily 10 antibiotic APIs.  APIs constitute the active substances in certain pharmaceuticals for the treatment of some skin, throat, intestinal and systemic infections.  The Company is a leading producer of bacitracin, polymyxin, and vancomycin; all of which are important pharmaceutical grade antibiotics. The Company's API business also manufactures other antibiotic active substances such as tobramycin, colistin and methsulfate and colistin and amphotericin B, a parenteral grade antifungal.  The primary applications for the API products are injectable and specialized topical and human surgical finished product applications.  API owns European marketing authorizations for vancomycin vial and capsule finished products which are manufactured (using the Company's active substance) and distributed for the Company by third parties. The Company has initiated a program of new product launches in it
s API business.  The program began in 2005 with the launch of Tobramycin and will continue with a planned launch of Fluticasone in non-regulated markets in the second quarter of 2006.  The Company will continue to invest in and develop its API pipeline and expects to launch one or two additional products before the end of the year.  Potential sources for additional new products are the API's research and development, co-development projects with third parities, partnerships and in-licensing.  See Risk Factors - "The Company depends on development, manufacture and marketing of new products for its future success" and "The Company could have difficulties in developing and integrating strategic alliances, co-development opportunities and other relationships".</P>
<P ALIGN="JUSTIFY"><A NAME="_DV_M93"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2003, the Company's API business implemented a significant price increase for two of its products in certain geographical markets and, during 2005, reduced the price with respect to one of such products.  The Company anticipates that further price reductions are possible on both of these products. </P>
<I><P ALIGN="JUSTIFY"><A NAME="_DV_M94"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Facilities.  </I>The Company manufactures its API products in its plants in Oslo, Norway, which also manufactures products for Animal Health, Copenhagen, Denmark and Budapest, Hungary.  Each plant includes fermentation, specialized recovery and purification equipment.  To support the production of vancomycin, the Company substantially expanded its production capacity at its Copenhagen facility and in 1998, acquired its facility in Budapest, Hungary. An expansion of manufacturing processes and capacity at the Budapest facility was substantially completed in 2004.<B>  <A NAME="_DV_C9"></B>The expansion of the Budapest facility cost a total of approximately $9.0 million and doubled the capacity of the facility for vancomycin and established capacity for the production of three additional products in the facility.<B>  <A NAME="_DV_M95"></A></A></B>The Company completed two expansion projects at its Copenhagen facility in 2004 for an aggreg
ate cost of $31.7 million.  One of these projects significantly increased the capacity of the Copenhagen facility for vancomycin. The Company is presently considering several options for additional vancomycin manufacturing capacity.  The Oslo, Copenhagen and Budapest facilities have been classified as acceptable by the FDA as a manufacturer of certain sterile and non-sterile bulk antibiotics.  Such FDA classification, subject to compliance with applicable FDA rules, allows imports of these products into the U.S. market and into most European markets.  (See "Information Applicable To All Business Segments - Environmental Compliance" for a discussion of environmental matters related to the Copenhagen, Oslo and Budapest facilities and "Government Regulation - FDA Compliance" for a discussion of the Company's FDA inspection results at the same three facilities.)  </P>
<I><P ALIGN="JUSTIFY"><A NAME="_DV_M96"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competition.  </I>In sales to large and small customers, price, quality and service are the determining factors.  The Company believes that its fermentation and purification expertise and established reputation provide it with a significant advantage in these antibiotic products.  Competition has increased on certain of its products, most notably from Asian based companies.  The Company's API business' principal competitors are: Abbott Laboratories and Bristol-Myers Squibb Company.</P>
<I><P ALIGN="JUSTIFY"><A NAME="_DV_M97"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Geographic Markets.</I>  The Company's API business sells its products in the U.S. and other areas of the world.  For the year ended December 31, 2005, sales in North America of API products represented approximately 63% of the Company's API business' total revenues. </P>
<I><P ALIGN="JUSTIFY"><A NAME="_DV_M98"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales, Distribution and Customers.  </I>Sales of API products are dependent on finished product sales, which are under the control of the Company's customers.  Sales of bulk antibiotic products are made to relatively few large customers, primarily pharmaceutical companies making generic and branded finished pharmaceutical products.  The Company distributes and sells its API products in North America and Europe using its own sales force.  Sales of the Company's API products in other parts of the world are primarily through the use of local agents and distributors. </FONT><FONT SIZE=3 COLOR="#ffffff"> </P>
</FONT><B><FONT SIZE=3><P ALIGN="JUSTIFY"><A NAME="_DV_M74"></A>ANIMAL HEALTH ("AH")</P>
</B><P ALIGN="JUSTIFY"><A NAME="_DV_M125"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's Animal Health ("AH") business is a global leader in the development, registration, manufacturing and marketing of medicated feed additives ("MFAs") and water soluble therapeutic type products for poultry, cattle and swine.  For the year ended December 31, 2005, AH had <A NAME="_DV_M126"></A>product sales of approximately <A NAME="_DV_C27">$325.1 million and operating income of approximately $<A NAME="_DV_M127"></A></A>66.3<B> </B>million.<A NAME="_DV_M128"><A NAME="_DV_M129"></A></A></P>
<I><P ALIGN="JUSTIFY"><A NAME="_DV_M132"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product Lines.  </I>The Company's principal animal health business is based on a portfolio of anti-infective animal health products that are added to the feed and water of livestock and poultry.  This market is comprised of three primary categories: antibiotics, anticoccidials and antibacterials.</P>
<I><P ALIGN="JUSTIFY"><A NAME="_DV_M133"></A>    Antibiotics</I>.  The Company's MFAs and water-soluble products are used to prevent and/or treat diseases and maintain health in poultry, swine and cattle.  The Company is the world's largest supplier of bacitracin and chlortetracycline for use in animal feeds.  The Company's major animal health antibiotic products include:</P><DIR>
<DIR>

</FONT><FONT FACE="CG Times (W1),Times New Roman" SIZE=3><P ALIGN="JUSTIFY"><A NAME="_DV_M134"><A NAME="_DV_M135"></A></A><FONT FACE="Symbol">&#183;</FONT>
&#9;Albac, a bacitracin-based MFA used to prevent and/or treat diseases, maintain health and/or improve feed efficiency in poultry, cattle and swine; </P>
<P ALIGN="JUSTIFY"><FONT FACE="Symbol">&#183;</FONT>
&#9;BMD, a bacitracin-based MFA used to prevent and/or treat diseases, maintain health and/or improve feed efficiency in poultry, cattle and swine; and</P>
<P ALIGN="JUSTIFY"><A NAME="_DV_M136"></A><FONT FACE="Symbol">&#183;</FONT>
&#9;ChlorMax and ChlorMax-combination products, and Aureomycin and Aureomycin-combination products, which are feed-grade antibiotics used in combination with an antibacterial to prevent and/or treat diseases, maintain health and/or improve feed efficiency in poultry, cattle, and swine. </P></DIR>
</DIR>

</FONT><I><FONT SIZE=3><P ALIGN="JUSTIFY"><A NAME="_DV_M137"></A>    Anticoccidials</I>.  These products are used to prevent coccidiosis, a condition caused by an intestinal parasite that affects growth in poultry and cattle.  The Company believes it is the world's second largest supplier of anticoccidials and the Company's major products include:</P><DIR>
<DIR>

</FONT><FONT FACE="CG Times (W1),Times New Roman" SIZE=3><P ALIGN="JUSTIFY"><A NAME="_DV_M138"></A><FONT FACE="Symbol">&#183;</FONT>
&#9;Bio-Cox and Cygro, MFAs used to prevent and control coccidiosis in poultry;</P>
<P ALIGN="JUSTIFY"><A NAME="_DV_M139"></A><FONT FACE="Symbol">&#183;</FONT>
&#9;Bovatec and Avatec, MFAs used to prevent and control coccidiosis in cattle and poultry and to maintain health and improve feed efficiency in cattle; </P>
<P ALIGN="JUSTIFY"><FONT FACE="Symbol">&#183;</FONT>
&#9;Deccox, an MFA used to prevent and control coccidiosis in poultry, cattle and calves;</P>
<P ALIGN="JUSTIFY"><A NAME="_DV_M140"></A><FONT FACE="Symbol">&#183;</FONT>
&#9;Robenz and Cycostat, used to prevent coccidiosis in poultry and rabbits;</P>
<P ALIGN="JUSTIFY"><A NAME="_DV_M141"></A><FONT FACE="Symbol">&#183;</FONT>
&#9;Rofenaid, used to prevent coccidiosis and diseases in poultry; and</P>
<P ALIGN="JUSTIFY"><A NAME="_DV_M142"></A><FONT FACE="Symbol">&#183;</FONT>
&#9;Zoamix, an MFA used to prevent and control coccidiosis in chickens and turkeys.</P></DIR>
</DIR>

</FONT><I><FONT SIZE=3><P ALIGN="JUSTIFY"><A NAME="_DV_M143"><A NAME="_DV_M144"></A></A>    Antibacterials</I>.  These products are used to prevent disease in poultry and swine.  The Company is the world's largest supplier of antibacterials for use in animal feeds and the Company's major products include:</P><DIR>
<DIR>

</FONT><FONT FACE="CG Times (W1),Times New Roman" SIZE=3><P ALIGN="JUSTIFY"><A NAME="_DV_M145"></A><FONT FACE="Symbol">&#183;</FONT>
&#9;3-Nitro, an MFA used to treat disease and improve feed efficiency in poultry and swine; and</P>
<P ALIGN="JUSTIFY"><A NAME="_DV_M146"></A><FONT FACE="Symbol">&#183;</FONT>
&#9;Histostat, an MFA used to prevent disease in chickens and turkeys.<A NAME="_DV_M147"></A></P></DIR>
</DIR>

</FONT><FONT SIZE=3><P ALIGN="JUSTIFY"><A NAME="_DV_M148"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to the Company's antibiotic, antibacterial and anticoccidial products, it also sells<A NAME="_DV_M149"></A> water soluble vitamins, minerals and electrolytes that are used as nutritional supplements for poultry, swine and cattle.  In the future AH plans to focus on new products from its research and development activities, the purchase of products from third parties, co-development and in-licensing.  See Risk Factors - "The Company depends on development, manufacture and marketing of new products for its future success" and "The Company could have difficulties in developing and integrating strategic alliances, co-development opportunities and other relationships".<A NAME="_DV_M150"><A NAME="_DV_M151"></A></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Animal drugs must be reviewed and receive registration from the FDA for marketing in the United States and approval or registration by similar regulatory agencies in other countries.  Regulatory approvals for products to be used in food producing animals are complex due to the possible impact on humans. </P>
<P ALIGN="JUSTIFY"><A NAME="_DV_M152"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Approval also must be granted in the U.S. for the use of an animal drug in combination with other animal drugs in feeds.  Such combination approval generally requires the cooperation of other manufacturers to consent to authorize the FDA to refer to such manufacturer's New Animal Drug Application (or NADA) in <A NAME="_DV_M153"></A>support of the Company's regulatory submissions.  This consent is necessary to obtain approval from the FDA for more than one animal drug to be included in a given animal drug animal feed at the same time.  To date, the Company has been successful in obtaining the cooperation of third parties to seek combination approval for many of its products.  Generally, the Company does not enter into written agreements with other manufacturers and does not pay any money to other manufacturers to obtain such consent.  These combination clearances significantly extend the reach and potential market share of the Company's p
roducts and provide a considerable competitive advantage.  Presently, the Company has sponsored a total of approximately 100 combination approvals in the U.S.</P>
<I><P ALIGN="JUSTIFY"><A NAME="_DV_M154"></A>&nbsp;&nbsp;Acquisitions and Divestitures</I>. </P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September of 2004, the Company entered into an agreement with Natinco N.V., the licensor of certain technology related to Reporcin, a product intended to improve meat quality, which substantially limited the markets in which the Company could market the product.   While at the 1999 inception of the Reporcin license it was the Company's intent to build a global market for the product, sales have not been material to the AH business and the Company intends to discontinue sales once product presently in inventory has been sold.  </P>
<P ALIGN="JUSTIFY"><A NAME="_DV_M155"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July 2004, the Company sold assets relating to its Aquatic Animal Health Business to the senior management of the business for approximately $4.4 million. Additionally, in March 2004, the Company sold its AH distribution company to IVS Animal Health Inc. for approximately $17.0 million.<A NAME="_DV_M156"></A></P>
<P ALIGN="JUSTIFY"><A NAME="_DV_M157"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<A NAME="_DV_M158"></A><I>Facilities.  </I>The Company produces its Animal Health products in several manufacturing facilities.  BMD is produced and blended at the Company's Chicago Heights, Illinois facility, which contains a modern fermentation and recovery plant.  Albac is manufactured at the Oslo, Norway facility, which is managed by API.  The majority of soluble antibiotics and vitamins are formulated in AH's Longmont, Colorado facility. Feed grade chlortetracycline is produced at AH's Willow Island, West Virginia facility in addition to being purchased from foreign suppliers.  It is then blended at either Company-owned or independent blending facilities.  In 2004, the Company received FDA approval to commence manufacturing lasalocid at its Willow Island facility for sales in the U.S.  Now, in addition to manufacturing chlortetracycline, the Willow Island facility also produces lasalocid for use in the U.S. as well as many other par
ts of the world. Bio-Cox is blended in AH's Van Buren, Arkansas facility as well as at a third party location, and Avatec and Bovatec are blended at its Salisbury, Maryland facility, as well as at a third party location.  The 3-Nitro product line <A NAME="_DV_M159"></A>is manufactured using the Company's technology at a third party facility.   Decoquinate, the active ingredient used in Deccox, is manufactured, using the Company's technology, at a facility owned and operated by a third party.  In June of 2003, the blending of Deccox was moved from the Company's Lowell, Arkansas facility to the Company's Chicago Heights facility.  Process improvement and manufacturing development is done primarily at AH's Chicago Heights and Willow Island facilities.  </P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, the Company makes significant use of third party facilities (some of which are in low-cost countries) in the manufacture of its AHD products and anticipates that this use will increase in the future.</P>
<I><P ALIGN="JUSTIFY"><A NAME="_DV_M161"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competition.  </I>The Company competes in a highly competitive market on the basis of price, brand name and customer service.  Some of the Company's competitors in the animal health industry offer a wide range of products with various therapeutic and production enhancing qualities.  Some of AH's principal competitors include Eli Lilly and Company (Elanco) and Phibro Animal Health.  Due to the Company's strong market position in MFAs and its experience in obtaining requisite FDA approvals for combination claims, the Company believes it enjoys a competitive advantage in marketing MFAs under the FDA approved combination clearances.  However, no assurances can be given that third parties will continue to cooperate in seeking combination approval for the Company's products, and the Company expects new entrants in the generic medicated animal feed additive market in 2006. </P>
<I><P ALIGN="JUSTIFY"><A NAME="_DV_M162"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Geographic Markets.  </I>The Company sells more than half of its animal health products in the U.S. and has significant presence in Europe, Latin America and Asia. </P>
<I><P ALIGN="JUSTIFY"><A NAME="_DV_M163"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales, Distribution and Customers.  </I>The Company's animal health products in the U.S., Europe, Canada, Mexico, Brazil and other selected markets are sold through a staff of approximately 100 technically trained sales and technical service and marketing employees, many of whom are veterinarians and nutritionists.  The Company has sales offices in the U.S., Canada, Mexico, Chile, Argentina, Thailand, China, Brazil, France and Belgium.  In the remainder of the world, AH's products are sold primarily through the use of distributors and sales companies. <A NAME="_DV_M166"></A>Sales are made principally to commercial animal feed manufacturers, wholesalers and integrated cattle, swine and poultry producers.  Therefore, as consolidation continues, the Company may become more dependent on certain individual customers as these customers increase their size and market share.    </P>
<B><P ALIGN="JUSTIFY">PARMED PHARMACEUTICALS ("PARMED")</P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ParMed, with 2005 sales of approximately $68.9 million is a telemarketing distributor of human generic pharmaceutical products.  ParMed primarily targets independent pharmacies and serves approximately 5,000 customers each month. Customers are contacted using a sophisticated telemarketing system supported by 70 sales representatives and sales support personnel.  ParMed operates from warehouse and office facilities in Niagara Falls, New York and sales offices in West Seneca and Jamestown New York.<A NAME="_DV_M123"><A NAME="_DV_M124"></A></A> (See "Discontinued Operations".)</P>
<B><U><P><A NAME="_DV_M167"></A>INFORMATION APPLICABLE TO ALL BUSINESS SEGMENTS</P>
</U><P ALIGN="JUSTIFY"><A NAME="_DV_M168"></A>Research, Product Development and Technical Activities</P>
</B><P ALIGN="JUSTIFY"><A NAME="_DV_M169"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development is important to each of the Company's continuing business segments.  The Company's research, product development and technical activities in the BP business is directed toward developing proprietary drug delivery systems, line extensions and next-generation pain products with abuse deterrent technology.  The Company's API business performs research and development activities on chemical synthesis, fermentation and purification technologies intended to permit the introduction of additional products.  The Company is focusing its AH product development spending on activities complementary to in-licensing and co-developing technologies through arrangements with third parties. </P>
<P ALIGN="JUSTIFY"><A NAME="_DV_M170"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<A NAME="_DV_M171"><A NAME="_DV_M176"><A NAME="_DV_M177"><A NAME="_DV_M178"><A NAME="_DV_M179"></A></A></A></A></A>The technical product development for BP is conducted in Elizabeth, New Jersey in laboratories leased from Purepac. The Company is in the process of establishing an R&amp;D center for BP in Piscataway, New Jersey.  The Company conducts its technical product development activities for AH at its facilities in Willow Island, West Virginia, Chicago Heights, Illinois, Fort Lee, New Jersey, and contract research organizations.  The Oslo, Norway and Copenhagen, Denmark facilities are used for API research and development.  Independent research facilities in the U.S. and Europe are used for all business segments except ParMed.  <A NAME="_DV_M180"><A NAME="_DV_M181"></A></A></P>
<P ALIGN="JUSTIFY"><A NAME="_DV_M182"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses, excluding Discontinued Operations, were $26.9 million, $25.4 million, and $21.8 million in 2005, 2004, and 2003, respectively.&nbsp;&nbsp;In 2006, the Company intends to increase its spending on research and development to approximately $50 million.  Most of this increased spending will be for the development of a next-generation pain product in the BP business. Research and development activities are inherently speculative.  Investments in research and development do not always result in the successful development of a product.  Accordingly, it should not be assumed that potential products in the Company's pipeline will be successfully commercialized.<A NAME="_DV_M184"><A NAME="_DV_M185"></A></A></P>
<B><P ALIGN="JUSTIFY">Government Regulation <A NAME="_DV_M192"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<A NAME="_DV_M193"><A NAME="_DV_M194"><A NAME="_DV_M195"><A NAME="_DV_M196"><A NAME="_DV_M197"><A NAME="_DV_M198"><A NAME="_DV_M199"><A NAME="_DV_M201"><A NAME="_DV_M202"><A NAME="_DV_M203"><A NAME="_DV_M204"><A NAME="_DV_M205"><A NAME="_DV_M206"><A NAME="_DV_M208"><A NAME="_DV_M209"><A NAME="_DV_M211"><A NAME="_DV_M212"><A NAME="_DV_M213"><A NAME="_DV_M216"><A NAME="_DV_M217"><A NAME="_DV_M220"><A NAME="_DV_M221"><A NAME="_DV_M222"><A NAME="_DV_M223"><A NAME="_DV_M224"><A NAME="_DV_M225"><A NAME="_DV_M226"><A NAME="_DV_M227"><A NAME="_DV_M228"><A NAME="_DV_M229"><A NAME="_DV_M230"><A NAME="_DV_M231"><A NAME="_DV_M232"><A NAME="_DV_M233"><A NAME="_DV_M234"><A NAME="_DV_M235"><A NAME="_DV_M237"><A NAME="_DV_M238"><A NAME="_DV_M239"><A NAME="_DV_M240"><A NAME="_DV_M242"><A NAME="_DV_M243"></A></A></A></A></A></A></A></A></A></A></A></A></A></A></A></A></A></A></A></A></A></A></A></A></A></A></A></A></A></A></A></A>
</A></A></A></A></A></A></A></A></A></A></P>
</B></FONT><FONT FACE="Courier New"><P ALIGN="JUSTIFY">&nbsp;&nbsp;</FONT><I><FONT SIZE=3>General</I>.  The research, development, manufacturing and marketing of the Company's Brand, API and Animal Health products are subject to extensive government regulation by either the FDA or the U.S. Department of Agriculture, as well as by the Drug Enforcement Administration, Federal Trade Commission, Consumer Products Safety Commission, and other government agencies and by comparable authorities in the EU, Norway and other countries.  Although Norway is not a member of the EU, it is a member of the European Economic Area and, as such, has accepted all EU regulations with respect to pharmaceuticals except in the area of feed antibiotics.  Government regulation includes detailed inspection of and controls over testing, manufacturing, safety, efficacy, labeling, storage, record keeping, reporting, approval, advertising, promotion, sale and distribution of pharmaceutical products.  Non-compliance with applicable requirem
ents can result in warning letters, civil or criminal fines, actions, including prosecution, recall or seizure of products, injunctions, total or partial suspension of production and distribution, suspension or withdrawal of product approvals, the Company's debarment or the debarment of individuals from obtaining new drug approvals or providing services to drug companies in any capacity, refusal of the government to approve new products or to purchase the Company's products and criminal prosecution.  The cost of complying with government regulations substantially increases the cost of producing the Company's products.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The evolving and complex nature of regulatory requirements (including the possibility of future changes in statutes or regulations), the broad authority and discretion of the FDA and analogous state and foreign agencies, and the generally high level of regulatory oversight results in a continuing possibility that from time to time the Company will be adversely affected by regulatory actions despite the Company's efforts to achieve and maintain compliance with all regulatory requirements.  As a result of actions the Company has taken to respond to the progressively more demanding regulatory environment in which the Company operates, the Company has spent, and will continue to spend, significant funds and management time on regulatory compliance. </P>
<I><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. Product Marketing Authority and Protection from Generic Competition</I>.  KADIAN is the subject of an approved New Drug Application, or NDA, which has been reviewed by the FDA for both safety and effectiveness. The Agency has the continuing authority to consider the safety and effectiveness of all drugs subject to an approved NDA and, in appropriate circumstances, to order labeling changes, changes in or restrictions upon the drug's use or a cessation of the drug's sale and marketing.  (See "The FDA is considering the potential effects of KADIAN if taken with alcohol" under Risk Factors.)  Third parties may offer a generic variation of a branded product that is the subject of an NDA if the generic product is the subject of an Abbreviated New Drug Application, or ANDA, and be approved by the FDA prior to marketing.  </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All applications for regulatory approval of generic drug products subject to ANDA requirements must contain data relating to product formulation, raw material suppliers, stability, manufacturing, packaging, labeling and quality control, among other information.  ANDAs also must contain data demonstrating the bioequivalence of the generic drug to the branded drug.  In addition to meeting the above requirements for an ANDA, a generic version of KADIAN will not be approved by the FDA until the earlier of the expiration of the last to expire of the patents applicable to KADIAN (March 23, 2010 and April 13, 2010) or the date upon which a third party is able to demonstrate in the manner provided by law that either the Company's KADIAN patents are invalid or the generic equivalent product does not infringe the KADIAN patents.  Under the Hatch-Waxman Act, which amended both the Patent Code and the Federal Food, Drug and Cosmetics Act, procedures were codified and expanded with respect t
o applications for obtaining FDA approval for generic versions of patented drugs; including the institution of a statutory 30 month stay on the FDA authority to issue an ANDA commencing from the date a patent holder files a lawsuit challenging the generic applicants assertion of brand patent invalidity or non-infringement.  (See Risk Factors --"The Company's branded drug product, KADIAN, may experience general generic competition".)</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P ALIGN="JUSTIFY">     Most of the Company's animal health products are regulated by the FDA or equivalent regulatory authorities around the world, similarly to the human pharmaceuticals, while other animal health products are regulated primarily by individual States.  Although the Company markets some generic animal drug products, which are subject to similar FDA requirements as applicable to its human generic pharmaceutical products, many of its animal drug products are considered to be branded or pioneer animal drug products.  Like their human counterparts, pre-marketing approval under stringent FDA rules for their testing, development, and manufacture is required for animal drugs as well as for any changes in label claims, specifications or manufacturing sites that occur post-approval.  The backlog of submissions pending review in FDA's Center for Veterinary Medicine has made the timing of such approvals difficult to predict.  Despite the difficulty and delays brought about by this situation, the Compan
y has been successful in obtaining such approvals.  As with human pharmaceutical products, FDA inspection and record keeping requirements as well as debarment provisions apply to the Company's Animal Health products.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legislative bills are introduced in the U.S. Congress and individual states from time to time, some of which, if adopted, could have an adverse effect on AH's business.  However, in the past, such bills that could have had a material adverse effect, have not had sufficient support to become law.  The animal health industry is actively engaged in the legislative process.  To address the previously mentioned review backlog, the industry supported legislation adopting user fees and performance standards similar to those in place for new human drugs and medical devices.  The Animal Drug User Fee Act of 2003 is now in effect (providing for such fees and standards).  The Company believes that this legislation will make the regulatory process for some of the Company's Animal Health products more predictable in the future.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>EU Product Marketing Authority.</I>  EU legislation requires that veterinary products used for medicinal purposes must have a marketing authorization before they are placed on the market in the EU.  The criteria upon which grant of an authorization is assessed are quality, safety and efficacy.  Demonstration of safety and efficacy in particular requires clinical trials, which are subject to the standards codified in the EU guideline on Good Clinical Practice; however certain countries granted membership in the EU as of May 1, 2004 may, until a given date specified for each country, individually authorize the continued marketing of products that do not qualify for marketing authorization under EU law if such products were approved by the individual country prior to being granted EU membership.  Analogous governmental and agency approvals are required in other countries where the Company conducts business.  If the Company fails to obtain such marketing authorizations, or fails 
to obtain them in a timely manner, it could have a material adverse effect on the business, financial condition and results of operations of the Company's Animal Health business.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generic medicinal products for veterinary use may be authorized in the EU through abridged authorization applications.  For example, the EU marketing authorization applications do not need to contain results of tests and results of pre-clinical and clinical trials provided that certain conditions are met, and in particular that the "original" medicinal product has been authorized in the EU for not less than 8 years in a Member State of the Community.  A generic vertinary medicinal product authorized pursuant to the abridged procedure may not be placed on the market until 10 years have elapsed from the initial authorization of the reference product.  This 10-year period may be extended to 13 years in the case of veterinary medicinal products for fish or bees or other species designated following certain requirements.  To qualify for abridged dossiers, the product must be considered to be a generic of a reference medicinal product.  A generic medicinal product is a medicinal produ
ct which has the same qualitative and quantitative composition in active substances, the same pharmaceutical form as the reference medicinal product, and whose bioequivalence to the reference medicinal product has been demonstrated by appropriate studies.  Different salts, esters, ethers, isomers, mixtures of isomers, complexes, or derivatives of an active substance shall be considered to be the same active substance, unless they differ significantly in properties with respect to safety and/or efficacy.  In such cases, additional information demonstrating the safety and/or efficacy of the various salts, esters, or, derivatives of an authorized substance must be supplied by the applicant.  However, results of safety and residue tests or pre-clinical tests or clinical trials are not required if the applicant can demonstrate that the active substances of the veterinary medicinal product have been in well-established veterinary use within the EU for at least 10 years, with recognized efficacy and an acceptable l
evel of safety.  If the Company fails to satisfy the conditions for the use of abridged authorization applications for new products being developed by the Company, the process for the approval of such products could take significantly longer and cost substantially more to the Company.   Generic feed additive products in the EU used to promote animal health (specifically anticoccidial products) and nutrition are regulated under different legislation than veterinary pharmaceuticals.  (Regulation 1831/2003).  Applications for generic feed additives will require the same types of data necessary needed to obtain authorization of the original product.</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The European Union and one non-EU country banned the use of four antibiotics to promote growth in food producing animals effective July 1, 1999, and will extend this ban to the remaining approved growth promoting antibiotics by 2006.  In the list of products banned in 1999, only one, bacitracin zinc, was manufactured and marketed by the Company.  The Company's attempt to reverse or limit the EU ban that affects the Company's Albac product, was not successful.  Similar actions to ban or severely restrict the use in animals of antibiotics have been taken by EU trading partners or are being contemplated. (See "Risk Factors".)  None of the products scheduled to be banned in 2006 are manufactured or marketed by the Company.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Other Product Marketing Authority.   </I>Requirements similar to those in the U.S. and EU apply to the granting of manufacturing and marketing authorizations for veterinary products in Asia and Africa.  Therefore, the Company must comply with local requirements that may be, but are not always, similar to those described above prior to receiving approvals for products in Asia and Africa.</P>
</FONT><I><FONT FACE="CG Times (W1),Times New Roman"><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=3>Facility Compliance</I>.</FONT><FONT FACE="CG Times (W1),Times New Roman">  </FONT><FONT SIZE=3>The Company's Animal Health manufacturing operations in the U.S., three of the Company's European API facilities that manufacture products for export to the U.S. and certain third party plants where products are manufactured for sale by the Company in the US, including Kadian, are required to comply with the FDA current Good Manufacturing Practices regulations ("cGMP").  cGMP encompasses all aspects of the production process, including validation and record keeping, in addition to standards for facilities, equipment and personnel, and involves changing and evolving standards.  There are similar cGMP regulations in other countries where the Company has manufacturing operations.  The approvals held by the Company's customers (i.e., the manufacturers of the finished antibiotic products) identify the Company facilities that are permitted to supply APIs under each speci
fic approval.  The Company's facilities that produce for export to the U.S. are required to be registered with FDA as drug establishments and each API exported to the U.S. must be the subject of a drug listing.  The Company is subject to continual review and periodic inspection by the FDA.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">     The EU requires that before a medicinal product can be manufactured and assembled, each company that carries out such an operation must hold a manufacturer's license and the manufacture and assembly must be in accordance with the marketing authorization and cGMP.  It also requires that active substances used in medicinal products for human and veterinary use be manufactured following EU guidelines on good manufacturing practice to be implemented by the EU Member States by October 30, 2005.  The EU follows the same international guidance with respect to cGMPs for APIs as FDA.  In addition, the EU has expanded its ability to conduct cGMP inspections of active substance manufacturers.  The EU cGMP guidelines do not affect the ability of the responsible national competent authorities to establish specific registration requirements regarding active substances within the context of marketing/manufacturing authorizations. </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">     While the Elizabeth plant is a part of the Discontinued Operations and is no longer the direct responsibility of the Company, its regulatory status continues to be important to the Company since it is the location where the Kadian product is manufactured.  Between November 2002 and January 2003, the FDA conducted a routine general inspection at the Elizabeth plant.  As a result of this inspection, the FDA issued inspection observations listing deviations from cGMP's (a "483 Report") on January 15, 2003.  A comprehensive response was submitted on February 5, 2003. The FDA performed a follow-up inspection in late 2003 and issued another 483 Report citing continued deficiencies in compliance with FDA regulations.   The Company has been informed that the FDA is currently performing a cGMP inspection at the Elizabeth plant.  The field portion of this inspection has been completed.  The Company understands that the FDA has not yet issued the final results of its inspection.  (See "An interr
uption in the supply of Kadian would be materially adverse to the Company's operations" under Risk Factors).  </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">     In October 2004, May 2005, and September 2005, the Company received 483 Reports with respect to its API facilities in Skoyen, Norway, Copenhagen, Denmark and Budapest, Hungary, respectively, that recorded observed deviations from cGMPs.  The Company has responded to the FDA and the Agency has determined that all three responses were satisfactory.  As a result, all three facilities have the right to manufacture products for sale in the United States.  The Company has received 483 Reports from time to time in the past for it U.S. Animal Health plants, all of which the Company believes it has adequately addressed.</P>
<I><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Potential Liability for Current Products</I>.  Continuing studies of the proper utilization, safety, and efficacy of pharmaceuticals and other health care products are being conducted by the industry, government agencies and others.  These studies, which increasingly employ sophisticated methods and techniques, can question the utilization, safety and efficacy of previously marketed products, including the Company's products, and in some cases have resulted, and may in the future result, in the discontinuance of their marketing and give rise to claims for damages from persons who believe they have been injured as a result of their use.  While the Company believes that it is unlikely that an adverse finding in any single study regarding any of the Company's products will result in such regulatory measures without further findings, publicity raised by such a study could cause some of the Company's customers to decrease or stop their use of such product, resulting in an adverse aff
ect on the sales of such product.</P>
<I><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Controlled Substances Act</I>.  The Company developed, and sells KADIAN which is a "controlled substance" as defined in the Controlled Substances Act, which establishes certain security, personnel, reporting, record keeping and import and export requirements administered by the Drug Enforcement Administration, or ("DEA"), a division of the Department of Justice.  The Company is registered by the DEA to distribute controlled substances; Purepac, the toll manufacturer of KADIAN, holds the DEA registration to manufacture KADIAN.  The DEA has a dual mission: law enforcement and regulation. The DEA deals with the control of abusable substances and the equipment and raw materials used in making them.  The DEA shares enforcement authority with the Federal Bureau of Investigation, another division of the Department of Justice.  The DEA's regulatory responsibilities are concerned with the control of licensed handlers of controlled substances, and with the substances themselves, equipment
 and raw materials used in their manufacture and packaging, in order to prevent such articles from being diverted into illicit channels of commerce.  The Company is not under any restrictions for noncompliance with the foregoing regulations, but there can be no assurance that restrictions or fines will not be imposed on the Company in the future.</P>
<I><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Health Care Reimbursement</I>.  The methods and level of reimbursement for pharmaceutical products, including KADIAN, under Medicare, Medicaid, and other domestic reimbursement programs are the subject of constant review by state and federal governments and private third party payers like insurance companies.  The Company believes that U.S. government agencies will continue to review and assess alternative payment methodologies and reform measures designed to reduce the cost of drugs to the public.  As a part of this effort, the federal government and several states and local jurisdictions have commenced administrative or court actions challenging the pricing practices of certain named drug manufacturers including the Company.  Because the outcome of these and other health care reform initiatives is uncertain, the Company cannot predict what impact, if any, they will have. </P>
<B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Medicaid legislation requires all pharmaceutical manufacturers to rebate to state governments a percentage of the average manufacturer's selling price based on sales of outpatient drug products reimbursed under state Medicaid programs.  The required rebate rate for manufacturers of brand products is currently the greater of 15.1% of the weighted average selling price to the retail pharmacy class of trade ("AMP") for each product at the unit level or the difference between the AMP and the Company's best price for KADIAN to any non-governmental customer.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_DV_M191"><A NAME="_DV_M244"></A></A>Environmental Compliance</P>
</B><P ALIGN="JUSTIFY"><A NAME="_DV_M245"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The environmental authorities having jurisdiction over the Copenhagen and Oslo API manufacturing facilities have given the Company notice of revised waste discharge requirements which will require plant alterations or modifications.  In Copenhagen, the Company is being required to comply with a newly instituted requirement that antibiotic wastes be "de-activated" before release into the sewer system.  In Oslo, the facility has been notified of a reduction in the amount of certain wastes which will be permitted to be discharged into the public sewer system.  In both cases, process improvements or modifications are being made to the facilities.  While the Company does not believe that the cost of these alterations or modifications will be material to the Company, the failure or inability to comply with applicable regulations and discharge requirements could result in administrative actions affecting produc
tion at these facilities which could be materially adverse to the Company.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><A NAME="_DV_M247"><A NAME="_DV_M248"></A></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although many major capital projects typically include a component for environmental control, including the Company's current expansion projects, no material expenditures specifically for environmental control are expected to be made during <A NAME="_DV_C70">200<A NAME="_DV_M249"></A></A>6.  However, the Company has implemented an integrated environmental health and safety management system across most of its operations, and the Company may incur significant expenses, including potential fines or penalties, if in the operation of such system the Company discovers environmental conditions or past non-compliance at the Company's facilities.  In addition, the discovery of previously unknown contamination or the imposition of new clean-up requirements at sites at which the Company is currently undertaking environmental remediation could require us to incur costs or become the basis of new or increased liabilities that 
could have a material adverse effect on the Company's business, financial condition or results of operations.</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the sale of the Discontinued Operations, the Company has retained, responsibility to comply with ISRA, a State of New Jersey statute that requires investigation, and if necessary, environmental remediation in connection with the transfer of the Elizabeth manufacturing facility of Purepac.  Since the investigation is not yet completed, no estimate of the cost of this procedure is possible; although the Company knows of no facts from which it would reasonably conclude that the cost of this procedure would be material to the Company.</P>
</FONT><B><FONT FACE="CG Times (W1),Times New Roman" SIZE=3><P ALIGN="JUSTIFY"><A NAME="_DV_M250"></A></FONT><FONT SIZE=3>Raw Materials<A NAME="_DV_M251"></A>&#9;</P>
</B></FONT><FONT FACE="CG Times (W1),Times New Roman" SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=3>Many raw materials are purchased from single suppliers.  Any interruption in the availability of these materials could cause production delays and decrease sales of the affected products. Such interruption in the business could have a material adverse effect on the Company's operations.  In this event, the Company may seek to enter into agreements with third parties to purchase raw materials which may require additional regulatory approvals, as approvals are specific to a single product produced by a specified manufacturer.  Any significant interruption of supply from the Company's sole source suppliers that are related to products that generate more than $5.0 million in gross profits or any adverse event at any of its manufacturing facilities could have a material adverse effect on the Company's operations. Six raw materials used in Company products that each generated more than 
$5.0 million in gross profits in 2005 came from sole source suppliers. The sole source suppliers that provided these raw materials were: Bayer, Cambrex, DSM, Jinhe, Kaken and Beijing #2. While the Company relies on single source suppliers for many of its raw materials, it relies on different suppliers for different raw materials. </P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY"><A NAME="_DV_M252"></A>Revisions of Financial Statements</P>
</B><P ALIGN="JUSTIFY"><A NAME="_DV_M253"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2005, the Company revised its quarterly financial statements for the first three quarters of 2004 to amend certain information relating to the separation of its US Human Pharmaceuticals business into two segments; US Generic Pharmaceuticals and BP, which had previously been aggregated.   In May 2005, the Company revised its 2004 annual and interim financial statements and its 2003 annual and third quarter financial statements to reclassify certain of its outstanding debt as current liabilities and to amend disclosures related to the Company's compliance with certain of its debt covenants at December 31, 2004 and 2003.  </P>
<B><P ALIGN="JUSTIFY"><A NAME="_DV_M254"></A>Employees</P>
</B><P ALIGN="JUSTIFY"><A NAME="_DV_M255"></A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December 31, 2005, the Company had approximately 1,400 employees, comprised of approximately 750 in the U.S. and 650 outside of the U.S.  One U.S. plant is subject to collective bargaining agreements and two of the Company's European facilities have works councils and are subject to national and multi-national labor agreements.  The Company believes its relations with all of these employee units <A NAME="_DV_C73">are<A NAME="_DV_M256"></A></A> satisfactory.  In February 2004 and December 2005, the Company experienced two-day work stoppages at its Copenhagen plant over union membership issues.  The Company continues to address these issues with the relevant work council but can give no assurance that further work actions will not be encountered.</P>
<B>
<P ALIGN="JUSTIFY">Executive Officers of the Registrant</P>
</B><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a list of the names and ages of all of the Company's corporate executive officers, indicating all positions and offices with the Registrant held by each such person and each such person's principal occupation or employment during the past five years.</P>
</FONT><FONT SIZE=3></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=4 WIDTH=633>
<TR><TD WIDTH="32%" VALIGN="BOTTOM">
<B><FONT SIZE=3><P ALIGN="CENTER">Name and Position<BR>
with the Company</B></FONT></TD>
<TD WIDTH="9%" VALIGN="BOTTOM">
<B><FONT SIZE=3><P ALIGN="CENTER">Age</B></FONT></TD>
<TD WIDTH="59%" VALIGN="BOTTOM">
<B><FONT SIZE=3><P ALIGN="CENTER">Principal Business Experience<BR>
During the Past Five Years</B></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="59%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=3><P>E.W. Sissener<BR>
Chairman and Director </FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">77</FONT></TD>
<TD WIDTH="59%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Chairman of the Company since 1975.  Chief Executive Officer from June 1994 to June 1999.  Member of the Office of the Chief Executive of the Company July 1991 to June 1994. Chairman of the Office of the Chief Executive June 1999 to December 1999. President, Alpharma AS October 1994 to February 2000. President, Apothekernes Laboratorium AS (now AL Industrier ASA) 1972 to 1994. Chairman of A.L. Industrier ASA since November 1994.</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="59%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=3><P>Ingrid Wiik<BR>
President, Chief Executive Officer, Vice Chairman and Director </FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">61</FONT></TD>
<TD WIDTH="59%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">President and Chief Executive Officer since January 2000. Vice Chairman since May 2004 and Director since January 2000. President of the Company's International Pharmaceuticals Division 1994 to 2000; President, Pharmaceutical Division of Apothekernes Laboratorium A.S. (now A.L. Industrier ASA) 1986 to 1994. </FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="59%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=3><P>Carl-Aake Carlsson<BR>
President, API</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">43</FONT></TD>
<TD WIDTH="59%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">President of API since January 2005.  President of Branded Pharmaceuticals and API from July 2003 to January 2005. President of Human Pharmaceuticals International from September 2001 to December 2003; President of International Pharmaceuticals from January 2000 to September 2001; Senior Vice President, Finance and Strategy Development of International Pharmaceuticals Division 1995 to 2000.</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="59%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=3><P>Richard J. Cella</P>
<P>Executive Vice President and Chief Information Officer</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">54</FONT></TD>
<TD WIDTH="59%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Executive Vice President since June 2002.  Chief Information Officer since September 2000; Vice President, September 2000 to January 2002.  Vice President Information and Technology for Pharmaceutical Section of Warner-Lambert Company, 1999 to 2000; Vice President of International Information Systems of Warner-Lambert Company, 1997-1999; Senior Director of Operations and Technology of Warner-Lambert Company, 1995-1997.</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="59%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=3><P>Matthew T. Farrell<BR>
Executive Vice President and Chief Financial Officer</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">49</FONT></TD>
<TD WIDTH="59%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Executive Vice President and Chief Financial Officer since April 2002.  Vice-President - Investor Relations and Communications of Ingersoll-Rand, July 2000 to April 2002; Chief Financial Officer of AlliedSignal - Specialty Chemicals, 1997 to July 2000.</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="59%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=3><P>George P. Rose<BR>
Executive Vice President, Human Resources and Communications</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">53</FONT></TD>
<TD WIDTH="59%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Executive Vice President, Human Resources and Communications since January 2002; Vice President September 2001 to January 2002.  Corporate Vice President of Leadership, Development and Learning at Honeywell International Inc., formerly known as AlliedSignal Inc., 2000 to September 2001; Vice President, Human Resources of Honeywell's Specialty Chemicals Division 1997 to 2000.</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="59%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=3><P>Ronald N. Warner, Phd<BR>
President BP and Executive Vice President, Compliance and Intellectual Property  </FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">52</FONT></TD>
<TD WIDTH="59%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">President of BP and Executive Vice President Compliance and Intellectual Property since January 2005. Executive Vice President, Compliance, Intellectual Property and Human Pharmaceuticals Medical and Regulatory Affairs from January 2004 to January 2005. Executive Vice President Intellectual Property and Human Pharmaceuticals Medical and Regulatory Affairs since February 2003; Vice President, Global Scientific Affairs, Human Pharmaceuticals December 2002 to February 2003.  Vice President and General Manager, ESI Lederle, 2001 to 2002; Vice President, Research and Development, ESI Lederle 1995 to 2001.</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="59%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=3><P>Carol A. Wrenn<BR>
President, Animal Health</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">45</FONT></TD>
<TD WIDTH="59%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">President, Animal Health since November 2001.  Held various executive positions at Honeywell International Inc. formerly known as AlliedSignal Inc. from 1984 to October 2001; Business Director for Honeywell's Refrigerants, Fluorine Products Division October 2000 to October 2001; Commercial Director and Managing Director for that division's European operations April 1997 to October 2000.</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="59%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=3><P>Robert F. Wrobel<BR>
Executive Vice President and Chief Legal Officer</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">61</FONT></TD>
<TD WIDTH="59%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Executive Vice President since January 2002; Chief Legal Officer since October 1997; Vice President October 1997 to January 2002. Vice President and Associate General Counsel of Duracell Inc., 1994 to September 1997 and Senior Vice President, General Counsel and Chief Administrative Officer of The Marley Company 1975 to 1993. </FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="59%" VALIGN="TOP">&nbsp;</TD>
</TR>
</TABLE>

<B><U><FONT SIZE=3><P>Item 1A. RISK FACTORS</P>
</B></U><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's reports filed from time to time pursuant to the Securities Exchange Act of 1934 include certain forward-looking statements.  Like any company subject to a competitive and changing business environment, the Company cannot guarantee the results predicted in any of the Company's forward-looking statements.  Important factors that could cause actual results to differ materially from those in the forward-looking statements include the following:</P>
<B><P ALIGN="JUSTIFY"><BR>
The Company depends on the development, manufacture and marketing of new products for its future success.</P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's future success is largely dependent upon its ability to develop, manufacture and market commercially successful new products.  Generally, the successful commercial marketing of the Company's products depends on completing the following steps in a time frame to allow the Company to be among the first to market a particular product:</P>
<P ALIGN="JUSTIFY"></P>

<UL>

<UL>
<P ALIGN="JUSTIFY"><LI>developing and testing the product;</LI></P></UL>
</UL>

<P ALIGN="JUSTIFY"></P>

<UL>

<UL>
<P ALIGN="JUSTIFY"><LI>proving that the product is safe and effective; and </LI></P></UL>
</UL>

<P ALIGN="JUSTIFY"></P>

<UL>

<UL>
<P ALIGN="JUSTIFY"><LI>filing for and receiving regulatory approvals to manufacture and sell the product in a timely manner.</LI></P></UL>
</UL>

<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delays in the development, manufacture or marketing of new products will impact the Company's expenses and revenues.  The Company cannot be sure that any product presently going through the process set forth above, or which may be chosen by the Company to enter this process in the future, will result in the timely and profitable commercial launch of a new product. </P>
<B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Research and development expenditures will negatively impact the Company's earnings in the short term, and there is no guarantee of success.</P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company, in its continuing businesses, expended approximately $26.9 million and $25.4 million on research and development efforts in 2005 and 2004, respectively, and expects to increase these expenditures to approximately $50 million in 2006, principally for the development of additional pain products. Such research and development expenditures will have an adverse impact on the Company's earnings in the short term. Further, the Company cannot be sure that its research and development expenditures will, in the long term, result in the commercialization of products, including a next-generation pain product, which prove to be economically successful.</P>
</FONT><FONT FACE="CG Times (W1),Times New Roman">
</FONT><B><FONT SIZE=3><P ALIGN="JUSTIFY">The Company is subject to government regulations and actions that increase the Company's costs and could prevent it from marketing and selling some of its products in certain countries.</P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The research, development, manufacturing and marketing of the Company's products are subject to extensive government regulation. Government regulation includes inspection of and controls over testing, manufacturing, safety, efficacy, labeling, record keeping, pricing, sale and distribution of pharmaceutical products.  While the Company does not keep records that segregate the cost of compliance with these government regulations, in the aggregate such regulations substantially increase the cost of manufacturing, developing and selling the Company's products.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The U.S. and other governments regularly review manufacturing operations, including API's plants in Oslo, Copenhagen and Budapest where products for the US market are, or are intended to be, manufactured.  These reviews can result in regulatory concerns requiring a response by the Company.  Failure to adequately address these concerns could have a material adverse effect on the Company, including product approval delays, reduced production and production interruptions, among other things.  The significance of the effect of any such failures depends on the severity of the remedy chosen by the government agency.  Non-compliance with applicable requirements can result in fines, recall or seizure of products, suspension of production or distribution and debarment of individuals from providing services to drug companies in any capacity or debarment of the Company from obtaining new drug approvals, resulting in current charges to income and the potential for future 
loss of income and increased operating expenses.  In recent years, besides stepped up enforcement of cGMP requirements, the federal government has utilized equitable disgorgement as a means of enforcing compliance with the FDA's cGMP regulations.  There can be no assurance that the FDA would not seek to impose similar sanctions on the Company and any such sanction could have a significant effect on the Company's business and operations.  </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, continuing studies of the proper utilization, safety and efficacy of pharmaceuticals and other health care products are continually being conducted by the industry, government agencies (including studies required to be performed from time to time by the pharmaceutical company marketing a particular drug) and others.  These studies, which increasingly employ more sophisticated methods and techniques, can question the utilization safety and efficacy of previously marketed products and in some cases have resulted, and may in the future result, in the discontinuance of their marketing and, in certain countries, give rise to claims for damages from person who believe they have been injured as a result of their use.  </P>
<B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">An expansion of the ban of the use of antibiotics used in food-producing animals could result in a decrease in the Company's total sales.</P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The issue of the potential transfer of increased bacterial resistance to certain antibiotics used in certain food-producing animals to human pathogens is the subject of discussions on a worldwide basis and, in certain instances, has led to government restrictions on the use of antibiotics in these food-producing animals.  While most of the government activity in this area has involved products other than those that the Company offers for sale, the European Union and one non-EU country banned the use of bacitracin zinc, a feed antibiotic growth promoter manufactured by the Company and others that has been used in livestock feeds for over 40 years.  The Company has not sold this product in these countries since the ban took effect.  The EU ban is based upon the "Precautionary Principle", which states that a product may be withdrawn from the market based upon a finding of a potential threat of serious or irreversible damage even if such finding is not support
ed by scientific certainty.  Although the EU action negatively impacted the Company's business, it was not material to the Company's financial position or its results of operations.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company cannot predict whether the present bacitracin zinc ban in the EU will be expanded.  If any one of the following occur: (i) the EU or countries within the EU act to prevent the importation of meat products from countries that allow the use of bacitracin-based products, (ii) there is an expansion of the zinc bacitracin ban to additional countries, such as the U.S., where the Company has material sales of bacitracin-based products, (iii) a similar ban is instituted relating to other antibiotic feed additives sold by the Company in the U.S. or in one or more other countries where the Company has material sales, or (iv) there is an increase in public pressure to discontinue the use of antibiotic feed additives, the resultant loss of sales could be material to the Company's financial condition, cash flows and results of operations.  The Company cannot predict whether this antibiotic resistance concern will result in expanded regulations or public pressure adversely affecti
ng other antibiotic-based animal health products previously sold by the Company in the EU or in other countries in which those products are presently sold.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discussions of the antibiotic resistance issue continue actively in the U.S.  Various sources have published reports concerning possible adverse human effects from the use of antibiotics in food animals.  Some of these reports have asserted that major animal producers, some of whom are the Company's customers or the end-users of its products, are reducing the use of antibiotics.  In July 2005, the FDA announced a restriction on the distribution and use of a medicated feed additive due to concerns regarding antibiotic resistance in humans.  While the Company does not market this drug this ruling would be significant if its conclusions were expanded to the medicated feed additives sold by the Company.  It is uncertain what additional actions, if any, the FDA may take for approved animal drug products.  However, the FDA has proposed a rating system to be used to compare the risks associated with the use of specific antibiotic products in food producing animals, i
ncluding those sold by the Company.  While the Company does not believe that the presently proposed risk assessment system would be materially adverse to its business, it is subject to change prior to adoption or to later amendment.  The sales of the Company's Animal Health segment are principally antibiotic-based products for use with food producing animals; therefore the future loss of major markets, including the U.S., or negative publicity regarding this use of antibiotic based products, could have a negative impact on the Company's sales and income.</P>
<B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Potential adverse effects on human health linked to the raising or consumption of food producing animals using the Company's products could result in a decrease in the Company's sales.</P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should the government find, or the public perceive a risk to human health from consumption of food producing animals (such as Avian flu) which utilize the Company's products or as a by-product to the raising of such animals (such as the "Chicken Litter" litigation referred to in Item 3 of this Report) there may be a decline in either the sale of such food products which would result in a decrease in the use of the Company's products or a decrease in the use of the Company's products in the growing of such food producing animals. </P>
</FONT>
<B><FONT SIZE=3><P ALIGN="JUSTIFY">Many of the third parties with whom the Company does business depend on government approvals, and the failure to maintain these approvals could affect the supply of materials to the Company, hinder the Company's ability to license products, or affect the promotion, distribution or sale of the Company's products.</P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has affiliations, license agreements and other arrangements with third parties that depend on regulatory approvals sought by such third parties. The Company's vendors and third party contract manufacturers, including Purepac the sole source of supply for KADIAN, are subject to regulatory compliance similar to those described herein with respect to the Company.  If any one of these third parties is found to have significant regulatory violations, the Company could be materially negatively impacted if such violations result in an interruption of the supply of a product which relates to material Company sales. While the Company takes measures where economically feasible and available to secure back-up suppliers, many of the Company's products come from a sole source supplier. There can be no assurance that such contingency plans will be able to provide adequate and timely product to eliminate any threat of interruption of supply of the Company's p
roducts to its customers or that these problems will not otherwise materially impact the Company's business.</P>
</FONT><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT SIZE=3>See "An interruption in the supply of KADIAN would be materially adverse to the Company's operations" below.</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">An interruption in the supply of the Company's raw materials or products or an adverse event at one of the Company's manufacturing facilities or third-party manufacturing facilities could adversely effect its operations.</P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company currently purchases many of its raw materials and a number of its finished products from single suppliers and many of its products are manufactured at a single facility; including KADIAN which is manufactured at the Purepac Elizabeth, New Jersey facility sold to Actavis Group. While the Company relies on single source suppliers for many of its raw materials and for a number of its finished products, it relies on different suppliers for different raw materials and finished products. Any interruption in the supply of these materials or products or an adverse event at the facilities that manufacture and blend the Company's products, could decrease sales of the affected products. In this event, the Company may seek to enter into agreements with third parties to purchase raw materials or products or to lease or purchase new manufacturing facilities. The Company may be unable to find a third party willing or able to provide the necessary products or 
facilities suitable for manufacturing pharmaceuticals on terms acceptable to the Company. If the Company had to obtain substitute materials or products, the Company would require additional regulatory approvals, as approvals are specific to a single product produced by a specified manufacturer. The use of new facilities, similarly, would require regulatory approvals. Any significant interruption of supply from the Company's sole source raw material suppliers or third-party manufacturing facilities that are related to products that generate more than $5.0 million in gross profits or any adverse event at any of its manufacturing facilities could have a material adverse effect on the Company's operations. Six raw materials used in Company products that each generated more than $5.0 million in gross profits in 2005 came from sole source suppliers. The sole source suppliers that provided these raw materials were: Bayer, Cambrex, DSM, Jinhe, Kaken, and Beijing #2. Additionally, four finished product sole source su
ppliers supplied finished products generating more than $5.0 million in gross profits in 2005 including Purepac; the supplier of KADIAN.  One finished goods supplier, whose corresponding products had 2005 gross profits over $10.0 million, is believed to be in financial difficulty. </P>
<B><P ALIGN="JUSTIFY"></P>
</B><P>     See "An interruption in the supply of KADIAN would be materially adverse to the Company's operations" below.</P>
</FONT><FONT FACE="CG Times (W1),Times New Roman">
</FONT><B><FONT SIZE=3><P ALIGN="JUSTIFY">An interruption in the supply of KADIAN would be materially adverse to the Company's operations.</P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The most significant Company product manufactured by a third party is KADIAN which is manufactured under a toll manufacturing agreement with Purepac; the Company's former generic subsidiary sold to Actavis as a part of the Generic Business transaction.   While the Company intends to use reasonable commercial efforts to locate a second source for the manufacture of KADIAN, Purepac is, at present, its sole supplier.  Purepac has, in the past, had substantial FDA regulatory issues at the plant where KADIAN is manufactured.  In addition, the Company no longer controls Purepac and it can no longer require that KADIAN manufacturing be given any particular priority when compared with the products manufactured for Purepac's own sales.  Any interruption in the supply of KADIAN would have a material adverse effect on the Company.  This effect could be particularly severe since many patients are particularly sensitive to the brand of pain product which they are using
 and, as a result, forcing a KADIAN user to switch to a competitive product could cause a reluctance of that individual to resume his or her use of KADIAN once supplies of the product were again available as well as potentially causing some physician to favor competitive products for new patients.</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">The FDA is considering the potential effects of KADIAN if taken with alcohol.</P>
<P ALIGN="JUSTIFY"></P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA has raised certain safety questions related to the possible adverse interaction of KADIAN with the co-ingestion of alcohol.  The Company is currently engaged in clinical studies with respect to this subject and plans to continue the dialog with the FDA once these studies are completed.  Since the studies and consideration of the results by the FDA are not complete no assurance can be given that the FDA will not assert its right to require a change the product labeling or the manner in which KADIAN is used.</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">A material portion of the Company's sales and gross profits is dependant on a relatively small number of products.</P>
<P ALIGN="JUSTIFY"></P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Seven products (BP's KADIAN, AH's CTC, BMD and Lacalocid and API's vancomycin, polymyxin and bacitracin) in the aggregate constitute approximately 79% and 84% of the Company's 2005 sales and gross profits, respectively.  The loss of significant sales of any one or more of such products for any reason, including any of the risks related to such products described in this Report, would have a material adverse effect upon the Company. </P>
</FONT><FONT FACE="CG Times (W1),Times New Roman">
</FONT><B><FONT SIZE=3><P ALIGN="JUSTIFY">The Company's foreign operations are subject to additional economic and political risks.</P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's foreign operations are subject to currency exchange fluctuations and restrictions, political instability in some countries, and uncertainty as to the enforceability of, and government control over, commercial rights. </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company sells its AH and API products in many countries that are susceptible to significant foreign currency fluctuations. The Company's API products are generally sold for U.S. dollars, eliminating the direct exposure to currency fluctuations, but increasing credit risk if the local currency devalues significantly and it becomes more expensive for customers to purchase U.S. dollars required to pay the Company.  </P>
<B><P ALIGN="JUSTIFY"><BR>
In all the Company's businesses, it may become more difficult for the Company to respond to competitive challenges because of its size and product mix and the rapidly changing market.</P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The industries in which the Company's sells its products are highly competitive and many of the Company's competitors are affiliated with entities which are substantially larger and have greater financial, technical and marketing resources than the Company possesses.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In certain countries, because of the Company's size and product mix, the Company may not be able to capitalize on such changes in competition and pricing as fully as the Company's competitors.  In recent years, there were new entrants in the generic medicated animal feed additive market, particularly in the United States.  Additionally, the Company's API business may be subject to increased competitive challenges; particularly with respect to those products which the Company implemented significant price increases during 2003.  </P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">The Company's branded drug product, KADIAN, may experience general generic competition</B>.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's branded drug product line may face competitive challenges from generic equivalents.  The Company has two patents for KADIAN (expiring in 2010) that are subject to potential paragraph IV challenges prior to their expiration date, though there have been no such challenges to date.   The Company cannot offer any assurance that it will be able to successfully defend its patent position or utilize the statutory 30 month stay on FDA approval of the generic ANDA, since either result is dependent upon the Company being able to meet the statutory requirements for filing a lawsuit challenging the generic product based upon a bona fide belief that the generic product infringes one or more of the KADIAN patents.  The existence of such belief cannot be determined until the Company has the opportunity to review the relevant paragraph IV filing.  Upon entry of a generic equivalent in the market, the Company's branded products could lose substantial sales and th
e price could materially decline.</P>
<B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">The Company's policies regarding sales returns, allowances and chargebacks, and marketing programs adopted by wholesalers and other customers, may reduce the Company's revenue in future fiscal periods.</B>  </P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on industry practice in the U.S., brand manufacturers such as the Company have return policies, rebates paid to commercial and government entities in connection with sales made to enrollees in certain health plans, chargebacks to wholesale customers in connection with sales they make to certain categories of customers such as hospitals or group purchasing organizations.  Although the Company establishes reserves based upon its prior experience and certain other information which constitute the Company's best estimate of the impact that these policies will have in subsequent periods, actual results could differ from these estimates. </P>
<B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">The Company's liability from accidents, product liability or other claims may exceed the Company's insurance coverage.</P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company seeks to obtain liability and direct damage insurance to protect it from the liability due to accidents, product liability and other claims that arise in the course of doing business. While, based upon historical claims levels, the Company believes its present insurance is adequate for current and projected operations, insurance that the Company seeks to obtain in the future to protect itself against these potential liabilities may be inadequate, unobtainable or prohibitively expensive.  A materially adverse result in the AH litigation relating to its 3-Nitro product (See "Chicken Litter Litigation") could result in insurance coverage which is not adequate to cover the risk of that litigation or future lawsuits. The Company is subject to renewal of most of its insurance policies each year and changes are anticipated at each renewal. In recent years, the Company has experienced significant increases in its insurance costs and coverage reductions
 including coverage exclusions pertaining to 3-Nitro and certain other products that it now manufacturers or may manufacture in the future. The Company's inability to obtain and maintain sufficient insurance coverage on reasonable terms could materially adversely affect the Company's business, financial condition and results of operations.</P>
<B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">The Company could have difficulties in developing and integrating strategic alliances, co-development opportunities and other relationships.</P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company intends to pursue product-specific licensing, marketing agreements, co-development opportunities and other partnering arrangements.  The Company may also pursue selective product acquisitions.  The Company cannot be sure that it will be able to locate suitable partners for these transactions.  In addition, assuming the Company identifies suitable partners, the process of effectively entering into these arrangements involves risks that the Company's management's attention may be diverted from other business concerns and that the Company may have difficulty integrating the new arrangements into its existing business.</P>
<P ALIGN="JUSTIFY"><BR>
<B>Non-compliance with environmental waste discharge regulations could adversely affect production at two European plants of the Company.</P>
</B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The environmental authorities having jurisdiction over the Copenhagen and Oslo API manufacturing facilities have given the Company notice of revised waste discharge requirements which will require plant alterations or modifications.  In Copenhagen, the Company is being required to alter its manufacturing process to comply with a newly instituted requirement that active antibiotic wastes are not released into the sewer system.  In Oslo, the facility has been notified of a reduction in the amount of certain wastes which will be permitted to be discharged into the public sewer system.  In both cases, process improvements are being made to the facilities.  While the Company does not believe that the cost of these alterations or modifications will be material to the Company, the failure or inability to comply with applicable regulations and discharge requirements could result in administrative actions affecting production at these facilities which could be materially adverse to the C
ompany.</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">The interests of the Company's controlling stockholder may conflict with interests of the Company.</P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Industrier is the beneficial owner of 11,872,897 shares of the Company's Class B common stock as of December 31, 2005, which represented 100% of the outstanding shares of the Company's Class B common stock as of that date.  As of December 31, 2005, Industrier had 52.8% of the voting power of the Company's common stock.  Therefore, Industrier has significant influence and control over the Company's business and is presently entitled to elect two-thirds of the members of its board of directors.  Einar W. Sissener, Chairman of the board of directors of the Company, controls a majority of Industrier's outstanding shares and is Chairman of Industrier.  In addition, Mr. Sissener beneficially owns 373,667 shares of the Company's Class A common stock.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Industrier has the ability to make decisions affecting the Company's business and capital structure, including, in some instances, the issuance of additional indebtedness.  Industrier may pursue future transactions that could enhance its equity investment while involving risks to the interests of the Company.  All contractual arrangements between the Company and Industrier are subject to review by, or the ratification of, the Audit and Corporate Governance Committee of the Company's board of directors as to the fairness of the terms and conditions of such arrangements to the Company.  This committee consists solely of directors who are unaffiliated with Industrier.</P>
</FONT><FONT FACE="CG Times (W1),Times New Roman">
</FONT><B><FONT SIZE=3><P ALIGN="JUSTIFY">Past restatements of the Company's financial statements and certain matters related to internal controls may present a risk of future restatements and lead to an inability to report on the financial status of the Company on a timely and fair basis. </P>
</B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the first quarter of 2004, as a result of a newly established internal review process, the Company revised its financial statements related to its International Generic business' accruals of product discounts in its operation in The Netherlands.  In May 2004, the Company revised its 2003 financial statements related to its US Generics business, to adjust previously reported inventory balances and cost of sales related to product purchased under a vendor supply contract.  </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2005, the Company revised its financial statements for the first three quarters of 2004 to disaggregate its US Generic Pharmaceuticals (USG) and Branded Pharmaceuticals (BP) businesses as separate reportable segments.  In addition, in May 2005, the Company revised its 2004 financial statements to change the classification of certain of its outstanding debt as current liabilities and to amend disclosures related to the Company's compliance with certain of its debt covenants at December 31, 2004 and 2003. </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has made significant investments to enable it to comply with Section 404 of the Sarbanes-Oxley Act of 2002 (the "Act").  Compliance with Section 404 of the Act was first required as of December&nbsp;31, 2004.  The Company has undergone a significant effort to document, test, and assess its internal controls.  At December 31, 2004, the Company identified four material weaknesses in its internal control over financial reporting: (i) ineffective internal controls to ensure the completeness and accuracy of customer discount reserves and certain accrual accounts at the Company's USG business; (ii) ineffective internal controls to ensure the completeness and accuracy of income tax accounts, including deferred tax assets and liabilities, taxes payable and income tax expense; (iii) ineffective internal controls over the determination of proper segment disclosures; and (iv) ineffective controls to ensure the appropriate review and monitoring of its complian
ce with certain of its debt covenants.  </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2005, the Company implemented actions to remediate the four material weaknesses identified at December 31, 2004.  The Company believes the actions it has taken in 2005 and the enhanced control procedures it has implemented have served to remediate the four material weaknesses identified at December 31, 2004.  However, at December 31, 2005, the Company identified a material weakness in its internal controls over financial reporting for income taxes related specifically to the timeliness and accuracy of tax accounting related to the disposition of the Generics Business and related fourth quarter transactions.  In addition, management identified, and has or is developing remediation plans to address, certain other control deficiencies which were not material weaknesses at December 31, 2005.  Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Also, projections of any evaluation of effecti
veness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">     As of December 31, 2005, the Company identified the material weakness described above and, as a result, the Company's management concluded that: (i) the Company's disclosure controls and procedures were not effective as of December 31, 2005 and (ii) the Company did not maintain effective internal control over financial reporting as of December 31, 2005. In future years, there are no assurances that the Company will not have material weaknesses (either that referred to above or additional material weaknesses) that would be required to be reported or that the Company will be able to comply with the requirements of Section 404. A significant material weakness or the failure to meet the requirements of Section 404 could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of the Company's financial statements. This loss of confidence could cause a decline in the market price of the Company's stock</FONT><FONT FACE="CG Times (W1),Times New R
oman">.</P>
</FONT><FONT SIZE=3><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<B><P ALIGN="JUSTIFY">Item 1B. Unresolved Staff Comments</P>
<P ALIGN="JUSTIFY"></P>
</B><P ALIGN="JUSTIFY">None.</P>
</FONT><FONT FACE="CG Times (W1),Times New Roman">
</FONT><B><FONT SIZE=3><P ALIGN="JUSTIFY">Item 2.&#9;Properties</P>
<P ALIGN="JUSTIFY">Manufacturing and Facilities</P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's corporate offices and principal production and technical development facilities are located in the U.S., Norway and Denmark. The Company also owns or leases offices and warehouses in the U.S. and elsewhere.</P>
<P> </P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=638>
<TR><TD WIDTH="25%" VALIGN="BOTTOM">
<B><FONT SIZE=2><P ALIGN="CENTER">Location</B></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM">
<B><FONT SIZE=2><P ALIGN="CENTER">Status</B></FONT></TD>
<TD WIDTH="15%" VALIGN="BOTTOM">
<B><FONT SIZE=2><P ALIGN="CENTER">Facility Size<BR>
(sq. ft.)</B></FONT></TD>
<TD WIDTH="48%" VALIGN="BOTTOM">
<B><FONT SIZE=2><P ALIGN="CENTER">Use</B></FONT></TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">
<FONT SIZE=2><P>Budapest, Hungary</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="CENTER">Owned</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">98,000</FONT></TD>
<TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=2><P>Manufacturing, warehousing and offices for API</FONT></TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">
<FONT SIZE=2><P>Chicago Heights, IL</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="CENTER">Owned</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">149,300</FONT></TD>
<TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=2><P>Manufacturing, warehousing, research and development and offices for AH</FONT></TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">
<FONT SIZE=2><P>Copenhagen, Denmark</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="CENTER">Owned</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">403,000</FONT></TD>
<TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=2><P>Manufacturing, warehousing, and offices for API; research and development for API.</FONT></TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">
<FONT SIZE=2><P>Fort Lee, NJ</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="CENTER">Leased</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">62,000</FONT></TD>
<TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=2><P>Company corporate and AH headquarters</FONT></TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">
<FONT SIZE=2><P>Longmont, CO</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="CENTER">Owned</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">65,000</FONT></TD>
<TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=2><P>Manufacturing, warehousing and offices for AH</FONT></TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">
<FONT SIZE=2><P>Niagara Falls, NY</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="CENTER">Owned</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">51,000</FONT></TD>
<TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=2><P>Warehousing and offices for ParMed</FONT></TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">
<FONT SIZE=2><P>Oslo, Norway</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="CENTER">Leased</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">223,000</FONT></TD>
<TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=2><P>Manufacturing  of AH and API products and API research and development corporate offices and headquarters</FONT></TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">
<FONT SIZE=2><P>Piscataway, NJ</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="CENTER">Owned</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">120,000</FONT></TD>
<TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=2><P>Headquarters for Branded Products</FONT></TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">
<FONT SIZE=2><P>Salisbury, MD</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="CENTER">Owned</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">20,000</FONT></TD>
<TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=2><P>Manufacturing, warehousing and offices for AH</FONT></TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">
<FONT SIZE=2><P>Van Buren, AR</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="CENTER">Leased</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">31,000</FONT></TD>
<TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=2><P>Manufacturing, warehousing and offices for AH</FONT></TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">
<FONT SIZE=2><P>Willow Island, WV</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="CENTER">Ground Lease</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">105,348</FONT></TD>
<TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=2><P>Manufacturing and warehousing for AH</FONT></TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">
<FONT SIZE=2><P>Eagle Grove, IA</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="CENTER">Owned</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">50,000</FONT></TD>
<TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=2><P>Manufacturing, warehousing and offices for AH</FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P ALIGN="JUSTIFY">______________________________<BR>
</P>
<P ALIGN="JUSTIFY"></P>
</FONT><FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;</P>
<B><P>Item 3. Legal Proceedings </P>
</B>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is involved in various legal proceedings, of a nature considered normal to its business.  It is the Company's policy to accrue for amounts related to these legal matters if it is probable that a liability has been incurred and an amount is reasonably estimable.</P>
</FONT><P ALIGN="JUSTIFY"></P>
<B><FONT SIZE=3><P ALIGN="JUSTIFY">SEC Investigation</P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June 2002, the SEC notified the Company that it had commenced a formal investigation of the circumstances surrounding the 2000 and 2001 restatements of its financial statements. The SEC has engaged in deposition and document discovery.</FONT>  </P>

<B><FONT SIZE=3><P ALIGN="JUSTIFY">Chicken Litter Litigation</P>
</B>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is one of the multiple defendants that has been named in several lawsuits which allege that one of its AH products causes chickens to produce manure that contains an arsenical compound which, when used as agricultural fertilizer by chicken farmers, degrades into inorganic arsenic and causes a variety of diseases in the plaintiffs (who allegedly live in close proximity to such farm fields).  The Company has provided notice to its insurance carriers and its primary insurance carriers have responded by accepting their obligations to defend or pay the Company's defense costs, subject to reservation of rights to later reject coverage for these lawsuits.  In addition, one of the Company's carriers has filed a Declaratory Judgment action in state court in which it has sought a ruling concerning the allocation of its coverage obligations to the Company among the Company's several insurance carriers and, to the extent the Company does not have full insuranc
e coverage, to the Company.  In addition, this Declaratory Judgment action requests that the Court rule that certain of the carrier's policies provide no coverage because certain policy exclusions allegedly operate to limit its coverage obligations under said policies.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to the potential for personal injury damages to the approximately 140 plaintiffs, the plaintiffs are asking for punitive damages and requesting that the Company be enjoined from the future sale of the product at issue.  Discovery is substantially complete with respect to the first trial which is scheduled for September 2006.  While the Company can give no assurance of the outcome of these matters, it believes that it will be able to present credible scientific evidence that its product is not the cause of any injuries the plaintiffs may have suffered.  There is also the possibility of an adverse customer reaction to the allegations in these lawsuits as well as additional lawsuits in other jurisdictions where the product has been sold.  Worldwide sales of this product were approximately $23.3 million in 2004 and $23.1 million in 2005.</FONT>  </P>
<P ALIGN="JUSTIFY"></P>
<B><FONT SIZE=3><P ALIGN="JUSTIFY">Brazilian Tax Claims</P>
</B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is the subject of several tax claims which aggregate approximately $10.0 million by the Brazilian authorities relating to the operations of the Company's Animal Health business in Brazil since 1999. The Company believes it has meritorious defenses and intends to vigorously defend its position against these claims.</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">European Environmental Regulations</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>The environmental authorities having jurisdiction over the Copenhagen and Oslo plants of the Company have given the Company notice of revised waste discharge requirements which will require plant alterations or modifications for compliance.  While the Company does not believe that the cost of these alterations or modifications will be material to the Company, the failure or inability to comply with applicable regulations and discharge requirements could result in administrative actions affecting production at these facilities which could be materially adverse to the Company.</P>
<B><P ALIGN="JUSTIFY"><BR>
Other Commercial Disputes</P>
</B>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is engaged in disputes with several suppliers, customers and distributors regarding certain obligations with respect to contracts under which the Company obtains raw materials and under which the Company supplies finished products.  Given the fact that these disputes will most probably be resolved over more than one year, management does not believe that the disputes in the aggregate will be material to the Company's financial position. However, they could be material to the Company's results of operations or cash flows in the period in which resolution occurs.</P>
</FONT><P ALIGN="JUSTIFY"></P>
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any further responsibility for substantially all of the material contingent liabilities related to the Generics Business have has been transferred to Actavis or entities owned by Actavis; subject to certain representations or warranties made by the Company to Actavis as a part of the transaction to the extent such representations and warranties were incorrect.  In addition, the Company has retained certain specified liabilities which the Company believes are not material to the Company and, it is possible that the Company may be held responsible for certain liabilities of the Generic Business transferred to Actavis in the event Actavis fails to or is unable to satisfy such liabilities.</P>
<P ALIGN="JUSTIFY"> </P>
<B><P ALIGN="JUSTIFY">Other Litigation</P>
</B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and its subsidiaries are, from time to time, involved in other litigation arising out of the ordinary course of business.  It is the view of management, after consultation with counsel, that the ultimate resolution of all other pending suits on an individual basis should not have a material adverse effect on the consolidated financial position, results of operations of the Company or cash flows of the Company.</P>
<B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 4. Submission of Matters to a Vote of Security Holders</P>
</B><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.</P>
</FONT><FONT FACE="Courier New" SIZE=3>
<P>&nbsp;</P>
</FONT><B><P>&nbsp;</P>
<U><FONT SIZE=3><P ALIGN="CENTER">PART II</U><BR>
</P>
<P ALIGN="JUSTIFY">Item 5.&nbsp;&nbsp;Market for Registrant's Common Equity and Related Stockholder Matters</P>
</B><U>
<P>Market Information</U><BR>
</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;The Company's Class A Common Stock is listed on the New York Stock Exchange ("NYSE"). Information concerning the 2005 and 2004 sales prices of the Company's Class A Common Stock is set forth in the table below.  </P>
</FONT><P ALIGN="JUSTIFY"></P>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=444>
<TR><TD WIDTH="36%" VALIGN="TOP" HEIGHT=18><P></P></TD>
<TD WIDTH="64%" VALIGN="TOP" COLSPAN=4 HEIGHT=18>
<B><U><FONT SIZE=3><P ALIGN="CENTER">Stock Trading Price</B></U></FONT></TD>
</TR>
<TR><TD WIDTH="36%" VALIGN="TOP" HEIGHT=18><P></P></TD>
<TD WIDTH="30%" VALIGN="TOP" COLSPAN=2 HEIGHT=18>
<B><U><FONT SIZE=3><P ALIGN="CENTER">2005</B></U></FONT></TD>
<TD WIDTH="34%" VALIGN="TOP" COLSPAN=2 HEIGHT=18>
<B><U><FONT SIZE=3><P ALIGN="CENTER">2004</B></U></FONT></TD>
</TR>
<TR><TD WIDTH="36%" VALIGN="TOP" HEIGHT=18>
<B><FONT SIZE=3><P ALIGN="JUSTIFY">Quarter</B></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=18>
<B><U><FONT SIZE=3><P ALIGN="CENTER">High</B></U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=18>
<B><U><FONT SIZE=3><P ALIGN="CENTER">Low</B></U></FONT></TD>
<TD WIDTH="19%" VALIGN="TOP" HEIGHT=18>
<B><U><FONT SIZE=3><P ALIGN="CENTER">High</B></U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=18>
<B><U><FONT SIZE=3><P ALIGN="CENTER">Low</B></U></FONT></TD>
</TR>
<TR><TD WIDTH="36%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="JUSTIFY">First</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">$16.62</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">$12.32</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">$22.49</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">$18.73</FONT></TD>
</TR>
<TR><TD WIDTH="36%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="JUSTIFY">Second</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">$14.69</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">$9.44</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">$24.00</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">$18.90</FONT></TD>
</TR>
<TR><TD WIDTH="36%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="JUSTIFY">Third</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">$27.36</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">$13.77</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">$20.17</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">$12.43</FONT></TD>
</TR>
<TR><TD WIDTH="36%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="JUSTIFY">Fourth</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">$30.57</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">$23.73</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">$19.85</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">$14.76</FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;As of December 31, 2005 and March 1, 2006 the Company's stock closing price was $28.51 and $30.88 respectively.</P>

<U><P ALIGN="JUSTIFY">Holders</P>
</U><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;As of March 1, 2006, there were 937 holders of record of the Company's Class A Common Stock and A.L. Industrier held all of the Company's Class B Common Stock.  Record holders of the Class A Common Stock include Cede &amp; Co., a clearing agency which held approximately 97.15% of the outstanding Class A Common Stock as a nominee.</P>
</FONT><U>
<FONT SIZE=3><P ALIGN="JUSTIFY">Dividends</P>
</U><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;The Company has declared consecutive quarterly cash dividends on its Class A and Class B Common Stock beginning in the third quarter of 1984.  Dividends per share in 2005 and 2004 were $0.045 per quarter or $0.18 annually.</P>
</FONT><P ALIGN="JUSTIFY"></P>
<B><FONT SIZE=3><P>Equity Compensation Plan Information</P>

</B><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information as of December 31, 2005 with respect to Alpharma's common shares issuable under our equity compensation plans:</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=638>
<TR><TD WIDTH="38%" VALIGN="TOP">
<B><U><FONT SIZE=1><P><BR>
<BR>
<BR>
<BR>
Plan Category</B></U></FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<B><FONT SIZE=1><P ALIGN="CENTER"><BR>
<BR>
Number of securities to be<BR>
 issued upon exercise of<BR>
 outstanding options,<BR>
<U> warrant and rights</B></U></FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<B><FONT SIZE=1><P ALIGN="CENTER"><BR>
<BR>
Weighted-average<BR>
 exercise price of<BR>
 outstanding options,<BR>
<U> warrants and rights</B></U></FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<B><FONT SIZE=1><P ALIGN="CENTER">Number of securities<BR>
 remaining available for<BR>
 future issuance under<BR>
 equity compensation plans<BR>
 (excluding securities<BR>
<U> reflected in column (a))</B></U></FONT></TD>
</TR>
<TR><TD WIDTH="38%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="CENTER">(a)</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="38%" VALIGN="TOP">
<FONT SIZE=1><P>Equity compensation plans approved by <BR>
&nbsp;&nbsp;&nbsp;security holders</FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<B><FONT SIZE=1><P ALIGN="RIGHT"><BR>
   2,426,993</B></FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<B><FONT SIZE=1><P ALIGN="RIGHT"><BR>
$21.90</B></FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<B><FONT SIZE=1><P ALIGN="RIGHT"><BR>
    3,153,425</B></FONT></TD>
</TR>
<TR><TD WIDTH="38%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="38%" VALIGN="TOP">
<FONT SIZE=1><P>Equity compensation plans not approved by<BR>
&nbsp;&nbsp;&nbsp;securities holders</FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<B><FONT SIZE=1><P ALIGN="RIGHT"><BR>
None</B></FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<B><FONT SIZE=1><P ALIGN="RIGHT"><BR>
None</B></FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<B><FONT SIZE=1><P ALIGN="RIGHT"><BR>
None</B></FONT></TD>
</TR>
<TR><TD WIDTH="38%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="38%" VALIGN="TOP">
<FONT SIZE=1><P>Total</FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<B><FONT SIZE=1><P ALIGN="RIGHT">2,426,993</B></FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<B><FONT SIZE=1><P ALIGN="RIGHT">$21.90</B></FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<B><FONT SIZE=1><P ALIGN="RIGHT">3,153,425</B></FONT></TD>
</TR>
</TABLE>

<B><P ALIGN="JUSTIFY"></P>
</B><FONT SIZE=3><P ALIGN="JUSTIFY">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The number of shares included in the table represent shares from the following equity compensation plans which have been approved by the Company's shareholders: (i) Alpharma Inc. 1997 Stock Option and Appreciation Right Plan, (ii) Alpharma Inc. Non-Employee Director Option Plan and (iii) Alpharma Inc. 2003 Omnibus Incentive Compensation Plan.  The table does not include shares to be issued under the Company's Employee Stock Purchase Plan which was approved by the Company's shareholders in 1991.  The Plan was not included because there are no limitations on the number of shares that may be purchased under the plan.  The Plan entitles employees to contribute up to 4% of his/her basic pay into the plan for the purchase of shares of the Company's Class A Common Stock.  The Company contributes to the plan an amount equal to 50% of each participating employee's contributions.  </P>

<B><P ALIGN="JUSTIFY">Item 6.&nbsp;&nbsp;<U>Selected Financial Data</P>
<P ALIGN="JUSTIFY"><BR>
</B></U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a summary of selected financial data for the Company and its subsidiaries.  The data for each of the three years in the period ended December 31, 2005 have been derived from, and all data should be read in conjunction with, the audited consolidated financial statements of the Company, included in Item 8 of the Report.  On December 19, 2005, the Company sold its Generics Business (see Note 3) and, as of December 31, 2005, had commenced a process to sell its ParMed business.  Both of these businesses are included in Discontinued Operations.  The following selected financial data is presented for continuing operations only. All amounts are in thousands, except per share data.</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=678>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<B><FONT SIZE=3><P>&nbsp;</B></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=16>
<B><FONT SIZE=3><P>&nbsp;</B></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=16>
<B><U><FONT SIZE=2><P ALIGN="CENTER">2005 </B></U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=16>
<B><U><FONT SIZE=2><P ALIGN="CENTER">2004 (1)</B></U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=16>
<B><U><FONT SIZE=2><P ALIGN="CENTER">2003(2) </B></U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=16>
<B><U><FONT SIZE=2><P ALIGN="CENTER">2002(3) </B></U></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=16>
<B><U><FONT SIZE=2><P ALIGN="CENTER">2001 </B></U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=4>
<B><FONT SIZE=3><P>&nbsp;</B></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=4>
<B><FONT SIZE=3><P>&nbsp;</B></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=4>
<B><FONT SIZE=3><P>&nbsp;</B></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=4>
<B><FONT SIZE=3><P>&nbsp;</B></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=4>
<B><FONT SIZE=3><P>&nbsp;</B></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=4>
<B><FONT SIZE=3><P>&nbsp;</B></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Total revenues</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$553,617</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$513,329</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$479,467 </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$442,706 </FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$404,253</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Cost of sales</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">   217,363</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">218,712 </U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">210,298 </U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">218,242 </U></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">225,976</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>   Gross profit</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">336,254</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">294,617 </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">269,169 </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">224,464 </FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">178,277</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Selling, general and administrative </FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">213,323</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">195,054 </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">174,379 </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">154,399 </FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">116,088</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Research and development</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">26,936</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">25,431 </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">21,837 </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">25,752 </FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">24,613</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Asset impairments and other</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">1,184</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">11,110 </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">4,091 </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">89,112 </FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">3,165</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Goodwill impairment</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">               -</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">               -</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">              -</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">  66,011</U></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">              -</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>   Operating income (loss)</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">94,811</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">63,022 </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">68,862 </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">(110,810)</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">34,411</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<B><FONT SIZE=2><P>&nbsp;</B></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Interest expense &amp; amortization of debt<BR>
&nbsp;&nbsp;&nbsp;issuance costs</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
(49,135)</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">(58,762)</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">(63,417)</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">(76,894)</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">(51,318)</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Loss on extinguishment of debt</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">(7,989)</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">(2,795)</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">(29,100)</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">(52,929)</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">-</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Other income (expense), net</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">6,091</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">1,238 </U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">     2,610 </U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">(2,144)</U></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">(13,577)</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=33>
<FONT SIZE=2><P>Income (loss) from continuing operations<BR>
&nbsp;&nbsp;&nbsp;before&nbsp;provision  for income taxes</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=33>
<FONT SIZE=2><P ALIGN="RIGHT">43,778</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=33>
<FONT SIZE=2><P ALIGN="RIGHT">2,703 </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=33>
<FONT SIZE=2><P ALIGN="RIGHT">(21,045)</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=33>
<FONT SIZE=2><P ALIGN="RIGHT">(242,777)</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=33>
<FONT SIZE=2><P ALIGN="RIGHT">(30,484)</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=9>
<FONT SIZE=2><P>Provision (benefit) for income taxes</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=9>
<U><FONT SIZE=2><P ALIGN="RIGHT">(18,398)</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=9>
<U><FONT SIZE=2><P ALIGN="RIGHT">49,466 </U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=9>
<U><FONT SIZE=2><P ALIGN="RIGHT">(11,416)</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=9>
<U><FONT SIZE=2><P ALIGN="RIGHT">94,477</U></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=9>
<U><FONT SIZE=2><P ALIGN="RIGHT">14,070</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" COLSPAN=2 HEIGHT=18>
<FONT SIZE=2><P>Net income (loss) from continuing operations</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">$<U>62,176</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">$<U>(46,763)</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">$<U> (9,629) </U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18>
<U><FONT SIZE=2><P ALIGN="RIGHT">$(337,254)</U></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<U><FONT SIZE=2><P ALIGN="RIGHT">$(44,554)</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" COLSPAN=2 HEIGHT=18><P></P></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18><P></P></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18><P></P></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" COLSPAN=2 HEIGHT=18>
<FONT SIZE=2><P>Earnings (loss) from continuing operations per common share:</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18><P></P></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18><P></P></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" COLSPAN=2 HEIGHT=18>
<FONT SIZE=2><P>  Basic</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18>
<U><FONT SIZE=2><P ALIGN="RIGHT">$1.18</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18>
<U><FONT SIZE=2><P ALIGN="RIGHT">$(0.90)</U>&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18>
<U><FONT SIZE=2><P ALIGN="RIGHT">$(0.19)</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18>
<U><FONT SIZE=2><P ALIGN="RIGHT">$(6.77)</U></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<U><FONT SIZE=2><P ALIGN="RIGHT">$(1.08)</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" COLSPAN=2 HEIGHT=18>
<FONT SIZE=2><P>  Diluted</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18>
<U><FONT SIZE=2><P ALIGN="RIGHT">$1.17</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18>
<U><FONT SIZE=2><P ALIGN="RIGHT">$(0.90)&nbsp;</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18>
<U><FONT SIZE=2><P ALIGN="RIGHT">$(0.19</U>)</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18>
<U><FONT SIZE=2><P ALIGN="RIGHT">$(6.77)&nbsp;</U></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<U><FONT SIZE=2><P ALIGN="RIGHT">$(1.08)</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" COLSPAN=2 HEIGHT=18><P></P></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 HEIGHT=18><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 HEIGHT=18><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 HEIGHT=18><P></P></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" HEIGHT=18><P></P></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" COLSPAN=2 HEIGHT=18>
<FONT SIZE=2><P>Dividend per common share</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18>
<U><FONT SIZE=2><P ALIGN="RIGHT">$0.18</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 HEIGHT=18>
<U><FONT SIZE=2><P ALIGN="RIGHT">$0.18</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 HEIGHT=18>
<U><FONT SIZE=2><P ALIGN="RIGHT">$0.18</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 HEIGHT=18>
<U><FONT SIZE=2><P ALIGN="RIGHT">$0.18</U></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" HEIGHT=18>
<U><FONT SIZE=2><P ALIGN="RIGHT">$0.18</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" COLSPAN=2 HEIGHT=18><P></P></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=18><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 HEIGHT=18><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 HEIGHT=18><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 HEIGHT=18><P></P></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" HEIGHT=18><P></P></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<B><FONT SIZE=2>
<P>&nbsp;</P>
<P>Balance Sheet Information</B></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<B><U><FONT SIZE=2><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">2005 </B></U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<B><U><FONT SIZE=2><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">2004</B></U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<B><U><FONT SIZE=2><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">2003</B></U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<B><U><FONT SIZE=2><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">2002 </B></U></FONT></TD>
<TD WIDTH="15%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<B><U><FONT SIZE=2><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">2001 </B></U></FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Total assets</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$1,623,383</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$2,039,612</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$2,342,147</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$2,312,438</FONT></TD>
<TD WIDTH="15%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$2,397,194</FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Cash and cash equivalents</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">800,010</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">105,212</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">58,623</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">23,872</FONT></TD>
<TD WIDTH="15%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">14,735</FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Total debt</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">416,686</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">701,735</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">817,156</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">895,858</FONT></TD>
<TD WIDTH="15%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">1,060,592</FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Total stockholders' equity</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">918,078</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">883,642</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">1,130,736</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">1,009,851</FONT></TD>
<TD WIDTH="15%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">888,503</FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3>
<OL>

<LI>Includes a $10.0 million charge to write down the carrying value of Aquatics assets to fair value.</LI>
<P ALIGN="JUSTIFY"><LI>Includes loss resulting from the extinguishment of $200 million 12 1/2% notes and the related issuance of $220 million of 8 5/8% notes.  The extinguishment resulted in the expensing of $22.2 million in placement fees and the recognition of $6.2 million of deferred debt expense.</LI></P>
<LI>Includes charges related to de-leveraging activities of $51.1 million, charges for reorganization, refocus and other actions of $49.0 million, and impairment charges of $103.1 million.</LI></OL>


<P>&nbsp;</P>
<B><P>Item 7.&nbsp;&nbsp;<U>Management's Discussion and Analysis of Financial Conditions</B> <B>and Results of Operations</P>
</B>
<P ALIGN="CENTER">(In millions, except per share data)</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">Alpharma Entities Defined</B> </P>
</U><P ALIGN="JUSTIFY"></P>
<B><P>Alpharma's business segments are defined as follows:</P>
</B></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=317>
<TR><TD WIDTH="18%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=3><P>BP</FONT></TD>
<TD WIDTH="7%" VALIGN="TOP" HEIGHT=14><P></P></TD>
<TD WIDTH="75%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=3><P>U.S. Branded Pharmaceuticals</FONT></TD>
</TR>
<TR><TD WIDTH="18%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=3><P>API</FONT></TD>
<TD WIDTH="7%" VALIGN="TOP" HEIGHT=14><P></P></TD>
<TD WIDTH="75%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=3><P>Active Pharmaceutical Ingredients</FONT></TD>
</TR>
<TR><TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P>AH</FONT></TD>
<TD WIDTH="7%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="75%" VALIGN="TOP">
<FONT SIZE=3><P>Animal Health</FONT></TD>
</TR>
</TABLE>
</P>

<B><U><P ALIGN="JUSTIFY"></P>
<FONT SIZE=3><P ALIGN="JUSTIFY">Overview<BR>
</B></U><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is a global specialty pharmaceutical company that develops, manufactures and markets pharmaceutical products for humans and animals.  Alpharma's businesses are organized in three business units.  The Company markets one branded pharmaceutical prescription product that is contract manufactured by a third party, a pain medication sold under the trademark KADIAN, in the U.S.  The Company manufactures and markets a line of fermentation-based active pharmaceutical ingredients ("APIs") that are used primarily by third parties in the manufacturing of generic and branded pharmaceutical products.  It also manufactures and markets animal health products in over 80 formulations and dosage forms.  The Company presently conducts business in more than 60 countries and has approximately 1,400 employees in over 19 countries.  </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December 19, 2005, the Company sold its world-wide human generic pharmaceutical business (the "Generics Business") to Actavis Group hf (see note 3 to the consolidated financial statements) as part of an overall plan to re-focus its business strategy.  The Generics Business is classified as a discontinued operation in the consolidated financial statements.  The sale of the Generics business on December 19, 2005 did not include ParMed Pharmaceuticals, Inc. ("ParMed"), the Company's telemarketing distributor of human generic pharmaceutical products.  On March 8, 2006, the Company reached a definitive agreement to sell ParMed for $40.1 million in cash.  The sale has been approved by the Company's Board of Directors and is expected to close in the first quarter of 2006. </P>
<P ALIGN="JUSTIFY"></P>
<I><P ALIGN="JUSTIFY">The main factors affecting the Branded Pharmaceuticals Products (BP) business are</I>:</P>
<P ALIGN="JUSTIFY"><BR>
<FONT FACE="Symbol">&#183;</FONT>
&nbsp;&nbsp;&nbsp;BP currently markets in the U.S. one prescription pain product, KADIAN, via a dedicated sales force.  The product is sole-sourced under a toll manufacturing agreement with Purepac, a former subsidiary of the Company purchased by Actavis Group hf ("Actavis") as part of its acquisition of the Company's Generics Business.  BP realizes significant gross profit margins on its sales of KADIAN; but competes in a highly competitive market, and is subject to potential challenges from generic equivalents.  The Company's business plan includes significant investments in research and development spending associated with the development of a next-generation pain product with abuse deterrent characteristics.  BP has experienced significantly improved profitability as a result of product prescription growth driven from sales force expansion and a new marketing campaign.</P>
<I><P ALIGN="JUSTIFY"><BR>
The main factors affecting the Active Pharmaceutical Ingredients (API) business are:</P>
</I><P ALIGN="JUSTIFY"><BR>
<FONT FACE="Symbol">&#183;</FONT>
&nbsp;&nbsp;&nbsp;API markets globally primarily 10 antibiotic API's that are generally used by third-parties in the manufacture of finished dose pharmaceutical products.  API realizes strong gross profit margins and has experienced and expects continuing increased global competition on its products and associated pricing pressure. </P>
<P ALIGN="JUSTIFY"><BR>
<I>The main factors affecting the Animal Health (AH) business are:</P>
</I><P ALIGN="JUSTIFY"><BR>
<FONT FACE="Symbol">&#183;</FONT>
&nbsp;&nbsp;&nbsp;The Company's Animal Health business is a global leader in the development, registration, manufacturing and marketing of medicated feed additives ("MFAs") and water soluble vitamin type substances for food producing animals including poultry, cattle, and swine.  Agricultural markets have historically had low growth rates.  In addition, demand for the Company's products has been and could be reduced by bans or restrictions on the use of antibiotics used in food-producing animals.   AH has significantly increased its profitability through enhanced market positions and cost-reduction and other productivity improvement initiatives. </P>
<P ALIGN="JUSTIFY"><BR>
<I>The Company as a whole:</P>
<P ALIGN="JUSTIFY"><BR>
</I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company sold its Generics Business to the Actavis Group hf for $810 million on December 19, 2005. The cash flow generated throughout 2005, including the net proceeds from this transaction, has provided the Company with sufficient cash to repay all of its outstanding debt.  At December 31, 2005, the Company had cash and cash equivalents amounting to $800.0 million and outstanding debt totaling $416.7 million.  This debt included the Company's 8.625% Senior Notes (the "Senior Notes") due in 2011 ($220.0 million) and its 3% Convertible Senior Subordinated Notes (the "Convertible Notes") due in 2006 ($160.9 million); both of which required a thirty day notification period prior to redemption.  On December 23, 2005, the Company gave notice to the Trustee's under both the Senior Notes and the Convertible Notes that it was irrevocably electing to redeem all such notes in accordance with the terms of the respective note indentures.  In January 2006, the Company repaid all of its
 outstanding debt, including accrued interest and call premiums of $23.7 million. </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The sale of the Generics business in December 2005, culminated a four-year period where the Company focused on de-leveraging its balance sheet with free cash flow generated through operational reorganizations and efficiencies, working capital reductions, and capital expenditure control.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following summarizes significant events and transactions for the past three years:</P>
<P ALIGN="JUSTIFY"></P>
<B><U><P ALIGN="JUSTIFY">2005</P>
<P ALIGN="JUSTIFY"></P>
</B></U><P ALIGN="JUSTIFY">&#9679;&nbsp;&nbsp;&nbsp;In December 2005, the Company sold its global Generics Business to Actavis Group hf for $810 million.</P>
<P ALIGN="JUSTIFY">&#9679;&nbsp;&nbsp;&nbsp;In December 2005, the Company gave notice to the Trustee's under both the Senior Notes and the Convertible Notes that it was irrevocably electing to redeem all such notes in accordance with the terms of the respective note indentures.  </P>
<P ALIGN="JUSTIFY">&#9679;&nbsp;&nbsp;&nbsp;During the fourth quarter of 2005, the Company commenced a program to sell its ParMed generic pharmaceutical telemarketing distribution business. </P>
<P ALIGN="JUSTIFY">&#9679;&nbsp;&nbsp;&nbsp;In October 2005, the Company entered into a new $210 million US asset-based loan agreement.  Proceeds from this new loan facility were used to pay off and cancel all outstanding amounts due under the Company's 2001 U.S. Bank Credit Facility.</P>
<P ALIGN="JUSTIFY">&#9679;&nbsp;&nbsp;&nbsp;In the fourth quarter, the Company reversed its deferred tax valuation allowance given its current and expected profitability, resulting in a benefit of $52.1 million.</P>
<P ALIGN="JUSTIFY">&#9679;&nbsp;&nbsp;&nbsp;The Company repatriated $497 million of cash in 2005 under the provisions of the American Jobs Creation Act of 2004.  The tax impact of repatriating this amount was approximately $28.6 million. </P>
<P ALIGN="JUSTIFY"></P>
<B><U><P ALIGN="JUSTIFY">2004</P>
</B></U><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9679;&nbsp;&nbsp;&nbsp;The Company purchased the outstanding 50% of Wynco LLC ("Wynco") equity subsidiary and subsequently sold the entire company within the first quarter of 2004.</P>
<P ALIGN="JUSTIFY">&#9679;&nbsp;&nbsp;&nbsp;In the first half of 2004, the Company prepaid $75.0 million of the 2001 U.S. Bank Credit Facility's term loans, $32.0 million of mortgage notes payable in Norwegian Kroner and $24.5 million of 5.75% convertible subordinated notes.</P>
<P ALIGN="JUSTIFY">&#9679;&nbsp;&nbsp;&nbsp;In May and August 2004 the Company amended the 2001 U.S. Bank Credit Facility to allow flexibility in complying with the covenants and permit the repayment of the mortgage notes and the convertible subordinated notes.</P>
<P ALIGN="JUSTIFY">&#9679;&nbsp;&nbsp;&nbsp;The Company sold its Aquatic Animal Health Group ("Aquatic") in July of 2004 and recorded a pretax loss of approximately $10.0 million. </P>
<P ALIGN="JUSTIFY">&#9679;&nbsp;&nbsp;&nbsp;In the fourth quarter of 2004, the Company adjusted its deferred tax valuation, primarily to set up a full valuation allowance for all U.S. deferred taxes.  This resulted in a charge of $59.5 million.</P>
<U><P ALIGN="JUSTIFY"><BR>
<B>2003</P>
</B></U><P ALIGN="JUSTIFY"><BR>
<FONT FACE="Symbol">&#183;</FONT>
&nbsp;&nbsp;&nbsp;In the first quarter, the Company prepaid $35.0 million of the 2001 U.S. Credit Facility's term loans.</P>
<P ALIGN="JUSTIFY"><FONT FACE="Symbol">&#183;</FONT>
&nbsp;&nbsp;&nbsp;In the second quarter of 2003, the Company sold $220.0 million aggregate principal amount of 8 5/8% Senior Notes due 2011. The proceeds of the offering, after deducting fees and expenses, were $197.0 million. These proceeds, together with funds available from other sources, were used to repay existing 12.5% Senior Subordinated Notes. The fees paid to the initial purchasers of the Senior Subordinated Notes of $22.2 million were made pursuant to arrangements originally entered into in December 2001. The transaction was accounted for as an extinguishment of the existing Senior Subordinated Notes. As a result, both the fees of $22.2 million paid in April 2003 and the unamortized loan costs of $6.2 million associated with the Senior Subordinated Notes were expensed in the second quarter 2003. </P>
<P ALIGN="JUSTIFY"><FONT FACE="Symbol">&#183;</FONT>
&nbsp;&nbsp;&nbsp;In the third quarter of 2003, the Company closed the sale of its French subsidiary, Alpharma SAS ("SAS") for approximately $6.0 million. The sale resulted in a pre-tax loss of $4.0 million. The operations of SAS have been reclassified as a discontinued operation. Prior periods have been reclassified to reflect this presentation. </P>
<P ALIGN="JUSTIFY"><FONT FACE="Symbol">&#183;</FONT>
&nbsp;&nbsp;&nbsp;In the fourth quarter of 2003, the Company had a program to reduce its workforce which resulted in a charge of $4.1 million.  Additionally, the Company amended its 2001 U.S. Credit Facility to allow for certain asset sales, permit exclusions for restructuring (including the fourth quarter severance) and refinancing charges from EBITDA and amended certain leverage ratios to delay the timing of more restrictive covenant requirements.</P>
</FONT><B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Results of Continuing Operations 2005 vs. 2004 </P>
</B><I><P ALIGN="JUSTIFY">(All comparisons of results of operations refer to continuing operations)</P>
</I><P ALIGN="JUSTIFY"></P>
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenue increased $40.3 million or 7.9% for the year ended December 31, 2005 compared to 2004.  Foreign exchange increased revenues by approximately $0.5 million or 0.1%.  2004 revenues included $26.2 million related to the divested Wynco and Aquatics operations.  Excluding the Wynco and Aquatic results and foreign exchange, revenues increased approximately $66.1 million or 13.5%.  Operating income was $94.8 million in 2005 compared to $63.0 million in 2004.  2004 operating income included the results of Wynco and Aquatics.  Excluding these operations, operating income increased $21.4 million, or 29.2% due to improvements in the BP and AH businesses which offset lower year-over-year operating income in API due to reduced pricing.  Diluted earnings per share was $1.17 in 2005 compared to a loss of $0.90 in 2004. 2005 results include the reversal of a deferred tax valuation allowance of $52.1 million ($0.98 earnings per share), taxes of $28.6 
million on the repatriation of approximately $497 million of cash dividends from controlled foreign corporations and pre-tax charges of $8.0 million for extinguishment of debt, primarily related to the write-off of deferred loan costs resulting from the prepayment of debt.  2004 results include pre-tax charges of approximately $59.5 million ($1.13 loss per share) resulting from the establishment of a deferred tax valuation allowance and $2.8 million for extinguishment of debt. </P>
</FONT><P ALIGN="JUSTIFY"></P>
<FONT SIZE=3><P ALIGN="JUSTIFY">The following table sets forth revenues and operating income by segment:</P>
<P ALIGN="JUSTIFY"></P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=667>
<TR><TD WIDTH="39%" VALIGN="TOP" HEIGHT=17>
<B><FONT SIZE=3><P ALIGN="JUSTIFY"><BR>
Year Ended December 31,</B></FONT></TD>
<TD WIDTH="31%" VALIGN="TOP" COLSPAN=3 HEIGHT=17>
<B><FONT SIZE=3><P ALIGN="CENTER"><BR>
<U>Revenues</B></U></FONT></TD>
<TD WIDTH="30%" VALIGN="TOP" COLSPAN=3 HEIGHT=17>
<B><FONT SIZE=3><P ALIGN="CENTER">Operating<BR>
<U>Income (Loss)</B></U></FONT></TD>
</TR>
<TR><TD WIDTH="39%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17>
<B><U><FONT SIZE=3><P ALIGN="CENTER">2005</B></U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<B><FONT SIZE=3><P ALIGN="JUSTIFY">   <U>2004</B></U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<B><FONT SIZE=3><P ALIGN="CENTER">%</B></FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17>
<B><U><FONT SIZE=3><P ALIGN="CENTER">2005</B></U></FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17>
<B><FONT SIZE=3><P ALIGN="JUSTIFY">   <U>2004</B></U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=17>
<B><FONT SIZE=3><P ALIGN="CENTER">%</B></FONT></TD>
</TR>
<TR><TD WIDTH="39%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P>Branded Pharmaceuticals ("BP")</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P ALIGN="RIGHT">$101.6</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P ALIGN="RIGHT">       $62.4</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P ALIGN="RIGHT">62.8%</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P ALIGN="RIGHT">$23.6</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P ALIGN="RIGHT">     $6.5</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P ALIGN="RIGHT">263.1%</FONT></TD>
</TR>
<TR><TD WIDTH="39%" VALIGN="TOP" HEIGHT=13><P></P></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=13><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=13><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=13><P></P></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=13><P></P></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=13><P></P></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=13><P></P></TD>
</TR>
<TR><TD WIDTH="39%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P>Active Pharmaceutical Ingredients ("API")</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
138.4</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P ALIGN="RIGHT">  <BR>
 143.2</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
(3.4%)</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
52.4</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P ALIGN="RIGHT">   <BR>
72.8</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
(28.0%)</FONT></TD>
</TR>
<TR><TD WIDTH="39%" VALIGN="TOP" HEIGHT=13><P></P></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=13><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=13><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=13><P></P></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=13><P></P></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=13><P></P></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=13><P></P></TD>
</TR>
<TR><TD WIDTH="39%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P>Animal Health ("AH")-base</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">325.1</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">     288.4</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">12.7%</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">66.3</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">     35.2</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">88.4%</FONT></TD>
</TR>
<TR><TD WIDTH="39%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P>Aquatic Animal Health</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">-</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">         7.0</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">-</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">  (10.3)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="39%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P>Wynco </FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17>
<U><FONT SIZE=3><P ALIGN="RIGHT">         -</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<U><FONT SIZE=3><P ALIGN="RIGHT">    19.2</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17>
<U><FONT SIZE=3><P ALIGN="RIGHT">         -</U></FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17>
<U><FONT SIZE=3><P ALIGN="RIGHT">   (0.1)</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="39%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total AH</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">325.1</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">     314.6</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">3.3%</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">66.3</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">     24.8</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">167.3%</FONT></TD>
</TR>
<TR><TD WIDTH="39%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="39%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P>Unallocated and Eliminations</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17>
<U><FONT SIZE=3><P ALIGN="RIGHT">(11.5)</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<U><FONT SIZE=3><P ALIGN="RIGHT">   (6.9)</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">(66.7%)</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17>
<U><FONT SIZE=3><P ALIGN="RIGHT">(47.5)</U></FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17>
<U><FONT SIZE=3><P ALIGN="RIGHT">(41.1)</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">(15.6%)</FONT></TD>
</TR>
<TR><TD WIDTH="39%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="39%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=18>
<U><FONT SIZE=3><P ALIGN="RIGHT">$553.6</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=18>
<U><FONT SIZE=3><P ALIGN="RIGHT">$513.3</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">7.9%</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=18>
<U><FONT SIZE=3><P ALIGN="RIGHT">$94.8</U></FONT></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=18>
<U><FONT SIZE=3><P ALIGN="RIGHT">$63.0</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">50.5%</FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3>
<P ALIGN="JUSTIFY">The following summarizes revenues and operating income by segment:</P>
<B>
<P>Revenues</P>

</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BP revenues increased 62.8% on higher prices (24.2%) and volume gains (38.5%) attributable to product prescription growth driven from sales force expansions and a new marketing campaign.  </P>
<B>
</B></FONT><FONT FACE="CG Times (W1),Times New Roman"><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=3>Revenues in API declined 3.4% mainly as a result of reduced pricing (11.9%), principally on a major product in the U.S., partially offset by volume gains of 9.0%.  Translation of revenues into the U.S. dollar decreased API revenues by 0.5%.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AH revenues, excluding Wynco and Aquatic revenues in 2004, increased 12.7% due primarily to increased sales in the U.S. livestock market (7.8%) and in the European markets (2.0%).  The majority of AH plants are operating at or near capacity.  During the year, as a result of increased demand and capacity constraints, AH reduced supply of certain products to customers.</P>
<P ALIGN="JUSTIFY"></P>
<B><P>Gross Profit</P>

<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>On a Company-wide basis,<B> </B>gross profit increased $41.6 million in 2005 compared to 2004.  As a percentage of sales, overall gross profit was 60.7% in 2005, versus 57.4% in 2004.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The increase in gross margin dollars results primarily from higher sales volumes in BP and AH, combined with cost reductions achieved through supply chain and other process improvement initiatives, offset partially, by pricing decreases in API.</P>
<B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Operating Expenses</P>
<P ALIGN="JUSTIFY"></P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On a consolidated basis, selling, general and administrative expenses increased $18.3 million or 9.4% in 2005 compared to 2004.  Included in 2004, are Wynco and Aquatic expenses of $3.3 million and $2.1 million, respectively.  Excluding these costs, selling, general and administrative expenses increased $23.7 million due primarily to marketing campaigns and sales force expansions within BP ($15.0 million) and increased costs within the BP and API segments related to realigning the remaining businesses as a result of the disposal of the Generics Business ($5.3 million).  Foreign exchange also contributed $1.1 million to the year-over-year increase in selling, general and administrative expenses.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses increased $1.5 million in 2005 compared to 2004, which included Aquatic expenses of $2.4 million. Excluding these costs, research and development increased $3.9 million, due primarily to new product development in BP and API.</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">Asset Impairments and Other</P>
</B></FONT><P ALIGN="JUSTIFY"></P>
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2005 asset impairments and other was $1.2 million compared to 2004 asset impairments of $11.1 million, which included a $10.0 million charge to write down the carrying value of Aquatic assets to fair value, as well as an associated pension curtailment loss and other costs associated with the sale, and severance charges of $1.1 million, primarily incurred in API. </P>
<B><I>
</I><P>Operating Income (Loss)</P>
</B><P ALIGN="JUSTIFY"><BR>
<I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I>The increase/(decrease) in operating income can be summarized as follows:</P>
<P ALIGN="JUSTIFY"></P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=559>
<TR><TD WIDTH="38%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=5>
<B><U><FONT SIZE=3><P ALIGN="CENTER"><BR>
BP</B></U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=5>
<B><U><FONT SIZE=3><P ALIGN="CENTER"><BR>
API</B></U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=5>
<B><U><FONT SIZE=3><P ALIGN="CENTER"><BR>
AH</B></U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP" HEIGHT=5>
<B><FONT SIZE=3><P ALIGN="CENTER">Corporate/<BR>
<U>Unallocated</B></U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=5>
<B><U><FONT SIZE=3><P ALIGN="CENTER"><BR>
Total</B></U></FONT></TD>
</TR>
<TR><TD WIDTH="38%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P>2004 as reported</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$6.5</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$72.8</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$24.8</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$(41.1)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$63.0</FONT></TD>
</TR>
<TR><TD WIDTH="38%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P>Aquatic loss, primarily asset impairment</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
- --</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
- --</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
10.0</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
- --</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
10.0</FONT></TD>
</TR>
<TR><TD WIDTH="38%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P>Research and development</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">(2.4)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">(2.1)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">3.7</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">(0.7)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">(1.5)</FONT></TD>
</TR>
<TR><TD WIDTH="38%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P>Brand sales force expansion</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">(15.0)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">(15.0)</FONT></TD>
</TR>
<TR><TD WIDTH="38%" VALIGN="TOP" HEIGHT=75>
<FONT SIZE=3><P>Net margin improvement (decrease) due to volume, price, foreign exchange and expenses</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=75>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
34.5</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=75>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
(18.3)</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=75>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
27.8</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP" HEIGHT=75>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
(5.7)</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=75>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
38.3</U></FONT></TD>
</TR>
<TR><TD WIDTH="38%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P>2005 as reported</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>23.6</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>52.4</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>66.3</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>(47.5)</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>94.8</U></FONT></TD>
</TR>
</TABLE>

<I>
</I><B><FONT SIZE=3><P>Interest Expense and Amortization of Debt Issuance Costs</P>

<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;</B>Interest expense and amortization of debt issuance costs declined $9.6 million to $49.1 million in 2005 due primarily to decreased debt levels and lower amortization of debt issuance costs.</P>
<P ALIGN="JUSTIFY"></P>
<B><P>Loss on Extinguishment of Debt</P>

<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>2005 results include $8.0 million of expense, which resulted primarily from the write-off of deferred loan costs.  In 2005, the Company prepaid $267.4 million of bank term debt.  2004 results include $2.8 million of expense associated with the write-off of deferred loan costs.  In 2004, the Company prepaid $75.0 million of bank term debt and $32.0 million of mortgage notes payable and repaid $24.5 million of the 5.75% convertible Notes.</P>
<B><I><P ALIGN="JUSTIFY"></P>
</I><P>Other Income, Net</P>

<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Other income/(expense), net is detailed as follows:</P>
<P ALIGN="JUSTIFY"></P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=415>
<TR><TD WIDTH="73%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="27%" VALIGN="TOP" COLSPAN=2 HEIGHT=5>
<B><FONT SIZE=3><P ALIGN="CENTER">Year Ended<BR>
December 31, </B></FONT></TD>
</TR>
<TR><TD WIDTH="73%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=5>
<B><U><FONT SIZE=3><P ALIGN="RIGHT">2005</B></U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=5>
<B><U><FONT SIZE=3><P ALIGN="RIGHT">2004</B></U></FONT></TD>
</TR>
<TR><TD WIDTH="73%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P>Other income/(expense), net:</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=5><P></P></TD>
</TR>
<TR><TD WIDTH="73%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P>&nbsp;&nbsp;Interest income</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$1.4</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$0.8</FONT></TD>
</TR>
<TR><TD WIDTH="73%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P>&nbsp;&nbsp;Foreign exchange gains (losses), net</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">2.8</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">1.6</FONT></TD>
</TR>
<TR><TD WIDTH="73%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P>&nbsp;&nbsp;Loss on sale of Wynco</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">(1.5)</FONT></TD>
</TR>
<TR><TD WIDTH="73%" VALIGN="TOP" HEIGHT=15>
<FONT SIZE=3><P>&nbsp;&nbsp;Other, net</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=15>
<U><FONT SIZE=3><P ALIGN="RIGHT">  1.9</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=15>
<U><FONT SIZE=3><P ALIGN="RIGHT">0.3</U></FONT></TD>
</TR>
<TR><TD WIDTH="73%" VALIGN="TOP" HEIGHT=16><P></P></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>6.1</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>1.2</U></FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P ALIGN="JUSTIFY"></P>
<B><P>Tax Provision </P>
</B>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred tax assets are evaluated quarterly to assess the likelihood of realization which is ultimately dependent upon generating future taxable income prior to the expiration of the net operating loss carryforwards.  At December 31, 2004, the Company had recorded significant U.S. federal deferred tax assets for which it had provided a full valuation allowance given that it was not considered to be "more likely than not" that these deferred tax assets would be realized. At December 31, 2005, the Company made the decision to reverse the remaining valuation allowance because it now believes that it is "more likely than not" that these assets will be realized.  The Company's cash flow generated throughout 2005, including the net proceeds from the sale of the Generics Business, enabled the Company to pay off all of its domestic debt by January 23, 2006 which in turn, will serve to eliminate related interest expense, thereby increasing future profitability.  In add
ition, it is expected that the remaining domestic business segments, which have been profitable for the past three years, will continue to be profitable.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The tax provision in 2005 was a benefit of $18.4 million compared to pre-tax income of $43.8 million.  The net tax benefit is primarily attributable to the removal of a valuation allowance for net U.S. deferred tax assets, offset partially by tax expense of $28.6 million, resulting from repatriating $497 million of cash in 2005.  The tax provision in 2004 was an expense of $49.5 million compared to pre-tax income of $2.7 million, resulting mainly from the establishment of a valuation allowance for net U.S. deferred tax assets.  </P>
<P ALIGN="JUSTIFY"></P>
</FONT><B><P ALIGN="JUSTIFY">Results of Continuing Operations 2004 vs. 2003 </P>
</B><FONT SIZE=3><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenue increased 7.1% for the year ended December 31, 2004 compared to 2003. The inclusion of sales of Wynco, acquired in January 2004 and sold on March 30, 2004, increased revenues by approximately $19.2 million while Aquatic Animal Health Group ("Aquatic") revenues declined approximately $8.0 million. Excluding the Wynco acquisition and the 2004 and 2003 Aquatic results, revenues increased approximately 4.9%. Operating income was $63.0 million in 2004 compared to $68.9 million in 2003. Excluding losses in Aquatics and Wynco, operating income was essentially even with the prior year.  </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted earnings per share from continuing operations was a loss of $0.90 in 2004 compared to a loss of $0.19 in 2003. The loss in 2004 was a result of setting up a deferred tax valuation allowance of approximately $59.5 million or $1.14 per share.  2003 results include a pre-tax charge of $28.4 million or $0.33 per share for extinguishment of debt related to the April 2003 issuance of senior notes due 2011.</P>
<P ALIGN="JUSTIFY"><BR>
The following table sets forth revenues and operating income by segment:</P>
<P ALIGN="JUSTIFY"></P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=687>
<TR><TD WIDTH="37%" VALIGN="TOP" HEIGHT=17>
<B><FONT SIZE=3><P ALIGN="JUSTIFY"><BR>
Year Ended December 31,</B></FONT></TD>
<TD WIDTH="35%" VALIGN="TOP" COLSPAN=3 HEIGHT=17>
<B><FONT SIZE=3><P ALIGN="CENTER"><BR>
Revenues</B></FONT></TD>
<TD WIDTH="28%" VALIGN="TOP" COLSPAN=3 HEIGHT=17>
<B><FONT SIZE=3><P ALIGN="CENTER">Operating<BR>
Income (Loss)</B></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=17>
<B><U><FONT SIZE=3><P ALIGN="CENTER">2004</B></U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<B><U><FONT SIZE=3><P ALIGN="CENTER">2003</B></U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<B><U><FONT SIZE=3><P ALIGN="CENTER">%</B></U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<B><U><FONT SIZE=3><P ALIGN="CENTER">2004</B></U></FONT></TD>
<TD WIDTH="8%" VALIGN="TOP" HEIGHT=17>
<B><U><FONT SIZE=3><P ALIGN="CENTER">2003</B></U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=17>
<B><U><FONT SIZE=3><P ALIGN="CENTER">%</B></U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=2><P>Branded Pharmaceuticals ("BP")</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P ALIGN="RIGHT">  $  62.4</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P ALIGN="RIGHT"> $  65.3</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P ALIGN="RIGHT"> (4.4)%</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P ALIGN="RIGHT">   $  6.5</FONT></TD>
<TD WIDTH="8%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P ALIGN="RIGHT"> $22.0</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P ALIGN="RIGHT"> (70.5)%</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="8%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=5><P></P></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=2><P>Active Pharmaceutical Ingredients ( "API</FONT><FONT SIZE=3>")</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="RIGHT">  143.2</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="RIGHT">   124.5</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="RIGHT"> (15.0)%</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="RIGHT">    72.8</FONT></TD>
<TD WIDTH="8%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="RIGHT">   65.7</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="RIGHT"> 10.8%</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="8%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=5><P></P></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=2><P>Animal Health ("AH")-base</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">    288.4</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">    280.7</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">  2.7%</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">      35.2</FONT></TD>
<TD WIDTH="8%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">    24.4</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT"> 44.3%</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=2><P>Aquatics Animal Health</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">      7.0</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">      15.0</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">    (10.3)</FONT></TD>
<TD WIDTH="8%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">   (4.3)</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=2><P>Wynco Acquisition</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=17>
<U><FONT SIZE=3><P ALIGN="RIGHT">      19.2</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<U><FONT SIZE=3><P ALIGN="RIGHT">          --</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<U><FONT SIZE=3><P ALIGN="RIGHT">      (0.1)</U></FONT></TD>
<TD WIDTH="8%" VALIGN="TOP" HEIGHT=17>
<U><FONT SIZE=3><P ALIGN="RIGHT">       --</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total AH</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">    314.6</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">    295.7</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">  6.4%</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">      24.8</FONT></TD>
<TD WIDTH="8%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">    20.1</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT"> 23.4%</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="8%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=2><P>Unallocated and Eliminations</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=17>
<U><FONT SIZE=3><P ALIGN="RIGHT">     (6.9)</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<U><FONT SIZE=3><P ALIGN="RIGHT">      (6.0)</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">(15.0)%</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17>
<U><FONT SIZE=3><P ALIGN="RIGHT">    (41.1)</U></FONT></TD>
<TD WIDTH="8%" VALIGN="TOP" HEIGHT=17>
<U><FONT SIZE=3><P ALIGN="RIGHT"> (38.9)</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=17>
<FONT SIZE=3><P ALIGN="RIGHT">(5.7)%</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="8%" VALIGN="TOP" HEIGHT=17><P></P></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">   $513.3</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">    $479.5</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">  7.0%</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">     $63.0</FONT></TD>
<TD WIDTH="8%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">  $68.9</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">(8.6)%</FONT></TD>
</TR>
</TABLE>

<B><FONT SIZE=3>
</B><P ALIGN="JUSTIFY">The following summarizes revenues and operating income by segment:</P>
<B>
<P>Revenues</P>

</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenues of BP declined by $2.9 million or 4.4% reflecting mostly the discontinuation of a product ($1.5 million). KADIAN revenues were approximately the same reflecting a price increase offset by lower volume due to lowering wholesaler inventories.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;API revenues increased 15% mainly as a result of increased volume and prices, particularly of Vancomycin and other selected products. Translation of revenues into the U.S. dollar increased API revenues by 2%.</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AH revenues, excluding Wynco and Aquatic revenues, increased 2.7% compared to the prior year due to the positive impact of foreign exchange (2.3%) and higher volumes in the poultry market, which were offset by price declines due to continued competition and lower volumes in the livestock market.</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">Gross Profit</P>
</B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On a Company-wide basis gross profit increased $15.4 million in 2004 compared to 2003. As a percentage of sales, overall gross profit was 57.4% as reported in 2004 and 56.1% in 2003</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The increase in gross margin results primarily from positive currency effects, increased prices and volumes in API and lower costs and product mix in AHD. </P>
<P><BR>
<B>Operating Expenses</P>
</B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On a consolidated basis, selling, general and administrative expenses increased $20.7 million or 11.9% in 2004 compared to 2003.  The increase is primarily attributable to increases in BP's KADIAN sales force ($10.0 million), costs incurred to comply with Sarbanes/Oxley regulations ($6.4 million), Wynco expenses ($3.3 million) and higher restricted stock amortization and pension costs.</P>
<P ALIGN="JUSTIFY"> </P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses increased 16.5% in 2004 due primarily to planned increases in BP research.</P>
<P><BR>
<B>Asset Impairments and Other </P>
</B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2004 asset impairments and other was $11.1 million and consists of a charge to write down the carrying value of Aquatic assets ($10.0 million) to fair value, including an associated pension curtailment loss and other costs associated with the sale, and severance charges of $1.1 million, incurred in API ($0.8 million) and AH ($0.3 million).  2003 asset impairments and other consists of severance charges totaling $4.1 million, primarily incurred in AH.</P>
<P ALIGN="JUSTIFY"></P>
<B><P>Operating Income </P>
</B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The decrease in operating income can be analyzed as follows:</P>
<P ALIGN="JUSTIFY"></P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=577>
<TR><TD WIDTH="35%" VALIGN="TOP" HEIGHT=5>
<I><FONT FACE="CG Times (W1),Times New Roman"><P ALIGN="JUSTIFY">($ in millions)</I></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=5>
<B><U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
BP</B></U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=5>
<B><U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
API</B></U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=5>
<B><U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
AH</B></U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=5>
<B><FONT SIZE=3><P ALIGN="CENTER">Corporate/<U> Unallocated</B></U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=5>
<B><U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
Total</B></U></FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P>2003 as reported</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$22.0</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$65.7</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$20.1</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$(38.9)</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$68.9</FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P>2003 severance</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">0.3</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">3.8</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">4.1</FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P>2004 severance</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">(0.8)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">(0.3)</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">(1.1)</FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P>Aquatic loss, primarily asset impairment</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
- --</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
- --</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
(10.0)</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
- --</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
(10.0)</FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P>Research and development</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">(2.3)</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">(2.6)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">1.9</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">(0.6)</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">(3.6)</FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P>Brand sales force expansion</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">(10.0)</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">(10.0)</FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP" HEIGHT=75>
<FONT SIZE=3><P>Net margin improvement (decrease) due to volume, price, foreign exchange and expenses</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=75>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
<BR>
(3.2)</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=75>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
<BR>
10.2<BR>
</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=75>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
<BR>
9.3</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=75>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
<BR>
(1.6)</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=75>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
<BR>
14.7</U></FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P>2004 as reported</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>6.5</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>72.8</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>24.8</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>(41.1</U>)</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>63.0</U></FONT></TD>
</TR>
</TABLE>

<B><FONT SIZE=3><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Interest Expense and Amortization of Debt Issuance Costs</P>
</B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense and amortization of debt issuance costs decreased $4.7 million to $58.8 million in 2004 due to decreased debt levels, lower amortization of debt issuance costs and lower interest rates versus a year ago. </P>
<P><BR>
<B>Loss on Extinguishment of Debt</P>
</B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2004 results include $2.8 million of expense associated with the write-off of deferred loan costs compared with $29.1 million of expense in 2003 results. In 2004, the Company prepaid $75.0 million of bank term debt and $32.0 million of mortgage notes payable and repaid $24.5 million of the 5.75% convertibles.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2003 loss resulted primarily from the extinguishment of $200 million 12 1/2% notes and the related issuance of $220 million of 8 5/8% notes. The extinguishment resulted in the expensing of $22.2 million in placement fees and the write-off of $6.2 million of deferred debt expense.</P>
<P ALIGN="JUSTIFY"><BR>
<B>Other Income (Expense), Net</P>
</B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income (expense), net is detailed as follows:</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=541>
<TR><TD WIDTH="67%" VALIGN="TOP" HEIGHT=7><P></P></TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=2 HEIGHT=7>
<B><FONT SIZE=3><P ALIGN="CENTER">Year Ended December 31,</B></FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP" HEIGHT=7><P></P></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=7>
<B><U><FONT SIZE=3><P ALIGN="CENTER">2004</B></U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=7>
<B><U><FONT SIZE=3><P ALIGN="CENTER">2003</B></U></FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Other income (expense), net:</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;Interest income</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$0.8</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$    --</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;Foreign exchange gains (losses), net</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1.6</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2.4</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;Litigation/Insurance settlements </FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1.2</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P>   Income from Wynco, carried at equity</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">0.3</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;Loss on sale of Wynco</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">(1.5)</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=18>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;Other, net</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">0.3</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(1.3</U>)</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>1.2</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$2.6</U></FONT></TD>
</TR>
</TABLE>

<B><FONT SIZE=3><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Tax Provision</P>
</B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred tax assets are evaluated quarterly to assess the likelihood of realization, which is ultimately dependent upon generating future taxable income prior to the expiration of the net operating loss carryforwards.  The Company had recorded U.S. deferred tax assets for net operating losses for which it has provided a full valuation allowance as of December 31, 2004.  In this assessment, factors such as current and previous U.S. operating losses are given substantially more weight than the outlook for future profitability.  A full valuation allowance was determined to be appropriate at December 31, 2004 due to a change in certain available tax planning strategies and continued U.S. losses.  </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The tax provision in 2004 was an expense of $49.5 million compared to a pre-tax income of $2.7 million.  The provision results mainly from income tax charges of approximately $59.5 million recorded to establish a valuation allowance for net U.S. deferred tax assets.</P>
</FONT><P ALIGN="JUSTIFY"></P>
<B><U><FONT SIZE=3><P ALIGN="JUSTIFY">Inflation</P>
</B></U><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The effect of inflation on the Company's operations during 2005, 2004 and 2003 was not significant.</P>

<B><U><P>Critical Accounting Policies</P>
</B></U><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements are presented on the basis of accounting principles that are generally accepted in the United States of America. All professional accounting standards that are effective as of December 31, 2005, have been taken into consideration in preparing the consolidated financial statements.  The Company has chosen to highlight certain policies, which include estimates that it considers critical to the operations of the business and its consolidated financial statements:</P>
<P ALIGN="JUSTIFY"><BR>
<B>Revenue Recognition</P>
</B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;Revenues are recognized when title to products and risk of loss are transferred to customers.  The Company's subsidiaries have terms of FOB shipping point where title and risk of loss transfer on shipment.  Additional conditions for recognition of revenue are that collection of sales proceeds is reasonably assured and the Company has no further performance obligations.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales to certain customers require that the business remit discounts to either customers or governmental authorities in the form of rebates, discounts, promotional allowances, or other managed-care allowances.  Additionally, sales are generally made with a limited right of return under certain conditions. </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provisions for these discounts are reflected in the Consolidated Statements of Operations as a reduction of total revenues.  The reserve balances relative to these provisions in the accompanying Consolidated Balance Sheets totaled $21.0 million and $9.8 million, respectively, at December 31, 2005 and 2004, the majority of which is included in "Accounts payable and accrued expenses".  The Company continually monitors the adequacy of procedures used to estimate these deductions from revenue by comparison of estimated amounts to actual experience.</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">Goodwill and Intangible Assets</P>
</B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The values assigned to goodwill and intangibles, as well as their related useful lives, are subject to judgment and estimation by the Company.  In 2002, upon adoption of SFAS No. 142, the Company ceased amortization of goodwill and periodically reviews goodwill for impairment.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill and intangibles related to acquisitions are determined based on purchase price allocations. These allocations, including an assessment of estimated useful lives, have generally been performed by qualified independent appraisers using reasonable valuation methodologies. Valuation of intangible assets is generally based on the estimated cash flows related to those assets, while the value assigned to goodwill is the residual of the purchase price over the fair value of all identifiable assets acquired and liabilities assumed.  Useful lives are determined based on the expected future period of benefit of the asset, the assessment of which considers various characteristics of the asset, including historical cash flows.</P>
</FONT><B><P ALIGN="JUSTIFY"><BR>
<FONT SIZE=3>Asset Impairments</P>
</B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Long-lived assets, including plant and equipment, and other intangible assets are reviewed for impairment when events or circumstances indicate that a diminution in value may have occurred, based on a comparison of undiscounted future cash flows to the carrying amount of the goodwill or intangible asset. If the carrying amount exceeds undiscounted future cash flows, an impairment charge is recorded based on the difference between the carrying amount of the asset and its fair value.  Goodwill is reviewed periodically for impairment in accordance with SFAS No. 142.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The assessment of potential impairment for a particular asset or set of assets requires certain judgments and estimates by the Company, including the determination of an event indicating impairment; the future cash flows to be generated by the asset, including the estimated life of the asset and likelihood of alternative courses of action; the risk associated with those cash flows; and the Company's cost of capital or discount rate to be utilized. </P>
<P ALIGN="JUSTIFY"><BR>
<B>Research and Development ("R&amp;D"), Including In-Process R&amp;D ("IPR&amp;D")</P>
</B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's products are subject to regulation by governmental authorities, principally the Food and Drug Administration ("FDA") in the United States and equivalent authorities in international markets. Research and development expenses are charged to the consolidated statement of operations when incurred, as the Company considers that regulatory and other uncertainties inherent in the development of new products preclude it from capitalizing development costs.   </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With respect to completed acquisitions, acquired products or projects which have achieved technical feasibility, signified by FDA or comparable regulatory body approval, are capitalized as intangible assets because it is probable that the costs will give rise to future economic benefits.   Estimates of the values of these intangible assets are subject to the estimation process described in "Goodwill and Intangible Assets" above.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquired products or projects which have not achieved technical feasibility (i.e., regulatory approval) are charged to the statement of operations on the date of acquisition. In connection with its acquisitions, the Company generally utilizes independent appraisers in the determination of IPR&amp;D charges. The amount of this charge is determined based on a variety of factors including the estimated future cash flows of the product or project, the likelihood of future benefit from the product or project, and the level of risk associated with future research and development activities related to the product or project.   </P>
<B><P ALIGN="JUSTIFY"><BR>
Inventories</P>
</B>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories are valued at the lower of cost or market.  Cost is determined on a first-in, first-out basis for all inventories. The determination of market value involves assessment of numerous factors, including costs to dispose of inventory and estimated selling prices. Inventories determined to be damaged, obsolete, or otherwise unsaleable are written down to net realizable value.  </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company also purchases raw materials, and manufactures finished goods, for certain products prior to the product receiving regulatory approval. The Company reviews these inventories on a case-by-case basis, and records a write-down of the inventory if it becomes probable that regulatory approval will not be obtained or the inventory's cost will not be recoverable based on other factors.   </P>
<B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Employee Benefit Plans</P>
</B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company provides a range of benefits to employees and retired employees, including pension, post-retirement, post-employment and health care benefits. The Company records annual amounts relating to these plans based on calculations, which include various actuarial assumptions, including discount rates, assumed rates of return, compensation increases, turnover rates, and health care cost and trend rates. The Company reviews its actuarial assumptions on an annual basis and makes modifications to the assumptions based on current rates and trends when it is deemed appropriate to do so. The effect of the modifications is generally recorded and amortized over future periods. The Company believes that the assumptions utilized for recording its obligations under its plans are reasonable based on input from actuaries.</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">Litigation and Contingencies</P>
</B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is subject to litigation in the ordinary course of business, and also to certain other contingencies (see Item 3 of this Form 10-K and Note 15 to the Financial Statements).  The Company records legal fees and other expenses related to litigation and contingencies as incurred. Additionally, the Company assesses, in consultation with its counsel, the need to record liability for litigation and contingencies on a case by case basis.  Reserves are recorded when the Company, in consultation with counsel, determines that a loss related to a matter is both probable and reasonably estimable.   </P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">Income Taxes</P>
</B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company applies an asset and liability approach to accounting for income taxes.  Deferred tax liabilities and assets are recognized for the expected future tax consequences of temporary differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  The recoverability of deferred tax assets is dependent upon the Company's assessment that it is more likely than not that sufficient future taxable income will be generated in the relevant tax jurisdiction to utilize the deferred tax asset.  In the event the Company determines that future taxable income will not be sufficient to utilize the deferred tax asset, a valuation allowance is recorded.  </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred tax assets are evaluated quarterly to assess the likelihood of realization, which is ultimately dependent upon generating future taxable income prior to the expiration of the net operating loss carryforwards.  At December 31, 2004, the Company had recorded significant U.S. federal deferred tax assets for which it had provided a full valuation allowance given that it was not considered to be "more likely than not" that these deferred tax assets would be realized. At December 31, 2005, the Company made the decision to reverse the remaining valuation allowance because it now believes that it is "more likely than not" that these assets will be realized.  The Company's cash flow generated throughout 2005, including the net proceeds from the sale of the Generics Business, enabled the Company to pay off all of its domestic debt by January 23, 2006 which in turn, will serve to eliminate related interest expense, thereby increasing future profitability.  In addition, it is expec
ted that the remaining domestic business segments, which have been profitable for the past three years, will continue to be profitable.   </P>
</FONT><P ALIGN="JUSTIFY"><BR>
<B><FONT SIZE=3>Liquidity and Capital Resources</P>
</B><U><P ALIGN="JUSTIFY"><BR>
</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December 31, 2005, stockholders' equity was $918.1 million compared to $883.6 million and $1,130.7 million at December&nbsp;31, 2004, and 2003, respectively. The increase from 2004 resulted from the improvement in net income which included improved results of operations, the gain on disposal of the Generics Business, and reversal of a previously recorded deferred tax valuation allowance, partially offset by the effects of foreign currencies which weakened against the US dollar during the year.  The reduction in Stockholders' Equity in 2004 from 2003 resulted primarily from a large net loss in 2004 mostly related to the US Generics Business (discontinued operations), including a $260 million pre-tax goodwill impairment charge and the Company's establishment of a deferred tax valuation allowance.  Changes in Accumulated Other Comprehensive Income also affected changes in Stockholders' Equity due primarily to changes in foreign currencies versus the U.S. dollar.</P>
</FONT><FONT FACE="CG Times (W1),Times New Roman"><P ALIGN="JUSTIFY"><BR>
</FONT><B><FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>In 2005, 2004 and 2003, long-term debt was reduced by $304.7 million, $122.0 million and $65.0 million, respectively.  On October 26, 2005, the Company entered into a five-year, Senior Secured Credit Facility with Bank of America N.A. consisting of a $175 million asset-based, revolving loan facility and a $35 million term loan. The Company used $119.1 million of this facility to repay and retire the 2001 U. S. Bank Credit Facility.  The Senior Secured Credit Facility was subsequently fully paid down with the proceeds from the sale of the Generics Business. The asset-based revolving loan availability was reduced to $75 million and the term loan was cancelled. </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Senior Secured Credit Facility is secured by the accounts receivable, inventory and certain fixed assets of the U.S. subsidiaries of the Company. The amount that is available to the Company to be borrowed is determined monthly, based upon the calculation of a Borrowing Base. As of December 31, 2005, there were no amounts outstanding under this Facility.  The interest rate that the Company would pay on outstanding amounts is based upon a spread over LIBOR or Base Rate. The spread ranges between 1.25% to 2.00% over LIBOR and 0% to 0.50% over the Base Rate. The determination of the spread is based upon the amount of availability under the facility with a lower spread payable based upon greater availability. As long as the Company does not have average availability less than $15.0 million over a consecutive 10 day period, there are no financial covenants. In the event that the Company was to breach the availability threshold, the Company would be subject to a minimum Fixed Charg
e Coverage Ratio of 1:1. </P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P ALIGN="JUSTIFY">     Cash flow from operations in 2005 was $247.3 million compared to $186.2 million and $155.1 million in 2004 and 2003, respectively. The improvement in 2005 compared to 2004 was largely due to improved operating results and continued working capital management.  2005 cash flows reflect net income of $133.8 million, a non-operational gain on disposal of the Generics business of $35.3 million and the removal of a deferred tax valuation allowance (non-cash) of $52.1 million.  2004 cash flows reflect net losses of $314.7 million, including non-cash expenses mostly for goodwill impairment of $260.0 million and depreciation, amortization and interest accretion totaling $103.0 million and the establishment of a deferred tax valuation allowance (non-cash).  Operating cash flow in 2004 also benefited from improved working capital.  Cash flow from operations in 2003 was negatively impacted by $22.2 million in debt placement fees paid in connection with the issuance of Senior Notes in the second q
uarter.  In 2005, inventory balances decreased $71.8 million compared to 2004, primarily as a result of reduced inventories in the Generics Business.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance sheet amounts decreased as of December 31, 2005 compared to December 2004 in U.S. Dollars as the functional currencies of the Company's principal foreign subsidiaries, the Norwegian Kroner, Danish Krones, and Euro declined versus the U.S. Dollar by approximately 11%, 13%, and 13%, respectively.  The approximate decrease due to currency translation of selected captions was: accounts receivable $6.5 million, inventories $11.1 million, accounts payable and accrued expenses $8.1 million and property, plant and equipment of $20.6.  Of the $113.8 million change in accumulated other comprehensive income, $49.0 million related to the recognition of currency translation on the sale of Generics Business.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash flow from investing activities in 2005 totaled $760.3 million compared with a use in 2004 and 2003 of $42.6 million and $39.5 million, respectively.  The cash provided in 2005 was due to the sale of the Generics Business which was sold on December 19, 2005 for $810 million on a debt free and cash-free basis; however, included in the assets sold was $5.6 million of cash in China that was legally restricted from being distributed outside the country.  While the Company is expecting to receive a portion of these funds in 2006, it has not included any such amounts in the recorded gain from the sale of Generics Business.  In 2004 and 2003, the use of cash for capital expenditures accounted for the majority of cash utilization.  In 2005, the Company's capital expenditures, including expenditures for purchased intangibles, was $44.1 million.  In 2006, the Company plans to spend approximately $35.0 million on capital expenditures.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Strong cash flows from operations, along with proceeds from sale of Generics Business, allowed for the repayment of approximately $312 million of debt in 2005.  In addition, in December, the Company notified the Notes Trustees that, subject to a mandatory thirty-day pre-notification period, it would pay off its 8.625% Senior Notes and its 3% Convertible Senior Subordinated Notes on January 23, 2006 in the aggregate amount of $405.1 million, including call premium and accrued interest.  </P>
<P><BR>
</FONT><FONT FACE="CG Times (W1),Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=3>At December 31, 2005, the Company's contractual cash obligations (in millions) can be summarized as follows:</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=1 WIDTH=654>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=3><P><BR>
<U>Contractual Cash Commitments</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER"><BR>
Total</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">Less than<BR>
<U>1Year</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">1 - 3<BR>
<U>Years</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">4 - 5<BR>
<U>Years</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">More than 5<BR>
<U>Years</U></FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=3><P>Long Term Debt</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;Senior and other</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$243.2</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$243.2</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;Convertible subordinated*</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">161.9</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">161.9</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=3><P>Operating leases</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">6.5</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">3.6</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1.8</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">0.5</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">0.6</FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=3><P>Purchase obligations</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">75.5</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">24.7</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">32.5</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">12.1</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">6.2</U></FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=3><P>Total contractual cash commitments</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$487.1</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$433.4</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$34.3</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$12.6</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$6.8</U></FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT FACE="CG Times (W1),Times New Roman"><P>&nbsp;</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT FACE="CG Times (W1),Times New Roman"><P>&nbsp;</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT FACE="CG Times (W1),Times New Roman"><P>&nbsp;</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT FACE="CG Times (W1),Times New Roman"><P>&nbsp;</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT FACE="CG Times (W1),Times New Roman"><P>&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT FACE="CG Times (W1),Times New Roman"><P>&nbsp;</FONT></TD>
</TR>
</TABLE>

<FONT FACE="CG Times (W1),Times New Roman"><P>*</FONT><FONT SIZE=3>Can be settled in shares of the Company's Class A common stock at option of holder.</P>
<P ALIGN="JUSTIFY">     On December 23, 2005, the Company gave notice to the Trustees under both the Senior Notes and the Convertible Notes that it was irrevocably electing to redeem all such notes in accordance with the terms of the respective note indentures.  On January 23, 2006, the Company paid off the balance due on both the 8.625% Senior Notes and 06 Notes including principal and accrued interest in the amounts of $224.3 million and $161.9 million, respectively.  In addition, call premium of $18.9 million was paid in connection with the repayments.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">     Under the terms of certain business and product acquisition agreements, the Company may be required to make additional payments in future years upon the occurrence of specified events. Additionally, the Company has a number of conditional supply agreements which obligate the Company to purchase products or services from vendors based on Company forecasts which are updated on a regular basis and at prices subject to negotiation and change. Certain of the supply agreements may require minimum payments under certain circumstances if minimum quantities are not purchased. See Note 15 to the financial statements for additional information. </P>

<B><P>Item 7a.&nbsp;&nbsp;&nbsp;&nbsp;Quantitative and Qualitative Disclosures about Market Risks</P>
</B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's earnings and cash flow are subject to fluctuations due to changes in foreign currency exchange rates and interest rates.  The Company's risk management practice includes the selective use, on a limited basis, of forward foreign currency exchange contracts and interest rate agreements.  Such instruments are used for purposes other than trading.</P>
<P ALIGN="JUSTIFY"><BR>
<B>Foreign Currency Exchange Rate Risk</P>
</B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency exchange rate movements create fluctuations in U.S. Dollar reported amounts of foreign subsidiaries whose local currencies are their respective functional currencies.  The Company has not used foreign currency derivative instruments to manage translation fluctuations.  The Company and its respective subsidiaries primarily use forward foreign exchange contracts to hedge certain cash flows denominated in currencies other than the subsidiary's functional currency.  Such cash flows are normally represented by actual receivables and payables and anticipated receivables and payables for which there is a firm commitment.</P>
<B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>At December 31, 2005, the Company had forward foreign exchange contracts mainly denominated in Euros, Danish Krones, British Pounds, Hungarian Forint and U.S. Dollars with a notional amount of $127.0 million.  The fair market value of such contracts has been recognized in the financial statements and is not material.  All contracts expire in the first quarter of 2006.  The cash flows expected from the contracts will generally offset the cash flows of related non-functional currency transactions.  The change in value of the foreign currency forward contracts resulting from a 10% movement in foreign currency exchange rates would be less than $15.1 million and generally would be offset by the change in value of the hedged receivable or payable.  Such contracts are not designated hedges for accounting purposes.</P>
<B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Interest Rate Risk</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Alpharma's interest rate risk relates primarily to the asset-based loan under the $75.0 million Senior Secured Credit Facility, which has variable interest rates which reset on a periodic basis. At December 31, 2005, there were no amounts outstanding under the Senior Secured Credit Facility.   </P>
<B><P ALIGN="JUSTIFY"><BR>
Item 8.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Supplementary Data</P>
</B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See page F-1 of this Report, which includes an index to the consolidated financial statements and financial statement schedule.</P>
</FONT><FONT FACE="CG Times (W1),Times New Roman" SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;<BR>
</FONT><B><FONT SIZE=3>Item 9A.&nbsp;&nbsp;&nbsp;&nbsp;Controls and Procedures</P>
<P ALIGN="JUSTIFY"><BR>
</B>(a)&#9;Disclosure Controls and Procedures</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has implemented and maintains disclosure controls and procedures designed to ensure that information required to be disclosed in reports the Company files or submits under the Securities Exchange Act of 1934, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to the Company's President and Chief Executive Officer ("CEO") and Executive Vice President and Chief Financial Officer ("CFO") as appropriate to allow timely decisions regarding disclosure.  The disclosure controls and procedures involve participation by various individuals in the Company having access to material information relating to the operations of the Company.  It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met.  In addition, the design of any control system
 is based in part upon certain assumptions about the likelihood of future events.  </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's CEO and CFO completed an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures pursuant to Exchange Rule 13a-15 as of December 31, 2005.  Based on this evaluation, they concluded that the Company's disclosure controls and procedures were not effective at the reasonable assurance level as of December 31, 2005. </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">(b)&#9;Management's Report on Internal Control over Financial Reporting </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management is responsible for establishing and maintaining adequate internal control over financial reporting.  The Company's internal control over financial reporting is a process that is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:</P>

<UL>
<P ALIGN="JUSTIFY"><LI>Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of assets of the Company,</LI></P>
<P ALIGN="JUSTIFY"><LI>Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and the board of directors of the Company, and </LI></P>
<P ALIGN="JUSTIFY"><LI>Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.         </LI></P></UL>

<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management performed an assessment of the effectiveness of the Company's internal control over financial reporting as of December 31, 2005, utilizing the criteria described in  "Internal Control - Integrated Framework" issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO").  The objective of this assessment is to determine whether the Company's internal control over financial reporting was effective as of December 31, 2005.  </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">      A material weakness is a control deficiency, or combination of control deficiencies that results in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected.  In its assessment of the effectiveness internal control over financial reporting as of December 31, 2005, the Company determined that there were deficiencies in its internal controls over the accounting for income taxes and that these deficiencies constituted a material weakness, as described below.</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The sale of the Company's Generics Business in the fourth quarter of 2005 required the Company to affect numerous transactions related to the disposition and to recast its financial statements to separately present results from continuing and discontinued operations.  This included disaggregating income tax accounts between continuing and discontinued operations, accounting for taxes associated with the sale transaction and the repatriation of earnings, and evaluating and adjusting valuation allowances that had been provided in prior years for certain US deferred tax assets.  The fourth quarter accounting for income taxes required significant reliance upon external tax professionals and senior financial internal review and oversight, due to the complexities of the issues involved.  The integration and oversight of the work of these service providers reduced the timeliness and accuracy of recording the final tax provisions and related entries in the year-end cl
osing process and the preparation of tax footnote disclosures.  The Company has concluded that this reliance principally on outside providers and internal detective controls reduces the effectiveness of the internal controls over tax accounting processes.  Accordingly, the Company has concluded that a material weakness existed at December 31, 2005 in that it did not maintain effective internal control over financial reporting for income taxes, based on the criteria in "Internal Control - Integrated Framework" issued by the COSO.    </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management's assessment of the effectiveness of the Company's internal control over financial reporting as of December 31, 2005 has been audited by BDO Seidman, LLP, an independent registered public accounting firm, as stated in their report which follows. </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">(c)&nbsp;&nbsp;&nbsp;&nbsp;Changes in Internal Control over Financial Reporting</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In its prior year assessment of internal control over financial reporting as of December 31, 2004, management identified four internal control deficiencies that it concluded were material weaknesses.  The four identified material weaknesses at December 31, 2004, were as follows:  (i) ineffective internal controls to ensure the completeness and accuracy of customer discount reserves and certain accrual accounts at the Company's US Generic Pharmaceuticals (USG) business; (ii) ineffective internal controls to ensure the completeness and accuracy of income tax accounts, including deferred tax assets and liabilities, taxes payable and income tax expense; (iii) ineffective internal controls over the determination of proper segment disclosures; and (iv) ineffective controls to ensure the appropriate review and monitoring of compliance with certain debt covenants. </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company completed its remediation of the deficiencies related to the determination of proper segment disclosures and the appropriate review and monitoring of debt covenant compliance during the first and third quarters of 2005, respectively.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The deficiency related to the controls over the determination of the completeness and accuracy of customer discount reserves related to the Company's US Generic Pharmaceuticals business that was sold as part of the sale of the Company's world-wide human generic pharmaceutical business on December 19, 2005.  Accordingly, this deficiency and the associated controls were not part of management's assessment of internal control over financial reporting as of December 31, 2005. </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2005, management implemented enhanced control procedures to remediate the control deficiency identified at December 31, 2004 related to the accounting for income taxes.  Remediation actions and changes in internal control surrounding the accounting for income taxes included the following:  (i) the development and communication of enhanced policies and procedures for the accounting for income taxes, including expanded documentation requirements to support financial statement assertions, (ii) retaining a public accounting firm and other external tax professional services to assist the Company in its quarterly review, analysis and documentation of both its US and international income tax accounts, and (iii) expanding internal financial management review and oversight of income tax accounts and the work of outside tax service providers.  </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">     While management believes the enhanced control procedures implemented in 2005 served to remediate the material weakness identified at December 31, 2004, these enhanced procedures did not contemplate a transaction of the magnitude and complexity of the December 19, 2005 sale of the Generics Business.  </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because the December 19, 2005 sale of the Generics Business has simplified the Company, the tax accounting complexities and workload created by the fourth quarter transactions described above have already been significantly reduced.  The Company believes that the combination of the completion of the sale of the Generics Business and expanded oversight of the work of external tax service providers will serve to remediate the material weakness.  </P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2005, in connection with the sale of the Company's US Generic Pharmaceutical business to Actavis, certain transitional service agreements were established, whereby Actavis will provide certain financial, administrative, and information technology services to the Company.&#9;</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other than as described above, there have not been any other changes in the Company's internal control over financial reporting during the quarter ended December 31, 2005 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.</P>
</FONT><FONT FACE="CG Times (W1),Times New Roman" SIZE=3><P ALIGN="JUSTIFY"></P>
</FONT><FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
</FONT><FONT SIZE=3><P ALIGN="JUSTIFY">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</P>
<P ALIGN="JUSTIFY">Board of Directors and Stockholders</P>
<P ALIGN="JUSTIFY">Alpharma Inc.</P>
<P ALIGN="JUSTIFY">Fort Lee, New Jersey</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">We have audited management's assessment, included in the accompanying Management's Report on Internal Control over Financial Reporting, that Alpharma Inc. did not maintain effective internal control over financial reporting as of December 31, 2005 because of the effect of the material weakness identified in management's assessment, based on the criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).  The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting.  Our responsibility is to express an opinion on management's assessment and an opinion on the effectiveness of the Company's internal control over financial reporting based on our audit.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.  Our audit included obtaining an understanding of internal control over financial reporting, evaluating management's assessment, testing and evaluating the design and operating effectiveness of internal control, and performing such other procedures as we considered necessary in the circumstances.  We believe that our audit provides a reasonable basis for our opinion.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.  A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or dispositio
n of the company's assets that could have a material effect on the financial statements.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">A material weakness is a control deficiency, or a combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected. The following material weakness has been identified and included in management's assessment; The sale of the Company's Generics Business in the fourth quarter of 2005 required the Company to affect numerous transactions related to the disposition and to recast its financial statements to separately present results from continuing and discontinued operations.  This included disaggregating income tax accounts between continuing and discontinued operations, accounting for taxes associated with the sale transaction and the repatriation of earnings, and evaluating and adjusting valuation allowances that had been provided in prior years for certain US deferred tax assets.  The fourth quarter accounting for income taxes required significant reliance upon ext
ernal tax professionals and senior financial internal review and oversight, due to the complexities of the issues involved.  The integration and oversight of the work of these service providers reduced the timeliness and accuracy of recording the final tax provisions and related entries in the year-end closing process and the preparation of tax footnote disclosures.  This reliance principally on outside providers and internal detective controls reduces the effectiveness of the internal controls over tax accounting processes.  Taken together, these deficiencies constitute a material weakness in the Company's system of internal controls over financial reporting.<U>  </P>
</U><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">This material weakness was considered in determining the nature, timing, and extent of audit tests applied in our audit of the Company's consolidated financial statements as of and for the year ended December 31, 2005, and this report does not affect our report dated March 15, 2006 on those consolidated financial statements.    </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">In our opinion, management's assessment that Alpharma Inc. did not maintain effective internal control over financial reporting as of December 31, 2005, is fairly stated, in all material respects, based on the criteria established in Internal Control-Integrated Framework issued by COSO.  Also in our opinion, because of the effect of the material weakness described above on the achievement of the objectives of the control criteria, the Company has not maintained effective internal control over financial reporting as of December 31, 2005, based on the criteria established in Internal Control - Integrated Framework issued by COSO.  </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">We do not express an opinion or any other form of assurance on management's statements referring to the Company's corrective action plan.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of Alpharma Inc. as of December 31, 2005 and the related consolidated statements of operations, stockholders' equity and cash flows for the year then ended and our report dated March 15, 2006 expressed an unqualified opinion.  </P>
<P ALIGN="JUSTIFY"></P>
<P>/s/ BDO Seidman, LLP<BR>
New York, NY<BR>
March 15, 2006<BR>
</P>
<P ALIGN="JUSTIFY"></P>
<P>&nbsp;</P>
<B><P>Item 9B.&nbsp;&nbsp;&nbsp;&nbsp;Other Information</P>

</B><P>None.</P>

<B><U><P ALIGN="CENTER">PART III</B></U><BR>
</P><DIR>
<DIR>
<DIR>
<DIR>

<B><P>Item 10.&nbsp;&nbsp;&nbsp;Directors and Executive Officers of the Registrant</P></DIR>
</DIR>
</DIR>
</DIR>

</B></FONT><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT SIZE=3>The information as to the Directors of the Registrant set forth under the caption "Election of Directors" of the Proxy Statement relating to the Annual Meeting of Stockholders to be held on May 23, 2006, which Proxy Statement will be filed on or prior to April 30, 2006, is incorporated by reference into this Report.  The information as to the Executive Officers of the Registrant is included in Part I hereof under the caption "Executive Officers of the Registrant" in reliance upon General Instruction G to Form 10-K and Instruction 3 to Item 401(b) of Regulation S-K.  The Information set forth under the sub-caption "Section 16(a) Beneficial Ownership Reporting Compliance" appearing under the caption "Security Ownership of Certain Beneficial Owners of Management" of the aforementioned Proxy Statement is also incorporated by reference into this Report.  The Company has adopted a code of ethics that applies to its Chief Executive Officer, Chief Financial Officer and Cont
roller (who is also its principal accounting officer), effective May 20, 2003.  The Company has posted a copy of its code of ethics on its Internet Website, located at www.Alpharma.com.  The Company will provide to any person, without charge, upon request to Kathleen Makrakis, Vice President of Investor Relations, a copy of its code of ethics.</P>
<B><P><BR>
Item 11.&nbsp;&nbsp;&nbsp;&nbsp;Executive Compensation</P>
</B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information set forth under the sub-captions "Directors' Compensation" and "Compensation Committee Interlocks and Insider Participation" appearing under the caption "Board of Directors and Committees" of the Proxy Statement relating to the Annual Meeting of Stockholders to be held on May 23, 2006, which Proxy Statement will be filed on or prior to April 30, 2006, and the information set forth under the captions "Executive Compensation" and "Performance Graph" in such Proxy Statement, are incorporated into this Report by reference.</P>
<P><BR>
<B>Item 12.&nbsp;&nbsp;&nbsp;&nbsp;Security Ownership of Certain Beneficial Owners and Management</P>
</B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information set forth under the caption "Security Ownership of Certain Beneficial Owners and Management" of the Proxy Statement relating to the Annual Meeting of Stockholders to be held on May 23, 2006, which Proxy Statement will be filed on or prior to April 30, 2006, is incorporated into this Report by reference.</P>
<P><BR>
<B>Item 13.&nbsp;&nbsp;&nbsp;&nbsp;Certain Relationships and Related Transactions</P>
</B><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information set forth under the caption "Certain Relationships and Related Transactions" of the Proxy Statement relating to the Annual Meeting of Stockholders to be held on May&nbsp;23, 2006, which Proxy Statement will be filed on or prior to April 30, 2006, is incorporated into this Report by reference.</P>
<P><BR>
<B>Item 14.&nbsp;&nbsp;&nbsp;&nbsp;Principal Accountant Fees and Services.</P>
</B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">   The Information set forth under the caption "Principal Accountant Fees and Services" of the Proxy Statement relating to the Annual Meeting of Stockholders to be held on May 23, 2006, which Proxy Statement will be filed on or prior to April 30, 2006, is incorporated into this Report by reference.</P>
</FONT><FONT FACE="CG Times (W1),Times New Roman">
</FONT><B><U><FONT SIZE=3><P ALIGN="CENTER">PART IV</P>
</B></U>
<B><P>Item 15.&#9;Exhibits and Financial Statement Schedules </P>
</B></FONT><P ALIGN="CENTER"></P>
<U><P ALIGN="CENTER">List of Financial Statements</P>
</U><FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See page F-1 of this Report, which includes an index to consolidated financial statements and financial statement schedule.</P>
<U>
<P>List of Exhibits</U>  (numbered in accordance with Item 601 of Regulation S-K)</P>
</FONT>
<TABLE BORDER CELLSPACING=1 CELLPADDING=7 WIDTH=640>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">2.1</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Stock and Asset Purchase Agreement, dated October 17, 2005, between Alpharma Inc., the other Seller named therein and Actavis Group hf was filed as Exhibit 10.1 to the Company's Form 8-K dated as of October 17, 2005 and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">3.1</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Amended and Restated Certificate of Incorporation of the Company, dated September 30, 1994 and filed with the Secretary of State of the State of Delaware on October 3, 1994, was filed as Exhibit 3.1 to the Company's 1994 Annual Report on Form 10-K and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">3.1a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Certificate of Amendment of the Certificate of Incorporation of the Company dated September 15, 1995 and filed with the Secretary of State of Delaware on September 15, 1995 was filed as Exhibit 3.1 to the Company's Amendment No. 1 to Form S-3 dated September 21, 1995 (Registration on No. 33-60029) and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">3.1b</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Certificate of Amendment to the Certificate of Incorporation of the Company dated July 2, 1999 and filed with the Secretary of State of Delaware on July 6, 1999 was filed as Exhibit 3.1 to the Company's June 30, 1999 quarterly report on Form 10-Q/A and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P>3.1c</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P>Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company, effective September 2000, was filed as Exhibit 3.0 to the Company's September 30, 2000 quarterly report on Form 10-Q and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">3.1d</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company, dated May 30, 2003 and filed with the Secretary of State of Delaware on June 2, 2003, was filed as Exhibit 3.1d to the Company's June 30, 2003 quarterly report on Form 10-Q and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">3.2</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Amended and Restated By-Laws of the Company, effective as of May 20, 2003, was filed as Exhibit 3.2 to the Company's June 30, 2003 quarterly report on Form 10-Q and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">4.1</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Notes Purchase Agreement among Alpharma Operating Corporation, certain of its subsidiaries as guarantors, Banc of America Bridge LLC, and CIBC Inc., dated December 12, 2001 was filed as Exhibit 4.2 to the Company's 2001 Annual Report on Form 10-K and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">4.2</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Shelf Registration Rights Agreement among Alpharma Operating Corporation, certain of its subsidiaries as guarantors, Banc of America Bridge LLC, and CIBC Inc., dated as of December 12, 2001 was filed as Exhibit 4.3 to the Company's 2001 Annual Report on Form 10-K and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">4.2a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Shelf Registration Joinder Agreement among Alpharma Operating Corporation, certain of its subsidiaries as guarantors, Banc of America Bridge LLC, and CIBC Inc., dated as of January 11, 2002 was filed as Exhibit 4.3a to the Company's 2001 Annual Report on Form 10-K and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">4.2b</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Letter Agreement relating to Shelf Registration Rights Agreement among Alpharma Inc (on behalf of Alpharma Operating Corporation and each of the guarantors), Banc of America Bridge LLC, and CIBC Inc., dated March 12, 2002 was filed as Exhibit 4.3b to the Company's 2001 Annual Report on Form 10-K and is incorporated by reference. </FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">4.3</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Indenture, dated as of March 30, 1998, by and among the Company and First Union National Bank, as trustee, with respect to the 5 3/4% Convertible Subordinated Notes due 2005 was filed as Exhibit 4.1 to the Company's Form 8-K dated as of March 30, 1998 and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">4.4</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Indenture dated as of June 2, 1999, by and between the Registrant and First Union National Bank, as trustee, with respect to the 3% Convertible Senior Subordinated Notes due 2006, was filed as Exhibit 4.1 to the Company's Form 8-K dated as of June 16, 1999 and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Copies of debt instruments (other than those listed above) for which the related debt does not exceed 10% of consolidated total assets as of December 31, 2003 will be furnished to the Commission upon request.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P>4.5</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P>Indenture dated April 24, 2003 by and between the Registrant and Wachovia Bank, National Association Trustee with respect to the 8 5/8% Senior Notes due 2011, was filed as Exhibit 4.3 to the Company's March 31, 2003 quarterly report on Form 10Q and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P>4.5a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P>Registration Rights Agreement by and among Alpharma and each of the Guarantors, Bank of America Securities LLC and CIBC World Markets Corp., dated April 24, 2003 was filed as Exhibit 4.3a to the Company's March 31, 2003 quarterly report on Form 10Q and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P>10.1</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P>Credit Agreement dated as of October 5, 2001 between the Company and Bank of America N.A. and other Lenders was filed as Exhibit 10.0 to the Company's September 30, 2001 Form 10Q and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.1a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Subsidiary Guaranty made by certain of the Company's subsidiaries in favor of Bank of America N.A., as Administrative Agent dated December 26, 2001 was filed as Exhibit 10.2a to the Company's 2001 Annual Report on Form 10-K and is incorporated by reference. </FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.1b</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Amendment No. 1 to the Credit Agreement dated as of December 16, 2002 between the Company and Bank of America and other lenders was filed as Exhibit 10.3 to the Company's 2002 Annual Report on Form 10K and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.1c</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Amendment No. 2 to the Credit Agreement dated as of April 3, 2003, among the Company, Bank of America and other lenders, was filed as Exhibit 10.1A to the Company's March 31, 2003 quarterly report on Form 10Q and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.1d</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Letter Waiver to the Credit Agreement, dated as of August 14, 2003, among the Company, Bank of America and other lenders was filed as an Exhibit to the Company's September 30, 2003 quarterly report on Form 10Q and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.1e</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Amendment No. 3 to the Credit Agreement dated as of December 18, 2003, among the Company, Bank of America and other lenders was filed as Exhibit 10.1e to the Company's 2003 Annual Report on Form 10K and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.1f</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Amendment No. 4 to the Credit Agreement, dated as of April 19 2004, among the Company, Bank of America and other lenders was filed as Exhibit 10.3 to the Company's June 30, 2004 Form 10Q and is incorporated by reference. </FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.1g</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Amendment No. 5 to the Credit Agreement, dated as of August 3, 2004, among the Company, Bank of America and other lenders was filed as Exhibit 10.4 to the Company's June 30, 2004 Form 10Q and is incorporated by reference. </P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.1h</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Amendment No. 6 to the Credit Agreement, dated as of March 8, 2005, among the Company, Bank of America and other lenders was  filed as Exhibit 10.1h to the Company's 2004 Annual Report on Form 10-K and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.2</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Loan and Security Agreement, dated October 26, 2005, among the Company, certain of its subsidiaries, Bank of America and other lenders is filed as an Exhibit to this Report.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.3</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Multicurrency Revolving Credit Facility, dated December 7, 2005, among a subsidiary of the Company as borrower, the Company as guarantor and DNB Nor Bank ASA was filed as Exhibit 10.1 to the Company's' Report on Form 8-K dated as of December 7, 2005 and is incorporated herein by reference.</FONT></TD>
</TR>
</TABLE>

<U><FONT SIZE=3><P ALIGN="JUSTIFY"></P></U></FONT>
<TABLE BORDER CELLSPACING=1 CELLPADDING=7 WIDTH=640>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.4&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Promissory Note provided by Alpharma AS to DnB Nor Bank ASA, dated December 28, 2005 is filed as an Exhibit to this Report.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P>10.5</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P>Consulting Agreement between I. Roy Cohen and the Company dated as of January 1, 2001 was filed as Exhibit 10.b to the Company's 2000 Annual Report on Form 10-K and is incorporated by reference.</P>
</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.6&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Agreement between the Company and Einar W. Sissener dated July 1, 1999 was filed as Exhibit 10.15 to the Company's 1999 Annual Report on Form 10-K and is incorporated by reference. </P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.6a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Amendment No. 1 to Sissener Employment Letter, effective March 23, 2004, was filed as  Exhibit 10.7a to the Company's 2004 Annual Report on Form 10-K and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.7 </FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Employment Contract between the Company and Ingrid Wiik dated December 1, 2000 was filed as Exhibit 10.14 to the Company's 2000 Annual Report on Form 10-K and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.8</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Employment Contract between the Company and Matthew Farrell dated April 12, 2002 was filed as Exhibit 10.2 to the Company's March 31, 2002 Form 10Q and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.9</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Employment Agreement, dated November 6, 2002, between the Company and Ronald Warner was filed as Exhibit 10.3 to the Company's March 31, 2003 quarterly report on Form 10Q, and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.9a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Amendments to Employment Agreement dated February 26, 2003, between the Company and Ronald Warner was filed as Exhibit 10.3A to the Company's March 31, 2003 quarterly report on Form 10Q, and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.9b</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Retention Agreement between the Company and Ronald Warner was filed as Exhibit 10.2 to the Company's December 19, 2005 current report on Form 8-K and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.10</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Employment contract between the Company and Carol Wrenn dated October 19, 2001 was filed as Exhibit 10.16 to the Company's 2002 Annual Report on Form 10K and is incorporated by reference. </P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.10a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Letter Agreement dated July 15, 2003 between the Company and Carol A. Wrenn was filed as Exhibit 10.2 to the Company's September 30, 2003 quarterly report on Form 10Q and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.10b</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Supplemental Letter Agreement dated February 11, 2004 between the Company and Carol A. Wrenn was filed as Exhibit 10.14b to the Company's 2003 Annual Report on Form 10K and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.10c</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Retention Agreement between the Company and Carol Wrenn was filed as Exhibit 10.3 to the Company's December 19, 2005 current report on Form 8-K and is incorporated by reference. </P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.11</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Employment Agreement, dated February 26, 2003, between the Company and Fred Lynch was filed as Exhibit 10.2 to the Company's March 31, 2003 quarterly report on Form 10Q, and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.12</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Employment contract between the Company and Carl-Aake Carlsson dated October 17, 2002 was filed as Exhibit 10.18 to the Company's 2002 Annual Report on Form 10K and is incorporated by reference. </P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.12a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Retention Agreement between the Company and Carl-Aake Carlsson dated December 5, 2005 is filed as an Exhibit to this Report</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.13</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Employment Agreement between the Company and Richard J. Cella dated August&nbsp;29, 2000, was filed as Exhibit 10.4 to the Company's 2001 Annual Report on Form 10-K and is incorporated by reference. </P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.14</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Employment contract between the Company and George Rose dated July 17, 2001 was filed as Exhibit 10.17 to the Company's 2002 Annual Report on Form 10K and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.15</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Employment Agreement, dated February 26, 2003, between the Company and Michael Nestor was filed as Exhibit 10.6 to the Company's March 31, 2003 quarterly report on Form 10Q, and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.15a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Separation Letter Agreement between the Company and Michael Nestor, dated March&nbsp;12, 2004, was filed as Exhibit 10.1 to the Company's March 31, 2004 quarterly report on Form 10Q, and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.16</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Employment Agreement, dated February 26, 2003, between the Company and Mark Stier was filed as Exhibit 10.5 to the Company's March 31, 2003 quarterly report on Form 10Q, and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.16a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Separation Letter Agreement, between the Company and Mark Stier, dated July 1, 2003, was filed as Exhibit 10.2 to the Company's June 30, 2003 quarterly report on Form 10Q, and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.17</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Employment Agreement, dated February 26, 2003, between the Company and Kurt Orlofski was filed as Exhibit 10.4 to the Company's March 31, 2003 quarterly report on Form 10Q, and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.17a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Separation Letter Agreement between the Company and Kurt Orlofski, dated January&nbsp;20, 2004, as amended, was filed as Exhibit 10.2 to the Company's March 31, 2004 quarterly report on Form 10Q, and is incorporated by reference. </P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.18</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Form of Retention Agreement between the Company and certain corporate executive (including Messrs. Farrell, Wrobel, Rose and Cella) was filed as Exhibit 10.1 to the Company's December 19, 2005 current report on Form 8-K and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.19</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Administrative Services Agreement, effective January 1, 2005, between A.L. Industrier ASA and Alpharma AS, was filed as Exhibit 10.21 to the Company's 2004 Annual Report and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.20</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Lease Agreement between A.L. Industrier ASA, as landlord, and Alpharma AS, as tenant dated October&nbsp;3, 1994 was filed as Exhibit 10.10 to the Company's 1994 Annual Report on Form 10-K and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.21</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Parking Lot Lease Agreement between A.L. Industrier ASA, as landlord, and Alpharma AS, as tenant dated as of February&nbsp;1, 2002 was filed as Exhibit 10.0 to the Company's September 30, 2002 quarterly report on Form 10Q and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.22</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Asset Purchase Agreement, dated August 5, 1999, between the Company and Southern Cross Biotech Pty Limited et al was filed as Exhibit 10.3 to the Company's September 30, 2003 quarterly report on Form 10Q, and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.23</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Technology License and Option Agreement, dated August 5, 1999, between the Company and Natinco N.V. et al, was filed as Exhibit 10.4 to the Company's September 30, 2003 quarterly report on Form 10Q, and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.24</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Settlement and Licence Agreement, effective as of September 23, 2004 between Alpharma Inc., Natinco N.V., BISA Holdings BV and BIL (SCB) Holdings Limited was filed as Exhibit 35b to the Company's 2004 Annual Report on Form 10K and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.25</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Asset Purchase Agreement between Wynco, LLC and Iowa Veterinary Supply Co, dated March 24, 2003, was filed as Exhibit 10.3 to the Company's March 31, 2004 quarterly report on Form 10Q, and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.26</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Amended and Restated Supply Agreement between Plantex USA, Inc. and Purepac Pharmaceutical Co., dated April 26, 2004 was filed as Exhibit 10.1 to the Company's June 30, 2004 quarterly report on Form 10Q, and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.26a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Amendment to the Amended and Restated Supply Agreement, dated as of February 7, 2005, between Purepac Pharmaceutical Co. and Plantex USA, Inc. was filed as Exhibit 10.37a to the Company's 2004 Annual Report on Form 10-K and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.26b</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Amendment No. 3 to Amended and Restated Supply Agreement dated as of April 1, 2005, between Purepac Pharmaceutical Co. and Plantex Inc. was filed as Exhibit 10.1 to the Company's June 30, 2005 quarterly report on Form 10Q and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.26c</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Amendment No. 4 to the Amended and Restated Supply Agreement, dated as of  October 14, 2005, between Purepac Pharmaceutical Co. and Plantex USA, Inc. was filed as Exhibit 10.1 to the Company's September 30, 2005 quarterly report on Form 10-Q and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.27</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Selective Waiver Agreement by and between Alpharma Inc. and Teva Pharmaceutical Industries Ltd., dated April 26, 2004 was filed as Exhibit 10.2 to the Company's June 30, 2004 quarterly report on Form 10Q, and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.27a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Amendment Number One to the Selective Waiver Agreement and the Amended and Restated Supply Agreement, dated as of September 24, 2004 among the Company, Purepac Pharmaceutical Co., Teva Pharmaceutical Industries Ltd. and Plantex USA, Inc. was filed as Exhibit 10.2 to the Company's September 30, 2004 quarterly report on Form 10Q, and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.27b</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Letter Agreement dated October 7, 2004 among the Company, Purepac Pharmaceutical Co., Teva Pharmaceutical Industries Ltd and Plantex USA, Inc. was filed as Exhibit 10.3 to the Company's September 30, 2004 quarterly report on Form 10Q, and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.27c</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Second Amendment to Selective Waiver Agreement, dated as of February 7, 2005, between Alpharma Inc. and Teva Pharmaceutical was filed as Exhibit 10.38c to the Company's 2004 annual report on Form 10-K and is incorporated herein by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.28</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Agreement between Purepac Pharmaceutical Co. and Orchid Chemicals &amp; Pharmaceuticals, Ltd, effective February 23, 2005, is filed as Exhibit 10.40 to the Company's 2004 annual report on Form 10-K and is incorporated herein by reference.*</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.29</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Master Development and Manufacturing Agreement by and among Purepac Pharmaceutical Co. and Shasun Chemicals and Drugs Limited, effective May 27, 2005 was filed as Exhibit 10.2 to the Company's June 30, 2005 quarterly report and is incorporated by reference.*</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.30</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Settlement Agreement between Alpharma Inc. and Purepac Pharmaceutical Co, on the one hand, and Ivax Pharmaceuticals on the other hand, dated as of February 10, 2005, was filed as Exhibit 10.41 to the Company's 2004 Annual Report and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.31</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Toll Manufacturing Agreement, dated December 19, 2005, between Alpharma Branded Products Division Inc. and Purepac Pharmaceutical Co. is filed as an Exhibit to this Report.*</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.32</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">2003 Omnibus Incentive Compensation Plan, effective May 19, 2003 was filed as Exhibit 10.1 to the Company's September 30, 2004 quarterly report on Form 10Q, and is incorporated by reference. </P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.33</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Amended Alpharma Inc. Executive Bonus Plan, effective January 1, 2004 was filed as Exhibit 10.20a to the Company's 2004 Annual Report on Form 10K and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.33a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY"> Amendment to Alpharma Inc. Executive Bonus Plan, effective August 15, 2005, is filed as an Exhibit to this Report.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.34</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">The Company's 1997 Incentive Stock Option and Appreciation Right Plan, as amended was filed as Exhibit 10.1 to the Company's June 30, 1999 quarterly report on Form 10Q/A and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.35</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Alpharma Inc. Employee Stock Purchase Plan (as Amended and Restated), effective as of January 1, 2005 is filed as an Exhibit to this Report.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.36</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Form of Restricted Stock Unit Award Agreement for members of Alpharma Inc.'s Board of Directors, effective March 8, 2004, was filed as Exhibit 10.44 to the Company's 2004 Annual Report on Form 10-K and is incorporated by reference</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.36a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Form of revised Restricted Stock Unit Award Agreement for members of Alpharma Inc.'s Board of Directors, effective March 8, 2004 was filed as Exhibit 10.3 to the Company's June 30, 2005 quarterly report on Form 10-Q and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.37</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Alpharma Inc. 2005 Supplemental Savings Plan, effective January 1, 2005, was filed as Exhibit 10.42 to the Company's 2004 Annual Report on Form 10-K, and is incorporated herein by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.37a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Amendment No. 1 to Alpharma Inc. 2005 Supplemental Savings Plan, dated December 30, 2005, is filed as an Exhibit to this Report.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.38</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Form of Restricted Stock Award Agreement, effective March 8, 2004, was filed as Exhibit 10.43 to the Company's 2004 Annual Report on Form 10-K and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.38a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Form of revised Restricted Stock Award Agreement, effective May 12, 2005, was filed as Exhibit 10.1 to the Company's May 12, 2005 current report on Form 8-K and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.39</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Form of Restricted Stock Unit Award Agreement for employees located outside of the United States, effective March 8, 2004, was filed as Exhibit 10.45 to the Company's 2004 Annual Report on Form 10-K and is incorporated by reference. </P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.39a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Form of Revised Restricted Stock Unit Award Agreement for employees located outside of the United States, effective May 12, 2005, was filed as Exhibit 10.2 to the Company's May 12, 2005 current report on Form 8-K and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.40</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Form of Non-Qualified Stock Option Award Agreement, effective March 8, 2004, was filed as Exhibit 10.46 to the Company's 2004 Annual Report on Form 10-K and is incorporated by reference.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.41</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Form of Performance Unit Award Agreement, effective March 8, 2004 was filed as Exhibit 10.47 to the Company's 2004 Annual Report on Form 10K and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.42</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Alpharma Inc.  Severance Plan, amended and restated as of January 1, 2005 is filed as an Exhibit to this Report.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">10.43</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Alpharma Inc. Change in Control Plan, amended and restated effective January 1, 2005 (the substance of the material amendments of which was disclosed in full in the Company's report on Form 8-K filed as of September 7, 2005) is filed as an Exhibit to this Report.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.46</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Alpharma Inc. Amended and Restated Deferred Compensation Plan, effective July 1, 1984, amended October 14, 1994 is filed as an Exhibit to this Report.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.46a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Amendment No. 1 to the Alpharma Inc. Amended and Restated Deferred Compensation Plan, dated December 30, 2005 is filed as an Exhibit to this Report.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.47</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">A.L. Pharma Inc. Supplemental Pension Plan, effective July 1, 1994, is filed as an Exhibit to this Report.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.47a</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">First Amendment of the A.L. Pharma Inc. Supplemental Pension Plan, effective July 1, 1998 is filed as an Exhibit to this Report.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">10.47b</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Second Amendment to Alpharma Inc. Supplemental Pension Plan, dated December 30, 2005 is filed as an Exhibit to this Report.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">16</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Letter from PricewaterhouseCoopers LLP was filed as an Exhibit to the Company's February&nbsp;22, 2006 Form 8-K and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">18</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Letter from PricewaterhouseCoopers regarding a change in accounting from LIFO to FIFO, dated March 31, 2003 was filed as Exhibit 18 to the Company's March 31, 2003 quarterly report on Form 10Q, and is incorporated by reference.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">21</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">A list of the subsidiaries of the Registrant as of March 8, 2006 is filed as an Exhibit to this Report.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">23.1</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Consent of PricewaterhouseCoopers LLP, an Independent Registered Public Accounting Firm, is filed as an Exhibit to this Report.</P>
<P ALIGN="JUSTIFY"></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">23.2</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Consent of BDO Seidman LLP, an Independent Registered Public Accounting Firm, is filed as an Exhibit to this Report.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">31.1</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 is filed as an Exhibit to this Report.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">31.2</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 is filed as an Exhibit to this Report.</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">32</FONT></TD>
<TD WIDTH="90%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Certification of the Principal Executive Officer and the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 is filed as an Exhibit to this Report.</FONT></TD>
</TR>
</TABLE>

<B><FONT SIZE=3><P ALIGN="JUSTIFY"></P>
</B><P>* &nbsp;&nbsp;Portions of this Exhibit have been omitted pursuant to a request for confidential treatment.<BR>
 </P>
</FONT><P ALIGN="JUSTIFY"> </P>
<P ALIGN="CENTER">Undertakings</P>
<P ALIGN="JUSTIFY"></P>
<FONT SIZE=3><P ALIGN="JUSTIFY">For purposes of complying with the amendments to the rules governing Registration Statements under the Securities Act of 1933, the undersigned Registrant hereby undertakes as follows, which undertaking shall be incorporated by reference into Registrant's Registration Statements on Form S-8 (Nos. 33-60495, effective July 13, 1990, 333-107873, 333-104253, 333-104252) and Form S-3 (File Nos. 333-57501, 333-86037, 333-86153 and 333-70229):</P>
<P ALIGN="JUSTIFY"><BR>
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable.  In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is 
against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</P>
<P ALIGN="JUSTIFY">&#9;&#9;</P>

<B><U><P ALIGN="CENTER">SIGNATURES</B></U><BR>
</P>
<P ALIGN="JUSTIFY">Pursuant to the requirements of Section B or 15(d) of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>
<P ALIGN="JUSTIFY"></P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=583>
<TR><TD WIDTH="50%" VALIGN="TOP" HEIGHT=51>
<FONT SIZE=3><P>Date: March 16, 2006<BR>
</FONT></TD>
<TD WIDTH="50%" VALIGN="TOP" HEIGHT=51>
<FONT SIZE=3><P>Alpharma Inc.<BR>
Registrant<BR>
</P>

<P>&nbsp;</P>
<P>By: <U>/s/ Einar W. Sissener</U> <BR>
Einar W. Sissener<BR>
Director and Chairman of the Board</FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP" HEIGHT=51><P></P></TD>
<TD WIDTH="50%" VALIGN="TOP" HEIGHT=51><P></P></TD>
</TR>
</TABLE>

<FONT SIZE=3><P ALIGN="JUSTIFY">Pursuant to the requirements of the Securities and Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</P>
</FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=638>
<TR><TD WIDTH="42%" VALIGN="TOP">
<FONT SIZE=3><P>Date: March 16, 2006</FONT></TD>
<TD WIDTH="58%" VALIGN="TOP">
<U><FONT SIZE=3><P>/s/ Einar W. Sissener</U><BR>
Einar W. Sissener<BR>
Director and Chairman of the Board</FONT></TD>
</TR>
<TR><TD WIDTH="42%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="42%" VALIGN="TOP">
<FONT SIZE=3><P>Date: March 16, 2006</FONT></TD>
<TD WIDTH="58%" VALIGN="TOP">
<U><FONT SIZE=3><P>/s/ Ingrid Wiik</U><BR>
Ingrid Wiik<BR>
Director, Vice Chairman, President and Chief Executive Officer</FONT></TD>
</TR>
<TR><TD WIDTH="42%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="42%" VALIGN="TOP">
<FONT SIZE=3><P>Date: March 16,<B> </B>2006</FONT></TD>
<TD WIDTH="58%" VALIGN="TOP">
<U><FONT SIZE=3><P>/s/ Matthew Farrell</U><BR>
Matthew Farrell<BR>
Executive Vice President and Chief Financial Officer</FONT></TD>
</TR>
<TR><TD WIDTH="42%" VALIGN="TOP">
<FONT SIZE=3>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>Date: March 16,<B> </B>2006</FONT></TD>
<TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<U><P>/s/ Finn Berg Jacobsen</U><BR>
Finn Berg Jacobsen<BR>
Director </FONT></TD>
</TR>
<TR><TD WIDTH="42%" VALIGN="TOP" BGCOLOR="#ffffff">&nbsp;</TD>
<TD WIDTH="58%" VALIGN="TOP" BGCOLOR="#ffffff">
<FONT SIZE=3>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="42%" VALIGN="TOP">
<FONT SIZE=3><P>Date: March 16, 2006</FONT></TD>
<TD WIDTH="58%" VALIGN="TOP">
<U><FONT SIZE=3><P>&#9;&#9;&#9;&#9;&#9;</U><BR>
Glen E. Hess<BR>
Director</FONT></TD>
</TR>
<TR><TD WIDTH="42%" VALIGN="TOP">
<FONT SIZE=3>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>Date: March 16, 2006</FONT></TD>
<TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<U><P>/s/ Peter G. Tombros&#9;</U><BR>
Peter G. Tombros<BR>
Director </P>

<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="42%" VALIGN="TOP">
<FONT SIZE=3><P>Date: March 16, 2006</FONT></TD>
<TD WIDTH="58%" VALIGN="TOP">
<U><FONT SIZE=3><P>/s/ William I. Jacobs&#9;</U><BR>
William I. Jacobs<BR>
Director and Chairman of the Audit Committee</P>

<P>&nbsp;</P>
<P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="42%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="58%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="42%" VALIGN="TOP">
<FONT SIZE=3><P>Date: March 16, 2006</FONT></TD>
<TD WIDTH="58%" VALIGN="TOP">
<U><FONT SIZE=3><P>/s/ Ramon Perez</P>
</U><P>Director</P>

<P>&nbsp;</P>
<P>&nbsp;</P>
<U><P>&nbsp;</U></FONT></TD>
</TR>
<TR><TD WIDTH="42%" VALIGN="TOP">
<FONT SIZE=3><P>Date: March 16, 2006</FONT></TD>
<TD WIDTH="58%" VALIGN="TOP">
<U><FONT SIZE=3><P>/s/ Robert Thong&#9;</U></FONT></TD>
</TR>
<TR><TD WIDTH="42%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P>Robert Thong<BR>
Director<BR>
</P>

<P>&nbsp;</P>
<P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="42%" VALIGN="TOP" BGCOLOR="#ffffff">
<FONT SIZE=3><P>Date: March 16, 2006</FONT></TD>
<TD WIDTH="58%" VALIGN="TOP" BGCOLOR="#ffffff">
<U><FONT SIZE=3><P>/s/ Farah M. Walters</U></FONT></TD>
</TR>
<TR><TD WIDTH="42%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P>Farah M. Walters<BR>
Director </P>

<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="42%" VALIGN="TOP">
<FONT SIZE=3><P>Date: March 16, 2006</FONT></TD>
<TD WIDTH="58%" VALIGN="TOP">
<U><FONT SIZE=3><P>/s/ Jill Kanin-Lovers&#9;</U></FONT></TD>
</TR>
<TR><TD WIDTH="42%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P>Jill Kanin-Lovers<BR>
Director and Chairperson of the Compensation Committee</P>

<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="42%" VALIGN="TOP">
<FONT SIZE=3><P>Date: March 16, 2006</FONT></TD>
<TD WIDTH="58%" VALIGN="TOP">
<U><FONT SIZE=3><P>/s/ Jeffrey S. Campbell</U><BR>
Jeffrey S. Campbell<BR>
Vice President, Finance</P>

<P>&nbsp;</P>
<P>&nbsp;</FONT></TD>
</TR>
</TABLE>

<FONT FACE="CG Times (W1),Times New Roman"><P>&nbsp;</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=638>
<TR><TD WIDTH="42%" VALIGN="TOP">
<FONT SIZE=3><P>Date:  March 16, 2006</FONT></TD>
<TD WIDTH="58%" VALIGN="TOP">
<U><FONT SIZE=3><P>/s/ John F. Konzelmann<BR>
</U>John F. Konzelmann<BR>
Vice President, Controller and Principal Accounting<BR>
Officer</FONT></TD>
</TR>
</TABLE>

<B><FONT SIZE=3><P ALIGN="CENTER">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AND SCHEDULES</P>
</B><P ALIGN="CENTER"></P>
<P><BR>
</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 WIDTH=636>
<TR><TD WIDTH="80%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">
<B><FONT SIZE=3><P ALIGN="CENTER">Page</B></FONT></TD>
</TR>
<TR><TD WIDTH="80%" VALIGN="TOP">
<FONT SIZE=3><P>Consolidated Financial Statements:</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="80%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="80%" VALIGN="TOP">
<FONT SIZE=3><P>Reports of Independent Registered Public Accounting Firms</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">F-2 - F-3</FONT></TD>
</TR>
<TR><TD WIDTH="80%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="80%" VALIGN="TOP">
<FONT SIZE=3><P>Consolidated Balance Sheets at December 31, 2005 and 2004</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">F-4</FONT></TD>
</TR>
<TR><TD WIDTH="80%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="80%" VALIGN="TOP">
<FONT SIZE=3><P>Consolidated Statements of Operations for the years ended December 31, <BR>
&nbsp;&nbsp;&nbsp;2005, 2004 and 2003</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER"><BR>
F-5</FONT></TD>
</TR>
<TR><TD WIDTH="80%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="80%" VALIGN="TOP">
<FONT SIZE=3><P>Consolidated Statements of Stockholders' Equity for the years ended<BR>
&nbsp;&nbsp;&nbsp;December 31, 2005, 2004 and 2003</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER"><BR>
F-6</FONT></TD>
</TR>
<TR><TD WIDTH="80%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="80%" VALIGN="TOP">
<FONT SIZE=3><P>Consolidated Statements of Cash Flows for the years ended December 31,<BR>
&nbsp;&nbsp;&nbsp;2005, 2004 and 2003</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER"><BR>
F-7</FONT></TD>
</TR>
<TR><TD WIDTH="80%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="80%" VALIGN="TOP">
<FONT SIZE=3><P>Notes to Consolidated Financial Statements </FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">F-8 to F-44</FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P><BR>
</P>
</FONT><P ALIGN="JUSTIFY">Financial statement schedules are omitted for the reason that they are not applicable or the required information is included in the consolidated financial statements or notes thereto.</P>
<FONT FACE="Arial"><P ALIGN="CENTER">&nbsp;</P>
</FONT><B><FONT SIZE=3><P ALIGN="CENTER"><A NAME="BDOStandard"></A>Report of Independent Registered Public Accounting Firm</P>
</B><P ALIGN="JUSTIFY">Board of Directors and Stockholders</P>
<P ALIGN="JUSTIFY">Alpharma Inc.</P>
<P ALIGN="JUSTIFY">Fort Lee, NJ</P>
<P ALIGN="JUSTIFY">We have audited the accompanying consolidated balance sheet of Alpharma Inc. as of December 31, 2005 and the related consolidated statements of operations, stockholders' equity and cash flows for the year then ended. These financial statements are the responsibility of the Company's management.  Our responsibility is to express an opinion on these financial statements based on our audit.</P>
<P ALIGN="JUSTIFY">We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.  We believe that our audit provides a reasonable basis for our opinion.</P>
<P ALIGN="JUSTIFY">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Alpharma Inc. at December 31, 2005, and the results of its operations and its cash flows in conformity with accounting principles generally accepted in the United States of America.</P>
<P ALIGN="JUSTIFY">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the effectiveness of Alpharma Inc.'s internal control over financial reporting as of December 31, 2005, based on criteria established in <I>Internal Control - Integrated Framework </I>issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) and our report dated March 15, 2006 expressed an unqualified opinion on management's assessment of the effectiveness of internal control over financial reporting and an adverse opinion on the effectiveness of internal control over financial reporting because of a material weakness.</P>
</FONT><FONT FACE="CG Times (W1),Times New Roman" SIZE=3><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P>/s/ BDO Seidman, LLP<BR>
New York, NY<BR>
March 15, 2006</P>
</FONT><FONT FACE="Arial"><P ALIGN="JUSTIFY"></P>
</FONT><B><FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;</P>
</B></FONT><FONT FACE="CG Times (W1),Times New Roman" SIZE=3><P ALIGN="JUSTIFY">&nbsp;</P>
</FONT><B><FONT SIZE=3><P ALIGN="CENTER">Report of Independent Registered Public Accounting Firm</P>
</B>
<P ALIGN="JUSTIFY">To the Stockholders and Board of Directors of Alpharma Inc.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">In our opinion, the consolidated balance sheet as of December 31, 2004 and the related consolidated statements of operations, stockholders' equity and cash flows listed in the index on page F-1 present fairly, in all material respects, the financial position of Alpharma Inc. and its subsidiaries at December 31, 2004, and the results of their operations and their cash flows for each of the two years in the period ended December 31, 2004, in conformity with accounting principles generally accepted in the United States of America.  These financial statements are the responsibility of the Company's management.  Our responsibility is to express an opinion on these financial statements based on our audits.  We conducted our audits of these statements in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
 misstatement.  An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation.  We believe that our audits provide a reasonable basis for our opinion.  </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">/s/ PricewaterhouseCoopers LLP</P>
<P ALIGN="JUSTIFY">Florham Park, New Jersey</P>
<P ALIGN="JUSTIFY">March 31, 2005, except for the restatement discussed in Note 2b (not presented herein) to the consolidated financial statements appearing under Item 15 of the Company's 2004 annual report on Form 10-K/A, as to which the date is May 5, 2005 and for the effects of discontinued operations discussed in Note 3 to the consolidated financial statements, as to which the date is March 16, 2006</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<B><P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="CENTER">ALPHARMA INC. AND SUBSIDIARIES<BR>
CONSOLIDATED BALANCE SHEETS<BR>
</B><I>(In thousands, except share data)</P></I></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=679>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="28%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=15>
<B><FONT SIZE=2><P ALIGN="CENTER">       <U>December 31,</B></U></FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<B><FONT SIZE=2><P>ASSETS</B></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<B><FONT SIZE=2><P ALIGN="CENTER">        <U>2005</B></U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<B><FONT SIZE=2><P ALIGN="CENTER">     <U>2004</B></U></FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>Current assets</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Cash and cash equivalents</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">$      800,010</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">$      105,212</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Accounts receivable, net</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">90,898</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">       72,336</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Inventories</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">92,741</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">      98,186</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">41,575</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">      21,352</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;Assets of discontinued operations</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<U><FONT SIZE=2><P ALIGN="RIGHT">   11,823</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<U><FONT SIZE=2><P ALIGN="RIGHT">374,986</U></FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">      1,037,047</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">     672,072</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="JUSTIFY">Property, plant &amp; equipment, net</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">      215,174</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">237,904</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="JUSTIFY">Goodwill</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">116,747</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">     117,169</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="JUSTIFY">Intangible assets, net</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">176,083</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">     195,181</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="JUSTIFY">Other assets and deferred charges</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">72,609</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">       84,795</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<FONT SIZE=2><P ALIGN="JUSTIFY">Assets of discontinued operations</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<U><FONT SIZE=2><P ALIGN="RIGHT">       5,723</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<U><FONT SIZE=2><P ALIGN="RIGHT">   732,491</U></FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=21>
<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=21>
<FONT SIZE=2><P ALIGN="RIGHT">$  <U> 1,623,383</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=21>
<FONT SIZE=2><P ALIGN="RIGHT">$ <U>2,039,612</U></FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<B><FONT SIZE=2><P ALIGN="JUSTIFY">LIABILITIES AND STOCKHOLDERS' EQUITY</B></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="JUSTIFY">Current liabilities</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;Short-term debt  </FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">$        35,713</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">$       16,096</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;Current portion of long-term debt</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">380,956</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">675,639</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;Accounts payable</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">  35,360</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">       19,162</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;Accrued expenses</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">140,381</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">       82,448</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;Accrued and deferred income taxes</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">61,251</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">       32,261</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;Liabilities of discontinued operations</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<U><FONT SIZE=2><P ALIGN="RIGHT">11,596</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<U><FONT SIZE=2><P ALIGN="RIGHT">214,800</U></FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">665,257</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">      1,040,406 </FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>Long-term debt</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp; Senior</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">17</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">       --</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Convertible subordinated notes</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">  10,000</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Deferred income taxes</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">18,468</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">  47,516</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Other non-current liabilities</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">21,106</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT"> 25,296</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Liabilities of discontinued operations</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<FONT SIZE=2><P ALIGN="RIGHT">  <U>   457</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<U><FONT SIZE=2><P ALIGN="RIGHT">32,752</U></FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total non-current liabilities</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">40,048</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">115,564</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>Commitments and contingencies (see Note 15)</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>Stockholders' equity:</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Class A common stock, $.20 par value (authorized 75,000,000;<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;issued 42,533,593 and 41,277,761)</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">8,507</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">8,256</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Class B common stock, $.20 par value (authorized 15,000,000;<BR>
&nbsp;&nbsp;&nbsp;&nbsp;issued 11,872,897 and 11,872,897)</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">2,375</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">   2,375</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Preferred Stock, $1 par value (authorized 500,000)</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Additional paid in capital</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">1,095,520</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT"> 1,073,921</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Unearned compensation</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;(5,395)</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">     (7,443)</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Accumulated deficit</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;(223,137)</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">   (347,425)</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;47,852</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">     161,602 </FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="TOP" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Treasury stock, at cost</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">  <U>   (7,644)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT"> <U>   (7,644)</U></FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<U><FONT SIZE=2><P ALIGN="RIGHT">&nbsp;918,078</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">   <U>  883,642 </U></FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="72%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P>Total liabilities and stockholders' equity</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">$   <U>1,623,383</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">$  <U> 2,039,612</U></FONT></TD>
</TR>
</TABLE>

<B><FONT SIZE=3><P ALIGN="CENTER"></P><DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

</B><P>See Notes to Consolidated Financial Statements.</P>
<B><P ALIGN="CENTER"></P></DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>

<P ALIGN="CENTER">ALPHARMA INC. AND SUBSIDIARIES<BR>
CONSOLIDATED STATEMENTS OF OPERATIONS<BR>
</B><I>(In thousands, except per share data</FONT>)</P></I>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=679>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="42%" VALIGN="BOTTOM" COLSPAN=3 BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="CENTER">Years Ended December 31,</U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=16>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=16>
<U><FONT SIZE=2><P ALIGN="CENTER">2005 </U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=16>
<U><FONT SIZE=2><P ALIGN="CENTER">2004 </U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=16>
<U><FONT SIZE=2><P ALIGN="CENTER">2003 </U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=4>
<B><FONT SIZE=2><P>&nbsp;</B></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=4>
<B><FONT SIZE=2><P>&nbsp;</B></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=4>
<B><FONT SIZE=2><P>&nbsp;</B></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=4>
<B><FONT SIZE=2><P>&nbsp;</B></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Total revenues </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$    553,617</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">    $   513,329 </FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT"> $    479,467 </FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Cost of sales </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">    217,363</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">    218,712 </U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">      210,298 </U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Gross profit </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;336,254</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">         294,617 </FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">        269,169 </FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=24>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Selling, general and administrative expenses  </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=24>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;213,323</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=24>
<FONT SIZE=2><P ALIGN="RIGHT">         195,054 </FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=24>
<FONT SIZE=2><P ALIGN="RIGHT">         174,379 </FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Research and development </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">26,936</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">           25,431 </FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">           21,837 </FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Asset impairments and other </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">       1,184</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">    11,110 </U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">         4,091 </U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Operating income </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">94,811</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">           63,022 </FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">           68,862 </FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<B><FONT SIZE=2><P>&nbsp;</B></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Interest expense and amortization of debt issuance cost </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">(49,135)</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">         (58,762)</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">         (63,417)</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Loss on extinguishment of debt </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">(7,989)</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">           (2,795)</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">         (29,100)</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Other income (expense), net </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">      6,091</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">       1,238 </U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">       2,610 </U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=33>
<FONT SIZE=2><P ALIGN="JUSTIFY">Income (loss) from continuing operations before&nbsp;</P>
<P ALIGN="JUSTIFY">provision for income taxes </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=33>
<FONT SIZE=2><P ALIGN="RIGHT">43,778                      </FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=33>
<FONT SIZE=2><P ALIGN="RIGHT">     2,703 </FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=33>
<FONT SIZE=2><P ALIGN="RIGHT">    (21,045)</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;Provision (benefit) for income taxes </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">  (18,398)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">     49,466 </U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">      (11,416)</U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="JUSTIFY">Income (loss) from continuing operations</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">62,176</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">(46,763)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">(9,629)</U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="JUSTIFY">Discontinued operations, net of taxes: (Note 3) </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>&nbsp;&nbsp;Income (loss) from discontinued operations </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;36,334</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">(267,974)</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">27,503</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>&nbsp;&nbsp;Gain (loss) from disposals </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">     35,259</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">               --</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">     (4,041)</U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income (loss) from discontinued operations</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<U><FONT SIZE=2><P ALIGN="RIGHT">71,593</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<U><FONT SIZE=2><P ALIGN="RIGHT">(267,974)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<U><FONT SIZE=2><P ALIGN="RIGHT">23,462</U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=10><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=10><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=10><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=10><P></P></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P>Net income (loss) </FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">$<U>   133,769</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">$<U>  (314,737)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">$<U>     13,833</U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP" BGCOLOR="#ffffff" HEIGHT=18><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18><P></P></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P>Earnings (loss) per common share: </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="CENTER">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="CENTER">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="CENTER">&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P>Basic </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="CENTER">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="CENTER">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="CENTER">&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;Income (loss) from continuing operations</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">$         1.18</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT"> $        (0.90)</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">$         (0.19) </FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;Income (loss) from discontinued operations </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<U><FONT SIZE=2><P ALIGN="RIGHT">$         1.37</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">$<U>        (5.15)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT"> $<U>            0.46</U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;Net income (loss) </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">$<U>         2.55</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">$<U>        (6.05)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT"> $<U>            0.27</U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="CENTER">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P>&nbsp;Diluted </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="CENTER">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Income (loss) from continuing operations </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">$        1.17</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT"> $          (0.90)</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT"> $         (0.19)</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Income (loss) from discontinued operations </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">$<U>        1.35</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT"> $<U>          (5.15)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT"> $<U>            0.46 </U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Net income (loss) </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT">$<U>        2.52 </U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT"> $<U>          (6.05)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18>
<FONT SIZE=2><P ALIGN="RIGHT"> $<U>            0.27 </U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP" BGCOLOR="#ffffff" HEIGHT=18><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=18><P></P></TD>
</TR>
</TABLE>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

<FONT SIZE=3><P>See Notes to Consolidated Financial Statements.</P>

</FONT><FONT FACE="CG Times (W1),Times New Roman"><P>&nbsp;</P>
<P>&nbsp;</P></DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</FONT>
<TABLE CELLSPACING=0 BORDER=0 WIDTH=672>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>ALPHARMA INC. AND SUBSIDIARIES<BR>
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY<BR>
<I>(In thousands)</I><BR>
</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="CENTER"><BR>
<BR>
<BR>
Common<BR>
 <U>Stock</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="CENTER"><BR>
<BR>
Additional <BR>
Paid-In <BR>
<U>Capital</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="CENTER"><BR>
<BR>
<BR>
Unearned<BR>
<U>Compensation</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="CENTER"><BR>
Accumulated<BR>
Other<BR>
Comprehensive<BR>
<U>Income (Loss)</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="CENTER"><BR>
<BR>
Retained Earnings <U>(Deficit)</U></FONT></TD>
<TD WIDTH="8%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="CENTER"><BR>
<BR>
<BR>
Treasury <U><BR>
Stock</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="CENTER"><BR>
<BR>
Total<BR>
Stockholders'<BR>
<U> Equity</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP" HEIGHT=10><P></P></TD>
<TD WIDTH="9%" VALIGN="TOP" HEIGHT=10><P></P></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=10><P></P></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=10><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=10><P></P></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=10><P></P></TD>
<TD WIDTH="8%" VALIGN="TOP" HEIGHT=10><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=10><P></P></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Balance, December 31, 2002</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$10,353</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$1,046,802</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>        --</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$(12,092)</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$(27,797)</U></FONT></TD>
<TD WIDTH="8%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$(7,415)</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$1,009,851</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Comprehensive income:</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Net income - 2003 </FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">13,833</FONT></TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">13,833</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Currency translation adjustment</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">103,796</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">103,796</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Minimum pension liability, net</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,514</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,514</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Unrealized gains on derivative contracts, net</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,313</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">1,313</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>&#9;Total comprehensive net loss</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">120,456</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Dividends declared ($.18 per common share)</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(9,320) </FONT></TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(9,320)</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Capital contribution from Parent</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,267</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,267</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Award of, and changes in, restricted stock</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">23</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,970</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(2,993)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">-</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Amortization of restricted shares</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">326</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">326</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Tax benefit realized from stock option plan</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">527</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">527</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Exercise of stock options (Class A) and other</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">46</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,361</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,407</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Employee stock purchase plan</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">       45</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">   4,177</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">        --</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">         --</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">        --</U></FONT></TD>
<TD WIDTH="8%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">        --</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">  4,222</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Balance, December 31, 2003</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>10,467</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>1,059,104</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>     (2,667)</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>94,531</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>(23,284</U>)</FONT></TD>
<TD WIDTH="8%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>(7,415</U>)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>1,130,736</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Comprehensive income:</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Net income - 2004</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(314,737)</FONT></TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(314,737)</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Currency translation adjustment</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">64,834</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">64,834</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Minimum pension liability, net</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">283</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">283</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Unrealized gains on derivative contracts, net</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,954</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">1,954</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>&#9;Total comprehensive net income</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">(247,666)</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Dividends declared ($.18 per common share)</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(9,404) </FONT></TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(9,404)</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Award of, and changes in, restricted stock</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">78</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">7,765</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(7,843)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Amortization of restricted shares</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">3,067</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">3,067</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Exercise of stock options (Class A) and other</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">28</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,585</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(229)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,384</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Employee stock purchase plan</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">     58</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">   4,467</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">        --</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">         --</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">        --</U></FONT></TD>
<TD WIDTH="8%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">        --</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">     4,525</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Balance, December 31, 2004</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>10,631</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>1,073,921</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>(7,443</U>)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>161,602</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>(347,425</U>)</FONT></TD>
<TD WIDTH="8%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>(7,644</U>)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>883,642</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Comprehensive income:</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Net income  - 2005</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">133,769</FONT></TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">133,769</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Currency translation adjustment</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(60,553)</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(60,553)</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Recognition of currency translation on sale of</P>
<P>   Generics business </FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="BOTTOM">
<FONT SIZE=1><P ALIGN="RIGHT">(48,958)</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="BOTTOM">
<FONT SIZE=1><P ALIGN="RIGHT">(48,958)</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Minimum Pension liability, net</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(4,239)</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">(4,239)</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>&#9;Total comprehensive net income</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">20,019</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Dividends declared ($.18 per common share)</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(9,481)</FONT></TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(9,481)</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Award of, and changes in, restricted stock</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">79</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">4,793</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(4,872)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Amortization of restricted shares</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">4,320</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">4,320</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Modification of restricted stock</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">             </FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">           2,349</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,600</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">              4,949</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Modification of stock options</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">            3,271</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT"> </FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">3,271</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Tax benefit realized from stock option plan</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,818</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,818</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Exercise of stock options (Class A) </FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">120</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">4,997</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">5,117</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Employee stock purchase plan</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">       52</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">     4,371</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">           --</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">       --</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">         --</U></FONT></TD>
<TD WIDTH="8%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">       --</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">   4,423</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=1><P>Balance, December 31, 2005</FONT></TD>
<TD WIDTH="9%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$10,882</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$1,095,520</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$(5,395)</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$47,852</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$(223,137)</U></FONT></TD>
<TD WIDTH="8%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$(7,644)</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$918,078</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
</TR>
</TABLE>


<P>&nbsp;</P>
<FONT SIZE=3><P ALIGN="CENTER">See Notes to Consolidated Financial Statements</FONT>.</P>
<B><FONT SIZE=3><P ALIGN="CENTER">ALPHARMA INC. AND SUBSIDIARIES<BR>
CONSOLIDATED STATEMENTS OF CASH FLOWS<BR>
</B><I><U>(In thousands)</I></U><BR>
</P></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=580>
<TR><TD WIDTH="53%" VALIGN="TOP" COLSPAN=3>&nbsp;</TD>
<TD WIDTH="47%" VALIGN="TOP" COLSPAN=5>
<U><FONT SIZE=2><P ALIGN="CENTER">Years Ended December 31,</U></FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="CENTER">2004</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="CENTER">2003</U></FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>Operating activities:</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp; Net income (loss) </FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">$133,769</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">$(314,737)</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">$13,833</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp; Adjustments to reconcile net income<BR>
&nbsp;&nbsp;&nbsp;      to net cash provided by operating&nbsp;activities:</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp; &nbsp;Depreciation and amortization</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">91,194</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">96,403</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">95,201</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Interest accretion on convertible debt</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">7,055</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">6,572</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">6,141</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Amortization of loan costs</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">2,168</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">2,736</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">3,941</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Gain on sale of property</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(2,294)</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;(Gain)/loss on disposal of discontinued operations</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(35,259)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">4,041</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp; Deferred income taxes</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(38,070)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">31,144</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(7,277)</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp; Other non-cash items</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">15,756</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">308,003</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">7,157</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;Change in assets and liabilities:</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Decrease (increase) in accounts receivable</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">9,210</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">25,908</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(12,426)</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Decrease (increase) in inventory</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">71,793</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(529)</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">51,942</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Increase) decrease in prepaid <BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;expenses and other current assets</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
(15,689)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
11,584</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
6,308</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) in accounts payable, accrued<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;expenses and accrued income taxes</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
3,696</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
3,060</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
(18,938)</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;Other, net </FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">1,658</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">  16,018</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">    7,441</U></FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating&nbsp;activities</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">247,281</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">186,162</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">155,070</U></FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>Investing activities:</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;Capital expenditures</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(38,939)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(49,306)</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(42,619)</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;Purchase of businesses and intangibles,<BR>
&nbsp;&nbsp;&nbsp;&nbsp;net of cash acquired</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
(5,159)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
(1,787)</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
(5,252)</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;Proceeds from sale of property</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">    2,355</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>  Purchase of Wynco</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(12,857)</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;Proceeds from sales of businesses</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">804,421</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">21,400</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">    5,967</U></FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided (used) in investing activities</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">760,323</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">(42,550)</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">(39,549</U>)</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>Financing activities:</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;Net advances under lines of credit</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">19,636</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">6,578</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">17,527</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;Proceeds of senior long-term debt</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">25,000</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;Reduction of long-term debt</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(311,836)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(154,264)</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(324,540)</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;(Decrease)/Increase in book overdraft</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(12,318)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">19,992</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">1,930</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;Dividends paid</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(9,481)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(9,404)</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(9,320)</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;Issuance of senior unsecured debt</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">220,000</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;Net capital contribution from parent</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">2,267</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;Proceeds from issuance of common stock </FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">    11,358</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">      6,909</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">    9,054</U></FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) provided by financing activities</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">(302,641)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">(105,189)</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">(83,082</U>)</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;Net cash flows from exchange rate changes</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">(9,977)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">8,166</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">    2,221</U></FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>Increase in cash and cash equivalents</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">694,986</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">46,589</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">34,660</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>Cash and cash equivalents at beginning of year</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">105,212</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">58,623</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">23,963</U></FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=2><P>Cash and cash equivalents at end of year</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">$800,198*</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$105,212</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">$<U>58,623</U></FONT></TD>
<TD WIDTH="2%" VALIGN="TOP">&nbsp;</TD>
</TR>
</TABLE>
</P>

<FONT SIZE=2><P ALIGN="CENTER"></P>
</FONT><FONT SIZE=1><P>*Includes cash of $188 included within Assets of discontinued operations</FONT><FONT SIZE=3>.</P>
<P ALIGN="CENTER"></P>
<P ALIGN="CENTER">See Notes to Consolidated Financial Statements</FONT>.</P>
<FONT SIZE=3><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P>
<B><P ALIGN="CENTER">ALPHARMA INC. AND SUBSIDIARIES<BR>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>
</B><U>(In thousands, except share data)</P>
</U><P><BR>
1.&nbsp;&nbsp;<U>The Company</U><BR>
</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alpharma Inc. and Subsidiaries, (the "Company") is a global specialty pharmaceutical company that develops, manufactures and markets pharmaceutical products for humans and animals.</P>
</FONT><P ALIGN="JUSTIFY"><BR>
<FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 1994, the Company acquired the pharmaceutical, animal health, bulk antibiotic and aquatic animal health business ("Alpharma Oslo") of A. L. Industrier ASA ("A. L. Industrier"), the beneficial owner of 100% of the outstanding shares of the Company's Class B Stock. The Class B stock represents approximately 22.0% of the total outstanding common stock as of December 31, 2005. A. L. Industrier, a Norwegian company, is able to control the Company through its ability to elect more than a majority of the Board of Directors and to cast a majority of the votes in any non-class vote of the Company's stockholders. See Note 17.</P>
</FONT><P ALIGN="JUSTIFY"><BR>
<FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's businesses are organized in three reportable segments, as follows:</P>
<P ALIGN="JUSTIFY"></P></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=310>
<TR><TD VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Branded Pharmaceuticals ("BP")</FONT></TD>
</TR>
<TR><TD VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Active Pharmaceutical Ingredients ("API")</FONT></TD>
</TR>
<TR><TD VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Animal Health ("AH")</FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BP markets one branded pharmaceutical prescription product that is contract manufactured by a third party, a pain medication sold under the trademark KADIAN&reg;.  </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;API develops, manufactures and markets a range of antibiotic fermentation based active pharmaceutical ingredients that are used, primarily by third parties, in the manufacture of finished dose pharmaceutical products.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AH develops, registers, manufactures and markets medicated feed additives ("MFAs") and water soluble vitamins type substances for food producing animals which include poultry, cattle and swine.  In 2004, AH divested its Aquatic Animal Health business. </P>

<P>2.&nbsp;&nbsp;<U>Summary of Significant Accounting Policies and other matters</P>
</U><P><BR>
Basis of Presentation:</P>

<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Consolidated Balance Sheets and Consolidated Statements of Operations have been presented for all periods to classify as Discontinued Operations, the Company's world-wide human generic pharmaceutical business (the "Generics Business", which was sold on December 19, 2005), the Company's former French subsidiary (which was sold in 2003), and ParMed Pharmaceuticals, Inc. ("ParMed", for which the Company reached a definitive agreement to sell on March 8, 2006).  See Note 3.  Consistent with Statement of Financial Accounting Standards ("SFAS") No 95, "Statement of Cash Flows", the Consolidated Statements of Cash Flows have not been reclassified for activities of the discontinued operations.  </P>

<P>Principles of consolidation:<BR>
</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Consolidated Financial Statements include the accounts of the Company and its domestic and foreign subsidiaries.  The effects of all significant intercompany transactions have been eliminated. Certain amounts have been reclassified to conform with the current year presentation.</P>
<P><BR>
Use of estimates:<BR>
</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions. The estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</P>
<P ALIGN="JUSTIFY"><BR>
Cash equivalents:</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash equivalents include all highly liquid investments that have an original maturity of three months or less. </P>

<P ALIGN="JUSTIFY">Accounts receivable and allowance for doubtful accounts:</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade accounts receivable are recorded at the invoiced amount and do not bear interest.  The allowance for doubtful accounts is the best estimate of the amount of probable credit losses in existing accounts receivable.  The allowance is based on historical write-off experience, current economic conditions and a review of individual accounts.  Past due balances over 90 days and over a specified amount are reviewed individually for collectibility.  A specific reserve for individual accounts is recorded when the Company becomes aware of a customer's inability to meet its financial obligations, such as in the case of bankruptcy filings or deterioration in the customer's operating results or financial position.  If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted.  Account balances are charged off against the allowance when it is probable the receivable will not be recovered.  There is no off-balanc
e-sheet credit exposure related to our customers.  </P>
<P ALIGN="JUSTIFY"><BR>
Inventories:</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories are valued at the lower of cost or market.  Cost is determined on a first-in, first-out basis for all inventories. The determination of market value to compare to cost involves assessment of numerous factors, including costs to dispose of inventory and estimated selling prices. Inventory determined to be damaged, obsolete, or otherwise unsaleable is written down to its net realizable value.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company also purchases raw materials, and manufactures finished goods, for certain products prior to the product receiving regulatory approval.  The Company reviews these inventories on a case-by-case basis, and records a write-down of the inventory if it becomes probable that regulatory approval will not be obtained or the cost of the inventory will not be recoverable based on other factors.  </P>
<P ALIGN="JUSTIFY"><BR>
Property, plant and equipment:</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property, plant and equipment are recorded at cost.  Expenditures for additions, major renewals and betterments are capitalized, and expenditures for maintenance and repairs are charged to income as incurred.  When assets are sold or retired, their cost and related accumulated depreciation are removed from the accounts, with any gain or loss included in net income.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciable assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable based on projected undiscounted cash flows associated with the assets. A loss is recognized for the difference between the fair value and the carrying amount of the assets. Fair value is determined based upon a market quote, if available, or is based on valuation techniques.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest is capitalized as part of the acquisition cost of major construction and software development projects.  In 2005, 2004, and 2003; $610, $405, and $167 of interest costs were capitalized, respectively.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation is computed by the straight-line method over the estimated useful lives which are generally as follows:</P>
</FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=370>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P>Buildings</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">30-40 years</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P>Building improvements</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">10-30 years</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P>Machinery and equipment</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"> 2-20 years</FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3>
<P>Goodwill and Intangible Assets:</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company follows SFAS No. 142, "Goodwill and Other Intangible Assets" for all goodwill and intangibles acquired in business combinations. Under SFAS No.142, all goodwill and certain intangible assets determined to have indefinite lives are not amortized but are tested for impairment at least annually. Intangible assets with finite useful lives, such as patents and trademarks are amortized over their useful lives, generally 5-20 years, and reviewed for impairment in accordance with SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets."  See Note 9 for additional detail relating to the Company's goodwill and other intangible assets.</P>
<P ALIGN="JUSTIFY"><BR>
Foreign currency translation and transactions:</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The assets and liabilities of the Company's foreign subsidiaries are translated from their respective functional currencies into U.S. Dollars at rates in effect at the balance sheet date.  Results of operations are translated using average rates in effect during the year.  Foreign currency transaction gains and losses are included in income.  Foreign currency translation adjustments are included in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. The foreign currency translation adjustment for 2005, 2004, and 2003 are net of $275, $(76), and $(1,358), respectively, representing the tax effects associated with long-term intercompany advances to foreign subsidiaries and other liabilities.</P>
<P><BR>
Derivative Instruments:</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's uses derivative instruments on a limited basis, principally to manage its exposures to changes in foreign currency exchange rates and interest rates. The Company carries its derivative instruments at their fair value on the balance sheet, recognizing changes in the fair value of forward foreign exchange contracts in current period earnings and changes in the fair value of interest rate swaps, which are classified as cash flow hedges, in stockholders' equity. </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company selectively enters into forward foreign exchange contracts to buy and sell certain cash flows in non-functional currencies and hedge certain firm commitments due in foreign currencies. Forward foreign exchange contracts, other than hedges of firm commitments, are accounted for as foreign currency transactions and gains or losses are included in income.</P>
<P ALIGN="JUSTIFY"> <BR>
Revenue Recognition:</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenues are recognized when title to products and risk of loss are transferred to customers.  The Company's subsidiaries have terms of FOB shipping point where title and risk of loss transfer on shipment.  Additional conditions for recognition of revenue are that collection of sales proceeds is reasonably assured and the Company has no further performance obligations.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Income taxes:</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The provision for income taxes includes federal, state and foreign income taxes currently payable and those deferred because of temporary differences in the basis of assets and liabilities between amounts recorded for financial statement and tax purposes. Deferred taxes are calculated using the liability method as required by SFAS No. 109 "Accounting for Income Taxes."  A valuation allowance is established, as needed, to reduce the carrying value of net deferred tax assets if realization of such assets is not considered to be "more likely than not."</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2005, virtually all of the undistributed earnings of the Company's foreign subsidiaries were distributed as dividends under the American Jobs Creation Act. </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">See Note 12 for additional disclosures regarding adjustment to deferred tax asset valuation reserves and the tax impact of distributions made under the provisions of the American Jobs Creation Act.</P>
<P><BR>
Proforma Stock Based Compensation:</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has stock-based employee compensation plans, which are described more fully in Note 19. The Company applies the intrinsic-value based method prescribed in Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to Employees", and related Interpretations. No stock-based employee compensation cost is reflected in net income for incentive stock options since all options granted under those plans had an exercise price equal to the market value of the underlying common stock on the date of the grant.  Compensation cost for restricted stock is recorded based on the market value on the date of grant.  The fair value of restricted stock is charged to unearned compensation in Stockholders' Equity and amortized to expense over the requisite vesting periods.  The following table illustrates the effect on net income and earnings per share if the Company had applied the fair value recognition provisions of SFAS No. 123, "Accounting for Stock-Based Compens
ation," as amended by SFAS No. 148, "Accounting for Stock-Based Compensation - Transition and Disclosure," to stock-based employee compensation. No tax benefits were attributed to the stock-based employee compensation expense during fiscal 2004 because the Company maintained a valuation allowance on substantially all of the net U.S. deferred tax assets.</P>
<P ALIGN="JUSTIFY"></P></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=594>
<TR><TD WIDTH="57%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="43%" VALIGN="TOP" COLSPAN=3>
<U><FONT SIZE=3><P ALIGN="CENTER">Years Ended December 31,</U></FONT></TD>
</TR>
<TR><TD WIDTH="57%" VALIGN="TOP" HEIGHT=11><P></P></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=11>
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=11>
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=11>
<U><FONT SIZE=3><P ALIGN="CENTER">2003</U></FONT></TD>
</TR>
<TR><TD WIDTH="57%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="57%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Net income (loss), as reported</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$  133,769</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$(314,737)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$13,833</FONT></TD>
</TR>
<TR><TD WIDTH="57%" VALIGN="TOP">
<FONT SIZE=3><P>Add:  Stock-based employee compensation<BR>
expense included in reported net income,<BR>
net of related tax effects </FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
4,320</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
3,067</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
202</FONT></TD>
</TR>
<TR><TD WIDTH="57%" VALIGN="BOTTOM">
<FONT SIZE=3><P>Deduct: Total stock-based employee<BR>
compensation expense determined <BR>
under fair value based method for all<BR>
awards, net of related tax effects </FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
<BR>
<BR>
8,743</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
<BR>
<BR>
8,206</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
<BR>
<BR>
  5,243</U></FONT></TD>
</TR>
<TR><TD WIDTH="57%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="57%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Pro forma net income (loss)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>  129,346</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>(319,876)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>8,792</U></FONT></TD>
</TR>
<TR><TD WIDTH="57%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="57%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Earnings (loss) per share:</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="57%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic-as reported</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>  2.55</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$(6.05)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>  0.27</U></FONT></TD>
</TR>
<TR><TD WIDTH="57%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic-pro forma</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>  2.46</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$(6.14)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>  0.17</U></FONT></TD>
</TR>
<TR><TD WIDTH="57%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="57%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted-as reported</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>  2.52</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$(6.05)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>  0.27</U></FONT></TD>
</TR>
<TR><TD WIDTH="57%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted-pro forma</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>  2.44</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$(6.14)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>  0.17</U></FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3><P ALIGN="JUSTIFY"></P>
<P>The Company estimated the fair value, as of the date of grant, of options outstanding in the plan using the Black-Scholes option pricing model, with the following assumptions:</P>
</FONT>
<P ALIGN="CENTER"><CENTER><TABLE CELLSPACING=0 BORDER=0 WIDTH=532>
<TR><TD WIDTH="56%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2005</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2004</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2003</U></FONT></TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">
<FONT SIZE=3><P>Expected life (years)</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">3.60</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">4.00</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">4.12</FONT></TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">
<FONT SIZE=3><P>Expected future dividend yield (average)</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1.42%</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">0.87%</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">0.98%</FONT></TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">
<FONT SIZE=3><P>Expected volatility</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">0.56</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">0.58</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">0.57</FONT></TD>
</TR>
</TABLE>
</CENTER></P>

<FONT SIZE=3>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;The risk-free interest rates for 2005, 2004 and 2003 were based upon U.S. Treasury instrument rates with maturity approximating the expected term. The weighted average interest rate in 2005, 2004 and 2003 amounted to 3.8%, 3.2% and 3.0%, respectively. The weighted average fair value of options granted during the years ended December 31, 2005, 2004, and 2003 with exercise prices equal to fair market value on the date of grant was $6.33, $9.31 and $8.81, respectively. </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Comprehensive Income (loss):</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SFAS No. 130, "Reporting Comprehensive Income" requires foreign currency translation adjustments and certain other items, which were reported separately in stockholders' equity, to be included in Other Comprehensive Income (loss). Included within Accumulated Other Comprehensive Income (loss) in 2005 for the Company are foreign currency translation adjustments and changes in the minimum pension liability of $4,239. Total comprehensive income (loss) for the years ended 2005, 2004, and 2003 is included in the Statement of Stockholders' Equity. </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The components of accumulated other comprehensive income/(loss) include:</P>
<P ALIGN="JUSTIFY"></P></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=505>
<TR><TD WIDTH="68%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="32%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="CENTER">           <U>December 31,</U></FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2005</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="TOP" HEIGHT=7><P></P></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=7><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=7><P></P></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Cumulative translation adjustment</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$52,091</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$161,602</FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Minimum pension liability, net</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(4,239)</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">___--</U></FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$47,852</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>161,602</U></FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Segment information:</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SFAS No. 131, "Disclosures about Segments of an Enterprise and Related Information" requires segment information to be prepared using the "management" approach. The management approach is based on the method that management organizes the segments within the Company for making operating decisions and assessing performance. SFAS No. 131 also requires disclosures about products and services, geographic areas, and major customers.  See Note 21 for further details. </P>
</FONT><P ALIGN="JUSTIFY"><BR>
<FONT SIZE=3>Shipping Costs</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for shipping costs in selling, general and administrative expenses for purposes of classification within the Consolidated Statement of Operations. These costs for continuing operations were approximately $13,000, $10,000, and $9,000 for the years ended December 31, 2005, 2004, and 2003, respectively.</P>
</FONT><P ALIGN="JUSTIFY"><BR>
<FONT SIZE=3>Software and Development Costs</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2005, 2004, and 2003, the Company capitalized purchased software from third party vendors and software development costs incurred under the provisions of SOP 98-1, "Accounting for the Cost of Computer Software Developed or Obtained for Internal Use".  Capitalized costs include only (1) external direct costs of materials and services incurred in developing or obtaining internal use software, (2) payroll and payroll-related costs for employees who are directly associated with and who devote substantial time to the internal-use software project, and (3) interest costs incurred, while developing internal-use software. Amortization begins as portions of the projects are completed, ready for their intended purpose and placed in service.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;Research and development costs, business process re-engineering costs, training and computer software maintenance costs are expensed as incurred. Software development costs are being amortized using the straight-line method over the expected life of the projects which are estimated to be five to seven years, depending on when placed in service.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capitalized software costs related to the Company's Enterprise Resource Planning System, net of amortization, through December 31, 2005 and 2004 amounted to approximately $9,105 and $12,053, respectively, and are included in other assets.  All significant software modules were completed and ready for their intended purpose during 2003. </P>
</FONT><P ALIGN="JUSTIFY"><BR>
<FONT SIZE=3>Recent Accounting Pronouncements  </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2004, the Financial Accounting Standards Board, (the "FASB"), issued SFAS No. 123(R), "Accounting for Share-Based Payments" which revises the way companies account for stock issued to employees and non-employees as previously required under Accounting Principles Board ("APB") No. 25,  "Stock Issued to Employees" and SFAS No. 123, "Accounting for Stock-Based Compensation," as amended. SFAS No. 123(R) requires companies to measure the cost of employee services received in exchange for an equity-based award using the grant-date fair value. That cost is to be recognized over the period during which the employee is required to provide service in exchange for the award. Changes in fair value during the requisite service period are to be recognized as compensation cost over that period. Liability-based awards, that is, where settlement will be made in cash rather than stock, will need to be re-measured to fair-value at each balance sheet date. The provisions of the revised 
statement are effective for financial statements issued by the Company for the first interim reporting period beginning after December 31, 2005. Accordingly, the Company will adopt it, effective, January 1, 2006. The Company will use the modified prospective method which requires companies to record compensation expense for all previously issued unvested stock options and restricted stock at the date of the initial adoption and any stock options or restricted stock issued after January 1, 2006. The Company currently uses the Black-Scholes valuation model to calculate compensation expense for stock options for current footnote disclosure purposes and will continue to use this model in determining future compensation expense. The Company expects compensation expense in 2006 to be approximately $3 million, an amount lower than that shown in prior years footnote disclosure because the number of employees has been reduced as a result of the sale of the Generics business.  </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2004, the FASB issued SFAS No. 151, "Inventory Costs". SFAS No. 151 amends the guidance in ARB No. 43, "Inventory Pricing," to clarify the accounting for abnormal amounts of idle facility expense, freight, handling costs, and wasted material (spoilage). ARB 43 states that under some circumstances, items such as idle facility expense, excessive spoilage, freight and handling costs may be so abnormal as to require treatment as current period charges.  This statement requires that those items be recognized as current-period charges regardless of whether they meet the criterion of "so abnormal." In addition, this statement requires that allocation of fixed production overheads to the costs of conversion be based on the normal capacity of the production facilities. SFAS No. 151 is effective for inventory costs incurred during fiscal years beginning after June&nbsp;15, 2005, with early application permitted.  The Company has evaluated the effects of Statement 151 and has d
etermined that it would not have a material effect on the Company's financial statements.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">3.&nbsp;&nbsp;<U>Discontinued Operations &amp; Other Activities</P>
</U></FONT><P ALIGN="JUSTIFY"></P>
<I><FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Sale of the Generics Business</B></I>- On December 19, 2005, the Company sold its world-wide human generic pharmaceutical business (the "Generics Business") to Actavis Group hf on a debt free and cash-free basis for $810,000.  The net assets sold to Actavis Group hf, included the net assets of the Company's operations in China where legal restrictions have prevented the distribution of cash.  The amount of cash so restricted is approximately $5,600.  While the Company may receive a portion of these funds in 2006, the recorded gain from the sale of the Generics Business does not include this cash.  In connection with the sale, the Company recognized a curtailment gain of $1,042 related to its pension plans, which was included in the gain on disposal.</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<I><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Sale of the French Subsidiary</B></I>- On September 30, 2003, the Company sold its French subsidiary, which was previously reported as part of the Generics business, for $5,967. The net loss for this subsidiary for 2003 was $5,611 and is included in the Company's Consolidated Statement of Operations as Income/(Loss) from Discontinued Operations. Included in the 2003 loss are the write-off on sale of the remaining $6,239 of intangible assets and the goodwill write-off on sale of $2,360.</P>
<P ALIGN="JUSTIFY"></P>
<B><I><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assets-held-for-sale </B>-</I>   In the fourth quarter of 2005, as part of its overall restructuring plans which included the sale of the Generics Business, the Company commenced a process to dispose of its generic pharmaceutical telemarketing distribution business, ParMed Pharmaceuticals, Inc. ("ParMed").  On March 8, 2006, the Company reached a definitive agreement to sell ParMed for $40.1 million in cash.  The sale has been approved by the Company's Board of Directors and is expected to close in the first quarter of 2006. </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">The following table details selected financial information for the Generics Business and ParMed, which have been classified as "Discontinued Operations":</P>
<P ALIGN="JUSTIFY"></P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=651>
<TR><TD WIDTH="50%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=16>
<FONT SIZE=2><P>Statements of Operations</FONT></TD>
<TD WIDTH="50%" VALIGN="BOTTOM" COLSPAN=3 BGCOLOR="#ffffff" HEIGHT=16><P></P></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=16><P></P></TD>
<TD WIDTH="50%" VALIGN="BOTTOM" COLSPAN=3 BGCOLOR="#ffffff" HEIGHT=16>
<U><FONT SIZE=2><P ALIGN="CENTER">Years  Ended December 31,</U></FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=4>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=4>
<FONT SIZE=2><P ALIGN="CENTER">              <U>2005 </U></FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=4>
<FONT SIZE=2><P ALIGN="CENTER">              <U>2004 </U></FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=4>
<FONT SIZE=2><P ALIGN="CENTER">            <U>2003* </U></FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Total revenues </FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$   870,178</FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$   826,151</FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">       $   821,914</FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>   Cost of sales </FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">580,683</U></FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">587,730</U></FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">      571,538</U></FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Gross profit </FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">289,495</FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">238,421</FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">250,376</FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>   Operating expenses  </FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">244,853</U></FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">524,572</U></FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">221,541</U></FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Operating income </FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">44,642</FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">(286,151)</FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">28,835</FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Interest expense and amortization of debt issuance cost</FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">(423)</FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">(299)</FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">(207)</FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Other income (expense), net</FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">2,309</U></FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">30,149</U></FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">9,829</U></FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>Income (loss) from discontinued operations before</P>
<P> provision for income taxes</FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">46,528</FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">(256,301)</FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">38,457</FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="JUSTIFY">Provision for income taxes </FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">   10,194</U></FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">11,673</U></FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">   10,954</U></FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P ALIGN="JUSTIFY">Net income (loss) from discontinued  operations</FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">$   36,334</U></FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">$  (267,974)</U></FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<U><FONT SIZE=2><P ALIGN="RIGHT">$   27,503</U></FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">* Includes results of the French subsidiary, which was previously classified as discontinued operations.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">The assets and liabilities of discontinued operations, including ParMed assets and liabilities held for sale are, as follows:</P>
<P ALIGN="JUSTIFY"></P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=486>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>Balance Sheets </FONT></TD>
<TD WIDTH="32%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
<TD WIDTH="32%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
<TD WIDTH="32%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=15>
<U><FONT SIZE=2><P ALIGN="CENTER">December 31,</U></FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>Assets of Discontinued Operations&nbsp;</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<U><FONT SIZE=2><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<U><FONT SIZE=2><P ALIGN="CENTER">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Cash</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<FONT SIZE=2><P ALIGN="RIGHT">$188</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<FONT SIZE=2><P ALIGN="RIGHT">$   -</FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Accounts receivable, net</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<FONT SIZE=2><P ALIGN="RIGHT">6,797</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=8>
<FONT SIZE=2><P ALIGN="RIGHT">154,255</FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Inventories&nbsp;</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">4,727</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">211,818</FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Other current assets</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<U><FONT SIZE=2><P ALIGN="RIGHT">111</U></FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<U><FONT SIZE=2><P ALIGN="RIGHT">   8,913</U></FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<U><FONT SIZE=2><P ALIGN="RIGHT">11,823</U></FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<U><FONT SIZE=2><P ALIGN="RIGHT">374,986</U></FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Property, plant &amp; equipment, net</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">2,365</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">219,392</FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Goodwill, net&nbsp;</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">3,358</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">361,452</FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Intangible assets, net</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">115,537</FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;Other non-current assets</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<U><FONT SIZE=2><P ALIGN="RIGHT">          --</U></FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<U><FONT SIZE=2><P ALIGN="RIGHT">     36,110</U></FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=4>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets&nbsp;</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=4>
<FONT SIZE=2><P ALIGN="RIGHT"> $<U> 17,546</U></FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=4>
<FONT SIZE=2><P ALIGN="RIGHT">$<U>1,107,477</U></FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>Liabilities of Discontinued Operations</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;Account payable&nbsp;</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">$5,819</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">$98,730</FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses&nbsp;</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">1,202</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">104,681</FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;Accrued other and deferred income tax</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<U><FONT SIZE=2><P ALIGN="RIGHT">     4,575</U></FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<U><FONT SIZE=2><P ALIGN="RIGHT">   11,389</U></FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<U><FONT SIZE=2><P ALIGN="RIGHT">   11,596</U></FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<U><FONT SIZE=2><P ALIGN="RIGHT">214,800</U></FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15><P></P></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes&nbsp;</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">457</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P ALIGN="RIGHT">22,939</FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;Other non-current liabilities</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<U><FONT SIZE=2><P ALIGN="RIGHT">           --</U></FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<U><FONT SIZE=2><P ALIGN="RIGHT">9,813</U></FONT></TD>
</TR>
<TR><TD WIDTH="68%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities</FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<U><FONT SIZE=2><P ALIGN="RIGHT">  $ 12,053</U></FONT></TD>
<TD WIDTH="16%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=15>
<U><FONT SIZE=2><P ALIGN="RIGHT">$   247,552</U></FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P ALIGN="JUSTIFY"></P>
<U><P ALIGN="JUSTIFY">Other Activities</P>
</U><P ALIGN="JUSTIFY"></P>
<I><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acquisition and disposal - Wynco, LLC </I> On January 7, 2004, the Company purchased the outstanding 50% interest in its joint venture, Wynco, LLC ("Wynco"), an Animal Health distribution company. The purchase price was $4,331, approximately $900 of which is payable over three years, beginning on December 31, 2004. In connection with the acquisition, the Company assumed debt of approximately $6,677. The investment was previously recorded in accordance with the equity method, with the original 50% interest included in the Company's Consolidated Statement of Operations. As of the date of purchase, the Company consolidated the results of Wynco in the Consolidated Statement of Operations and included all related assets and liabilities in the Consolidated Balance Sheet. Wynco's first quarter 2004 revenues and operating losses were $19,169 and ($111), respectively.  The Company considered this an immaterial acquisition. </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March 30, 2004, the Company sold its 100% interest in this distribution company for $17,000. In connection with the sale, the Company recognized a charge within other income (expense) of $1,090 related to an intangible asset previously held. Excluding this charge, the Company has recognized a loss on the sale of $433.  As part of the transaction, the Company entered into an Agency and Distribution Agreement and Logistics Services Agreement with the buyer.  The operations of Wynco are not classified as Discontinued Operations, as the Company and Wynco had significant continuing involvement.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Disposal-Aquatic Animal Health Group -</I> In July 2004, the Company completed the sale of its Aquatic Animal Health Group ("Aquatic").  This business was included in the Animal Health segment and manufactures and markets vaccines primarily for use in immunizing farmed fish (principally salmon) worldwide. </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets", at June 30, 2004 an impairment loss of $9,474 was recognized in results of operations. In July, the sale was consummated.  Through December 31, 2004, proceeds of approximately $4,400 were received and a net loss of $7,314 was recognized.  </P>

<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The loss does not include a potential "earn out" of up to $2,900 that is contingently payable over three years through 2007, dependent on Aquatic's future profitability.  As of December 31, 2005, no payments had been received and no income was recorded as part of the "earn out".  </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The operations of Aquatic are not classified as discontinued operations, as the Company and Aquatic have significant continuing involvement. The Company and Aquatic will continue to manufacture certain products for each other for at least 3 years from the date of sale and the potential earn out is significant to the cash flows of Aquatic.  The loss on the sale of Aquatics is reported in "Asset Impairments and Other" in the Consolidated Statement of Operations.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The results of Aquatic operations included in the Animal Health segment for the years ended December 31, 2004 and 2003 are summarized, as follows:</P>
</FONT>
<P ALIGN="CENTER"><CENTER><TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=470>
<TR><TD WIDTH="66%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="34%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="CENTER">Years Ended<BR>
<U>December 31,</U></FONT></TD>
</TR>
<TR><TD WIDTH="66%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2003</U></FONT></TD>
</TR>
<TR><TD WIDTH="66%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="66%" VALIGN="TOP">
<FONT SIZE=3><P>Revenues</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$7,044</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$14,976</FONT></TD>
</TR>
<TR><TD WIDTH="66%" VALIGN="TOP">
<FONT SIZE=3><P>Operating loss, including impairments</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$(10,330)</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$(4,322)</FONT></TD>
</TR>
</TABLE>
</CENTER></P>

<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;</P>
<P>4.&nbsp;&nbsp;<U>Reorganization, Refocus and other Actions</P>
</U><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the last three years, the Company incurred severance related to actions in connection with management's reorganization and refocus to improve future operations. These charges are classified as Asset impairments and other within the Consolidated Statements of Operations. The Company has only included severance related to specific programs. Other severance charges not related to specific programs are not segregated from normal operations.  A summary of severance charges recorded, by segment, for the last three years, is as follows:</P>
<B><P ALIGN="JUSTIFY"></P></B></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=520>
<TR><TD WIDTH="38%" VALIGN="TOP">
<FONT SIZE=3><P>Severance charges:</FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2005</U></FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2004</U></FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2003</U></FONT></TD>
</TR>
<TR><TD WIDTH="38%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;API</FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$310</FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$823</FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$305</FONT></TD>
</TR>
<TR><TD WIDTH="38%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AH</FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">84</FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">300</FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">3,786</FONT></TD>
</TR>
<TR><TD WIDTH="38%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate</FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">790</U></FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">      --</U></FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">      --</U></FONT></TD>
</TR>
<TR><TD WIDTH="38%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$1,184</U></FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$1,123</U></FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>4,091</U></FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A summary of liabilities for severance related actions in connection with management's reorganization and refocus is, as follows:</P>
<P ALIGN="JUSTIFY"></P></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=407>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="40%" VALIGN="TOP" COLSPAN=3>
<U><FONT SIZE=3><P ALIGN="CENTER">Severance</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="19%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
<TD WIDTH="0%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Balance, January 1,</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$1,666</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$6,463</FONT></TD>
<TD WIDTH="0%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>Charges, net</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">453</U></FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">351</U></FONT></TD>
<TD WIDTH="0%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2,119</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">6,814</FONT></TD>
<TD WIDTH="0%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="19%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="0%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>Payments</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(675)</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(5,160)</FONT></TD>
<TD WIDTH="0%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="19%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="0%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>Translation adjustments</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(167)</U></FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">     12</U></FONT></TD>
<TD WIDTH="0%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="19%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="0%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>Balance December 31,</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$1,277</U></FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>1,666</U></FONT></TD>
<TD WIDTH="0%" VALIGN="TOP">&nbsp;</TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The liabilities for severance are included in accrued expenses. The Company expects to settle the majority of these liabilities over the next 12 months.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A summary of current liabilities recorded by the Animal Health segment which were established for 2002 closure and exit costs, and 2005 and 2004 related activity is, as follows:</P>
<P ALIGN="JUSTIFY"></P></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=402>
<TR><TD WIDTH="54%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="46%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="CENTER">Other Closure and Exit Costs</U></FONT></TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="24%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="24%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Balance, January 1,</FONT></TD>
<TD WIDTH="22%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$6,449</FONT></TD>
<TD WIDTH="24%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$13,637</FONT></TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="TOP">
<FONT SIZE=3><P>Additions/(deletions)</FONT></TD>
<TD WIDTH="22%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">      304</U></FONT></TD>
<TD WIDTH="24%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">  (560</U>)</FONT></TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">6,753</FONT></TD>
<TD WIDTH="24%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">13,077</FONT></TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="24%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="TOP">
<FONT SIZE=3><P>Payments</FONT></TD>
<TD WIDTH="22%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(1,306)</FONT></TD>
<TD WIDTH="24%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(6,461)</FONT></TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="24%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="TOP">
<FONT SIZE=3><P>Translation adjustments</FONT></TD>
<TD WIDTH="22%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">     (37)</U></FONT></TD>
<TD WIDTH="24%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">  (167</U>)</FONT></TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="24%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="TOP">
<FONT SIZE=3><P>Balance December 31,</FONT></TD>
<TD WIDTH="22%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$5,410</U></FONT></TD>
<TD WIDTH="24%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>6,449</U></FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The remaining balances as of December 31, 2005 are included in accrued expenses and primarily relate to contractually required demolition costs, payments related to a discontinued product, lease obligations and other contractually committed costs associated with facility closures announced in 2002. The Company expects to settle these liabilities over the next twelve months.</P>
</FONT><P><BR>
<FONT SIZE=3>5.&nbsp;&nbsp;<U>Earnings Per Share (shares in thousands)</P>
</U><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A reconciliation of weighted average shares outstanding for basic to diluted shares outstanding used in the calculation of EPS is, as follows:</P>
</FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=559>
<TR><TD WIDTH="53%" VALIGN="TOP" HEIGHT=19><P></P></TD>
<TD WIDTH="47%" VALIGN="TOP" COLSPAN=3 HEIGHT=19>
<U><FONT SIZE=3><P ALIGN="CENTER">For the years ended December 31,</U></FONT></TD>
</TR>
<TR><TD WIDTH="53%" VALIGN="TOP" HEIGHT=19><P></P></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=19>
<U><FONT SIZE=3><P ALIGN="RIGHT">2005</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP" HEIGHT=19>
<U><FONT SIZE=3><P ALIGN="RIGHT">2004</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=19>
<U><FONT SIZE=3><P ALIGN="RIGHT">2003</U></FONT></TD>
</TR>
<TR><TD WIDTH="53%" VALIGN="TOP" HEIGHT=19>
<FONT SIZE=3><P>Average shares outstanding-basic</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=19>
<FONT SIZE=3><P ALIGN="RIGHT">52,526</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP" HEIGHT=19>
<FONT SIZE=3><P ALIGN="RIGHT">52,060</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=19>
<FONT SIZE=3><P ALIGN="RIGHT">51,606</FONT></TD>
</TR>
<TR><TD WIDTH="53%" VALIGN="TOP" HEIGHT=19>
<FONT SIZE=3><P>Stock options</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=19><DIR>
<DIR>
<DIR>

<U><FONT SIZE=3><P ALIGN="RIGHT">455</DIR>
</DIR>
</DIR>
</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP" HEIGHT=19><DIR>
<DIR>
<DIR>

<U><FONT SIZE=3><P ALIGN="RIGHT">__--</DIR>
</DIR>
</DIR>
</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=19><DIR>
<DIR>
<DIR>

<U><FONT SIZE=3><P ALIGN="RIGHT">404</DIR>
</DIR>
</DIR>
</U></FONT></TD>
</TR>
<TR><TD WIDTH="53%" VALIGN="TOP" HEIGHT=19>
<FONT SIZE=3><P>Average shares outstanding-diluted</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=19>
<U><FONT SIZE=3><P ALIGN="RIGHT">52,981</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP" HEIGHT=19>
<U><FONT SIZE=3><P ALIGN="RIGHT">52,060</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=19>
<U><FONT SIZE=3><P ALIGN="RIGHT">52,010</U></FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The amount of dilution attributable to the stock options determined by the treasury stock method depends on the average market price of the Company's common stock for the year. For the years ended December 31, 2005, 2004 and 2003 stock options to purchase approximately 1,355, 1,860 and 1,915 shares, respectively, were not included because the option price was greater than the average price.  Stock options had an anti-dilutive effect in 2004 and therefore stock options to purchase approximately 1,597 were not included in the diluted EPS calculation. </P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P ALIGN="JUSTIFY">     The numerator for the calculation of basic EPS is Net income (loss) for all periods.  The numerator for the calculation of diluted EPS is Net income (loss) plus an add back for interest expense and debt cost amortization, net of income tax effects, related to the convertible notes when applicable.  The effects of the 5.75% Convertible Subordinated Notes (the "05 Notes") were not included in the calculation of diluted EPS for the years ended December 31, 2005, 2004 or 2003 because the result was anti-dilutive. On April 1, 2005, the Company repaid the 05 Notes ($9,752 as of March 31, 2005).  In addition, the effects of the 06 Notes were not included in the calculation of the diluted EPS for the years ended December 31, 2005, 2004 and 2003 because the result was anti-dilutive.  On January 23, 2006, the Company paid off the balance due on the 06 Notes, including accrued interest, in the amount of $161,929.  </P>
</FONT><P><BR>
6.&nbsp;&nbsp;<U><FONT SIZE=3>Accounts Receivable, Net</P>
</U><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Accounts receivable consists of the following:</P>
<P ALIGN="JUSTIFY"></P></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=408>
<TR><TD WIDTH="63%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<I><FONT SIZE=3><P>&nbsp;</I></FONT></TD>
<TD WIDTH="37%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P ALIGN="CENTER">December 31, </FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P>&nbsp;</FONT></TD>
<TD WIDTH="18%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="19%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P>Accounts receivable, trade</FONT></TD>
<TD WIDTH="18%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P ALIGN="RIGHT">$82,475</FONT></TD>
<TD WIDTH="19%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P ALIGN="RIGHT"> $69,714 </FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P>Other</FONT></TD>
<TD WIDTH="18%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<U><FONT SIZE=3><P ALIGN="RIGHT">9,188&nbsp;</U></FONT></TD>
<TD WIDTH="19%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<U><FONT SIZE=3><P ALIGN="RIGHT">  3,778 </U></FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P>&nbsp;</FONT></TD>
<TD WIDTH="18%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P ALIGN="RIGHT">&nbsp;91,663</FONT></TD>
<TD WIDTH="19%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P ALIGN="RIGHT">73,492 </FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=22>
<FONT SIZE=3><P>Less, allowance for doubtful accounts</FONT></TD>
<TD WIDTH="18%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=22>
<U><FONT SIZE=3><P ALIGN="RIGHT">     765</U></FONT></TD>
<TD WIDTH="19%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=22>
<U><FONT SIZE=3><P ALIGN="RIGHT">1,156</U></FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=24>
<FONT SIZE=3><P>&nbsp;</FONT></TD>
<TD WIDTH="18%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=24>
<U><FONT SIZE=3><P ALIGN="RIGHT">$ 90,898</U></FONT></TD>
<TD WIDTH="19%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=24>
<U><FONT SIZE=3><P ALIGN="RIGHT">$72,336 </U></FONT></TD>
</TR>
</TABLE>
</P>

<B><FONT SIZE=3><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
</B><P ALIGN="JUSTIFY">The allowance for doubtful accounts for the three years ended December 31, consists of the following:</P>
</FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=595>
<TR><TD WIDTH="54%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
<TD WIDTH="15%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<U><FONT SIZE=3><P ALIGN="CENTER">2003</U></FONT></TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P>Balance at January 1,</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P ALIGN="RIGHT">&nbsp;$1,156</FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P ALIGN="RIGHT">$1,642 </FONT></TD>
<TD WIDTH="15%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P ALIGN="RIGHT">$2,059</FONT></TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P>Provision for doubtful accounts</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P ALIGN="RIGHT">&nbsp;358</FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P ALIGN="RIGHT">(267)</FONT></TD>
<TD WIDTH="15%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P ALIGN="RIGHT">(9)</FONT></TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P>Reduction for accounts written off</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P ALIGN="RIGHT">&nbsp;(550)</FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P ALIGN="RIGHT">(261)</FONT></TD>
<TD WIDTH="15%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P ALIGN="RIGHT">(188)</FONT></TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=21>
<FONT SIZE=3><P>Translation and other</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=21>
<U><FONT SIZE=3><P ALIGN="RIGHT"> (199)</U></FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=21>
<U><FONT SIZE=3><P ALIGN="RIGHT">    42 </U></FONT></TD>
<TD WIDTH="15%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=21>
<U><FONT SIZE=3><P ALIGN="RIGHT"> (220)</U></FONT></TD>
</TR>
<TR><TD WIDTH="54%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=25>
<FONT SIZE=3><P>Balance at December 31, </FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=25>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>   765</U></FONT></TD>
<TD WIDTH="17%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=25>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>1,156 </U></FONT></TD>
<TD WIDTH="15%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=25>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>1.642</U></FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3>
<P>7.&nbsp;&nbsp;<U>Inventories</P>
</U><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories consist of the following:&#9;</P>
<P ALIGN="JUSTIFY"></P></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=468>
<TR><TD WIDTH="60%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<I><FONT SIZE=3><P>&nbsp;</I></FONT></TD>
<TD WIDTH="40%" VALIGN="BOTTOM" COLSPAN=2 BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P ALIGN="CENTER">December 31, </FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P>&nbsp;</FONT></TD>
<TD WIDTH="19%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="21%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P>Finished product</FONT></TD>
<TD WIDTH="19%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P ALIGN="RIGHT">$49,857</FONT></TD>
<TD WIDTH="21%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P ALIGN="RIGHT"> $54,182</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P>Work-in-progress</FONT></TD>
<TD WIDTH="19%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P ALIGN="RIGHT">28,061</FONT></TD>
<TD WIDTH="21%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P ALIGN="RIGHT"> 28,977</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<FONT SIZE=3><P>Raw materials</FONT></TD>
<TD WIDTH="19%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<U><FONT SIZE=3><P ALIGN="RIGHT"> 14,823</U></FONT></TD>
<TD WIDTH="21%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=20>
<U><FONT SIZE=3><P ALIGN="RIGHT"> 15,027</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=24>
<FONT SIZE=3><P>Total</FONT></TD>
<TD WIDTH="19%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=24>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>92,741</U></FONT></TD>
<TD WIDTH="21%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=24>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>98,186</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=21>
<FONT SIZE=3><P>&nbsp;</FONT></TD>
<TD WIDTH="19%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=21><P></P></TD>
<TD WIDTH="21%" VALIGN="BOTTOM" BGCOLOR="#ffffff" HEIGHT=21>
<FONT SIZE=3><P ALIGN="RIGHT">&nbsp;</FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3>
<P>&nbsp;&nbsp;8.&nbsp;&nbsp;<U>Property, Plant and Equipment, Net</P>
</U><P><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property, plant and equipment, net, consists of the following:</P>
</FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=468>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="40%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="CENTER">December 31,</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="19%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="19%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="21%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>Land</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$    6,096</FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$    6,394</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>Buildings and building improvements</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">93,573</FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">102,083</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>Machinery and equipment</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">293,883</FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">283,693</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>Construction in-progress</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">6,271</U></FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">25,199</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">399,823</FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">417,369</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>Less, accumulated depreciation</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">184,649</U></FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">179,465</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U> 215,174</U></FONT></TD>
<TD WIDTH="21%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U> 237,904</U></FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the Company's closing of plant facilities, the assets representing the fair value of Animal Health's Lowell and Terre Haute facilities totaling $4,325 as of December 31, 2005, are being held for sale, and are included in property, plant and equipment.  </P>
<P ALIGN="JUSTIFY"><BR>
9.&nbsp;&nbsp;<U>Goodwill and Intangible Assets</P>
<P ALIGN="JUSTIFY"></P>
</U><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible assets consist principally of products rights, including regulatory and/or marketing approvals by relevant government authorities. Annual intangible asset amortization expense for the years 2006 through 2010 is currently estimated to be approximately $19,400, $18,300, $18,100, $17,900 and $17,900, respectively.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible assets and accumulated amortization are summarized, as follows:</P>
<P ALIGN="JUSTIFY"></P></FONT>
<P ALIGN="CENTER"><CENTER><TABLE CELLSPACING=0 BORDER=0 WIDTH=462>
<TR><TD WIDTH="74%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Balance, December 31, 2003</FONT></TD>
<TD WIDTH="26%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$218,109</FONT></TD>
</TR>
<TR><TD WIDTH="74%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="26%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="74%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Additions</FONT></TD>
<TD WIDTH="26%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">300</FONT></TD>
</TR>
<TR><TD WIDTH="74%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Amortization</FONT></TD>
<TD WIDTH="26%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(19,536)</FONT></TD>
</TR>
<TR><TD WIDTH="74%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Impairments (product rights)</FONT></TD>
<TD WIDTH="26%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(5,565)</FONT></TD>
</TR>
<TR><TD WIDTH="74%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Translation adjustment</FONT></TD>
<TD WIDTH="26%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">1,873</U></FONT></TD>
</TR>
<TR><TD WIDTH="74%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="26%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="74%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Balance, December 31, 2004</FONT></TD>
<TD WIDTH="26%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">195,181</FONT></TD>
</TR>
<TR><TD WIDTH="74%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="26%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="74%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Additions</FONT></TD>
<TD WIDTH="26%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">3,297</FONT></TD>
</TR>
<TR><TD WIDTH="74%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Amortization</FONT></TD>
<TD WIDTH="26%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(19,693)</FONT></TD>
</TR>
<TR><TD WIDTH="74%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Write-off of intangibles on sale and impairments</FONT></TD>
<TD WIDTH="26%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(600)</FONT></TD>
</TR>
<TR><TD WIDTH="74%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Translation adjustment</FONT></TD>
<TD WIDTH="26%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(2,102)</U></FONT></TD>
</TR>
<TR><TD WIDTH="74%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="26%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="74%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Balance, December 31, 2005</FONT></TD>
<TD WIDTH="26%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>176,083</U></FONT></TD>
</TR>
<TR><TD WIDTH="74%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="26%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="74%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Accumulated amortization, December 31, 2004</FONT></TD>
<TD WIDTH="26%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>113,930</U></FONT></TD>
</TR>
<TR><TD WIDTH="74%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Accumulated amortization, December 31, 2005</FONT></TD>
<TD WIDTH="26%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>133,623</U></FONT></TD>
</TR>
</TABLE>
</CENTER></P>

<FONT SIZE=3><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The changes in the carrying amount of goodwill attributable to the Company's reportable segments for the years ended December 31, 2004 and 2005, are as follows:</P>
</FONT><P ALIGN="JUSTIFY"></P>
<P ALIGN="CENTER"><CENTER><TABLE CELLSPACING=0 BORDER=0 WIDTH=445>
<TR><TD WIDTH="53%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=5>
<U><FONT SIZE=3><P ALIGN="CENTER">BP</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=5>
<U><FONT SIZE=3><P ALIGN="CENTER">API</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=5>
<U><FONT SIZE=3><P ALIGN="CENTER">Total</U></FONT></TD>
</TR>
<TR><TD WIDTH="53%" VALIGN="TOP">
<FONT SIZE=3><P>Balance December 31, 2003</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$115,219</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$2,952</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$118,171</FONT></TD>
</TR>
<TR><TD WIDTH="53%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="53%" VALIGN="TOP" HEIGHT=57>
<FONT SIZE=3><P>Reduction of goodwill due to <BR>
  realization of pre-acquisition tax    <BR>
  benefit</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=57>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
(1,246)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=57>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
</U>--</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=57>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
(1,246)</FONT></TD>
</TR>
<TR><TD WIDTH="53%" VALIGN="TOP">
<FONT SIZE=3><P>Translation adjustment</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">         --</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">     244</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">       244</U></FONT></TD>
</TR>
<TR><TD WIDTH="53%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="53%" VALIGN="TOP">
<FONT SIZE=3><P>Balance December 31, 2004</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">113,973</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">3,196</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">117,169</FONT></TD>
</TR>
<TR><TD WIDTH="53%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="53%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Translation adjustment</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">             --</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">  (422)</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">      (422)</U></FONT></TD>
</TR>
<TR><TD WIDTH="53%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="53%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Balance December 31, 2005</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$113,973</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$2,774</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$116,747</U></FONT></TD>
</TR>
</TABLE>
</CENTER></P>

<FONT SIZE=3><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As required in the fourth quarter of 2005, the Company performed the required annual test for impairment. The assessment was made in conjunction with the budgeting and long-range planning by each segment. The assessment utilized forecasted cash flows discounted at a rate of 10%. </P>

<P>10.&nbsp;&nbsp;<U>Long-Term Debt</U><BR>
</P>
<P>Long-term debt consists of the following:</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 WIDTH=517>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER"><BR>
<U>2005</U></FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER"><BR>
<U>2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Senior debt:</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;U.S. Dollar Denominated:</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2001 U.S. Bank Credit Facility </FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Term A</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$           --</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$51,792</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Term B</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">225,177</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revolving Credit</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"> --        </FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">   25,000</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP" HEIGHT=8>
<FONT SIZE=3><P ALIGN="JUSTIFY">     Other, foreign</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP" HEIGHT=8>
<U><FONT SIZE=3><P ALIGN="RIGHT">         25</U></FONT></TD>
<TD WIDTH="20%" VALIGN="TOP" HEIGHT=8>
<U><FONT SIZE=3><P ALIGN="RIGHT">           --</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP" HEIGHT=8><P></P></TD>
<TD WIDTH="20%" VALIGN="TOP" HEIGHT=8>
<FONT SIZE=3><P ALIGN="RIGHT">25</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP" HEIGHT=8>
<FONT SIZE=3><P ALIGN="RIGHT">301,969</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.625% Senior Notes due 2011</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">220,000</U></FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">220,000</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total senior debt</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">220,025</U></FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">521,969</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Subordinated debt:</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP"><DIR>

<FONT SIZE=3><P>&nbsp;&nbsp;3%&nbsp;&nbsp;Convertible Senior Subordinated<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notes due 2006 (6.875% yield), <BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;including interest accretion</DIR>
</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
160,948</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
<BR>
153,918</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP"><DIR>

<FONT SIZE=3><P>&nbsp;&nbsp;5.75% Convertible Subordinated Notes  due 2005</DIR>
</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">            -</U></FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">  9,752</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;Total subordinated debt</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">160,948</U></FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">163,670</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total long-term debt</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">380,973</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">685,639</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less, current maturities</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">380,956</U></FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">  675,639</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$        17</U></FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>10,000</U></FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balances at December 31, 2004 include the classification of certain long-term debt of $503,293 as current, due to violations of certain debt covenants at December 31, 2004, that served to make the associated debt obligations callable.  In April and May 2005, the Company cured all such violations and accordingly, the associated debt obligations were no longer callable.  </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2005, the Company generated significant cash flow from operations, which when combined with the net proceeds from the sale of its Generics Business in December 2005, allowed the Company to pay down a significant amount of its debt.  Charges resulting from the write off of deferred loan costs resulting from such prepayments of debt totaled $7,989 and are included in Loss on extinguishment of debt within the Consolidated Statement of Operations.  At December 31, 2005, the Company's 8.625% Senior Notes, due 2011, in the amount of $220,000, and its 06 Notes, due June 30, 2006, in the amount of $160,948 and certain international short-term debt of $35,713 were outstanding.  The short-term international debt outstanding was repaid in January 2006.  The Senior Notes and the Convertible Notes required a 30 day notice prior to redemption.  On December 23, 2005, the Company gave notice to the Trustee's under both the Senior Notes and the Convertible Notes that it
 was irrevocably electing to redeem all such notes in accordance with the terms of the respective note indentures.  On January 23, 2006, the Company paid off the balance due on both the 8.625% Senior Notes and 06 Notes including principal and accrued interest of $386,251 and call premium in the amount of $18,894.</P>
<P ALIGN="JUSTIFY">   </P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On October 26, 2005, the Company entered into a five-year, Senior Secured Credit Facility with Bank of America N.A. consisting of a $175,000 asset-based, revolving loan facility and a $35,000 term loan. The Company used $119,122 of this facility to repay and retire the 2001 U. S. Bank Credit Facility in October 2005.  The Senior Secured Credit Facility was subsequently fully paid down in December 2005 with the proceeds from the sale of the Generics business. The asset-based, revolving loan availability was reduced to $75,000 and the term loan was cancelled. </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Senior Secured Credit Facility is secured by the accounts receivable, inventory and certain fixed assets of the U.S. subsidiaries of the Company. The amount that is available to Company to be borrowed is determined monthly based upon the calculation of a Borrowing Base. As of December 31, 2005, there were no amounts outstanding under this Facility.  The interest rate that the Company would pay on outstanding amounts is based upon a spread over LIBOR or Base Rate. The spread ranges between 1.25% to 2.00% over LIBOR and 0% to 0.50% over the Base Rate. The determination of the spread is based upon the amount of availability under the facility with a lower spread payable based upon greater availability. As long as the Company does not have average availability less than $15,000 over a consecutive 10 day period, there are no financial covenants. In the event that the Company was to breach the availability threshold, the Company would be subject to a minimum Fix
ed Charge Coverage Ratio of 1:1.</P>
<P ALIGN="JUSTIFY"></P>
<P>11.&nbsp;&nbsp;<U>Short-Term Debt</P>
</U>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Short-term debt consists of the following:<BR>
</P></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=288>
<TR><TD WIDTH="50%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="50%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="CENTER">December 31,</FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="27%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="23%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="27%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="23%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>Domestic</FONT></TD>
<TD WIDTH="27%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$        --</FONT></TD>
<TD WIDTH="23%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$16,000</FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>Foreign</FONT></TD>
<TD WIDTH="27%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">35,713</U></FONT></TD>
<TD WIDTH="23%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">      96</U></FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="27%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$35,713</U></FONT></TD>
<TD WIDTH="23%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>16,096</U></FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December 28, 2005, Alpharma AS, a subsidiary of the Company, borrowed 30,000 EUR ($35,713) under a three month, short-term loan facility from DnB NOR Bank ASA.  On January 3, 2006, the Company fully repaid this loan, including interest.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">12.&nbsp;&nbsp;<U>Income Taxes</U>   </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Domestic and foreign income (loss) before taxes were $(10,576) and $54,354, respectively in 2005, $(68,763) and $71,466, respectively in 2004 and $(37,840) and $16,795 respectively in 2003. Taxes on income of foreign subsidiaries are provided at the tax rates applicable to their respective foreign tax jurisdictions. The provision (benefit) for income taxes consists of the following:</P>
</FONT>
<TABLE CELLSPACING=0 BORDER=0 WIDTH=636>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="40%" VALIGN="TOP" COLSPAN=3>
<FONT SIZE=3><P ALIGN="CENTER">For the years ended December 31,</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2003</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>Current</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;Federal</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ 24,333</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ 4,246</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ 16,412</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;Foreign</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">11,824</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">16,520</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">5,592</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;State</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2,372</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">1,805</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2,708</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">38,529</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">22,571</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">24,712</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>Deferred</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;Federal</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(55,857)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">22,151</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(34,227)</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;Foreign</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(1,726)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(678)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(1,420)</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;State</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">656</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">5,422</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(481)</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(56,927)</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">26,895</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(36,128)</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>Provision (benefit) for income<BR>
&nbsp;taxes from continuing operations</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM">
<FONT SIZE=3><P ALIGN="RIGHT">(18,398)</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM">
<FONT SIZE=3><P ALIGN="RIGHT">49,466</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM">
<FONT SIZE=3><P ALIGN="RIGHT">(11,416)</FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>Provision (benefit) for discontinued operations</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">10,194</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">11,673</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">10,954</U></FONT></TD>
</TR>
<TR><TD WIDTH="60%" VALIGN="TOP">
<FONT SIZE=3><P>Provision (benefit) for income taxes</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ (8,204)</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ 61,139</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ (462)</U></FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A reconciliation of U.S. federal income taxes to tax provision for continuing operations follows:<BR>
</P></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=557>
<TR><TD WIDTH="58%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="42%" VALIGN="TOP" COLSPAN=3>
<FONT SIZE=3><P ALIGN="CENTER">Years Ended December 31,</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2003</U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P>Statutory U.S. federal </FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ 15,322</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ 946</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ (7,366)</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P>State income tax, net of federal tax benefit</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,968</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">4,501</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,447</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P>Lower taxes on foreign earnings, net</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(9,243)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(7,467)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(2,041)</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P>Tax credits</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(1,108)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(1,159)</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P>Non-deductible costs, principally impairment of <BR>
&nbsp;&nbsp;intangibles related to acquired companies</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
- --</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">              1,962       </FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">                144</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P>Section 965 tax on repatriation</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">28,564</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P>Change in valuation allowance</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(52,121)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">59,534</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,110</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P>Other, net</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(2,888)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(8,902)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(3,551)</U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax provision, continuing operations</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ (18,398)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ 49,466</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ (11,416)</U></FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3>
<P>Deferred tax assets (liabilities) are comprised of the following:<BR>
</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 WIDTH=558>
<TR><TD WIDTH="70%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="30%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="CENTER">Years Ended December 31,</FONT></TD>
</TR>
<TR><TD WIDTH="70%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="70%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="70%" VALIGN="TOP">
<FONT SIZE=3><P>Accelerated depreciation and amortization for income tax purposes</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$(18,468)</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"> $(47,130)</FONT></TD>
</TR>
<TR><TD WIDTH="70%" VALIGN="TOP">
<FONT SIZE=3><P>Excess of book basis of acquired assets over tax basis</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(309)</FONT></TD>
</TR>
<TR><TD WIDTH="70%" VALIGN="TOP">
<FONT SIZE=3><P>Difference between inventory valuation methods used for book and <BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;tax purposes</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
290</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
(1,707)</FONT></TD>
</TR>
<TR><TD WIDTH="70%" VALIGN="TOP">
<FONT SIZE=3><P>Other</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(4,112)</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(77)</U></FONT></TD>
</TR>
<TR><TD WIDTH="70%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross deferred tax liabilities</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(22,290)</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(49,223)</U></FONT></TD>
</TR>
<TR><TD WIDTH="70%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="70%" VALIGN="TOP">
<FONT SIZE=3><P>Accrued liabilities and other reserves</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">30,686</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">55,145</FONT></TD>
</TR>
<TR><TD WIDTH="70%" VALIGN="TOP">
<FONT SIZE=3><P>Pension liabilities</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">6,334</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">4,057</FONT></TD>
</TR>
<TR><TD WIDTH="70%" VALIGN="TOP">
<FONT SIZE=3><P>Loss carryforwards and tax credits</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">94,717</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">90,152</FONT></TD>
</TR>
<TR><TD WIDTH="70%" VALIGN="TOP">
<FONT SIZE=3><P>Deferred compensation</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">880</FONT></TD>
</TR>
<TR><TD WIDTH="70%" VALIGN="TOP">
<FONT SIZE=3><P>Deferred income</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,263</FONT></TD>
</TR>
<TR><TD WIDTH="70%" VALIGN="TOP">
<FONT SIZE=3><P>Other</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">1,345</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">6,878</U></FONT></TD>
</TR>
<TR><TD WIDTH="70%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;Gross deferred tax assets</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">133,082</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT"> 158,375</U></FONT></TD>
</TR>
<TR><TD WIDTH="70%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="70%" VALIGN="TOP">
<FONT SIZE=3><P>Deferred tax assets valuation allowance</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(49,040)</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(103,251)</U></FONT></TD>
</TR>
<TR><TD WIDTH="70%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="70%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net deferred tax assets (liabilities) </FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$61,752</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>5,901</U></FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred tax assets are evaluated quarterly to assess the likelihood of realization which is ultimately dependent upon generating future taxable income prior to the expiration of the net operating loss carryforwards.  At December 31, 2004, the Company had recorded significant U.S. federal deferred tax assets for which it had provided a full valuation allowance given that it was not considered to be "more likely than not" that these deferred tax assets would be realized. At December 31, 2005, the Company made the decision to reverse the remaining valuation allowance because it now believes that it is "more likely than not" that these assets will be realized.  The Company's cash flow generated throughout 2005, including the net proceeds from the sale of the Generics Business, enabled the Company to pay off all of its domestic debt by January 23, 2006 which in turn, will serve to eliminate related interest expense, thereby increasing future profitability.  In add
ition, it is expected that the remaining domestic business segments, which have been profitable for the past three years, will continue to be profitable.   </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has state loss carryforwards in several states which are available to offset future taxable income.  The Company has recognized a deferred tax asset related to these loss carryforwards.  Based on analysis of current information, which indicated that it is not more likely than not that the state losses will be realized, a valuation allowance has been established for $15,124 of these loss carryforwards.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">     Gross deferred tax liabilities of $3,822 and $1,707 are included within accrued and deferred income taxes, at December 31, 2005 and 2004, respectively.  Non-current deferred income taxes amount to $18,468 and $47,516 at December 31, 2005 and 2004, respectively.  Current deferred tax assets are included within prepaid expenses and other current assets and, net of valuation allowance, amount to $32,031 and $0 at December 31, 2005 and 2004, respecitively.  Other assets and deferred charges include deferred tax assets, net of valuation allowances, of $52,011 and $55,123 as of December 31, 2005 and 2004, respectively.</P>
<P ALIGN="JUSTIFY"></P>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the U.S. federal, state and foreign tax loss and tax credit carryforwards, and the corresponding valuation allowances, as of December 31, 2005:</P>
</FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=680>
<TR><TD WIDTH="30%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="JUSTIFY"><BR>
Description</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER"><BR>
Gross NOL</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER"><BR>
<U>Asset</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">Valuation <BR>
<U>Allowance</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="JUSTIFY"><BR>
Expiration</U></FONT></TD>
</TR>
<TR><TD WIDTH="30%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Federal net operating losses</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$152,656</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$53,430</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$  --</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2021 to 2024</FONT></TD>
</TR>
<TR><TD WIDTH="30%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">State net operating losses</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">364,151</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">15,124</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">15,124</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2009 to 2024</FONT></TD>
</TR>
<TR><TD WIDTH="30%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Foreign net operating losses</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">45,364</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">12,702</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">11,812</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2005 to Unlimited</FONT></TD>
</TR>
<TR><TD WIDTH="30%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Research credit</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">N/A</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">7,006</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">7,006</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2021 to 2024</FONT></TD>
</TR>
<TR><TD WIDTH="30%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Capital loss carryforward</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">N/A</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">6,455</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">6,455</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2010</FONT></TD>
</TR>
<TR><TD WIDTH="30%" VALIGN="TOP">
<B><FONT SIZE=3><P ALIGN="JUSTIFY">Total</B></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$94,717</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$40,397</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">&nbsp;</TD>
</TR>
</TABLE>

<P ALIGN="JUSTIFY"><BR>
<FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal income tax returns for all years after 2002 are still subject to audit by the Internal Revenue Service. The provisions for unpaid foreign, U.S., federal and state and local income taxes reflected in the consolidated balance sheet are adequate to cover assessments which might result from examinations to be made by the respective tax jurisdictions. </P>
</FONT><P ALIGN="JUSTIFY"><BR>
<FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The American Jobs Creation Act of 2004 (the "Act") was signed into law on October 22, 2004.  The Act provided for a temporary incentive for U.S. corporations to repatriate accumulated income earned outside the U.S. by allowing an 85% dividend-received deduction for certain dividends from controlled foreign corporations. At December 31, 2004, the Company had not determined whether or to what extent it would repatriate any foreign earnings under the Act and therefore did not accrue any taxes in 2004.  In 2005, the Company made a decision to repatriate foreign earnings of $497,000 under the Act. The tax impact of repatriating this $497,000 is approximately $28,600 and is included in the provision for income taxes. </P>
</FONT><P ALIGN="JUSTIFY"><BR>
<FONT SIZE=3>13.&nbsp;&nbsp;<U>Pension Plans and Postretirement Benefits</P>
</U><P><BR>
<B><U>Domestic:</P>
</B></U><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains two qualified noncontributory, defined benefit pension plans covering the majority of its U.S. (domestic) employees: the Alpharma Inc. Pension Plan and the frozen Faulding Inc. Pension Plan.  The liabilities associated with these Plans were retained by the Company in connection with the sale of the Generics Business. The benefits are based on years of service and the employee's highest consecutive five years compensation during the last ten years of service. The Company's funding policy is to contribute annually an amount that can be deducted for federal income tax purposes. Ideally, the Plan assets will approximate the accumulated benefit obligation ("ABO"). The plan assets are held under two custodians and two investment managers. Plan assets are invested in equities, government securities and bonds. In addition, the Company has unfunded supplemental executive pension plans providing additional benefits to certain employees. </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company also has an unfunded postretirement medical and nominal life insurance plan ("postretirement benefits") covering certain domestic employees who were eligible as of January 1, 1993. The plan has not been extended to any additional employees. Retired eligible employees are required to contribute for coverage as if they were active employees.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The postretirement transition obligation as of January 1, 1993 of $1,079 is being amortized over twenty years. The discount rate used in determining the 2005, 2004 and 2003 expense was 5.75%, 6.00% and 6.25%, respectively. The health care cost trend rate was 8% for 2006, declining to 5% for 2010, remaining level thereafter. Assumed health care cost trend rates do not have a significant effect on the amounts reported for the health care plans. A one-percentage-point change in assumed health care cost trend rates would not have a material effect on the reported amounts.</P>
<P ALIGN="JUSTIFY"><BR>
<B>Benefit Obligations</P>
<P ALIGN="JUSTIFY"></P></B></FONT>
<P ALIGN="RIGHT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=649>
<TR><TD WIDTH="46%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="28%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="CENTER"><BR>
<U>Pension Benefits</U></FONT></TD>
<TD WIDTH="26%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="CENTER">Postretirement<BR>
<U>Benefits</U></FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P>Change in benefit obligation</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P>Projected benefit obligation at beginning of year</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ 48,045</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ 44,160</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ 2,967</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ 3,364</FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Service cost</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">3,799</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">4,645</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">90</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">78</FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Interest cost</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">3,062</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2,977</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">240</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">192</FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P>Plan participants' contributions</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">70</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">67</FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Actuarial (gain) loss</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,687</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(2,760)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,192</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(390)</FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Benefits paid</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(765)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(977)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(303)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(344)</FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P>Plan amendments</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="RIGHT">(64)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P>Curtailment</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="RIGHT">(4,485)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P>Special termination benefits</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=5>
<U><FONT SIZE=3><P ALIGN="RIGHT">566</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=5>
<U><FONT SIZE=3><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=5>
<U><FONT SIZE=3><P ALIGN="RIGHT">          --</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=5>
<U><FONT SIZE=3><P ALIGN="RIGHT">          --</U></FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P>Projected benefit obligation at end of year</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=5>
<U><FONT SIZE=3><P ALIGN="RIGHT">$ 51,909</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" HEIGHT=5>
<U><FONT SIZE=3><P ALIGN="RIGHT">$ 48,045</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=5>
<U><FONT SIZE=3><P ALIGN="RIGHT">$  4,192</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=5>
<U><FONT SIZE=3><P ALIGN="RIGHT">$ 2,967</U></FONT></TD>
</TR>
</TABLE>
</P>

<P ALIGN="JUSTIFY"><BR>
<FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accumulated benefit obligation for the pension plans at the end of 2005 and 2004 was $47,593 and $37,765, respectively.&nbsp;&nbsp;The accumulated postretirement benefit obligation for plans at the end of 2005 and 2004 was $4,192 and $2,967, respectively.</P>
</FONT><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT SIZE=3>The Company uses a measurement date of December 31 for its pension plans and other postretirement plans.</P>
</FONT><B><P><BR>
<FONT SIZE=3>Plan Assets</P>
</B></FONT>
<P ALIGN="RIGHT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=649>
<TR><TD WIDTH="46%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="28%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="CENTER"><BR>
<U>Pension Benefits</U></FONT></TD>
<TD WIDTH="26%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="CENTER">Postretirement<BR>
<U>Benefits</U></FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P>Change in plan assets</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P>Fair value of plan assets at beginning of year</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ 34,091</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ 28,964</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$        --</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$        --</FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Actual return on plan assets</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">659</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2,059</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Employer contribution</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">4,012</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">4,045</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">233</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">277</FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Plan participant contributions</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">-</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">70</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">67</FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Benefits paid</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(765)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">  (977)</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(303)</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(344)</U></FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P>Fair value of plan assets at end of year</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ 37,997</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ 34,091</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$        --      </U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT"> $        --</U></FONT></TD>
</TR>
</TABLE>
</P>

<P ALIGN="JUSTIFY"><BR>
<FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employer contributions and benefits paid in the above table for the pension plans primarily include those amounts contributed directly to, or paid directly from plan assets.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The asset allocation for the Faulding Inc. Pension Plan was 60% equities and 40% debt securities at the end of 2005 (Fair Value of Plan assets were $8,056).  The asset allocation for the Alpharma Inc. Pension Plan at the end of 2005 and 2004, and the target allocation for 2006, by asset category, follows.</P>
<P ALIGN="JUSTIFY"></P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=638>
<TR><TD WIDTH="35%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">Target Allocation</U></FONT></TD>
<TD WIDTH="43%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="CENTER">Percentage of Plan Assets at Year End</U></FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<P ALIGN="JUSTIFY">Asset Category</TD>
<TD WIDTH="22%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2006</U></FONT></TD>
<TD WIDTH="24%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2005</U></FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="24%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="19%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Equity Securities</FONT></TD>
<TD WIDTH="22%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">75%</FONT></TD>
<TD WIDTH="24%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">73%</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">75%</FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Debt Securities</FONT></TD>
<TD WIDTH="22%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">20%</FONT></TD>
<TD WIDTH="24%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">20%</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">20%</FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Cash</FONT></TD>
<TD WIDTH="22%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">5%</FONT></TD>
<TD WIDTH="24%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">7%</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Other</FONT></TD>
<TD WIDTH="22%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="24%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">5%</FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Total</FONT></TD>
<TD WIDTH="22%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">100%</FONT></TD>
<TD WIDTH="24%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">100%</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">100%</FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The investment strategy for pension plan assets is to invest in a diversified, professionally managed portfolio of equity and fixed income investments.  Equities are typically selected from the S&amp;P 500 in proportion to the S&amp;P 500's sector weightings.  Fixed income investments consist of government bonds, high quality corporate bonds and mortgage backed securities.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">    The fair value of plan assets for these plans is $37,997 and $34,091 at the end of 2005 and 2004, respectively. The expected long-term rate of return on these plan assets was 8.00% in 2005 and 8.75% in 2004.</P>
</FONT><P ALIGN="JUSTIFY"><BR>
</P>
<B><FONT SIZE=3><P ALIGN="JUSTIFY">Funded Status</P>
</B></FONT><P ALIGN="JUSTIFY"><BR>
<FONT SIZE=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The funded status represents the difference between the projected benefit obligation and the fair value of the plan assets. Below is a reconciliation of the funded status of the benefit plans to the net liability recognized for the years ended December 31, 2005 and 2004.</P>
</FONT>
<P ALIGN="RIGHT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=649>
<TR><TD WIDTH="46%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="28%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="CENTER">Pension Benefits</U></FONT></TD>
<TD WIDTH="26%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="CENTER">Postretirement Benefits</U></FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Funded status</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ (13,912)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ (13,955)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ (4,192)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ (2,967)</FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P>Unrecognized net actuarial loss</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">8,676</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">10,015</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2,206</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,168</FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P>Unrecognized net transition obligation </FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">23</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">26</FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P>Unrecognized prior service cost (benefit)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">      (120)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">  (337</U>)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(482)</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(542)</U></FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Accrued benefit cost</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ (5,356)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ (4,277)</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ (2,445)</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ (2,315)</U></FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=648>
<TR><TD WIDTH="46%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="28%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="CENTER">Pension Benefits</U></FONT></TD>
<TD WIDTH="26%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="CENTER">Postretirement Benefits</U></FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P>End of Year</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P>Prepaid benefit cost</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$   609</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$      455</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$         --</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$         --</FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P>Accrued benefit cost</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(5,965)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(4,732)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(2,445)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(2,315)</FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P>Additional minimum liability</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(4,239)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P>Accumulated other comprehensive income</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">4,239</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">       --</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">        --</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">        --</U></FONT></TD>
</TR>
<TR><TD WIDTH="46%" VALIGN="TOP">
<FONT SIZE=3><P>Net amount recognized</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ (5,356)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ (4,277)</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(2,445)</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ (2,315)</U></FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the end of 2005 and 2004 the projected benefit obligation, the accumulated benefit obligation and the fair value of plan assets for pension plans with accumulated benefit obligations in excess of plan assets were as follows:</P>
<P ALIGN="JUSTIFY"></P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=462>
<TR><TD WIDTH="62%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">End of Year</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="62%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="19%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="62%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Projected benefit obligation</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>(51,909)</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>(48,045</U>)</FONT></TD>
</TR>
<TR><TD WIDTH="62%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Accumulated benefit obligation</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(47,593)</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(37,765)</FONT></TD>
</TR>
<TR><TD WIDTH="62%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Fair value of plan assets</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">37,997</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT"> 34,091</U></FONT></TD>
</TR>
<TR><TD WIDTH="62%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Unfunded accumulated benefit obligation</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$(9,596)</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>(3,674)</U></FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Expected Cash Flows</P>
</B><P ALIGN="JUSTIFY"><BR>
Information about expected cash flows for the plans follows:</P>
<P ALIGN="JUSTIFY"><BR>
Employer Contributions</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=402>
<TR><TD WIDTH="34%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="39%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">Pension Benefits</U></FONT></TD>
<TD WIDTH="27%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">Postretirement<U> Benefits</U></FONT></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">2006 Expected</FONT></TD>
<TD WIDTH="39%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$    4,000</FONT></TD>
<TD WIDTH="27%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$    202</FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P ALIGN="JUSTIFY"><BR>
<B>Expected Benefit Payments </P>
</B><P ALIGN="JUSTIFY"></P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=402>
<TR><TD WIDTH="34%" VALIGN="TOP" HEIGHT=10>
<FONT SIZE=3><P ALIGN="JUSTIFY">2006</FONT></TD>
<TD WIDTH="39%" VALIGN="TOP" HEIGHT=10>
<FONT SIZE=3><P ALIGN="RIGHT"> $  825</FONT></TD>
<TD WIDTH="27%" VALIGN="TOP" HEIGHT=10>
<FONT SIZE=3><P ALIGN="RIGHT">$ 202</FONT></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">2007</FONT></TD>
<TD WIDTH="39%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,003</FONT></TD>
<TD WIDTH="27%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">210</FONT></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">2008</FONT></TD>
<TD WIDTH="39%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,176</FONT></TD>
<TD WIDTH="27%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">207</FONT></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">2009</FONT></TD>
<TD WIDTH="39%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,364</FONT></TD>
<TD WIDTH="27%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">221</FONT></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">2010</FONT></TD>
<TD WIDTH="39%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,653</FONT></TD>
<TD WIDTH="27%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">244</FONT></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">2011 - 2015</FONT></TD>
<TD WIDTH="39%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">13,698</FONT></TD>
<TD WIDTH="27%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,428</FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P></FONT>
<P ALIGN="RIGHT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=647>
<TR><TD WIDTH="50%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="22%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="CENTER">Pension Benefits</U></FONT></TD>
<TD WIDTH="29%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="CENTER">Postretirement Benefits</U></FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2005</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2004</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2005</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>Weighted-average assumptions used to<BR>
determine obligations as of December 31</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>Discount rate</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">5.75%</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">6.00%</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">5.75%</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">6.00%</FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>Expected return on plan assets</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">8.00%</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">8.75%</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">N/A</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">N/A</FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>Rate of compensation increase</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">4.50%</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">4.25%</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">N/A</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">N/A</FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The expected rate of return on plan assets was determined by applying the Company's target asset allocations to long-term historical rates of return, which are compared to the current investment management plan.</P>
</FONT>
<P ALIGN="RIGHT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=655>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP" COLSPAN=6>
<U><FONT SIZE=3><P ALIGN="CENTER">Pension Benefits</U></FONT></TD>
<TD WIDTH="31%" VALIGN="TOP" COLSPAN=4>
<U><FONT SIZE=3><P ALIGN="CENTER">Postretirement Benefits</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="RIGHT">2005</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="RIGHT">2004</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="RIGHT">2003</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2005</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="RIGHT">2004</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2003</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP" HEIGHT=31>
<FONT SIZE=3><P>Components of net<BR>
periodic benefit cost</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2 HEIGHT=31><P></P></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2 HEIGHT=31><P></P></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2 HEIGHT=31><P></P></TD>
<TD WIDTH="11%" VALIGN="TOP" HEIGHT=31><P></P></TD>
<TD WIDTH="10%" VALIGN="TOP" COLSPAN=2 HEIGHT=31><P></P></TD>
<TD WIDTH="10%" VALIGN="TOP" HEIGHT=31><P></P></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=3><P>Service cost</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">$3,799</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">$4,645</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">$3,982</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$  90</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">$78</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$100</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=3><P>Interest cost</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">3,062</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">2,977</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">2,609</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">240</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">192</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">225</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=3><P>Expected return on plan assets</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">(2,702)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">(2,574)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">(1,759)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=3><P>Net amortization of transition<BR>
&nbsp;&nbsp;&nbsp;obligation</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
- --</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
6</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
30</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
3</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
3</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
3</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=3><P>Amortization of prior service<BR>
&nbsp;&nbsp;&nbsp;cost</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
(67)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
(67)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
(78)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
(125)</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
(125)</FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
(125)</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=3><P>Recognized net actuarial<BR>
&nbsp;&nbsp;&nbsp;(gain) loss</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
583</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
   550</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
<U>   569</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
154</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
   68</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
  112</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">
<FONT SIZE=3><P>Net periodic benefit cost</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="RIGHT">$ 4,675</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>5,537</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>5,353</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$362</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>216</U></FONT></TD>
<TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>  315</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P>Weighted-average assumptions<BR>
used to determine net cost</FONT></TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=4>
<U><FONT SIZE=3><P ALIGN="CENTER"><BR>
Pension Benefits</U></FONT></TD>
<TD WIDTH="33%" VALIGN="TOP" COLSPAN=5>
<U><FONT SIZE=3><P ALIGN="CENTER"><BR>
Postretirement Benefits</U></FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" COLSPAN=3>
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Discount rate</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">6.00%</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">6.25%</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" COLSPAN=3>
<FONT SIZE=3><P ALIGN="RIGHT">6.00%</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">6.25%</FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Expected return on plan assets</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">8.00%</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">8.75%</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" COLSPAN=3>
<FONT SIZE=3><P ALIGN="RIGHT">N/A</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">N/A</FONT></TD>
</TR>
<TR><TD WIDTH="33%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="JUSTIFY">Rate of compensation increase</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">4.50%</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">4.25%</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" COLSPAN=3>
<FONT SIZE=3><P ALIGN="RIGHT">N/A</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">N/A</FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with SFAS No. 87, "Employers' Accounting for Pensions", the Company has included approximately $4,239 and $(283) within other comprehensive income as of December 31, 2005 and December 31, 2004, respectively, for the change in additional minimum pension liability.  </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and its domestic subsidiaries also have two defined contribution plans, one qualified and one non-qualified, which allow eligible employees to withhold a fixed percentage of their salary (maximum 25%) and provide for a Company match based on service (maximum 6%). The Company's contributions to these plans were approximately $2,600 in 2005 and $2,300 in 2004 and 2003.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has an unfunded benefit for selected executives (Supplemental Pension Plan) that provides for the payment of benefits upon retirement or death. Accrued costs included in the Consolidated Balance Sheets as of December 31, 2005 and 2004 are $4,894 and $4,893, respectively. Expense (credit) charged to operations during the years ended December 31, 2005, 2004, and 2003 was approximately $595, $(24) and $613, respectively.</P>
<P><BR>
<B><U>International:<BR>
</P>
</B></U><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The liabilities associated with the Company's Norwegian subsidiary defined benefit plan was retained by the Company in connection with the sale of the Generics Business. This subsidiary has a defined benefit plan which is available to a majority of employees. Pension plan contributions from the Company and the participants are paid to independent trustees and invested in fixed income and equity securities in accordance with local practices.  The pension plan information is as follows:</P>
<P ALIGN="JUSTIFY"><BR>
<B>Benefit Obligations</P></B></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=527>
<TR><TD WIDTH="67%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2005</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP" HEIGHT=13>
<FONT SIZE=3><P ALIGN="JUSTIFY">Change in benefit obligation:</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=13><P></P></TD>
<TD WIDTH="18%" VALIGN="TOP" HEIGHT=13><P></P></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P>Benefit obligation at beginning of year</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ 52,220</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$51,119</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Service cost</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">3,203</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">3,450</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Interest cost</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2,268</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2,463</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP" HEIGHT=8>
<FONT SIZE=3><P ALIGN="JUSTIFY">Curtailment</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=8>
<FONT SIZE=3><P ALIGN="RIGHT">(11,384)</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP" HEIGHT=8>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP" HEIGHT=8>
<FONT SIZE=3><P ALIGN="JUSTIFY">Actuarial (gain)/loss</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=8>
<FONT SIZE=3><P ALIGN="RIGHT">(2,154)</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP" HEIGHT=8>
<FONT SIZE=3><P ALIGN="RIGHT">(8,135)</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Benefits paid</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(1,472)</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(1,414)</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Translation adjustment</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(5,073)</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">4,737</U></FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P>Benefit obligation at end of year</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$37,608</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ 52,220</U></FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
<B>Plan Assets</P></B></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=527>
<TR><TD WIDTH="66%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">   <U>2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="66%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Change in plan assets:</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="66%" VALIGN="TOP">
<FONT SIZE=3><P>Fair value of plan assets at beginning of year</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ 27,672</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"> $ 23,715</FONT></TD>
</TR>
<TR><TD WIDTH="66%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Actual return on plan assets</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,587</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,065</FONT></TD>
</TR>
<TR><TD WIDTH="66%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Employer contributions</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">3,442</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,221</FONT></TD>
</TR>
<TR><TD WIDTH="66%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Benefits paid</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(950)</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(879)</FONT></TD>
</TR>
<TR><TD WIDTH="66%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="JUSTIFY">Curtailment</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="RIGHT">(4,702)</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="66%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="JUSTIFY">Actuarial (gain)/loss</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="RIGHT">(234)</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="66%" VALIGN="TOP" HEIGHT=5>
<FONT SIZE=3><P ALIGN="JUSTIFY">Translation adjustment</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=5>
<U><FONT SIZE=3><P ALIGN="RIGHT">(2,885)</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=5>
<U><FONT SIZE=3><P ALIGN="RIGHT">   2,550</U></FONT></TD>
</TR>
<TR><TD WIDTH="66%" VALIGN="TOP">
<FONT SIZE=3><P>Fair value of plan assets at end of year</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$23,930</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ 27,672</U></FONT></TD>
</TR>
</TABLE>
</P>

<B><FONT SIZE=3></B></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=527>
<TR><TD WIDTH="67%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2005</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Funded status</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"> $ (13,678)</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">  $  (24,548)</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P>Unrecognized net actuarial loss</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(212)</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">5,657</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P>Unrecognized transitional obligation</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">109</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">369</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P>Unrecognized prior service cost</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,206</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">3,317</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Additional minimum liability</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">       (635)</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">  (2,585)</U></FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P>Accrued benefit cost</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ <U>(13,210</U>)</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ <U>(17,790</U>)</FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3><P><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the end of 2005 and 2004 the projected benefit obligation, the accumulated benefit obligation and the fair value of plan assets for pension plans with accumulated benefit obligation in excess of plan assets were as follows:</P>
</FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=528>
<TR><TD WIDTH="67%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P>End of Year</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P>Projected benefit obligation</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ (37,608)</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ (<U>52,220)</U></FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P>Accumulated benefit obligation</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(30,510)</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(39,358)</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P>Fair value of plan assets</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">23,930</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">27,672</U></FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P>Unfunded accumulated benefit obligation</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$  (6,580)</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$  (<U>11,686)</U></FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P><BR>
</P></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=527>
<TR><TD WIDTH="67%" VALIGN="TOP" HEIGHT=13><P></P></TD>
<TD WIDTH="16%" VALIGN="TOP" HEIGHT=13>
<U><FONT SIZE=3><P ALIGN="RIGHT">2005</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=13>
<U><FONT SIZE=3><P ALIGN="RIGHT">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Weighted-average assumptions at year-end:</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP" HEIGHT=15>
<FONT SIZE=3><P ALIGN="JUSTIFY">Discount rate</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP" HEIGHT=15>
<FONT SIZE=3><P ALIGN="RIGHT">4.7%</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=15>
<FONT SIZE=3><P ALIGN="RIGHT">4.7%</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Expected return on plan assets</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">5.7%</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">5.7%</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Rate of compensation increase</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">3.5%</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">3.5%</FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3><P><BR>
</P>
<B><P>Net Periodic Cost</P>
</B></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=611>
<TR><TD WIDTH="58%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2005</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2004</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2003</U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Components of net periodic benefit cost:</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Service cost</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ 3,203</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ 3,450</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ 2,639</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Interest cost</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2,268</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2,463</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2,155</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Expected return on plan assets</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(1,587)</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(1,515)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(1,590)</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P>Amortization of transition obligation</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">87</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">103</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">98</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P>Amortization of prior service cost</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">244</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">266</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">253</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P>Recognized net actuarial loss</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">      68</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">303</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">    -</U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Net periodic benefit cost</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$4,283</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$5,070</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ <U>3,555</U></FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;</P>
<P>14.&nbsp;&nbsp;<U>Transactions with A. L. Industrier ASA</U><BR>
</P></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=613>
<TR><TD WIDTH="58%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="42%" VALIGN="TOP" COLSPAN=3>
<FONT SIZE=3><P ALIGN="CENTER">Years Ended December 31,</FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2005</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2004</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2003</U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P>Sales to and commissions received from<BR>
&nbsp;&nbsp;&nbsp;A. L. Industrier ASA</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
</U>$<U>    --</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
</U>$<U>    --</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
$506</U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P>Compensation received for management<BR>
&nbsp;&nbsp;&nbsp;services rendered to A. L. Industrier ASA</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
</U>$  <U>61</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
</U>$<U>148</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
$423</U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P>Inventory purchased from and commissions<BR>
&nbsp;&nbsp;&nbsp;paid to A. L. Industrier ASA</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
</U>$<U>    --</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
</U>$<U>    --</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
$   9</U></FONT></TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="58%" VALIGN="TOP">
<FONT SIZE=3><P>Rent expense</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>372</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>338</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$340</U></FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;In 2003, the Company and Industrier had an administrative service agreement whereby the Company provides management services to Industrier. The agreement provided for payment equal to the direct and indirect cost of providing the services subject to a minimum amount. Effective January 1, 2004, the Company and Industrier entered into a new administrative service agreement whereby the Company provides management services and rents space to Industrier. The agreement provided for payment of a fixed yearly fee of approximately $146. This agreement was approved by the Company's Audit and Corporate Governance Committee.  Effective January 1, 2005, the Company and Industrier entered into a new administrative service agreement whereby the Company provides limited administrative services to Industrier.  The new agreement replaced and reduced amounts due under the previous agreement.  The 2005 agreement provides for payment of a fixed yearly fee of approximately $60.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;In connection with the agreement to purchase Alpharma Oslo, Industrier retained the ownership of the Sk&oslash;yen manufacturing facility and administrative offices (not including leasehold improvements and manufacturing equipment) and leases it to the Company. The Company is required to pay all expenses related to the operation and maintenance of the facility in addition to nominal rent. The lease has an initial 20-year term and is renewable at the then fair rental value at the option of the Company for four consecutive five year terms.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;In 2002, the Company signed a net lease agreement with Industrier that provides for the leasing of a parking lot at the Skoyen Facility through an initial term of October 2014 with the possibility of four consecutive five-year renewal terms. The annual rental is 2.4 million Norwegian Kroner (approximately $372 at 2005 average exchange rates).</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;In January 2003, the Company divested its Norwegian vitamin business to Nopal, a subsidiary of Industrier, for approximately $3,300. The divestiture was a transaction between companies under common control and accordingly, the gain on the sale was accounted for as a capital transaction net of related taxes ($2,267 net increase to Additional Paid-in Capital). </P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;As required, all of the above related party transactions were approved by the Company's Audit and Corporate Governance Committee.</P>

<P ALIGN="JUSTIFY">15.<B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><U>Contingent Liabilities and Litigation </P>
</U></FONT>
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is involved in various legal proceedings, of a nature considered normal to its business.  It is the Company's policy to accrue for amounts related to these legal matters if it is probable that a liability has been incurred and an amount is reasonably estimable.</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">SEC Investigation</P>
</B><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June 2002, the SEC notified the Company that it had commenced a formal investigation of the circumstances surrounding the 2000 and 2001 restatements of its financial statements. The SEC has engaged in deposition and document discovery.</FONT>  </P>

<B><FONT SIZE=3><P ALIGN="JUSTIFY">Chicken Litter Litigation</P>
</B>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is one of the multiple defendants that has been named in several lawsuits which allege that one of its AH products causes chickens to produce manure that contains an arsenical compound which, when used as agricultural fertilizer by chicken farmers, degrades into inorganic arsenic and causes a variety of diseases in the plaintiffs (who allegedly live in close proximity to such farm fields).  The Company has provided notice to its insurance carriers and its primary insurance carriers have responded by accepting their obligations to defend or pay the Company's defense costs, subject to reservation of rights to later reject coverage for these lawsuits.  In addition, one of the Company's carriers has filed a Declaratory Judgment action in state court in which it has sought a ruling concerning the allocation of its coverage obligations to the Company among the Company's several insurance carriers and, to the extent the Company does not have full insuranc
e coverage, to the Company.  In addition, this Declaratory Judgment action requests that the Court rule that certain of the carrier's policies provide no coverage because certain policy exclusions allegedly operate to limit its coverage obligations under said policies.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to the potential for personal injury damages to the approximately 140 plaintiffs, the plaintiffs are asking for punitive damages and requesting that the Company be enjoined from the future sale of the product at issue.  Discovery is substantially complete with respect to the first trial which is scheduled for September 2006.  While the Company can give no assurance of the outcome of these matters, it believes that it will be able to present credible scientific evidence that its product is not the cause of any injuries the plaintiffs may have suffered.  There is also the possibility of an adverse customer reaction to the allegations in these lawsuits as well as additional lawsuits in other jurisdictions where the product has been sold.  Worldwide sales of this product were approximately $23.3 million in 2004 and $23.1 million in 2005.</FONT>  </P>
<P ALIGN="JUSTIFY"></P>
<B><FONT SIZE=3><P ALIGN="JUSTIFY">Brazilian Tax Claims</P>
</B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is the subject of several tax claims which aggregate approximately $10.0 million by the Brazilian authorities relating to the operations of the Company's Animal Health business in Brazil since 1999. The Company believes it has meritorious defenses and intends to vigorously defend its position against these claims.</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">European Environmental Regulations</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>The environmental authorities having jurisdiction over the Copenhagen and Oslo plants of the Company have given the Company notice of revised waste discharge requirements which will require plant alterations or modifications for compliance.  While the Company does not believe that the cost of these alterations or modifications will be material to the Company, the failure or inability to comply with applicable regulations and discharge requirements could result in administrative actions affecting production at these facilities which could be materially adverse to the Company.</P>
<B><P ALIGN="JUSTIFY"><BR>
Other Commercial Disputes</P>
</B>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is engaged in disputes with several suppliers, customers and distributors regarding certain obligations with respect to contracts under which the Company obtains raw materials and under which the Company supplies finished products.  Given the fact that these disputes will most probably be resolved over more than one year, management does not believe that the disputes in the aggregate will be material to the Company's financial position. However, they could be material to the Company's results of operations or cash flows in the period in which resolution occurs.</P>
</FONT><P ALIGN="JUSTIFY"></P>
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any further responsibility for substantially all of the material contingent liabilities related to the Generics Business have has been transferred to Actavis or entities owned by Actavis; subject to certain representations or warranties made by the Company to Actavis as a part of the transaction to the extent such representations and warranties were incorrect.  In addition, the Company has retained certain specified liabilities which the Company believes are not material to the Company and, it is possible that the Company may be held responsible for certain liabilities of the Generic Business transferred to Actavis in the event Actavis fails to or is unable to satisfy such liabilities.</P>
<P ALIGN="JUSTIFY"> </P>
<B><P ALIGN="JUSTIFY">Other Litigation</P>
</B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and its subsidiaries are, from time to time, involved in other litigation arising out of the ordinary course of business.  It is the view of management, after consultation with counsel, that the ultimate resolution of all other pending suits on an individual basis should not have a material adverse effect on the consolidated financial position, results of operations of the Company or cash flows of the Company.</P>
<P ALIGN="JUSTIFY">     </P>
<P ALIGN="JUSTIFY">16.&nbsp;&nbsp;<U>Leases</P>
</U><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;Rental expense under operating leases for the years ended December 31, 2005, 2004 and 2003 was $5,074, $4,581 and $4,673, respectively. Future minimum lease commitments under non-cancelable operating leases during each of the next five years and thereafter are as follows:</P>
<P ALIGN="JUSTIFY"></P></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=324>
<TR><TD WIDTH="59%" VALIGN="TOP">
<B><FONT SIZE=3><P ALIGN="JUSTIFY">Years Ending December 31,</B></FONT></TD>
<TD WIDTH="41%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="59%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">2006</FONT></TD>
<TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ 3,599</FONT></TD>
</TR>
<TR><TD WIDTH="59%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">2007</FONT></TD>
<TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,235</FONT></TD>
</TR>
<TR><TD WIDTH="59%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">2008</FONT></TD>
<TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">566</FONT></TD>
</TR>
<TR><TD WIDTH="59%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">2009</FONT></TD>
<TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">292</FONT></TD>
</TR>
<TR><TD WIDTH="59%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">2010</FONT></TD>
<TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">236</FONT></TD>
</TR>
<TR><TD WIDTH="59%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Thereafter</FONT></TD>
<TD WIDTH="41%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">   604</U></FONT></TD>
</TR>
<TR><TD WIDTH="59%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ <U>6,532</U></FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3>
<P>17.&nbsp;&nbsp;<U>Stockholders' Equity</U><BR>
</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;The holders of the Company's Class B Common Stock (totally held by A. L. Industrier ASA at December&nbsp;31, 2005), are entitled to elect 66 2/3% of the Board of Directors of the Company and may convert each share of Class B Common Stock held into one fully paid share of Class A Common Stock. Whenever the holders of the Company's Common Stock are entitled to vote as a combined class, each holder of Class A and Class B Common Stock is entitled to one and four votes, respectively, for each share held.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The number of authorized shares of Preferred Stock is 500,000; the number of authorized shares of Class A Common Stock is 75,000,000; and the number of authorized shares of Class B Common Stock is 15,000,000.</P>
<P ALIGN="JUSTIFY"><BR>
A summary of activity in common and treasury stock is as follows:</P></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=593>
<TR><TD WIDTH="48%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2005</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2004</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2003</U></FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="JUSTIFY">Class A Common Stock Issued</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP" HEIGHT=12>
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance, January 1,</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=12>
<FONT SIZE=3><P ALIGN="RIGHT">41,277,761</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP" HEIGHT=12>
<FONT SIZE=3><P ALIGN="RIGHT">40,483,818</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP" HEIGHT=12>
<FONT SIZE=3><P ALIGN="RIGHT">39,895,214</FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P>Exercise of stock options and other</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">762,067</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">199,565</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">209,098</FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Restricted stock issued, net of forfeitures </FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">245,991</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">350,430</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">154,754</FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P>Employee stock purchase plan</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">247,774</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">243,948</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">224,752</U></FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance, December 31,</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">42,533,593</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">41,277,761</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">40,483,818</U></FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP" HEIGHT=11>
<U><FONT SIZE=3><P ALIGN="JUSTIFY">Class B Common Stock Issued</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=11><P></P></TD>
<TD WIDTH="18%" VALIGN="TOP" HEIGHT=11><P></P></TD>
<TD WIDTH="18%" VALIGN="TOP" HEIGHT=11><P></P></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP" HEIGHT=11><P></P></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=11><P></P></TD>
<TD WIDTH="18%" VALIGN="TOP" HEIGHT=11><P></P></TD>
<TD WIDTH="18%" VALIGN="TOP" HEIGHT=11><P></P></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance, January 1 and December 31,</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">11,872,897</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">11,872,897</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">11,872,897</U></FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="JUSTIFY">Treasury Stock (Class A)</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance, January 1,</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">328,658</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">320,734</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP" HEIGHT=16>
<FONT SIZE=3><P ALIGN="RIGHT">320,734</FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Purchases</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">                --</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">   7,924</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">         --</U></FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance, December 31,</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">      328,658</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">328,658</U></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">320,734</U></FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2005, 2004 and 2003, the Company issued 328,490, 370,550 and 154,754 shares of restricted stock, respectively.  Compensation cost for restricted stock is recorded based on the market value on the date of grant.  The fair value of restricted stock is charged to unearned compensation in Stockholders' Equity and amortized to expense over the requisite vesting periods.  Compensation expense related to restricted stock was $4,320 in 2005, $3,067 in 2004 and $326 in 2003. A summary of restricted stock activity is as follows:</P>
<P ALIGN="JUSTIFY"></P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=567>
<TR><TD WIDTH="67%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2005</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Outstanding awards - beginning of year</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">505,184</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">154,754</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">New awards granted</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">328,490</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">370,550</FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Restricted shares forfeited</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(82,499)</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(20,120)</U></FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Outstanding awards - end of year</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">751,175</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">505,184</U></FONT></TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="17%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="67%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Weighted average market value of new awards on award date</FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$12.85</U></FONT></TD>
<TD WIDTH="17%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$18.31</U></FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P ALIGN="JUSTIFY"></P>
<P>18.&nbsp;&nbsp;<U>Derivatives and Fair Value of Financial Instruments</U>:<BR>
</P>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company currently uses the following derivative financial instruments for purposes other than trading:</P>
</FONT>
<P ALIGN="CENTER"><CENTER><TABLE CELLSPACING=0 BORDER=0 WIDTH=570>
<TR><TD WIDTH="35%" VALIGN="TOP">
<B><U><FONT SIZE=3><P>Derivative</B></U></FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<B><U><FONT SIZE=3><P>Use</B></U></FONT></TD>
<TD WIDTH="45%" VALIGN="TOP">
<B><U><FONT SIZE=3><P>Purpose</B></U></FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="45%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P>Forward foreign exchange contracts</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Occasional</FONT></TD>
<TD WIDTH="45%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Entered into selectively to sell or buy cash flows in non-functional currencies.</FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P>Interest rate agreements </FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Occasional</FONT></TD>
<TD WIDTH="45%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Entered into selectively to fix interest rate for specified periods on variable rate long-term debt.</FONT></TD>
</TR>
</TABLE>
</CENTER></P>

<FONT SIZE=3>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December 31, 2005 and 2004, the Company had forward foreign exchange contracts outstanding with a notional amount of approximately $126,973 and $255,850, respectively. These contracts called for the exchange of Scandinavian and other European currencies and in some cases the U.S. Dollar to meet commitments in or sell cash flows generated in non-functional currencies. All outstanding contracts will expire in 2006 and the unrealized gains and losses are not material.  The Company does not account for these transactions as hedges under SFAS 133. </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparties to derivative agreements are major financial institutions. Management believes the risk of incurring losses related to credit risk is remote.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The carrying amounts reported in the Consolidated Balance Sheets for cash and cash equivalents, accounts receivable, accounts payable and short-term debt approximate fair value because of the immediate or short-term maturity of these financial instruments. The carrying amount reported for long-term debt other than the subordinated notes approximates fair value because a significant portion of the underlying debt is at variable rates and reprices frequently. The fair value of the 2005 and 2006 subordinated notes is based on the bid price of the notes, which are publicly traded.  The fair value of the 2011 senior notes, which are not publicly traded, have been calculated based on comparable market yields at December 31, 2005 and December 31, 2004, respectively. The estimated fair value of the subordinated notes at December 31, 2005 and 2004 was as follows:</P>
<P ALIGN="JUSTIFY"></P></FONT>
<P ALIGN="RIGHT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=622>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="32%" VALIGN="TOP" COLSPAN=3>
<U><FONT SIZE=3><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="31%" VALIGN="TOP" COLSPAN=4>
<U><FONT SIZE=3><P ALIGN="CENTER">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">Carrying<U> Amount</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="CENTER">Fair<BR>
<U>Value</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="CENTER">Carrying<BR>
<U>Amount</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="CENTER">Fair<BR>
<U>Value</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">
<FONT SIZE=3><P>5.75% Convertible<BR>
Subordinated Notes due 2005</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
</U>$<U>        --</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
</U>$<U>        --</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
$9,752</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
$9,813</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">
<FONT SIZE=3><P>3% Convertible Senior Subordinated Notes due 2006</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
</U>$<U>160,948</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
</U>$<U>161,399</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
</U>$<U>153,918</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT"><BR>
</U>$<U>151,369</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">
<FONT SIZE=3><P>8.625% Senior Notes due 2011</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>220,000</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>238,894</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=3><P ALIGN="RIGHT">$<U>220,000</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$<U>229,482</U></FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3>
<P>19.&nbsp;&nbsp;<U>Stock Options and Employee Stock Purchase Plan</U> <BR>
</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;Prior to May 19, 2003, the Company granted options to key employees to purchase shares of Class A Common Stock under the 1997 Incentive Stock Option and Appreciation Right Plan (the "Plan"). The maximum number of Class A shares available for grant under the Plan was 8,000,000. In addition, the Company had a Non-Employee Director Option Plan (the "Director Plan") which provided for the issue of up to 350,000 shares of Class A Common stock. The exercise price of options granted under the Plan could not be less than 100% of the fair market value of the Class A Common Stock on the date of the grant. Options granted expired from three to ten years after the grant date. Generally, options were exercisable in installments of 25% beginning one year from date of grant. The Plan permitted a cash appreciation right to be granted to certain employees. Included in options outstanding at December&nbsp;31, 2005, are options to purchase 15,625 shares with cash appreciation rights, 
all of which are exercisable. If an option holder ceased to be an employee of the Company or its subsidiaries for any reason prior to vesting of any options, all options which were not vested at the date of termination were forfeited. </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;On May 19, 2003, the Company's stockholders approved the Alpharma Inc. 2003 Omnibus Incentive Compensation Plan (the "Incentive Compensation Plan").  The Incentive Compensation Plan permits stock option grants, stock appreciation rights grants ("SARs"), annual incentive awards, stock grants, restricted stock grants, restricted stock unit grants, performance stock grants, performance units grants, and cash awards.  Upon adoption of the Incentive Compensation Plan, no additional options were granted under the previously existing plans and all shares reserved under these existing plans were returned to the Company's supply of authorized but unissued shares, not reserved for any purpose, although outstanding options granted pursuant to the previously existing plans will remain outstanding.  Upon adoption, the maximum number of Class A shares available for grant under the Incentive Compensation Plan was 4,750,000 and the number of shares that were permitted to be issued for Awards other th
an stock options or SARS (both with a grant price equal to at least fair market value at date of grant), were not to exceed a total of 2,000,000 shares.  Options granted expire from three to ten years after the grant date.  Generally, options are exercisable in installments of 25% beginning one year from date of grant.  If an option holder ceases to be an employee of the Company or its subsidiaries for any reason prior to vesting of any options, all options which are not vested at the date of termination are forfeited.  As of December 31, 2005, there were 3,153,425 shares available for future grant under all plans.</P>
<P ALIGN="JUSTIFY"><BR>
The table below summarizes the activity of the Plan:</P>
<P ALIGN="JUSTIFY"></P></FONT>
<P ALIGN="RIGHT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=643>
<TR><TD WIDTH="35%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER"><BR>
<BR>
Options<BR>
<U>Outstanding</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">Weighted<BR>
Average<BR>
Exercise <BR>
<U>Price</U></FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER"><BR>
<BR>
Options<BR>
<U>Exercisable</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">Weighted<BR>
Average<BR>
Exercise<BR>
<U>Price</U></FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P>Balance at</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="19%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;December 31, 2002</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">4,220,335</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$20.57</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">970,023</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$30.58</FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Granted in 2003<SUP>(1)</SUP></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">427,900</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$17.78</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forfeited in 2003</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(494,541)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$20.02</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercised in 2003</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(212,356)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$10.67</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P>Balance at<BR>
&nbsp;&nbsp;&nbsp;December 31, 2003</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
3,941,338</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
$20.85</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
1,911,398</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
$25.29</FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Granted in 2004<SUP>(1)</SUP></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">383,710</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$19.72</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forfeited in 2004</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(671,301)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$22.44</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercised in 2004</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(196,887)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$12.31</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P>Balance at <BR>
&nbsp;&nbsp;&nbsp;December 31, 2004</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
3,456,860</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
$20.85</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
2,091,857</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
$23.78</FONT></TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Granted in 2005<SUP>(1)</SUP></FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">203,400</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$13.36</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forfeited in 2005</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(439,028)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$20,87</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercised in 2005</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(794,239)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$15.69</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="35%" VALIGN="TOP">
<FONT SIZE=3><P>Balance at <BR>
&nbsp;&nbsp;&nbsp;December 31, 2005</FONT></TD>
<TD WIDTH="18%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
2,426,993</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
$21.90</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
1,826,167</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"><BR>
$24.01</FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3>
<OL>

<LI>&nbsp;&nbsp;&nbsp;All options granted in 2003, 2004 and 2005 were with exercise prices equal to fair market value of Class A stock on the date of grant.</LI></OL>


<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes information about stock options outstanding at December 31, 2005:</P>
<P ALIGN="JUSTIFY"></P></FONT>
<P ALIGN="RIGHT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=638>
<TR><TD WIDTH="25%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="43%" VALIGN="TOP" COLSPAN=3>
<U><FONT SIZE=3><P ALIGN="CENTER">OPTIONS OUTSTANDING</U></FONT></TD>
<TD WIDTH="32%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=3><P ALIGN="CENTER">OPTIONS EXERCISABLE</U></FONT></TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">
<FONT SIZE=3><P><BR>
<BR>
<BR>
<U>Range of Exercise Prices</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER"><BR>
Number Outstanding<BR>
<U>at 12/31/05</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">Weighted Average Remaining<BR>
<U>Life</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">Weighted Average Exercise<BR>
<U>Price</U></FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER"><BR>
Number Exercisable at<BR>
<U>12/31/05</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">Weighted<BR>
Average<BR>
Exercise<BR>
<U>Price</U></FONT></TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">
<FONT SIZE=3><P>$8.54 - $14.44</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">770,267</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">6.39</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">11.96</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">476,733</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">11.91</FONT></TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">
<FONT SIZE=3><P>$15.85 - $20.98</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">635,197</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">7.03</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">18.09</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">346,405</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">17.79</FONT></TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">
<FONT SIZE=3><P>$21.05 - $32.25</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">696,517</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">3.52</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">28.22</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">678,017</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">28.36</FONT></TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">
<FONT SIZE=3><P>$35.00 - $62.56</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">325,012</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">0.87</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">39.33</U></FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">325,012</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">39.33</U></FONT></TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="20%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="25%" VALIGN="TOP">
<FONT SIZE=3><P>$8.54 - $62.56</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2,426,993</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">5.00</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">21.90</FONT></TD>
<TD WIDTH="20%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,826,167</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">24.01</FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3><P ALIGN="JUSTIFY"><BR>
</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT SIZE=3>The Company's 2003 Omnibus Incentive Compensation Plan provides for the issuance of performance units that are valued based on the Company's Total Shareholder Return as compared to a market index of peer companies and the satisfaction of a free cash flow threshold. Each performance unit had a potential value between zero and $200. In conjunction with the sale of the Generics Business which made the peer group comparison no longer relevant, the Company, with the approval of the Board, terminated the plan effective December 18, 2005. Prior to terminating the plan, the Company fixed the final payout at $100 per unit.   A total of 95,082 performance units were granted in 2004 and 73,605 in 2005. The final cost of the plan was $8,968 of which $2,869 was for Generics employees and was paid out on a prorated basis in December 2005. The balance of the cost, which was for non-generics employees, amounted to $6,099 and will be paid out at the end of the plan's original
 three year vesting periods; December 31, 2006 and 2007, respectively.  This cost will be amortized to expense over the remaining service period.  In 2006, the cost is estimated to be approximately $5,000.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has an Employee Stock Purchase Plan by which eligible employees of the Company may authorize payroll deductions up to 4% of their regular base salary to purchase shares of Class A Common Stock at fair market value. The Company matches these contributions with an additional contribution equal to 50% of the employee's contribution. Shares are issued on the last day of each calendar quarter. The Company's contributions to the plan were approximately $1,400, $1,500, and $1,400 in 2005, 2004 and 2003, respectively, and are included within operating income.</P>
</FONT><P><BR>
<FONT SIZE=3>20.&nbsp;&nbsp;<U>Supplemental Data</P>
</U></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=569>
<TR><TD VALIGN="TOP" COLSPAN=3>
<FONT SIZE=3><P>Other assets and deferred charges at December 31 include:</FONT></TD>
</TR>
<TR><TD WIDTH="65%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="19%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2005</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2004</U></FONT></TD>
</TR>
<TR><TD WIDTH="65%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="19%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="65%" VALIGN="TOP">
<FONT SIZE=3><P>Capitalized software cost, net of amortization</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ 11,223</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT"> $ 11,883</FONT></TD>
</TR>
<TR><TD WIDTH="65%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Deferred borrowing costs, net of amortization</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,641</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">8,848</FONT></TD>
</TR>
<TR><TD WIDTH="65%" VALIGN="TOP">
<FONT SIZE=3><P>Supplemental Savings Plan</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">6,977</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">6,410</FONT></TD>
</TR>
<TR><TD WIDTH="65%" VALIGN="TOP">
<FONT SIZE=3><P>Unfunded ABO</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">635</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2,585</FONT></TD>
</TR>
<TR><TD WIDTH="65%" VALIGN="TOP">
<FONT SIZE=3><P>Deferred tax assets      </FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">52,011</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">55,123</FONT></TD>
</TR>
<TR><TD WIDTH="65%" VALIGN="TOP">
<FONT SIZE=3><P>Other</FONT></TD>
<TD WIDTH="19%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">      122</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">     (54)</U></FONT></TD>
</TR>
<TR><TD WIDTH="65%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="19%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ 72,609</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ 84,795</U></FONT></TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=570>
<TR><TD WIDTH="50%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="50%" VALIGN="TOP" COLSPAN=5>
<FONT SIZE=3><P ALIGN="RIGHT">Years Ended December 31,</FONT></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2005</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2004</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2003</U></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="16%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="4%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=5><P></P></TD>
<TD WIDTH="3%" VALIGN="TOP" HEIGHT=5><P></P></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>Depreciation expense</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$47,413</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ 51,745</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ 49,681</U></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>Amortization expense</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">43,781</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">44,658</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">45,520</U></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>Interest cost incurred:</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;Interest expense</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">46,967</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">56,025</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">59,476</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;Amortization of loan costs </FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">  2,168</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2,737</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">3,941</U></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subtotal</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">49,135</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">58,762</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">63,417</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;Capitalized interest</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">     610</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">    405</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">167</U></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;Interest cost incurred</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$49,745</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ 59,167</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$ 63,584</U></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>Asset impairment and other:</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;Loss on sale of Aquatic Animal Health Group</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$--</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ 9,987</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$ --</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;Severance as a result of reorganization</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">1,184</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">1,123</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">4,091</U></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP" HEIGHT=8><P></P></TD>
<TD WIDTH="15%" VALIGN="TOP" HEIGHT=8>
<U><FONT SIZE=3><P ALIGN="RIGHT">$1,184</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP" HEIGHT=8>
<U><FONT SIZE=3><P ALIGN="RIGHT">$11,110</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP" HEIGHT=8><P></P></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=8>
<U><FONT SIZE=3><P ALIGN="RIGHT">$4,091</U></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP" HEIGHT=8><P></P></TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>Other income (expense), net:</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;Interest income</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$  1,385</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$     780</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$         48</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange gains (losses), net  </FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2,763</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,574</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2,365</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;Litigation/insurance settlements</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,200</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;Income from Wynco, carried at equity</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">335</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;Loss on sale of Wynco</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">(1,523)</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;&nbsp;&nbsp;&nbsp;Other, net</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">1,943</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">407</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">(1,338)</U></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="50%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$  6,091</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$  1,238</U></FONT></TD>
<TD WIDTH="4%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$  2,610</U></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3>
</FONT><P>&nbsp;</P>
<FONT SIZE=3><P>Supplemental cash flow information:<BR>
</P></FONT>
<P ALIGN="RIGHT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=631>
<TR><TD WIDTH="56%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2005</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2004</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">2003</U></FONT></TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">
<FONT SIZE=3><P>Cash paid for interest (net of amount capitalized)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$42,216</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$  48,089</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$  54,923</U></FONT></TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">
<FONT SIZE=3><P>Cash paid for income taxes (net of refunds)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$20,293</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$  11,564</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$    2,935</U></FONT></TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">
<FONT SIZE=3><P>Other non-cash operating activities:</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">
<FONT SIZE=3><P>Goodwill impairment</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$     815</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$  260,000</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$        -</FONT></TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">
<FONT SIZE=3><P>Fixed asset impairments</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">624</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">19,181</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">-</FONT></TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">
<FONT SIZE=3><P>Inventory impairments</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,319</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">6,995</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">-</FONT></TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">
<FONT SIZE=3><P>Intangible asset impairments</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">601</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">4,450</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">-</FONT></TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">
<FONT SIZE=3><P>Other non-cash asset write-downs</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">88</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,528</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">-</FONT></TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">
<FONT SIZE=3><P>Restricted stock amortization</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">4,320</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">3,067</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">326</FONT></TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">
<FONT SIZE=3><P>Loss on early extinguishment of debt</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">7,989</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2,795</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">6,909</FONT></TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">
<FONT SIZE=3><P>Loss on sale of Aquatics business</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">9,987</FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">-</FONT></TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">
<FONT SIZE=3><P>Undistributed earnings of equity subsidiary</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">        --</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">               -</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">          (78)</U></FONT></TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$15,756</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$  308,003</U></FONT></TD>
<TD WIDTH="16%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="RIGHT">$      7,157</U></FONT></TD>
</TR>
<TR><TD WIDTH="56%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="16%" VALIGN="TOP">&nbsp;</TD>
</TR>
</TABLE>
</P>

<FONT SIZE=3><P><BR>
21.&nbsp;&nbsp;<U>Information Concerning Business Segments and Geographic Operations</P>
</U><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;The operations of each segment are evaluated based on earnings before interest and taxes (operating income).  Unallocated includes corporate expenses for administration, finance, legal and certain unallocated expenses primarily related to the implementation of a company-wide Enterprise Resource Planning System and the amortization of restricted stock. Eliminations include inter-segment sales. Geographic revenues represent sales to third parties by country in which the selling legal entity is domiciled. Operating assets directly attributable to business segments are included in identifiable assets (i.e. sum of accounts receivable, inventories, net property, plant and equipment and net intangible assets). Operating assets for BP do not include manufacturing property, plant and equipment but do include an allocation of goodwill based on relative fair values as of the first quarter of 2004. Cash, prepaid expenses, and other corporate and non-allocated assets are included in unallocated. D
iscontinued operations include the Generics Business and the ParMed.  For geographic reporting, long-lived assets include net property, plant and equipment and net intangibles.  Segment data includes immaterial inter-segment revenues. AH revenues for the year ended December 31, 2005 include two products that individually account for more than 10% of consolidated revenues; Chlorotetracyline ($102,808) and BMD ($57,098).  No customer accounts for more than 10% of consolidated revenues.</P>
<P ALIGN="JUSTIFY"></P></FONT>
<P ALIGN="LEFT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=612>
<TR><TD WIDTH="31%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="CENTER"><BR>
</U>Total<U><BR>
Revenue</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="CENTER"><BR>
Operating<BR>
 <U>Income</U></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="CENTER"><BR>
</U>Identifiable<U> <BR>
Assets</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="CENTER">Depreciation<BR>
and<BR>
<U>Amortization</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="CENTER"><BR>
Capital <BR>
<U>Expenditures</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">
<B><U><FONT SIZE=2><P>2005</B></U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">
<FONT SIZE=2><P>BP</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">$ 101,579</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">$ 23,582</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">$ 208,371</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">$ 7,963</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">$ 907</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">
<FONT SIZE=2><P>API</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"> 138,355</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">52,419</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">   139,073</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">   11,100</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">   7,697</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">
<FONT SIZE=2><P>AH</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">325,065</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">66,279</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">329,216</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">18,890</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">5,090</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">
<FONT SIZE=2><P>Unallocated &amp; Eliminations</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(11,382)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(47,469)</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">921,399</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">5,874</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">8,505</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">
<FONT SIZE=2><P>Discontinued Operations</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">            --</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">             --</U></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">       17,358</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">47,367</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">16,740</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$ 553,617</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$ 94,811</U></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$ 1,615,417</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$ 91,194</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$ 38,939</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">
<B><U><FONT SIZE=2><P>2004</B></U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">
<FONT SIZE=2><P>BP</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">$ 62,399</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">$ 6,452</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">$ 198,220</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">$ 7,770</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">$ 696</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">
<FONT SIZE=2><P>API</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"> 143,199</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"> 72,772</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"> 155,109</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"> 9,508</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">25,723</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">
<FONT SIZE=2><P>AH</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">314,642</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">24,810</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">329,870</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">20,206</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">5,057</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">
<FONT SIZE=2><P>Unallocated  &amp; Eliminations</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(6,911)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(41,012)</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">248,936</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">7,616</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">1,723</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">
<FONT SIZE=2><P>Discontinued Operations</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">             --</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">             --</U></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">1,107,477</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">51,303</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">16,107</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$ 513,329</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$ 63,022</U></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$ 2,039,612</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$96,403</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$49,306</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">
<B><U><FONT SIZE=2><P>2003</B></U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">
<FONT SIZE=2><P>BP</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">$ 65,258</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">$ 21,971</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">$ 198,484</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">$ 7,738</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">$ 459</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">
<FONT SIZE=2><P>API</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"> 124,485</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">  65,651</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">  132,385</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">7,683</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">13,059</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">
<FONT SIZE=2><P>AH</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">295,706</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">20,133</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">407,590</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">20,772</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">3,985</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">
<FONT SIZE=2><P>Unallocated  &amp; Eliminations</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(5,982)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(38,893)</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">236,460</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">11,791</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">6,756</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">
<FONT SIZE=2><P>Discontinued Operations</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">            --</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">            --</U></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">1,367,228</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">47,217</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">18,360</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$ 479,467</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$  68,862</U></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$  2,342,147</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$  95,201</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$  42,619</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
</TR>
</TABLE>
</P>

<B><U><FONT SIZE=3><P>Geographic Information<BR>
</P></B></U></FONT>
<TABLE CELLSPACING=0 BORDER=0 WIDTH=690>
<TR><TD WIDTH="23%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="38%" VALIGN="TOP" COLSPAN=3>
<U><FONT SIZE=2><P ALIGN="CENTER">Revenues</U></FONT></TD>
<TD WIDTH="38%" VALIGN="TOP" COLSPAN=3>
<U><FONT SIZE=2><P ALIGN="CENTER">Long-lived Identifiable Assets</U></FONT></TD>
</TR>
<TR><TD WIDTH="23%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="CENTER">2004</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="CENTER">2003</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="CENTER">2005</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="CENTER">2004</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="CENTER">2003</U></FONT></TD>
</TR>
<TR><TD WIDTH="23%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="23%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P>United States</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">$ 421,600</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">$ 368,400</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">$ 334,500</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">$343,600</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">$362,034</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" HEIGHT=14>
<FONT SIZE=2><P ALIGN="RIGHT">$406,311</FONT></TD>
</TR>
<TR><TD WIDTH="23%" VALIGN="TOP">
<FONT SIZE=2><P>Norway</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">10,200</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">18,600</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">22,400</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">19,000</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">23,897</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">33,787</FONT></TD>
</TR>
<TR><TD WIDTH="23%" VALIGN="TOP">
<FONT SIZE=2><P>Denmark</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">33,500</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">24,300</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">17,700</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">84,700</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">80,234</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">63,266</FONT></TD>
</TR>
<TR><TD WIDTH="23%" VALIGN="TOP">
<FONT SIZE=2><P>Other </FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">88,317</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">  102,029</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">104,867</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">60,704</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">84,089</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">85,676</U></FONT></TD>
</TR>
<TR><TD WIDTH="23%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$553,617</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$513,329</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$ 479,467</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$508,004</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$550,254</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$ 589,040</U></FONT></TD>
</TR>
</TABLE>

<FONT FACE="CG Times (W1),Times New Roman"><P><BR>
<U>22.&nbsp;&nbsp;Selected Quarterly Financial Data (unaudited)</P>
</U></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=633>
<TR><TD WIDTH="34%" VALIGN="BOTTOM" HEIGHT=34>
<U><FONT SIZE=2><P>2005</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=34>
<U><FONT SIZE=2><P ALIGN="CENTER">First Quarter</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=34>
<U><FONT SIZE=2><P ALIGN="CENTER">Second Quarter</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" HEIGHT=34>
<U><FONT SIZE=2><P ALIGN="CENTER">Third Quarter</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=34>
<U><FONT SIZE=2><P ALIGN="CENTER">Fourth Quarter (a)</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=34>
<U><FONT SIZE=2><P ALIGN="CENTER">Full Year</U></FONT></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P>Total Revenue</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT"> $ 124,093</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT"> $ 137,639 </FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT"> $ 135,525 </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$ 156,360</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$ 553,617</FONT></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P>Gross Profit</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$   73,678</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$   83,926 </FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$   83,285 </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$   95,365</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$ 336,254</FONT></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P>Net Income (loss)</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$     8,814</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$   20,026</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$   17,849</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$   87,080</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$  133,769</FONT></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="BOTTOM" HEIGHT=34>
<U><FONT SIZE=2><P>2004</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=34>
<FONT SIZE=2><P ALIGN="CENTER">First <U>Quarter</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=34>
<FONT SIZE=2><P ALIGN="CENTER">Second<U> Quarter</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" HEIGHT=34>
<U><FONT SIZE=2><P ALIGN="CENTER">Third Quarter</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=34>
<FONT SIZE=2><P ALIGN="CENTER">Fourth<U> Quarter (b)</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=34>
<U><FONT SIZE=2><P ALIGN="CENTER">Full Year</U></FONT></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P>Total Revenue</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT"> $  126,967</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT"> $  126,915 </FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT"> $  127,163 </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT"> $  132,284 </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT"> $  513,329 </FONT></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P>Gross Profit</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$    67,804 </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT"> $    72,401 </FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT"> $    73,207 </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT"> $    81,205 </FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT"> $  294,617 </FONT></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17><P></P></TD>
</TR>
<TR><TD WIDTH="34%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P>Net Income (loss)</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$    (3,142)</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$         594</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$    (4,668)</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$(307,521)</FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM" HEIGHT=17>
<FONT SIZE=2><P ALIGN="RIGHT">$(314,737)</FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3>
<P ALIGN="JUSTIFY">a)  In the fourth quarter of 2005, the Company reversed its U.S. deferred tax valuation allowance given its current and expected profitability, resulting in a tax benefit of $52,121.  In addition, the Company recognized a gain on the sale of the Generics business of $35,259.</P>
<P ALIGN="JUSTIFY">b)   The fourth quarter of 2004 includes an income tax charge of approximately $59,500 to establish a valuation allowance for net U.S. deferred tax assets.</P>
</FONT><P ALIGN="JUSTIFY"><BR>
<FONT SIZE=3>23.&nbsp;&nbsp;<U>Guarantor and Nonguarantor Condensed Consolidated Financial Information</U> </P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December 23, 2005, the Company irrevocably notified the Note Trustees that it would redeem the full amount oustanding of its Senior Unsecured Notes due 2011, plus accrued interest and call premium on January 23, 2006.  Subsequently, on January 23, 2006, the Company paid the full amount required.  The following financial information is presented because the Company's Senior Unsecured Notes due 2011 were outstanding on December 31, 2005.  </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">     At December 31, 2005, the parent and certain of its wholly-owned subsidiaries were guarantors under the Senior Unsecured Notes due 2011 from non-guarantor subsidiaries. The guarantors jointly and severally, and fully and unconditionally, guaranteed the Company's obligation under the Notes. The consolidating financial information to follow presents the consolidating balance sheet as of December 31, 2005 and December 31, 2004 and the related consolidating statements of operations and cash flows for the twelve months ended December 31, 2005, 2004 and 2003 for:</P>
<P ALIGN="JUSTIFY"></P></FONT>
<P ALIGN="CENTER"><CENTER><TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=529>
<TR><TD WIDTH="6%" VALIGN="TOP">
<B><FONT SIZE=3><P ALIGN="JUSTIFY"><FONT FACE="Symbol">&#183;</FONT>
</B></FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">Alpharma Inc., the parent;</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY"><FONT FACE="Symbol">&#183;</FONT>
</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">The guarantor subsidiaries;</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY"><FONT FACE="Symbol">&#183;</FONT>
</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">The nonguarantor subsidiaries; and</FONT></TD>
</TR>
<TR><TD WIDTH="6%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY"><FONT FACE="Symbol">&#183;</FONT>
</FONT></TD>
<TD WIDTH="94%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">The Company on a consolidated basis.</FONT></TD>
</TR>
</TABLE>
</CENTER></P>

<FONT SIZE=3><P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information includes elimination entries necessary to consolidate Alpharma Inc., the parent, with guarantor and nonguarantor subsidiaries.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments in subsidiaries are accounted for by the parent using the equity method of accounting. The guarantor and nonguarantor subsidiaries are presented on a combined basis.  The principal elimination entries eliminate investments in subsidiaries and intercompany balances and transactions.</P>
<P ALIGN="JUSTIFY"><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Separate financial statements for the guarantor subsidiaries and the nonguarantor subsidiaries are not presented because management believes that such financial statements would not be meaningful to investors.</P>
<B><P ALIGN="CENTER">ALPHARMA INC.<BR>
Consolidating Balance Sheet<BR>
December 31, 2005<BR>
</B><I>(in thousands)</P>
</I></FONT>
<TABLE CELLSPACING=0 BORDER=0 WIDTH=675>
<TR><TD WIDTH="37%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">
<U><FONT SIZE=1><P ALIGN="CENTER">Parent</U></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM">
<FONT SIZE=1><P ALIGN="CENTER">Guarantor<U> Subsidiaries</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM">
<FONT SIZE=1><P ALIGN="CENTER">Nonguarantor <U>Subsidiaries</U></FONT></TD>
<TD WIDTH="15%" VALIGN="BOTTOM">
<U><FONT SIZE=1><P ALIGN="CENTER">Eliminations</U></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM">
<FONT SIZE=1><P ALIGN="CENTER">Consolidated<BR>
<U>Total</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P ALIGN="JUSTIFY">Current assets:</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Cash and cash equivalents</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$736,480</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$5,283</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$58,247</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="JUSTIFY">          $800,010</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Accounts receivable, net</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">51,026</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">12,731</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">27,141</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">90,898</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Inventories</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">50,633</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">617</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">50,762</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(9,271)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">92,741</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Prepaid expenses and other</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">29,929</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">884</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">8,866</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,896</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">41,575</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Assets of discontinued operations</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">11,823</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">11,823</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Intercompany receivables</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">262,548</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">422,008</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">1,464,484</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">(2,149,040)</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">--</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,130,616</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">453,346</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,609,500</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(2,156,415)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,037,047</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Property, plant &amp; equipment, net</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">107,187</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">20,726</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">87,261</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">215,174</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Goodwill</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">113,973</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,774</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">116,747</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Intangible assets, net</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">38,676</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">63,014</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">74,393</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">176,083</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Investment in subsidiaries</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">79,599</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">472,741</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(552,340)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Assets of discontinued operations</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">5,723</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">5,723</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Other assets and deferred charges</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">60,850</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">10,330</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">1,429</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">72,609</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$1,416,928</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$1,139,853</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$1,775,357</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$(2,708,755)</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$1,623,383</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Current liabilities:</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Short term debt</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$35,713</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$35,713</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Long term debt, current portion</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">380,948</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">8</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">380,956</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">
<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">100,589</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">30,284</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">45,240</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(372)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">175,741</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">
<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Accrued and deferred income taxes</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">10,576</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">26,857</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">21,007</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,811</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">61,251</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">
<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Liabilities of discontinued operations</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">11,596</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">11,596</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intercompany payables</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">(240)</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">693,883</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">1,454,149</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">(2,147,792)</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">--</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">491,873</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">762,620</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,556,117</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(2,145,353)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">665,257</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Long term debt:</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Senior</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">17</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">17</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Liabilities of discontinued operations</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">457</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">457</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Deferred income taxes</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">12,738</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">5,730</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">18,468</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Other non-current liabilities</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">6,977</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">14,129</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">21,106</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Stockholders' equity:</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Class&nbsp;A Common Stock</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">8,507</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">193,272</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,075</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(195,347)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">8,507</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Class&nbsp;B Common Stock</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,375</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,375</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Additional paid-in-capital</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,095,520</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(92,213)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,252,908</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(1,160,695)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,095,520</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Deferred stock cost</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(5,395)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(5,395)</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>   Parent Equity</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">200,662</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">789</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(201,451)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Retained earnings</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(223,137)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">62,317</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(1,087,731)</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,025,414</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(223,137)</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">47,852</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">31,323</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(31,323)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">47,852</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Treasury stock, at cost</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">(7,644)</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">(7,644)</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">918,078</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">364,038</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">199,364</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">(563,402)</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">918,078</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">
<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities &amp; stockholders' equity</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$1,416,928</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$1,139,853</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$1,775,357</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$(2,708,755)</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$1,623,383</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
</TR>
</TABLE>


<P>&nbsp;</P>
<P>&nbsp;</P>
<B><FONT SIZE=3><P ALIGN="CENTER">ALPHARMA INC.<BR>
Consolidating Balance Sheet<BR>
December 31, 2004<BR>
</B><I>(in thousands)</P>
</I></FONT><P ALIGN="CENTER"></P>
<TABLE CELLSPACING=0 BORDER=0 WIDTH=675>
<TR><TD WIDTH="37%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">
<U><FONT SIZE=1><P ALIGN="CENTER">Parent</U></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM">
<FONT SIZE=1><P ALIGN="CENTER">Guarantor<U> Subsidiaries</U></FONT></TD>
<TD WIDTH="13%" VALIGN="BOTTOM">
<FONT SIZE=1><P ALIGN="CENTER">Nonguarantor <U>Subsidiaries</U></FONT></TD>
<TD WIDTH="15%" VALIGN="BOTTOM">
<U><FONT SIZE=1><P ALIGN="CENTER">Eliminations</U></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM">
<FONT SIZE=1><P ALIGN="CENTER">Consolidated<BR>
<U>Total</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P ALIGN="JUSTIFY">Current assets:</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Cash and cash equivalents</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$1,614</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$(157)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$103,755</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$      --</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$105,212</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Accounts receivable, net</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">32,851</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">9,134</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">30,351</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">72,336</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Inventories</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">51,997</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,441</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">54,467</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(10,719)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">98,186</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Prepaid expenses and other</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">33,239</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(18,634)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">3,984</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,763</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">21,352</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Assets of discontinued operations</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Intercompany receivables</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,972,659</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">700,973</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,193,641</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">        (3,867,273)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Assets of discontinued operations</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">226,158</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">148,828</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">374,986</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,092,360</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">919,915</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,535,026</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(3,875,229)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">672,072</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Property, plant &amp; equipment, net</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">112,353</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">22,268</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">103,283</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">237,904</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Goodwill</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">4,475</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">112,969</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,945</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(2,220)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">117,169</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Intangible assets, net</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">40,960</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">71,230</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">82,991</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">195,181</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Investment in subsidiaries</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">112,319</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">534,611</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(646,930)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Other assets and deferred charges</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">  30,528</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">      18,991</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">    35,276</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">         --</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">  84,795</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Assets of discontinued operations</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">___--</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">248,627</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">483,864</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">___--</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">732,491</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>2,392,995</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>1,928,611</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>2,242,385</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>(4,524,379</U>)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>2,039,612</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Current liabilities:</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Short term debt</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$        --</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$16,000</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$    96</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$      --</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$16,096</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Long term debt, current portion</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">373,670</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">301,969</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">675,639</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">
<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">60,387</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">11,336</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">27,457</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,430</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">101,610</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">
<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Accrued and deferred income taxes</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">6,248</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">209</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">25,804</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">32,261</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Intercompany payables</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,092,428</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,603,303</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,171,542</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">          (3,867,273)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">
<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Liabilities of discontinued operations</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">139,204</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">75,596</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">214,800</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,532,733</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,072,021</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,300,495</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(3,864,843)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,040,406</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Long term debt:</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Senior</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Convertible subordinated notes</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">10,000</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">10,000</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Deferred income taxes</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(39,790)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">69,860</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">17,446</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">47,516</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Other non-current liabilities</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">6,410</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">18,886</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">25,296</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Liabilities of discontinued operations</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">7,099</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">25,653</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">32,752</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Stockholders' equity:</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Class&nbsp;A Common Stock</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">8,256</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">8,256</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Class&nbsp;B Common Stock</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,375</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">2,375</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Additional paid-in-capital</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,073,921</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">12,347</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">490,547</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(502,894)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">1,073,921</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Deferred stock cost</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(7,443)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(7,443)</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Retained earnings</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(347,425)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(232,716)</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">246,104</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(13,388)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(347,425)</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">161,602</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">143,254</FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(143,254)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">161,602</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;Treasury stock, at cost</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">   (7,644</U>)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">              --</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">              --</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">              --</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">   (7,644</U>)</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity</DIR>
</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">   883,642</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT"> (220,369)</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">    879,905</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">(659,536</U>)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">     883,642</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">
<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities &amp; stockholders' equity</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>2,392,995</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>1,928,611</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>2,242,385</U></FONT></TD>
<TD WIDTH="15%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>(4,524,379</U>)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$<U>2,039,612</U></FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="13%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="15%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM">&nbsp;</TD>
</TR>
</TABLE>


<P>&nbsp;</P>
<B><FONT SIZE=3><P ALIGN="CENTER">ALPHARMA INC.<BR>
Consolidating Statement of Operations<BR>
For the Year Ended December 31, 2005<BR>
</B><I>(in thousands)</P>
</I><P ALIGN="CENTER"></P></FONT>
<TABLE CELLSPACING=0 BORDER=0 WIDTH=654>
<TR><TD WIDTH="31%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="CENTER">Parent</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>
<FONT SIZE=1><P ALIGN="CENTER">Guarantor<U> Subsidiaries</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>
<FONT SIZE=1><P ALIGN="CENTER">Nonguarantor <U>Subsidiaries</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="CENTER">Eliminations</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM">
<FONT SIZE=1><P ALIGN="CENTER">Consolidated<BR>
<U>Total</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="14%" VALIGN="BOTTOM">&nbsp;</TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Total revenue</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$365,343</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">$93,731</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">$223,391</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">$(128,848)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">$553,617</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Cost of sales</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">234,933</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">(871)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">112,149</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">(128,848)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">217,363</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">130,410</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">94,602</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">111,242</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">336,254</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Selling, general and administrative<BR>
expenses</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">              122,225</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">                60,364</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">                58,854</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">241,443</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating income (loss) </DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">8,185</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">34,238</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">52,388</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">94,811</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Interest expense</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(35,049)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">(12,605)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">(1,481)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">(49,135)</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Other income (expense), net</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(15,722)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">771,549</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">(757,725)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">(1,898)</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Equity in earnings of subsidiaries</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">97,545</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">(594,908)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">497,363</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">--</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income before taxes</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">54,959</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">198,274</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">(706,818)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">497,363</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">43,778</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Provision (benefit) for income taxes</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">10,516</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">(44,884)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">15,970</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">(18,398)</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Net income (loss) from continuing operations</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">                 $44,443</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">            $243,158</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">            $(722,788)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">497,363</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">62,176</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Net discontinued operations</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">89,326</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">(145,613)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">127,880</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">71,593</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Net income (loss)</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$133,769</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">$97,545</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">$(594,908)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">$497,363</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">$133,769</U></FONT></TD>
</TR>
</TABLE>

<B><FONT SIZE=3><P>&#9;&#9;&#9;</P>

<P ALIGN="CENTER">ALPHARMA INC.<BR>
Consolidating Statement of Operations<BR>
For the Year Ended December 31, 2004<BR>
</B><I>(in thousands)</P>
</I><P ALIGN="CENTER"></P></FONT>
<TABLE CELLSPACING=0 BORDER=0 WIDTH=654>
<TR><TD WIDTH="31%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="CENTER">Parent</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>
<FONT SIZE=1><P ALIGN="CENTER">Guarantor<U> Subsidiaries</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>
<FONT SIZE=1><P ALIGN="CENTER">Nonguarantor <U>Subsidiaries</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="CENTER">Eliminations</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM">
<FONT SIZE=1><P ALIGN="CENTER">Consolidated<BR>
<U>Total</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="14%" VALIGN="BOTTOM">&nbsp;</TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Total revenue</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$338,788</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">$77,131</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">$235,307</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">$(137,897)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">$513,329</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Cost of sales</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">233,720</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">16,643</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">106,246</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">(137,897</U>)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">218,712</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">105,068</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">60,488</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">129,061</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">294,617</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Selling, general and administrative<BR>
expenses</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT"><BR>
104,595</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT"><BR>
53,958</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT"><BR>
73,042</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT"><BR>
          --</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT"><BR>
231,595</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating income (loss) </DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">473</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">6,530</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">56,019</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">63,022</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Interest expense</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(36,618)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">(20,470)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">(1,674)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">(58,762)</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Other income (expense), net</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(1,963)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">(706)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">1,112</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">(1,557)</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Equity in earnings of subsidiaries</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">(274,547)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">55,238</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">      --</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">219,309</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">          --</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income before taxes</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(312,655)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">40,592</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">55,457</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">219,309</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=1><P ALIGN="RIGHT">2,703</FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Provision (benefit) for income taxes</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">     2,082</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">   22,857</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT"> 24,527</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">          --</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">  49,466</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) from continuing<BR>
&nbsp;&nbsp;&nbsp;operations</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM">
<U><FONT SIZE=1><P ALIGN="RIGHT">$(314,737)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">     $17,735</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">$30,930</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">$219,309</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">$(46,763)</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Net discontinued operations</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">                --</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">  (292,282)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">    24,308</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">              --</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">  (267,974)</U></FONT></TD>
</TR>
<TR><TD WIDTH="31%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Net income (loss)</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$(314,737)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">$(274,547)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">    55,238</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">  $219,309</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=1><P ALIGN="RIGHT">$(314,737)</U></FONT></TD>
</TR>
</TABLE>

<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<B><FONT SIZE=3><P ALIGN="CENTER">ALPHARMA INC.<BR>
Consolidating Statement of Operations<BR>
For the Year Ended December 31, 2003<BR>
</B><I>(in thousands)</P>
</I><B><P ALIGN="CENTER"></P></B></FONT>
<TABLE CELLSPACING=0 BORDER=0 WIDTH=660>
<TR><TD WIDTH="32%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="BOTTOM">
<U><FONT SIZE=1><P ALIGN="CENTER">Parent</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM">
<FONT SIZE=1><P ALIGN="CENTER">Guarantor<U><BR>
Subsidiaries</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM">
<FONT SIZE=1><P ALIGN="CENTER">Nonguarantor<BR>
<U>Subsidiaries</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM">
<U><FONT SIZE=1><P ALIGN="CENTER">Eliminations</U></FONT></TD>
<TD WIDTH="14%" VALIGN="BOTTOM">
<FONT SIZE=1><P ALIGN="CENTER">Consolidated<BR>
<U>Total</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="14%" VALIGN="BOTTOM">&nbsp;</TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Total revenue</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$318,661</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$58,409</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$221,244</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$(118,847)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">$479,467</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Cost of sales</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">215,085</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">(871)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">114,931</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">(118,847)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">   210,298</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">103,576</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">59,280</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">106,313</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">269,169</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Selling, general and administrative<BR>
expenses</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT"><BR>
97,227</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT"><BR>
36,857</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT"><BR>
66,223</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<I><U><FONT SIZE=1><P ALIGN="RIGHT"><BR>
        --</I></U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT"><BR>
200,307</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating income (loss) </DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">6,349</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">22,423</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">40,090</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">68,862</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Interest expense</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(56,046)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(4,327)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(3,044)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(63,417)</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Other income (expense), net</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(27,502)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">20,350</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(19,338)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(26,490)</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Equity in earnings of subsidiaries</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">   77,871</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">  36,406</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">        --</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT"> (114,277</U>)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">          --</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income (loss) before taxes</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">672</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">74,852</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">17,708</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(114,277)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT">(21,045)</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Provision (benefit) for income taxes</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT"> (13,161)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">   1,137</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">    608</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">          --</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">(11,416)</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) from continuing<BR>
&nbsp;&nbsp;&nbsp;operations</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT"><BR>
13,833</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT"><BR>
73,715</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT"><BR>
 17,100</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT"><BR>
(114,277)</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=1><P ALIGN="RIGHT"><BR>
 (9,629)</FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Net discontinued operations</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">          --</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">    4,156</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">  19,306</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">         --</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">23,462</U></FONT></TD>
</TR>
<TR><TD WIDTH="32%" VALIGN="TOP"><DIR>

<FONT SIZE=1><P>Net income (loss)</DIR>
</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$13,833</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$77,871</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$36,406</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$(114,277)</U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<U><FONT SIZE=1><P ALIGN="RIGHT">$13,833</U></FONT></TD>
</TR>
</TABLE>

<B><FONT SIZE=3><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">Alpharma Inc.<BR>
Consolidating Statement of Cash Flows<BR>
For the Year Ended December 31, 2005<BR>
</B><I>(in thousands)</P>
</I><P ALIGN="JUSTIFY"></P></FONT>
<TABLE CELLSPACING=0 BORDER=0 WIDTH=667>
<TR><TD WIDTH="40%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="CENTER">Parent</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="CENTER"><BR>
Guarantor</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="CENTER">Non<BR>
Guarantor</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="CENTER"><BR>
Eliminations</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="CENTER"><BR>
Consolidated</U></FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=2><P>Net cash provided by (used in) operating<BR>
&nbsp;&nbsp;&nbsp;activities</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$625,110</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">$254,281</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">$(632,110)</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">$--</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">$247,281</U></FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=2><P>Investing Activities</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(8,138)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(10,199)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(20,602)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(38,939)</FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of Generics</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">125,784</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">94,072</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">584,565</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">804,421</FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase of businesses &amp; intangibles,<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;net of cash required</FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM">
<U><FONT SIZE=2><P ALIGN="RIGHT">(3,069)</U></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">(2,090)</U></FONT></TD>
<TD WIDTH="12%" VALIGN="BOTTOM" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="13%" VALIGN="BOTTOM" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">(5,159)</U></FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">114,577</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">83,873</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">561,873</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">760,323</U></FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=2><P>Financing Activities:</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) in short-term debt</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(16,000)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">35,636</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">19,636</FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reduction of senior long-term debt</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(9,752)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(301,969)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(311,721)</FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of stock</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">11,358</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">11,358</FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase in bank overdraft</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">3,169</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(15,487)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(12,318)</FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment of debt issuance costs</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(115)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(115)</FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends paid</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">(9,481)</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">(9,481)</U></FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) <BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;financing activities</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(4,821)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(333,456)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">35,636</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(302,641)</FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash flows from exchange rate<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;changes</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(9,977)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(9,977)</FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=2><P>Increase (decrease) in cash</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">734,866</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">4,698</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(44,578)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">694,986</FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=2><P>Cash and cash equivalents at beginning of<BR>
&nbsp;&nbsp;&nbsp;year</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">1,614</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">773</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">102,825</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">105,212</U></FONT></TD>
</TR>
<TR><TD WIDTH="40%" VALIGN="TOP">
<FONT SIZE=2><P>Cash and cash equivalents at end of period</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$736,480</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">$5,471</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">$58,247</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">$--</U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">$800,198</U></FONT></TD>
</TR>
</TABLE>

<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<B><FONT SIZE=3><P ALIGN="CENTER">Alpharma Inc.<BR>
Consolidating Statement of Cash Flows<BR>
For the Year Ended December 31, 2004<BR>
</B><I>(in thousands)</P>
</I><P ALIGN="JUSTIFY"></P></FONT>
<TABLE CELLSPACING=0 BORDER=0 WIDTH=685>
<TR><TD WIDTH="41%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="CENTER"><BR>
Parent</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="CENTER"><BR>
Guarantor</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="CENTER">Non<BR>
Guarantor</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="CENTER"><BR>
Eliminations</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="CENTER"><BR>
Consolidated</U></FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>Net cash provided by (used in) operating<BR>
&nbsp;&nbsp;&nbsp;activities</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT"><BR>
$27,463</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT"><BR>
$58,088</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT"><BR>
$100,611</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT"><BR>
$   --</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT"><BR>
$186,162</U></FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>Investing Activities</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(4,805)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(11,202)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(33,299)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(49,306)</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of property</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">17,000</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">17,000</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of subsidiary</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">4,400</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">--</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">4,400</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase of businesses &amp; intangibles,<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;net of cash required</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
<U>   (286</U>)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
<U>(12,857</U>)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
<U>  (1,501</U>)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT"><BR>
        --</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
<U> (14,644</U>)</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(5,091)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(7,059)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(30,400)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(42,550)</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>Financing Activities:</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) in short-term debt</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">6,500</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">78</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">6,578</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reduction of senior long-term debt</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(95,600)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(32,520)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(128,120)</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from senior long-term debt</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">25,000</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">25,000</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of stock</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">7,027</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">111</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">7,138</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase in bank overdraft</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(24,455)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(24,455)</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in long-term intercompany<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;rec/pay</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">2,885</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">17,107</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">19,992</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in intercompany dividends</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">8,479</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(8,479)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in treasury stock</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(229)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(229)</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment of debt issuance costs</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(1,689)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(1,689)</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends paid</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">  (9,404</U>)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">        --</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">        --</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">        --</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT"> (9,404</U>)</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) <BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;financing activities</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
(17,386)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
(55,361)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
(32,442)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
- --</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
(105,189)</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash flows from exchange rate<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;changes</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
- --</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
- --</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
8,166</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
- --</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
8,166</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>Increase (decrease) in cash</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">4,986</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">(4,332)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">45,935</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<FONT SIZE=2><P ALIGN="RIGHT">46,589</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>Cash and cash equivalents at beginning of<BR>
&nbsp;&nbsp;&nbsp;year</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT"><BR>
(3,372</U>)</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT"><BR>
 5,105</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT"><BR>
  56,890</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT"><BR>
        --</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT"><BR>
  58,623</U></FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>Cash and cash equivalents at end of period</FONT></TD>
<TD WIDTH="11%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$  1,614</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">$     773</U></FONT></TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">$102,825</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">$  --</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>
<U><FONT SIZE=2><P ALIGN="RIGHT">$105,212</U></FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="11%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP" COLSPAN=2>&nbsp;</TD>
</TR>
</TABLE>

<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<B><FONT SIZE=3><P ALIGN="CENTER">Alpharma Inc.<BR>
Consolidating Statement of Cash Flows<BR>
For the Year Ended December 31, 2003<BR>
</B><I>(in thousands)</P>
</I><P ALIGN="JUSTIFY"></P></FONT>
<TABLE CELLSPACING=0 BORDER=0 WIDTH=679>
<TR><TD WIDTH="41%" VALIGN="BOTTOM">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="CENTER"><BR>
Parent</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="CENTER"><BR>
Guarantor</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="CENTER">Non-<BR>
Guarantor</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="CENTER"><BR>
Eliminations</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="CENTER"><BR>
Consolidated</U></FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>Net cash provided by (used in) operating<BR>
&nbsp;&nbsp;&nbsp;activities</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
$<U> 57,972</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT"><BR>
</U>$<U>38,751</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT"><BR>
</U>$<U>58,347</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT"><BR>
</U>$   <U>--</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT"><BR>
</U>$<U>155,070</U></FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>Investing Activities</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(7,329)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(16,554)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(18,736)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(42,619)</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>        Proceeds from sale of property</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">2,355</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">2,355</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>        Proceeds from sale of subsidiary</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">5,967</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">5,967</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   Purchase of businesses &amp; intangibles,<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;net of cash required</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
<U>  (2,093</U>)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
 <U>      (84</U>)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
<U>(3,075</U>)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
<U>       --</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
<U>  (5,252</U>)</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(1,100)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(16,638)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(21,811)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(39,549)</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>Financing Activities:</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase (Decrease) in short-term debt</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(10,500)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">27</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(10,473)</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reduction of senior long-term debt</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(319,789)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(2,499)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(1,676)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(323,964)</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from senior long-term debt</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">248,000</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">248,000</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>      Proceeds from issuance of stock</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">11,321</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">11,321</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>      Increase in bank overdraft</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">104</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">1,826</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">1,930</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in long-term intercompany<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;rec/pay</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
8,456</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
(8,456)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
- --</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
- --</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT"><BR>
- --</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment of debt issuance costs</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(576)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(576)</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends paid</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT"> (9,320</U>)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">        --</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">        --</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">        --</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">(9,320</U>)</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) <BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;financing activities</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(61,804)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(19,629)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(1,649)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(83,082)</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash flows from exchange rate<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;changes</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">2,221</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">2,221</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>Increase (decrease) in cash</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">(4,932)</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">2,484</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">37,108</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">34,660</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>Cash and cash equivalents at beginning of<BR>
&nbsp;&nbsp;&nbsp;year</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">1,560</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">2,621</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">19,782</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">--</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=2><P ALIGN="RIGHT">23,963</FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">
<FONT SIZE=2><P>Cash and cash equivalents at end of period</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$ (3,372)</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$  5,105</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$56,890</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$   --</U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<U><FONT SIZE=2><P ALIGN="RIGHT">$  58,623</U></FONT></TD>
</TR>
<TR><TD WIDTH="41%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="12%" VALIGN="TOP">&nbsp;</TD>
</TR>
</TABLE>

<FONT SIZE=3><P ALIGN="JUSTIFY"></P></FONT></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>exh10_2.htm
<DESCRIPTION>LOAN AND SECURITY AGREEMENT
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>Note:</TITLE>
<META NAME="Wtx_List_3227" CONTENT="CF-Loan Agreement #3227|L1-3227|L2-3227|L3-3227|L4-3227|L5-3227|L6-3227|L7-3227|L8-3227|L9-3227|78|True|True|True|True|True|">
<META NAME="WTXDocID" CONTENT="414211_33">
<META NAME="WTXMatterID" CONTENT="001809-00041">
<META NAME="WTXDocPath" CONTENT="414211_33.DOC">
<META NAME="_AdHocReviewCycleID" CONTENT="-1956943299">
<META NAME="_EmailSubject" CONTENT="Alpharma ">
<META NAME="_AuthorEmail" CONTENT="RK@phrd.com">
<META NAME="_AuthorEmailDisplayName" CONTENT="Raj Kini">
</HEAD>
<BODY LINK="#0000ff">

<B><FONT SIZE=3><P ALIGN="CENTER">LOAN AND SECURITY AGREEMENT</P>
<P ALIGN="JUSTIFY"><A NAME="_Toc38346516">THIS  LOAN  AND  SECURITY  AGREEMENT</B> is made on October 26, 2005, by and among <B>Alpharma Inc.</B>, a Delaware corporation (individually and, in its capacity as the representative of the other Borrowers pursuant to <B>Section 4.4</B>, "Parent"), <B>Alpharma Operating Corporation</B>, a Delaware corporation, <B>Alpharma USPD Inc.</B>, a Maryland corporation, <B>Alpharma U.S. Inc.</B>, a Delaware corporation, <B>G.F. Reilly Company</B>, a Delaware corporation, <B>Parmed Pharmaceuticals, Inc.</B>, a Delaware corporation, <B>Alpharma Euro Holdings Inc.</B>, a Delaware corporation, <B>Alpharma (Bermuda) Inc.</B>, a Delaware corporation, <B>Alpharma USHP Inc.</B>, a Delaware corporation, <B>Alpharma Animal Health Company</B>, a Texas corporation, <B>Mikjan Corporation</B>, an Arkansas corporation, <B>Alpharma Holdings Inc.</B>, a Delaware corporation, <B>Alpharma Pharmaceuticals Inc.</B>, a Delaware corporation, <B>Purepac Pharmaceutical Holdings, Inc.</B>, a Delaware
 corporation, <B>Alpharma Branded Products Division Inc.</B>, a Delaware corporation, <B>Purepac Pharmaceutical Co.</B>, a Delaware corporation and <B>Alpharma Investment Inc.</B>, a Delaware corporation (collectively referred to herein as "Borrowers," and individually as a "Borrower"); the various financial institutions listed on the signature pages hereof (together with their respective successors and permitted assigns, the "Lenders"); and <B>Bank of America, N.A.</B>, a national bank, in its capacity as a Lender, Issuing Bank and collateral and administrative agent for the Lenders pursuant to <B>Section 13</B> (together with its successors in such capacity, "Agent").  Capitalized terms used in this Agreement have the meanings assigned to them in <B>Section&nbsp;1</B>.</P>
<B><U><P ALIGN="CENTER">R e c i t a l s</B></U>:</P>
<P ALIGN="JUSTIFY">Each Borrower has requested that Lenders make available a revolving credit, term loan and letter of credit facility to Borrowers, which shall be used by Borrowers to finance their mutual and collective enterprise of developing, manufacturing and marketing pharmaceutical products for humans and animals.  In order to utilize the financial powers of each Borrower in the most efficient and economical manner, and in order to facilitate the financing of each Borrower<B>'</B>s needs, Lenders will, at the request of any Borrower, make loans to all Borrowers under the term loan and  revolving credit facility on a combined basis and in accordance with the provisions hereinafter set forth.  Borrowers<B>'</B> business is a mutual and collective enterprise, and Borrowers believe that the consolidation of all<B><I> </B></I>term loan and revolving credit loans under this Agreement will enhance the aggregate borrowing powers of each Borrower and ease the administration of their<I> </I>term and revolving c
redit loan relationship with Lenders, all to the mutual advantage of Borrowers.  Lenders<B>'</B> willingness to extend credit to Borrowers and to administer each Borrower<B>'</B>s collateral security therefor, on a combined basis as more fully set forth in this Agreement, is done solely as an accommodation to Borrowers and at Borrowers<B>'</B> request in furtherance of Borrowers<B>'</B> mutual and collective enterprise.</P>
<P ALIGN="JUSTIFY">Each Borrower has agreed to be jointly and severally liable for loans and all outstanding other obligations under this Agreement and to guarantee the obligations of each of the other Borrowers under this&nbsp;Agreement and each of the other Loan Documents.</P>
<P ALIGN="JUSTIFY">NOW, THEREFORE, for Ten Dollars ($10.00) and other good and valuable consideration, the&nbsp;parties hereto, intending to be bound hereby, agree as follows:</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc102963307"><A NAME="_Toc105998278"><A NAME="_Toc105998688"><A NAME="_Toc105998820"><A NAME="_Toc117052333">SECTION 1.&nbsp;&nbsp;&nbsp;DEFINITIONS; RULES OF CONSTRUCTION</A></A></A></A></A></P>
<P ALIGN="JUSTIFY"><A NAME="_Toc102963308"><A NAME="_Toc105998279"><A NAME="_Toc105998689"><A NAME="_Toc105998821"><A NAME="_Toc117052334">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>.</A></A></A></A></A></P>
</B><P ALIGN="JUSTIFY">As used in this Agreement, the following terms shall have the following meanings ascribed to them (terms used in the singular to have the same meaning when used in the plural, and <I>vice versa</I>):</P><DIR>
<DIR>

<U><P ALIGN="JUSTIFY">Account</U> - shall have the meaning given to the term "account" in the UCC and shall include any&nbsp;and all rights of a Borrower to payment for goods sold, leased, licensed, assigned or otherwise disposed of, or for services rendered that are not evidenced by an Instrument or Chattel Paper, whether or not they have been earned by performance.</P>
<U><P ALIGN="JUSTIFY">Account Debtor</U> - a Person who is or becomes obligated under or on account of an Account, Chattel Paper or General Intangible.</P>
<U><P>Accounts Formula Amount</U> - on any date of determination thereof, an amount equal to the lesser of:</P>
<P>(i)&nbsp;the Revolver Commitments on such date or </P>
<P>(ii) the sum of:</P><DIR>
<DIR>

<P>(x)&nbsp;85% of the net amount of Eligible Accounts (other than Eligible Generic Accounts) on such date, and </P>
<P>(y) the lesser of (I) $30,000,000, (II) 90% of Trailing Receipts and (III) the Applicable Advance Rate of the net amount of Eligible Generic Accounts on such date.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">As used herein, the phrase "net amount of Eligible Accounts" and "net amount of Eligible Generic Accounts" shall mean (a) the face amount of such Accounts on any date less (without duplication) (b) any and all actual returns, rebates, discounts, credits, allowances, including, any and all direct and indirect customer rebates, floor stock adjustments, general sales allowances and other allowances, accrued free goods, and customer rebate accruals, or Taxes (including sales, excise or other taxes) at any time issued, owing, claimed by Account Debtors, granted, outstanding or payable in connection with, or any interest accrued on the amount of, such Accounts at such date, in each case, in accordance with GAAP and consistent with past practices of Borrowers; provided that in no event shall such reserve be greater than the amount of the Account for which a reserve has been established under GAAP.</P>
<U><P ALIGN="JUSTIFY">Adjusted LIBOR Rate</U> - for any Interest Period, with respect to LIBOR Loans, the rate of interest per annum determined pursuant to the following formula:</P></DIR>
</DIR>
</FONT>
<P ALIGN="RIGHT"><TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=456>
<TR><TD WIDTH="37%" VALIGN="TOP"><DIR>

<FONT SIZE=3><P ALIGN="JUSTIFY">LIBOR Rate &#9;=</DIR>
</FONT></TD>
<TD WIDTH="63%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="JUSTIFY">Offshore Base Rate&#9;&#9;____</P>
</U><P ALIGN="JUSTIFY">1.00 - Eurodollar Reserve Percentage</FONT></TD>
</TR>
<TR><TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="63%" VALIGN="TOP">&nbsp;</TD>
</TR>
</TABLE>
</P>
<DIR>
<DIR>
<DIR>
<DIR>

<FONT SIZE=3><P ALIGN="JUSTIFY">Where,</P>
<P ALIGN="JUSTIFY">"<U>Offshore Base Rate</U>" means the rate per annum appearing on Telerate Page 3750 (or any successor page) as the London interbank offered rate for deposits in Dollars at approximately 11:00 a.m. (London time) 2 Business Days prior to the first day of such Interest Period for a term comparable to such Interest Period.  If for any reason such rate is not available, the Offshore Base Rate shall be, for any Interest Period, the rate per annum appearing on Reuters Screen LIBO Page as the London interbank offered rate for deposits in Dollars at approximately 11:00 a.m. (London time) 2 Business Days prior to the first day of such Interest Period for a term comparable to such Interest Period; <U>provided</U>, <U>however</U>, if more than one rate is specified on Reuters Screen LIBO Page, the applicable rate shall be the arithmetic mean of all such rates.  If for any reason none of the foregoing rates is available, the Offshore Base Rate shall be, for any Interest Period, the rate per annum dete
rmined by Agent as the rate of interest at which Dollar deposits in the approximate amount of the applicable LIBOR Loan would be offered by BofA<B>'</B>s London Branch to major banks in the offshore Dollar market at their request at or about 11:00 a.m. (London time) 2 Business Days prior to the first day of such Interest Period for a term comparable to such Interest Period.</P>
<P ALIGN="JUSTIFY">"<U>Eurodollar Reserve Percentage</U>" means for any day during any Interest Period, the reserve percentage (expressed as a decimal, rounded upward to the next 1/100th of 1%) in effect on such day applicable to member banks under regulations issued from time to time by the Board of Governors for determining the maximum reserve requirement (including any emergency, supplemental or other marginal reserve requirement) with respect to Eurocurrency funding (currently referred to as "Eurocurrency liabilities").  The Offshore Rate for each outstanding LIBOR Loan shall be adjusted automatically as of the effective date of any change in the Eurodollar Reserve Percentage.</P></DIR>
</DIR>

<U><P ALIGN="JUSTIFY">Affiliate</U> - with respect to any Person, any other Person (i)&nbsp;who directly or indirectly through one or more intermediaries controls, or is controlled by, or is under common control with, such Person; or (ii)&nbsp;who is an officer, director, partner or managing member of such Person.  For purposes hereof, "control" means the possession, directly or indirectly, of the power to vote 10% or more of the voting interests of such Person or to direct or cause the direction of the management and policies of such Person, whether through the ownership of any Equity Interest, by contract or otherwise.</P>
<U><P ALIGN="JUSTIFY">After-Acquired Real Estate</U> - as such term is defined in <B>Section 7.3</B> hereof.</P>
<U><P ALIGN="JUSTIFY">Agent Advances</U> - as defined in <B>Section 2.1.6</B>.</P>
<U><P ALIGN="JUSTIFY">Agent Indemnitees</U> - Agent and all of it<B>'</B>s present and future officers, directors, employees, agents and attorneys.</P>
<U><P ALIGN="JUSTIFY">Agent Professionals</U> - attorneys, accountants, appraisers, business valuation experts, environmental engineers or consultants, turnaround consultants and other professionals or experts retained by Agent.</P>
<U><P ALIGN="JUSTIFY">Agreement</U> - this Loan and Security Agreement and all Exhibits and Schedules thereto.</P>
<U><P ALIGN="JUSTIFY">ALI</U> - A.L. Industrier AS.</P>
<U><P ALIGN="JUSTIFY">ANDA</U> - an Abbreviated New Drug Application that is filed with the FDA.</P>
<U><P ALIGN="JUSTIFY">Anti-Terrorism Laws</U> - any laws relating to terrorism or money laundering, including Executive Order No. 13224 and the USA Patriot Act.</P>
<U><P ALIGN="JUSTIFY">Applicable Advance Rate</U> -  85%, subject to adjustment from time to time by Agent in its reasonable credit judgment based upon the Dilution Adjustment.</P>
<U><P ALIGN="JUSTIFY">Applicable Law</U> - all laws, rules and regulations applicable to the Person, conduct, transaction, covenant or Loan Document in question, including all applicable common law and equitable principles; all provisions of all applicable state, federal and foreign constitutions, statutes, rules, regulations and orders of Governmental Authorities; and all applicable orders, judgments and decrees of all&nbsp;courts and arbitrators.</P>
<U><P ALIGN="JUSTIFY">Applicable Margin</U> - a percentage equal to 0.25% with respect to Revolver Loans that are Base Rate Loans, 1.75% with respect to Revolver Loans that are LIBOR Loans, 1.75% with respect to each Term Loan Advance made or outstanding as a Base Rate Loan, 3.25% with respect to each Term Loan Advance made or outstanding as a LIBOR Loan and 0.30% with respect to the Unused Line Fee, provided that the Applicable Margin shall be increased or decreased, on a quarterly basis (commencing with the first full Fiscal Quarter after the Closing Date), according to the performance of Borrowers as measured by the Average Availability for the immediately preceding Fiscal Quarter, as follows:</P></DIR>
</DIR>
</FONT>
<P ALIGN="CENTER"><CENTER><TABLE BORDER CELLSPACING=1 CELLPADDING=7 WIDTH=638>
<TR><TD WIDTH="10%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="24%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="27%" VALIGN="TOP" COLSPAN=2>
<B><U><FONT SIZE=3><P ALIGN="CENTER"><BR>
REVOLVER LOANS</B></U></FONT></TD>
<TD WIDTH="26%" VALIGN="TOP" COLSPAN=2>
<B><U><FONT SIZE=3><P ALIGN="CENTER"><BR>
TERM LOAN</B></U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<B><U><FONT SIZE=3><P ALIGN="CENTER"><BR>
<BR>
LEVEL</B></U></FONT></TD>
<TD WIDTH="24%" VALIGN="TOP">
<B><FONT SIZE=3><P ALIGN="CENTER"><BR>
AVERAGE<BR>
<U>AVAILABILITY</B></U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<B><FONT SIZE=3><P><BR>
LIBOR<BR>
<U>LOANS</B></U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<B><FONT SIZE=3><P>BASE<BR>
RATE<BR>
<U>LOANS</B></U></FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<B><FONT SIZE=3><P><BR>
LIBOR <BR>
<U>LOANS</B></U></FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<B><FONT SIZE=3><P>BASE<BR>
RATE<BR>
<U>LOANS</B></U></FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<B><FONT SIZE=3><P ALIGN="CENTER"><BR>
UNUSED</B><BR>
<B><U>LINE-FEE</B></U></FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">I</FONT></TD>
<TD WIDTH="24%" VALIGN="TOP">
<FONT SIZE=3><P>Less than $50,000,000</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2.00%</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">0.50%</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">3.50%</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2.00%</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">0.25%</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">II</FONT></TD>
<TD WIDTH="24%" VALIGN="TOP">
<FONT SIZE=3><P>Greater than or equal to $50,000,000 but less than $100,000,000</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1.75%</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">0.25%</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">3.25%</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1.75%</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">0.30%</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">III</FONT></TD>
<TD WIDTH="24%" VALIGN="TOP">
<FONT SIZE=3><P>Greater than or equal to $100,000,000 but less than $150,000,000</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1.50%</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">Zero</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">3.00%</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1.50%</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">0.35%</FONT></TD>
</TR>
<TR><TD WIDTH="10%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">IV</FONT></TD>
<TD WIDTH="24%" VALIGN="TOP">
<FONT SIZE=3><P>Greater than or equal to $150,000,000</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1.25%</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">Zero</FONT></TD>
<TD WIDTH="14%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2.75%</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1.25%</FONT></TD>
<TD WIDTH="13%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">0.35%</FONT></TD>
</TR>
</TABLE>
</CENTER></P>
<DIR>
<DIR>

<FONT SIZE=3><P ALIGN="JUSTIFY">Any such increase or reduction in the Applicable Margin shall be calculated as of the last day of the immediately preceding Fiscal Quarter based upon the Average Availability for such Fiscal Quarter and subject to receipt of a month-end Borrowing Base Certificate for the last Fiscal Month of the immediately preceding Fiscal Quarter.  Any such adjustment in the Applicable Margin shall be effective on the third Business Day after Agent<B>'</B>s receipt of such Borrowing Base Certificate.  Notwithstanding the foregoing, Agent and Lenders shall be entitled to accrue and receive (and Borrowers shall be obligated to pay) interest at the&nbsp;Default Rate to the extent authorized by <B>Section&nbsp;3.1.5.</P>
</B><U><P ALIGN="JUSTIFY">Appraised Fair Market Value of Eligible Real Estate</U> - on any date and with respect to any Eligible Real Estate, the fair market value of the applicable Eligible Real Estate as determined by reference to the most recent appraisal of the fair market value of such Real Estate received by Agent and acceptable to Agent and performed by an independent appraiser reasonably satisfactory to Agent.</P>
<U><P ALIGN="JUSTIFY">Appraised Net Orderly Liquidation Value of Eligible Equipment</U> - on any date with respect to any Eligible Equipment, the value of such Eligible Equipment expected to be realized at an orderly, negotiated sale of such Eligible Equipment that is held within a reasonable period of time, as such value is determined by reference to the most recent Net Orderly Liquidation Value Appraisal received by Agent and acceptable to Agent on or before such date.</P>
<U><P ALIGN="JUSTIFY">Approved Credit Enhancement</U> - in Agent<B>'</B>s discretion and at its option, either (i) an irrevocable letter of credit that is in form and substance reasonably acceptable to Agent, issued or confirmed by a bank reasonably acceptable to Agent, and payable in Dollars at a place of payment within the United States that is acceptable to Agent (except for sight drafts that are advised by a United States bank acceptable to Agent), where the proceeds of such letter of credit have been assigned to Agent for the benefit of Secured Parties (with such assignment acknowledged by the issuing or confirming bank) or, if so requested by Agent, duly transferred to Agent for the benefit of Lenders (together with sufficient documentation to permit direct draws under any such letter of credit by Agent for the benefit of Lenders) or (ii) credit insurance that is issued by a credit insurance company acceptable to Agent and is in form and substance reasonably acceptable to Agent (which credit insurance 
shall be payable to Agent for the benefit of Secured Parties in Dollars).</P>
<U><P ALIGN="JUSTIFY">Approved Escrow</U> - an escrow of cash with Agent (and over which Agent has control for purposes of the UCC) or with a trustee of the Senior Notes or Convertible Notes that is in an amount sufficient to repay in full the Senior Notes or Convertible Notes, as applicable, and that is subject to an irrevocable letter of instruction from Borrowers that is acceptable to Agent to repay in full the Senior Notes or Convertible Notes, as applicable.</P>
<U><P ALIGN="JUSTIFY">Asset Disposition</U> - a sale, lease, license or other transfer or disposition of Property of an Obligor, including a disposition of Property in connection with a sale-leaseback transaction.</P>
<U><P ALIGN="JUSTIFY">Assignment and Acceptance</U> - an assignment and acceptance entered into by a Lender and an Eligible Assignee and accepted by Agent, and, if applicable, Borrowers, in the form of <B><U>Exhibit&nbsp;H</B></U>.</P>
<U><P ALIGN="JUSTIFY">Audit Spring Back Date</U> - as defined in <B>Section 3.2.4</B> hereof.</P>
<U><P ALIGN="JUSTIFY">Availability</U>&nbsp;- on any date, the amount that Borrowers are entitled to borrow as Revolver Loans on such date, such amount being the difference derived when the sum of the principal amount of Revolver Loans then outstanding (including any outstanding Swingline Loans) is subtracted from the Borrowing Base on such date.  If the amount outstanding is equal to or greater than the Borrowing Base, Availability is zero.</P>
<U><P ALIGN="JUSTIFY">Availability Reserve</U> - on any date of determination thereof, an amount equal to the sum of the&nbsp;following (without duplication):  (i)&nbsp;the Inventory Reserve; (ii)&nbsp;the Rent Reserve; (iii)&nbsp;the LC&nbsp;Reserve; (iv)&nbsp;the aggregate amount of reserves established by Agent from time to time in its reasonable credit judgment in respect of Banking&nbsp;Relationship Debt; (v) the Environmental Reserve; (vi) the aggregate amount of all&nbsp;liabilities and obligations that are secured by Liens upon any of the Collateral that are senior in priority to Agent<B>'</B>s Liens if such Liens are not Permitted Liens (provided that the imposition of a reserve hereunder on account of such Liens shall not be deemed a waiver of the Event of Default that arises from the existence of such Liens) or are Permitted Liens for property taxes under <B>Section 10.2.5(ii)</B>; (vii) at Agent<B>'</B>s election 60 days prior to the maturity of the Convertible Notes, the Convertible Note Reserve
; (viii) at Agent<B>'</B>s election, a reserve in an amount equal to the amount payable to Plantex USA, Inc. from time to time under the Amended and Restated Supply Agreement dated April 26, 2004, between Plantex and Purepac Pharmaceutical Co.; and (ix)&nbsp;such additional reserves, in such amounts and with respect to such&nbsp;matters, as Agent in its reasonable credit judgment may elect to impose from time to time.  If Agent shall elect to establish any reserve under clause (ix) above or to change any of the foregoing reserves to increase the amount of such reserves, then unless an Event of Default exists, Agent agrees to give Borrower Representative notice of such reserve but Agent<B>'</B>s failure to give such notice shall not result in any liability to Agent hereunder but until such notice is given, such reserve shall not be effective.  If an Event of Default exists, Agent shall not be required to give such notice as provided in the forgoing sentence but may do so at its election.</P>
<U><P ALIGN="JUSTIFY">Average Availability</U> - for any period, an amount equal to the sum of the actual&nbsp;amount of Availability on each calendar day during such period, as determined in good faith by Agent, divided&nbsp;by the number of calendar days in such period.</P>
<U><P ALIGN="JUSTIFY">Average Revolver Loan Balance</U> - for any period, the amount obtained by adding the unpaid balance of Revolver Loans (excluding Swingline Loans) and LC Obligations at the end of each calendar day for the period in question and by dividing such sum by the number of calendar days in such period.</P>
<U><P ALIGN="JUSTIFY">Bank Products</U> - any one or more of the following types of products, services or facilities extended to any Obligor by any Lender or any Affiliate of a Lender: (i) commercial credit cards; (ii)&nbsp;merchant card services; (iii)&nbsp;products or services under Cash Management Agreements; (iv) products under Hedging Agreements; and (v) interstate depository network services.</P>
<U><P ALIGN="JUSTIFY">Banking Relationship Debt</U> - Debt or other obligations of an Obligor to any Lender or any Affiliate of a Lender arising out of or relating to Bank Products.</P>
<U><P ALIGN="JUSTIFY">Bankruptcy Code</U> - title 11 of the United States Code.</P>
<U><P ALIGN="JUSTIFY">Base Rate</U> - the rate of interest announced or quoted by BofA from time to time as its prime rate. The prime rate announced by BofA is a reference rate and does not necessarily represent the lowest or best rate charged by BofA.  BofA from time to time makes loans or other extensions of credit at, above or below its announced prime rate.  If the prime rate is discontinued by BofA as a standard, a comparable reference rate designated by BofA as a substitute therefor shall be the Base Rate.</P>
<U><P ALIGN="JUSTIFY">Base Rate Loan</U> - a Loan, or portion thereof, during any period in which it bears interest at a rate based upon the Base Rate.</P>
<U><P ALIGN="JUSTIFY">Blocked Person</U> - (a) a Person that is listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224; (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224; (c) a Person or entity with which any bank or other financial institution is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law; (d) a Person or entity that commits, threatens or conspires to commit or supports "terrorism" as defined in Executive Order No. 13224; (e) a Person or entity that is named as a "specially designated national" on the most current list published by the U.S. Treasury Department Office of Foreign Asset Control (OFAC) at its official website or any replacement website or other replacement  official publication of such list; (f) a Person or entity who is affiliated with a Person or entity listed above; or (g) 
an agency of the government of, an organization directly or indirectly controlled by, or a Person resident in, a country on any official list maintained by OFAC.</P>
<U><P ALIGN="JUSTIFY">Board of Governors</U> - the Board of Governors of the Federal Reserve System.</P></DIR>
</DIR>

<U><P ALIGN="JUSTIFY">BofA</U> - Bank of America, N.A., a national bank, and its successors and assigns.</P><DIR>
<DIR>

<U><P ALIGN="JUSTIFY">BofA Indemnitees</U> - BofA, Banc of America Securities LLC, and all of their respective present and future officers, directors, employees, agents and attorneys.</P>
<U><P ALIGN="JUSTIFY">Borrower Representative</U> - as defined in <B>Section&nbsp;4.4</B>.</P>
<U><P ALIGN="JUSTIFY">Borrowing</U> - a borrowing consisting of Loans of one Type made on the same day by Lenders (or by BofA in the case of a Borrowing funded by Swingline Loans) or a conversion of a Loan or Loans of one Type from Lenders on the same day.</P>
<U><P ALIGN="JUSTIFY">Borrowing Base</U> - on any date of determination thereof, an amount equal to the lesser of: (a)&nbsp;the aggregate amount of the Revolver Commitments on such date <U>minus</U> the LC Reserve on such&nbsp;date, or (b)&nbsp;an amount equal to (i)&nbsp;the sum of the Accounts Formula Amount <U>plus</U> the Inventory Formula Amount <U>plus</U> the Fixed Asset Sublimit on such date <U>minus</U> (ii)&nbsp;the Availability Reserve on such date; provided that at any time, the amounts set forth in clause (b) shall be determined by reference to the most recent Borrowing Base Certificate that has been delivered to Agent in accordance with, and subject to the terms of, <B>Section 8.6</B> hereof and, subject to the adjustment of the Borrowing Base from time to time by Agent in accordance with the terms of this Agreement.</P>
<U><P ALIGN="JUSTIFY">Borrowing Base Certificate</U> - a certificate, in a form similar to <B><U>Exhibit L</B></U>, as adjusted from time to time in accordance with this Agreement, by which Borrowers shall certify to Agent and Lenders, the amount of the&nbsp;Borrowing Base as of the date of the certificate (which date shall be not more than 25 days earlier than the date of submission of such certificate to Agent) and the calculation of such&nbsp;amount.</P>
<U><P ALIGN="JUSTIFY">Business Day</U> - any day excluding Saturday, Sunday and any other day that is a legal holiday under the laws of the State of New York, the State of North Carolina or the State of Georgia or is a day on which banking institutions located in such state are closed; <U>provided</U>, <U>however</U>, that when used with reference to a LIBOR Loan (including the making, continuing, prepaying or repaying of any LIBOR Loan), the term "Business&nbsp;Day" shall also exclude any day on which banks are not open for dealings in Dollar deposits on the London interbank market.</P>
<U><P ALIGN="JUSTIFY">Capital Adequacy Regulation</U> - any guideline, request or directive of any central bank or other Governmental Authority, or any other law, rule or regulation, whether or not having the force of law, in each case regarding capital adequacy of any bank or of any corporation controlling a bank.</P>
<U><P ALIGN="JUSTIFY">Capital Expenditures</U> - expenditures made or liabilities incurred by a Borrower for the acquisition of any fixed assets or improvements, replacements, substitutions or additions thereto which have a useful life of more than one year, including Capitalized Lease Obligations, that are set forth in a consolidated statement of cash flow of Consolidated Group Members for such period prepared in accordance with GAAP.</P>
<U><P ALIGN="JUSTIFY">Capitalized Lease Obligation</U> - any Debt represented by obligations under a lease that is required to be capitalized for financial reporting purposes in accordance with GAAP.</P>
<U><P ALIGN="JUSTIFY">Cash Collateral</U> - cash, and any interest or other income earned thereon, that is deposited with Agent in accordance with this Agreement for the Pro Rata benefit of Lenders to Cash Collateralize any LC Obligations or other Obligations.</P>
<U><P ALIGN="JUSTIFY">Cash Collateral Account</U> - a demand deposit, money market or other account established by Agent at BofA or such other such financial institution as Agent may select in its discretion, which account shall be in Agent<B>'</B>s name and subject to Agent<B>'</B>s Liens.</P>
<U><P ALIGN="JUSTIFY">Cash Collateralize</U> - with respect to LC Obligations arising from Letters of Credit outstanding on any date or Obligations arising under Hedging Agreements on such date, the deposit with Agent of immediately available funds into the Cash Collateral Account in an amount equal to 103% of the sum of the aggregate Undrawn Amounts of such Letters of Credit and other LC Obligations, all Obligations existing under such Hedging Agreements, and all related fees and other amounts due in connection with such LC Obligations and Hedging Agreements.</P>
<U><P ALIGN="JUSTIFY">Cash Equivalents</U> - (i)&nbsp;marketable direct obligations issued or unconditionally guaranteed by the United States government and backed by the full faith and credit of the United States government having maturities of not more than 12 months from the date of acquisition; (ii)&nbsp;domestic certificates of deposit and time deposits having maturities of not more than 12&nbsp;months from the date of acquisition, bankers<B>'</B> acceptances having maturities of not more than 12&nbsp;months from the date of acquisition and overnight bank deposits, in each case issued by any commercial bank organized under the laws of the United States, any state thereof or the District of Columbia, which at the time of acquisition are rated A-1 (or better) by S&amp;P or P-1 (or better) by Moody<B>'</B>s, and (unless issued by a Lender) not subject to offset rights in favor of such bank arising from any&nbsp;banking relationship with such bank; (iii)&nbsp;repurchase obligations with a term of not more t
han 30 days for underlying securities of the&nbsp;types described in clauses (i) and (ii) entered into with any&nbsp;financial institution meeting the&nbsp;qualifications specified in clause (ii) above or with any primary dealer; (iv)&nbsp;commercial paper having at the time of investment therein or a contractual commitment to&nbsp;invest therein a rating of A-1 or next highest (or better) by S&amp;P or P-1 or next highest (or better) by Moody<B>'</B>s, and having a&nbsp;maturity within 12 months after the date of acquisition thereof; and (v) shares of any money market fund that (a) has substantially all of its assets invested continuously in the types of investments referred to in clauses (i) - (iv), (b) has net assets not less than $500,000,000 and (c) has the highest or next highest rating obtainable from either Moody<B>'</B>s or S&amp;P.</P>
<U><P ALIGN="JUSTIFY">Cash Management Agreements</U> - any agreement entered into from time to time between any Borrower or any of its Subsidiaries, on the one hand, and any Lender or any of its Affiliates, on the other, in connection with cash management services for operating, collections, payroll and trust accounts of such Borrower or its Subsidiaries provided by such banking or financial institution, including automatic clearinghouse services, controlled disbursement services, electronic funds transfer services, information reporting services, lockbox services, stop payment services and wire transfer services.</P>
<U><P ALIGN="JUSTIFY">CERCLA</U> - the Comprehensive Environmental Response Compensation and Liability Act (42 U.S.C. Section9601 <U>et</U> <U>seq</U>.).</P>
<U><P ALIGN="JUSTIFY">Change of Control</U> - the occurrence of any of the following: (i) at any time after ALI and the EWS Parties cease to beneficially own (within the meaning of Rule 13d-3 promulgated under the Exchange Act) shares of common stock of Parent with a combined voting power sufficient to elect a majority of the board of directors of Parent, any Person (other than Parent or any of its Subsidiaries, ALI or the EWS Parties or any employee benefit plan of Parent or any of its Subsidiaries which acquires beneficial ownership of voting interests of Parent) shall acquire, or acquire the power to vote or direct the voting of, 30% or more, on a fully diluted basis, of the outstanding Equity Interests of Parent; (ii)&nbsp;a Consolidated Group Member is merged with or into another Person, other than a Consolidated Group Member except as permitted under <B>Section 10.2.1</B>; (iii) any Person or related group of Persons acquires by way of a purchase, merger, consolidation or other business combination a m
ajority of the Equity Interests entitled to vote in the election of directors of Parent (other than ALI or an EWS Party); or (iv) a change in the majority of the board of directors of Parent unless approved by the then majority of the board of directors of Parent, <B>provided, however</B>, that for the purpose of clauses (i) and (iii) above, the terms "Person" shall not be deemed to include (x) ALI, (y) the stockholders of ALI in the case of a distribution of shares of capital stock of  Parent beneficially owned by ALI to the stockholders of ALI, unless a Change of Control of ALI has occurred or occurs concurrently with such a distribution, or in a series of related transactions of which such distribution is a part (determined without regard to the exclusion for stockholders of ALI provided for in this clause (y) of this proviso), provided that the exclusion for stockholders of ALI provided for in this clause (y) shall not apply to any subsequent acquisition of shares of common stock of  Parent by any such p
erson (other than any of the persons described in clause (z) below) or (z) E.W. Sissener, his spouse, any heir or descendant of Mr. Sissener or the spouse of any such heir or descendant or the estate of Mr. Sissener (each, an "EWS Party") <A NAME="rider"></A>or any trust or other similar arrangement for the benefit of any EWS Party or any corporation or other person or entity controlled by one or more EWS Parties, or any group controlled by one or more EWS Parties.  For purposes of the above sentence, (i) a "liquidation" or "dissolution" shall not be deemed to include any transfer of the Equity Interests in Parent solely to any of the Persons described in clauses (x), (y) and (z) of the proviso in such sentence and (ii) a "Change of Control of ALI" shall be determined in accordance with this definition of "Change of Control" (without regard to clauses (x) and (y) in the proviso of the preceding sentence), with each reference to Parent in such definition being deemed to refer to ALI.</P>
<U><P ALIGN="JUSTIFY">Chattel Paper</U> - shall have the meaning given to the term "chattel paper" in the UCC.</P>
<U><P ALIGN="JUSTIFY">Claims</U> - all liabilities, losses, damages, actions, judgments, suits and related charges, expenses and disbursements of any kind or nature (including reasonable attorneys<B>'</B> fees and expenses for one counsel (and local counsels if determined by Agent) for Agent, and one counsel for all other Indemnitees) which may at any time (including at any time following Full Payment of the Obligations, termination of the Commitments, resignation or replacement of Agent or replacement of any Lender) be imposed on, incurred by, or asserted against any Indemnitee in any way relating to or arising out of (i) the enforcement under any of the Loan Documents or consummation of any of the transactions described herein, (ii) any action taken or omitted to be taken by any Indemnitee under or in connection with any of the Loan Documents or Applicable Law, (iii) the existence, perfection or realization upon Agent<B>'</B>s Liens upon any Collateral, (iv) the exercise by Agent or any Lender of any of it
s rights or remedies under any of the Loan Documents or Applicable Law, or (v) the failure of any Obligor to observe, perform or discharge any of such Obligor<B>'</B>s covenants or duties under any of the Loan Documents or the inaccuracy or incompleteness of any representation or warranty of any Borrower in any of the Loan Documents, in each case including any costs or expenses incurred by any Indemnitee in connection with any investigation, litigation, arbitration or other judicial or non-judicial proceeding (including any Insolvency Proceeding or appellate proceedings) whether or not such Indemnitee is a party thereto; <U>provided</U>, <U>however</U> that notwithstanding anything to the contrary contained in this Agreement, no party shall have any obligation under this Agreement to indemnify an Indemnitee with respect to any Claim to the extent that it is determined in a final, non-appealable judgment by a court of competent jurisdiction that such Claim resulted from the gross negligence or willful miscond
uct of such Indemnitee (or its officers, directors, employees, agents or attorneys).</P>
<U><P ALIGN="JUSTIFY">Closing Date</U> - the date on which all of the conditions precedent in <B>Section&nbsp;11</B>  are satisfied or waived and the initial Loans are made under this Agreement.</P>
<U><P ALIGN="JUSTIFY">Collateral</U> - all of the Property and interests in Property described in <B>Section&nbsp;7</B>; all Property described in any of the Security Documents as security for the payment or performance of any of the Obligations; and all other Property and interests in Property that now or hereafter secure (or are intended to secure) the payment and performance of any of the Obligations.</P>
<U><P ALIGN="JUSTIFY">Commercial Tort Claim</U> - shall have the meaning given to the term "commercial tort claim" in the UCC.</P>
<U><P ALIGN="JUSTIFY">Commitment</U> - at any date for any Lender, the amount of such Lender<B>'</B>s Revolver Commitment and Term Loan Commitment on such date, and "<U>Commitments</U>" means the&nbsp;aggregate amount of all&nbsp;Revolver Commitments and Term Loan Commitments on such date.</P>
<U><P ALIGN="JUSTIFY">Commitment Termination Date</U> - the date that is the soonest to occur of (i)&nbsp;the last day of the Term; (ii)&nbsp;the date on which either Borrowers or Agent terminate the Revolver Commitments pursuant to <B>Section 6.2</B>; or (iii)&nbsp;the date on which the Revolver Commitments are automatically terminated pursuant to <B>Section&nbsp;12.2</B>.</P>
<U><P ALIGN="JUSTIFY">Compliance Certificate</U> - a Compliance Certificate to be provided by Borrowers to Agent in accordance with, and in the form annexed as <B><U>Exhibit&nbsp;F</B></U> to, this Agreement and the supporting schedules to be annexed thereto.</P>
<U><P ALIGN="JUSTIFY">Consolidated</U> - the consolidation in accordance with GAAP of the accounts or other items as to which such term applies.</P>
<U><P ALIGN="JUSTIFY">Consolidated Group</U> - Parent and each of its Domestic Subsidiaries.</P>
<U><P ALIGN="JUSTIFY">Consolidated Group Member</U> - a Person that is in the Consolidated Group.</P>
<U><P ALIGN="JUSTIFY">Consolidated Net Income</U> - for any period, the net income of the Consolidated Group for such period, determined on a Consolidated basis and in accordance with GAAP but excluding for each such period (without duplication):</P>
<P ALIGN="JUSTIFY">(a)&#9;any gain or loss arising from the sale of capital assets;</P>
<P ALIGN="JUSTIFY">(b)&#9;any gain arising from any write-up of assets during such period and any loss arising from any write down of assets during such period;</P>
<P ALIGN="JUSTIFY">(c)&#9;net income of any Consolidated Group Member accrued prior to the date it became a Consolidated Group Member;</P>
<P ALIGN="JUSTIFY">(d)&#9;net income of any other Person, substantially all the assets of which have been acquired in any manner by a Consolidated Group Member, realized by such Person and accrued prior to the date of such acquisition;</P>
<P ALIGN="JUSTIFY">(e)&#9;net income of any entity (other than a Consolidated Group Member) in which a Consolidated Group Member has an ownership interest (unless such net income has actually been received by a Consolidated Group Member in the form of cash Distributions but excluding such cash Distributions that have been used to repay, defease or redeem the Senior Notes or the Convertible Notes);</P>
<P ALIGN="JUSTIFY">(f)&#9;the net income of any Consolidated Group Member to the extent that such Consolidated Group Member is prohibited from making any payment of Distributions to any Consolidated Group Member;</P>
<P ALIGN="JUSTIFY">(g)&#9;the net income of any Person (other than a Consolidated Group Member) into which a Consolidated Group Member shall have merged or consolidated with, accrued prior to the date of such transaction; and</P>
<P ALIGN="JUSTIFY">(h)&#9;the net income of any Person in which a Person other than such Person or any of its Subsidiaries owns or otherwise holds an Equity Interest, except to the extent such income (or loss) shall have been received in the form of distributions actually paid to such Person or any of its Subsidiaries by such other Person during such period.</P>
<U><P ALIGN="JUSTIFY">Contingent Obligation</U> - with respect to any Person, any obligation of such Person arising from any guaranty or other assurance of payment or performance of any Debt, lease, dividend or other obligation ("primary&nbsp;obligations") of any other Person (the "primary obligor") in any manner, whether directly or indirectly, including (i)&nbsp;the direct or indirect guaranty, endorsement (other than for collection or&nbsp;deposit in the Ordinary Course of Business), co-making, discounting with recourse or sale with recourse by such Person of the obligation of a primary obligor, (ii)&nbsp;the obligation to make take-or-pay or similar payments, if required, regardless of nonperformance by any other party or parties to an agreement (excluding standard minimum purchase requirements under supply agreements with Borrowers<B>'</B> vendors in the Ordinary Course of Business), (iii)&nbsp;any obligation of such Person, whether or not contingent, (A)&nbsp;to purchase any such primary obligation or 
any Property constituting direct or indirect security therefor, (B)&nbsp;to advance or supply funds (1)&nbsp;for the purchase or payment of any such primary obligations or (2)&nbsp;to maintain working capital or equity capital of the primary obligor or otherwise to maintain the net worth or solvency of the primary obligor, (C)&nbsp;to purchase Property or services primarily for the purpose of assuring the owner of any such primary obligation of the ability of the primary obligor to make payment of such primary obligation or (D)&nbsp;otherwise to assure or hold harmless the holder of such primary obligation against loss in respect thereof; <U>provided</U>, <U>however</U> that the term "Contingent Obligations" shall not include contingent obligations incurred in the Ordinary Course of Business or any indemnities given under or liabilities retained in connection with any Permitted Asset Disposition, Permitted Acquisition or Permitted Investment.  The amount of any Contingent Obligation shall be deemed to be an 
amount equal to the stated or determinable amount of the primary obligation with respect to which such Contingent Obligation is made (or, if less, the maximum amount of such primary obligation for which such Person may be liable pursuant to the terms of the instrument evidencing such Contingent Obligation) or, if not stated or determinable, the maximum reasonably anticipated liability with respect thereto, as determined by such Person in good faith.</P>
<U><P ALIGN="JUSTIFY">Controlled Disbursement Account</U> - a demand deposit account maintained by Borrowers at BofA and to which proceeds of Loans may be wired from time to time.</P>
<U><P ALIGN="JUSTIFY">Convertible Indenture</U> - that certain Indenture dated as of June 2, 1999, between Parent and First Union National Bank (now known as Wachovia Bank, National Association), as Trustee, pursuant to which Parent issued the Convertible Notes, as amended or modified in accordance herewith.</P>
<U><P ALIGN="JUSTIFY">Convertible Note Documents</U> - the Convertible Notes, the Convertible Indenture and any and all other documents, agreements or instruments executed in connection therewith or pursuant thereto.</P>
<U><P ALIGN="JUSTIFY">Convertible Note Reserve</U> - a reserve in an amount equal to the outstanding principal amount of the Convertible Notes plus all accrued interest thereon and fees payable under the terms of the Convertible Notes.</P>
<U><P ALIGN="JUSTIFY">Convertible Notes</U> - the $170,000,000 3% Convertible Senior Subordinated Notes due June 1, 2006 issued by Parent.</P>
<U><P ALIGN="JUSTIFY">Covenant Spring-Back Date</U> - as such term is defined in <B>Section 10.3.1</B>.</P>
<U><P ALIGN="JUSTIFY">CWA</U> - the Clean Water Act (33 U.S.C. SectionSection 1251 <U>et</U> <U>seq</U>.).</P>
<U><P ALIGN="JUSTIFY">Debt</U> - as applied to a Person means, without duplication:  (i)&nbsp;all items which in accordance with GAAP would be included in determining total liabilities as shown on the liability side of a balance sheet of such Person as of the date as of which Debt is to be determined, including Capitalized Lease Obligations; (ii)&nbsp;all Contingent Obligations of such Person; (iii)&nbsp;all reimbursement obligations in connection with letters of credit or letter of credit guaranties issued for the account of such Person; and (iv)&nbsp;in the case of a Borrower (without duplication), the Obligations; provided that the amount of any contingent liability under any indemnity obligation existing under any document or agreement evidencing such Debt shall, to the extent such contingent liability is unrelated to the underlying financial obligations of such Person in respect of such Debt, be excluded from the definition of "Debt" until such time as when such contingent liability matures or is or sho
uld be reported as "debt" for the purposes of GAAP.  The Debt of a&nbsp;Person shall include any recourse Debt of any partnership or joint venture in which such Person is a general partner or joint venturer to the extent such Person is liable therefor.</P>
<U><P ALIGN="JUSTIFY">Default</U> - an event or condition the occurrence of which would, with the lapse of time or the giving of notice, or both, become an Event of Default.</P>
<U><P ALIGN="JUSTIFY">Default Rate</U> - on any date, a rate per annum that is equal to (i)&nbsp;in the case of each Revolver Loan outstanding on such date and the principal balance of the Term Loan outstanding on such date, 2% in excess of the rate otherwise applicable to such Loans on such date, and (ii)&nbsp;in the case of any of the other Obligations outstanding on such date, 2.50% in excess of the Base Rate in effect on such date.</P>
<U><P ALIGN="JUSTIFY">Deposit Account</U> - shall have the meaning given to the term "deposit account" in the UCC.</P>
<U><P ALIGN="JUSTIFY">Deposit Account Control Agreements</U> - the Deposit Account Control Agreements to be executed by each depository institution of a Borrower in favor of Agent as security for the Obligations, in accordance with <B>Section 8.5</B>.</P>
<U><P ALIGN="JUSTIFY">Dilution Adjustment</U>- a reduction in the advance rate against Eligible Generic Accounts from time to time based upon dilution of Borrowers<B>'</B> Generic Accounts during a calendar month prior to the date of determination, as established by Borrowers<B>'</B> records or by a field examination conducted by Agent<B>'</B>s employees or representatives,  as the same may be adjusted by Agent in the exercise of its reasonable credit judgment.</P>
<U><P ALIGN="JUSTIFY">Distribution</U> - in respect of any entity, (i)&nbsp;any payment of any dividends or other distributions on Equity Interests of the entity (except distributions in such Equity Interests) and (ii)&nbsp;any purchase, redemption or other acquisition or retirement for value of any Equity Interests of the entity unless made contemporaneously from the net proceeds of the sale of Equity Interests.</P>
<U><P ALIGN="JUSTIFY">Document</U> - shall have the meaning given to the term "document" in the UCC.</P>
<U><P ALIGN="JUSTIFY">Dollars and the sign $</U> - lawful money of the United States of America.</P>
<U><P ALIGN="JUSTIFY">Domestic Subsidiary</U> - a Subsidiary of a Borrower (other than a Subsidiary that is a Borrower) that is incorporated under the laws of a state of the United States or the District of Columbia.</P>
<U><P ALIGN="JUSTIFY">Dominion Account</U> - a special account of Agent established by Borrowers at BofA and over which Agent shall have exclusive access and control for withdrawal purposes.</P>
<U><P ALIGN="JUSTIFY">Dominion Spring-Back Date</U> - as such term is defined in <B>Section 8.2.5(ii)</B>.</P>
<U><P ALIGN="JUSTIFY">EBITDA</U> - on any date of determination thereof, with respect to the Consolidated Group (A) Consolidated Net Income plus to the extent included (i) non-cash expenses including non-cash restructuring charges and impairment charges; (ii) any non-cash gain arising from extraordinary or non-recurring items; (iii) impairment or amortization of goodwill and other intangibles; (iv) costs and expenses incurred in connection with the entering into by the Obligors of the Loan Documents, any defeasance, redemption, refinancing or escrow of the Senior Notes and the Convertible Notes occurring after the Closing Date, acquisitions or dispositions permitted hereunder (including any Permitted Portfolio Transaction); (v) all non-cash expenses taken in connection with employee stock options and other employee equity awards following adoption of Financial Accounting Standard 123R; (vi) provision for taxes based upon income; (vii) interest expense; and (viii) depreciation and amortization expenses, all a
s determined in accordance with GAAP on a Consolidated basis.</P>
<U><P ALIGN="JUSTIFY">Electronic Chattel Paper</U> - shall have the meaning given to the term "electronic chattel paper" in the UCC.</P>
<U><P ALIGN="JUSTIFY">Eligible Account</U> - an Account that arises in the Ordinary Course of Business of a Borrower from the sale of goods, is payable in Dollars, is subject to Agent<B>'</B>s duly perfected Lien, and is deemed by Agent, in its reasonable credit judgment, to be an Eligible&nbsp;Account.  Without limiting the generality of the foregoing, no Account shall be an Eligible&nbsp;Account if (i)&nbsp;it arises out of a sale made by a Borrower to an Affiliate of a Borrower, a Person controlled by an Affiliate of a Borrower or a Blocked Person; (ii)&nbsp;it is unpaid for more than 60 days after the original due date shown on the invoice; (iii)&nbsp;it is due or unpaid more than 150<B><I>&nbsp;</B></I>days after the original invoice date; (iv)&nbsp;50% or more of the&nbsp;Accounts from the Account Debtor are not deemed Eligible Accounts hereunder; (v)&nbsp;the total unpaid Accounts of the Account Debtor exceed 15%<B><I>&nbsp;</B></I>of the aggregate amount of all Eligible Accounts (or exceed 40% of the
 aggregate amount of all Accounts if the Account Debtor is AmeriSource, Wal-Green, Cardinal Health or McKesson) or exceed a higher credit limit established by Agent for such Account Debtor, in each case, to the extent of such excess; (vi)&nbsp;any covenant, representation or warranty contained in this Agreement with respect to such Account has been breached in any material respect; (vii)&nbsp;the Account Debtor is also such Borrower<B>'</B>s creditor or supplier, or has disputed liability with respect to such Account or has made any claim with respect to any other Account due from such Account Debtor to such Borrower, or the Account otherwise is or may become subject to any right of setoff, counterclaim, recoupment, reserve, defense or chargeback, provided that, the Accounts of such Account Debtor shall be ineligible only to the extent of such&nbsp;dispute or right of offset, counterclaim, recoupment, reserve, defense or chargeback; (viii)&nbsp;an Insolvency Proceeding has been commenced by or against the Ac
count Debtor or the Account Debtor has failed, suspended or ceased doing business or the Account Debtor is unable in general to pay its debts as they become due; (ix) it arises from a sale to an Account Debtor that is organized under the laws of any jurisdiction outside of the United States except to the extent that the sale is supported or secured by an Approved Credit Enhancement; (x) it arises from a sale to the Account Debtor on a bill-and-hold, guaranteed sale, sale-or-return, sale-on-approval, or consignment basis (unless each of the Permitted Consignment Sale Conditions have been satisfied) or any other repurchase or return basis; (xi)&nbsp;the Account Debtor is the United States of America or any department, agency or instrumentality thereof, unless the applicable Borrower is not prohibited from assigning the Account and does assign its right to payment of such Account to Agent, in a manner satisfactory to Agent, so as to comply with the Assignment of Claims Act of 1940 (31&nbsp;U.S.C. Section3727 an
d 41 U.S.C. Section15), or is a state, county or municipality, or a political subdivision or agency thereof and Applicable Law disallows or restricts an assignment of Accounts on which it is the Account Debtor; (xii)&nbsp;the Account Debtor is located in New Jersey, Minnesota, Indiana or any other jurisdiction which imposes conditions on the right of, or restricts the ability of, a creditor to collect accounts receivable unless the applicable Borrower has either qualified to transact business in such jurisdiction as a foreign entity or filed a Notice of Business Activities Report or other required report with the appropriate officials in those jurisdictions for the then current year; (xiii)&nbsp;the Account is subject to a Lien other than a Permitted Lien; (xiv)&nbsp;the goods giving rise to such Account have not been delivered to and accepted by the Account Debtor or the Account otherwise does not represent a final sale; (xv)&nbsp;the Account is evidenced by Chattel Paper or an Instrument of any kind, or ha
s been reduced to judgment; (xvi)&nbsp;the Account represents a progress billing or a retainage or arises from a sale on a cash-on-delivery basis; (xvii)&nbsp;such Borrower has made any agreement with the Account Debtor for any&nbsp;deduction therefrom, except for discounts or allowances which are made in the Ordinary&nbsp;Course of Business and which discounts or allowances are reserved for by Borrowers in accordance with GAAP; (xviii)&nbsp;such Borrower has made an agreement with the Account Debtor to extend the time of payment thereof; (xix)&nbsp;the Account represents, in whole or in part, a billing for interest, fees or late charges, provided that such Account shall be ineligible only to the extent of the amount of such billing; (xx)&nbsp;the Account Debtor has made a partial payment with respect to such Account; (xxi)&nbsp;it arises from the sale of Inventory that is not Eligible Inventory pursuant to clause (ii) of the definition of "Eligible Inventory"; or (xxii)&nbsp;it arises from a retail sale of 
Inventory to a Person who is purchasing the same primarily for personal, family or household purposes; <U>provided</U>, <U>that</U>, notwithstanding anything to the contrary set forth in this definition, Accounts arising from the generics business of Borrowers shall be included in Eligible Accounts subject to a reserve (which in no event shall be greater than the amount of the Account for which a reserve has been established under GAAP) in accordance with GAAP, consistent with the past practices of Borrowers and so long as Agent otherwise deems such Account to be an Eligible Account in its reasonable credit judgment.</P>
<U><P ALIGN="JUSTIFY">Eligible Assignee</U> - a Person that is a Lender, a U.S. based Affiliate of a Lender or an Approved Fund (as defined below); a commercial bank, finance company, or other financial institution, in each case that is organized under the laws of the United States or any state, has total assets in excess of $5 billion, extends asset-based lending facilities of the type contemplated herein in the Ordinary Course of Business and whose becoming an assignee would not constitute a prohibited transaction under Section 4975 of ERISA or any other Applicable Law, is acceptable to Agent and, unless an Event of Default exists, Borrowers (such approval by Borrowers, when required, not&nbsp;to be unreasonably withheld or delayed) and, at any time that an Event of Default exists, any other Person (other than a competitor of Borrowers) acceptable to Agent in its discretion.  The term "Approved Fund" means with respect to any Lender, any Person (other than a natural person) that is engaged in making, purch
asing, holding or investing in bank loans and similar extensions of credit in the Ordinary Course of Business of such Person and that is administered or managed by (i) such Lender, (ii) an Affiliate of such Lender or (iii) an entity or an Affiliate of an entity that administers or manages a Lender.</P>
<U><P ALIGN="JUSTIFY">Eligible Equipment</U> - new Equipment located in the United States which (i) is owned by a Borrower and has been delivered to and accepted by a Borrower and installed at premises owned or leased by a Borrower; (ii) is subject to Agent<B>'</B>s duly perfected security interest and no other Lien that is not a Permitted Lien; (iii) does not and will not, after delivery to and installation at a Borrower<B>'</B>s premises (other than premises owned by any Consolidated Group Member), constitute a fixture under Applicable Law unless each landlord and mortgagee in respect of such premises have executed in favor of  Agent a Lien Waiver; and (iv) does not and will not, after delivery to and installation at a Borrower<B>'</B>s premises, constitute an accession to other Equipment that is subject to any Lien (whether or not a Permitted Lien) in favor of any Person other than Agent unless the holder of any such Lien agrees to disclaim any interest in the Eligible Equipment.</P>
<U><P ALIGN="JUSTIFY">Eligible Generic Account </U>- a Generic Account that otherwise constitutes an Eligible Account.</P>
<U><P ALIGN="JUSTIFY">Eligible Inventory</U> - Inventory which is owned by a Borrower (other than packaging or shipping materials, labels, samples, display items, bags and manufacturing supplies) and which Agent, in its reasonable credit judgment, deems to be Eligible Inventory.  Without limiting the generality of the foregoing, no Inventory shall be Eligible Inventory unless: (i)&nbsp;it is raw materials or finished goods; (ii)&nbsp;it is owned by a Borrower and it is not held by such Borrower on consignment from or subject to any guaranteed sale, sale-or-return, sale-on-approval or repurchase agreement with any supplier; (iii)&nbsp;it is not damaged, not defective, not obsolete, not otherwise unfit for sale and is in good and saleable condition and is not goods returned to such Borrower by or repossessed from an Account Debtor; (v)&nbsp;it is and continues to be FDA-approved and meets all other material standards imposed by any&nbsp;Governmental Authority; (vi)&nbsp;it conforms in all material respects to 
the warranties and representations set forth in this Agreement and is fully insured in the manner required by this Agreement; (vii)&nbsp;it is at all times subject to Agent<B>'</B>s duly perfected, first&nbsp;priority security interest and no other Lien except a Permitted Lien; (viii)&nbsp;it is in such Borrower<B>'</B>s possession and control at a&nbsp;location in&nbsp;compliance with this Agreement, is not in transit or outside the United States (except for Permitted Canadian Inventory) and is&nbsp;not consigned to any Person unless each of the Permitted Consignment Sale Conditions have been satisfied; (ix) it is not the subject of a negotiable warehouse receipt or other&nbsp;negotiable Document; (x)&nbsp;it has not been sold or leased and such Borrower has not received any deposit or downpayment in respect thereof in anticipation of a sale; (xi)&nbsp;no more than 50% of such Inventory consists of a single product; (xii) the age for a human health generic or an animal health generic is no more than 360 day
s and 180 days, respectively, prior to its expiration date; and (xiii) it appears in the details of a current perpetual inventory report.</P>
</FONT><U><FONT FACE="TimesNewRoman,Bold" SIZE=3><P ALIGN="JUSTIFY">Eligible Real Estate </U>- the Real Estate listed on <B><U>Exhibit K</U> </B>and other </FONT><FONT FACE="TimesNewRoman,Bold" SIZE=3>Real Estate in the United States that is owned by a Borrower in fee simple title or which is subject to a ground lease reasonably acceptable to Agent, which satisfies each of the following conditions as determined by Agent:</P>
<P ALIGN="JUSTIFY">(i)&#9;Agent has a perfected first-priority Lien in such Real Estate for the benefit of the Secured Parties (subject only to Permitted Liens) and </FONT><FONT SIZE=3>the applicable Borrower has executed and delivered to Agent such Mortgages and other documents as Agent may request;</P>
</FONT><FONT FACE="TimesNewRoman,Bold" SIZE=3><P ALIGN="JUSTIFY">(ii)&#9;such Real Estate has been appraised by a third party appraiser reasonably acceptable to Agent and the results of such appraisal are satisfactory in all respects to Agent;</P>
<P ALIGN="JUSTIFY">(iii)&#9;Agent has received an environmental site assessment of such Real Estate acceptable to Agent in all respects;</P>
</FONT><FONT SIZE=3><P ALIGN="JUSTIFY">(iv)&#9;such Real Estate is improved by fully constructed buildings occupied by Borrowers and utilized as Borrowers<B>'</B> corporate offices or for their manufacturing, development and distribution of pharmaceutical products; and</P>
<P ALIGN="JUSTIFY">(v)&#9;the applicable Borrower has delivered to Agent title insurance, surveys, flood insurance certifications and other real estate items, as required by, and satisfactory to, Agent, including, but not limited to, those items required by FIRREA.</P>
<U><P ALIGN="JUSTIFY">Enforcement Action</U> - action taken or to be taken by Agent, during any period that an Event of Default exists, to enforce collection of the Obligations or to realize upon the Collateral (whether by judicial action, under power of sale, by self-help repossession, by notification to Account Debtors, or by exercise of rights of setoff or recoupment).</P>
<U><P ALIGN="JUSTIFY">Environmental Agreement</U> - the Agreement Regarding Environmental Matters to be executed by Borrowers in favor of Agent on or about the Closing Date, which Agreement sets forth the understanding and agreements of Indemnitees, Agent and Lenders with respect to environmental matters and by which each Borrower shall, among other things, indemnify Agent and Lenders from liability for such Borrower<B>'</B>s failure to comply with any Environmental Laws.</P>
<U><P ALIGN="JUSTIFY">Environmental Laws</U> - all federal, state, local and foreign laws, rules, regulations, codes, ordinances, orders and consent decrees (together with all programs, permits and guidance documents promulgated by regulatory agencies, to the extent having the force of law), now or hereafter in effect,  that relate to public health (but excluding occupational safety and health, to the extent regulated by OSHA) or the protection or pollution of the environment, whether new or hereafter in effect, including CERCLA, RCRA and CWA.</P>
<U><P ALIGN="JUSTIFY">Environmental Reserve</U> - a reserve to be included in the Availability Reserve in an amount equal to the costs and expenses of remediation with respect to any of the Real Estate, as determined by Agent in its reasonable credit judgment.  Agent may release all or any portion of such Environmental Reserve upon receipt by Agent of written evidence, satisfactory to Agent in all respects, that such remediation has been completed and that the Real Estate is in compliance with all Environmental Laws.</P>
<U><P ALIGN="JUSTIFY">Equipment</U> - shall have the meaning given to the term "equipment" in the UCC and shall include all of each Borrower<B>'</B>s machinery, apparatus, equipment, fittings, furniture, fixtures and other tangible personal Property (other than Inventory) of every kind and description, whether now owned or hereafter acquired by such Borrower and wherever located, and all parts, accessories and special tools therefor, all accessions thereto, and all substitutions and replacements thereof, excluding motor vehicles.</P>
<P ALIGN="JUSTIFY"></P>
<U><P ALIGN="JUSTIFY">Equity Interest</U> - the interest of (i)&nbsp;a shareholder in a corporation, (ii)&nbsp;a partner (whether general or limited) in a partnership (whether general, limited or limited liability), (iii)&nbsp;a member in a limited liability company, or (iv)&nbsp;any other Person having any other form of equity security or ownership interest.</P>
<U><P ALIGN="JUSTIFY">ERISA</U> - the Employee Retirement Income Security Act of 1974.</P>
<U><P ALIGN="JUSTIFY">Euro Debt</U>- any Debt incurred or issued by any Foreign Subsidiary of Parent, which indebtedness could include, without limitation, a European high yield offering, an asset based credit facility and/or a bridge facility.</P>
<U><P ALIGN="JUSTIFY">Event of Default</U> - as defined in<B> Section&nbsp;12</B>.</P>
<U><P ALIGN="JUSTIFY">EWS Party</U> - has the meaning ascribed to such term in the definition of "Change of Control."</P>
<U><P ALIGN="JUSTIFY">Excess Borrowing Base Amount</U> - the amount by which the Borrowing Base on any date of determination exceeds the Pro Forma Borrowing Base.</P>
<U><P ALIGN="JUSTIFY">Excess FAS Amount</U> - on any date of determination, the difference between (i) the Fixed Asset Sublimit on the Closing Date, as reduced after the Closing Date by the quarterly amortization amounts referenced in the definition of Fixed Asset Sublimit and (ii) on any date of determination after the Closing Date in connection with a prepayment under <B>Section 5.3.3</B>, an amount equal to the sum of (I) 85% of the Appraised Net Orderly Liquidation Value of Eligible Equipment and (II) 65% of the Appraised Fair Market Value of Eligible Real Estate.</P>
<U><P ALIGN="JUSTIFY">Exchange Act</U> - the Securities Exchange Act of 1934, as amended from time to time, and the regulations promulgated and the rulings issued thereunder.</P>
<U><P ALIGN="JUSTIFY">Excluded Subsidiary</U> - a Domestic Subsidiary of Parent that is formed by Parent solely for purposes of administrative filings with the FDA and that does not have any assets on an on-going basis other than (i) ANDAs that are subsequently transferred to a Borrower and (ii) sufficient capitalization to carry out the purposes for which it was formed.</P>
<U><P ALIGN="JUSTIFY">Executive Order No. 13224</U> - Executive Order No. 13224 on Terrorist Financing, effective September 24, 2001.</P>
<U><P ALIGN="JUSTIFY">Extraordinary Expenses</U> - all costs, expenses, fees (including fees incurred to Agent Professionals) or advances that Agent (or any Lender) may&nbsp;suffer or incur in connection with the Obligations or the Loan Documents during any period that an Event of Default exists, or during the pendency of an&nbsp;Insolvency Proceeding of an Obligor, on account of or in connection with (i)&nbsp;the audit, inspection, repossession, storage, repair, appraisal, insuring, completion of the manufacture of, preparing for sale, advertising for sale, selling, collecting or otherwise preserving or realizing upon any Collateral; (ii)&nbsp;any action, suit, litigation, arbitration, contest or other judicial or non-judicial proceeding (whether instituted by or against Agent, any Lender, any Obligor, any representative of creditors of any Obligor or any other Person) in any way arising out of or relating to any of the Collateral (or the validity, perfection, priority or avoidability of Agent<B>'</B>s Lien
s with respect to any of the Collateral), any of the Loan Documents or the validity, allowance or amount of any of the Obligations, including any lender liability or other Claims asserted against Agent or any Lender; (iii) the exercise, protection or enforcement of any rights or remedies of Agent in, or the monitoring of, any Insolvency Proceeding; (iv)&nbsp;the settlement or satisfaction of any&nbsp;Liens upon any Collateral (whether or not such Liens are Permitted Liens); (v)&nbsp;the collection or enforcement of any of the Obligations, whether by Enforcement Action or otherwise; (vi)&nbsp;the negotiation, documentation, and closing of any&nbsp;amendment, waiver, restructuring or forbearance agreement with respect to the Loan&nbsp;Documents or Obligations; (vi)&nbsp;amounts advanced by Agent pursuant to<B> Sections 8.1.3 or 15.10</B>; or (viii)&nbsp;the enforcement of any of the provisions of any of the Loan Documents; <U>provided</U>, <U>however</U>, that such expenses shall include the reasonable legal f
ees and expenses of only one counsel to Agent (and any necessary local counsel as determined by Agent) and in addition, Lenders who are not the Agent shall be entitled to reimbursement for no more than one counsel representing all such Lenders (absent a conflict of interest in which case Lenders may engage and be reimbursed for additional counsel).  Extraordinary Expenses shall not include the allocation of any overhead expenses consisting of rent, utilities and employee salaries of any Secured Party.  Such costs, expenses and advances may include transfer fees, taxes, storage fees, insurance costs, permit fees, utility reservation and standby fees, legal fees, appraisal fees, brokers<B>'</B> fees and commissions, auctioneers<B>'</B> fees and commissions, accountants<B>'</B> fees, environmental study fees, wages and salaries paid to employees of any Borrower or independent contractors in liquidating any Collateral, travel expenses, all other fees and expenses payable or reimbursable by Borrowers or any other
 Obligor under any of the Loan Documents, and all other reasonable fees and expenses associated with the enforcement of rights or remedies under any of the Loan&nbsp;Documents, but excluding compensation paid to employees (including inside legal counsel who are employees) of Agent or any Lender and in each case, subject to the limitations set forth above.</P>
<U><P ALIGN="JUSTIFY">FDA</U> - the United States Food and Drug Administration, and any Governmental Authority succeeding to any of its principal functions.</P>
<U><P ALIGN="JUSTIFY">Federal Funds Rate</U> - for any period, a fluctuating interest rate per annum equal for each date during such period to the weighted average of the rates on overnight federal funds transactions with members of the Federal Reserve System arranged by federal funds brokers, as published for such day (or, if such day is not a Business Day, for the next preceding Business Day) by the Federal Reserve Bank of New York, or if such rate is not so published for any day which is a Business Day, the average of the quotations for such day on such transactions received by Agent from 3 federal funds brokers of recognized standing selected by Agent.</P>
<U><P ALIGN="JUSTIFY">Fee Letter</U> - the fee letter agreement dated on or before the Closing Date among Agent, Banc of America Securities LLC and Borrowers.</P>
<U><P ALIGN="JUSTIFY">FEIN</U> - with respect to any Person, the Federal Employer Identification Number of such Person.</P>
<U><P ALIGN="JUSTIFY">Financed Capital Expenditures</U> - (i) Capital Expenditures funded with the proceeds of Debt permitted under <B>Section 10.2.3</B>, including Permitted Purchase Money Debt (excluding Loans) and those represented by Capitalized Lease Obligations, (ii) Capital Expenditures funded with the proceeds of any equity securities issued or capital contributions received, or Debt borrowed (other than Borrowings under this Agreement) by any Consolidated Group Member, (iii) Capital Expenditures that satisfy the requirements of a Permitted Acquisition or Permitted Investment, (iv) any expenditures which are contractually required to be, and are, reimbursed to a Consolidated Group Member in cash by a third party (including landlords) during such period of calculation, (v) Capital Expenditures made with the cash proceeds of any insurance, condemnation or eminent domain event, or (vi) Capital Expenditures made with the cash proceeds from any Permitted Asset Disposition (other than proceeds of any Inven
tory, Accounts, Eligible Equipment and Eligible Real Estate).</P>
<U><P ALIGN="JUSTIFY">FIRREA</U> - Financial Institutions Reform, Recovery, and Enforcement Act of 1989.</P>
<U><P ALIGN="JUSTIFY">Fiscal Month</U> - each calendar month in Borrowers<B>'</B> Fiscal Year.</P>
<U><P ALIGN="JUSTIFY">Fiscal Quarter</U> - the period commencing January 1 in any Fiscal Year and ending on the next succeeding March 31, the period commencing April 1 in any Fiscal Year and ending on the next succeeding June 30, the period commencing July 1 in any Fiscal Year and ending on the next succeeding September 30 or the period commencing October 1 in any Fiscal Year and ending on the next succeeding December 31, as the context may require, or, if any such Subsidiary was not in existence on the first day of any such period, the period commencing on the date on which such Subsidiary is incorporated, organized, formed or otherwise created and ending on the last day of such period.</P>
<U><P ALIGN="JUSTIFY">Fiscal Year</U> - the fiscal year of Borrowers and their Subsidiaries for accounting and tax&nbsp;purposes, which ends on December 31 of each year.</P>
<U><P ALIGN="JUSTIFY">Fixed Asset Sublimit</U> - on any date of determination thereof, an amount equal to the lesser of (i) the sum of (x) 85% of the Appraised Net Orderly Liquidation Value of Eligible Equipment and (y) 65% of the Appraised Fair Market Value of Eligible Real Estate or (ii) $50,000,000.  The Fixed Asset Sublimit shall be reduced on a quarterly basis in accordance with the following schedule:</P></DIR>
</DIR>
</FONT>
<P ALIGN="CENTER"><CENTER><TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=301>
<TR><TD WIDTH="49%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">Amortization Date</U></FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">Quarterly<BR>
<U>Amortization Amount</U></FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">12/31/2006</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,250,000</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">03/31/2007</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,250,000</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">06/30/2007</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,250,000</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">09/30/2007</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,250,000</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">12/31/2007</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,250,000</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">03/31/2008</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,250,000</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">06/30/2008</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,250,000</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">09/30/2008</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">1,250,000</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">12/31/2008</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2,750,000</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">03/31/2009</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2,750,000</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">06/30/2009</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2,750,000</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">09/30/2009</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">2,750,000</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">12/31/2009</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">4,375,000</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">03/31/2010</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">4,375,000</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">06/30/2010</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">4,375,000</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">09/30/2010</FONT></TD>
<TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">4,375,000</FONT></TD>
</TR>
<TR><TD WIDTH="49%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="51%" VALIGN="TOP">&nbsp;</TD>
</TR>
</TABLE>
</CENTER></P>
<DIR>
<DIR>

<FONT SIZE=3><P ALIGN="JUSTIFY">The remainder of the Fixed Asset Sublimit shall be reduced to zero on the Commitment Termination Date.</P>
<U><P ALIGN="JUSTIFY">Fixed Charge Coverage Ratio</U> - for any period, the ratio of (a) EBITDA for such period <U>minus</U> Capital Expenditures (excluding Financed Capital Expenditures) for such period, to (b) the sum of all Fixed Charges for such period, all calculated for the Consolidated Group on a Consolidated basis.</P>
<P ALIGN="JUSTIFY"></P>
<U><P ALIGN="JUSTIFY">Fixed Charges</U> - for any fiscal period, the sum of (i) interest expense of the Consolidated Group (other than interest payable-in-kind to the extent not paid in cash) for such period less interest income of the Consolidated Group for such period <U>plus</U> (ii) scheduled principal payments on Funded Debt of the Consolidated Group (including scheduled principal payments of Capitalized Lease Obligations but excluding the scheduled reductions of the Fixed Asset Sublimit, and any repurchase or defeasance of the Convertible Notes or the Senior Notes) during such period <U>plus</U> (iii) Distributions made by Parent or Distributions made by any other Borrower to a Person that is not a Borrower during such period <U>plus</U> (iv) cash incomes taxes (net of cash refunds received) paid during such period.</P>
<U><P ALIGN="JUSTIFY">FLSA</U> - the Fair Labor Standards Act of 1938.</P>
<U><P ALIGN="JUSTIFY">Food and Drug Laws</U> - all federal, state or local statues, rules, regulations, ordinances and codes, together with all administrative orders, directed duties, licenses, authorization and permits of, and agreements with, any United States and foreign Governmental Authority, in each case relating to manufacture, sale, testing, handling, management, marketing and disposal or pharmaceutical, medical device, biological and drug products, including but not limited to those relating to good manufacturing practices, good clinical practices, labeling, record keeping and obligations for products for which (a) monograph conditions must be met, or (b) a 510K or similar application must be filed, or (c) approval of the FDA and/or similar foreign Governmental Authority is required, before they may be marketed or sold.</P>
<U><P ALIGN="JUSTIFY">Foreign Lender</U> - any Lender that is organized under the laws of a jurisdiction other than the laws of the United States, any state thereof or the District of Columbia.</P>
<U><P ALIGN="JUSTIFY">Foreign Subsidiary</U> - a Subsidiary that is not a Domestic Subsidiary.</P>
<U><P ALIGN="JUSTIFY">Full Payment</U> - with respect to any of the Obligations, the full and final payment in full, in cash and in Dollars, of such Obligations (other than contingent indemnification obligations for which no claim has been made or asserted), including all interests, fees and other charges payable in connection therewith under any of the Loan Documents, whether such interests, fees or other charges accrue or are incurred prior to or during the pendency of an Insolvency Proceeding and whether or not any of the same are allowed or recoverable in any bankruptcy case pursuant to Section 506 of the Bankruptcy Code or otherwise; with respect to any LC Obligations represented by undrawn Letters of Credit and Banking Relationship Debt (including Debt arising under Hedging Agreements), the depositing of cash with Agent, as security for the payment of such Obligations, not to exceed 103% of the aggregate undrawn amount of such Letters of Credit and 100% of Agent<B>'</B>s good faith estimate of the amou
nt of Banking Relationship Debt due and to become due after termination of such Bank Products; and with respect to any Obligations that are contingent in nature (other than Obligations consisting of LC Obligations or Banking Relationship Debt), such as a right of Agent or a Lender to indemnification by any Obligor, the depositing of cash with Agent in an amount equal to 100% of such Obligations or, if such Obligations are unliquidated in amount and represent a claim which has been overtly asserted (or is reasonably probable of assertion) against Agent or a Lender and for which an indemnity has been provided by Borrowers in any of the Loan Documents, in an amount that is equal to such claim or Agent<B>'</B>s good faith estimate of such claim.  None of the Loans shall be deemed to have been paid in full until all Commitments related to such Loans have expired or been terminated.</P>
<U><P ALIGN="JUSTIFY">Funded Debt</U> - with respect to the Consolidated Group, the sum, without duplication, of (i) the aggregate amount of Debt of the Consolidated Group consisting of (a) the borrowing of money or the obtaining of credit (other than accrued expenses and accounts payables incurred in the Ordinary Course of Business and any repurchase, redemption, refinancing in full or defeasance of, or Approved Escrow with respect to, the Senior Notes or the Convertible Notes and the Senior Notes and the Convertible Notes to the extent so defeased or escrowed), including the Obligations on any date of determination (but excluding repayment and reborrowing of Revolver Loans), and any other notes or bonds, (b) the deferred purchase price of assets (other than trade payables incurred in the Ordinary Course of Business), or (c) Capitalized Lease Obligations, <U>plus</U> (ii) Debt of the type referred to in clause (i) of another Person guaranteed by a Consolidated Group Member, in each case as determined on a C
onsolidated basis.</P>
<U><P ALIGN="JUSTIFY">GAAP</U> - generally accepted accounting principles in the United States of America in effect from time to time.</P>
<U><P ALIGN="JUSTIFY">General Intangibles</U> - shall have the meaning given to the term "general intangibles" in the UCC and shall include each Borrower<B>'</B>s choses in action, causes of action, company or other business records, inventions, blueprints, designs, patents, patent applications, trademarks, trademark applications, trade names, trade secrets, service marks, goodwill, brand names, copyrights, registrations, licenses, franchises, customer lists, permits, tax refund claims, computer&nbsp;programs, operational manuals, internet addresses and domain names, insurance refunds and premium rebates, all rights to indemnification and all other intangible property of such Borrower of every kind and nature (other than Accounts).</P>
<U><P ALIGN="JUSTIFY">Generic Account</U> - an Account that arises from sales of generic pharmaceuticals made through Alpharma USPD Inc. or Purepac Pharmaceutical Co.</P><DIR>
<DIR>

<U><P ALIGN="JUSTIFY">Goods</U> - shall have the meaning given to the term "goods" in the UCC.</P></DIR>
</DIR>

<U><P ALIGN="JUSTIFY">Governmental Approvals</U> - all authorizations, consents, approvals, licenses and exemptions of, registrations and filings with, and reports to, all Governmental Authorities.</P>
<U><P ALIGN="JUSTIFY">Governmental Authority</U> -  any federal, state, municipal, national, foreign or other governmental department, commission, board, bureau, court, agency or instrumentality or political subdivision thereof or any entity exercising executive, legislative, judicial, regulatory or administrative functions of any&nbsp;government or any court, in each case whether associated with a state of the United States, the District of Columbia or a foreign entity or&nbsp;government.</P>
<U><P ALIGN="JUSTIFY">Guarantors</U> - each Person after the Closing Date who guarantees payment or performance of the whole or any part of the Obligations.</P>
<U><P ALIGN="JUSTIFY">Guaranty</U> - each guaranty agreement now or hereafter executed by a Guarantor in favor of Agent with respect to any of the Obligations.</P>
<U><P ALIGN="JUSTIFY">Hedging Agreement</U> - any interest rate protection agreement, interest rate swap, cap, collar agreements, foreign currency exchange agreement, forward, future or option contract, currency swap agreement, commodity price protection agreement or other interest or currency exchange rate or commodity price hedging arrangement or other similar agreements.</P>
<U><P ALIGN="JUSTIFY">Impermissible Qualification</U> - any qualification or exception to the opinion or certification of any independent public accountant as to any financial statement of Parent and its Subsidiaries which (i)&nbsp;is of a "going concern" or similar nature, or (ii)&nbsp;relates to the limited scope of examination of matters relevant to such financial statements.</P>
<U><P ALIGN="JUSTIFY">Indemnitees</U> - the Agent Indemnitees, the Lender Indemnitees, the Issuing Bank Indemnities and the BofA Indemnitees.</P>
<U><P ALIGN="JUSTIFY">Initial Lender</U> - BofA, in its capacity as a "Lender" under this Agreement on the Closing Date.</P>
<U><P ALIGN="JUSTIFY">Insolvency Proceeding</U> - any action, case or proceeding commenced by or against a Person under any state, federal or foreign bankruptcy, insolvency, receivership or similar law for (i)&nbsp;the entry of an order for relief under any chapter of the Bankruptcy Code or other bankruptcy insolvency, receivership or similar law (whether state, federal or foreign), (ii)&nbsp;the appointment of a receiver (or administrative receiver), trustee, liquidator, administrator or conservator for such Person or any substantial part of its&nbsp;Property, (iii)&nbsp;a general assignment or trust mortgage for the benefit of creditors of such Person, or (iv)&nbsp;except to the extent otherwise expressly permitted herein, the liquidation, dissolution or winding up of the affairs of such Person.</P>
<U><P ALIGN="JUSTIFY">Instrument</U> - shall have the meaning given to the term "instrument" in the UCC.</P>
<U><P ALIGN="JUSTIFY">Intellectual Property</U> - all intellectual and intangible Property and other similar Property of a Person of every kind and description, including inventions, designs, patents, patent applications, copyrights, trademarks, service marks, trade names, mask works, trade secrets, confidential or proprietary information, know-how, software and databases and all embodiments or fixations thereof and related&nbsp;documentation, registrations and all licenses, or other rights to use any of the foregoing.</P>
<U><P ALIGN="JUSTIFY">Intellectual Property Claim</U> - the assertion by any Person of a claim (whether asserted in writing, by action, suit or proceeding or otherwise) that any Borrower<B>'</B>s ownership, use, marketing, sale or distribution of any Inventory, Equipment, Intellectual Property or other Property is violative of any ownership of or right to use any Intellectual Property of such Person.</P>
<U><P ALIGN="JUSTIFY">Interest Period</U> - shall have the meaning ascribed to it in <B>Section&nbsp;3.1.3</B>.</P>
<U><P ALIGN="JUSTIFY">Inventory</U> - shall have the meaning given to the term "inventory" in the UCC and shall include all goods intended for sale or lease by a Borrower, or for display or demonstration; all work in process, all raw materials and other materials and supplies of every nature and description used or which might be used in connection with the manufacture, printing, packing, shipping, advertising, selling, leasing or furnishing of such goods or otherwise used or consumed in a Borrower<B>'</B>s business (but excluding Equipment).</P>
<U><P ALIGN="JUSTIFY">Inventory Formula Amount</U> - on any date of determination thereof, an amount equal to the lesser of (A) the Revolver Commitments or (B) the sum of (i)&nbsp;the lesser of (x)&nbsp;65% of the Value of Eligible Inventory consisting of finished goods on such date or (y)&nbsp;85% of the product obtained by multiplying the Value of Eligible Inventory on such date consisting of finished goods by the Net Orderly Liquidation Value Percentage; <U>plus</U> (ii)&nbsp;the lesser of (x) 65% of the Value of Eligible Inventory consisting of raw materials on such date or (y) 85% of the<B><I> </B></I>product obtained by multiplying the Value of Eligible Inventory on such date consisting of raw materials by the Net Orderly Liquidation Value Percentage.</P>
<U><P ALIGN="JUSTIFY">Inventory Reserve</U> - such reserves as may be established from time to time by Agent in its reasonable credit judgment to reflect changes in the salability of any Eligible Inventory in the Ordinary Course of Business or such other factors as could be reasonably expected to negatively impact the Value of any Eligible Inventory.  Without limiting the generality of the foregoing, such reserves may include reserves based on obsolescence, theft or other shrinkage, markdowns, and vendor chargebacks; provided that any reserve for returns and rebates shall be determined consistent with Borrowers<B>'</B> past practice and in accordance with GAAP and shall otherwise be acceptable to Agent in its reasonable credit judgment.</P>
<U><P ALIGN="JUSTIFY">Investment Property</U> - shall have the meaning given to the term "investment property" in the UCC and shall include all securities (whether certificated or uncertificated), security entitlements, securities accounts, commodity contracts and commodity accounts.</P>
<U><P ALIGN="JUSTIFY">Issuing Bank</U> - BofA or an Affiliate of BofA.</P>
<U><P ALIGN="JUSTIFY">Issuing Bank Indemnitees</U> - Issuing Bank and all of its present and future officers, directors, employees, agents and attorneys.</P>
<U><P ALIGN="JUSTIFY">LC Application</U> - an application by any or all Borrowers to Issuing Bank, pursuant to a form approved by Issuing Bank, for the issuance of a Letter of Credit, that is submitted to Issuing Bank at least 3 Business Days prior to the requested issuance of such Letter of Credit.</P>
<U><P ALIGN="JUSTIFY">LC Conditions</U> - the following conditions, the satisfaction of each of which is required before Issuing Bank shall be obligated issue a Letter of Credit: (i)&nbsp;each of the conditions set forth in <B>Section&nbsp;11.1 </B>and <B>Section 11.2 </B>in connection with the issuance of Letters of Credit on the Closing Date and each of the conditions set forth in <B>Section 11.2</B> for Letters of Credit issued thereafter has been and continues to be satisfied, including the absence of any Default or Event of Default; (ii)&nbsp;after giving effect to the issuance of the requested Letter of Credit and all other unissued Letters of Credit for which an&nbsp;LC Application has been signed by a Borrower and approved by Agent and Issuing Bank, the LC Obligations would not exceed $25,000,000 and no Out-of-Formula Condition would exist, and, if no Revolver Loans are outstanding, the LC Obligations do not, and would not upon the issuance of the requested Letter of Credit, exceed the Borrowing Base
; (iii)&nbsp;such Letter of Credit has an expiration date that is no more than 365 days from the date of issuance in the case of standby Letters of Credit and no more than 120 days from the date of issuance in the case of documentary Letters of Credit and, in either event, such expiration date is at least 30 days prior to the last Business Day of the Term unless otherwise agreed by Agent in its discretion; (iv)&nbsp;the currency in which payment is to be made under the Letter of Credit is Dollars; and (v) the form of the proposed Letter of Credit is satisfactory to Agent and Issuing Bank in their discretion, provides for sight drafts only and does not contain any language that automatically increases the amount available to be drawn under the Letter of Credit.</P>
<U><P ALIGN="JUSTIFY">LC Documents</U> - any and all agreements, instruments and documents (including an LC Application) required by Issuing Bank to be executed by Borrowers or any other Person and delivered to Issuing Bank for the issuance, amendment or renewal of a Letter of Credit.</P>
<U><P ALIGN="JUSTIFY">LC Facility</U> - the subfacility for Letters of Credit established as part of the Revolver Commitments pursuant to <B>Section&nbsp;2.3</B>.</P>
<U><P ALIGN="JUSTIFY">LC Obligations</U> - on any date, an amount (in Dollars) equal to the sum of (without duplication) (i)&nbsp;all amounts then due and payable by any Obligor on such date by reason of any payment that is made by Issuing Bank under a Letter of Credit and that has not been repaid to Issuing Bank, <U>plus</U> (ii)&nbsp;the aggregate Undrawn Amount of all Letters of Credit which are then outstanding or for which an LC Application has been delivered to and accepted by Issuing Bank, <U>plus</U> (iii)&nbsp;all fees and other amounts due and payable in respect of Letters of Credit outstanding on such date.</P>
<U><P ALIGN="JUSTIFY">LC Request</U> - a Letter of Credit Request from Borrowers to Issuing Bank in the form of <B><U>Exhibit&nbsp;J</B></U> annexed hereto.</P>
<U><P ALIGN="JUSTIFY">LC Reserve</U> - at any date, the aggregate of all LC Obligations on such date, other than (i) LC Obligations that Borrowers shall Cash Collateralize on or prior to such date and (ii) during any period that no Default or Event of Default exists, the portion of LC Obligations described in clause (iii) of the definition thereof.</P>
<U><P ALIGN="JUSTIFY">Lender Indemnitees</U> - Lenders and all of their respective present and future officers, directors, employees, agents and attorneys.</P>
<U><P ALIGN="JUSTIFY">Lenders</U> - shall have the meaning given to it in the preamble to this Agreement and shall include BofA (whether in its capacity as a provider of Loans under <B>Section&nbsp;2</B> or as the provider of Swingline Loans under <B>Section&nbsp;4.1.3</B> ) and any other Person who may from time to time become a "Lender" under this Agreement, including each assignee that becomes a party to this Agreement pursuant to <B>Section 14.3</B>.</P>
<U><P ALIGN="JUSTIFY">Letter of Credit</U> - any standby or documentary letter of credit issued by Issuing Bank for the account of any Borrower.</P>
<U><P ALIGN="JUSTIFY">Letter-of-Credit Right</U> - shall have the meaning given to the term "letter-of-credit-right" in the UCC.</P>
<U><P ALIGN="JUSTIFY">LIBOR Lending Office</U> - with respect to a Lender, the office designated as a LIBOR Lending Office for such Lender on the signature page hereof (or on any Assignment and Acceptance, in the case of an assignee) or such other office of such Lender or any of its Affiliates that is hereafter designated by written notice to Agent.</P>
<U><P ALIGN="JUSTIFY">LIBOR Loan</U> - a Loan, or portion thereof, during any period in which it bears interest at a rate based upon the applicable Adjusted LIBOR Rate.</P>
<U><P ALIGN="JUSTIFY">License Agreement</U> - any agreement between a Borrower and a Licensor pursuant to which such Borrower is authorized to use any Intellectual Property in connection with the manufacturing, marketing, sale or other distribution of any Inventory of such Borrower.</P>
<U><P ALIGN="JUSTIFY">Licensor</U> - any Person from whom a Borrower obtains the right to use (whether on an exclusive or non-exclusive basis) any Intellectual Property in connection with such Borrower<B>'</B>s manufacture, marketing, sale or other distribution of any Inventory.</P>
<U><P ALIGN="JUSTIFY">Lien</U> - means, with respect to any asset, (a) any mortgage, deed of trust, lien, pledge, hypothecation, encumbrance, collateral assignment, charge or security interest in, on or of such asset, (b) the interest of a vendor or a lessor under any conditional sale agreement, capital lease or title retention agreement (or any financing lease having substantially the same economic effect as any of the foregoing) relating to such asset and (c) in the case of securities, any purchase option, call or similar right of a third party with respect to such securities.</P>
<U><P ALIGN="JUSTIFY">Lien Waiver</U> -  an agreement duly executed in favor of Agent, in form and content reasonably acceptable to Agent, by which (i)&nbsp;for locations leased by an Obligor, an owner or mortgagee of premises upon which the Property of an Obligor is located agrees to waive or subordinate any Lien it may have with respect to such Property in favor of Agent<B>'</B>s Lien therein and to permit Agent to enter upon such premises and remove such Property or to use such premises to store or dispose of such Property, or (ii)&nbsp;for locations at which any Obligor places Inventory with a warehouseman or a processor, such warehouseman or processor agrees to waive or subordinate any Lien it may have with respect to such Property in favor of Agent<B>'</B>s Lien therein and to permit Agent to enter upon such premises and remove such Property or to use such premises to store or dispose of such Property, or, in either case, otherwise reasonably acceptable to Agent.</P>
<U><P ALIGN="JUSTIFY">Loan</U> - a Revolver Loan or a Term Loan Advance (and, without duplication, each Base Rate Loan and LIBOR&nbsp;Loan comprising such Loan).</P>
<U><P ALIGN="JUSTIFY">Loan Account</U> - the loan account established by each Lender on its books pursuant to <B>Section&nbsp;5.8.</P>
</B><U><P ALIGN="JUSTIFY">Loan Documents</U> - this Agreement, the Other Agreements and the Security Documents.</P>
<U><P ALIGN="JUSTIFY">Loan Year</U> - a period commencing each calendar year on the same month and day as the date of this Agreement and ending on the same month and day in the immediately succeeding calendar year, with the first such period (<U>i.e.</U> the first Loan Year) to commence on the date of this Agreement.</P>
<U><P ALIGN="JUSTIFY">Margin Stock</U> - shall have the meaning ascribed to it in Regulation U and of the Board of Governors.</P>
<U><P ALIGN="JUSTIFY">Material Adverse Effect</U> - the effect of any event, condition or circumstance, which (i)&nbsp;has a material adverse effect upon the business, operations, Properties, or financial condition of Parent and its Subsidiaries, taken as a whole or the ability of the Consolidated Group to repay the Obligations; (ii)&nbsp;has or could be reasonably expected to have any material adverse effect whatsoever upon the validity or enforceability of this Agreement or any of the other Loan Documents; or (iii)&nbsp;has a material adverse effect upon the value of the whole or any substantial part of the Collateral, the Liens of Agent with respect to such Collateral or the priority of any such Liens; or (iv)&nbsp;has a material adverse effect on the ability of Agent or any Lender to enforce or collect the&nbsp;Obligations or realize upon any material portion of the Collateral in accordance with the Loan Documents and Applicable Law.</P>
<U><P ALIGN="JUSTIFY">Material Contract</U> - an agreement to which an Obligor is a party (other than the Loan&nbsp;Documents) for which breach, termination, cancellation, nonperformance or failure to renew could reasonably be expected to have a Material&nbsp;Adverse Effect.</P>
<U><P ALIGN="JUSTIFY">Maximum Rate</U> - the maximum non-usurious rate of interest permitted by Applicable Law that at any time, or from time to time, may be contracted for, taken, reserved, charged or received on the Debt in question or, to the extent that at any time Applicable Law may thereafter permit a higher maximum non-usurious rate of interest, then such higher rate.  Notwithstanding any other provision hereof, the Maximum Rate shall be calculated on a daily basis (computed on the actual number of days elapsed over a year of 365 or 366 days, as the case may be).</P>
<U><P ALIGN="JUSTIFY">Money Borrowed</U> - as applied to any Obligor, without duplication, (i)&nbsp;Debt arising from the lending of money by any other Person to such Obligor; (ii)&nbsp;Debt, whether or not in any such case arising from the lending of money by another Person to such Obligor, (A)&nbsp;which is represented by notes payable or drafts accepted that evidence extensions of credit, (B)&nbsp;which constitutes obligations evidenced by bonds, debentures, notes or similar instruments, or (C)&nbsp;upon which interest charges are customarily paid (other than accounts payable) or that was issued or assumed as full or partial payment for Property; (iii)&nbsp;Debt that constitutes a Capitalized Lease Obligation; (iv)&nbsp;reimbursement obligations with respect to letters of credit or guaranties of letters of credit; and (v)&nbsp;Debt of such Obligor under any guaranty of obligations that would constitute Debt for Money Borrowed under clauses (i) through (iii) hereof, if owed directly by such Obligor.</P>
<U><P ALIGN="JUSTIFY">Moody's</U> - Moody's Investors Services, Inc.</P>
<U><P ALIGN="JUSTIFY">Mortgages</U> - the mortgages, deeds of trust and/or deeds to secure debt to be executed by a Borrower on or before the Closing Date in favor of Agent and pursuant to which such Borrower shall grant and convey to Agent, for the benefit of Secured Parties, Liens upon the Real Estate of such Borrower listed on <B><U>Exhibit K</B></U> attached hereto as security for the payment of the Obligations.</P>
<U><P ALIGN="JUSTIFY">Multiemployer Plan</U> - has the meaning set forth in Section 4001(a)(3) of ERISA.</P>
<U><P ALIGN="JUSTIFY">Negative Pledge Agreement</U> - each Negative Pledge Agreement to be executed by the applicable Borrower on or before the Closing Date, pursuant to which such Borrower agrees that it shall not consensually pledge, assign, transfer, encumber or grant any Lien in favor of any other Person in any of the Specified Real Estate of such Borrower that has not been pledged to Agent or permit any Lien to exist thereon (other than a Permitted Lien) until the Full Payment of the Obligations.</P>
<U><P ALIGN="JUSTIFY">Net Disposition Proceeds</U> - proceeds (including cash receivable (when received) by way of deferred payment) received by an Obligor in cash from an Asset Disposition under clause (ii), (ix) or (x) of the definition of Permitted Asset Disposition, net of: (i)&nbsp;the reasonable fees and out-of-pocket costs and expenses actually incurred in connection with such Asset Disposition (including legal fees, accountants, appraisals, brokerage, title fees and expenses and sales commissions); (ii)&nbsp;amounts applied to repayment of Debt (other than the Obligations) secured by a Permitted Lien on such Collateral disposed of that is senior in priority to Agent's Liens; (iii) recording, transfer, sales or similar taxes; and (iv) reserves for escrows and indemnities, until such reserves are no longer required and such reserves or escrows are released to a Borrower.</P>
<U><P ALIGN="JUSTIFY">Net Orderly Liquidation Value Appraisal</U> - an appraisal of the orderly liquidation value of Inventory or Equipment (as applicable) of Borrowers performed by an appraiser reasonably satisfactory to Agent, which appraisal shall deduct as a factor in the determination of orderly liquidation value, all costs and expenses projected to be incurred in the conduct of any liquidation of all or any portion of the Inventory or Equipment (as applicable).</P>
<U><P ALIGN="JUSTIFY">Net Orderly Liquidation Value Percentage</U> - at any date and with respect to any Inventory, the percentage of the value of such Inventory expected to be realized at an orderly, negotiated sale of such Inventory that is held within a reasonable period of time, as such percentage is determined by Agent from the most recent Net Orderly Liquidation Value Appraisal received by Agent and acceptable by Agent on or before such date.</P>
<U><P ALIGN="JUSTIFY">Notes</U> - each Revolver Note, each Term Note, the Swingline Note and any other promissory note executed by Borrowers at Agent's request to evidence any of the Obligations.</P>
<U><P ALIGN="JUSTIFY">Notice of Borrowing</U> - as defined in <B>Section 4.1.1(i)</B>.</P>
<U><P ALIGN="JUSTIFY">Notice of Conversion/Continuation</U> - as defined in <B>Section 3.1.2(ii).</P>
</B><P ALIGN="JUSTIFY"></P>
<U><P ALIGN="JUSTIFY">Obligations</U> - in each case, whether now in existence or hereafter arising, (i)&nbsp;the principal of, and interest and premium, if any, on the Loans, (ii)&nbsp;all LC Obligations and all other obligations of any Obligor to Agent or Issuing Bank arising in connection with the issuance of any Letter&nbsp;of Credit, (iii) all liabilities and obligations of Borrowers under any indemnity for Claims, (iv) all Extraordinary Expenses, (v)&nbsp;all other Debts, covenants, duties and obligations (including Contingent Obligations) now or at any time or times hereafter owing by any Obligor to Agent or any Lender under or pursuant to this Agreement or any of the other Loan Documents, in each case, whether evidenced by any note or other writing, whether arising from any extension of credit, opening of a letter of credit, acceptance, loan, guaranty, indemnification or otherwise and whether direct or indirect, absolute or contingent, due or to become due, primary or secondary, or joint or several, 
including all interest, charges, expenses, fees or other sums chargeable to any or all&nbsp;Obligors under any of the Loan&nbsp;Documents, and (vi) any Banking Relationship Debt.</P>
<U><P ALIGN="JUSTIFY">Obligor</U> - each Borrower and each Guarantor.</P>
<U><P ALIGN="JUSTIFY">Ordinary Course of Business</U> - with respect to any transaction involving any Person, the&nbsp;ordinary course of such Person's business and undertaken by such Person in good faith and not for the purpose of evading any&nbsp;covenant or restriction in any Loan Document.</P>
<U><P ALIGN="JUSTIFY">Organic Documents</U> - with respect to any Person, its charter, certificate or articles of incorporation, bylaws, articles of organization, limited liability agreement, operating agreement, members agreement, shareholders agreement, partnership agreement, certificate of partnership, certificate of formation, voting trust, or similar agreement or instrument governing the formation or operation of such Person.</P>
<U><P ALIGN="JUSTIFY">OSHA</U> - the Occupational Safety and Hazard Act of 1970.</P>
<U><P ALIGN="JUSTIFY">Other Agreements</U> - the Notes, the Fee Letter, the LC Documents, each Lien Waiver, and any and all other agreements, instruments and documents (other than this Agreement and the Security Documents), heretofore, now or hereafter executed by any Borrower, any other Obligor or any other Person and delivered to Agent or any Lender, in each case in respect of the transactions contemplated by this Agreement or other Loan Documents.</P>
<U><P ALIGN="JUSTIFY">Out-of-Formula Condition</U> - as defined in <B>Section&nbsp;2.1.2</B>.</P>
<U><P ALIGN="JUSTIFY">Out-of-Formula Loan</U> - a Revolver Loan made or existing when an Out-of-Formula Condition exists or the amount of any Revolver Loan which, when funded, results in an Out-of-Formula Condition.</P>
<U><P ALIGN="JUSTIFY">Participant</U> - as defined in <B>Section&nbsp;14.2.1</B>.</P>
<U><P ALIGN="JUSTIFY">Participating Lender</U> - as defined in <B>Section 2.3.2(i)</B>.</P>
<U><P ALIGN="JUSTIFY">Patent Security Agreement</U> - each Patent Security Agreement to be  executed by Borrowers in favor of Agent on or before the Closing Date and by which Borrowers shall grant to Agent, for the benefit of Secured Parties, as security for the Obligations, a security interest in all of Borrowers' right, title and interest in and to the patents and patent applications listed therein.</P>
<U><P ALIGN="JUSTIFY">Payment Account</U> - an account maintained by Agent to which all monies from time to time deposited to a Dominion Account shall be transferred and all other payments shall be sent in immediately available federal funds.</P>
<U><P ALIGN="JUSTIFY">Payment Intangible</U> - shall have the meaning given to the term "payment intangible" in the UCC.</P>
<U><P ALIGN="JUSTIFY">Payment Item</U> - each check, draft, or other item of payment payable to a Borrower, including those evidencing or constituting proceeds of any of the Collateral.</P>
<U><P ALIGN="JUSTIFY">Pending Revolver Loans</U> - at any date, the aggregate principal amount of all Revolver Loans which have been requested in any Notice of Borrowing received by Agent but which have not theretofore been advanced by Agent or Lenders.</P>
<U><P ALIGN="JUSTIFY">Permitted Acquisition</U> - the acquisition by a Borrower of all or a portion of the capital stock or assets of a Person organized under the laws of the United States of America or any state thereof so long as each of the following conditions is satisfied:</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such acquired Person is engaged primarily in one or more businesses in which Borrowers are engaged or businesses reasonably related  or incidental thereto;</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Pro Forma Fixed Charge Coverage Ratio for the immediately preceding twelve Fiscal Months (if a Restrictive Trigger Event has occurred, based upon the monthly financial statements required pursuant to <B>Section 10.1.3(ii)</B>, and if a Restrictive Trigger Event has not occurred, then based upon the financial statements required pursuant to <B>Section 10.1.3(iii)</B>) is at least 1.0 to 1.0 and Availability at the time of and after giving effect thereto is at least $35,000,000 if any Term Loan is outstanding and $25,000,000 if no Term Loan is outstanding;</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with respect to any Person that is or becomes a Subsidiary, such Person  (i)&nbsp;if requested by Agent, executes and delivers to Agent, for the benefit of  Lenders, a joinder agreement to this Agreement and such other documents (including, if requested by Agent, an amendment to any Hedging Agreement to add such Subsidiary thereto) as may be determined by Agent to add such Subsidiary as an additional "Borrower" hereunder, and/or a new pledge agreement or such amendments to the relevant Security Documents as Agent shall deem necessary or reasonably advisable to grant to Agent, for the benefit of  Secured Parties, a Lien on the capital stock of such Subsidiary (and if such Person has any direct Foreign Subsidiaries, a Lien on at least 65% of the capital stock of each direct Foreign Subsidiary), (ii)&nbsp;delivers to Agent the certificates representing such capital stock, together with undated stock powers executed and delivered
 in blank by a duly authorized officer of the Borrowers or such Subsidiary, as the case may be, (iii)&nbsp;if requested by Agent, in lieu of being joined as a Borrower, causes such new Subsidiary to become a party to a subsidiary guarantee, if applicable, or such comparable documentation which is in form and substance reasonably satisfactory to Agent, and (iv)&nbsp; takes all actions deemed necessary or advisable by Agent to cause the Lien created by this Agreement to be duly perfected against such Person in accordance with all Applicable Law (subject to <B>Section 7.6</B> hereof) including the filing of financing statements in such jurisdictions as may be requested by Agent, subject to and in accordance with the Loan Documents; <A NAME="OLE_LINK1"><U>provided</U>, <U>however</U>, that if such Subsidiary constitutes an Excluded Subsidiary, then Agent and Lenders will not require that such Subsidiary be joined to this Agreement as a Borrower or a Guarantor but may require that 100% of the capital stock of suc
h Subsidiary be pledged to Agent, for the benefit of Lenders, as security for the Obligations and that all of the other provisions of this definition (other than the joinder provisions of this clause (iii)) be satisfied</A>;</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the applicable Borrower has made available to Agent, not later than 10 Business Days (or such later date to which Agent may agree) prior to the proposed date of such acquisition, copies of lien search results and copies of the acquisition documents (including a copy of the purchase and sale agreement with all schedules and exhibits thereto) and other due diligence information as reasonably requested by Agent;</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Borrowers shall have executed and deliver such amendments or supplements to this Agreement or the other Security Documents or such other documents as Agent may deem necessary or advisable to grant Agent a first priority Lien on all of the acquired assets to the extent required by the terms hereof and thereof;</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Agent shall have received a certificate of the Borrower Representative executed on its behalf by a Senior Officer, certifying that both before and after giving pro forma effect to such acquisition, the Consolidated Group, taken as a whole is Solvent; and</P>
<P ALIGN="JUSTIFY">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;no Default or Event of Default has occurred and is continuing or would result therefrom.</P>
<P ALIGN="JUSTIFY">In connection with any merger (or other distribution of the assets) of a Subsidiary that is not a Borrower with and into (or to) a Borrower, or any acquisition, whether by purchase of stock, merger, or purchase of assets and whether in a single transaction or series of related transactions, by a Borrower, Agent shall have the right to determine in its reasonable credit judgment which Inventory or Accounts so acquired shall be included in the Borrowing Base (subject to the provisions of the definitions "Borrowing Base," "Eligible Inventory" and "Eligible Accounts" and any other provisions of this Agreement and the other Loan Documents applicable to the computation and reporting of the Borrowing Base).  In connection with such determination, Agent may obtain, at  Borrowers' expense, such appraisals, commercial finance exams and other assessments of such Accounts and Inventory as it may reasonably deem desirable and all such appraisals, exams and other assessments shall be paid for by Borrowe
rs and shall not be limited by or included in the number of appraisals and field exams reimbursable under <B>Section 3.2.4</B>.</P>
<U><P ALIGN="JUSTIFY">Permitted Asset Disposition</U> - an Asset Disposition that consists of (i)&nbsp; the sale of Inventory in the Ordinary Course of Business; (ii) for so long as no Default or Event of Default exists, dispositions of Property (other than Accounts, Inventory, Eligible Equipment or Eligible Real Estate) which, in the aggregate as to all Borrowers during any consecutive 12-month period, has a fair market value or book value, whichever is more, of $5,000,000 or less, provided that all Net Disposition Proceeds thereof are remitted to Agent for application to the Obligations, (iii) replacements of Equipment that is substantially worn, damaged or obsolete with Equipment of like kind, function and value, provided that the replacement Equipment shall be acquired prior to or concurrently with any disposition of the Equipment that is to be replaced, the replacement Equipment shall be free and clear of Liens other than Permitted Liens that are not Purchase Money Liens and Borrowers shall have given A
gent at least 10 days prior written notice of such disposition, (iv) the licensing of Intellectual Property in the Ordinary Course of Business; (v) sales, transfers, licenses, leases or other dispositions of assets made by a Consolidated Group Member to another Consolidated Group Member (other than an Excluded Subsidiary or a Restrictive Subsidiary); (vi) transfers or forgiveness of Accounts in the Ordinary Course of Business and in connection with the collection or compromise thereof; (vii) the abandonment, failure to maintain or renew or cancellation of Intellectual Property of any Consolidated Group Member that is not material to such Consolidated Group Member's business in such Consolidated Group Member's reasonable business judgment; (viii) any sublease, sale or other disposition of any Specified Real Estate (ix) for so long as no Default or Event of Default exists, any sale or other disposition of the Piscataway New Jersey site; (x) for so long as no Default or Event of Default exists, any Permitted Po
rtfolio Transaction; (xi) condemnations by Governmental Authorities of Real Estate (other than Eligible Real Estate); and (xii) for so long as no Default or Event of Default exists, mergers and consolidations permitted under <B>Section 10.2.11</B>.</P>
<U><P ALIGN="JUSTIFY">Permitted Canadian Inventory</U> - Inventory of a Borrower that would otherwise constitute Eligible Inventory but for the fact that it is located in Canada and in which Agent has a first-priority, perfected Lien.</P>
<U><P ALIGN="JUSTIFY">Permitted Consignment Sale Conditions</U> - each of the following conditions, the satisfaction of each of which shall be determined by Agent in its reasonable credit judgment (i) the consignee shall have executed a consignment agreement, in form and scope acceptable to Agent, granting a Borrower and its assigns a purchase money lien and security interest in all consigned Inventory that is consigned by such Borrower to such consignee, together with the cash and non-cash proceeds thereof; (ii) consignee and such Borrower shall have executed UCC financing statements, in form acceptable to Agent, based upon the requirements of the filing jurisdiction, naming such consignee as debtor and such Borrower as secured party (and, if requested by Agent, naming Agent as assignee), covering the consigned Inventory and the cash and non-cash proceeds thereof; such financing statement shall have been filed of record in all appropriate filing locations for the perfection of a first priority security inte
rest in such consigned Inventory and the cash and non-cash proceeds thereof; and, after filing of such financing statements, such Borrower shall have conducted searches of all filings made against such consignee in such filing offices and taken such other action as Agent may reasonably request, including notification pursuant to the UCC to each holder of a conflicting Lien in such consigned Inventory, which shall confirm that the security interest in the consigned Inventory in favor of such Borrower that such Borrower has assigned to Agent, together with the cash and non-cash proceeds thereof, is and shall be a first priority Lien; (iii) if requested by Agent, after determination by Agent that such agreement is necessary for the protection of its assigned Lien in such consigned Inventory, based upon Applicable Law of the state in which the consigned Inventory is located, such Borrower shall obtain an agreement from the landlord of the premises where the consigned Inventory is to be located, in form and subst
ance reasonably acceptable to Agent, waiving in favor of such Borrower and its assigns such landlord's Liens in such consigned Inventory; (v) if requested by Agent, Lender shall have received the originals of the consignment agreement, the filed UCC financing statements, the UCC searches, the landlord's agreement and the insurance agreement referred to in clauses (i) through (iv) above, and such other instruments, documents, certificates, opinions or assurances, and such Borrower shall have taken such other action as Agent may have reasonably requested in connection with the consignee; and (vi) consignee shall maintain the consigned Inventory at a location in the United States.</P>
<U><P ALIGN="JUSTIFY">Permitted Contingent Obligations</U> - Contingent Obligations arising from endorsements of items of payment for collection or deposit in the Ordinary Course of Business; Contingent Obligations of any Consolidated Group Member existing as of the Closing Date, including extensions and renewals thereof that do not increase the&nbsp;amount of such Contingent Obligations as of the date of such extension or renewal; Contingent Obligations arising under indemnity agreements to title insurers to cause such title insurers to issue to Agent title&nbsp;insurance policies; Contingent Obligations with respect to customary indemnification obligations in favor of purchasers in&nbsp;connection with dispositions of Equipment permitted under <B>Section 8.4.2;</B> Contingent Obligations consisting of reimbursement obligations from time to time owing by any Borrower to Issuing Bank with respect to Letters of Credit (but in no event to include reimbursement obligations at any time owing by a Borrower to any
 other Person that may issue letters of credit for the account of Borrowers); unsecured guaranties made by a Consolidated Group Member for Debt or other obligations of another Consolidated Group Member that is expressly permitted to be incurred hereunder or not prohibited; other unsecured Contingent Obligations not to exceed $25,000,000 in the aggregate at any time; the Permitted Euro Debt Guaranty; and unsecured guaranties made by a Consolidated Group Member for Debt of another Consolidated Group Member that is expressly permitted to be incurred hereunder.</P>
<U><P ALIGN="JUSTIFY">Permitted Euro Debt Guaranty</U> - the unsecured guaranty by Parent of the Euro Debt, not to exceed $400,000,000.</P>
<U><P ALIGN="JUSTIFY">Permitted Investment</U> - investments in, or loans or investments to, (a) any Foreign Subsidiary of a Borrower or (b) joint ventures with other Persons organized under the laws of the United States of America or any state thereof, so long as each of the following conditions is satisfied as determined by Agent:</P></DIR>
</DIR>

<OL TYPE="i">
<DIR>
<DIR>

<OL TYPE="i">

<P ALIGN="JUSTIFY"><LI>such Person is engaged primarily in one or more businesses in which Borrowers are engaged or reasonably related or incidental thereto;</LI></P>

<P ALIGN="JUSTIFY"><LI>Availability at the time of and after giving effect thereto is at least $35,000,000 if any Term Loan is outstanding and $25,000,000 if no Term Loan is outstanding;</LI></P>

<P ALIGN="JUSTIFY"><LI>with respect to any Person that is or becomes a Domestic Subsidiary, such Person  (i)&nbsp;if requested by Agent, executes and delivers to Agent, for the benefit of  Lenders, a joinder agreement to this Agreement and such other documents (including, if requested by Agent, an amendment to any Hedging Agreement to add such Domestic Subsidiary thereto) as may be determined by Agent to add such Domestic Subsidiary as an additional "Borrower" hereunder, and/or a new pledge agreement or such amendments to the relevant Security Documents as Agent shall deem necessary or advisable to grant to Agent, for the benefit of  Secured Parties, a Lien on the capital stock of such Domestic Subsidiary (and if such Person has any direct Foreign Subsidiaries, a Lien on at least 65% of the capital stock of such Foreign Subsidiary), (ii)&nbsp;delivers to Agent the certificates representing such capital stock, together with undated stock powers executed and delivered in blank by a duly authorized officer of t
he Borrowers or such Subsidiary, as the case may be, and (iii)&nbsp;if requested by Agent, cause such new Domestic Subsidiary (a)&nbsp;to become a party to a subsidiary guarantee, if applicable, or such comparable documentation which is in form and substance reasonably satisfactory to Agent, and (b)&nbsp;to take all actions necessary or advisable to cause the Lien created by this Agreement to be duly perfected against such Person in accordance with all Applicable Law (subject to <B>Section 7.6</B> hereof), including the filing of financing statements in such jurisdictions as may be requested by Agent subject to and in accordance with the Loan Documents; <U>provided</U>, <U>however</U>, that if such Subsidiary constitutes an Excluded Subsidiary, then Agent and Lenders will not require that such Subsidiary be joined to this Agreement as a Borrower or a Guarantor but may require that 100% of the capital stock of such Subsidiary be pledged to Agent, for the benefit of Lenders, as security for the Obligations and
 that all of the other provisions of this definition (other than the joinder provisions of this clause (iii)) be satisfied;</LI></P>

<P ALIGN="JUSTIFY"><LI>the applicable Borrower has made available to Agent, not later than 10 Business Days prior to the proposed date of such investment, copies of the applicable investment documents, Organic Documents  and other due diligence information as requested by Agent;</LI></P>

<P ALIGN="JUSTIFY"><LI>Agent shall have received a certificate of the Borrower Representative executed on its behalf by a Senior Officer, certifying that both before and after giving pro forma effect to such investment, the Consolidated Group is Solvent; and </LI></P>

<P ALIGN="JUSTIFY"><LI>No Default or Event of Default shall exist or result therefrom.</LI></P></OL>
</DIR>
</DIR>
</OL>

<DIR>
<DIR>

<U><P ALIGN="JUSTIFY">Permitted Lien</U> - a Lien of a kind specified in <B>Section&nbsp;10.2.5</B>.</P>
<U><P ALIGN="JUSTIFY">Permitted Payment Conditions</U> - each of the following conditions, the satisfaction of each shall be required before any Borrower shall be permitted to repurchase, redeem or prepay any Funded Debt under <B>Section 10.2.6(ii)</B>:</P></DIR>
</DIR>

<OL TYPE="i">
<DIR>
<DIR>

<OL TYPE="i">

<P ALIGN="JUSTIFY"><LI>Availability at the time of and after giving effect thereto is at least $35,000,000 if any Term Loan is outstanding and $25,000,000 if no Term Loan is outstanding; </LI></P>
<P ALIGN="JUSTIFY"><LI>the applicable Borrower has  given Agent at least 10 Business Days' prior notice of such payment (or such later date as is acceptable to Agent); and</LI></P>
<P ALIGN="JUSTIFY"><LI>no Default or Event of Default shall exist or result therefrom.</LI></P></OL>
</DIR>
</DIR>
</OL>
<DIR>
<DIR>

<U><P ALIGN="JUSTIFY">Permitted Portfolio Transaction</U> - a Portfolio Transaction so long as each of the following conditions is satisfied:</P></DIR>
</DIR>

<OL TYPE="i">
<DIR>
<DIR>

<OL TYPE="i">

<P ALIGN="JUSTIFY"><LI>Agent shall have received (a) at least thirty (30) days prior to the date of the consummation of such proposed Portfolio Transaction (or such later date as is acceptable to Agent) drafts of the purchase agreement and all other related documents, instruments and agreements and (b) at least five (5) days (or such later date as is acceptable to Agent) prior to the date of the consummation of such proposed Portfolio Transaction final copies of all such documents;</LI></P>
<P ALIGN="JUSTIFY"><LI>Concurrently with the consummation of such Portfolio Transaction, Agent shall receive the Net Disposition Proceeds from such Portfolio Transaction for application in accordance with <B>Section 5.3.5</B>; </LI></P>
<P ALIGN="JUSTIFY"><LI>If the Term Loan and Fixed Asset Sublimit are not to be repaid in full, Agent shall have received from a Senior Officer of Borrowers a written list of all Equipment and Real Estate to be sold as part of such Portfolio Transaction, including, with respect to such Equipment, the net book value and net orderly liquidation value of each piece of Equipment;</LI></P>
<P ALIGN="JUSTIFY"><LI>Availability at the time of, and after giving pro forma effect to such Portfolio Transaction and the application of proceeds thereof, (a) shall not be less than $25,000,000 if no Term Loan is outstanding at such time and (b) shall not be less than $35,000,000 if any Term Loan is outstanding at such time and such Term Loan is not to be repaid in full upon consummation of such Portfolio Transaction;</LI></P>
<P ALIGN="JUSTIFY"><LI>Borrowers shall have delivered to Agent a Pro Forma Borrowing Base Certificate, in form and substance reasonably satisfactory to Agent, that confirms that after application of the proceeds of the Portfolio Transaction there will be no Out-of-Formula Condition;</LI></P>
<P ALIGN="JUSTIFY"><LI>no Default or Event of Default shall exist at the time or result therefrom;</LI></P>
<P ALIGN="JUSTIFY"><LI>such Portfolio Transaction shall occur on or before December 31, 2006; and</LI></P>
<P ALIGN="JUSTIFY"><LI>no more than 3 such Portfolio Transactions shall occur prior to the Full Payment of the Obligations; <U>provided</U>, <U>that</U> any series of related transactions that occur within one month shall be deemed to be one Portfolio Transaction (but subject to the satisfaction of each of the above conditions at each stage).</LI></P></OL>
</DIR>
</DIR>
</OL>
<DIR>
<DIR>

<U><P ALIGN="JUSTIFY">Permitted Purchase Money Debt</U> - Purchase Money Debt of Borrowers and their Subsidiaries (or of any target to the extent constituting a Permitted Acquisition) that is incurred after the date of this Agreement and that is unsecured or is secured only by a Purchase Money Lien, provided that the aggregate amount of Purchase Money Debt outstanding at any time does not exceed $25,000,000 and the incurrence of such Purchase Money Debt does not violate any limitation in the Loan Documents regarding Capital Expenditures.  For the purposes of this definition, the principal amount of any Purchase Money Debt consisting of capitalized leases shall be computed as a Capitalized Lease Obligation.</P>
<U><P ALIGN="JUSTIFY">Permitted Subsidiary</U> - a Person that becomes a Domestic Subsidiary of a Borrower after the Closing Date, subject to the satisfaction of each of the following conditions:</P></DIR>
</DIR>

<OL TYPE="i">

<OL TYPE="i">

<P ALIGN="JUSTIFY"><LI>No Default or Event of Default exists at the time of the creation or formation of such Subsidiary;</LI></P>
<P ALIGN="JUSTIFY"><LI>Borrowers give Agent not less than 10 Business Days prior written notice of the formation of such Subsidiary (or such later date as is acceptable to Agent);</LI></P>
<P ALIGN="JUSTIFY"><LI>such Subsidiary is engaged primarily in one or more businesses in which Borrowers are engaged or businesses reasonably related  or incidental thereto; and</LI></P>
<P ALIGN="JUSTIFY"><LI>with respect to any such Subsidiary, such Person  (i)&nbsp;if requested by Agent, executes and delivers to Agent, for the benefit of  Lenders, a joinder agreement to this Agreement and such other documents (including, if requested by Agent, an amendment to any Hedging Agreement to add such Subsidiary thereto) as may be determined by Agent to add such Subsidiary as an additional "Borrower" hereunder, and/or a new pledge agreement or such amendments to the relevant Security Documents as Agent shall deem necessary or reasonably advisable to grant to Agent, for the benefit of  Secured Parties, a Lien on the capital stock of such Subsidiary (and if such Person has any direct Foreign Subsidiaries, a Lien on at least 65% of the capital stock of each direct Foreign Subsidiary), (ii)&nbsp;delivers to Agent the certificates representing such capital stock, together with undated stock powers executed and delivered in blank by a duly authorized officer of the Borrowers or such Subsidiary, as the c
ase may be, (iii)&nbsp;if requested by Agent, in lieu of being joined as a Borrower, causes such new Subsidiary to become a party to a subsidiary guarantee, if applicable, or such comparable documentation which is in form and substance reasonably satisfactory to Agent, and (iv)&nbsp; takes all actions deemed necessary or advisable by Agent to cause the Lien created by this Agreement to be duly perfected against such Person in accordance with all Applicable Law (subject to <B>Section 7.6</B> hereof), including the filing of financing statements in such jurisdictions as may be requested by Agent subject to and in accordance with the Loan Documents; <U>provided</U>, <U>however</U>, that if such Subsidiary constitutes an Excluded Subsidiary, then Agent and Lenders will not require that such Subsidiary be joined to this Agreement as a Borrower or a Guarantor but may require that 100% of the capital stock of such Subsidiary be pledged to Agent, for the benefit of Lenders, as security for the Obligations and that a
ll of the other provisions of this definition (other than the joinder provisions of this clause (iv)) be satisfied.</LI></P></OL>
</OL>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">Agent shall have the right to determine in its reasonable credit judgment which Inventory or Accounts of such Subsidiary shall be included in the Borrowing Base (subject to the provisions of the definitions "Borrowing Base," "Eligible Inventory" and "Eligible Accounts" and any other provisions of this Agreement and the other Loan Documents applicable to the computation and reporting of the Borrowing Base).  In connection with such determination, Agent may obtain, at Borrowers' expense, such appraisals, commercial finance exams and other assessments of such Accounts and Inventory as it may reasonably deem desirable and all such appraisals, exams and other assessments shall be paid for by Borrowers and shall not be limited by or included in the number of appraisals and field exams reimbursable under <B>Section 3.2.4</B>.</P>

<U><P ALIGN="JUSTIFY">Person</U> - an individual, partnership, corporation, limited liability company, limited liability partnership, joint stock company, land trust, business trust, or unincorporated organization, or a Governmental Authority.</P>
<U><P ALIGN="JUSTIFY">Plan</U> - an employee pension benefit plan that is covered by Title IV of ERISA or subject to the minimum funding standards under Section 412 of the Internal Revenue Code and that is either (i)&nbsp;maintained by a Borrower for employees or (ii)&nbsp;maintained pursuant to a collective bargaining agreement or any other arrangement under which more than one employer makes contributions and to which a Borrower is then making or accruing an obligation to make contributions or has within the preceding 5 years made or accrued such contributions.</P>
<U><P ALIGN="JUSTIFY">Pledge Agreements</U> - the Pledge Agreements to be executed by each Borrower on or before the Closing Date, pursuant to which each Borrower shall pledge to Agent, for the benefit of the Secured Parties, 100% of the Equity Interests of each of its Domestic Subsidiaries and 65% of the Equity Interests of each of its direct Foreign Subsidiaries, as security for the Obligations.</P>
<U><P ALIGN="JUSTIFY">Portfolio Transaction</U> - a sale, transfer or other disposition in one or a series of transactions of all or any portion of the Equity Interests, properties and assets, rights or other interests constituting or relating to the generics pharmaceutical business.</P>
<U><P ALIGN="JUSTIFY">Prior Lenders</U> - Bank of America, N.A., as agent for a syndicate of lenders which provided credit facilities to Borrowers pursuant to a certain Credit Agreement dated as of October 5, 2001, as amended.</P>
<U><P ALIGN="JUSTIFY">Pro Forma Borrowing Base</U> - the Borrowing Base certified by Borrowers in a Borrowing Base Certificate, as of the month ended no more than 25 days prior to the proposed date of a Portfolio Transaction, that gives pro forma effect to a Portfolio Transaction.</P>
<U><P ALIGN="JUSTIFY">Pro Forma Fixed Charge Coverage Ratio</U> - for any period, the ratio of (a) EBITDA for such period <U>minus</U> Capital Expenditures (excluding Financed Capital Expenditures) for such period, to (b) the sum of all Fixed Charges for such period, all calculated for the Consolidated Group on a Consolidated basis, <U>provided</U>,<U> that</U> for purposes of computing this ratio for Permitted Acquisitions only (and without duplication in each case): </P></DIR>
</DIR>

<OL TYPE="i">
<DIR>
<DIR>

<OL TYPE="i">

<P ALIGN="JUSTIFY"><LI>the last 12 months of EBITDA of the acquired target shall be added to the  EBITDA of the Consolidated Group (as adjusted to give effect to any cost savings reasonably acceptable to Agent and certified by Borrowers in good faith arising from the synergies of the combination of the target's and the Consolidated Group's workforce, administration and business operations); </LI></P>
<P ALIGN="JUSTIFY"><LI>the last 12 months of Capital Expenditures of the acquired target shall be added to the Capital Expenditures of the Consolidated Group;</LI></P>
<P ALIGN="JUSTIFY"><LI>there shall be added to cash interest expense of the Consolidated Group the last 12 months of cash interest expense on Debt acquired in connection with such acquisition, plus, on a proforma basis, 12 months of cash interest expense on the incremental Loans undertaken by the Borrowers on the closing date of the acquisition; and </LI></P>
<P ALIGN="JUSTIFY"><LI>there shall be added to scheduled and actual principal payments of the Consolidated Group the last 12 months of scheduled principal payments on Debt acquired in connection with such acquisition.</LI></P></OL>
</DIR>
</DIR>
</OL>
<DIR>
<DIR>

<U><P ALIGN="JUSTIFY">Pro Rata</U> - with respect to any Lender on any date, a percentage (expressed as a decimal, rounded to the ninth decimal place) derived by dividing the amount of the total Commitments of such Lender on such date by the&nbsp;aggregate amount of the Commitments of all Lenders on such date (regardless of whether or not any of such Commitments have been terminated on or before such date).</P>
<U><P ALIGN="JUSTIFY">Projections</U> - (i)&nbsp;prior to the Closing Date and thereafter until Agent receives new projections pursuant to <B>Section&nbsp;10.1.5</B>, the projections of Borrowers' consolidated balance sheets, income statements and cash flow statements and projected Availability, prepared on a quarterly basis for the Fiscal Year ending December 31, 2006, and on an annual basis for the Fiscal Years ending 2007, 2008, 2009 and 2010; and (ii)&nbsp;thereafter, the projections most recently received by Agent and Lenders pursuant to and as required by <B>Section&nbsp;10.1.5</B>.</P>
<U><P ALIGN="JUSTIFY">Properly Contested</U> - in the case of any Debt of an Obligor (including any Taxes) that is not paid as and when due or payable by reason of such Obligor's bona fide dispute concerning its liability to pay same or concerning the amount thereof, (i)&nbsp;such Debt is being properly contested in good faith by appropriate proceedings promptly instituted and diligently conducted; (ii)&nbsp;such Obligor has established appropriate reserves as shall be required in conformity with GAAP; (iii)&nbsp;the non-payment of such Debt will not have a Material Adverse Effect; (iv)&nbsp;no Lien in excess of $500,000 is imposed upon any of such Obligor's assets with respect to such Debt unless such Lien is at all times junior and subordinate in priority to the Liens in favor of Agent (except only with respect to property taxes that have priority as a&nbsp;matter of Applicable Law) and enforcement of such Lien is stayed during the period prior to the final resolution or disposition of such dispute; and (v
) if such contest is abandoned, settled or determined adversely (in&nbsp;whole or in part) to such Obligor, such Obligor forthwith pays such Debt.</P>
<U><P ALIGN="JUSTIFY">Property</U> - any interest in any kind of property or asset, whether real, personal or mixed and whether tangible or intangible.</P>
<U><P ALIGN="JUSTIFY">Purchase Money Debt</U> - means and includes (i)&nbsp;Debt (other than the Obligations but including capitalized leases) for the payment of all or any part of the purchase price of any fixed or capital assets consisting of Equipment, Real Estate or Software, (ii)&nbsp;any Debt (other than the Obligations) incurred or assumed at the time of or within 90 days prior to or after the acquisition or completion of construction of any fixed or capital assets consisting of Equipment, Real Estate or Software for the purpose of financing all or any part of the purchase price or construction or improvement thereof, including deferred purchase price and industrial revenue bonds or similar municipal or governmental bonds, and (iii)&nbsp;any renewals, extensions or refinancings (but not any increases in the principal amounts) thereof outstanding at the time.</P>
<U><P ALIGN="JUSTIFY">Purchase Money Lien</U> - a Lien upon fixed or capital assets consisting of Equipment, Real Estate or Software which secures Purchase Money Debt, but only if such Lien shall at all times be confined solely to such asset acquired through the incurrence of the Purchase Money Debt secured by such Lien.</P>
<U><P ALIGN="JUSTIFY">RCRA</U> - the Resource Conservation and Recovery Act (42&nbsp;U.S.C. SectionSection&nbsp;6991-6991i).</P>
<U><P ALIGN="JUSTIFY">Real Estate</U> - all right, title and interest of a Borrower (whether as owner, lessor or lessee) at any time or times held by such Borrower in real Property or any buildings, structures, parking areas or other improvements thereon (excluding the Specified Real Estate).</P>
<U><P ALIGN="JUSTIFY">Refinancing Conditions</U> - the following conditions, each of which must be satisfied before Refinancing Debt shall be permitted under <B>Section&nbsp;10.2.3</B>: (i)&nbsp;the Refinancing Debt is in an aggregate principal amount that does not exceed the aggregate principal amount of the Debt being extended, renewed or refinanced, plus the amount of fees and expenses payable in connection with such refinancing and any premiums penalties, accrued interest and accreted amounts payable with respect to such Refinancing Debt, (ii)&nbsp;the Refinancing Debt has a later or equal final maturity and a longer or equal weighted average life than the Debt being extended, renewed or refinanced, (iii)&nbsp;the Refinancing Debt does not bear a rate of interest that exceeds, as of the date of such extension, renewal or refinancing, a market rate (as determined in good faith by a Senior Officer) for Debt of such type issued by an entity similar to the Borrower that is liable on the Debt being extended, 
renewed or refinanced, (iv)&nbsp;if the Debt being extended, renewed or refinanced is subordinate to the Obligations, the Refinancing Debt is subordinated to the same extent (other than the Convertible Notes), (v)&nbsp;the financial and other material covenants contained in any instrument or agreement relating to the Refinancing Debt are no less favorable when taken as a whole in any material respect to Borrowers than those relating to the Debt being extended, renewed or refinanced, (vi)&nbsp;at the time of and after giving effect to such extension, renewal or refinancing, no Default or Event&nbsp;of Default shall&nbsp;exist, and (vii) no additional Lien is granted to secure the repayment of the Refinancing Debt.</P>
<U><P ALIGN="JUSTIFY">Refinancing Debt</U> - Debt that is permitted by <B>Section&nbsp;10.2.3</B> and that is the subject or the result of an extension, renewal or refinancing.</P>
<U><P ALIGN="JUSTIFY">Regulation D</U> - Regulation D of the Board of Governors.</P>
<U><P ALIGN="JUSTIFY">Register</U> - the register maintained by Agent in accordance with <B>Section&nbsp;5.8.2</B>.</P>
<U><P ALIGN="JUSTIFY">Reimbursement Date</U> - as defined in <B>Section&nbsp;2.3.1(iii)</B>.</P>
<U><P ALIGN="JUSTIFY">Rent Reserve</U> - on any date, the aggregate of (i) all past due rent, fees or other charges owing on such date by any Obligor to any landlord of any premises where any of the Collateral is located or to any processor, repairman, mechanic or other Person who is in possession of any Collateral or has asserted any Lien or claim thereto, and (ii) a reserve equal to 3 months rent or other charges with respect to any Collateral in the possession of, or at a location owned by, a Person other than a Borrower if such Person has not duly executed and delivered to Agent a Lien Waiver reasonably satisfactory to Agent.</P>
<U><P ALIGN="JUSTIFY">Report</U> - as defined in <B>Section 13.1.5</B>.</P>
<U><P ALIGN="JUSTIFY">Reportable Event</U> - any of the events set forth in Section 4043(c) of ERISA.</P>
<U><P ALIGN="JUSTIFY">Reporting Spring-Back Date</U> - as such term is defined in <B>Section 10.1.3(ii)</B>.</P>
<U><P ALIGN="JUSTIFY">Required Lenders</U> - at any date of determination thereof, Lenders having Commitments representing greater than 50% of the aggregate Commitments at such time; <U>provided</U>, <U>however</U>, that if any Lender shall be in breach of any of its obligations hereunder to Borrowers or Agent, including any breach resulting from its failure to honor its Commitment in accordance with the terms of this Agreement, then, for so long as such breach continues, the term "Required&nbsp;Lenders" shall mean Lenders (excluding each Lender that is in breach of its obligations under this Agreement) having Commitments representing greater than 50% of the aggregate Commitments (excluding the Commitments of each Lender that is in breach of its obligations under this Agreement) at such time; <U>provided</U> <U>further</U>, <U>however</U>, that if all of the Commitments have been terminated, the term "Required Lenders" shall mean Lenders (excluding each Lender that is in breach of its obligations under this 
Agreement) holding Loans (including Swingline Loans) representing greater than 50% of the aggregate principal amount of Loans (including Swingline Loans) outstanding at such time.</P>
<U><P ALIGN="JUSTIFY">Restricted Investment</U> - any acquisition of Property comprising a division or business unit or all or a substantial part of the business of any Person by a Consolidated Group Member, or the purchase or acquisition by any Consolidated Group Member of Equity Interests in or Debt of any Person, or a loan, advance, capital contribution or subscription, except for the following: (a) acquisitions of the following: (i)&nbsp;fixed assets to be used in the Ordinary Course of Business of such Consolidated Group Member so long as the acquisition costs thereof are Capital&nbsp;Expenditures permitted hereunder; (ii)&nbsp;goods held for sale or lease or to be used in the&nbsp;manufacture of goods or the provision of services by such Consolidated Group Member in the Ordinary Course of Business; and (iii)&nbsp;current assets arising from the sale or lease of goods or the rendition of services in the Ordinary Course of Business of such Consolidated Group Member; (b) investments in Subsidiaries to the
 extent existing on the Closing Date; (c) investments in Cash Equivalents; (d) loans and other advances of money to the extent not prohibited by <B>Section&nbsp;10.2.2</B>; (e) investments existing on the date hereof and described on <B><U>Schedule 10.2.13</B> </U>hereto; (f) investments in the Hedging Agreements permitted under this Agreement; (g) investments received in connection with the bankruptcy or reorganization of, or settlement of delinquent accounts and disputes with, customers and suppliers, in each case in the Ordinary Course of Business, (h) Permitted Acquisitions; (i) Permitted Investments; (j) other investments not totaling more than $10,000,000 in the aggregate; (k) contingent obligations permitted under <B>Section 10.2.3</B>; (l) investments in Consolidated Group Members; (m) investments in Subsidiaries of Parent that are not Consolidated Group Members subject to the limitations set forth in <B>Section 10.2.2(iii)</B> hereof; and (n) notes receivable received by a Borrower in connection wit
h a Permitted Portfolio Transaction as a portion of the purchase price.</P>
<U><P ALIGN="JUSTIFY">Restrictive Agreement</U> - an agreement (other than any of the Loan Documents) that, if and for so long as an Obligor is a party thereto, would prohibit, condition or restrict such Obligor's right to incur the Obligations; grant Liens upon any of such Obligor's assets (including Liens granted in favor of Agent pursuant to the Loan Documents); declare or make Distributions; amend, modify, extend or renew any of the Loan Documents; or repay any Debt owed to another&nbsp;Obligor.</P>
<U><P ALIGN="JUSTIFY">Restrictive Subsidiary</U> - each Subsidiary listed on <B><U>Schedule 10.2.1</B></U>.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<U><P ALIGN="JUSTIFY">Restrictive Trigger Event</U> - shall mean: </P>
<P ALIGN="JUSTIFY">(i) for purposes of <B>Sections 3.2.4, </B>and<B> 8.2.5(ii</B>)<B>,</B> any of the following events: (a) if Average Availability  is less than $25,000,000 during any 10 Business Day period, with such measurement period commencing on the first day that Availability is less than $25,000,000, (b) any Event of Default exists, or (c) Availability is less than $20,000,000 at any time (<U>provided</U>, <U>that</U>, for purposes of this clause (c), Availability may be below $20,000,000 for 1 day during any consecutive 30 day period without causing a Restrictive Trigger Event to occur under this clause (c));</P>
<P ALIGN="JUSTIFY">(ii) for purposes of <B>Section 7.6</B>, any of the following events:</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">(a) Average Availability is less than $25,000,000 during any 10 Business Day period, with such measurement period commencing on the first day that Availability is less than $25,000,000, or</P>
<P ALIGN="JUSTIFY">(b) any Event of Default exists, or </P>
<P ALIGN="JUSTIFY">(c) Availability is less than $20,000,000 at any time (<U>provided</U>, <U>that</U>, for purposes of this clause (c) Availability may be below $20,000,000 for 2 days during any consecutive 30 day period without causing a Restrictive Trigger Event to occur under this clause (c));</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">(iii) for purposes of <B>Section 10.1.3(ii</B>), any of the following events: </P><DIR>
<DIR>

<P ALIGN="JUSTIFY">(a) if Average Availability is less than the lesser of (I) $35,000,000 or (II) the then outstanding principal amount of the Term Loan (but in no event less than $25,000,000) during any 10 Business Day period, with such measurement period commencing on the first day that Availability is less than such amount, </P>
<P ALIGN="JUSTIFY">(b) any Event of Default exists or </P>
<P ALIGN="JUSTIFY">(c) Availability is less than the lesser of (I) $30,000,000 or (II) $30,000,000 less (the difference between $35,000,000 and the then outstanding principal amount of the Term Loan) but in no event less than $20,000,000, at any time (<U>provided</U>, <U>that</U> for purposes of this clause (c), Availability may be below such amount for 2 days during any consecutive 30 day period without causing a Restrictive Trigger Event to occur under this clause (c)); and</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">(iv) for purposes of <B>Section 10.3.1</B>, any of the following events: </P><DIR>
<DIR>

<P ALIGN="JUSTIFY">(a)(I) if the Full Payment of the Term Loan has not occurred and if Average Availability is less than the lesser of (A) $35,000,000 or (B) the then outstanding principal amount of the Term Loan (but in no event less than $25,000,000) during any 10 Business Day period, with such measurement period commencing on the first day that Availability is less than such amount, or (II) if the Full Payment of the Term Loan has occurred and if Average Availability is less than $25,000,000 during any 10 Business Day period, with such measurement period commencing on the first day that Availability is less than $25,000,000, </P>
<P ALIGN="JUSTIFY">(b) any Event of Default exists or </P>
<P ALIGN="JUSTIFY">(c) Availability is less than the lesser of (I) $30,000,000 or (II) $30,000,000 less (the difference between $35,000,000 and the then outstanding principal amount of the Term Loan) but in no event less than $20,000,000, at any time (<U>provided</U>, <U>that</U> for purposes of this clause (c), Availability may be below such amount for 2 days during any consecutive 30 day period without causing a Restrictive Trigger Event to occur under this clause (c)).</P></DIR>
</DIR>

<U><P ALIGN="JUSTIFY">Revolver Commitment</U> - at any date for any Lender, the obligation of such Lender to make Revolver Loans and to purchase participations in LC Obligations pursuant to the terms and conditions of this Agreement, which shall not exceed the principal amount set forth opposite such&nbsp;Lender's name under the heading "Revolver Commitment" on the signature pages of this Agreement or the principal amount set forth in the Assignment and Acceptance by which it became a Lender, as modified from time to time pursuant to the terms of this Agreement or to give effect to any applicable Assignment and Acceptance; and "<U>Revolver Commitments</U>" means the aggregate principal amount of the Revolver Commitments of all Lenders, the maximum amount of which on any date shall be $175,000,000, as reduced from time to time pursuant to <B>Section 2.1.5</B>.</P>
<U><P ALIGN="JUSTIFY">Revolver Loan</U> - a loan made by Lenders as provided in <B>Section 2.1</B> (including any Out-of-Formula Loan) or a Swingline Loan funded solely by BofA.</P>
<U><P ALIGN="JUSTIFY">Revolver Note</U> - a Revolver Note to be executed by Borrowers in favor of each Lender in the form of <B><U>Exhibit A</B></U> attached hereto, which shall be in the face amount of such Lender's Revolver Commitment and which shall evidence all Revolver Loans made by such Lender to Borrowers pursuant to this Agreement.</P>
<U><P ALIGN="JUSTIFY">Royalties</U> - with respect to a License Agreement, all royalties, fees, expense reimbursement and other amounts at any time owing by a Borrower under such License Agreement.</P>
<U><P ALIGN="JUSTIFY">S&amp;P</U> - Standard &amp; Poor's Ratings Group, a division of McGraw-Hill, Inc.</P>
<U><P ALIGN="JUSTIFY">Schedule of Accounts</U>&nbsp;- as defined in <B>Section 8.2.1</B>.</P>
<U><P ALIGN="JUSTIFY">SEC</U> - Securities and Exchange Commission.</P>
<U><P ALIGN="JUSTIFY">Secured Parties</U> - Agent, Issuing Bank, Lenders (including BofA as the provider of Swingline Loans) and any Lender or any Affiliate of a Lender as the provider of any Bank Products.</P>
<U><P ALIGN="JUSTIFY">Security Documents</U> - the Patent Security Agreements, each Guaranty, the Trademark Security Agreements, the Deposit Account Control Agreements, the Pledge Agreements, the Mortgages, the Environmental Agreement, the Negative Pledge Agreements, and all other instruments and agreements now or at any time hereafter securing the whole or any part of the Obligations.</P>
<U><P ALIGN="JUSTIFY">Senior Note Documents</U> - the Senior Notes, the Senior Notes Indenture and any and all other agreements, instruments or documents executed in connection therewith or pursuant thereto, as amended, supplemented, modified or restated in accordance with the terms hereof.</P>
<P ALIGN="JUSTIFY"></P>
<U><P ALIGN="JUSTIFY">Senior Notes</U> - the 8 5/8% Senior Notes due 2011 issued by Parent, in the aggregate principal amount of $220,000,000.</P>
<U><P ALIGN="JUSTIFY">Senior Notes Indenture</U> - that certain Indenture dated as of April 24, 2003, between Parent and Wachovia Bank, National Association, as Trustee, pursuant to which Parent issued the Senior Notes, as amended, supplemented, modified or restated in accordance with the terms hereof.</P>
<U><P ALIGN="JUSTIFY">Senior Officer</U> - the chairman of the board of directors, the president, the chief financial officer, in-house legal counsel, the chief executive officer, the principal accounting officer or the treasurer of a Borrower (or the equivalent of any of the foregoing) or any other officer, partner or member (or person performing similar functions) of a Borrower responsible for overseeing the administration of, or reviewing compliance with, all or any portion of this Agreement or any of the other Loan Documents.</P>
<U><P ALIGN="JUSTIFY">Settlement Date</U> - as defined in <B>Section 4.1.3(i)</B>.</P>
<U><P ALIGN="JUSTIFY">Settlement Report</U> - a report delivered by Agent to Lenders summarizing the amount of the&nbsp;outstanding Revolver Loans as of the Settlement Date and the calculation of the Borrowing Base as of such Settlement Date.</P>
<U><P ALIGN="JUSTIFY">Software</U> - shall have the meaning given to the term "software" in the UCC.</P>
<U><P ALIGN="JUSTIFY">Solvent</U> - as to any Person, such Person (i)&nbsp;owns Property whose fair salable value is greater than the amount required to pay all of such Person's debts (including contingent liabilities), (ii)&nbsp;owns Property whose present fair salable value (as defined below) is greater than the amount that will be required to pay the probable total liabilities (including contingent liabilities), of such Person on its debts as they become absolute and matured, (iii)&nbsp;is not engaged in business or a transaction, and is not about to engage in business or a transaction, for which such Person's property would constitute an unreasonably small capital, and (iv) does not intend to, and does not believe that it will, incur debt or liabilities beyond such Person's ability to pay such debts and liabilities as they mature.  As used herein, the term "fair salable value" of a Person's assets means the amount that may be realized within a reasonable time, either through collection or sale of such as
sets at the regular market value, based upon the amount that could be obtained for such assets within such period by a capable and diligent seller from an interested buyer who is willing (but is under no compulsion) to purchase under ordinary selling conditions.  The amount of contingent liabilities at any time shall be computed as the amount that in light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability.</P>
<U><P ALIGN="JUSTIFY">Specified Real Estate</U> - the Real Estate of Borrowers located in Salisbury, Maryland, Terre Haute, Indiana, Lowell, Arkansas and Palmyra, Missouri on the Closing Date.</P>
<U><P ALIGN="JUSTIFY">Statutory Reserves</U> - on any date, the percentage (expressed as a decimal) established by the Board of Governors which is the then stated maximum rate for all reserves (including all basic, emergency, supplemental or other marginal reserve requirements and taking into account any transitional adjustments or other scheduled in reserve requirements) applicable to any member bank of the Federal Reserve System in respect to Eurocurrency Liabilities (or any successor category of liabilities under Regulation&nbsp;D).  Such reserve percentage shall include those imposed pursuant to said Regulation&nbsp;D.  The Statutory Reserve shall be adjusted automatically on and as of the effective date of any change in such percentage.</P>
<U><P ALIGN="JUSTIFY">Subordinated Debt</U> - Debt incurred by a Borrower that is expressly subordinated and made junior in right of payment to the Full Payment of the Obligations and, to the extent that such Debt is incurred on or after the Closing Date, such Debt is payable on terms and conditions (including terms relating to repayment and subordination but excluding interest, fees and any call protection provisions) that are reasonably satisfactory to Agent.</P>
<U><P ALIGN="JUSTIFY">Subsidiary</U> - any Person in which more than 50% of its outstanding Voting Securities or more than 50% of all Equity Interests is owned directly or indirectly by a Borrower, by one or more other Subsidiaries of such Borrower or by a Borrower and one or more other Subsidiaries.</P>
<U><P ALIGN="JUSTIFY">Supporting Obligation</U> - shall have the meaning given to the term "supporting obligation" in the UCC.</P>
<U><P ALIGN="JUSTIFY">Swingline Loan</U> - as defined in <B>Section 4.1.3(ii)</B>.</P>
<U><P ALIGN="JUSTIFY">Swingline Note</U> - the Swingline Note to be executed by Borrowers to the order of BofA on or before the Closing Date in the form of <B><U>Exhibit C</B></U>, to evidence the outstanding Swingline Loans owing to BofA from time to time pursuant to <B>Section 4.1.3</B>.</P>
<U><P ALIGN="JUSTIFY">Taxes</U> - any present or future taxes, levies, imposts, duties, fees, assessments, deductions, withholdings or other charges of whatever nature, including income, receipts, excise, property, sales, use, transfer, license, payroll, withholding, social security and franchise taxes now or hereafter imposed or levied by the United States or any other Governmental Authority and all&nbsp;interest, penalties, additions to tax and similar liabilities with respect thereto, but excluding, in&nbsp;the case of each Lender, taxes imposed on or measured by the net income or overall gross&nbsp;receipts of such Lender.</P>
<U><P ALIGN="JUSTIFY">Term</U> - as defined in <B>Section 6.1</B>.</P>
<U><P ALIGN="JUSTIFY">Term Loan</U> - the aggregate of the Term Loan Advances made by Lenders to Borrowers pursuant to <B>Section 2.2.1</B>.</P>
<U><P ALIGN="JUSTIFY">Term Loan Advance</U> - an advance made by a Lender as part of the Term Loan on the Closing Date and thereafter means such Lender's portion of the Term Loan.</P>
<U><P ALIGN="JUSTIFY">Term Loan Commitment</U> - at any date for any Lender, the obligation of such Lender to make Term Loan Advances pursuant to the terms and conditions of this Agreement, which shall not exceed the principal amount set forth opposite such Lender's name under the heading "Term Loan Commitment" on the signature pages hereof or the principal amount set forth in any Assignment and Acceptance by which it became a Lender, as modified from time to time pursuant to the terms of this Agreement or to give effect to any applicable Assignment and Acceptance; and the term "Term Loan Commitments" means the aggregate principal amount of the Term Loan Commitment of each Lender, the maximum amount of which shall be $35,000,000.</P>
<U><P ALIGN="JUSTIFY">Term Note</U> - as defined in <B>Section 2.2.2</B>.</P>
<U><P ALIGN="JUSTIFY">Trademark Security Agreement</U> - each Trademark Security Agreement to be executed by the applicable Borrower in favor of Agent on or before the Closing Date and by which such Borrower shall grant to Agent, for the benefit of Secured Parties, as security for the&nbsp;Obligations, a security interest in all of such Borrower's right, title and interest in and to all of the trademark registrations and trademark applications listed therein.</P>
<U><P ALIGN="JUSTIFY">Trailing Receipts</U> - on any date of determination, collections of Generic Accounts received by Borrowers for the immediately preceding 31 day period from the date of determination.</P>
<U><P ALIGN="JUSTIFY">Transferee</U> - as defined in <B>Section&nbsp;14.3.3</B>.</P>
<U><P ALIGN="JUSTIFY">Type</U> - any type of a Loan determined with respect to the interest option applicable thereto, which shall be either a LIBOR Loan or a Base Rate Loan.</P>
<U><P ALIGN="JUSTIFY">UCC</U> -  the Uniform Commercial Code (or any successor statute) as adopted and in force in the State of New York or, when the laws of any other state govern the method or manner of the&nbsp;perfection or enforcement of any security interest in any of the Collateral, the Uniform Commercial Code (or any successor statute) of such state.</P>
<U><P ALIGN="JUSTIFY">Undrawn Amount</U> - on any date with respect to a particular Letter of Credit, the total amount then available to be drawn under such Letter of Credit in Dollars.</P>
<U><P ALIGN="JUSTIFY">Unused Line Fee</U> - as defined in <B>Section 3.2.2</B>.</P>
<U><P ALIGN="JUSTIFY">Upstream Payment</U> - a payment or distribution directly or indirectly of cash or other Property by a Subsidiary of an Obligor to such Obligor, or by a Subsidiary that is not an Obligor to another Subsidiary that is not an Obligor, whether in repayment of Debt owed by such Subsidiary to such Obligor, as a dividend or distribution on account of such Obligor's ownership of Equity Interests or otherwise.</P>
<U><P ALIGN="JUSTIFY">USA Patriot Act</U> - the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001, Pub. L. No. 107-56, 115 Stat.&nbsp;272 (2001).</P>
<U><P ALIGN="JUSTIFY">Value</U> - with reference to the value of Inventory, value determined by Agent in good faith on the basis of the lower of cost or market of such Eligible Inventory, with the cost thereof calculated on a first-in, first-out basis in accordance with GAAP consistently applied.</P>
<U><P ALIGN="JUSTIFY">Voting Securities</U> - Equity Interests of any class or classes of a corporation or other entity the&nbsp;holders of which are ordinarily, in the absence of contingencies, entitled to elect a majority of the&nbsp;corporate directors or individuals performing similar functions.</P></DIR>
</DIR>

<B><P ALIGN="JUSTIFY"><A NAME="_Toc102963309"><A NAME="_Toc105998280"><A NAME="_Toc105998690"><A NAME="_Toc105998822"><A NAME="_Toc117052335">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accounting Terms</A></A></A></A></A></U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Unless otherwise specified herein, all terms of an accounting character used in this Agreement shall be interpreted, all accounting determinations under this Agreement shall be made, and all financial statements required to be delivered under this Agreement shall be prepared in accordance with GAAP, applied on a basis consistent with the most recent audited Consolidated financial statements of Parent and its Subsidiaries delivered to Agent and Lenders hereunder and using the&nbsp;same&nbsp;method for inventory valuation as used in such audited financial statements, except for any change required by GAAP; provided, however, that for purposes of determining Borrowers' compliance with financial covenants contained in Section 10.3 and 
other financial terms and definitions used therein, all accounting terms shall be interpreted and all accounting&nbsp;determinations shall be made in accordance with GAAP as in effect on the date of this Agreement and applied on a basis consistent with the application used in the financial statements referred to in Section&nbsp;9.1.9; provided, further however, that in the event that any accounting change under GAAP shall occur and such change results in a material change in the method of calculation of financial covenants or related financial definitions in this Agreement, then Borrowers and Agent agree to enter into negotiations in order to amend such provisions of this Agreement so as to equitably reflect such accounting changes with the desired result that the criteria for evaluating Borrowers' financial condition shall be the same after such accounting changes as if such accounting changes had not been made.  Until such time as such an amendment shall have been executed and delivered by Borrowers, Agent
 and Required Lenders, all financial covenants and related financial definitions in this Agreement shall continue to be calculated or construed as if such accounting changes had not occurred.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc102963310"><A NAME="_Toc105998281"><A NAME="_Toc105998691"><A NAME="_Toc105998823"><A NAME="_Toc117052336">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Terms</A></A></A></A></A></U>&nbsp;&nbsp;&nbsp;</B> All other terms contained in this Agreement shall have, when the context so indicates, the meanings provided for by the UCC to the extent the same are used or defined therein.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc102963311"><A NAME="_Toc105998282"><A NAME="_Toc105998692"><A NAME="_Toc105998824"><A NAME="_Toc117052337">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain Matters of Construction</A></A></A></A></A></B></U>&nbsp;&nbsp;&nbsp;The terms "herein," "hereof" and "hereunder" and other words of similar import refer to this Agreement as a whole and not to any particular section, paragraph or subdivision.  Any pronoun used shall be deemed to cover all genders.  In the computation of periods of time from a specified date to a later specified date, the word "from" means "from and including" and the words "to" and "until" each means "to but excluding."  The section titles, table of contents and list of exhibits appear as a matter of convenience only and shall not affect the interpretation of this Agreement.  All references to statutes shall include all related rules and implementing regulations and any amendments of same and any successor statutes, rules and re
gulations; to any agreement, instrument or other documents (including any of the Loan Documents) shall include any and all modifications and supplements thereto and any and all restatements, extensions or renewals thereof to the extent such modifications, supplements, restatements, extensions or renewals of any such documents are permitted by the terms thereof; to any Person (including Agent, a Borrower, a Lender or BofA) shall mean and include the successors and permitted assigns of such Person; to&nbsp;"including" and "include" shall&nbsp;be understood to mean "including, without limitation" (and, for purposes of each Loan Document, the parties agree that the rule of <I>ejusdem&nbsp;generis</I> shall not be applicable to limit a general statement, which is followed by or referable to an enumeration of specific matters to matters similar to the matters specifically mentioned); to the time of day shall mean the time of day on the day in question in New York, New York, unless otherwise expressly provided in t
his Agreement; or to the "discretion" of Agent or a Lender shall mean the sole and absolute discretion of such Person unless otherwise qualified.  An Event of Default shall be deemed to exist at all times during the period commencing on the date that such Event of Default occurs to the date on which such Event of Default is waived in writing by Agent (acting with the consent or at the direction of the Lenders or the Required Lenders, as applicable) pursuant to this Agreement or, in the case of a Default,  is cured within any period of cure expressly provided in this Agreement; and an Event of Default shall "continue" or be "continuing" until such Event of Default has been waived in writing by Agent (acting with the consent or at the direction of the Lenders or the Required Lenders, as applicable).  All&nbsp;calculations of Value shall be in Dollars, all Loans shall be funded in Dollars and all Obligations shall&nbsp;be repaid in Dollars.  Whenever the phrase "to&nbsp;the best of Borrowers' knowledge" or word
s of similar import relating to the knowledge or the awareness of a Borrower are used in this Agreement or other Loan Documents, such phrase shall mean and refer to the actual knowledge of a Senior Officer of any Borrower.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc102963312"><A NAME="_Toc105998283"><A NAME="_Toc105998693"><A NAME="_Toc105998825"><A NAME="_Toc117052338">SECTION 2.&nbsp;&nbsp;&nbsp;&nbsp;CREDIT FACILITIES</A></A></A></A></A></A></P>
</B><P ALIGN="JUSTIFY"><A NAME="_Toc38346517">Subject to the terms and conditions of, and in reliance upon the representations and warranties made in, this Agreement and the other Loan Documents, Lenders severally agree to the extent and in the manner hereinafter set forth to make their respective shares of the Commitments available to Borrowers in an aggregate amount up to $210,000,000, as set forth hereinbelow:</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc102963313"><A NAME="_Toc105998284"><A NAME="_Toc105998694"><A NAME="_Toc105998826"><A NAME="_Toc117052339">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Revolver Commitments.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">2.1.1&nbsp;&nbsp;&nbsp;<U>Revolver Loans</P>
</U><P ALIGN="JUSTIFY">.  Each Lender agrees, severally to the extent of its Revolver Commitment and not jointly with the other Lenders, upon the terms and subject to the conditions set forth herein, to make Revolver Loans to Borrowers on any Business Day during the period from the Closing Date through the Business Day before the last day of the Term, not&nbsp;to exceed in aggregate principal amount outstanding at any time such Lender's Revolver Commitment at such time, which Revolver Loans may be repaid and reborrowed in accordance with the provisions of this Agreement; <U>provided</U>, <U>however</U>, that Lenders shall have no obligation to Borrowers whatsoever to honor any request for a Revolver Loan on or after the Commitment Termination Date or if at the time of the proposed funding thereof the aggregate principal amount of all of the Revolver Loans then&nbsp;outstanding (including Swingline Loans) and Pending Revolver Loans exceeds, or would exceed after the funding of such Revolver Loan, the Borrowin
g Base.  Each&nbsp;Borrowing of Revolver Loans shall be funded by Lenders on a Pro Rata basis in accordance with their respective Revolver Commitments (except for BofA with respect to Swingline Loans).  The Revolver Loans shall bear interest as set forth in <B>Section 3.1.</B>  Each&nbsp;Revolver Loan shall, at the option of Borrowers, be made or continued as, or converted into, part of one or more Borrowings that, unless specifically provided herein, shall consist of Base Rate Loans or LIBOR&nbsp;Loans.</P>
<P ALIGN="JUSTIFY">2.1.2&nbsp;&nbsp;&nbsp;<U>Out-of-Formula Loans</P>
</U><P ALIGN="JUSTIFY">.  If the unpaid balance of Revolver Loans outstanding at any&nbsp;time should exceed the Borrowing Base at such time (an "Out-of-Formula Condition"), such&nbsp;Revolver&nbsp;Loans shall nevertheless constitute Obligations that are secured by the Collateral and entitled to all&nbsp;of the benefits of the Loan Documents.  In the event that Lenders are willing in their discretion to make Out-of-Formula Loans or are required to do so by <B>Section&nbsp;13.9.4</B> or <B>Section 2.1.6</B>, such Out-of-Formula Loans shall&nbsp;bear interest as provided in <B>Section 3.1.5 </B>and shall be payable <B>on demand</B>, <U>provided</U>, <U>that</U>, any Out-of-Formula Loans made by Lenders under <B>Section 13.9.4</B> or <B>Section 2.1.6</B> shall be payable at the end of the applicable period permitted by Lenders under <B>Section 13.9.4</B>, or <B>on demand</B> if an Event of Default exists.</P>
<P ALIGN="JUSTIFY">2.1.3&nbsp;&nbsp;&nbsp;<U>Use of Proceeds</P>
</U><P ALIGN="JUSTIFY">.  The proceeds of the Revolver Loans shall be used by Borrowers solely for one or more of the following purposes:  (i) to satisfy the Debt owing on the Closing Date to the Prior Lenders; (ii) to pay the fees and transaction expenses associated with the closing of the transactions described herein; (iii) to pay any of the Obligations in accordance with this Agreement; and (iv) to make expenditures for working capital and other lawful corporate purposes of Borrowers to the extent such expenditures are not prohibited by this&nbsp;Agreement or Applicable Law.  In no event may any Revolver Loan proceeds be used by any&nbsp;Borrower (x) to purchase or to carry, or to reduce, retire or refinance any Debt incurred to purchase or carry, any Margin Stock or for any related purpose that violates the provisions of Regulations T, U or X of the&nbsp;Board of Governors, or (y) to fund any operations or finance any investments or activities in, or to make payments to, a Blocked Person.</P>
<P ALIGN="JUSTIFY">2.1.4&nbsp;&nbsp;&nbsp;<U>Revolver Notes</P>
</U><P ALIGN="JUSTIFY">.  The Revolver Loans made by each Lender and interest accruing thereon shall be evidenced by the records of Agent and such Lender and by the Revolver Note payable to such&nbsp;Lender (or the assignee of such Lender), which shall be executed by Borrowers, completed in conformity with this Agreement and delivered to such Lender.  All outstanding principal amounts and accrued interest under the Revolver Notes shall be due and payable as set forth in <B>Section 5.2</B>.</P>
<P ALIGN="JUSTIFY">2.1.5&nbsp;&nbsp;&nbsp;<U>Voluntary Reductions of Revolver Commitments</P>
</U><P ALIGN="JUSTIFY">.  Borrowers shall have the right to permanently reduce the amount of the Revolver Commitments, on a Pro Rata basis for each Lender, at any&nbsp;time and from time to time upon 3 Business Days written notice to Agent of such reduction, which notice shall specify the amount of such reduction, shall be irrevocable once given, and shall be effective on the fourth day after Agent's receipt of such notice.  Agent shall promptly transmit such notice to each Lender.  If on the effective date of any such reduction in the Revolver Commitments and after giving effect thereto an Out-of-Formula Condition exists, then the provisions of <B>Section 5.2.1(iii)</B> shall apply, except that such repayment shall be due immediately upon such effective date without further&nbsp;notice to or demand upon Borrowers.  If&nbsp;the Revolver Commitments are reduced to zero, then such reduction shall&nbsp;be deemed a termination of the&nbsp;Commitments by Borrowers pursuant to <B>Section 6.2.2</B>.  The&nbsp;Revol
ver Commitments, once reduced, may not be reinstated without the written consent of all Lenders.</P>
<P ALIGN="JUSTIFY">2.1.6&nbsp;&nbsp;&nbsp;<U>Agent Advances</U>.  </P>
<P ALIGN="JUSTIFY">Agent shall be authorized, in its discretion, at any time or times that an Event of Default exists or any of the conditions precedent set forth in <B>Section&nbsp;11 </B>have not been satisfied, to make Revolver Loans that are Base Rate Loans in an aggregate amount outstanding at&nbsp;any time not to exceed $10,000,000, but only to the extent that Agent, in the exercise of its sole credit judgment, deems the funding of such Loans (herein called "Agent Advances") to be necessary or desirable (i)&nbsp;to preserve or protect the Collateral or any portion thereof, (ii)&nbsp; to enhance the likelihood, or increase the amount, of repayment of the Obligations or (iii)&nbsp;to pay any other amount chargeable to Borrowers pursuant to the terms of this&nbsp;Agreement, including costs, fees and expenses, all of which Agent Advances shall&nbsp;be deemed part of the Obligations and secured by the Collateral, and shall be treated for all purposes of this Agreement (including <B>Sections&nbsp;5.6.1 </B>a
nd <B>15.4</B>) as advances for the repayment to Agent and Lenders of Extraordinary Expenses; <U>provided</U>,&nbsp;<U>however</U>, that the Required Lenders may at any time revoke Agent's authorization to make any&nbsp;such Agent Advances by written notice to Agent, which shall become effective prospectively upon and after Agent's actual receipt thereof.  Absent such revocation, Agent's determination that the making of an Agent Advance is required for any such purposes shall be conclusive.  Each Lender shall participate in each Agent Advance in an amount equal to its Pro Rata share of the Revolver Commitments.  Notwithstanding the foregoing, the maximum amount of Agent Advances outstanding at any time, when added to the aggregate of Revolver Loans and LC Obligations outstanding at such time, shall not exceed the total of the Revolver Commitments (unless otherwise agreed by the Required Lenders) and shall not exceed 30 days if such Agent Advance constitutes an Out-of-Formula Loan.  The aggregate amount of Lo
ans made pursuant to this <B>Section 2.1.6</B> and <B>Section 13.9.4</B> shall not exceed $10,000,000 in the aggregate at any time.  Nothing in this <B>Section&nbsp;2.1.6 </B>shall be construed to limit in any way the amount of Extraordinary Expenses that may be incurred by Agent and that Borrowers shall be obligated to reimburse to Agent to the extent provided for in the Loan Documents.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346518"><A NAME="_Toc102963314"><A NAME="_Toc105998285"><A NAME="_Toc105998695"><A NAME="_Toc105998827"><A NAME="_Toc117052340">2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Term Loan Commitment</U>.<A NAME="_Toc38346519"><A NAME="_Toc102963315"><A NAME="_Toc105998286"><A NAME="_Toc105998696"><A NAME="_Toc105998828"></A></A></A></A></A></A></P>
</B><P ALIGN="JUSTIFY">2.2.1.&nbsp;&nbsp;&nbsp;<U>Term Loan</U>.  <U>  </P>
</U><P ALIGN="JUSTIFY">Subject to and upon the terms and conditions herein set forth, each Lender severally agrees to make to Borrowers a Term Loan Advance in an amount not to exceed such Lender's Term Loan Commitment.  The Term Loan shall be comprised of Term Loan Advances in the aggregate principal amount of $35,000,000 and shall be funded by Lenders on the Closing Date, concurrently with Lenders' funding of their initial Revolver Loans.  The proceeds of the Term Loan Advances shall be used by Borrowers solely for purposes for which the proceeds of the Revolver Loans are authorized to be used.  The Term Loan Commitment of each Lender shall expire on the funding by such Lender of its Term Loan Advance.  Borrowers shall not be entitled to reborrow any amounts repaid with respect to the Term Loan Advances.  All Term Loan Advances shall bear interest as set forth in <B>Section 3.1</B>, shall initially be Base Rate Loans and shall be repaid as provided in <B>Section 5.3</B>.  Each Lender shall make its Term Loa
n Advance available to Agent in immediately available funds, to such account of Agent as Agent may designate, not later than 12:00 noon on the Closing Date.  After Agent's receipt of the proceeds of such Term Loan Advance, and upon satisfaction of the conditions precedent set forth in <B>Section 11</B>, Agent shall make the proceeds of all such Term Loan Advances available to Borrowers on the Closing Date by transferring same day funds equal to the proceeds of such Term Loan Advances received by Agent to an account designated by Borrowers in writing.</P>
<P ALIGN="JUSTIFY">2.2.2.&nbsp;&nbsp;&nbsp;<U>Term Notes</U>.  </P>
<P ALIGN="JUSTIFY">Borrowers shall execute and deliver to Agent on behalf of each Lender, on the Closing Date, a promissory note substantially in the form of <B><U>Exhibit B</U> </B>attached hereto and made a part hereof (such promissory note, together with any new notes issued pursuant to <B>Section 14.3.2 </B>upon the assignment of any portion of any Lender's Term Loan Advance, being hereinafter referred to collectively as the "Term Notes" and each of such promissory notes being hereinafter referred to individually as a "Term Note"), to evidence such Lender's Term Loan Advance to Borrowers, in the original principal amount equal to the amount of such Lender's Term Loan Commitment.  Each Term Note shall be dated the Closing Date (or the date of the applicable Assignment and Acceptance) and shall provide for payment of the Term Loan Advance evidenced thereby as specified in <B>Section 5.3</B>.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc117052341">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>LC Facility</U>.</A></A></A></A></A></A></P>
</B><P ALIGN="JUSTIFY">2.3.1.&nbsp;&nbsp;&nbsp;<U>Issuance of Letters of Credit</P>
</U><P ALIGN="JUSTIFY">.  Subject to all of the terms and conditions hereof, Issuing Bank agrees to establish the LC Facility pursuant to which, during the period from the date hereof to (but&nbsp;excluding) the 30th day prior to the last day of the Term, Issuing Bank shall issue one or more Letters of Credit on any Borrower's request therefor from time to time, subject to the following terms and conditions:</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">(i)&#9;Each Borrower acknowledges that Issuing Bank's willingness to issue any Letter of Credit is conditioned upon Issuing Bank's receipt of (A) an LC Application with respect to the requested Letter of Credit and (B) such other standard instruments and agreements as Issuing Bank may customarily require for the issuance of a letter of credit of equivalent type and amount as the requested Letter of Credit.  Issuing Bank shall have no obligation to issue any Letter of Credit unless (x) Issuing Bank receives an LC&nbsp;Request and LC Application at least 3 Business Days prior to the date of issuance of a Letter of Credit, and (y) each of the LC Conditions is satisfied on the date of Issuing Bank's receipt of the LC Request and at the time of the requested issuance of a Letter of Credit.  If Issuing Bank shall have received written notice from a Lender on or before the Business Day immediately prior to the date of Issuing Bank's issuance of a Letter of Credit that one or more of the condition
s set forth in <B>Section&nbsp;11.2</B> has not been satisfied, Issuing Bank shall have no obligation to issue the requested Letter of Credit or any other Letter of Credit until such notice is withdrawn in writing by that Lender or until the Required Lenders shall have effectively waived such condition in accordance with this Agreement.  In no event shall Issuing Bank be deemed to have notice or knowledge of any existence of any Default or Event of Default or the failure of any conditions in <B>Section 11.2</B> to be satisfied prior to its receipt of such notice from a Lender.</P>
<P ALIGN="JUSTIFY">(ii)&#9;Letters of Credit may be requested by a Borrower only if they are to be used (a) to support obligations of such Borrower incurred in the Ordinary Course of Business of such Borrower or (b) for such other purposes as Agent may approve from time to time.</P>
<P ALIGN="JUSTIFY">(iii)&#9;Borrowers shall comply with all of the terms and conditions imposed on Borrowers by Issuing Bank that are contained in any LC Application or in&nbsp;any&nbsp;other standard agreement customarily or reasonably required by Issuing Bank in connection with the issuance of any Letter of Credit.  If Issuing Bank shall honor any request for payment under a Letter of Credit, Borrowers shall be jointly and severally obligated to pay to Issuing Bank, in Dollars on the same day as the date on which payment was made by Issuing Bank (the "Reimbursement Date"), an amount equal to the amount paid by Issuing Bank under such Letter of Credit, together with interest from and after the&nbsp;Reimbursement Date until Full Payment is made by Borrowers at the&nbsp;Default Rate for&nbsp;Revolver Loans constituting Base Rate Loans.  Until Issuing Bank has received payment from Borrowers in accordance with the foregoing provisions of this clause (iii), Issuing Bank, in addition to all of its other rights a
nd remedies under this Agreement and any LC Application, shall be fully&nbsp;subrogated to the rights and remedies of each beneficiary under such&nbsp;Letter of Credit whose claims against Borrowers have been discharged with the proceeds of such&nbsp;Letter of Credit.  Whether or not a Borrower submits any Notice of Borrowing to Agent, Borrowers shall be deemed to have requested from Lenders a Borrowing of Base Rate Loans in an&nbsp;amount necessary to pay to Issuing Bank all amounts due Issuing Bank on any Reimbursement Date and each&nbsp;Lender agrees to fund its Pro Rata share of such Borrowing whether or not any Default or Event of Default has occurred or exists, the Commitments have been terminated, the funding of the&nbsp;Borrowing would result in (or increase the amount of) any Out-of-Formula Condition, or any of the conditions set forth in <B>Section 11</B> are not satisfied.</P>
<P ALIGN="JUSTIFY">(iv)&#9;Borrowers assume all risks of the acts, omissions or misuses of any Letter&nbsp;of Credit by the beneficiary thereof.  The obligation of Borrowers to reimburse Issuing Bank for any&nbsp;payment made by Issuing Bank under a Letter of Credit shall be absolute, unconditional, irrevocable and joint and several and shall be paid without regard to any lack of validity or enforceability of any Letter of Credit or the existence of any claim, setoff, defense or other right which Borrowers may have at any time against a beneficiary of any Letter of Credit.  In connection with the issuance of any documentary Letter of Credit, none of Agent, Issuing Bank or any Lender shall be responsible for the existence, character, quality, quantity, condition, packing, value or delivery of any goods purported to be represented by any Documents; any differences or variation in the character, quality, quantity, condition, packing, value or delivery of any goods from that expressed in the Documents; the form,
 validity, sufficiency, accuracy, genuineness or legal effect of any Documents or of any endorsements thereon, even if such Documents should in fact prove to be in any or all respects invalid, insufficient, fraudulent or forged; the time, place, manner or order in which shipment of goods is made; partial or incomplete shipment of, or failure or omission to ship, any or all of the goods referred to in a documentary Letter of Credit or Documents applicable thereto; any deviation from instructions, delay, default or fraud by the shipper and/or any Person in connection with any goods or any shipping or delivery thereof; any breach of contract between the shipper or vendors and a Borrower; errors, omissions, interruptions or delays in transmission or delivery of any messages, by mail, cable, telegraph, telex or otherwise, whether or not they be in cipher, unless such errors, omissions, interruptions or delays are the result of the gross negligence or willful misconduct of Issuing Bank; errors in interpretation of
 technical terms; the misapplication by the beneficiary of any Letter of Credit of the proceeds of any drawing under such Letter of Credit;<B><I> </B></I>or any consequences arising from causes beyond the control of Issuing Bank including any act or omission (whether rightful or wrongful) of any present or future Governmental Authority.  The rights, remedies, powers and privileges of Issuing Bank under this Agreement with respect to Letters of Credit shall be in addition to, and cumulative with, all rights, remedies, powers and privileges of Issuing Bank under any of the LC Documents.  Nothing herein shall be deemed to release Issuing Bank from any liability or obligation that it may have in respect to any Letter of Credit arising out of and directly resulting from its own gross negligence or willful misconduct.</P>
<P ALIGN="JUSTIFY">(v)&#9;No Letter of Credit shall be extended or increased in amount, unless all of the LC Conditions are met as though a new Letter of Credit were being requested and issued.  With respect to any Letter of Credit that contains any "evergreen" or automatic renewal provision, each Lender shall be deemed to have consented to any such extension or renewal, unless any such Lender shall have provided to Agent written notice that it declines to&nbsp;consent to any such extension or renewal at least 30 days prior to the date on which Issuing Bank is entitled to decline to extend or renew the Letter of Credit.  If all of the LC&nbsp;Conditions are met and no Default or Event of Default exists, each Lender shall be deemed to have consented to any such extension or renewal.</P>
<P ALIGN="JUSTIFY">(vi)&#9;Unless otherwise provided in any of the LC Documents, each LC Application and each Letter of Credit shall be subject to the Uniform Customs and Practice for Documentary Credits (1993 Revision), International Chamber of Commerce No. 500, and any amendments or revisions thereto.</P>
<P ALIGN="JUSTIFY">2.3.2.&nbsp;&nbsp;&nbsp;<U>Participations.</P>
</U><P ALIGN="JUSTIFY">(i)&#9;Immediately upon the issuance of any Letter of Credit, each Lender shall be deemed to have irrevocably and unconditionally purchased and received from Issuing Bank, without recourse or warranty, an undivided interest and participation equal to the Pro&nbsp;Rata share of such Lender (a "Participating Lender") in all LC Obligations arising in&nbsp;connection with such Letter of Credit, but in no event greater than an amount which, when added to such Lender's Pro Rata share of all&nbsp;Revolver Loans and LC Obligations then outstanding, exceeds such Lender's Revolver&nbsp;Commitment.</P>
<P ALIGN="JUSTIFY">(ii)&#9;If Issuing Bank makes any payment under a Letter of Credit and Borrowers do not repay or cause to be repaid the amount of such payment on the Reimbursement Date, Issuing Bank&nbsp;shall&nbsp;promptly notify Agent, which shall promptly notify each Participating Lender, of such&nbsp;payment and each Participating Lender shall promptly (and in any event within 1 Business Day after its&nbsp;receipt of notice from Agent) and unconditionally pay to Agent, for the account of Issuing Bank, in&nbsp;immediately available funds, the amount of such Participating Lender's Pro Rata share of such&nbsp;payment, and Agent shall promptly pay such amounts to Issuing Bank.  If a Participating Lender does&nbsp;not make its Pro Rata share of the amount of such payment available to Agent on a timely&nbsp;basis as herein provided, such Participating Lender agrees to pay to Agent for the account of Issuing Bank, forthwith <B>on&nbsp;demand</B>, such amount together with interest thereon at the Federal Fund
s Rate until paid.  The&nbsp;failure of any&nbsp;Participating Lender to make available to Agent for the account of Issuing Bank such&nbsp;Participating Lender's Pro Rata share of the LC Obligations shall not relieve any other Participating Lender of its obligation hereunder to make available to Agent its Pro Rata share of the&nbsp;LC Obligations.  No Participating Lender shall be responsible for the failure of any other Participating Lender to make available to Agent its Pro Rata share of the LC Obligations on the&nbsp;date such payment is&nbsp;to&nbsp;be made.</P>
<P ALIGN="JUSTIFY">(iii)&#9;Whenever Issuing Bank receives a payment on account of the LC Obligations, including any interest thereon, as to which Agent has previously received payments from any&nbsp;Participating Lender for the account of Issuing Bank, Issuing Bank shall promptly pay to each Participating Lender which has funded its&nbsp;participating interest therein, in immediately available funds, an amount equal to such Participating Lender's Pro Rata share thereof.</P>
<P ALIGN="JUSTIFY">(iv)&#9;The obligation of each Participating Lender to make payments to Agent for the account of Issuing Bank in connection with Issuing Bank's payment under a Letter of Credit shall be absolute, unconditional and irrevocable, not subject to any counterclaim, setoff, qualification or exception whatsoever, and shall be made in accordance with the terms and conditions of this Agreement under all circumstances and irrespective of whether or not Borrowers may assert or have any claim for any lack of validity or unenforceability of this Agreement or any of the other Loan Documents; any Borrower's dispute as to its liability for any of the LC Obligations; the existence of any Default or Event of Default; any draft, certificate or other document presented under a Letter of Credit having been determined to be forged, fraudulent, invalid or insufficient in any respect or any statement therein being untrue or inaccurate in any respect; the existence of any setoff or defense any Obligor may have with
 respect to any of the Obligations; or the termination of the&nbsp;Commitments.</P>
<P ALIGN="JUSTIFY">(v)&#9;Neither Issuing Bank nor any of its officers, directors, employees or agents shall&nbsp;be liable to any Participating Lender for any action taken or omitted to be taken under or in&nbsp;connection with any of the LC Documents except as a result of actual gross negligence or willful&nbsp;misconduct on the part of Issuing Bank.  Issuing Bank does not assume any responsibility for any failure or delay in performance or breach by a Borrower or any other Person of its obligations under any of the LC Documents.  Issuing Bank does not make to Participating Lenders any express or implied warranty, representation or guaranty with respect to the Collateral, the LC Documents, or any Obligor.  Issuing Bank shall not be responsible to any Participating Lender for any recitals, statements, information, representations or warranties contained in, or for the execution, validity, genuineness, effectiveness or enforceability of or any of the LC Documents; the validity, genuineness, enforceability, c
ollectibility, value or sufficiency of any of the Collateral or the perfection of any Lien therein; or the assets, liabilities, financial condition, results of operations, business, creditworthiness or legal&nbsp;status of any Obligor or any Account Debtor.  In&nbsp;connection with its&nbsp;administration of and enforcement of rights or remedies under any of the&nbsp;LC&nbsp;Documents, Issuing Bank&nbsp;shall be entitled to act, and shall be fully protected in acting upon, any&nbsp;certification, notice or other communication in whatever form believed by Issuing Bank, in good faith, to be genuine and correct and to have been signed, sent or made by a proper Person.  Issuing Bank may consult with and employ legal counsel, accountants and other experts and to advise it concerning its rights, powers and privileges under the LC Documents and shall be entitled to act upon, and shall be fully protected in any action taken in good faith reliance upon, any advice given by such experts.  Issuing Bank&nbsp;may employ 
agents and attorneys-in-fact in connection with any matter relating to the LC&nbsp;Documents and shall&nbsp;not be liable for the negligence, default or misconduct of any such agents or attorneys-in-fact selected by Issuing Bank with reasonable care.  Issuing Bank shall not have any liability to any&nbsp;Participating Lender by reason of Issuing Bank's refraining to take any action under any of the LC&nbsp;Documents without having first received written instructions from the Required Lenders to take such action.</P>
<P ALIGN="JUSTIFY">(vi)&#9;Upon the request of any Participating Lender, Issuing Bank shall furnish to such Participating Lender copies (to the extent then available to Issuing Bank) of each outstanding Letter of Credit and related LC Documents as may be in the&nbsp;possession of Issuing Bank and reasonably requested from time to time by such&nbsp;Participating Lender.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">2.3.3.&nbsp;&nbsp;&nbsp;<U>Cash Collateral Account</P>
</U><P ALIGN="JUSTIFY">.  If any LC Obligations, whether or not then due or payable, shall for any reason be outstanding (i)&nbsp;on any date that Availability is less than zero, (ii)&nbsp;on or at any time after the Commitment Termination Date, or (iii)&nbsp;on the day that is 5&nbsp;Business Days prior to the last day of the Term, then Borrowers shall, on Issuing Bank's or Agent's request, forthwith pay to Agent, for the account of Issuing Bank, the amount of any LC Obligations that are then due and payable and shall, upon the occurrence of any of the events described in clauses (ii) or (iii) hereinabove, Cash Collateralize all outstanding Letters of Credit.  If any LC Obligations, whether or not then due or payable, shall for any reason be outstanding at any time that an Event of Default exists, then Borrowers shall, on Issuing Bank's or Agent's (acting at the direction of the Required Lenders) request, forthwith pay to Agent, for the account of Issuing Bank, the amount of any LC Obligations that are then
 due and payable and shall Cash Collateralize all outstanding Letters of Credit.  If Borrowers fail to Cash Collateralize any outstanding Letters of Credit on the first Business Day following Agent's or Issuing Bank's demand therefor as provided in the immediately preceding sentences, Lenders&nbsp;may (and shall upon direction of Agent) advance such amount as Revolver Loans (whether or not the Commitment Termination Date has occurred or an Out-of-Formula Condition is created thereby), to be funded to Agent for the account of Borrowers.  Such cash (together with any interest accrued thereon) shall&nbsp;be held by Agent in the Cash Collateral Account and may be invested, in Agent's discretion, in Cash&nbsp;Equivalents.  Each Borrower hereby pledges to Agent and grants to Agent a security interest in, for the benefit of Agent in such&nbsp;capacity and for the Pro Rata benefit of Lenders, all Cash Collateral held in the&nbsp;Cash&nbsp;Collateral Account from time to time and all proceeds thereof, as security for
 the payment of all&nbsp;Obligations (including LC Obligations), whether or not then due or payable.  From time to time after cash is deposited in the Cash&nbsp;Collateral Account, Agent may apply Cash&nbsp;Collateral then held in the Cash Collateral Account to reimburse the Issuing Bank for payments on account of drawings under Letters of Credit for which it has not been reimbursed, and, to the extent not so applied, to the payment of the other LC Obligations.  Neither Borrowers nor any other Person claiming by, through or under or on behalf of Borrowers shall have any right to withdraw any of the Cash&nbsp;Collateral held in the Cash Collateral Account, including any accrued interest, provided that upon termination or expiration of all Letters of Credit and the payment and satisfaction of all of the LC Obligations, any Cash Collateral remaining in the Cash Collateral Account shall be returned to Borrowers unless an Event of Default then exists (in which event Agent may apply such Cash&nbsp;Collateral to th
e payment of any other Obligations outstanding in accordance with the provisions of <B>Section 5.6</B>, with any surplus to be turned over to Borrowers).</P>
<P ALIGN="JUSTIFY">2.3.4&nbsp;&nbsp;&nbsp;<U>Indemnifications.</P><DIR>
<DIR>

</U><P ALIGN="JUSTIFY">(i)&#9;In addition to and without limiting any other indemnity which Borrowers may have to any Indemnitees under any of the Loan Documents, each Borrower hereby agrees to indemnify and defend each of the Indemnitees and to hold each of the Indemnitees harmless from and against any and all actual out-of-pocket losses, claims, damages and expenses which any Indemnitee may suffer, incur or be subject to as a consequence, directly or indirectly, of (a) the issuance of, payment or failure to pay or any performance or failure to perform under any Letter of Credit, (b)&nbsp;any suit, investigation or proceeding as to which Agent or any&nbsp;Lender is or may&nbsp;become a party to as a consequence, directly or indirectly, of the issuance of any&nbsp;Letter of Credit or the payment or failure to pay thereunder or (c) Issuing Bank following any instructions of a Borrower with respect to any Letter of Credit or any Document received by Issuing Bank with reference to any Letter of Credit, in each 
case, unless such losses, claims, damages or expenses result from the gross negligence or willful misconduct of such Indemnitee (including such Indemnitee's officers, directors, employees, agents and attorneys but such defense shall not apply to any other Indemnitees).</P>
<P ALIGN="JUSTIFY">(ii)&#9;Each Participating Lender agrees to indemnify and defend each of the&nbsp;Issuing Bank&nbsp;Indemnitees (to the extent the Issuing Bank Indemnitees are not reimbursed by Borrowers or any&nbsp;other Obligor, but without limiting the indemnification obligations of Borrowers under this Agreement), to the extent of such Lender's Pro Rata share of the Revolver Commitments, from and against any and all Claims which may be imposed on, incurred by or asserted against any of the Issuing Bank Indemnitees in any way related to or arising out of Issuing Bank's administration or enforcement of rights or remedies under any of the LC Documents or any&nbsp;of the&nbsp;transactions contemplated thereby (including costs and expenses which Borrowers are obligated to pay under <B>Section 15.2</B>).</P></DIR>
</DIR>

<P ALIGN="JUSTIFY"><A NAME="_Toc102963316"><A NAME="_Toc105998287"><A NAME="_Toc105998697"><A NAME="_Toc105998829"><A NAME="_Toc117052342">2.4.&nbsp;&nbsp;&nbsp;<B><U>Bank Products</U>.</A></A></A></A></A></B>  </P>
<P ALIGN="JUSTIFY">Borrowers may request any Lender to provide, or to arrange for one or more of its Affiliates to provide, Bank Products, but no Lender shall have any obligation whatsoever to provide, or to arrange for the provision of, any Bank Products.  If Bank Products are provided by an Affiliate of a Lender, Borrowers agree to indemnify and hold Agent and Lenders harmless from and against any and all Claims at any time incurred by Agent or any Lender that arise from any indemnity given to such Affiliates that relate to such Bank Products other than those Claims that arise from Agent's or any such Lender's gross negligence or willful misconduct.  Borrowers acknowledge that obtaining Bank Products from any Lender or any Lender's Affiliate is in the discretion of such Lender or its Affiliates and is subject to all rules and regulations of such Lender and its Affiliates that are applicable to such Bank Products.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346520"><A NAME="_Toc102963317"><A NAME="_Toc105998288"><A NAME="_Toc105998698"><A NAME="_Toc105998830"><A NAME="_Toc117052343">SECTION 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;INTEREST, FEES AND CHARGES</A></A></A></A></A></A></P>
<P ALIGN="JUSTIFY"><A NAME="_Toc38346521"><A NAME="_Toc102963318"><A NAME="_Toc105998289"><A NAME="_Toc105998699"><A NAME="_Toc105998831"><A NAME="_Toc117052344">3.1.&nbsp;&nbsp;&nbsp;<U>Interest.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">3.1.1.&nbsp;&nbsp;&nbsp;<U>Rates of Interest</P>
</U><P ALIGN="JUSTIFY">.  Borrowers agree to pay interest in respect of all unpaid principal amounts of the Revolver Loans from the respective dates such principal amounts are advanced until paid (whether at stated maturity, on acceleration or otherwise) at a rate per annum equal to the applicable rate indicated below:</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">(i)&#9;for Revolver Loans made or outstanding as Base Rate Loans, the&nbsp;Applicable Margin <U>plus</U> the Base Rate in effect from time to time; or</P>
<P ALIGN="JUSTIFY">(ii)&#9;for Revolver Loans made or outstanding as LIBOR Loans, the&nbsp;Applicable Margin <U>plus</U> the relevant Adjusted LIBOR Rate for the applicable Interest Period selected by Borrowers in conformity with this Agreement.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">Borrowers agree to pay interest in respect of all unpaid principal amounts outstanding with respect to Term Loan Advances from the respective dates such principal amounts are advanced until paid (whether at stated maturity, on acceleration, or otherwise) at a rate per annum equal to the applicable rate indicated below:</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">(i)&#9;for any portion of Term Loan Advances made or outstanding as Base Rate Loans, the Applicable Margin <U>plus</U> the Base Rate in effect from time to time; or</P>
<P ALIGN="JUSTIFY">(ii)&#9;for any portion of Term Loan Advances made or outstanding as LIBOR Loans, the Applicable Margin <U>plus</U> the relevant Adjusted LIBOR Rate for the applicable Interest Period selected by Borrowers in conformity with this Agreement.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">Upon determining the Adjusted LIBOR Rate for any Interest Period requested by Borrowers, Agent shall promptly notify Borrowers thereof by telephone and, if so requested by Borrowers, confirm the same in writing.  Such determination shall, absent manifest error, be final, conclusive and binding on all parties and for all purposes.  The applicable rate of interest for all Loans (or portions thereof) bearing interest based upon the Base Rate shall be increased or decreased, as the case may be, by an amount equal to any&nbsp;increase or decrease in the Base Rate, with such adjustments to be effective as of the opening of business on the day that any such change in the Base Rate becomes effective.  Interest on each Loan shall accrue from and including the date on which such Loan is made, converted to a Loan of another Type or continued as a LIBOR&nbsp;Loan to (but excluding) the date of any repayment thereof; <U>provided</U>, <U>however</U>, that, if a Loan is repaid on the same day made, one d
ay's interest shall be paid on such&nbsp;Loan.</P>
<P ALIGN="JUSTIFY">3.1.2.&nbsp;&nbsp;&nbsp;<U>Conversions and Continuations.</P><DIR>
<DIR>

</U><P ALIGN="JUSTIFY">(i)&#9;Borrowers may on any Business Day, subject to the giving of a proper Notice&nbsp;of Conversion/Continuation as hereinafter described, elect (A)&nbsp;to continue all or any part of a LIBOR Loan by selecting a new Interest Period therefor, to commence on the last day of the&nbsp;immediately preceding Interest Period, or (B)&nbsp;to convert all or any part of a Loan of one Type into a Loan of another Type; <U>provided</U>, <U>however</U>, during the period that any Default or Event of Default exists, Agent may (and shall at the direction of the Required Lenders) declare that no Loan may be made or continued as or converted into a LIBOR Loan.  Any conversion of a LIBOR&nbsp;Loan into a Base Rate Loan shall be made on the last day of the Interest Period for such&nbsp;LIBOR Loan.  Any conversion or continuation made with respect to less than the entire&nbsp;outstanding balance of the Loans must be allocated among Lenders on a Pro Rata basis, and the Interest Period for Loans converted
 into or continued as LIBOR&nbsp;Loans shall be coterminous for each Lender.</P>
<P ALIGN="JUSTIFY">(ii)&#9;Whenever Borrowers desire to convert or continue Loans under <B>Section&nbsp;3.1.2(i)</B>, Borrower Representative shall give Agent written notice (or telephonic notice promptly confirmed in writing) substantially in the form of <B><U>Exhibit&nbsp;D</U> </B>(a "Notice of Conversion/Continuation"), signed by an authorized officer of Borrower Representative, at least 1 Business Day before the requested conversion date, in the case of a conversion into Base Rate Loans, and at least 3 Business Days before the requested conversion or continuation date,  in the case of a&nbsp;conversion into or continuation of LIBOR&nbsp;Loans.  Promptly after receipt of a Notice of Conversion/Continuation, Agent shall notify each Lender in writing of the proposed conversion or continuation.  Each such Notice of Conversion/Continuation shall be irrevocable and shall specify the&nbsp;aggregate principal amount of the Loans to be converted or continued, the date of such conversion or continuation (which sh
all be a Business Day) and whether the Loans are being converted into or continued as LIBOR Loans (and, if so, the duration of the Interest Period to be applicable thereto and, in the absence of any specification by Borrowers of the Interest Period, an Interest Period of one month will be deemed to be specified) or Base Rate Loans.  If, upon the expiration of any Interest Period in&nbsp;respect of any LIBOR Loans, Borrowers shall have failed to deliver the Notice of Conversion/Continuation, Borrowers shall be deemed to have elected to convert such LIBOR Loans to Base Rate Loans.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">3.1.3.&nbsp;&nbsp;&nbsp;<U>Interest Periods</P>
</U><P ALIGN="JUSTIFY">.  In connection with the making or continuation of, or conversion into, each Borrowing of LIBOR Loans, Borrowers shall select an interest period (each an "Interest Period") to be applicable to such LIBOR Loan, which interest period shall consist of 1, 2, 3 or 6 months and shall commence on the date such LIBOR Loan is made; <U>provided</U>,&nbsp;<U>however</U>, that:</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">(i)&#9;the initial Interest Period for a LIBOR Loan shall commence on the date of such Borrowing (including the date of any conversion from a Loan of another Type) and each Interest Period occurring thereafter in respect of such Revolver Loan shall commence on the date on which the next preceding Interest Period expires;</P>
<P ALIGN="JUSTIFY">(ii)&#9;if any Interest Period would otherwise expire on a day that is not a&nbsp;Business Day, such Interest Period shall expire on the next succeeding Business Day, provided that, if&nbsp;any&nbsp;Interest Period in respect of LIBOR Loans would otherwise expire on a day that is&nbsp;not a&nbsp;Business&nbsp;Day but is a day of the month after which no further Business Day occurs in such&nbsp;month, such Interest Period shall expire on the immediately preceding Business Day;</P>
<P ALIGN="JUSTIFY">(iii)&#9;any Interest Period that begins on a day for which there is no numerically corresponding day in the calendar month at the end of such Interest Period shall expire on the&nbsp;last&nbsp;Business Day of such calendar month; and</P>
<P ALIGN="JUSTIFY">(iv)&#9;no Interest Period shall extend beyond the last day of the Term.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">3.1.4.&nbsp;&nbsp;&nbsp;<U>Interest Rate Not Ascertainable</P>
</U><P ALIGN="JUSTIFY">.  If Agent shall reasonably determine (which determination shall, absent manifest error, be final, conclusive and binding upon all parties) that on any date for determining the&nbsp;Adjusted LIBOR Rate for any Interest Period, by reason of any changes arising after the date of this&nbsp;Agreement affecting the London interbank market or any Lender's position in such market, adequate and fair means do not exist for ascertaining the applicable interest rate on the basis provided for in the&nbsp;definition of Adjusted LIBOR Rate, then, and in any such event, Agent shall forthwith give notice (by&nbsp;telephone promptly confirmed in writing) to Borrowers of such determination.  Until Agent notifies Borrowers that the&nbsp;circumstances giving rise to the suspension described herein no longer exist, the obligation of Lenders to&nbsp;make LIBOR Loans shall be suspended, and such affected Loans then outstanding shall, at the end of the&nbsp;then applicable Interest Period or at such earlier 
time as may be required by Applicable Law, bear the same&nbsp;interest as Base Rate Loans.</P>
<P ALIGN="JUSTIFY">3.1.5.&nbsp;&nbsp;&nbsp;<U>Default Rate of Interest</P>
</U><P ALIGN="JUSTIFY">.  Borrowers shall pay interest at a rate per annum equal to the Default&nbsp;Rate (i)&nbsp;with respect to the principal amount of any portion of the Obligations (and, to the extent permitted by Applicable Law, all past due interest) that is not paid on the due date thereof (whether due at stated maturity, <B>on demand</B>, upon acceleration or otherwise) until Full Payment; (ii)&nbsp;with respect to the principal amount of all of the Obligations (and, to the extent permitted by Applicable Law, all past due interest) upon the earlier to occur of (x)&nbsp;Borrower Representative's receipt of notice from Agent of the Required Lenders' election to charge the Default Rate based upon the existence of any Event of Default (which notice Agent shall send only with the consent or at the direction of the Required Lenders), whether or not acceleration or demand for payment of the Obligations has been made, or (y)&nbsp;the commencement by or against any Borrower of an Insolvency Proceeding whethe
r or not under the circumstances described in clauses (i) or (ii) hereof Lenders elect to accelerate the maturity or demand payment of any of the Obligations; and (iii)&nbsp;with respect to the principal amount of any Out-of-Formula Loans (unless otherwise agreed in writing by the Required Lenders), whether or not demand for payment thereof has been made by Agent.  To the fullest extent permitted by Applicable Law, the Default Rate shall apply and accrue on any judgment entered with respect to any of the Obligations and to the unpaid principal amount of the Obligations during any Insolvency Proceeding of a Borrower.  Each Borrower acknowledges that the cost and expense to Agent and each Lender attendant upon the occurrence of an Event of Default are difficult to ascertain or estimate and that the Default Rate is a fair and reasonable estimate to compensate Agent and Lenders for such added cost&nbsp;and expense.  Interest accrued at the Default Rate shall be due and payable <B>on demand</B>.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346522"><A NAME="_Toc102963319"><A NAME="_Toc105998290"><A NAME="_Toc105998700"><A NAME="_Toc105998832"><A NAME="_Toc117052345">3.2.&nbsp;&nbsp;&nbsp;<U>Fees</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.  </B>In consideration of Lenders' establishment of the Commitments in favor of Borrowers, and Agent's agreement to serve as collateral and administrative agent hereunder, Borrowers jointly and severally agree to pay the following fees:</P>
<P ALIGN="JUSTIFY">3.2.1.&nbsp;&nbsp;&nbsp;<U>Fee Letter</P>
</U><P ALIGN="JUSTIFY">.  Borrowers shall be jointly and severally obligated to pay to Agent such fees as are required by the Fee Letter on the dates set forth therein.</P>
<P ALIGN="JUSTIFY">3.2.2.&nbsp;&nbsp;&nbsp;<U>Unused Line Fee</P>
</U><P ALIGN="JUSTIFY">.  Borrowers shall be jointly and severally obligated to pay to Agent for the Pro Rata benefit of Lenders a fee (the "Unused Line Fee") equal to the Applicable Margin (for the Unused Line Fee) of the amount by which the Average Revolver Loan Balance for any quarter (or portion thereof that the Commitments are in effect) is less than the aggregate Revolver Commitments, such Unused Line Fee to be paid quarterly, in arrears, on the first day of each calendar quarter and on the Commitment Termination Date; <U>provided</U>, <U>however</U>, that if an Event of Default exists and the Default Rate is then in effect, then such Unused Line Fees shall be paid on a monthly basis, on the first day of each calendar month.</P>
<P ALIGN="JUSTIFY">3.2.3.&nbsp;&nbsp;&nbsp;<U>LC Facility Fees</P>
</U><P ALIGN="JUSTIFY">.  Borrowers shall be jointly and severally obligated to pay:  (a)(i) to Agent for the Pro Rata account of each Lender for all Letters of Credit, the Applicable Margin in effect for Revolver Loans that are LIBOR Loans on a per annum basis based on the average amount available to be drawn under Letters of Credit outstanding and all Letters of Credit that are paid or expire during the period of measurement, payable quarterly, in arrears, on the first day of each calendar quarter; (ii) to Issuing Bank for its own account a Letter of Credit fronting fee of 0.125% per annum based on the average amount available to be drawn under all Letters of Credit outstanding and all Letters of Credit that are paid or expire during the period of measurement, payable quarterly, in arrears, on the first Business Day of the following calendar quarter; and (iii) to Issuing Bank for its own account all customary charges associated with the issuance, amending, negotiating, payment, processing and administratio
n of all Letters of Credit; <U>provided</U>, <U>however</U>, that if an Event of Default exists and the Default Rate is then in effect, then such fees and charges shall be paid on a monthly basis, on the first day of each calendar month.  All Letter of Credit fees that are expressed as a percentage shall be increased to a percentage that is 2% greater than the percentage that would otherwise be applicable to LIBOR Loans when the Default Rate is in effect.</P>
<P ALIGN="JUSTIFY">3.2.4.&nbsp;&nbsp;&nbsp;<U>Audit and Appraisal Fees and Expenses</P>
</U><P ALIGN="JUSTIFY">.  Borrowers shall reimburse Agent for all&nbsp;reasonable costs and expenses incurred by Agent (including standard fees charged by Agent's internal appraisal department) in connection with (i) examinations and reviews of any Obligor's books and records, (A) up to 3&nbsp;times per Loan Year for any and all such examinations and reviews unless a Default or Event of Default exists (in which event, there shall be no limit on the number of examinations and reviews for which Borrowers shall be obligated to reimburse Agent) and (B) up to 2 times per Loan Year if no Restrictive Trigger Event has occurred and is continuing, and shall pay to Agent the standard amount charged by Agent per day ($850&nbsp;per day as of the Closing Date) <U>plus</U> reasonable out-of-pocket expenses for each day that an employee or agent of Agent shall be engaged in an examination or review of any Obligor's books and records under this clause (i), and (ii)&nbsp;appraisals of Inventory no more frequently than 2 time
s per Loan Year, unless a Default or Event of Default exists (in which event, there shall be no limit on the number of Inventory appraisals for which Borrowers shall be obligated to reimburse Agent).  If after the occurrence of a Restrictive Trigger Event, Availability is at least $25,000,000 for 90 consecutive days and no Event of Default exists, then as soon as practicable but in any event within 1 Business Day thereafter (the "Audit Spring-Back Date"), Agent will not require such examinations and reviews more frequently than 2 times per Loan Year unless another Restrictive Trigger Event occurs.  If a Restrictive Trigger Event has occurred as a result of an Event of Default and not as a result of the failure of Borrowers to meet the Availability or Average Availability requirements, and Agent (or to the extent required by this Agreement, all Lenders or Required Lenders) waive the Event of Default in writing, then the Audit Spring-Back Date shall occur on the date of the waiver in writing of such Event of D
efault.  The foregoing shall  not be construed to limit Agent's right to conduct audits as provided in <B>Section 10.1.1</B> (but shall limit Borrowers' obligation to reimburse Agent and Lenders for any such audit) or as provided in the definition of Permitted Acquisitions or to otherwise obtain appraisals of the Collateral at the expense of Agent and Lenders.</P>
<P ALIGN="JUSTIFY">3.2.5.&nbsp;&nbsp;&nbsp;<U>General Provisions</P>
</U><P ALIGN="JUSTIFY">.  All fees shall be fully earned by the identified recipient thereof pursuant to the foregoing provisions of this Agreement on the due date thereof (and, in the case of Letters of Credit, upon each issuance, renewal or extension of such Letter of Credit) and, except as otherwise set forth herein or required by Applicable Law, shall not be subject to rebate, refund or proration.  All fees provided for in <B>Section 3.2</B> are and shall be deemed to be compensation for services and are not, and shall&nbsp;not be deemed to be, interest or any other charge for the use, forbearance or detention of money.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346523"><A NAME="_Toc102963320"><A NAME="_Toc105998291"><A NAME="_Toc105998701"><A NAME="_Toc105998833"><A NAME="_Toc117052346">3.3.&nbsp;&nbsp;&nbsp;<U>Computation of Interest and Fees</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  All fees and other charges provided for in this Agreement that are calculated as a per annum percentage of any amount and all interest shall be calculated daily and shall&nbsp;be computed on the actual number of days elapsed over a year of 360 days (except 365/366 days for Base Rate Loans).  Each determination by Agent of interest and fees hereunder shall be presumptive evidence of the correctness of such interest and fees.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346524"><A NAME="_Toc102963321"><A NAME="_Toc105998292"><A NAME="_Toc105998702"><A NAME="_Toc105998834"><A NAME="_Toc117052347">3.4.&nbsp;&nbsp;&nbsp;<U>Reimbursement Obligations.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">3.4.1&nbsp;&nbsp;&nbsp;Borrowers shall reimburse Agent and Lenders for any Extraordinary Expenses, on the sooner to occur of 10 Business Days after Agent's demand therefor or Agent's receipt of any proceeds of Collateral in connection with any Enforcement Action (subject to the provisions of <B>Section 5.6</B> with respect to the application of any proceeds of Collateral).  Borrowers also shall reimburse Agent for all reasonable accounting, appraisal and consulting fees, and reasonable attorney's fees and out-of-pocket expenses of one counsel to Agent (and local counsels as determined by Agent) and other reasonable fees and expenses suffered or incurred by Agent in connection with: (i) the negotiation and preparation of any of the Loan&nbsp;Documents, any&nbsp;amendment or modification thereto; (ii) the administration of the Loan&nbsp;Documents and the transactions contemplated thereby; (iii)&nbsp;action taken to perfect or maintain the perfection or priority of any of Agent's Lien
s with respect to any of the Collateral; (iv)&nbsp;any inspection of or audits conducted by Agent with respect to any Obligor's books and records or any of the&nbsp;Collateral (subject to the limitations set forth in <B>Section 3.2.4</B> hereof); and (v)&nbsp;any effort by Agent to verify or appraise any of the Collateral (subject to the limitations set forth in <B>Section 3.2.4</B>).  All amounts chargeable to or reimbursable Borrowers under this <B>Section 3.4</B> shall constitute Obligations that are secured by all of the Collateral and if not sooner paid, shall be payable to Agent within 10 Business Days after demand by Agent.  Borrowers shall also reimburse Agent for reasonable expenses incurred by Agent in its administration of any of the&nbsp;Collateral to the extent and in the&nbsp;manner provided in <B>Section&nbsp;8</B> or in any of the other Loan Documents.  The foregoing shall be in&nbsp;addition to, and shall not be construed to limit, any other provision of any of the Loan Documents regarding t
he indemnification or reimbursement by Borrowers of Claims suffered or incurred by Agent or any Lender.</P>
<P ALIGN="JUSTIFY">3.4.2.&nbsp;&nbsp;&nbsp;If at any time Agent or (with the prior consent of Agent) any Lender shall agree to&nbsp;indemnify any Person against losses or damages that such Person may suffer or incur in its dealings or transactions with Borrowers, or shall guarantee or otherwise assure payment of any liability or obligation of Borrowers to such Person, or otherwise shall provide assurances of Borrowers' payment or performance under any&nbsp;agreement with such Person, including indemnities, guaranties or other assurances of payment or performance given by Agent or any Lender with respect to Banking Relationship Debt, then the Contingent Obligation of Agent or any&nbsp;Lender providing any such indemnity, guaranty or other assurance of payment or performance, together with any payment made or liability incurred by Agent or any Lender in connection therewith, shall&nbsp;constitute Obligations that are secured by the Collateral and Borrowers shall repay, within 10 Business Days, any&nbsp;amount 
so paid or any liability incurred by Agent or any Lender in&nbsp;connection with any such indemnity, guaranty or assurance (other than liabilities resulting from Agent's or such Lender's gross negligence or willful misconduct).  Nothing&nbsp;herein shall be construed to impose upon Agent or any Lender any obligation to provide any&nbsp;such indemnity, guaranty or assurance.  The&nbsp;foregoing agreement of Borrowers shall apply whether or not such indemnity, guaranty or assurance is in writing or oral and regardless of any Borrower's knowledge of the existence thereof, shall survive termination of the Commitments and Full Payment of the Obligations and any other provisions of the Loan Documents regarding reimbursement or indemnification by Borrowers of Claims suffered or incurred by Agent or any Lender.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346525"><A NAME="_Toc102963322"><A NAME="_Toc105998293"><A NAME="_Toc105998703"><A NAME="_Toc105998835"><A NAME="_Toc117052348">3.5.&nbsp;&nbsp;&nbsp;<U>Bank Charges</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Borrowers shall pay to Agent, <B>on demand</B>, any and all fees, costs or expenses which Agent pays to a bank or other similar institution (including any fees paid by Agent or any&nbsp;Lender to any Participant) arising out of or in connection with (i)&nbsp;the forwarding to a Borrower or any other Person on behalf of Borrower by Agent of proceeds of Loans made by Lenders to a Borrower pursuant to this Agreement and (ii)&nbsp;the depositing for collection by Agent of any Payment Item received or delivered to Agent on account of the Obligations.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346526"><A NAME="_Toc102963323"><A NAME="_Toc105998294"><A NAME="_Toc105998704"><A NAME="_Toc105998836"><A NAME="_Toc117052349">3.6.&nbsp;&nbsp;&nbsp;<U>Illegality</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Notwithstanding anything to the contrary contained elsewhere in this&nbsp;Agreement, if (i)&nbsp;any change in any law or regulation or in the interpretation thereof after the Closing Date by any Governmental Authority charged with the administration thereof shall make it unlawful for a Lender to make or maintain a LIBOR Loan or to give effect to its obligations as contemplated hereby with respect to a LIBOR Loan or (ii)&nbsp;at any time such Lender determines that the making or continuance of any LIBOR Loan has become impracticable as a result of a contingency occurring after the date hereof which adversely affects the&nbsp;London interbank market or the&nbsp;position of such Lender in such market, then such Lender shall give after such determination Agent and Borrowers notice thereof and may thereafter (1)&nbsp;declare that LIBOR Loans will not thereafter be made by such Lender, whereupon any request by a Borrower for a LIBOR Loan from such Lender shall be deemed a request for
 a Base Rate Loan unless such Lender's declaration shall be subsequently withdrawn (which declaration shall be withdrawn promptly after the&nbsp;cessation of the circumstances described in clause (i) or (ii) above); and (2) require that all outstanding LIBOR Loans made by such Lender be converted to Base Rate Loans, under&nbsp;the circumstances of clause (i) or (ii) of this <B>Section&nbsp;3.6</B> insofar as such Lender determines the continuance of LIBOR Loans to be impracticable, in which event all such LIBOR Loans of such Lender shall be converted automatically to Base Rate Loans as of the date of any Borrower's receipt of the aforesaid&nbsp;notice from such Lender.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc99510185"><A NAME="_Toc102963324"><A NAME="_Toc105998295"><A NAME="_Toc105998705"><A NAME="_Toc105998837"><A NAME="_Toc117052350">3.7.&nbsp;&nbsp;&nbsp;<U>Increased Costs</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  If, by reason of (a)&nbsp;the introduction after the date hereof of or any change (including any change by way of imposition or increase of Statutory Reserves or other reserve requirements) in or in the interpretation of any law or regulation, or (b)&nbsp;the compliance with any guideline or request from any central bank or other Governmental Authority or quasi-Governmental Authority exercising control over banks or financial institutions generally (whether or not having the force of law) made after the date hereof (any such event a "Change in Law"):</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">(i)&#9;any Lender shall be subject after the date hereof to any Tax, duty or other&nbsp;charge with respect to any LIBOR Loan or Letter of Credit or its obligation to make LIBOR Loans or to issue Letters of Credit or participate in the LC Obligations arising from the issuance of Letters of Credit, or a change shall result in the basis of taxation of payment to any Lender of the principal of or interest on its&nbsp;LIBOR&nbsp;Loans or its obligation to make LIBOR Loans, issue Letters of Credit or participate in the LC Obligations arising from the issuance of Letters of Credit (except for changes in the rate of Tax on the&nbsp;overall net income or gross receipts or franchise tax of such Lender imposed by the jurisdiction in which such&nbsp;Lender's principal executive office is located); or</P>
<P ALIGN="JUSTIFY">(ii)&#9;any reserve (including any imposed by the Board of Governors), special deposits or similar requirement against assets of, deposits with or for the account of, or credit extended by, any Lender shall be imposed or deemed applicable or any other condition affecting its LIBOR Loans or Letters of Credit or its obligation to make LIBOR Loans or to issue Letters of Credit or participate in the LC Obligations arising from the issuance of Letters of Credit shall be imposed on such Lender or the London interbank&nbsp;market;</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">and as a result thereof there shall be any increase in the cost to such Lender in any material amount in excess of those incurred by similarly situated Lenders of agreeing to make or making, funding or maintaining LIBOR Loans or issuing Letters of Credit (except to the extent already included in the determination of the applicable Adjusted LIBOR Rate for LIBOR Loans), or there shall be a reduction in any material respect in the amount received or receivable by such Lender, then such Lender shall, promptly after determining the existence or amount of any&nbsp;such increased costs for which such Lender seeks payment hereunder, give any Borrower notice thereof and Borrowers shall from time to time, upon written notice from and demand by such Lender setting forth in reasonable detail the manner in which such amount was determined (with a copy of such&nbsp;notice and demand to Agent), pay to Agent for the account of such Lender, within 10&nbsp;Business Days after the date specified in such noti
ce and demand, an additional amount sufficient to indemnify such Lender against such increased costs.  A certificate as to the amount of such&nbsp;increased costs, submitted to Borrowers by such&nbsp;Lender, shall be final, conclusive and binding for all purposes, absent manifest error.</P>
<P ALIGN="JUSTIFY">If any Lender shall advise Agent at any time that, because of the circumstances described hereinabove in this <B>Section 3.7</B> or any other circumstances arising after the date of this Agreement affecting such Lender or the London interbank market or such Lender's position in such market, the&nbsp;Adjusted LIBOR Rate, as&nbsp;determined by Agent, will not adequately and fairly reflect the cost to such&nbsp;Lender of funding LIBOR Loans or issuing Letters of Credit, then, and in any such event:</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">(i)&#9;Agent shall forthwith give notice (by telephone confirmed promptly in writing) to Borrowers and Lenders of such event;</P>
<P ALIGN="JUSTIFY">(ii)&#9;Borrowers' right to request and such Lender's obligation to make LIBOR Loans or to issue Letters of Credit or participate in the LC Obligations arising from the issuance of Letters of Credit shall be immediately suspended and Borrowers' right to continue a LIBOR Loan as such beyond the then applicable Interest Period or to request a Letter of Credit shall also be suspended, until each condition giving rise to such suspension no longer exists; and</P>
<P ALIGN="JUSTIFY">(iii)&#9;such Lender shall make a Base Rate Loan as part of the requested Borrowing of LIBOR Loans, which Base Rate Loan shall, for all purposes, be considered part of such Borrowing.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">For purposes of this <B>Section&nbsp;3.7</B>, all references to a Lender shall be deemed to include any bank holding company or bank parent of such Lender.  If any Lender provides notice that, due to the circumstances described in this <B>Section 3.7</B>, the Adjusted LIBOR Rate will not adequately and fairly reflect the cost to such Lender of funding LIBOR Loans or participating in LC Obligations arising from the issuance of Letters of Credit, then such Lender may be replaced pursuant to the provisions of <B>Section 13.17</B>.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc99510186"><A NAME="_Toc102963325"><A NAME="_Toc105998296"><A NAME="_Toc105998706"><A NAME="_Toc105998838"><A NAME="_Toc117052351">3.8.&nbsp;&nbsp;&nbsp;<U>Capital Adequacy</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  If any Lender determines that (i) the introduction after the date hereof of any Capital Adequacy Regulation, (ii) any change in any Capital Adequacy Regulation after the date hereof, (iii) any change in the interpretation or administration of any Capital Adequacy Regulation by any central bank or other Governmental Authority charged with the interpretation or administration thereof, or (iv) compliance by such Lender or any corporation or other entity controlling such Lender with any Capital Adequacy Regulation, after the date hereof affects or would affect the amount of capital required or expected to be maintained by such Lender or any Person controlling such Lender and (taking into consideration such Lender's or such corporation's or other entity's policies with respect to capital adequacy) determines that the amount of such capital is increased as a consequence of its Commitments, loans, credits or obligations under this Agreement to a level below that which such Lender or su
ch Lender's holding company would have achieved but for such change in law, then:  (a) Agent shall promptly, after its receipt of a certificate from such Lender setting forth such Lender's determination of such occurrence, give notice thereof to Borrowers and Lenders; and (b) Borrowers shall pay to Agent, for the account of such Lender, as an additional fee from time to time, <B>on demand</B>, such amount as such Lender certifies in reasonable detail to be the amount reasonably calculated to compensate such Lender for such reduction.  A certificate of such Lender claiming entitlement to compensation as set forth above will be conclusive in the absence of manifest error.  Such certificate will set forth the nature of the occurrence giving rise to such compensation, the additional amount or amounts to be paid to such Lender (including the basis for such Lender's determination of such amount), and the method by which such amounts were determined, all in reasonable detail.  In determining such amount, such Lende
r may use any reasonable averaging and attribution method.  For purposes of this <B>Section 3.8</B> all references to a Lender shall be deemed to include any bank holding company or bank parent of such Lender.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc102963326"><A NAME="_Toc105998297"><A NAME="_Toc105998707"><A NAME="_Toc105998839"><A NAME="_Toc117052352"><A NAME="_Toc38346529">3.9.&nbsp;&nbsp;&nbsp;<U>Mitigation</U>.</A></A></A></A></A></P>
</B><P ALIGN="JUSTIFY"><A NAME="_Toc44837420"><A NAME="_Toc44837545">Each Lender agrees that, with reasonable promptness after such Lender becomes aware that such Lender is entitled to receive payments under <B>Sections 3.6, 3.7 or 3.8</B>, or is or has become subject to U.S. withholding taxes payable by any Borrower in respect of its Loans, it will, to the extent not inconsistent with any internal policy of such Lender or any applicable legal or regulatory restriction, (i) use all reasonable efforts to make, fund or maintain the Commitment of such Lender or the Loans of such Lender through another lending office of such Lender or (ii) take such other reasonable measures, if, as a result thereof, the circumstances which would relieve Borrowers from their obligations to pay such additional amounts (or reduce the amount of such payments), or such withholding taxes would be reduced, and if the making, funding or maintaining of such Commitment or Loans through such other lending office or in accordance with such
 other measures, as the case may be, would not otherwise adversely affect such Commitment or Loans or the interests of such Lender.</A></A>  </P>
<P ALIGN="JUSTIFY">Failure or delay on the part of any Lender or any Issuing Bank to demand compensation pursuant to <B>Sections 3.7, 3.8 or 3.9</B> shall not constitute a waiver of such Lender's right to demand such compensation, provided that Borrowers shall not be required to compensate a Lender pursuant to any such Section for any increased costs or reductions incurred more than 120 days prior to the date that such Lender notifies the Borrowers of the change in law giving rise to such increased costs or reductions and of such Lender's intention to claim compensation therefor, and provided further that, if the change in law giving rise to such increased costs or reductions is retroactive, then the 120 day period referred to above shall be extended to include the period of retroactive effect thereof.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc99510188"><A NAME="_Toc102963327"><A NAME="_Toc105998298"><A NAME="_Toc105998708"><A NAME="_Toc105998840"><A NAME="_Toc117052353">3.10.&nbsp;&nbsp;&nbsp;<U>Funding Losses</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  If for any reason (other than due to a default by a Lender or as a result of a Lender's refusal to honor a LIBOR Loan request due to circumstances described in this Agreement) a Borrowing of, or conversion to or continuation of, LIBOR Loans does not occur on the date specified therefor in a Notice of Borrowing or Notice of Conversion/Continuation (whether or not withdrawn), or if any&nbsp;repayment (including any conversions pursuant to <B>Section 3.1.2</B>) of any of its LIBOR Loans occurs on a date that is not the last day of an Interest Period applicable thereto, or if for any reason Borrowers default in their obligation to repay LIBOR Loans when required by the terms of this Agreement, then Borrowers shall be jointly and severally obligated to pay to each Lender an amount equal to all losses and expenses which such Lender may sustain or incur as a consequence thereof, including any such loss or expense arising from the liquidation or redeployment of funds obtained by it to m
aintain its LIBOR Loans or from fees payable to terminate the deposits from which such funds were obtained.  Borrowers shall pay all such amounts due to any Lender upon presentation by such Lender of a statement setting forth the amount and such Lender's calculation thereof in reasonable detail, which statement shall be deemed true and correct absent manifest error.  For purposes of this <B>Section&nbsp;3.10</B>, all references to a Lender shall be deemed to include any bank holding company or bank parent of such Lender.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346530"><A NAME="_Toc102963328"><A NAME="_Toc105998299"><A NAME="_Toc105998709"><A NAME="_Toc105998841"><A NAME="_Toc117052354"></A>3.11.&nbsp;&nbsp;&nbsp;<U>Maximum Interest</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Regardless of any provision contained in any of the Loan&nbsp;Documents, in no contingency or event whatsoever shall the aggregate of all amounts that are contracted for, charged or received by Agent and Lenders pursuant to the terms of this Agreement or any&nbsp;of the other Loan Documents and that are deemed interest under Applicable Law exceed the highest&nbsp;rate permissible under any Applicable Law (including, to the extent applicable, 12 U.S.C.Section85).  No agreements, conditions, provisions or stipulations contained in this Agreement or any of the other&nbsp;Loan Documents or the exercise by Agent of the right to accelerate the payment or the maturity of all&nbsp;or any portion of the Obligations, or the exercise of any&nbsp;option whatsoever contained in any of the Loan&nbsp;Documents, or the prepayment by Borrowers of any of the Obligations, or the occurrence of any&nbsp;contingency whatsoever, shall entitle Agent or any Lender to charge or receive in any event, inte
rest or any charges, amounts, premiums or fees deemed interest by Applicable Law (such interest, charges, amounts, premiums and fees referred to herein collectively as "Interest") in excess of the Maximum Rate and in no event shall Borrowers be obligated to pay Interest exceeding such Maximum Rate, and all&nbsp;agreements, conditions or stipulations, if any, which&nbsp;may in any&nbsp;event or contingency whatsoever operate to bind, obligate or compel Borrowers to pay Interest exceeding the Maximum Rate shall be without binding force or effect, at law or in equity, to the extent only of the excess of Interest over such Maximum Rate.  If any Interest is charged or received with respect to the Obligations in excess of the&nbsp;Maximum Rate ("Excess"), Borrowers stipulate that any such charge or receipt shall&nbsp;be the result of an accident and bona fide error, and such Excess, to the extent received, shall&nbsp;be applied first to reduce the principal of such Obligations and the balance, if any, returned to 
Borrowers, it&nbsp;being the intent of the parties hereto not to enter into a usurious or otherwise illegal relationship.  Each Borrower recognizes that, with fluctuations in the rates of interest set forth in <B>Section&nbsp;3.1.1</B>, and the Maximum Rate, such an unintentional result could inadvertently occur.  All&nbsp;monies paid to Agent or any Lender hereunder or under any of the other Loan Documents, whether at maturity or by prepayment, shall be subject to any rebate of unearned Interest as and to the extent required by Applicable Law.  By the execution of this Agreement, each Borrower covenants that (i)&nbsp;the credit or return of any Excess shall constitute the acceptance by such Borrower of such Excess, and (ii)&nbsp;such Borrower shall&nbsp;not seek or pursue any other remedy, legal or equitable, against Agent or any Lender, based in whole or in part upon contracting for, charging or receiving any Interest in excess of the Maximum Rate.  For&nbsp;the purpose of determining whether or not any Ex
cess has been contracted for, charged or received by Agent or any Lender, all Interest at any time contracted for, charged or received from Borrowers in connection with any of the Loan&nbsp;Documents shall, to the extent permitted by Applicable Law, be amortized, prorated, allocated and spread in equal parts throughout the full&nbsp;term of the Obligations.  Borrowers, Agent and Lenders shall, to the maximum extent permitted under Applicable Law, (i)&nbsp;characterize any non-principal payment as an expense, fee or premium rather than as Interest and (ii)&nbsp;exclude voluntary prepayments and the effects thereof.  The provisions of this <B>Section&nbsp;3.11</B> shall be deemed to be incorporated into every Loan&nbsp;Document (whether or not any&nbsp;provision of this Section is referred to therein).  All such Loan&nbsp;Documents and communications relating to any Interest owed by Borrowers and all figures set forth therein shall, for the sole purpose of computing the&nbsp;extent of Obligations, be automatic
ally recomputed by Borrowers, and by any court considering the same, to give effect to the&nbsp;adjustments or credits required by this <B>Section&nbsp;3.11</B>.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346531"><A NAME="_Toc102963329"><A NAME="_Toc105998300"><A NAME="_Toc105998710"><A NAME="_Toc105998842"><A NAME="_Toc117052355">SECTION 4.&nbsp;&nbsp;&nbsp;&nbsp;LOAN ADMINISTRATION</A></A></A></A></A></A></P>
<P ALIGN="JUSTIFY"><A NAME="_Toc38346532"><A NAME="_Toc102963330"><A NAME="_Toc105998301"><A NAME="_Toc105998711"><A NAME="_Toc105998843"><A NAME="_Toc117052356">4.1.&nbsp;&nbsp;&nbsp;<U>Manner of Borrowing and Funding Revolver Loans</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Borrowings under the Commitments established pursuant to<B> Section 2.1</B> shall be made and funded as follows:</P>
<P ALIGN="JUSTIFY">4.1.1.&nbsp;&nbsp;&nbsp;<U>Notice of Borrowing.</P><DIR>
<DIR>

</U><P ALIGN="JUSTIFY">(i)&#9;Whenever Borrowers desire to make a Borrowing under <B>Section&nbsp;2.1</B>  (other than a Borrowing resulting from a conversion or continuation pursuant to <B>Section&nbsp;3.1.2</B>), Borrowers shall give Agent prior written notice (or telephonic notice promptly confirmed in writing) of such Borrowing request (a "Notice of Borrowing"), which shall&nbsp;be in the&nbsp;form of <B><U>Exhibit&nbsp;E</B></U> annexed hereto and signed by an authorized officer of Borrower Representative.  Such&nbsp;Notice&nbsp;of Borrowing shall be given by Borrower Representative no later than 12:00 noon at the office designated by Agent from time to time (a) on the Business Day of the requested funding date of such&nbsp;Borrowing, in the case of Base Rate Loans, and (b) at least 3 Business Days prior to the&nbsp;requested funding date of such Borrowing, in the case of LIBOR Loans.  Notices received after 12:00 noon shall be deemed received on the next Business Day.  Each&nbsp;Notice of Borrowing (or
 telephonic notice thereof) shall be irrevocable and shall&nbsp;specify (a)&nbsp;the principal amount of the Borrowing, (b) the date of Borrowing (which shall be a Business Day), (c)&nbsp;whether the Borrowing is to consist of Base Rate Loans or LIBOR Loans, (d)&nbsp;in the case of LIBOR Loans, the duration of the Interest Period to be applicable thereto, and (e)&nbsp;the account of Borrowers to which the proceeds of such Borrowing are to be disbursed.</P>
<P ALIGN="JUSTIFY">(ii)&#9;Unless payment is otherwise timely made by Borrowers, the becoming due of any amount required to be paid with respect to any of the Obligations (whether as principal, accrued interest, fees or other charges, including Extraordinary Expenses and LC Obligations, and any amounts owed for Banking Relationship Debt) shall be deemed irrevocably to be a request (without any requirement for the submission of a Notice of Borrowing) for Revolver Loans on the due date of, and in an aggregate amount required to pay, such Obligations, and the proceeds of such Revolver Loans may be disbursed by way of direct payment of the relevant Obligation and shall bear interest as Base&nbsp;Rate Loans.  Neither Agent nor any Lender shall have any obligation to Borrowers to honor any&nbsp;deemed request for a Revolver Loan on or after the Commitment Termination Date, when an&nbsp;Out-of-Formula Condition exists or would result therefrom, or when any applicable condition precedent set forth in <B>Section&nbsp
;11</B> is not satisfied, but may do so in the discretion of Agent (or at the direction of the Required Lenders) and without regard to the existence of, and without being deemed to have waived, any Default or Event of Default and regardless of whether such Revolver Loan is funded after the Commitment Termination Date.</P>
<P ALIGN="JUSTIFY">(iii)&#9;If Borrowers elect to establish a Controlled Disbursement Account with BofA or any Affiliate of BofA, then the presentation for payment by BofA of any check or other item of payment drawn on the Controlled Disbursement Account at a time when there are insufficient funds in such account to cover such check shall be deemed irrevocably to be a request (without any&nbsp;requirement for the submission of a Notice&nbsp;of Borrowing) for Revolver Loans on the&nbsp;date of such presentation and in an amount equal to the aggregate amount of the items presented for payment, and the proceeds of such Revolver Loans may be disbursed to the Controlled Disbursement Account and shall bear interest as Base&nbsp;Rate Loans.  Neither Agent nor any Lender shall have any obligation to honor any deemed request for a Revolver Loan on or after the Commitment Termination Date or when an Out-of-Formula Condition exists or would result therefrom or when any condition precedent in <B>Section 11</B> is not sa
tisfied, but may do so in the discretion of Agent (or at the direction of the Required Lenders) and without regard to the existence of, and without being deemed to have waived, any Default or Event of Default and regardless of whether such&nbsp;Revolver Loan is funded after the&nbsp;Commitment Termination Date.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">4.1.2.&nbsp;&nbsp;&nbsp;<U>Fundings by Lenders</P>
</U><P ALIGN="JUSTIFY">.  Subject to its receipt of notice from Agent of a Notice of Borrowing as provided in <B>Section&nbsp;4.1.1(i)</B> (except in the case of a deemed request by Borrower Representative for a Revolver Loan as provided in <B>Section 4.1.1(ii) </B>or<B> (iii)</B> or <B>Section 4.1.3(ii)</B>, in which event no Notice of Borrowing need be submitted), each Lender shall timely honor its Revolver Commitment by funding its Pro Rata share of each&nbsp;Borrowing of Revolver Loans that is properly requested and that Borrowers are entitled&nbsp;to receive under this Agreement.  Agent shall endeavor to notify Lenders of each Notice of Borrowing (or&nbsp;deemed request for a Borrowing pursuant to <B>Section 4.1.1(ii)</B> or <B>(iii)</B>), by 1:00 p.m. on the&nbsp;proposed funding date (in the case of Base Rate Loans) or by 3:00 p.m. at least 2&nbsp;Business Days before the proposed funding date (in the case of LIBOR Loans).  Each Lender shall deposit with Agent an amount equal to its Pro Rata share of 
the Borrowing requested or deemed requested by Borrowers at Agent's designated bank in immediately available funds not later than 2:00&nbsp;p.m. on the date of funding of such Borrowing, unless Agent's notice to Lenders is received after 1:00 p.m. on the proposed funding date of a Base Rate Loan, in which event Lenders shall deposit with Agent their respective Pro Rata shares of the requested Borrowing on or before 12:00 noon of the next Business Day.  Subject to its receipt of such&nbsp;amounts from Lenders, Agent shall make the proceeds of the Revolver Loans received by it available&nbsp;to Borrowers by disbursing such proceeds in accordance with Borrower Representative's disbursement instructions set forth in the applicable Notice of Borrowing.  Neither Agent nor any Lender shall have any liability on account of any delay by any bank or other depository institution in treating the proceeds of any Revolver Loan as collected funds or any delay in receipt, or any loss, of funds that constitute a Revolver Loa
n, the wire transfer of which was initiated by Agent in accordance with wiring&nbsp;instructions provided to Agent.  Unless Agent shall have been notified in&nbsp;writing by a Lender prior&nbsp;to the proposed time of funding that such Lender does not intend to deposit with Agent an amount equal such Lender's Pro Rata share of the requested Borrowing (or deemed request for a Borrowing pursuant to clauses (ii) or (iii) of <B>Section 4.1.1</B>), Agent&nbsp;may&nbsp;assume that such Lender has&nbsp;deposited or promptly will deposit its share with Agent and Agent may&nbsp;in its discretion disburse a&nbsp;corresponding amount to Borrowers on the applicable funding date.  If a Lender's Pro&nbsp;Rata share of such&nbsp;Borrowing is not in fact deposited with Agent, then, if Agent has disbursed to Borrowers an amount corresponding to such share, then such Lender agrees to pay, and in addition Borrowers agree to repay, to Agent forthwith <B>on demand</B> such corresponding amount, together with interest thereon, fo
r&nbsp;each day from the date such amount is disbursed by Agent to or for the benefit of Borrowers until the date such amount is paid or repaid to Agent, (a)&nbsp;in the case of Borrowers, at the interest rate applicable to such&nbsp;Borrowing and (b)&nbsp;in the case of such Lender, at the Federal Funds Rate.  If such Lender repays to Agent such corresponding amount, such amount so repaid shall constitute a Revolver Loan, and if both such Lender and Borrowers shall have repaid such corresponding amount, Agent shall promptly return to Borrowers such&nbsp;corresponding amount in same day funds.  A notice from Agent submitted to any Lender with respect to amounts owing under this&nbsp;<B>Section&nbsp;4.1.2</B> shall be conclusive, absent manifest error.</P>
<P ALIGN="JUSTIFY">4.1.3.&nbsp;&nbsp;&nbsp;<U>Settlement and Swingline Loans.</P>
</U><P ALIGN="JUSTIFY">(i)&#9;In order to facilitate the administration of the Revolver Loans under this&nbsp;Agreement, Lenders and Agent agree (which agreement shall be solely between Lenders and Agent and shall&nbsp;not be for the benefit of or enforceable by any Borrower) that settlement among them with respect to the Revolver Loans may take place on a periodic basis on dates determined from time to time by Agent (each a "Settlement Date"), which may occur before or after the occurrence or during the continuance of a Default or Event of Default and whether or not all&nbsp;of the conditions set forth in <B>Section&nbsp;11</B> have been met.  On each Settlement Date, payment shall be made by or to each Lender in the manner provided herein and in accordance with the Settlement Report delivered by Agent to Lenders with&nbsp;respect to such Settlement Date so that, as of each Settlement Date and after giving effect to the&nbsp;transaction to take place on such Settlement Date, each Lender shall hold its Pro R
ata share of all Revolver Loans and participations in LC Obligations.</P>
<P ALIGN="JUSTIFY">(ii)&#9;Between Settlement Dates, Agent may request BofA to advance, and BofA&nbsp;may, but shall in no event be obligated to, advance to Borrowers out of BofA's own funds the&nbsp;entire principal amount of any Borrowing of Revolver Loans that are Base Rate Loans requested or deemed requested pursuant to this Agreement (any such Revolver Loan funded exclusively by BofA being referred to as a "Swingline Loan").  Each Swingline Loan shall&nbsp;constitute a Revolver Loan hereunder and shall be subject to all of the terms, conditions and security applicable to other Revolver&nbsp;Loans, except that all payments thereon shall be payable to BofA solely for its own account.  The obligation of Borrowers to repay such Swingline Loans to BofA shall be evidenced by the records of BofA and need not be evidenced by any promissory note.  Unless a funding is required by all Lenders pursuant to <B>Sections 2.1.6 </B>or <B>13.9.4<I>,</B></I> Agent&nbsp;shall not request BofA to make any Swingline Loan if 
(A) Agent shall have received written notice from any Lender that one or more of the applicable conditions precedent set forth in <B>Section&nbsp;11</B> will not be satisfied on the requested funding date for the&nbsp;applicable Borrowing and Agent has made a determination (without any liability to any Person) that such condition precedent will not be satisfied or (B) the requested Borrowing would exceed the amount of Availability on the funding date or (C) the aggregate principal amount of all Swingline Loans outstanding exceeds (or with the funding of the requested Swingline Loans, would exceed) $20,000,000 at any time.  BofA&nbsp;shall not be required to determine whether the applicable conditions precedent set forth in <B>Section 11</B> have been satisfied or the requested Borrowing would exceed the amount of Availability on the funding date applicable thereto prior to making, in its discretion, any&nbsp;Swingline Loan.  On each Settlement Date, or, if earlier, <B>on demand</B> by Agent for payment there
of, the then outstanding Swingline Loans shall be immediately due and payable.  As provided in <B>Section&nbsp;4.1.1(ii)</B>, Borrowers shall be deemed to have requested (without&nbsp;the necessity of submitting any Notice of Borrowing) Revolver Loans to be made on each&nbsp;Settlement Date in the amount of all&nbsp;outstanding Swingline Loans and to have Agent cause the proceeds of such Revolver Loans to&nbsp;be applied to the repayment of such Swingline Loans and interest accrued thereon.  Agent shall notify the Lenders of the outstanding balance of Revolver&nbsp;Loans prior to 12:00 noon on each Settlement Date and each Lender (other than BofA) shall deposit with Agent (without setoff, counterclaim or reduction of any kind) an amount equal&nbsp;to its Pro Rata share of the amount of Revolver Loans deemed requested in immediately available funds not later than 2:00 p.m. on such Settlement Date.  Each&nbsp;Lender's obligation to make such deposit with Agent shall be absolute and unconditional, without defen
se, offset, counterclaim or other defense, and without regard to whether any of the&nbsp;conditions precedent set forth in <B>Section&nbsp;11</B> are satisfied, any Out-of-Formula Condition exists or the Commitment Termination Date has occurred.  If, as the result of the commencement by or against Borrowers of any Insolvency Proceeding or otherwise, any Swingline Loan may not be repaid by the funding by Lenders of Revolver Loans, then each&nbsp;Lender (other than BofA) shall be deemed to have purchased a participating interest in any&nbsp;unpaid Swingline Loan in an amount equal to such Lender's Pro&nbsp;Rata share of such Swingline Loan and shall transfer to BofA, in immediately available funds not later than the second Business Day after BofA's request therefor, the amount of such Lender's participation.  The proceeds of Swingline Loans may be used solely for purposes for which Revolver Loans generally may be used in accordance with <B>Section&nbsp;2.1.3</B>.  If any amounts received by BofA in&nbsp;respec
t of any Swingline Loans are later required to be returned or repaid by BofA to Borrowers or any other Obligor or their respective representatives or successors-in-interest, whether by court order, settlement or otherwise, the other Lenders shall, <B>on demand</B> by BofA with notice to Agent, pay to Agent for the account of BofA, an amount equal to each other Lender's Pro Rata share of all such amounts required to be returned or repaid.</P>
<P ALIGN="JUSTIFY">4.1.4.&nbsp;&nbsp;&nbsp;<U>Disbursement Authorization</P>
</U><P ALIGN="JUSTIFY">.  Each Borrower hereby irrevocably authorizes Agent to disburse the proceeds of each Revolver Loan requested by any Borrower, or deemed to be requested pursuant to <B>Section&nbsp;4.1.1</B> or <B>Section 4.1.3(ii)</B>, as follows:  (i) the proceeds of each Revolver Loan requested under <B>Section&nbsp;4.1.1(i)</B> shall&nbsp;be disbursed by Agent in accordance with the terms of the written disbursement letter from Borrowers in the case of the initial Borrowing, and, in the case of each subsequent Borrowing, by wire transfer to such&nbsp;bank account of Borrowers as may be agreed upon by Borrowers and Agent from time to time or elsewhere if pursuant&nbsp;to a written direction from any Borrower that is approved by Agent; and (ii)&nbsp;the proceeds of each Revolver Loan requested under <B>Section&nbsp;4.1.1(ii)</B> or <B>Section&nbsp;4.1.3(ii)</B> shall be disbursed by Agent by way of direct payment of the relevant interest or other&nbsp;Obligation.  Any Loan proceeds received by any Bo
rrower or in payment of any of the Obligations shall be deemed to have been received by all Borrowers.</P>
<P ALIGN="JUSTIFY">4.1.5.&nbsp;&nbsp;&nbsp;<U>Telephonic Notices.</P>
</U><P ALIGN="JUSTIFY">Each Borrower authorizes Agent and Lenders to extend, convert or continue Loans, effect selections of Types of Loans and transfer funds to or on behalf of Borrowers based on telephonic notices or instructions from any individual whom Agent or any Lender in good faith believes to be acting on behalf of any Borrower.  Borrowers shall confirm each such telephonic request for a Borrowing or conversion or continuation of Loans by prompt delivery to Agent of the required Notice of Borrowing or Notice of Conversion/Continuation, as applicable, duly executed by an authorized officer of Borrower Representative.  If the written confirmation differs in any material respect from the action taken by Agent or Lenders, the records of Agent and Lenders shall govern.  Neither Agent nor any Lender shall have any liability for any loss suffered by any Borrower as a result of Agent's or any Lender's acting upon its understanding of telephonic instructions or requests from a person believed in good faith b
y Agent or any Lender to be a Person authorized by a Borrower to give such instructions or to make such requests on Borrowers' behalf.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346533"><A NAME="_Toc99510192"><A NAME="_Toc102963331"><A NAME="_Toc105998302"><A NAME="_Toc105998712"><A NAME="_Toc105998844"><A NAME="_Toc117052357">4.2.&nbsp;&nbsp;&nbsp;<U>Defaulting Lender</A></A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  If any Lender shall, at any time, fail to make any payment to Agent or BofA that is required hereunder, Agent may, but shall not be required to, retain payments that would otherwise be made to such defaulting Lender hereunder and apply such payments to such defaulting Lender's defaulted obligations hereunder, at such time, and in such order, as Agent may elect in its discretion.  With respect to the payment of any funds from Agent to a Lender or from a Lender to Agent, the party failing to make the&nbsp;full payment when due pursuant to the terms hereof shall, <B>on demand</B> by the other party, pay such amount together with interest on such amount at the Federal Funds Rate.  The failure of any Lender to fund its portion of any Loan or payment in&nbsp;respect of an LC Obligation<B><I> </B></I>shall not relieve any other Lender of its obligation, if any, to fund its&nbsp;portion of the Revolver Loan or payment in respect of an LC&nbsp;Obligation<B><I> </B></I>on the date of Borr
owing, but no Lender shall be responsible for the failure of any other Lender to make any Loan or&nbsp;payment in respect of an LC Obligation<B><I> </B></I>to be made by such Lender on the date of any Borrowing.  Solely as among the Lenders and solely for purposes of voting or consenting to matters with respect to any of the&nbsp;Loan&nbsp;Documents, Collateral or any Obligations and determining a defaulting Lender's share of payments and proceeds of Collateral pending such defaulting Lender's cure of its defaults hereunder, a&nbsp;defaulting Lender shall not be deemed to be a "Lender" and such Lender's Commitment shall be deemed to&nbsp;be zero (0).  The provisions of this <B>Section&nbsp;4.2</B> shall be solely for the benefit of Agent and Lenders and may not be enforced by Borrowers.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346534"><A NAME="_Toc102963332"><A NAME="_Toc105998303"><A NAME="_Toc105998713"><A NAME="_Toc105998845"><A NAME="_Toc117052358">4.3.&nbsp;&nbsp;&nbsp;<U>Special Provisions Governing LIBOR Loans.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">4.3.1.&nbsp;&nbsp;&nbsp;<U>Number of LIBOR Loans</P>
</U><P ALIGN="JUSTIFY">.  In no event may the number of LIBOR Loans outstanding at any time to any Lender exceed 10.</P>
<P ALIGN="JUSTIFY">4.3.2.&nbsp;&nbsp;&nbsp;<U>Minimum Amounts</P>
</U><P ALIGN="JUSTIFY">.  Each Borrowing of LIBOR Loans pursuant to <B>Section&nbsp;4.1.1(i)</B>, and each continuation of or conversion to LIBOR Loans pursuant to <B>Section 3.1.2</B>, shall be in a minimum amount of $1,000,000 and integral multiples of $250,000 in excess of that&nbsp;amount.</P>
<P ALIGN="JUSTIFY">4.3.3.&nbsp;&nbsp;&nbsp;<U>LIBOR Lending Office</P>
</U><P ALIGN="JUSTIFY">.  Each Lender's initial LIBOR Lending Office is set forth opposite its name on the signature pages hereof.  Each Lender shall have the right at any time and from time to time to designate a different office of itself or of any Affiliate as such Lender's LIBOR Lending Office, and to transfer any outstanding LIBOR Loans to such LIBOR Lending Office.  No such designation or transfer shall result in any liability on the part of Borrowers for increased costs or expenses.  Increased costs for expenses resulting from a change in Applicable Law occurring subsequent to any such designation or transfer shall&nbsp;be deemed not to result solely from such&nbsp;designation or transfer.</P>
<P ALIGN="JUSTIFY">4.3.4.&nbsp;&nbsp;&nbsp;<U>Funding of LIBOR Loans</P>
</U><P ALIGN="JUSTIFY">. Each Lender may, if it so elects, fulfill its obligation to make, continue or convert LIBOR Loans hereunder by causing one of its foreign branches or Affiliates (or an international banking facility created by such Lender) to make or maintain such LIBOR Loans; <U>provided</U>, <U>however</U>, that such LIBOR Loans shall nonetheless be deemed to have been made and to be held by such Lender, and the obligation of Borrowers to repay such LIBOR Loans shall nevertheless be to such Lender for the account of such foreign branch, Affiliate or international banking facility.  The calculation of all amounts payable to Lender under <B>Sections&nbsp;3.7</B> and <B>3.10</B> shall be made as if each Lender had actually funded or committed to fund its LIBOR Loan through the purchase of an underlying deposit in an amount equal to the amount of such LIBOR Loan and having a maturity comparable to the relevant Interest Period  for such LIBOR Loans; <U>provided</U>, <U>however</U>, each Lender may fund 
its LIBOR Loans in any manner it deems fit and the foregoing presumption shall be utilized only for the calculation of amounts payable under <B>Sections&nbsp;3.7</B> and <B>3.10</B>.<A NAME="_Toc38346535"></P>
<B><P ALIGN="JUSTIFY">4.4.&nbsp;&nbsp;&nbsp;<U>Borrower Representative</P>
</U><P ALIGN="JUSTIFY">.</B>  Each Borrower hereby irrevocably appoints Parent and Parent agrees to act under this Agreement, as the agent and representative of itself and each&nbsp;other Borrower for all purposes under this Agreement (in such capacity, "Borrower Representative"), including requesting Borrowings, submitting LC Requests, selecting whether any Loan or portion thereof is to bear interest as a Base Rate Loan or a LIBOR Loan, and receiving account statements and other notices and communications to Borrowers (or any of them) from Agent.  Agent may rely, and shall be fully protected in relying, on any Notice of Borrowing, Notice of Conversion/Continuation, LC Request, disbursement instructions, reports, information, Borrowing Base Certificate or any other notice or communication made or given by Borrower Representative, whether in its own name, on behalf of any Borrower or on&nbsp;behalf of "the Borrowers," and Agent shall have no obligation to make any inquiry or request any&nbsp;confirmation from
 or on behalf of any other Borrower as to the binding effect on such Borrower of any&nbsp;such Notice of Borrowing, Notice of Conversion/Continuation, LC Request, instruction, report, information, Borrowing Base Certificate or other notice or communication, nor shall the joint and several&nbsp;character of Borrowers' liability for the Obligations be affected, provided that the provisions of this <B>Section&nbsp;4.4</B> shall not be construed so as to preclude any&nbsp;Borrower from directly requesting Borrowings or taking other actions permitted to be taken by "a&nbsp;Borrower" hereunder.  Agent may maintain a single Loan Account in the name of "Alpharma Inc." hereunder, and each Borrower expressly agrees to such arrangement and confirms that such&nbsp;arrangement shall have no effect on the joint and several character of such Borrower's liability for the&nbsp;Obligations.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc99510195"><A NAME="_Toc102963333"><A NAME="_Toc105998304"><A NAME="_Toc105998714"><A NAME="_Toc105998846"><A NAME="_Toc117052359">4.5.&nbsp;&nbsp;&nbsp;<U>All Loans to Constitute One Obligation</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  The Loans and LC Obligations shall constitute one general obligation of Borrowers and (unless otherwise expressly provided in any Security Document) shall be secured by Agent's Lien upon all of the Collateral; <U>provided</U>, <U>however</U>, that Agent and each Lender shall&nbsp;be deemed to be a creditor of each Borrower and the holder of a separate claim against each&nbsp;Borrower to the extent of any Obligations jointly and severally owed by Borrowers to Agent or such&nbsp;Lender.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346536"><A NAME="_Toc102963334"><A NAME="_Toc105998305"><A NAME="_Toc105998715"><A NAME="_Toc105998847"><A NAME="_Toc117052360"></A>section 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PAYMENTS</A></A></A></A></A></A></P>
<P ALIGN="JUSTIFY"><A NAME="_Toc38346537"><A NAME="_Toc102963335"><A NAME="_Toc105998306"><A NAME="_Toc105998716"><A NAME="_Toc105998848"><A NAME="_Toc117052361">5.1.&nbsp;&nbsp;&nbsp;<U>General Payment Provisions</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  All payments (including all prepayments) of principal of and interest on the Loans, LC Obligations and other Obligations that are payable to Agent or any&nbsp;Lender shall&nbsp;be made to Agent in Dollars without any offset or counterclaim, and, with respect to payments made other than by application of balances in the Payment Account, in immediately available funds not later than 12:00&nbsp;noon on the due date (and&nbsp;payment made after such time on the due date to be deemed to have been made on the next succeeding Business Day).  Borrowers shall, at the time Borrowers make any payment under this Agreement, specify to Agent the Obligations to which such payment is to be applied and, if Borrowers fail so to specify or if the application specified by Borrowers would be inconsistent with the terms of this Agreement or if an Event of Default exists, Agent shall distribute such payment to Lenders for application to the Obligations then due and payable in such manner as Agent, sub
ject to the provisions of this Agreement, may determine to be appropriate.  All payments received by Agent shall be subject to the rights of offset that Agent may have as to amounts otherwise to be remitted to a particular Lender by reason of amounts due and payable to Agent from such Lender under any of the&nbsp;Loan&nbsp;Documents.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346538"><A NAME="_Toc102963336"><A NAME="_Toc105998307"><A NAME="_Toc105998717"><A NAME="_Toc105998849"><A NAME="_Toc117052362">5.2.&nbsp;&nbsp;&nbsp;<U>Repayment of Revolver Loans.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">5.2.1.&nbsp;&nbsp;&nbsp;<U>Payment of Principal</P>
</U><P ALIGN="JUSTIFY">.  The outstanding principal amounts with respect to the&nbsp;Revolver Loans shall be repaid as follows:</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">(i)&#9;Any portion of the Revolver Loans consisting of the principal amount of Base&nbsp;Rate Loans shall be paid by Borrowers to Agent, for the Pro Rata benefit of Lenders (or,&nbsp;in&nbsp;the&nbsp;case of Swingline Loans, for the sole benefit of BofA) unless timely converted to a&nbsp;LIBOR&nbsp;Loan in accordance with this Agreement, immediately upon (a)&nbsp;subject to <B>Section 8.2.5</B>, each receipt by Agent, any&nbsp;Lender or Borrowers of any proceeds of any of the Accounts or Inventory, to the extent of such&nbsp;proceeds, (b)&nbsp;the Commitment Termination Date, and (c)&nbsp;in the case of Swingline Loans, the&nbsp;earlier of BofA's demand for payment or on each Settlement Date with respect to all Swingline Loans outstanding on such date.</P>
<P ALIGN="JUSTIFY">(ii)&#9;Any portion of the Revolver Loans consisting of the principal amount of LIBOR Loans shall be paid by Borrowers to Agent, for the Pro Rata benefit of Lenders, unless converted to a Base Rate Loan or continued as a LIBOR Loan in accordance with the terms of this Agreement, immediately upon (a)&nbsp;the last day of the Interest Period applicable thereto and (b)&nbsp;the Commitment Termination Date.  In no event shall Borrowers be authorized to make a voluntary prepayment with respect to any Revolver Loan outstanding as a LIBOR Loan prior to the last day of the Interest Period applicable thereto unless Borrowers pay to Agent, for the Pro Rata benefit of Lenders, concurrently with any prepayment of a LIBOR Loan, any amount due Agent and Lenders under <B>Section&nbsp;3.10 </B>as a consequence of such prepayment.  Notwithstanding the&nbsp;foregoing provisions of this <B>Section&nbsp;5.2.1(ii)</B>, if, on any date that Agent receives proceeds of any of the Accounts or Inventory, there are 
no Revolver Loans outstanding as Base Rate Loans, Agent may either hold such proceeds as cash security for the timely payment of the Obligations or apply such proceeds to any outstanding Revolver Loans bearing interest as LIBOR Loans as the same become due and payable (whether at the end of the applicable Interest Periods or on the Commitment Termination Date).</P>
<P ALIGN="JUSTIFY">(iii)&#9;Notwithstanding anything to the contrary contained elsewhere in this&nbsp;Agreement, if an Out-of-Formula Condition shall exist, Borrowers shall, on the sooner to occur of Agent's demand or the first Business Day after any Borrower has obtained knowledge of such&nbsp;Out-of-Formula Condition, repay the outstanding Revolver Loans that are Base Rate Loans in an amount sufficient to reduce the aggregate unpaid principal amount of all Revolver Loans by an amount equal to such excess; and, if such payment of Base Rate Loans is not sufficient to eliminate the Out-of-Formula Condition, then Borrowers shall immediately deposit with Agent, for the Pro&nbsp;Rata benefit of Lenders, for application to any outstanding Revolver Loans bearing interest as LIBOR Loans as the same become due and payable (whether at the end of the applicable Interest Periods or on the Commitment Termination Date) cash in an amount sufficient to eliminate such Out-of-Formula Condition, and Agent may (a)&nbsp;hold su
ch deposit as cash security pending disbursement of same to Lenders for application to the Obligations, or (b)&nbsp;if an Event of Default exists, immediately apply such proceeds to the payment of the&nbsp;Obligations, including the Revolver Loans outstanding as LIBOR Loans (in which event Borrowers shall also pay to Agent for the Pro Rata benefit of Lenders any amounts required by <B>Section&nbsp;3.10</B> to be paid by reason of the prepayment of a LIBOR Loan prior to the last day of the Interest Period applicable thereto).</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">5.2.2.&nbsp;&nbsp;&nbsp;<U>Payment of Interest</P>
</U><P ALIGN="JUSTIFY">.  Interest accrued on the Revolver Loans shall be due and payable (i)&nbsp;quarterly in arrears on the first day of each calendar quarter, with respect to any Revolver Loan that is a Base Rate Loan and (ii)&nbsp;the last day of the applicable Interest Period in the case of a LIBOR Loan and if such LIBOR Loan has an Interest Period of greater than ninety (90) days, also on the 90<SUP>th</SUP> day and the last day of such Interest Period; <U>provided</U>, <U>however</U> that if an Event of Default exists and the Default Rate is then in effect, interest shall be due and payable monthly, in arrears, on the first day of each calendar month and if such Revolver Loan is a LIBOR Loan, also at the end of each Interest Period.  Accrued&nbsp;interest shall also be paid by Borrowers on the Commitment Termination Date.  With respect to any&nbsp;Base Rate Loan converted into a LIBOR Loan pursuant to<B> Section&nbsp;3.1.2</B> on a day when interest would not otherwise have been payable with respect 
to such Base Rate Loan, accrued interest to the date of such&nbsp;conversion on the amount of such Base Rate Loan so converted shall be paid on the&nbsp;conversion&nbsp;date.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346539"><A NAME="_Toc102963337"><A NAME="_Toc105998308"><A NAME="_Toc105998718"><A NAME="_Toc105998850"><A NAME="_Toc108513092"><A NAME="_Toc117052363">5.3.&nbsp;&nbsp;&nbsp;<U>Repayment of Term Loan Advances.<A NAME="_Toc38346540"><A NAME="_Toc102963338"><A NAME="_Toc105998309"><A NAME="_Toc105998719"><A NAME="_Toc105998851"></A></A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">5.3.1.&nbsp;&nbsp;&nbsp;<U>Payment of Principal</P>
</U><P ALIGN="JUSTIFY">.  The principal amount of each Term Note shall be paid in consecutive quarterly installments equal to the following amounts: </P></FONT>
<P ALIGN="CENTER"><CENTER><TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=292>
<TR><TD WIDTH="51%" VALIGN="TOP">
<U><FONT SIZE=3><P ALIGN="CENTER"><BR>
Payment Dates</U></FONT></TD>
<TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="CENTER">Quarterly<BR>
<U>Payment Amounts</U></FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">12/31/2005</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$1,250,000</FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">3/31/2006</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$1,250,000</FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">6/30/2006</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$1,250,000</FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">9/30/2006</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$1,250,000</FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">12/31/2006</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$3,125,000</FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">3/31/2007</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$3,125,000</FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">6/30/2007</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$3,125,000</FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">9/30/2007</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$3,125,000</FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">12/31/2007</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$3,125,000</FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">3/31/2008</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$3,125,000</FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">6/30/2008</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$3,125,000</FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">9/30/2008</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$3,125,000</FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">12/31/2008</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$1,250,000</FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">3/31/2009</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$1,250,000</FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">6/30/2009</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$1,250,000</FONT></TD>
</TR>
<TR><TD WIDTH="51%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="JUSTIFY">9/30/2009</FONT></TD>
<TD WIDTH="49%" VALIGN="TOP">
<FONT SIZE=3><P ALIGN="RIGHT">$1,250,000</FONT></TD>
</TR>
</TABLE>
</CENTER></P>

<FONT SIZE=3><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Each installment shall be paid to Agent for the account and Pro Rata benefit of each Lender.  Each Term Loan Advance, if not sooner paid, shall be due and payable in full on the&nbsp;Commitment Termination Date.</P>
<P ALIGN="JUSTIFY">5.3.2.&nbsp;&nbsp;&nbsp;<U>Payment of Interest</P>
</U><P ALIGN="JUSTIFY">.  Interest accrued on each Term Loan Advance shall be due and payable (i)&nbsp;quarterly in arrears on the first day of each calendar quarter if the Term Loan Advance bears interest as a Base Rate Loan, (ii)&nbsp;the last day of the applicable Interest&nbsp;Period in the case of any portion of such Term Loan Advance that is a LIBOR Loan and, in addition, if such LIBOR Loan has an Interest Period of greater than ninety (90) days, on the 90<SUP>th</SUP> day and the last day of such Interest Period, (iii)&nbsp;the date of any prepayment of Term Loan Advances and (iv) the Commitment Termination Date; <U>provided</U>, <U>however</U>, that if an Event of Default exists and the Default Rate is then in effect, interest shall be due and payable on a monthly basis, in arrears, on the first day of each calendar month and if any portion of the Term Loan Advances consists of LIBOR Loans, also on the last day of the applicable Interest Period.  With respect to any Base Rate Loan converted into a LI
BOR&nbsp;Loan pursuant to <B>Section&nbsp;3.1.2</B> on a day when interest would not otherwise have been payable with respect to such Base Rate Loan, accrued interest to the date of such conversion on the amount of such Base&nbsp;Rate Loan so converted shall be paid on the conversion date.</P>
<P ALIGN="JUSTIFY">5.3.3.&nbsp;&nbsp;&nbsp;<U>Mandatory Prepayments</P>
</U><P ALIGN="JUSTIFY">.  In addition to Borrowers' obligation to pay the Obligations upon the Commitment Termination Date, Borrowers shall also be jointly and severally required to prepay the Obligations as follows:</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">(i)&#9;Borrowers shall prepay the Obligations in accordance with <B>Section 5.3.5</B> in the amount of Net Disposition Proceeds from Permitted Asset Dispositions of Equipment or Real Estate;</P>
<P ALIGN="JUSTIFY">(ii)&#9;Borrowers shall prepay the Obligations in accordance with <B>Section 5.3.5</B> from the proceeds of insurance or condemnation awards paid in respect of any Equipment or Real Estate; and</P>
<P ALIGN="JUSTIFY">(iii)&#9;Concurrently with the consummation of a Portfolio Transaction, Agent shall receive the Net Disposition Proceeds thereof for application to the Obligations in accordance with <B>Section 5.3.5</B>.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">5.3.4.&nbsp;&nbsp;&nbsp;<U>Optional Prepayments of Term Loan Advances</P>
</U><P ALIGN="JUSTIFY">.  Borrowers may, at their option, prepay any portion of the Term Loan Advances consisting of Base Rate Loans in whole at any time or in&nbsp;part from time to time, in amounts aggregating $1,000,000 or any greater integral multiple of $250,000 by paying the principal amount to be prepaid together with interest accrued or unpaid thereon to the date of prepayment.  Any portion of the Term Loan Advances consisting of LIBOR Loans may be prepaid, at Borrowers' option, at any time in whole or from time to time in part, in&nbsp;amounts aggregating $1,000,000 or any greater integral multiple of $250,000, together with any applicable charges pursuant to <B>Section 3.10</B>, interest accrued or unpaid thereon to the date of prepayment.  Borrowers shall give written notice (or telephonic notice promptly confirmed in writing) to Agent of any intended prepayment not less than 1 Business Day prior to any prepayment of Base Rate Loans and not less than 2 Business Days prior to any prepayment of LIBO
R Loans.  Such notice, once given, shall be irrevocable and, upon receipt of any such notice of optional prepayment, Agent shall promptly notify each Lender of the contents thereof and of such Lender's share of the prepayment as provided in <B>Section&nbsp;5.3.5</B>.</P>
<P ALIGN="JUSTIFY">5.3.5.&nbsp;&nbsp;&nbsp;<U>Application of Prepayments</P>
</U><P ALIGN="JUSTIFY">(i)&#9;Except as otherwise provided in <B>Section&nbsp;5.6</B>, each mandatory prepayment pursuant to <B>Section&nbsp;5.3.3 </B>shall be remitted by Borrowers to Agent for application (i)&nbsp;<U>first,</U> to eliminate any Out-of-Formula Condition and repay all Out-of-Formula Loans (including any Excess Borrowing Base Amount) (<U>provided</U>, <U>that</U> nothing contained herein shall permit Borrowers to have any Out-of-Formula Condition or Out-of-Formula Loans); (ii)&nbsp;<U>second</U>, to the Fixed Asset Sublimit in the inverse order of the quarterly amortization amounts specified in the definition thereof to the extent of the Excess FAS Amount; (iii) <U>third</U>, to the principal due under the Term Notes, with such amounts applied to the principal installments under the Term Notes in the inverse order of maturities until Full Payment thereof; and (iv) <U>fourth</U>, to reduce the Fixed Asset Sublimit, in the inverse order of  the quarterly amortization amounts specified in the de
finition thereof.</P>
<P ALIGN="JUSTIFY">(ii)&#9;Each optional prepayment of Term Loan Advances pursuant to <B>Section&nbsp;5.3.4</B> shall be remitted by Borrowers to Agent and distributed by Agent to Lenders to prepay installments of the Term Loan Notes, in the inverse order of their maturities, until Full Payment of the Term Notes.</P>
<P ALIGN="JUSTIFY">(iii)&#9;All distributions of prepayments by Agent to Lenders shall be on a Pro Rata basis.  Each&nbsp;Lender shall apply the portion of a prepayment that is to be applied to principal installments first to outstanding Base Rate Loans and then to any outstanding LIBOR Loans with the shortest Interest Periods remaining; but if application to any LIBOR Loans would cause the same to be paid prior to the end of an applicable Interest Period, then, by prior written notice to Agent, Borrowers may elect as to such LIBOR Loan to deliver cash to Agent in the amount of the required prepayment, to be held by Agent as Cash Collateral until the end of the applicable Interest Period, at which time Agent shall disburse such Cash Collateral to the affected Lenders for application to such LIBOR Loans.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc117052364">5.4.&nbsp;&nbsp;&nbsp;<U>Payment of Other Obligations</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  The balance of the Obligations requiring the payment of money, including LC Obligations and Extraordinary Expenses incurred by Agent or any Lender, shall be repaid by Borrowers to Agent for allocation among Agent and Lenders as provided in the Loan Documents, or, if no date of payment is otherwise specified in the Loan Documents, <B>on demand</B>.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346541"><A NAME="_Toc102963339"><A NAME="_Toc105998310"><A NAME="_Toc105998720"><A NAME="_Toc105998852"><A NAME="_Toc117052365">5.5.&nbsp;&nbsp;&nbsp;<U>Marshaling; Payments Set Aside</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  None of Agent or Lenders shall be under any obligation to marshal any assets in favor of Borrowers or any other Obligor or against or in payment of any&nbsp;or all of the&nbsp;Obligations.  To the extent that Borrowers make a payment to Agent or Lenders or Agent or any Lender receives payment from the proceeds of any Collateral or exercises its right of setoff, and such&nbsp;payment or the proceeds of such Collateral or setoff (or any part thereof) are subsequently invalidated, declared to be fraudulent or preferential, set aside or required to be repaid to a trustee, receiver or any other Person, then to the extent of any loss by Agent or Lenders, the Obligations or part thereof originally intended to be satisfied, and all Liens, rights and remedies therefor, shall be revived and continued in full force and effect as if such payment or proceeds had not been made or received and any such enforcement or setoff had&nbsp;not occurred.  The provisions of the&nbsp;immediately precedi
ng sentence of this <B>Section&nbsp;5.5</B> shall survive any termination of the Commitments and Full Payment of the Obligations.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346542"><A NAME="_Toc102963340"><A NAME="_Toc105998311"><A NAME="_Toc105998721"><A NAME="_Toc105998853"><A NAME="_Toc117052366">5.6.&nbsp;&nbsp;&nbsp;<U>Post Default Allocation of Payments.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">5.6.1.&nbsp;&nbsp;&nbsp;<U>Allocation</P>
</U><P ALIGN="JUSTIFY">.  For so long as an Event of Default exists, all monies to be applied to the&nbsp;Obligations, whether such&nbsp;monies represent voluntary or mandatory payments or prepayments by one or more Obligors or are received pursuant to demand for payment or realized from any disposition of Collateral and irrespective of any designation by Borrowers of the Obligations that are intended to be satisfied, shall be allocated among Agent and such of the&nbsp;Lenders as are entitled thereto (and,&nbsp;with respect to monies allocated to Lenders, on a Pro Rata basis unless otherwise provided herein):  (i)&nbsp;<U>first</U>, to Agent to pay the&nbsp;amount of Extraordinary Expenses that have not been reimbursed to Agent by Borrowers or Lenders, together with interest accrued thereon at the rate applicable to Revolver Loans that are Base Rate Loans, until Full Payment of all such Obligations; (ii)&nbsp;<U>second</U>, to Agent to pay principal and accrued interest on any portion of the Loans (including
 Agent Advances) which Agent may&nbsp;have advanced on behalf of any&nbsp;Lender and for which Agent has not been reimbursed by such Lender or Borrowers, until Full Payment of all such Obligations; (iii)&nbsp;<U>third</U>, to BofA to pay the principal and accrued interest on any portion of the Swingline Loans outstanding, to be shared with Lenders that have acquired and paid for a participating interest in such Swingline Loans, until Full Payment of all such Obligations; (iv)&nbsp;<U>fourth</U>, to the extent that Issuing Bank has not received from any Participating Lender a payment as required by <B>Section 2.3.2</B>, to Issuing Bank to pay all&nbsp;such required payments from each Participating Lender, until Full Payment of all such Obligations; (v)&nbsp;<U>fifth</U>, to Agent to pay any Claims that have not been paid pursuant to any indemnity of Agent Indemnitees by any Obligor, or to pay amounts owing by Lenders to Agent Indemnitees pursuant to <B>Section 13.6</B>, in each case together with interest acc
rued thereon at the rate applicable to Revolver Loans that are Base Rate Loans, until Full Payment of all such Obligations; (vi)&nbsp;<U>sixth</U>, to Agent to pay any fees due and payable to Agent, until Full Payment of all such Obligations; (vii)&nbsp;<U>seventh</U>, to each Lender, ratably, for any Claims that such Lender has paid to Agent Indemnitees pursuant to its indemnity of Agent Indemnitees and any Extraordinary Expenses that such Lender has reimbursed to Agent or such Lender has incurred, to the extent that such Lender has not been reimbursed by Obligors therefor; (viii)&nbsp;<U>eighth</U>, to Issuing Bank to pay principal and interest with respect to LC Obligations (or to the extent any of the LC Obligations are contingent and an Event of Default then exists, deposited in the Cash Collateral Account to Cash Collateralize the LC Obligations), which payment shall be shared with the Participating Lenders in accordance with <B>Section&nbsp;2.3.2(iii)</B>; (ix)&nbsp;<U>ninth</U>, to Lenders in&nbsp;pa
yment of the unpaid principal and accrued interest in&nbsp;respect of the Loans and other Obligations (excluding Banking&nbsp;Relationship Debt) then outstanding, in such order of application as shall be designated by Agent (acting at the direction or with the consent of the Required Lenders); and (x)&nbsp;<U>tenth</U>, to any Lender or any Affiliate of any Lender in payment of any Banking Relationship Debt owed to such Person and secured by the Collateral hereunder (subject to <B>Section 13.19</B> hereof).  The allocations set forth in this <B>Section&nbsp;5.6</B> are solely to determine the rights and priorities of Agent and Lenders as among themselves and may be changed by Agent and Lenders without notice to or the consent or approval of any Borrower or any other Person.</P>
<P ALIGN="JUSTIFY">5.6.2.&nbsp;&nbsp;&nbsp;<U>Erroneous Allocation</P>
</U><P ALIGN="JUSTIFY">.  Agent shall not be liable for any allocation or distribution of payments made by it in good faith and, if any such allocation or distribution is subsequently determined to have been made in error, the sole recourse of any Lender to which payment was due but not made shall be to recover from the other Lenders any payment in excess of the amount to which such other Lenders are determined to be entitled (and such other Lenders hereby agree to return to such Lender any such erroneous payments received by them).</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346543"><A NAME="_Toc102963341"><A NAME="_Toc105998312"><A NAME="_Toc105998722"><A NAME="_Toc105998854"><A NAME="_Toc117052367">5.7.&nbsp;&nbsp;&nbsp;<U>Application of Payments and Collateral Proceeds</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  All Payment Items received by Agent by 12:00 noon, on any Business Day shall be deemed received on that Business&nbsp;Day.  All Payment Items received by Agent after 12:00 noon, on any&nbsp;Business Day shall be deemed received on the following Business Day.  Each Borrower does hereby irrevocably agree that Agent shall have the&nbsp;continuing&nbsp;exclusive right to apply and reapply any&nbsp;and all such payments and Collateral proceeds (subject to <B>Section 8.2.5</B> hereof) received at any time or times hereafter by Agent or its&nbsp;agent against the Obligations, in such manner as Agent may deem advisable, notwithstanding any&nbsp;entry by Agent upon any of its books and records; <U>provided</U>, <U>however</U>, that any payments or proceeds of Collateral received by Agent on any date that an Event of Default does not exist shall be applied in&nbsp;accordance with any provisions of this Agreement that govern the application of such payment or proceeds.  If, as the result o
f Agent's collection of proceeds of Accounts and other Collateral as authorized by <B>Section&nbsp;8.2.6</B> a credit balance exists, such credit balance shall not accrue interest in favor of Borrowers, but shall be available to Borrowers at any time or times for so long as no Event of Default exists.<B><I>  </B></I>Agent may apply such credit balance against any of the Obligations during the existence of an Event&nbsp;of Default in the manner specified in <B>Section&nbsp;5.6.1</B>.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346544"><A NAME="_Toc102963342"><A NAME="_Toc105998313"><A NAME="_Toc105998723"><A NAME="_Toc105998855"><A NAME="_Toc117052368">5.8.&nbsp;&nbsp;&nbsp;<U>Loan Accounts; the Register; Account Stated.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">5.8.1.&nbsp;&nbsp;&nbsp;<U>Loan Accounts</P>
</U><P ALIGN="JUSTIFY">.  Each Lender shall maintain in accordance with its usual and customary practices an account or accounts (a "Loan Account") evidencing the Debt of Borrowers to such Lender resulting from each Loan owing to such Lender from time to time, including the amount of principal and interest payable to such Lender from time to time hereunder and under each Note payable to such Lender.  Any failure of a Lender to record in the Loan Account, or any error in doing so, shall not limit or otherwise affect the obligation of Borrowers hereunder (or under any Note) to pay any amount owing hereunder to such Lender.</P>
<P ALIGN="JUSTIFY">5.8.2.&nbsp;&nbsp;&nbsp;<U>The Register</P>
</U><P ALIGN="JUSTIFY">.  Agent shall maintain a register (the "Register"), which shall include a master account and a subsidiary account for each Lender and in which accounts (taken together) shall be recorded (i)&nbsp;the date and amount of each Borrowing made hereunder, the Type of each Loan comprising such&nbsp;Borrowing and any Interest Period applicable thereto, (ii)&nbsp;the effective date and amount of each Assignment and Acceptance delivered to and accepted by it and the parties thereto, (iii)&nbsp;the amount of any&nbsp;principal or interest due and payable or to become due and payable from Borrowers to each Lender hereunder or under the Notes, and (iv)&nbsp;the amount of any sum received by Agent from Borrowers or any&nbsp;other Obligor and each Lender's Pro Rata share thereof.  The Register shall be available for inspection by Borrowers or any&nbsp;Lender at the offices of Agent at any reasonable time and from time to time upon reasonable prior notice.  Any failure of Agent to record in the Regis
ter, or any error in doing so, shall not limit or otherwise affect the obligation of Borrowers hereunder (or under any Note) to pay any amount owing with respect to the Loans or provide the basis for any claim against Agent.</P>
<P ALIGN="JUSTIFY">5.8.3.&nbsp;&nbsp;&nbsp;<U>Entries Binding</P>
</U><P ALIGN="JUSTIFY">.  The entries made in the Register and each Loan Account shall constitute rebuttably presumptive evidence of the information contained therein absent manifest error; <U>provided</U>, <U>however</U>, that if a copy of information contained in the Register or any Loan Account is provided to any Person, or any Person inspects the Register or any Loan Account, at any time or from time to time, then the information contained in the Register or the Loan Account, as applicable, shall be conclusive and binding on such Person for all purposes absent manifest error, unless such Person notifies Agent in writing within 30 days after such Person's receipt of such copy or such Person's inspection of the Register or Loan Account of its intention to dispute the information contained therein.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346545"><A NAME="_Toc102963343"><A NAME="_Toc105998314"><A NAME="_Toc105998724"><A NAME="_Toc105998856"><A NAME="_Toc117052369">5.9.&nbsp;&nbsp;&nbsp;<U>Gross Up for Taxes</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  If Borrowers shall be required by Applicable Law to withhold or deduct any Taxes from or in respect of any sum payable under this Agreement or any of the other Loan Documents, (a)&nbsp;the sum payable to Agent or such Lender shall be increased as may be necessary so that, after making all required withholding or deductions, Agent or such Lender (as the case may be) receives an amount equal to the sum it would have received had no such withholding or deductions been made, (b)&nbsp;Borrowers shall make such withholding or deductions, and (c)&nbsp;Borrowers shall pay the full amount withheld or deducted to the relevant taxation authority or other authority in accordance with Applicable&nbsp;Law.  Borrowers shall not be required to indemnify any Foreign Lender or to pay any additional amounts to any Foreign Lender in respect of U.S. Federal withholding tax pursuant to this <B>Section 5.9</B> to the extent that the obligation  to pay such additional amounts would not have arisen but 
for a failure by such Foreign Lender to comply with the provisions of <B>Section 5.10</B> below.  If Agent or any Lender determines that it has received a refund, credit, or other reduction of taxes in respect of any Taxes paid by Borrowers pursuant to this <B>Section 5.9</B>, such Person shall within 30 days from the date of actual receipt of such refund or the filing of the tax return in which such credit or other reduction results in a lower tax payment, pay over such refund or the amount of such tax reduction to Borrowers (but only to the extent of Taxes paid by Borrowers pursuant to this <B>Section&nbsp;5.9</B>), net of all out-of-pocket expenses of such Person, and without interest (other than interest paid by the relevant Governmental Authority with respect to such refund).</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346546"><A NAME="_Toc102963344"><A NAME="_Toc105998315"><A NAME="_Toc105998725"><A NAME="_Toc105998857"><A NAME="_Toc117052370">5.10.&nbsp;&nbsp;&nbsp;<U>Withholding Tax Exemption</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  At least 5 (five) Business Days prior to the first date on which interest or fees are payable hereunder for the account of any Foreign Lender, if such Foreign Lender is entitled to an exemption from or reduction in withholding tax, it shall deliver to Borrowers and the Agent two (2) copies of (i) either United States Internal Revenue Service Form W-8BEN or Form W-8ECI, or any subsequent versions thereof or successors thereto, or, (ii) in the case of a Foreign Lender claiming exemption from or reduction in U.S. Federal withholding tax under Section 871(h) or 881(c) of the Code with respect to payments of "portfolio interest," a (A) Form W-8BEN, or any subsequent versions thereof or successors thereto and (B) a certificate representing that such Foreign Lender (1) is not a bank for purposes of Section 881(c) of the Code, (2) is not a 10 percent shareholder (within the meaning of Section 871(h)(3)(B) of the Code) of any Obligor and (3) is not a controlled foreign corporation relate
d to Obligors (within the meaning of Section 864(d)(4) of the Code), in all cases, properly completed and duly executed by such Foreign Lender claiming, as applicable, complete exemption from or reduced rate of, U.S. Federal withholding tax on payments by Obligors under this Agreement and the other Loan Documents, or in the case of a Foreign Lender claiming exemption for "portfolio interest" certifying that it is not a foreign corporation, partnership, estate or trust.  In addition, each Foreign Lender shall deliver such forms promptly upon the obsolescence or invalidity of any form previously delivered by such Foreign Lender and at such other times as may be reasonably requested by Agent or Borrower Representative.  Notwithstanding any other provisions of this <B>Section 5.10</B>, a Foreign Lender shall not be required to deliver any form pursuant to this <B>Section 5.10</B> that such Foreign Lender is not legally able to deliver.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc102963345"><A NAME="_Toc105998316"><A NAME="_Toc105998726"><A NAME="_Toc105998858"><A NAME="_Toc117052371">5.11&nbsp;&nbsp;&nbsp;<U>Nature and Extent of Each Borrower's Liability</U>.</A></A></A></A></A></P>
</B><P ALIGN="JUSTIFY">5.11.1&nbsp;&nbsp;&nbsp;<U>Joint and Several Liability</P>
</U><P ALIGN="JUSTIFY">.  Each Borrower shall be liable for, on a joint and several basis, and hereby guarantees the timely payment by all other Borrowers of, all of the Loans and other Obligations, regardless of which Borrower actually may have received the proceeds of any Loans or other extensions of credit hereunder or the amount of such Loans received or the manner in which Agent or any Lender accounts for such Loans or other extensions of credit on its books and records, it being acknowledged and agreed that Loans to any Borrower inure to the mutual benefit of all Borrowers and that Agent and Lenders are relying on the joint and several liability of Borrowers in extending the Loans and other financial accommodations hereunder.  Each Borrower hereby unconditionally and irrevocably agrees that upon default in the payment when due (whether at stated maturity, by acceleration or otherwise) of any principal of, or interest owed on, any of the Loans or other Obligations, such Borrower shall forthwith pay the 
same, without notice or demand.</P>
<P ALIGN="JUSTIFY">5.11.2.&nbsp;&nbsp;&nbsp;<U>Unconditional Nature of Liability</P>
</U><P ALIGN="JUSTIFY">.  Each Borrower's joint and several liability hereunder with respect to, and guaranty of,  the Loans and other Obligations shall, to the fullest extent permitted by Applicable Law, be unconditional irrespective of (i) the validity, enforceability, avoidance or subordination of any of the Obligations or of any promissory note or other document evidencing all or any part of the Obligations, (ii) the absence of any attempt to collect any of the Obligations from any other Obligor or any Collateral or other security therefor, or the absence of any other action to enforce the same, (iii) the waiver, consent, extension, forbearance or granting of any indulgence by Agent or any Lender with respect to any provision of any instrument evidencing or securing the payment of any of the Obligations, or any other agreement now or hereafter executed by any other Borrower and delivered to Agent or any Lender, (iv) the failure by Agent to take any steps to perfect or maintain the perfected status of its
 security interest in or Lien upon, or to preserve its rights to, any of the Collateral or other security for the payment or performance of any of the Obligations or Agent's release of any Collateral or of its Liens upon any Collateral, (v) Agent's or Lenders' election, in any proceeding instituted under the Bankruptcy Code, for the application of Section 1111(b)(2) of the Bankruptcy Code, (vi) any borrowing or grant of a security interest by any other Borrower, as debtor-in-possession under Section 364 of the Bankruptcy Code, (vii) the release or compromise, in whole or in part, of the liability of any Obligor for the payment of any of the Obligations, (viii) any amendment or modification of any of the Loan Documents or any waiver of a Default or Event of Default, (ix) any increase in the amount of the Obligations beyond any limits imposed herein or in the amount of any interest, fees or other charges payable in connection therewith, or any decrease in the same, (x) the disallowance of all or any portion of
 Agent's or any Lender's claims against any other Obligor for the repayment of any of the Obligations under Section 502 of the Bankruptcy Code, or (xi) any other circumstance that might constitute a legal or equitable discharge or defense of any Obligor (other than Full Payment of the Obligations).  After the occurrence and during the continuance of any Event of Default, Agent may proceed directly and at once, without notice to any Obligor, against any or all of Obligors to collect and recover all or any part of the Obligations, without first proceeding against any other Obligor or against any Collateral or other security for the payment or performance of any of the Obligations, and each Borrower waives any provision under Applicable Law to the fullest extent permitted by Applicable Law that might otherwise require Agent to pursue or exhaust its remedies against any Collateral or Obligor before pursuing another&nbsp;Obligor.  Each Borrower  consents and agrees that Agent shall be under no obligation to marsh
al any assets in favor of any Obligor or against or in payment of any or all of the Obligations.</P>
<P ALIGN="JUSTIFY">5.11.3.&nbsp;&nbsp;&nbsp;<U>No Reduction in Liability for Obligations</P>
</U><P ALIGN="JUSTIFY">.  No payment or payments made by an Obligor or received or collected by Agent from a Borrower or any other Person by virtue of any action or proceeding or any setoff or appropriation or application at any time or from time to time in reduction of or in payment of the Obligations shall be deemed to modify, reduce, release or otherwise affect the liability of any Borrower under this Agreement, each of whom shall remain jointly and severally liable for the payment and performance of all Loans and other Obligations until Full Payment of the Obligations.</P>
<P ALIGN="JUSTIFY">5.11.4.&nbsp;&nbsp;&nbsp;<U>Contribution</P>
</U><P ALIGN="JUSTIFY">.  Each Borrower is unconditionally obligated to repay the Obligations as a joint and several obligor under this Agreement.  If, as of any date, the aggregate amount of payments made by a Borrower on account of the Obligations and proceeds of such Borrower's Collateral that are applied to the Obligations exceeds the aggregate amount of Loan proceeds actually used by such Borrower in its business (such excess amount being referred to as an "Accommodation&nbsp;Payment"), then each of the other Borrowers (each such Borrower being referred to as a "Contributing Borrower") shall be obligated to make contribution to such Borrower (the "Paying&nbsp;Borrower") in an amount equal to (A) the product derived by multiplying the sum of each&nbsp;Accommodation Payment of each Borrower by the Allocable Percentage of the Borrower from whom contribution is sought <U>less</U> (B) the amount, if any, of the then outstanding Accommodation Payment of such Contributing Borrower (such last mentioned amount w
hich is to be subtracted from the aforesaid product to be increased by any amounts theretofore paid by such Contributing Borrower by way of contribution hereunder, and to be decreased by any amounts theretofore received by such Contributing&nbsp;Borrower by way of contribution hereunder); <U>provided</U>, <U>however</U>, that a Paying Borrower's recovery of contribution hereunder from the other Borrowers shall be limited to that amount paid by the Paying Borrower in excess of its Allocable Percentage of all Accommodation Payments then outstanding of all Borrowers.  As used herein, the term "Allocable Percentage" shall mean, on any date of determination thereof, a fraction the denominator of which shall be equal to the number of Borrowers who are parties to this Agreement on such date and the numerator of which shall be 1; <U>provided</U>, <U>however</U>, that such percentages shall be modified in the event that contribution from a Borrower is not possible by reason of insolvency, bankruptcy or otherwise by r
educing  such Borrower's Allocable Percentage equitably and by adjusting the Allocable Percentage of the other Borrowers proportionately so that the Allocable Percentages of all Borrowers at all times equals 100%.</P>
<P ALIGN="JUSTIFY">5.11.5.&nbsp;&nbsp;&nbsp;<U>Subordination</P>
</U><P ALIGN="JUSTIFY">.  Each Borrower hereby subordinates any claims, including any&nbsp;right of payment, subrogation, contribution and indemnity, that it may have from or against any other Obligor, and any successor or assign of any other Obligor, including any trustee, receiver or debtor-in-possession, howsoever arising, due or owing or whether heretofore, now or hereafter existing, to the Full Payment of all of the Obligations.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346547"><A NAME="_Toc102963346"><A NAME="_Toc105998317"><A NAME="_Toc105998727"><A NAME="_Toc105998859"><A NAME="_Toc117052372">section 6.&nbsp;&nbsp;&nbsp;TERM AND TERMINATION OF COMMITMENTS</A></A></A></A></A></A></P>
<P ALIGN="JUSTIFY"><A NAME="_Toc38346548"><A NAME="_Toc102963347"><A NAME="_Toc105998318"><A NAME="_Toc105998728"><A NAME="_Toc105998860"><A NAME="_Toc117052373">6.1.&nbsp;&nbsp;&nbsp;<U>Term of Commitments</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Subject to each Lender's right to cease making Loans and other extensions of credit to Borrowers when any Default or Event of Default exists or upon termination of the Commitments as provided in <B>Section 6.2</B>, the Commitments shall be in effect for a period (the "Term") commencing on the date hereof and continuing until the close of business on October 26, 2010, unless sooner terminated as provided in <B>Section 6.2</B>.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346549"><A NAME="_Toc102963348"><A NAME="_Toc105998319"><A NAME="_Toc105998729"><A NAME="_Toc105998861"><A NAME="_Toc117052374">6.2.&nbsp;&nbsp;&nbsp;<U>Termination.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">6.2.1.&nbsp;&nbsp;&nbsp;<U>Termination by Agent</P>
</U><P ALIGN="JUSTIFY">.  Agent may (and upon the direction of the Required Lenders, shall) terminate the Commitments without notice at any time that an Event of Default exists; <U>provided</U>, <U>however</U>, that the Commitments shall automatically terminate as provided in <B>Section 12.2</B>.</P>
<P ALIGN="JUSTIFY">6.2.2.&nbsp;&nbsp;&nbsp;<U>Termination by Borrowers</P>
</U><P ALIGN="JUSTIFY">. Upon at least 10 days prior written notice to Agent (or upon at least 3 days prior written notice to Agent if a Permitted Portfolio Transaction is to occur concurrently with such termination), Borrowers may, at their option, terminate the Commitments; <U>provided</U>, <U>however</U>, no such termination by Borrowers shall be effective until Full Payment of the Obligations.  Any notice of termination given by Borrowers shall be irrevocable unless Agent otherwise agrees in writing.  Borrowers may elect to&nbsp;terminate the Commitments in their entirety only, provided that nothing contained herein shall affect Borrowers' right to voluntarily reduce the Revolver Commitments as provided in <B>Section&nbsp;2.1.5</B>.  No section of this Agreement, Type of Loan available hereunder or Commitment may be terminated by Borrowers singly.</P>
<P ALIGN="JUSTIFY">6.2.3..&nbsp;&nbsp;&nbsp;<U>Reserved</P>
</U><P ALIGN="JUSTIFY">6.2.4.&nbsp;&nbsp;&nbsp;<U>Effect of Termination</P>
</U><P ALIGN="JUSTIFY">.  On the effective date of termination of the Commitments by Agent or by Borrowers, all of the Obligations shall be immediately due and payable, Lenders shall have no obligation to make any Loans, Issuing Bank shall have no obligation to issue any Letters of Credit, and BofA may terminate any Bank Products (including any services or products under Cash Management Agreements).  Agent shall retain its Liens in the Collateral and all&nbsp;of its rights and remedies under the Loan Documents notwithstanding such termination until Full Payment of the Obligations.  Notwithstanding the Full Payment of the Obligations, Agent shall not be required to terminate its Liens in any&nbsp;of the Collateral unless, with respect to any&nbsp;loss or damage Agent may&nbsp;incur as a result of the dishonor or return of any Payment Items applied to the Obligations, Agent shall have received either (i)&nbsp;a written agreement, executed by Borrowers and any Person deemed financially responsible by Agent whos
e loans or other advances to Borrowers are used in whole or in part to satisfy the Obligations, indemnifying Agent and Lenders from any such loss or damage for a period of no more than 60 days; or (ii)&nbsp;such monetary reserves and Liens on the Collateral for such period of time as Agent, in its reasonable discretion, may deem necessary to protect Agent from any such loss or damage.  The provisions of <B>Sections 3.4, 3.7, 3.8, 3.10, 5.5,</B> <B>5.9 </B>and this<B> Section 6.2.4</B> and all obligations of Borrowers to indemnify Agent or any Lender pursuant to this Agreement or any of the other Loan Documents, shall in all&nbsp;events survive any&nbsp;termination of the Commitments and Full Payment of the Obligations.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346550"><A NAME="_Toc102963349"><A NAME="_Toc105998320"><A NAME="_Toc105998730"><A NAME="_Toc105998862"><A NAME="_Toc117052375">section 7.&nbsp;&nbsp;&nbsp;COLLATERAL</A></A></A></A></A></A></P>
<P ALIGN="JUSTIFY"><A NAME="_Toc38346551"><A NAME="_Toc99510211"><A NAME="_Toc102963350"><A NAME="_Toc105998321"><A NAME="_Toc105998731"><A NAME="_Toc105998863"><A NAME="_Toc117052376">7.1.&nbsp;&nbsp;&nbsp;<U>Grant of Security Interest</A></A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  To secure the prompt payment and performance of all of the&nbsp;Obligations, each Borrower hereby grants to Agent, for the benefit of Secured Parties, a continuing security interest in and Lien upon all of such Borrower's right, title and interest in all of the following Property and interests in Property of such Borrower, whether now owned or existing or hereafter created, acquired or arising and wheresoever located:</P>
<P>(i)&#9;all Accounts;</P>
<P>(ii)&#9;all Supporting Obligations</P>
<P ALIGN="JUSTIFY">(iii)&#9;all Goods, including all Inventory and Equipment;</P>
<P>(iv)&#9;all Instruments;</P>
<P>(v)&#9;all Chattel Paper, including Electronic Chattel Paper;</P>
<P>(vi)&#9;all Documents;</P>
<P ALIGN="JUSTIFY">(vii)&#9;all General Intangibles, including Payment Intangibles, Software and Intellectual Property;</P>
<P>(viii)&#9;all Deposit Accounts;</P>
<P ALIGN="JUSTIFY">(ix)&#9;all Investment Property (but excluding any portion thereof that constitutes Margin&nbsp;Stock unless otherwise expressly provided in any Security Documents);</P>
<P>(x)&#9;all Letter-of-Credit Rights;</P>
<P ALIGN="JUSTIFY">(xi)&#9;all monies now or at any time or times hereafter in the possession or under the control of Agent or a Lender or a bailee or Affiliate of Agent or a Lender, including any Cash&nbsp;Collateral in the Cash Collateral Account;</P>
<P ALIGN="JUSTIFY">(xii)&#9;all accessions to, substitutions for and all replacements, products and cash and non-cash proceeds of (i) through (xi) above, including proceeds of and unearned premiums with&nbsp;respect to insurance policies insuring any of the Collateral and claims against any Person for loss of, damage to or destruction of any of the Collateral; and</P>
<P ALIGN="JUSTIFY">(xiii)&#9;all books and records (including customer lists, files, correspondence, tapes, computer programs, print-outs, and other computer materials and records) of such Borrower pertaining to any of (i)&nbsp;through (xii) above.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346552"><A NAME="_Toc102963351"><A NAME="_Toc105998322"><A NAME="_Toc105998732"><A NAME="_Toc105998864"><A NAME="_Toc117052377">7.2.&nbsp;&nbsp;&nbsp;<U>Lien on Deposit Accounts</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  As additional security for the payment and performance of the&nbsp;Obligations, each Borrower hereby grants to Agent, for the benefit of Secured Parties, a continuing security interest in and Lien upon all of such Borrower's right, title and interest in and to each Deposit&nbsp;Account of such Borrower and in and to any deposits or other sums at any time credited to each&nbsp;such Deposit Account, including any sums in any blocked account or any special lockbox account and in the accounts in which sums are deposited.  In&nbsp;connection with the foregoing, each Borrower hereby authorizes and directs each such bank or other depository to pay or deliver to Agent upon&nbsp;its&nbsp;written demand therefor made at any time that an&nbsp;Event&nbsp;of Default exists and without further notice to such Borrower (such&nbsp;notice being hereby expressly waived), all&nbsp;balances in each Deposit Account maintained by such&nbsp;Borrower with such depository for application to the&nbsp;Obli
gations then outstanding, and the rights given Agent in this&nbsp;Section shall be cumulative with and in&nbsp;addition to Agent's other rights and remedies in regard to the&nbsp;foregoing Property as proceeds of Collateral.  Each Borrower hereby irrevocably appoints Agent as such Borrower's attorney-in-fact to collect any and all such balances to the extent any such&nbsp;payment is not made to Agent by such bank or other depository after demand thereon is made by Agent pursuant hereto.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346553"><A NAME="_Toc102963352"><A NAME="_Toc105998323"><A NAME="_Toc105998733"><A NAME="_Toc105998865"><A NAME="_Toc117052378">7.3.&nbsp;&nbsp;&nbsp;<U>Real Estate Collatera</A></A></A></A></A>l</A></P>
</U><P ALIGN="JUSTIFY">.</B>  The due and punctual payment and performance of the Obligations shall also be secured by the Lien created by the Mortgages upon the Real Estate described on <B><U>Exhibit K</U> </B>hereto.  The Mortgages shall be executed by Borrowers in favor of Agent (for the benefit of Secured Parties) on or before the Closing Date and shall be duly recorded, at Borrowers' expense, in each office where such recording is required to&nbsp;constitute a fully perfected Lien upon the Real Estate covered thereby.  If any Borrower shall obtain any interest in any additional Real Estate after the Closing Date (the "After-Acquired Real Estate"), Borrowers shall execute and deliver to Agent, for the benefit of Secured Parties, an amendment to the Negative Pledge Agreements and such other documentation as Agent may reasonably request, pursuant to which Borrowers shall agree that they shall not consensually pledge, assign, transfer, encumber or grant any Lien in favor of any other Person in any such Afte
r-Acquired Real Estate or permit to exist any Lien thereon (other than a Permitted Lien) until the Full Payment of the Obligations.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346554"><A NAME="_Toc102963353"><A NAME="_Toc105998324"><A NAME="_Toc105998734"><A NAME="_Toc105998866"><A NAME="_Toc117052379">7,4,&nbsp;&nbsp;&nbsp;<U>Other Collateral</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">7.4.1<B>.&nbsp;&nbsp;&nbsp;</B><U>Cash Collateral</U>.  </P>
<P ALIGN="JUSTIFY">In addition to the items of Property referred to in <B>Section&nbsp;7.1</B> above, the Obligations shall also be secured by the Cash Collateral to the extent provided herein and all of the&nbsp;other items of Property from time to time described in any of the Security Documents as security for any of the Obligations.</P>
<P ALIGN="JUSTIFY">7.4.2.&nbsp;&nbsp;&nbsp;<U>Commercial Tort Claims</P>
</U><P ALIGN="JUSTIFY">.  Borrowers shall promptly notify Agent in writing upon any Borrower's obtaining a Commercial Tort Claim (other than, for so long as no Default or Event of Default exists, a Commercial Tort Claim that is less than $2,500,000) after the Closing Date against any Person and, upon Agent's written request, promptly execute such instruments or agreements and do such other acts or things deemed appropriate by Agent to confer upon Agent (for the benefit of Secured Parties) a security interest in each such Commercial Tort Claim.</P>
<P ALIGN="JUSTIFY">7.4.3.&nbsp;&nbsp;&nbsp;<U>Certain After-Acquired Collateral</P>
</U><P ALIGN="JUSTIFY">.  Borrowers shall promptly notify Agent in writing upon any Borrower's obtaining any Collateral after the Closing Date consisting of Deposit Accounts (other than any Deposit Account specifically and exclusively used for payroll taxes and other employee wage and benefit payments to or for the benefit of such Borrower's employees), or of any Investment Property, Letter-of-Credit Rights or Chattel Paper involving an amount in excess of $250,000 and, upon Agent's request, shall promptly execute such documents and do such other acts or things deemed necessary by Agent to confer upon Agent a duly perfected first priority Lien upon and (to the extent applicable for the perfection of a Lien) control with respect to such Collateral subject to the terms of and in accordance with the Loan Documents; and promptly notify Agent in writing upon any Borrower's obtaining any Collateral after the Closing Date consisting of Documents or Instruments involving an amount in excess of $250,000 and, upon Age
nt's request, shall promptly execute such documents and do such other acts or things deemed necessary by Agent to deliver to it possession of such Documents and such Instruments.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346555"><A NAME="_Toc102963354"><A NAME="_Toc105998325"><A NAME="_Toc105998735"><A NAME="_Toc105998867"><A NAME="_Toc117052380">7.5.&nbsp;&nbsp;&nbsp;<U>No Assumption of Liability</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.  </B>The security interest granted pursuant to this Agreement is granted as security only and shall not subject Agent or any Lender to, or in any way alter or modify, any&nbsp;obligation or liability of Borrowers with respect to or arising out of the Collateral.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346556"><A NAME="_Toc102963355"><A NAME="_Toc105998326"><A NAME="_Toc105998736"><A NAME="_Toc105998868"><A NAME="_Toc117052381">7.6.&nbsp;&nbsp;&nbsp;<U>Lien Perfection; Further Assurances</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.  </B>Promptly after Agent's request therefor, Borrowers shall execute or cause to be executed and deliver to Agent such instruments, assignments or other documents as are necessary under the UCC or other Applicable Law to perfect (or continue the perfection of) Agent's Lien upon the&nbsp;Collateral and shall take such other action as may be requested by Agent to give effect to or carry out the intent and purposes of this&nbsp;Agreement; <U>provided</U>, <U>however</U>, that Agent will not seek to perfect its Lien on any Collateral under any Applicable Law other than the laws of the United States (other than the Permitted Canadian Inventory) unless (i) a Restrictive Trigger Event has occurred and (ii) Agent elects to do so after the occurrence and during the continuance of a Restrictive Trigger Event.  Unless prohibited by Applicable Law, each Borrower hereby irrevocably authorizes Agent to execute and file in any jurisdiction any&nbsp;financing statement or amendment thereto on such 
Borrower's behalf, including financing statements that indicate the Collateral (i)&nbsp;as all assets or all personal property of such Borrower or words to similar effect or (ii)&nbsp;as being of equal or lesser scope, or with greater or lesser detail, than as set forth in this <B>Section&nbsp;7</B>.  Each Borrower also hereby ratifies its authorization for Agent to have filed in any jurisdiction any like financing statement or amendment thereto if filed prior to the date hereof.  The parties agree that a carbon, photographic or other&nbsp;reproduction of this Agreement shall be sufficient as a financing statement and may be filed in any&nbsp;appropriate office in lieu thereof.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346558"><A NAME="_Toc102963357"><A NAME="_Toc105998328"><A NAME="_Toc105998738"><A NAME="_Toc105998870"><A NAME="_Toc117052382">7.7&nbsp;&nbsp;&nbsp;<U>Foreign Subsidiary Stock</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">.  Notwithstanding anything to the contrary set forth in <B>Section&nbsp;7.1</B> above or in any other provision herein, the types or items of Collateral described in such Section shall include (i) no more than sixty-six percent (66%) of the Equity Interests of any direct Foreign Subsidiary (other than the Equity Interests in Alpharma Bermuda G.P. and, for the avoidance of doubt, any Foreign Subsidiary of Alpharma Bermuda G. P. none of which shall be pledged to the Secured Parties) and (ii) no more than sixty-six percent (66%) of the Equity Interests of any Domestic Subsidiary whose sole asset is the stock of Foreign Subsidiaries.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc117052383">7.8.&nbsp;&nbsp;&nbsp;<U>Certain Exclusions</A></P>
</B></U><P ALIGN="JUSTIFY">(a)&#9;Notwithstanding anything to the contrary set forth in <B>Section 7.1 </B>above, the types or items of Collateral described in <B>Section 7.1</B> shall not include any rights or interests in any contract if under the terms of such contract, or any Applicable Law with respect thereto, the valid grant of a security interest or other Lien therein to Agent is prohibited and such prohibition has not been or is not waived or the consent of the other party to such contract has not been or is not otherwise obtained or under Applicable Law such prohibition cannot be waived, provided that the foregoing exclusion shall in no way be construed (i) to apply if any such prohibition is ineffective or unenforceable under the UCC (including Sections 9-406, 9-407, 9-408 or 9-409) or any other Applicable Law or (ii) so as to limit, impair or otherwise affect Agent's unconditional continuing security interest in and Lien upon any rights or interests of Borrowers in or to monies due or to become d
ue under any such contract (including any Accounts).  If requested by Agent, Borrowers shall make a good faith and diligent effort to obtain the consent of any other party to a contract for the creation of a security interest in favor of Agent in each Borrower's rights under such contract.</P>
<P ALIGN="JUSTIFY">(b)&#9;Notwithstanding anything to the contrary set forth in <B>Section 7.1</B> above, the types or items of Collateral described in <B>Section 7.1</B> shall not include any rights or interests in any intent-to-use trademark applications ("ITUs") to the extent that the pledge or encumbrance of such ITUs would render them invalid.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346559"><A NAME="_Toc102963358"><A NAME="_Toc105998329"><A NAME="_Toc105998739"><A NAME="_Toc105998871"><A NAME="_Toc117052384">section 8.&nbsp;&nbsp;&nbsp;COLLATERAL ADMINISTRATION</A></A></A></A></A></A></P>
<P ALIGN="JUSTIFY"><A NAME="_Toc38346560"><A NAME="_Toc102963359"><A NAME="_Toc105998330"><A NAME="_Toc105998740"><A NAME="_Toc105998872"><A NAME="_Toc117052385">8.1&nbsp;&nbsp;&nbsp;<U>General Provisions.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">8.1.1.&nbsp;&nbsp;&nbsp;<U>Location of Collateral</P>
</U><P ALIGN="JUSTIFY">.  All tangible items of Collateral, other than Inventory in&nbsp;transit, shall at all times be kept by Borrowers at one or more of the business locations of Borrowers set&nbsp;forth in <B><U>Schedule&nbsp;8.1.1</B></U> hereto and shall not be moved therefrom, without the prior written approval of Agent, except that in the absence of an Event of  Default and acceleration of the maturity of the&nbsp;Obligations in consequence thereof, Borrowers may (i)&nbsp;make sales or other dispositions of any Collateral to the extent authorized by <B>Section&nbsp;10.2.10</B> and (ii)&nbsp;move Inventory or Equipment or any record relating to any Collateral to a location in the United&nbsp;States or Canada other than those shown on <B><U>Schedule&nbsp;8.1.1</B></U> hereto so long as (a) Borrowers have given Agent at least 10&nbsp;days prior written notice of such new location, (b) to the extent that any Equipment constitutes fixtures, a UCC fixture filing has been filed with respect to such Equipmen
t, (c) if the location of such Collateral is not owned by a Borrower, then a Lien Waiver has been delivered to Agent or if Agent elects, a Rent Reserve has been established by Agent (<U>provided</U>, <U>however</U>, that no Lien Waiver shall be required if Agent elects to establish a Rent Reserve or alternatively, elects to not impose a Rent Reserve); <U>provided</U>, that if the book value of the Collateral is less than $250,000 and such Collateral is ineligible for purposes of the Borrowing Base then no Rent Reserve or Lien Waiver shall be required; and (d) Borrowers shall have executed and delivered to Agent or caused to be executed and delivered to Agent such other documentation as Agent may reasonably request to ensure Agent's first priority Lien in the Collateral.</P>
<P ALIGN="JUSTIFY">8.1.2.&nbsp;&nbsp;&nbsp;<U>Insurance of Collateral; Condemnation Proceeds.</P>
</U><P ALIGN="JUSTIFY">(i)&#9;The Borrowers shall maintain and pay for insurance upon all Collateral, wherever located, covering casualty, hazard, public liability, theft, malicious mischief, and such other risks in such amounts and with such insurance companies as are reasonably satisfactory to Agent.  <B><U>Schedule&nbsp;8.1.2</B></U> describes all insurance of Borrowers in effect on the date hereof.  All&nbsp;proceeds payable under each such policy in respect of loss to Collateral (other than business interruption insurance, workers compensation, executive management coverages, and key man life insurance) shall be payable to Agent for application to the&nbsp;Obligations in accordance with this Agreement.  Borrowers shall deliver certified copies of such policies to Agent with satisfactory lender's loss payable endorsements reasonably satisfactory to Agent naming Agent as sole lender's loss payee or additional insured, and mortgagee, as appropriate.  Each policy of insurance or endorsement shall contain a 
clause requiring the insurer to give not less than 30 days prior written notice to Agent in the event of cancellation of the policy for any reason whatsoever and a clause specifying that the interest of Agent shall not be impaired or invalidated by any act or neglect of any Borrower or the owner of the Property or by the occupation of the premises for purposes more hazardous than are permitted by said policy.  If Borrowers fail to provide and pay for such insurance, Agent may, at its option, but shall&nbsp;not be required to, procure the same and charge Borrowers therefor.  At Agent's request, Borrowers agree to deliver to Agent, promptly as rendered, true copies of all loss runs and valuations.  Borrowers shall have the right to settle, adjust and compromise any claim with respect to any insurance maintained by such Borrower provided that all proceeds thereof (other than business interruption insurance, workers compensation, executive management coverages, and key man life insurance) are applied in the mann
er specified in this Agreement, and Agent agrees promptly to provide any necessary endorsement to any checks or drafts issued in payment of any such claim.  At any time that an Event of Default exists, Agent shall have the right to settle, adjust and compromise such claims in respect of loss to Collateral (other than business interruption insurance, workers compensation, executive management coverages, and key man life insurance), and Agent shall have all rights and remedies with respect to such&nbsp;policies of insurance as are provided for in this Agreement and the other Loan Documents.</P>
<P ALIGN="JUSTIFY">(ii)&#9;Any proceeds of insurance referred to in this <B>Section&nbsp;8.1.2</B> in respect of loss to Collateral (other than proceeds from any workers' compensation, executive management coverages insurance, key man or business interruption insurance) and any&nbsp;condemnation awards that are paid to Agent in connection with a condemnation of any of the&nbsp;Collateral shall be paid to Agent and applied (except to the extent otherwise provided in <B>Section 5.3.3</B>), first to the payment of the Revolver Loans, and then to any other Obligations outstanding; <U>provided</U>, <U>however</U>, that if an Event of Default exists on the date of Agent's receipt thereof, Agent may apply such proceeds to the Obligations in the order of application provided in <B>Section 5.6.1</B>.</P>
<P ALIGN="JUSTIFY">8.1.3.&nbsp;&nbsp;&nbsp;<U>Protection of Collateral</P>
</U><P ALIGN="JUSTIFY">.  All expenses of protecting, storing, warehousing, insuring, handling, maintaining and shipping any Collateral, all Taxes imposed under any Applicable Law on any of the&nbsp;Collateral or in respect of the sale thereof, and all other payments required to be made by Agent to any&nbsp;Person to realize upon any Collateral shall be borne and paid by Borrowers.  Agent shall not be liable or responsible in any way for the safekeeping of any of the Collateral or for any loss or damage thereto (except for reasonable care in the custody thereof while any&nbsp;Collateral is in Agent's actual possession) or for any diminution in the value thereof, or for any act or default of any warehouseman, carrier, forwarding agency, or other Person whomsoever, but the same shall be at Borrowers' sole risk.</P>
<P ALIGN="JUSTIFY">8.1.4.&nbsp;&nbsp;&nbsp;<U>Defense of Title to Collateral</P>
</U><P ALIGN="JUSTIFY">.  Each Borrower shall at all times defend such Borrower's title to the Collateral and Agent's Liens therein against all Persons and all claims and demands whatsoever other than Permitted Liens.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346561"><A NAME="_Toc102963360"><A NAME="_Toc105998331"><A NAME="_Toc105998741"><A NAME="_Toc105998873"><A NAME="_Toc117052386">8.2&nbsp;&nbsp;&nbsp;<U>Administration of Accounts.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">8.2.1.&nbsp;&nbsp;&nbsp;<U>Records and Schedules of Accounts</P>
</U><P ALIGN="JUSTIFY">.  Each Borrower shall keep accurate and complete records of its Accounts and all payments and collections thereon and shall submit to Agent on such periodic basis as Agent shall request (but no more frequently than monthly unless an Event of Default exists) a sales and collections report for the preceding period, in form satisfactory to Agent.  Each Borrower shall also provide to Agent on or before the 25th day of each month, a detailed aged trial balance of all Accounts existing as of the last day of the preceding month, specifying the names, addresses, face&nbsp;value, dates of invoices and due dates for each Account Debtor obligated on an Account so listed ("Schedule of Accounts"), and, upon Agent's request therefor, copies of proof of delivery and a&nbsp;copy of all documents, including repayment histories and present status reports relating to the Accounts so scheduled and such other matters and information relating to the status of then&nbsp;existing Accounts as Agent shall&nbsp
;reasonably request.  In addition, if Accounts in an aggregate&nbsp;face&nbsp;amount in excess of $2,500,000 either cease to be or become Eligible Accounts in whole or in part, Borrowers (x) shall notify Agent of such occurrence relating to Accounts ceasing to be Eligible Accounts promptly (and in any&nbsp;event within 3 Business Days) after any Borrower's having obtained actual knowledge of such occurrence and (y) may notify Agent of such occurrence relating to Accounts becoming Eligible Accounts and the&nbsp;Borrowing Base shall thereupon be adjusted to reflect such&nbsp;occurrence.</P>
<P ALIGN="JUSTIFY">8.2.2.&nbsp;&nbsp;&nbsp;<U>Discounts, Disputes and Returns</P>
</U><P ALIGN="JUSTIFY">.  If any Borrower grants any material discounts, allowances or credits outside of the Ordinary Course of Business for the Account involved, such Borrower shall report such discounts, allowances or credits, as the case may be, to Agent as part of the next required Schedule of Accounts.  If any amounts due and owing in excess of $2,500,000 are in dispute between any Borrower and any Account Debtor, such Borrower shall at the Agent's reasonable request provide Agent with written notice thereof at the time of submission of the next Schedule of Accounts, explaining in detail the reason for the dispute, all claims related thereto and the amount in controversy.</P>
<P ALIGN="JUSTIFY">8.2.3.&nbsp;&nbsp;&nbsp;<U>Taxes</P>
</U><P ALIGN="JUSTIFY">.  If an Account of any Borrower includes a charge for any Taxes payable to any&nbsp;Governmental Authority, Agent is authorized, in its discretion, to pay the amount thereof to the&nbsp;proper taxing authority for the account of such Borrower and to charge Borrowers therefor; <U>provided</U>, <U>however</U>, that neither Agent nor Lenders shall be liable for any Taxes that may be due by Borrowers.</P>
<P ALIGN="JUSTIFY">8.2.4.&nbsp;&nbsp;&nbsp;<U>Account Verification</P>
</U><P ALIGN="JUSTIFY">.  Whether or not a Default or an Event of Default exists, Agent&nbsp;shall have the right at any time, in the name of Agent, any designee of Agent or any Borrower to verify the&nbsp;validity, amount or any other matter relating to any Accounts of such Borrower by mail, telephone, telegraph or otherwise.  Borrowers shall cooperate fully with Agent in an effort to facilitate and promptly conclude any&nbsp;such verification process.</P>
<P ALIGN="JUSTIFY">8.2.5.&nbsp;&nbsp;&nbsp;<U>Maintenance of Dominion Account.</P>
</U><P ALIGN="JUSTIFY">(i)&#9;Borrowers shall establish and maintain a Dominion Account pursuant to a lockbox or other arrangement acceptable to Agent with BofA or any of its Affiliates.  Borrowers shall issue to each such lockbox bank an irrevocable letter of instruction directing such bank to deposit all payments or other remittances received in the lockbox to the Dominion Account.  Borrowers shall enter into agreements, in form reasonably satisfactory to Agent, with each bank at which a Dominion Account is maintained regarding the transfer of monies from the Dominion Account to the Payment Account to the extent required by <B>subparagraph (ii) </B>below. All funds deposited in each Dominion Account shall be subject to Agent's Lien.  Borrowers shall obtain the agreement (in favor of and in form and content reasonably satisfactory to Agent and Lenders) by each bank at which a Dominion Account is maintained to waive any offset rights against the funds deposited into such Dominion Account, except offset right
s in respect of charges incurred in the administration of such Dominion Account.  Neither Agent nor Lenders assume any responsibility to Borrowers for such lockbox arrangement or Dominion Account, including any claim of accord and satisfaction or release with respect to deposits accepted by any bank thereunder.</P>
<P ALIGN="JUSTIFY">(ii)&#9;If  a Restrictive Trigger Event occurs, then all monies in the Dominion Account shall be deposited by Agent in the Payment Account and applied to the Obligations as determined by Agent.  If after the occurrence of a Restrictive Trigger Event, Availability is at least $25,000,000 for 90 consecutive days and no Event of Default exists, then as soon as practicable but in any event within 10 Business Days thereafter (the "Dominion Spring-Back Date"), Agent will permit Borrowers to access the monies in the Dominion Account for use as provided in <B>Section 2.1.3 hereof.</B>  If an Event of Default exists, Borrowers shall not be permitted to access any monies in the Dominion Account.  If a Restrictive Trigger Event has occurred as a result of an Event of Default and not as a result of the failure by Borrowers to meet the Availability or Average Availability requirements, and Agent (or to the extent required by this Agreement, all Lenders or Required Lenders) waives the Event of Default i
n writing, then the Dominion Spring-Back Date shall occur on the 10<SUP>th</SUP> Business Day after the waiver of such Event of Default.</P>
<P ALIGN="JUSTIFY">8.2.6.&nbsp;&nbsp;&nbsp;<U>Collection of Accounts and Proceeds of Collateral</P>
</U><P ALIGN="JUSTIFY">.  To expedite collection of Accounts, each&nbsp;Borrower shall endeavor in the first instance to make collection of such Borrower's Accounts for Agent and Lenders.  Borrowers shall request in writing and otherwise take such reasonable steps to ensure that all Account Debtors forward payment directly to such Dominion Account (or lockboxes related to the Dominion Account), and (ii) deposit and cause its Subsidiaries to deposit or cause to be deposited promptly, and in any event no later than the first Business Day after the date of receipt thereof, all cash, checks, drafts or other similar items of payment relating to or constituting payments made in respect of any and all Collateral (whether or not otherwise delivered to a lockbox) into the Dominion Account.  Borrowers shall issue to each such lockbox bank an irrevocable letter of instruction directing such bank to deposit all payments or other remittances received in the lockbox to the Dominion Account.  All&nbsp;Payment Items receive
d by any Borrower in respect of its Accounts, together with the&nbsp;proceeds of any other Collateral, shall be held by such Borrower as trustee of an express trust for Agent's and Lenders' benefit; Borrowers shall immediately deposit same in kind in the Dominion Account.  Agent retains the right at all&nbsp;times that an Event&nbsp;of Default exists to notify Account Debtors of any Borrower that Accounts have been assigned to Agent, to collect Accounts directly in its own name (and, in connection therewith, to settle or adjust all disputes and claims directly with the Account Debtor and to compromise the amount or extend the time for payment of any Accounts upon such terms and conditions as Agent may deem advisable in its reasonable credit judgment and to charge&nbsp;to Borrowers the collection costs and expenses incurred by Agent, including reasonable attorneys' fees).</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346562"><A NAME="_Toc102963361"><A NAME="_Toc105998332"><A NAME="_Toc105998742"><A NAME="_Toc105998874"><A NAME="_Toc117052387">8.3&nbsp;&nbsp;&nbsp;<U>Administration of Inventory.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">8.3.1.&nbsp;&nbsp;&nbsp;<U>Records and Reports of Inventory</P>
</U><P ALIGN="JUSTIFY">.  Each Borrower shall keep accurate and complete records of its Inventory (including records showing the cost thereof and daily withdrawals therefrom and additions thereto) in all material respects and shall furnish Agent inventory report summaries respecting such Inventory in form and detail reasonably satisfactory to Agent at such times as Agent may reasonably request.  Each Borrower shall, at its own expense, conduct a physical inventory no less frequently than annually (and on a more frequent basis if requested by Agent when an Event of Default exists) and periodic cycle counts consistent with such Borrower's historical practices and shall&nbsp;provide to Agent a report based on each such physical inventory and cycle count promptly after completion thereof, together with such supporting information as Agent&nbsp;shall reasonably request.  Agent may participate in and observe each physical count of Inventory, which participation shall be at Borrowers' expense at any time that an Ev
ent of Default exists.</P>
<P ALIGN="JUSTIFY">8.3.2.&nbsp;&nbsp;&nbsp;<U>Returns of Inventory</P>
</U><P ALIGN="JUSTIFY">.  No Borrower shall return any of its Inventory to a supplier or vendor thereof, or any other Person, whether for cash, credit against future purchases or then existing payables, or otherwise, unless (i)&nbsp;such return is in the Ordinary Course of Business of such Borrower and such&nbsp;Person; (ii)&nbsp;no Default or Event of Default exists or would result therefrom; (iii)&nbsp;the return of such&nbsp;Inventory will not result in an Out-of-Formula Condition; (iv)&nbsp;such Borrower promptly notifies Agent thereof if the aggregate Value of all&nbsp;Inventory returned in any month exceeds $2,500,000.</P>
<P ALIGN="JUSTIFY">8.3.3.&nbsp;&nbsp;&nbsp;<U>Acquisitions and Sale of Inventory</P>
</U><P ALIGN="JUSTIFY">.  No Borrower shall acquire or accept any Inventory on&nbsp;consignment or approval and will use all reasonable efforts to insure that all Inventory that is produced in the&nbsp;United States of America will be produced in accordance with the FLSA.</P>
<P ALIGN="JUSTIFY">8.3.4.&nbsp;&nbsp;&nbsp;<U>Maintenance of Inventory</U>.  </P>
<P ALIGN="JUSTIFY">Borrowers shall produce, use, store and maintain all Inventory with all reasonable care and caution in accordance with applicable standards of any insurance and in conformity with Applicable Law (including the requirements of the FLSA and the United States Food and Drug Administration).</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346563"><A NAME="_Toc102963362"><A NAME="_Toc105998333"><A NAME="_Toc105998743"><A NAME="_Toc105998875"><A NAME="_Toc117052388">8.4&nbsp;&nbsp;&nbsp;<U>Administration of Equipment.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">8.4.1&nbsp;&nbsp;&nbsp;<U>Records and Schedules of Equipment</P>
</U><P ALIGN="JUSTIFY">.  Each Borrower shall keep accurate records itemizing and describing the kind, type, quality, quantity and cost of its Equipment and all dispositions made in accordance with <B>Section&nbsp;8.4.2</B> in all material respects.  So long as the Fixed Asset Sublimit and the Term Loan remain outstanding, at Agent's request, Borrowers shall furnish Agent with a current schedule containing the foregoing information (but no more frequently than annually unless an Event of Default exists).</P>
<P ALIGN="JUSTIFY">8.4.2.&nbsp;&nbsp;&nbsp;<U>Dispositions of Equipment</P>
</U><P ALIGN="JUSTIFY">.  No Borrower shall sell, lease or otherwise dispose of or transfer any of the Equipment or any part thereof, whether in a single transaction or a series of related transactions, without the prior written consent of Agent (acting at the direction of the Required Lenders), other than (i)&nbsp;a disposition of Equipment that qualifies as a Permitted Asset Disposition and (ii)&nbsp;disposition of Equipment that is&nbsp;substantially worn, damaged or obsolete, provided that any replacement Equipment shall be free and clear of Liens other than Permitted Liens.</P>
<P ALIGN="JUSTIFY">8.4.3.&nbsp;&nbsp;&nbsp;<U>Condition of Equipment</P>
</U><P ALIGN="JUSTIFY">.  The Equipment is in good operating condition and repair, and all necessary replacements of and repairs thereto shall be made so that the value and operating efficiency of the Equipment shall be maintained and preserved, reasonable wear and tear excepted.  No Borrower shall permit any of the Eligible Equipment or Equipment having a book value in excess of $1,000,000 to become affixed to any real Property leased to such Borrower so that an interest arises therein under the real estate laws of the applicable jurisdiction unless the landlord of such real Property has executed a Lien Waiver in favor of and in form acceptable to Agent or if Agent elects, a Rent Reserve has been established by Agent (provided, that no Lien Waiver shall be required if Agent elects to establish a Rent Reserve or alternatively, elects not to impose a Rent Reserve), and no Borrower will permit any of the Eligible Equipment or Equipment having a book value in excess of $1,000,000 to become an accession to any p
ersonal Property that is&nbsp;subject to a Lien unless the Lien is a Permitted Lien.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc102963363"><A NAME="_Toc105998334"><A NAME="_Toc105998744"><A NAME="_Toc105998876"><A NAME="_Toc117052389">8.5&nbsp;&nbsp;&nbsp;<U>Administration of Deposit Accounts</A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">Each Borrower represents that, as of the closing date, <B><U>Schedule&nbsp;8.5</B></U> (as the same may be amended or supplemented from time to time) sets forth all of the Deposit Accounts maintained by each Borrower, including Deposit Accounts into which all Payment Items relating to any Collateral will be deposited; each Borrower is the sole account holder of each such Deposit Account and is not aware of any Person (other than Agent) having either dominion or control (within the meaning of Section 9-104 of the UCC) over any such Deposit Account or any property deposited therein (other than any such control that has been released or terminated on or before the Closing Date and control arising by operation of law in favor the depository bank in which such Deposit Account is maintained); and on or before November 30, 2005, each Borrower shall take all actions required to establish Agent's "control" (within the meaning of Section 9-104 of the UCC) over all Deposit Accounts (other tha
n any Deposit Accounts specially and exclusively used for payroll taxes and other employee wage and benefit payments to or for the benefit of such Borrower's employees).  Each Borrower shall promptly notify Agent of any additional Deposit Account opened and any Deposit Account that is closed (other than any Deposit Accounts specifically and exclusively used for payroll tax and other employee wage and benefit payments to or for the benefit of such Borrower's employees), and such notice will amend <B><U>Schedule&nbsp;8.5</B></U> to reflect such addition or deletion.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346564"><A NAME="_Toc102963364"><A NAME="_Toc105998335"><A NAME="_Toc105998745"><A NAME="_Toc105998877"><A NAME="_Toc117052390">8.6.&nbsp;&nbsp;&nbsp;<U>Borrowing Base Certificates</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  On the Closing Date and on or before the 25<SUP>th</SUP> day after the last day of each month thereafter, Borrowers shall deliver to Agent (and Agent shall, on request from a Lender, promptly deliver to such Lender) a Borrowing Base Certificate prepared as of the close of business of the previous month, and at such other times as Agent may request.  All calculations of Availability in connection with any Borrowing Base Certificate shall originally be made by Borrowers and certified by a Senior Officer to Agent, provided that Agent shall have the right to review and adjust, in the exercise of its reasonable credit judgment, any such calculation to the extent that such calculation is not in accordance with this Agreement or does not accurately reflect the amount of the Availability&nbsp;Reserve.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346565"><A NAME="_Toc102963365"><A NAME="_Toc105998336"><A NAME="_Toc105998746"><A NAME="_Toc105998878"><A NAME="_Toc117052391">section 9.&nbsp;&nbsp;&nbsp;REPRESENTATIONS AND WARRANTIES</A></A></A></A></A></A></P>
<P ALIGN="JUSTIFY"><A NAME="_Toc38346566"><A NAME="_Toc102963366"><A NAME="_Toc105998337"><A NAME="_Toc105998747"><A NAME="_Toc105998879"><A NAME="_Toc117052392">9.1&nbsp;&nbsp;&nbsp;<U>General Representations and Warranties</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  To induce Agent and Lenders to enter into this Agreement and to make available the Commitments, each Borrower warrants and represents to Agent and Lenders that:</P>
<P ALIGN="JUSTIFY">9.1.1.&nbsp;&nbsp;&nbsp;<U>Organization and Qualification</P>
</U><P ALIGN="JUSTIFY">.  Each Borrower and each of its Domestic Subsidiaries is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization.  Each Borrower and each of its Domestic Subsidiaries is duly qualified and is authorized to do business and is in good&nbsp;standing as a foreign corporation in each state or jurisdiction listed on <B><U>Schedule&nbsp;9.1.1</B></U> hereto and in all other states and jurisdictions in which the failure of such Borrower or any of such Domestic Subsidiaries to be so qualified would have a&nbsp;Material Adverse Effect.</P>
<P ALIGN="JUSTIFY">9.1.2.&nbsp;&nbsp;&nbsp;<U>Power and Authority</P>
</U><P ALIGN="JUSTIFY">.  Each Borrower and each of its Domestic Subsidiaries is duly authorized and empowered to enter into, execute, deliver and perform this Agreement and each of the other Loan Documents to&nbsp;which it is a party.  The execution, delivery and performance of this Agreement and each of the other Loan Documents have been duly authorized by all necessary corporate action and do not and will not (i)&nbsp;require any consent or approval of any of the holders of the Equity Interests of any Borrower or any of its Domestic Subsidiaries other than those obtained on or prior to the date hereof; (ii)&nbsp;contravene the Organic Documents of any Borrower or any of its Domestic Subsidiaries; (iii)&nbsp;violate, or cause any Borrower or any of its Domestic Subsidiaries to be in default under, any provision of any Applicable  Law, order, writ, judgment, injunction, decree, determination or award in effect having applicability to any Borrower or any of its Domestic Subsidiaries except to the extent such
 violation or default could not reasonably be expected to result in a Material Adverse Effect; (iv)&nbsp;result in a breach of or constitute a default under any indenture or loan or credit agreement or any other agreement, lease or instrument to which any Borrower or any of its Domestic Subsidiaries is a party or by which it or its Properties may be bound or affected; or (v)&nbsp;result in, or require, the creation or imposition of any Lien (other than Permitted Liens) upon or with respect to any of the Properties now owned or hereafter acquired by any Borrower or any of its Domestic Subsidiaries.</P>
<P ALIGN="JUSTIFY">9.1.3.&nbsp;&nbsp;&nbsp;<U>Legally Enforceable Agreement</P>
</U><P ALIGN="JUSTIFY">.  This Agreement is, and each of the other Loan Documents when delivered under this Agreement will be, a legal, valid and binding obligation of each&nbsp; Borrower and each of its Domestic Subsidiaries signatories thereto enforceable against them in accordance with the&nbsp;respective terms of such Loan Documents, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors'&nbsp;rights and subject to general principles of equity, regardless of whether considered in a proceeding in equity or at law.</P>
<P ALIGN="JUSTIFY">9.1.4.&nbsp;&nbsp;&nbsp;<U>Capital Structure</P>
</U><P ALIGN="JUSTIFY">.  As of the date hereof, <B><U>Schedule&nbsp;9.1.4</B></U> hereto states (i)&nbsp;the correct name of each Borrower, its jurisdiction of incorporation and except for Parent, the percentage of its Equity Interests having voting powers owned by each Person, (ii)&nbsp;the name of each Borrower's Subsidiaries and (iii)&nbsp;the number of authorized and issued Equity Interests (and treasury&nbsp;shares) of each Borrower (other than Parent) and its Subsidiaries.  Each Borrower has good title to all of the shares it purports to own of the Equity Interests of each of its Domestic Subsidiaries and any Foreign Subsidiary subject to a Pledge Agreement, free and clear in each case of any Lien other than Permitted Liens.  All&nbsp;such Equity Interests have been duly issued and are fully paid and non-assessable.  As of the date hereof, since the date of the financial statements of Borrowers referred to in <B>Section&nbsp;9.1.9</B>, Borrowers have not made, or obligated themselves to make, any Dist
ribution.  Except as set forth in <B><U>Schedule 9.1.4</B></U>, as of the date hereof, there are no outstanding options to purchase, or any rights or warrants to subscribe for, or any commitments or agreements to issue or sell, or any Equity Interests or obligations convertible into, or any powers of attorney relating to, shares of the capital stock of any Borrower or any of its Domestic Subsidiaries and any Foreign Subsidiary subject to a Pledge Agreement.  Except as set forth on <B><U>Schedule&nbsp;9.1.4</B></U> hereto, as of the date hereof there are no outstanding agreements or instruments binding upon the holders of any Borrower's Equity Interests relating to the ownership of its Equity Interests.</P>
<P ALIGN="JUSTIFY">9.1.5.&nbsp;&nbsp;&nbsp;<U>Corporate Names</P>
</U><P ALIGN="JUSTIFY">.  During the 4-year period preceding the date of this Agreement, no Borrower nor any of its Domestic Subsidiaries has been known as or used any corporate, fictitious or trade names except those listed on <B><U>Schedule&nbsp;9.1.5</B></U> hereto.  During the 4-year period preceding the date of this Agreement, except as set forth on <B><U>Schedule&nbsp;9.1.5</B></U>, no Borrower nor any&nbsp;of its Domestic Subsidiaries has been the surviving corporation of a merger or consolidation or acquired all or substantially all&nbsp;of the assets of any Person other than another Borrower or Subsidiary.</P>
<P ALIGN="JUSTIFY">9.1.6.&nbsp;&nbsp;&nbsp;<U>Business Locations; Agent for Process</P>
</U><P ALIGN="JUSTIFY">.  As of the date hereof, the chief executive office and other places of business of each Borrower and its Domestic Subsidiaries are as listed on <B><U>Schedule&nbsp;8.1.1</B></U> hereto.  During the 4-year period preceding the date of this Agreement, no Borrower nor any of its Domestic Subsidiaries has had an office or place of business at which Inventory or Equipment having a book value of $1,000,000 or more was located other than as listed on <B><U>Schedule&nbsp;8.1.1</B></U>.  Except as shown on <B><U>Schedule&nbsp;8.1.1</B></U> on the date hereof, no Inventory of any Borrower or any of its Domestic Subsidiaries is stored with a&nbsp;bailee, warehouseman or similar Person, nor is any Inventory consigned to any Person other than IVS Animal Health, Inc.</P>
<P ALIGN="JUSTIFY">9.1.7.&nbsp;&nbsp;&nbsp;<U>Title to Properties; Priority of Liens</P>
</U><P ALIGN="JUSTIFY">.  Each Borrower and each of its Domestic Subsidiaries has good and marketable title to and fee simple ownership of, or valid and subsisting leasehold interests in, all of its Eligible Real Estate, and good title to all of its personal Property, including all Property reflected in the financial statements referred to in <B>Section 9.1.9</B> or delivered pursuant to <B>Section&nbsp;10.1.3</B>, in each case free and clear of all Liens except Permitted Liens.  Each Borrower has paid or discharged, or will timely pay or discharge, and has caused each of its Domestic Subsidiaries to pay and discharge or will cause them to timely pay or discharge, all lawful claims which, if unpaid, could become a Lien against any Properties of such Borrower or any such&nbsp;Subsidiary that is not a Permitted Lien.  The Liens granted to Agent pursuant to this&nbsp;Agreement and the other Security Documents are duly perfected Liens.</P>
<P ALIGN="JUSTIFY">9.1.8.&nbsp;&nbsp;&nbsp;<U>Accounts</P>
</U><P ALIGN="JUSTIFY">.  Agent may rely, in determining which Accounts are Eligible Accounts, on&nbsp;all statements and representations made by Borrowers with respect to any Account.  Unless otherwise indicated in writing to Agent or specifically excluded by Borrowers in their calculation of the Borrowing Base in any Borrowing Base Certificate, with respect to each Eligible Account, each Borrower warrants that:</P>
<P ALIGN="JUSTIFY">(i)&#9;It is genuine and in all respects what it purports to be, and it is not evidenced by a judgment;</P>
<P ALIGN="JUSTIFY">(ii)&#9;It arises out of a completed, <I>bona fide</I> sale and delivery of goods by a Borrower in the Ordinary Course of Business and substantially in&nbsp;accordance with the terms and conditions of all purchase orders, contracts or other documents relating thereto and forming a part of the contract between a Borrower and the Account Debtor;</P>
<P ALIGN="JUSTIFY">(iii)&#9;It is for a sum certain (subject to the adjustments contemplated in the contract giving rise to such Account) maturing as stated in the duplicate invoice covering such sale or the contract giving rise to such Account, a copy of which has been furnished or is available to Agent on request;</P>
<P ALIGN="JUSTIFY">(iv)&#9;Such Account, and Agent's security interest therein, is not subject to any offset, Lien, deduction, defense, dispute, counterclaim or any other adverse condition except for disputes resulting in returned goods where the amount in controversy is immaterial, and except for offsets, deductions, rebates or returns contemplated by the invoice or the contract giving rise to such Account or evidencing an Account or arising in the Ordinary Course of Business, each&nbsp;such Account is absolutely owing to a Borrower and is not contingent in any respect or for any&nbsp;reason;</P>
<P ALIGN="JUSTIFY">(v)&#9;Such Borrower has not made any agreement with any Account Debtor thereunder for any extension, compromise, settlement or modification of any such Account or any&nbsp;deduction therefrom, except discounts or allowances which are granted by a Borrower in the&nbsp;Ordinary Course of Business; and</P>
<P ALIGN="JUSTIFY">(vi)&#9;To the best of such Borrower's knowledge, there are no facts, events or occurrences which are reasonably likely to impair the collectibility, validity or enforceability of such Account or reduce the amount payable thereunder from the face amount of the invoice as may be adjusted pursuant to the related contract and statements delivered to Agent with respect thereto.</P>
<P ALIGN="JUSTIFY">9.1.9.&nbsp;&nbsp;&nbsp;<U>Financial Statements; Fiscal Year</P>
</U><P ALIGN="JUSTIFY">.  The Consolidated and consolidating balance sheets of Parent and its Subsidiaries as of December 31, 2004, and the related statements of income, changes in stockholder's equity, and changes in financial position for the periods ended on such dates, have been prepared in accordance with GAAP and present fairly in all material respects the financial positions of Parent's and its Subsidiaries', including Borrowers' at such dates and the results of Parent's and its Subsidiaries', including Borrowers' operations for such periods.  Since&nbsp;December 31, 2004, there has been no Material Adverse Effect.</P>
<P ALIGN="JUSTIFY">9.1.10.&nbsp;&nbsp;&nbsp;<U>Full Disclosure</P>
</U><P ALIGN="JUSTIFY">.  The financial statements referred to in <B>Section&nbsp;9.1.9</B> do not contain any untrue statement of a material fact and no written statement concerning the Consolidated Group furnished by or on behalf of Borrowers under this Agreement to Agent or any Lender contains or omits any material fact necessary, when taken as a whole, as of the date hereof to make the statements contained herein or therein not materially misleading; <U>provided</U>, that, with respect to projected financial information Borrowers represent only that such information was prepared in good faith based upon assumptions believed in good faith to be reasonable at the time made.  There is no fact or circumstances in existence on the date hereof which any Borrower has failed to disclose to Agent in writing that could reasonably be expected to have a Material Adverse Effect.</P>
<P ALIGN="JUSTIFY">9.1.11.&nbsp;&nbsp;&nbsp;<U>Solvent Financial Condition</P>
</U><P ALIGN="JUSTIFY">.  The Consolidated Group, taken as a whole, is now Solvent and, after giving effect to the Loans to be made hereunder, the LC Obligations to be incurred in connection herewith and the consummation of the other transactions described in the Loan Documents, will be Solvent.</P>
<P ALIGN="JUSTIFY">9.1.12.&nbsp;&nbsp;&nbsp;<U>Surety Obligations</P>
</U><P ALIGN="JUSTIFY">.  As of the date hereof, except as set forth on <B><U>Schedule 9.1.12</B></U> on the date hereof, no Borrower nor any of its Domestic Subsidiaries is obligated as surety or indemnitor under any surety or similar bond or other contract issued or entered into any agreement to assure payment, performance or completion of performance of any undertaking or obligation of any Person.</P>
<P ALIGN="JUSTIFY">9.1.13.&nbsp;&nbsp;&nbsp;<U>Taxes</P>
</U><P ALIGN="JUSTIFY">.  The FEIN and organizational identification number of each Borrower and each of its Domestic Subsidiaries is as shown on <B><U>Schedule&nbsp;9.1.13</B></U>.  Each Borrower and each of its Domestic Subsidiaries has filed all federal, state and local material tax returns and other material tax reports it is required by law to file and has paid, or made provision for the payment of, all Taxes upon it, its income and Properties as and when such Taxes are due and payable, except to the extent being Properly&nbsp;Contested or to the extent in an amount less than $2,500,000.</P>
<P ALIGN="JUSTIFY">9.1.14.&nbsp;&nbsp;&nbsp;<U>Brokers</P>
</U><P ALIGN="JUSTIFY">.  There are no claims against any Borrower for brokerage commissions, finder's&nbsp;fees or investment banking fees in connection with the transactions contemplated by this Agreement or any of the other Loan Documents.</P>
<P ALIGN="JUSTIFY">9.1.15.&nbsp;&nbsp;&nbsp;<U>Intellectual Property</P>
</U><P ALIGN="JUSTIFY">. Each Borrower and each of its Domestic Subsidiaries owns or has the&nbsp;lawful right to use all&nbsp;Intellectual Property necessary for the present and planned future conduct of its&nbsp;business without, to Borrowers' knowledge, any&nbsp;conflict with the rights of others that Borrowers believe would be reasonably likely to be determined adversely to Borrowers and if determined adversely would have a Material Adverse Effect; except as may be disclosed on <B><U>Schedule 9.1.15</B></U>, no Borrower has received any written notice of any objection to, and there is no pending (or, to any Borrower's knowledge, threatened) Intellectual Property Claim with respect to, any Borrower's or any of its Domestic Subsidiaries' right to use any such Intellectual Property which Borrowers believe is reasonably likely to be determined adversely to such Borrower and if determined adversely to any Borrower, would reasonably be expected to have a Material Adverse Effect; and, except as may be disclosed
 on <B><U>Schedule&nbsp;9.1.15</B></U>, as of the date hereof, no Borrower nor any of its Domestic Subsidiaries pays any royalty or other compensation to any Person for the right to use any Intellectual Property material to any Borrower's or any Domestic Subsidiary's business.  All patents, trademarks, service marks, trade names, copyrights, and License Agreements owned or used by each Borrower and each Domestic Subsidiary as of the date hereof are listed on <B><U>Schedule&nbsp;9.1.15</B></U> hereto, to the extent they are registered under any Applicable Law or are otherwise material to any Borrower's or any of its Domestic Subsidiaries' business.</P>
<P ALIGN="JUSTIFY">9.1.16.&nbsp;&nbsp;&nbsp;<U>Governmental Approvals</P>
</U><P ALIGN="JUSTIFY">.  Each Borrower and each of its Domestic Subsidiaries has all Governmental Approvals (excluding under any Food and Drug Laws, which compliance is addressed in <B>Section 9.1.29</B> hereof) necessary to continue to conduct its business as heretofore or proposed to be conducted by it and to sell its Inventory and to own or lease and operate its Properties as now owned or leased by it except, in each case, to the extent failure to receive such approval is not reasonably likely to have a Material Adverse Effect.</P>
<P ALIGN="JUSTIFY">9.1.17.&nbsp;&nbsp;&nbsp;<U>Compliance with Laws</P>
</U><P ALIGN="JUSTIFY">.  Each Borrower and each of its Domestic Subsidiaries has duly complied with, and its Properties, business operations and leaseholds are in compliance in all material respects with, the provisions of all Applicable Law (excluding all Food and Drug Laws which compliance is addressed in <B>Section 9.1.29</B> hereof and all Environmental Laws which compliance is addressed in the Environmental Agreement) (except to the extent that any such non-compliance could not reasonably be expected to result in a Material Adverse Effect) and there have been no material citations, notices or orders of noncompliance issued to any Borrower or any of its Domestic Subsidiaries under any&nbsp;such law, rule or regulation with respect to any matter that could reasonably be expected to have a Material Adverse Effect.  No Inventory has been produced in violation of the FLSA.  With&nbsp;respect to matters arising under any Environmental Laws, the&nbsp;representations and warranties contained in the Environment
al Agreement are true and correct on the&nbsp;date hereof.</P>
<P ALIGN="JUSTIFY">9.1.18.&nbsp;&nbsp;&nbsp;<U>Burdensome Contracts</P>
</U><P ALIGN="JUSTIFY">.  No Borrower nor any of its Domestic Subsidiaries is a party or subject to any Restrictive Agreements, except as permitted under <B><U>Section 10.2.16</B></U>, none of which prohibit the execution or delivery of any of the Loan Documents by any Obligor or the performance by any Obligor of its obligations under any of the Loan Documents to  which it is a party, in accordance with the terms of such Loan Documents.</P>
<P ALIGN="JUSTIFY">9.1.19.&nbsp;&nbsp;&nbsp;<U>Litigation</P>
</U><P ALIGN="JUSTIFY">.  Except as set forth on <B><U>Schedule 9.1.19</B></U>, there are no&nbsp;actions, suits, proceedings or investigations pending or, to the knowledge of any Borrower, threatened on the date hereof against or affecting any Borrower, or any of its Domestic Subsidiaries or the business, operations, Properties, or financial condition of any Borrower or any of its Domestic Subsidiaries, (i)&nbsp;which relate to any of the Loan Documents or any of the transactions contemplated thereby or (ii) which, is reasonably likely to be adversely determined and if so determined to any Borrower or any of its Domestic Subsidiaries, is reasonably likely to have a Material Adverse Effect.  To the knowledge of each Borrower, no Borrower nor any of its Domestic Subsidiaries is in default on the date hereof with&nbsp;respect to any court or arbitration board order, injunction, or judgment.</P>
<P ALIGN="JUSTIFY">9.1.20.&nbsp;&nbsp;&nbsp;<U>No Defaults</P>
</U><P ALIGN="JUSTIFY">.  No Borrower nor any of its Domestic Subsidiaries is in default, and no event has occurred and no condition exists which constitutes or which with the passage of time or the&nbsp;giving of notice or both would constitute a default, under any Material Contract or in the payment of any Debt of a Borrower or a Domestic Subsidiary to any Person for Money Borrowed, which default, in each case, could be reasonably likely to result in a Material Adverse Effect.</P>
<P ALIGN="JUSTIFY">9.1.21.&nbsp;&nbsp;&nbsp;<U>Leases</P>
</U><P ALIGN="JUSTIFY">.  <B><U>Schedule 9.1.21</B></U> hereto is a complete listing of each lease of Real Property by each Borrower with annual rent in excess of $1,000,000 or with respect to a location at which more than $1,000,000 of Inventory or Equipment is located as of the date hereof.</P>
<P ALIGN="JUSTIFY">9.1.22.&nbsp;&nbsp;&nbsp;<U>ERISA</P>
</U><P ALIGN="JUSTIFY">.  Except as disclosed on <B><U>Schedule&nbsp;9.1.22</B></U> hereto, no Borrower nor any of its Subsidiaries has any Multiemployer Plan on the date hereof.  Each Borrower and each of its Subsidiaries is in full compliance in all material respects with the requirements of ERISA and the regulations promulgated thereunder with respect to each Multiemployer Plan.  No fact or situation that is reasonably likely to result in a Material Adverse Effect exists in&nbsp;connection with any Multiemployer Plan.  No&nbsp;Borrower nor any of its Subsidiaries has incurred any withdrawal liability in&nbsp;connection with a Multiemployer Plan.</P>
<P ALIGN="JUSTIFY">9.1.23.&nbsp;&nbsp;&nbsp;<U>Trade Relations</P>
</U><P ALIGN="JUSTIFY">.  There exists no actual or threatened termination, cancellation or limitation of, or any materially adverse modification or change in, the business relationship between any Borrower and any customer or any group of customers whose purchases individually or in the aggregate are material to the business of such Borrower, or with any material supplier or group of suppliers, which is reasonably likely to have a Material Adverse Effect.</P>
<P ALIGN="JUSTIFY">9.1.24.&nbsp;&nbsp;&nbsp;<U>Labor Relations</P>
</U><P ALIGN="JUSTIFY">.  Except as described on <B><U>Schedule&nbsp;9.1.24</B></U> hereto, no Borrower nor any of its Domestic Subsidiaries is on the date hereof a party to or bound by any collective bargaining agreement.  On the date hereof, there are no material grievances, disputes or controversies with any union or any other organization of any Borrower's or any Domestic Subsidiary's employees, or, to any Borrower's knowledge, any threats of strikes, work stoppages or any asserted pending demands for collective bargaining by any union or organization which are reasonably likely to result in a Material Adverse Effect.</P>
<P ALIGN="JUSTIFY">9.1.25.&nbsp;&nbsp;&nbsp;<U>Not a Regulated Entity</P>
</U><P ALIGN="JUSTIFY">.  No Borrower nor any of its Domestic Subsidiaries is (i)&nbsp;an "investment company" or a "person&nbsp;directly or indirectly controlled by or acting on behalf of an investment company" within the meaning  of the Investment Company Act of 1940; (ii)&nbsp;a "holding company," or a "subsidiary company" of a "holding company," or an "affiliate" of a "holding company" or of a "subsidiary company" of a&nbsp;"holding company," within the meaning of the Public Utility Holding Company Act of 1935; or (iii)&nbsp;subject to regulation under the Federal Power Act or the Interstate Commerce Act.</P>
<P ALIGN="JUSTIFY">9.1.26.&nbsp;&nbsp;&nbsp;<U>Margin Stock</P>
</U><P ALIGN="JUSTIFY">.  No Borrower nor any of its Domestic Subsidiaries is engaged, principally or as one of its important activities, in the business of extending credit for the purpose of purchasing or carrying any Margin Stock.</P>
<P ALIGN="JUSTIFY">9.1.27.&nbsp;&nbsp;&nbsp;<U>Anti-Terrorism Laws</P>
</U><P ALIGN="JUSTIFY"> None of Borrowers and their Affiliates is in violation of any Anti-Terrorism Law, or engages in or conspires to engage in any transaction that attempts to violate, or otherwise evades or avoids (or has the purpose of evading or avoiding) any prohibitions set forth in any Anti-Terrorism Law.  None of Borrowers and their Affiliates (a) is a Blocked Person; (b) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person; (c) has any of its assets in a Blocked Person; (d) deals in, or otherwise engages in any transaction relating to, any Property blocked pursuant to Executive Order No. 13224; or (e) derives any of its operating income from investments in or transactions with a Blocked Person.</P>
<P ALIGN="JUSTIFY">9.1.28.&nbsp;&nbsp;&nbsp;<U>Not the Holder of Plan Assets.</U>  </P>
<P ALIGN="JUSTIFY">No Borrower is an entity deemed to hold "plan assets" within the meaning of 29 C.F.R. Section2510.3-101 of an "employee benefit plan" (as defined in Section 3(3) of ERISA) that is subject to Title I of ERISA or any "plan" (within the meaning of Section 4975 of the Internal Revenue Code) (collectively, a "Plan Assets Entity"), and based on the representation that no Lender is a Plan Assets Entity, neither the execution of this Agreement nor the funding of any Loans gives rise to a prohibited transaction within the meaning of Section 406 of ERISA or Section 4975 of the Internal Revenue Code.</P>
<P ALIGN="JUSTIFY">9.1.29&nbsp;&nbsp;&nbsp;<U>Food and Drug Laws</U>.</P>
<P ALIGN="JUSTIFY">(i)&nbsp;&nbsp;&nbsp;Except as otherwise disclosed on <B><U>Schedule 9.1.29</B></U>, each Borrower and each Domestic Subsidiary has been and is in compliance in all material respects with all applicable Food and Drug Laws, including federal and state laws, statutes, rules and regulations that relate to the manufacture, handling, transport, management, disposal or sale of pharmaceutical and drug products, including those relating to (i) "good manufacturing practices," "good laboratory practices," "good clinical practices," labeling, record keeping, or filing of reports, or (ii) obligations for products under an Investigational New Drug Application ("INDA"), a New Drug Application ("NDA") or an ANDA except, in each case, to the extent such failure is not reasonably likely to result in a Material Adverse Effect.</P>
<P ALIGN="JUSTIFY">(ii)&nbsp;&nbsp;&nbsp;Except as otherwise disclosed on <B><U>Schedule 9.1.29</B></U>, each Borrower has all material licenses, permits, designations, applications and approvals necessary or required under applicable Food and Drug Laws for the conduct of the business of Borrowers and the Domestic Subsidiaries taken as a whole in its present form, and no material licenses, permits, designations, applications and approvals have been terminated, suspended or revoked, and there are presently no termination, suspension or revocation proceedings, actual, pending, or threatened, in respect thereof, in each case, except to the extent any such termination, suspension or revocation of such material licenses, permits, designations, applications and approvals, individually or in the aggregate, could not reasonably be likely to result in a Material Adverse Effect.</P>
<P ALIGN="JUSTIFY">(iii)&nbsp;&nbsp;&nbsp;Except as disclosed on<B> <U>Schedule 9.1.29</B>,</U> no Borrower nor any Domestic Subsidiary is the subject of any current or pending investigations, enforcement action or orders, <I>qui tam</I> actions, consent decrees, corporate integrity agreements, settlements, recalls or other extraordinary examinations or review by any Governmental Authority under Food and Drug Laws, that Borrowers believe are reasonably likely to be determined adversely to Borrowers and that if adversely determined to Borrowers would have a Material Adverse Effect.  Subject to <B>Section 10.1.13</B>, each Borrower has provided to the Agent true, complete and correct copies of all material notices from the FDA relating to actual investigations, violations or any instances of alleged non-compliance with applicable Food and Drug Laws to the extent Borrowers believe are reasonably likely to be determined adversely to Borrowers and if adversely determined could reasonably result in a Material Adve
rse Effect.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346567"><A NAME="_Toc102963367"><A NAME="_Toc105998338"><A NAME="_Toc105998748"><A NAME="_Toc105998880"><A NAME="_Toc117052393">9.2.&nbsp;&nbsp;&nbsp;<U>Reaffirmation of Representations and Warranties</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Each representation and warranty contained in this Agreement and the other Loan Documents shall be deemed to be made on the Closing Date and reaffirmed by each Borrower on each day that Borrowers request or are deemed to have requested any Loan, Letter of Credit or other extension of credit hereunder, except for changes in the nature of a Borrower's or, if applicable, any Domestic Subsidiary's business or operations that may occur after the date hereof in the&nbsp;Ordinary Course of Business so long as Agent has consented to such changes or such changes are not violative of any provision of this Agreement.  Notwithstanding the foregoing, representations and warranties which by their terms are applicable only as of a specific date shall be deemed made only at and as&nbsp;of such date.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346568"><A NAME="_Toc102963368"><A NAME="_Toc105998339"><A NAME="_Toc105998749"><A NAME="_Toc105998881"><A NAME="_Toc117052394">9.3.&nbsp;&nbsp;&nbsp;<U>Survival of Representations and Warranties</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  All representations and warranties of Borrowers contained in this Agreement or any of the other Loan Documents shall survive the execution, delivery and acceptance thereof by Agent, Lenders and the parties thereto and the closing of the transactions described therein or related thereto.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346569"><A NAME="_Toc102963369"><A NAME="_Toc105998340"><A NAME="_Toc105998750"><A NAME="_Toc105998882"><A NAME="_Toc117052395">SECTION 10.&nbsp;&nbsp;&nbsp;COVENANTS AND CONTINUING AGREEMENTS</A></A></A></A></A></A></P>
<P ALIGN="JUSTIFY"><A NAME="_Toc38346570"><A NAME="_Toc102963370"><A NAME="_Toc105998341"><A NAME="_Toc105998751"><A NAME="_Toc105998883"><A NAME="_Toc117052396">10.1&nbsp;&nbsp;&nbsp;<U>Affirmative Covenants</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  For so long as there are any Commitments outstanding and thereafter until Full Payment of the Obligations, each Borrower covenants that it shall and shall cause each Domestic Subsidiary to:</P>
<P ALIGN="JUSTIFY">10.1.1&nbsp;&nbsp;&nbsp;<U>Visits and Inspections</P>
</U><P ALIGN="JUSTIFY">.  Permit representatives of Agent from time to time, as often as may be reasonably requested, but only during normal business hours and upon reasonable prior notice to a Borrower, to visit and inspect the Properties of such Borrower and each of its Subsidiaries, inspect, audit and make extracts from such Borrower's and each Subsidiary's books and records, and discuss with its officers and its independent accountants (so long as, unless an Event of Default exists, a Borrower is afforded an opportunity to be present), such Borrower's and each Domestic Subsidiary's business, financial condition, business prospects and results of operations.  Representatives of each Lender shall be authorized to accompany Agent on each such visit and inspection and to participate with Agent therein, but at their own expense (unless an Event of Default exists, in which event Borrowers shall promptly reimburse reasonable expenses of Agent in connection with such inspection).  Neither Agent nor any Lender sh
all have any duty to make any&nbsp;such&nbsp;inspection and shall not incur any&nbsp;liability by reason of its failure to conduct or delay in&nbsp;conducting any such inspection.</P>
<P ALIGN="JUSTIFY">10.1.2.&nbsp;&nbsp;&nbsp;<U>Notices</P>
</U><P ALIGN="JUSTIFY">.  Notify Agent and Lenders in writing, promptly after a Borrower's obtaining actual knowledge thereof, (i)&nbsp;of the commencement of any litigation affecting any Consolidated Group Member and of the institution of any administrative proceeding against a Consolidated Group Member, in each case, to the extent that such litigation or proceeding, if&nbsp;determined adversely to such Consolidated Group Member, could reasonably be expected to have a Material&nbsp;Adverse Effect; (ii)&nbsp;of any material labor dispute to which any Consolidated Group Member may become a party, any pending or threatened&nbsp;strikes or walkouts relating to any of its plants or other facilities, and the expiration of any labor contract to which it is a party or by which it is bound; (iii)&nbsp;of any material default by any Obligor under any note, indenture, loan agreement, mortgage, lease, deed,&nbsp;guaranty or other similar agreement relating to any Debt of such Obligor exceeding $5,000,000; (iv)&nbsp;of 
the existence of any Default or Event of Default; (v)&nbsp;of any judgment against any Consolidated Group Member in an amount exceeding $5,000,000; (vi)&nbsp;of the assertion by any Person of any&nbsp;Intellectual Property Claim, the adverse resolution of which could reasonably be expected to have a Material Adverse Effect; (vii)&nbsp;of any violation or asserted violation by any Consolidated Group Member of any Applicable Law (including ERISA, OSHA, FLSA, and Food and Drug Law), the adverse resolution of which could reasonably be expected to have a Material Adverse Effect; and (viii)&nbsp;of the&nbsp;discharge of Borrowers' independent accountants or any&nbsp;withdrawal of resignation by such independent accountants from their acting in such capacity.  In&nbsp;addition, Borrowers shall give Agent at&nbsp;least 10&nbsp;days prior written notice of any Consolidated Group Member's opening of any new office or place of business at which any Collateral having a book value of $250,000 or more or any books and rec
ords of a Borrower or constituting Eligible Inventory or Eligible Equipment is located.  Furthermore, Borrowers shall notify Agent promptly upon any Consolidated Group Member (i)&nbsp;being required to file reports under Section 15(b) of the Securities Exchange Act of 1934, (ii) registering securities under Section 12 of the Securities Exchange Act of 1934 or (iii) filing a registration statement under the Securities Act of 1933.</P>
<P ALIGN="JUSTIFY">10.1.3.&nbsp;&nbsp;&nbsp;<U>Financial and Other Information</P>
</U><P ALIGN="JUSTIFY">.  Keep adequate records and books of account with respect to its business activities in which proper entries are made in accordance with GAAP reflecting all its financial transactions; and cause to be prepared and furnished to Agent the following (all to be prepared in accordance with GAAP applied on a consistent basis subject to <B>Section&nbsp;1.2 </B>hereof):</P>
<P ALIGN="JUSTIFY">(i)&#9;as soon as available, and in any event within 75 days after the close of each Fiscal Year audited balance sheets of Parent and its Subsidiaries as of the end of such Fiscal Year and the related statements of income, shareholders' equity and cash flow, on a Consolidated and consolidating basis, certified without an Impermissible Qualification by BDO Seidman, LLP or other firm of independent certified public accountants of recognized national standing selected by Borrowers but reasonably acceptable to Agent and setting forth in each case in comparative form the corresponding Consolidated and consolidating figures for the preceding Fiscal Year (<U>provided</U>, that for purposes of this <B>subsection 10.1.3(i)</B>, so long as Parent and its Subsidiaries are subject to SEC reporting requirements, the 10K of Parent for such period shall satisfy the requirement with respect to audited annual financial statements but, in any event, included in such financial statements shall be a footnote 
containing Consolidated and consolidating balance sheet, income statement, and statement of cash flow, and related intercompany eliminations and previous year comparison, for the Consolidated Group), and Borrowers also shall provide to Agent a separate unaudited footnote or schedule containing Consolidated and consolidating balance sheet, income statement and statement of cash flow for the Consolidated Group, for the fourth Fiscal Quarter of such Fiscal Year;</P>
<P ALIGN="JUSTIFY">(ii)&#9;if a Restrictive Trigger Event occurs, as soon as available, and in any event within 30 days after the end of each Fiscal Month commencing with the first Fiscal Month to end after such Restrictive Trigger Event occurs, (x) if on or before June 30, 2006, internally generated segment profit and loss statements of the Consolidated Group, and (y) if after June 30, 2006, unaudited balance sheets of the Consolidated Group as of the end of such Fiscal Month and the related unaudited statements of income and cash flow for such Fiscal Month and for the portion of Parent's Fiscal Year then elapsed, on a&nbsp;Consolidated and consolidating basis, setting forth in each case in comparative form the corresponding figures for the preceding Fiscal Year and certified by the principal financial officer of Parent as prepared in accordance with GAAP and fairly presenting in all material respects the Consolidated financial position and results of operations of the Consolidated Group for such Fiscal Mon
th and period subject only to changes from audit and year-end adjustments and except that such statements need not contain notes.  If after the occurrence of a Restrictive Trigger Event, Availability is at least $35,000,000 for 60 consecutive days and no Event of Default exists, then as soon as practicable but in any event within 1 Business Day thereafter (the "Reporting Spring-Back Date"), Agent will not require that Borrowers provide monthly financial statements as provided above unless another Restrictive Trigger Event occurs.  If a Restrictive Trigger Event has occurred as a result of an Event of Default and not as a result of the failure by Borrowers to meet the Availability or Average Availability requirements, and Agent (or to the extent required by this Agreement, all Lenders or Required Lenders) waive the Event of Default in writing, then the Reporting Spring-Back Date shall occur on the date of the waiver in writing of such Event of Default.</P>
<P ALIGN="JUSTIFY">(iii)&#9;as soon as available, and in any event within 45 days after the end of each of the first three Fiscal Quarters hereafter in any Fiscal Year, unaudited balance sheets of Parent and its Subsidiaries as of the end of such Fiscal Quarter and the related unaudited Consolidated statements of income and cash flow for such Fiscal Quarter and for the portion of Parent's Fiscal Year then elapsed, on a&nbsp;Consolidated and consolidating basis, setting forth in each case in comparative form the&nbsp;corresponding figures for the preceding Fiscal Year and certified by the principal financial officer of Parent as prepared in accordance with GAAP and fairly presenting in all material respects the Consolidated financial position and results of operations of Parent and its Subsidiaries for such Fiscal Quarter and period subject only to changes from audit and year-end adjustments and except that such statements need not contain notes (<U>provided</U>, that for purposes of this <B>subsection 10.1.3
(iii)</B>, so long as Parent and its Subsidiaries are subject to SEC reporting requirements, the 10Q of Parent for such period shall satisfy the requirement with respect to unaudited financial statements but, in any event, included in such financial statements shall be a footnote containing Consolidated and consolidating balance sheet, income statement, and statement of cash flow, and related intercompany eliminations and previous year comparison, for the Consolidated Group); </P>
<P ALIGN="JUSTIFY">(iv)&#9;not later than 25 days after each Fiscal Month, a summary of all of each Borrower's trade payables as of the last Business Day of such month, in form acceptable to Agent;</P>
<P ALIGN="JUSTIFY">(v)&#9;promptly after the sending or filing thereof, as the case may be, (a) copies of any proxy statements, financial statements or material reports which any Borrower has made generally available to its shareholders (unless Agent receives notice of any such filings from the SEC); (b) copies of any material regular and periodic reports or registration statements or prospectuses which any Borrower files with the SEC or any Governmental Authority which may be substituted therefor, or any national securities exchange (unless Agent receives notice of any such filings from the SEC); and (c) copies of any press releases or other statements made available by a Borrower to the public concerning material changes to or developments in the business of such Borrower; and</P>
<P ALIGN="JUSTIFY">(vi)&#9;promptly after the sending or filing thereof, copies of any annual report to be filed in accordance with ERISA in connection with each Plan and such other data and information (financial or otherwise) as Agent, from time to time, may request, bearing upon or related to the Collateral or any Consolidated Group Member's financial condition or results of operations.</P>
<P ALIGN="JUSTIFY">Concurrently with the delivery of the financial statements described in clause (i) of this <B>Section&nbsp;10.1.3</B>, Borrowers shall deliver to Agent a copy of the accountants' letter to Borrowers' management that is prepared in connection with such financial statements and also shall cause to be prepared and shall deliver to Agent a certificate of the aforesaid certified public accountants stating to Agent and Lenders that, based upon such accountants' audit of the Consolidated financial statements of Parent and its Subsidiaries performed in connection with their examination of said financial statements, nothing came to their attention that caused them to believe that Borrowers were not in&nbsp;compliance with <B>Sections 10.2 or 10.3</B>, or, if they are aware of such noncompliance, specifying the nature thereof.  Concurrently with the delivery of the financial statements described in clauses (i), (ii) and (iii) of this <B>Section 10.1.3</B>, or more frequently if requested by Agent du
ring any period that a Default or Event of Default exists and in any event within five (5) Business Days after the occurrence of a Restrictive Trigger Event (based upon the most current financial statements received by Agent prior to such Restrictive Trigger Event in accordance with this Agreement), Borrowers shall cause to be prepared and furnished to Agent a Compliance Certificate executed by the chief financial officer of Borrowers, which Compliance Certificate shall include the calculation of the Fixed Charge Coverage Ratio for such prior 12 month period (if it is then being tested under <B>Section 10.3.1</B>).</P>
<P ALIGN="JUSTIFY">10.1.4.&nbsp;&nbsp;&nbsp;<U>Landlord and Storage Agreements</P>
</U><P ALIGN="JUSTIFY">.  Within 30 days after execution thereof, unless requested more frequently by Agent, provide Agent with copies of all future agreements, between any Borrower and any landlord, warehouseman or bailee which owns any premises at which any (i) Eligible Inventory, (ii) Eligible Equipment, (iii) books and records or (iv) other Collateral having a book value of $250,000 or more may, from time to time, be kept.</P>
<P ALIGN="JUSTIFY">10.1.5.&nbsp;&nbsp;&nbsp;<U>Projections</P>
</U><P ALIGN="JUSTIFY">.  No later than 30 days after the end of each Fiscal Year of Borrowers, deliver to Agent the Projections of Borrowers for the forthcoming Fiscal Year, on a quarterly basis.</P>
<P ALIGN="JUSTIFY">10.1.6.&nbsp;&nbsp;&nbsp;<U>Taxes</U>.  </P>
<P ALIGN="JUSTIFY">Pay and discharge all Taxes prior to the date on which such Taxes become delinquent or penalties attach thereto, except and to the extent only that such Taxes are being Properly&nbsp;Contested or such Taxes do not exceed $2,500,000 in the aggregate at any time.</P>
<P ALIGN="JUSTIFY">10.1.7.&nbsp;&nbsp;&nbsp;<U>Compliance with Laws</P>
</U><P ALIGN="JUSTIFY">.  Comply with all Applicable Law (excluding all Food and Drug Laws and Environmental Laws, the compliance with which is addressed in <B>Section 10.1.13</B> hereof and in the Environmental Agreement, respectively), including ERISA, FLSA, OSHA, Anti-Terrorism Laws and all laws, statutes, regulations and ordinances regarding the collection, payment and deposit of Taxes, and obtain and keep in force any and all Governmental Approvals necessary to the&nbsp;ownership of its Properties or to the conduct of its business, in each case to the extent that any such failure to comply, obtain or keep in force could be reasonably expected to have a Material Adverse Effect.</P>
<P ALIGN="JUSTIFY">10.1.8.&nbsp;&nbsp;&nbsp;<U>Insurance</P>
</U><P ALIGN="JUSTIFY">.  In addition to the insurance required herein with respect to the Collateral, maintain with its current insurers or with other financially sound and reputable insurers having a rating of at least A- or better and being in a size category of "vii" or better by <I>Best's Ratings</I>, a publication of A.M. Best Company, insurance with respect to its Properties and business against such&nbsp;casualties and contingencies of such type (including product liability, workers' compensation, larceny, business insurance, embezzlement, or other criminal misappropriation insurance) and in such&nbsp;amounts and with such coverages, limits and deductibles as is customary in the business of the Borrowers and their Domestic Subsidiaries.</P>
<P ALIGN="JUSTIFY">10.1.9.&nbsp;&nbsp;&nbsp;<U>Intellectual Property</P>
</U><P ALIGN="JUSTIFY">.  Together with each Compliance Certificate delivered pursuant to <B>Section 10.1.3</B>, notify Agent of any registered Intellectual Property acquired or applied for by Borrowers or any Domestic Subsidiary during the Fiscal Quarter for which such Compliance Certificate is being delivered (or at Agent's request from time to time, such non-registered Intellectual Property) and, upon the request of Agent, deliver to Agent, in form and substance reasonably acceptable to Agent and in recordable&nbsp;form, all documents necessary for Agent to obtain and perfect a first priority Lien on such Intellectual Property (subject to the provisions of <B>Section 7.6</B> with respect to perfection under the laws of a jurisdiction other than the United States).</P>
<P ALIGN="JUSTIFY">10.1.10.&nbsp;&nbsp;&nbsp;<U>License Agreements</P>
</U><P ALIGN="JUSTIFY">.  Keep each License Agreement relating to Intellectual Property or Eligible Inventory in full force and effect for so long as any Borrower or any Domestic Subsidiary has any Inventory, the manufacture, sale or distribution of which is in any manner governed by or subject to such License Agreement; promptly notify Agent of any proposed material amendments to any License Agreement; pay all Royalties under each License Agreement as and when the same become due and payable to the extent not being Properly Contested; and notify Agent of any default or breach asserted by any party to have occurred under such License Agreement.</P>
<P ALIGN="JUSTIFY">10.1.11.&nbsp;&nbsp;&nbsp;<U>Convertible Notes</P>
</U><P ALIGN="JUSTIFY">.  Cause the Convertible Notes to be refinanced or defeased in their entirety or an Approved Escrow established at least 60 days prior to their scheduled maturity date of June 1, 2006 (<U>provided</U>, <U>that</U> if proceeds of the Loans are used, no Default or Event of Default shall exist at the time or result therefrom and Availability shall be at least $35,000,000 at the time of and after giving effect thereto), unless the Convertible Note Reserve has been established by Agent in its<B><I> </B></I>sole discretion.</P>
<P ALIGN="JUSTIFY">10.1.12.&nbsp;&nbsp;&nbsp;<U>Depository Relationships</P>
</U><P ALIGN="JUSTIFY">.  Maintain Borrowers' and their Domestic Subsidiaries' principal depository, operating and cash management accounts at BofA.</P>
<P ALIGN="JUSTIFY">10.1.13.&nbsp;&nbsp;&nbsp;<U>Food and Drug Laws.</P>
</U><P ALIGN="JUSTIFY">(i)&nbsp;&nbsp;&nbsp;Each Borrower and each Domestic Subsidiary shall conduct its business in compliance in all material respects with all Food and Drug Laws applicable to it, including those relating to the manufacture, sale, disposal and transport of pharmaceutical, drug and biological products, except as could not reasonably be expected to have a Material Adverse Effect.</P>
<P ALIGN="JUSTIFY">(ii)&nbsp;&nbsp;&nbsp;Any notices or allegations of non-compliance under Food and Drug Laws, constituting a request or order to recall a product or to curtail manufacturing at its facilities or loss of eligibility for new product approval or other notice of non-compliance outside the Ordinary Course of Business, provided to any Borrower or any Domestic Subsidiary shall be forwarded to Agent or any Lender as soon as possible but no later than thirty (30) days after receipt by a Borrower.  Upon the reasonable request of Agent or Lenders, Borrowers shall forward all material communications to any Borrower or any of its Domestic Subsidiaries with any Governmental Authority regarding the alleged violation or non-compliance with Food and Drug Laws.  Upon receipt of notice from the FDA that any of Borrowers' facilities must curtail manufacturing or is no longer eligible to receive new product approval, Borrowers shall, at Agent's or Required Lenders' reasonable request and at Borrowers' expense, 
(i) retain an independent contractor reasonably acceptable to Agent to evaluate the operations and the alleged violations (excluding alleged violations with respect to products that have not been launched) (it being understood that so long as no Default or Event of Default has occurred and is continuing, any such evaluation of operations shall be limited to the operations that are the subject of the alleged violations), and (ii) prepare and deliver to Agent, in sufficient quantity for distribution by Agent to Lenders, a report setting forth the results of such evaluation, a proposed plan for responding to any potential liabilities described therein, and an estimate of the costs thereof.</P>
<P ALIGN="JUSTIFY">(iii)&nbsp;&nbsp;&nbsp;Upon receipt of notice by any Borrower or any of its Domestic Subsidiaries from the FDA with respect to an alleged violation or non-compliance with Food and Drug Laws in all material respects (excluding alleged violations with respect to products that have not been launched) or at any time that a Default or Event of Default has occurred and is continuing, the Agent or its representatives or independent contractors shall have the right at any reasonable time to enter and visit any real estate currently owned and/or leased by any Borrower or any Domestic Subsidiary for the purposes of observing and reviewing the operations of Borrowers and their Domestic Subsidiaries with respect to their compliance with Food and Drug Laws. Agent is under no duty, however, to undertake such visits, and any such acts by Agent will be solely for the purposes of protecting Agent's Liens and preserving Agent and Lenders' rights under the Loan Documents.  No site visit, observation or testi
ng by Agent and Lenders will result in a waiver of any Default of Borrowers or impose any liability on Agent or Lenders.  In no event shall any such site visit or reports therefrom be a representation that any Borrower or any Domestic Subsidiary is in compliance or non-compliance with any Food and Drug Laws.  No Borrower, any Domestic Subsidiary nor any other party is entitled to rely on any site visit, observation or testing by Agent.</P>
<P ALIGN="JUSTIFY">10.1.14.&nbsp;&nbsp;&nbsp;<U>Dissolution of Restrictive Subsidiaries</P>
</U><P ALIGN="JUSTIFY">(a)&#9;Within sixty (60) days after the Closing Date, cause to be filed with the appropriate Governmental Authority articles of dissolution for Alpharma N.W. Inc., Barre Parent Corporation and A.L. Specialty Chemicals, Inc.; and</P>
<P ALIGN="JUSTIFY">(b)&#9;Upon receipt by Borrowers of tax clearance letters or other determination letters from the applicable Governmental Authority or the winding up or termination by Borrowers of any employee benefit plan in accordance with Applicable Law (but no later than 360 days after the Closing Date without the consent of Agent), cause to be filed with the appropriate Governmental Authority, articles of dissolution for each of Alpharma (Barbados) SRL, Danz Nutritional Limited, NMC Laboratories and Wynco LLC.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346571"><A NAME="_Toc102963371"><A NAME="_Toc105998342"><A NAME="_Toc105998752"><A NAME="_Toc105998884"><A NAME="_Toc117052397">10.2&nbsp;&nbsp;&nbsp;<U>Negative Covenants</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  For so long as there are any Commitments outstanding and thereafter until Full Payment of the Obligations, each Borrower covenants that it shall not and shall not permit any Domestic Subsidiary to:</P>
<P ALIGN="JUSTIFY">10.2.1.&nbsp;&nbsp;&nbsp;<U>Fundamental Changes</P>
</U><P ALIGN="JUSTIFY">.  (a) Merge, reorganize, consolidate or amalgamate with any&nbsp;Person, or liquidate, wind up its affairs or dissolve itself, in each case whether in a single transaction or in a series of related transactions, except for (i) mergers, amalgamations, liquidations, dissolutions, or consolidations of any Consolidated Group Member with or into another Consolidated Group Member (other than a Borrower into a Restrictive Subsidiary or an Excluded Subsidiary), (ii)&nbsp;Permitted Acquisitions and Permitted Asset Dispositions; and (iii) dissolutions, liquidations or winding up of any of the Restrictive Subsidiaries as provided in <B>Section 10.1.14</B>; (b) change a Borrower's or any Domestic Subsidiaries name or conduct business under any new&nbsp;fictitious name without providing Agent with 30 days prior written notice and subject to the recordation of all necessary UCC financing statements or amendments; or (c) change a Borrower's or any Domestic Subsidiary's FEIN, organizational identific
ation number or state of organization without providing Agent with 30 days prior written notice and subject to the recordation of all necessary UCC financing statements or amendments.</P>
<P ALIGN="JUSTIFY">10.2.2.&nbsp;&nbsp;&nbsp;<U>Loans</P>
</U><P ALIGN="JUSTIFY">.  Make any loans or other advances of money to any Person other than: (i)&nbsp;to an officer or employee of a Borrower or a Domestic Subsidiary for salary, travel advances, advances against commissions and other similar advances in the Ordinary Course of Business, (ii) investments permitted under <B>Section 10.2.12, </B>and (iii) so long Availability at the time of and after giving effect thereto is not less than $35,000,000 if the Term Loan is outstanding (and not less than $25,000,000 if the Term Loan is not outstanding) and no Default or Event of Default exists or would result therefrom, loans to a Subsidiary that is not a Borrower.</P>
<P ALIGN="JUSTIFY">10.2.3.&nbsp;&nbsp;&nbsp;<U>Permitted Debt</P>
</U><P ALIGN="JUSTIFY">.  Create, incur, assume, guarantee or suffer to exist any Debt, except:</P>
<P ALIGN="JUSTIFY">(i)&#9;the Obligations;</P>
<P ALIGN="JUSTIFY">(ii)&#9;accrued expenses and accounts payable by such Borrower or a Domestic Subsidiary, in&nbsp;each&nbsp;case incurred in the&nbsp;Ordinary Course of Business;</P>
<P ALIGN="JUSTIFY">(iii)&#9;Permitted Purchase Money Debt;</P>
<P ALIGN="JUSTIFY">(iv)&#9;Debt for accrued payroll, Taxes and other operating expenses (other than for Money Borrowed) incurred in the Ordinary Course of Business of such Borrower or such Domestic Subsidiary, including Cash Management Obligations, in each case so long as payment thereof is&nbsp;not past due and payable unless, in the case of Taxes, such Taxes are being Properly Contested or do not exceed $2,500,000 in the aggregate at any time;</P>
<P ALIGN="JUSTIFY">(v)&#9;Debt for Money Borrowed by such Borrower (other than the Obligations, Permitted Purchase Money Debt and Subordinated Debt permitted herein), but only to the extent that such Debt is outstanding on the date of this Agreement and is not to be satisfied on or about the Closing Date from the proceeds of the initial Loans and any refinancings, modifications or extensions thereof so long as the Refinancing Conditions are satisfied;</P>
<P ALIGN="JUSTIFY">(vi)&#9;Permitted Contingent Obligations;</P>
<P ALIGN="JUSTIFY">(vii)&#9;Refinancing Debt so long as each of the Refinancing Conditions is met with respect thereto;</P>
<P ALIGN="JUSTIFY">(viii)&#9;the Senior Notes and the Convertible Notes and refinancings thereof so long as the Refinancing Conditions are satisfied; </P>
<P ALIGN="JUSTIFY">(ix)&#9;unsecured Debt of any Borrower acquired pursuant to a Permitted Acquisition (or Debt assumed at the time and as a result of a Permitted Acquisition); <U>provided</U>, that in each case such Debt was not incurred in connection with, or in anticipation or contemplation of, such Permitted Acquisition and in no event shall such Debt constitute working capital Debt or revolving credit Debt;</P>
<P ALIGN="JUSTIFY">(x)&#9;secured Debt of any Borrower acquired pursuant to a Permitted Acquisition (or assumed at the time and as a result of a Permitted Acquisition) consisting of Permitted Purchase Money Debt and in no event shall such Debt constitute working capital Debt or revolving credit Debt;</P>
<P ALIGN="JUSTIFY">(xi)&#9;Debt relating to surety and appeal bonds, performance bonds and other obligations of a like nature incurred in the Ordinary Course of Business;</P>
<P ALIGN="JUSTIFY">(xii)&#9;unsecured Debt with respect to the deferred purchase price for any Permitted Acquisition, provided that such Debt does not required the payment in cash of principal (other than in respect of working capital adjustments) prior to the Commitment Termination Date;</P>
<P ALIGN="JUSTIFY">(xiii)&#9;intercompany Debt owing or payable by a Consolidated Group Member to another Consolidated Group Member;</P>
<P ALIGN="JUSTIFY">(xiv)&#9;unsecured intercompany Debt owing or payable by a Consolidated Group Member to a Subsidiary that is not a Consolidated Group Member;</P>
<P ALIGN="JUSTIFY">(xv)&#9;any unsecured Debt owing by any Subsidiary of Parent that is not an Obligor to any Obligor consisting of intercompany accounts receivable of Obligor representing in each case the bona fide sale and delivery of product inventory to such Subsidiary in the Ordinary Course of Business, and which receivables have been reclassified as Debt owing to such Obligor in accordance with GAAP consistent with prior practice;</P>
<P ALIGN="JUSTIFY">(xvi)&#9;unsecured Debt constituting the obligation to make purchase price adjustments and indemnities in connection with Permitted Acquisitions;</P>
<P ALIGN="JUSTIFY">(xvii)&#9;Debt that is not included in any of the preceding paragraphs of this <B>Section&nbsp;10.2.3</B>, is not secured by a Lien, has a stated maturity that is longer than the Term, and does not exceed at any time, in the&nbsp;aggregate, the sum of $200,000,000 as to all Borrowers and their Domestic Subsidiaries; </P>
<P ALIGN="JUSTIFY">(xviii)&#9;without duplication of any other Debt, non-cash accruals of interest, accretion or amortization of original issue discount and/or pay-in-kind interest in connection with the Senior Notes or Convertible Notes or any refinancing thereof.</P>
<P ALIGN="JUSTIFY">10.2.4.&nbsp;&nbsp;&nbsp;<U>Affiliate Transactions</P>
</U><P ALIGN="JUSTIFY">.  Enter into, or be a party to any transaction with any Affiliate, except:  (i)&nbsp;the transactions contemplated by the Loan Documents; (ii)&nbsp;payment of reasonable compensation to officers, directors, consultants and employees for services actually rendered to such Borrower or its Subsidiaries; (iii)&nbsp;payment of customary directors' fees and indemnities; (iv)&nbsp;transactions with Affiliates that were consummated prior to the date hereof and have been disclosed to Agent prior to the Closing Date; (v) transactions among Consolidated Group Members in the Ordinary Course of Business and consistent with past practices; (vi) payments that are expressly permitted under <B>Section 10.2.7</B>; and (vii)&nbsp;transactions with Affiliates pursuant to the reasonable requirements of such Borrower's or such Subsidiary's business and upon fair and reasonable terms that, if requested by Agent, are fully disclosed to Agent and are no less favorable to such Borrower or such Subsidiary than 
such Borrower or such&nbsp;Subsidiary would obtain in a comparable arm's length transaction with a Person not an Affiliate of such Borrower or such Subsidiary (it being understood that the transactions specified in <B>Sections 10.2.1, 10.2.2, 10.2.3, 10.2.5, 10.2.6, 10.2.10, 10.2.12, 10.2.13, 10.2.18 or 10.2.19</B> to the extent such provisions relate to Affiliates shall be permitted to be made in accordance with this Section, and provided that nothing in this <B>Section 10.2.4</B> shall prohibit Borrower's or their Domestic Subsidiaries from engaging in the following transactions; (x) the performance of any Borrower's or any Domestic Subsidiary's obligations under any employment contract, collective bargaining agreement, employee benefit plan, related trust agreement or any other similar arrangement heretofore or hereafter entered into in the Ordinary Course of Business or (y) the maintenance of benefit programs or arrangements for employees, officers or directors, including, vacation plans, health and life
 insurance plans, deferred compensation plans, and retirement or savings plans and similar plans, in each case, in the Ordinary Course of Business.</P>
<P ALIGN="JUSTIFY">10.2.5.&nbsp;&nbsp;&nbsp;<U>Limitation on Liens</P>
</U><P ALIGN="JUSTIFY">.  Create or suffer to exist any Lien upon any of its Property, income or profits, whether now owned or hereafter acquired, except the following (collectively, "Permitted&nbsp;Liens"):</P>
<P ALIGN="JUSTIFY">(i)&nbsp;&nbsp;&nbsp;Liens at any time granted in favor of Agent;</P>
<P ALIGN="JUSTIFY">(ii)&nbsp;&nbsp;&nbsp;Liens for Taxes (excluding any Lien imposed pursuant to any of the&nbsp;provisions of ERISA) not yet due or being Properly Contested or in an amount not in excess of $2,500,000 in the aggregate at any time;</P>
<P ALIGN="JUSTIFY">(iii)&nbsp;&nbsp;&nbsp;statutory Liens (excluding any Lien for Taxes, including any Lien imposed pursuant to any of the provisions of ERISA) arising in the Ordinary Course of Business of a Borrower or a Domestic Subsidiary, but only if and for so long as (x)&nbsp;payment in respect of any such Lien is not at the time delinquent or the&nbsp;Debt secured by any such Liens is being Properly Contested or is in an amount not in excess of $2,500,000 in the aggregate at any time and (y)&nbsp;such Liens do not materially detract from the value of the Property of such Borrower or such Domestic Subsidiary and do not materially impair the use thereof in the operation of such Borrower's or such Domestic Subsidiary's business;</P>
<P ALIGN="JUSTIFY">(iv)&nbsp;&nbsp;&nbsp;Purchase Money Liens securing Permitted Purchase Money Debt;</P>
<P ALIGN="JUSTIFY">(v)&nbsp;&nbsp;&nbsp;Liens securing Debt of a Domestic Subsidiary of a Borrower to another Borrower or to another such Domestic Subsidiary;</P>
<P ALIGN="JUSTIFY">(vi)&nbsp;&nbsp;&nbsp;Liens arising by virtue of the rendition, entry or issuance against such Borrower or any of its Domestic Subsidiaries, or any Property of such Borrower or any of its Domestic Subsidiaries, of any judgment, writ, order, or decree for so long as each such Lien (a) is in existence for less than 20 consecutive days after it first arises or is being Properly Contested and (b) is at all times junior in priority to any Liens in favor of Agent;</P>
<P ALIGN="JUSTIFY">(vii)&nbsp;&nbsp;&nbsp;Liens incurred or deposits made in the Ordinary Course of Business to secure the performance of tenders, bids, leases, contracts (other than for the repayment of Money Borrowed), statutory obligations and other similar obligations or arising as a result of progress payments under government contracts, provided that, to the extent any such Liens in an aggregate amount in excess of $1,000,000 attach to any&nbsp;of the Collateral (other than a cash deposit for such specific project), such&nbsp;Liens are at all times subordinate and junior to the Liens upon the&nbsp;Collateral in favor of Agent;</P>
<P ALIGN="JUSTIFY">(viii)&nbsp;&nbsp;&nbsp;easements, rights-of-way, restrictions, covenants, conditions or other agreements of record and other similar charges or encumbrances affecting title to real Property of such Borrower or any of its Domestic Subsidiaries that do not secure any monetary obligation and do not materially interfere with the ordinary conduct of the business of such Borrower or such Domestic Subsidiary and such other minor title defects, or survey matters that are disclosed by current surveys, but that, in each case, in the reasonable opinion of Agent, do not interfere with the current use of the real Property in any material respect;</P>
<P ALIGN="JUSTIFY">(ix)&nbsp;&nbsp;&nbsp;normal and customary rights of setoff upon deposits of cash in favor of banks and other depository institutions and Liens of a collecting bank arising under the UCC on checks and other items of payment in the course of collection;</P>
<P ALIGN="JUSTIFY">(x)&nbsp;&nbsp;&nbsp;Liens in existence immediately prior to the Closing Date that are satisfied in full and released on the Closing Date as a result of the application of such Borrower's cash on hand at the Closing Date or the proceeds of Loans to be made on the Closing Date;</P>
<P ALIGN="JUSTIFY">(xi)&nbsp;&nbsp;&nbsp;such other Liens as appear on <B><U>Schedule&nbsp;10.2.5</B></U>, to the extent provided therein;</P>
<P ALIGN="JUSTIFY">(xii)&nbsp;&nbsp;&nbsp;pledges and deposits made in the ordinary course of business in compliance with workers' compensation, unemployment insurance and other social security laws or regulations;</P>
<P ALIGN="JUSTIFY">(xiii)&nbsp;&nbsp;&nbsp;landlords' and lessors' Liens in respect of rent not in default for more than sixty (60) days and for which a Rent Reserve has been established if required by Agent or a Lien Waiver has been delivered (except to the extent otherwise provided in <B>Section 8.1.1 </B>hereof);</P>
<P ALIGN="JUSTIFY">(xiv)&nbsp;&nbsp;&nbsp;Liens attaching solely to cash earnest money deposits in connection with any letter of intent or purchase agreement in connection with a Permitted Acquisition;</P>
<P ALIGN="JUSTIFY">(xv)&nbsp;&nbsp;&nbsp;Liens arising from precautionary UCC filings regarding "true" operating leases or the consignment of goods to a Obligor, to the extent such lease or consignment is not otherwise violative of this Agreement;</P>
<P ALIGN="JUSTIFY">(xvi)&nbsp;&nbsp;&nbsp;Purchase Money Liens on Equipment or real Property in existence at the time such Equipment or real Property is acquired pursuant to a Permitted Acquisition or on Equipment or real Property of a Subsidiary of a Borrower in existence at the time such Subsidiary is acquired pursuant to a Permitted Acquisition; provided,  that such Liens are not incurred in connection with or in anticipation of such Permitted Acquisition and do not attach to any other assets of any Consolidated Group Member;</P>
<P ALIGN="JUSTIFY">(xvii)&nbsp;&nbsp;&nbsp;any title or interest of a licensor, sublicensor, lessor or sublessor under any license or operating or true lease agreement, to the extent such license or lease agreement (including any licenses of Intellectual Property) is not violative of this Agreement;</P>
<P ALIGN="JUSTIFY">(xviii)&nbsp;&nbsp;&nbsp;zoning, building codes, and other land use laws regulating the use or occupancy of real Property of such Borrower or any of its Domestic Subsidiaries or the activities conducted thereon which are imposed by any Governmental Authority having jurisdiction over such real Property which are not violated by the current use or occupancy of such real Property or the operation of such Borrower's or such Domestic Subsidiary's business conducted thereon;</P>
<P ALIGN="JUSTIFY">(xix)&nbsp;&nbsp;&nbsp;matters disclosed on current surveys of the real Property owned by such Borrower and any of its Domestic Subsidiaries and delivered on or before the Closing Date;</P>
<P ALIGN="JUSTIFY">(xx)&nbsp;&nbsp;&nbsp;any retention of title reserved by any supplier of goods pursuant to such supplier's standard terms and conditions, but only to the extent (a) contained in such supplier's form response to purchase orders that are not executed by any Consolidated Group Member and (b) such Lien does not have priority over any Liens in favor of Agent, (except that if such Lien would have priority over the Lien of Agent such Lien shall only constitute a Permitted Lien if Agent has either elected to put an Availability Reserve in place with respect thereto (and such Availability Reserve does not create an Out-of-Formula Condition) or has elected not to require any such Availability Reserve); and</P>
<P ALIGN="JUSTIFY">(xxi)&nbsp;&nbsp;&nbsp;such other Liens as Agent and the Required Lenders in their discretion may hereafter approve in writing.</P>
<P ALIGN="JUSTIFY">provided, however, that, except as provided in any of the clauses above, the term "Permitted Liens" shall not include any Lien securing Debt for Money Borrowed. The designation of a Lien as a Permitted Lien shall not limit or restrict the ability of the Agent to establish any Reserve relating thereto.</P>
<P ALIGN="JUSTIFY">The foregoing negative pledge shall not apply to any Margin Stock to the extent that the application of such negative pledge to such Margin Stock would require filings or other actions by any Lender under Regulation U or other regulations of the Board of Governors, or otherwise result in a violation of any&nbsp;such regulations.</P>
<P ALIGN="JUSTIFY">10.2.6.&nbsp;&nbsp;&nbsp;<U>Restrictions on Payment of Certain Debt</U>.  </P>
<P ALIGN="JUSTIFY">Make any payments of or in respect of principal or interest on, or on account of the purchase, redemption, retirement or satisfaction of any:</P>
<P ALIGN="JUSTIFY">(i)&#9;Subordinated Debt other than (a) payment of regularly scheduled installments of principal and interest and fees and other charges when required to be paid by any instrument or agreement evidencing such Subordinated Debt, but in each case only to the extent that payment thereof is not violative of any subordination agreement or subordination provisions expressly contained therein relating to such Subordinated Debt; (b) payments in equity securities (as long as no Change in Control would result therefrom) and payments of interest in-kind; (c) prepayment in whole or in part with the proceeds of any equity securities issued or capital contributions received by any Borrower or any Domestic Subsidiary for the purpose of making such payment or prepayment; (d) refinancings of Debt to the extent permitted under <B>Section 10.2.3(vii)</B>; (e) any payments or prepayments of Debt that is owing by an Obligor to another Obligor unless an Event of Default exists and Agent has commenced any Enforc
ement Action; and (f) any prepayments, repurchase, defeasance, retirement, satisfaction or redemption of the Convertible Notes so long as, if such payment is made with proceeds of the Loans, the provisions of <B>Section 10.1.11</B> are satisfied; or</P>
<P ALIGN="JUSTIFY">(ii)&#9;Funded Debt (including the Senior Notes but excluding the Obligations) prior to the date on which any such payment is required to be made pursuant to any instrument or agreement evidencing such Funded Debt, including any voluntary prepayment, redemption, defeasance or other acquisition for value of any such Funded Debt unless each of the Permitted Payment Conditions are satisfied, and other than (a) payments in equity securities (as long as no Change in Control would result therefrom); (b) payments of interest in-kind; (c) prepayment in whole or in part with the proceeds of any equity securities issued or capital contributions received by any Borrower or any Domestic Subsidiary for the purpose of making such payment or prepayment; (d) refinancings of Debt to the extent permitted under <B>Section 10.2.3(vii)</B>; (e) payments, prepayments, repurchase, defeasance, retirement, satisfaction or redemption of the Convertible Notes so long as, if such payment is made with proceeds of the 
Loans, the provisions of <B>Section 10.1.11</B> are satisfied; (f) prepayments, repurchase, defeasance, retirement, satisfaction or redemption of the Senior Notes so long as each of the Permitted Payment Conditions is satisfied; and (g) payments permitted under <B>Section 10.2.6(i)</B>.</P>
<P ALIGN="JUSTIFY">10.2.7.&nbsp;&nbsp;&nbsp;<U>Distributions</P>
</U><P ALIGN="JUSTIFY">.  Declare or make any Distributions, except for (i)&nbsp;Upstream Payments, (ii) Distributions to a Borrower, (iii) so long as no Event of Default exists or would result therefrom and the aggregate amount of all such Distributions do not exceed $12,000,000 during any Fiscal Year, Distributions by Parent to shareholders of Parent, and (iv) Distribution of net proceeds of a Portfolio Transaction so long as (a) the Fixed Asset Sublimit has been reduced to zero, (b) the Term Loan has been Paid in Full, (c) no Event of Default exists or would result therefrom and (d) at the time of and after giving effect to any such Distribution, Availability is not less than $25,000,000.</P>
<P ALIGN="JUSTIFY">10.2.8.&nbsp;&nbsp;&nbsp;<U>Upstream Payments</P>
</U><P ALIGN="JUSTIFY">.  Create or suffer to exist any encumbrance or restriction on the ability of a Domestic Subsidiary to make any Upstream Payment, except for encumbrances or restrictions (i)&nbsp;pursuant to the Loan Documents, (ii)&nbsp;existing under Applicable Law (iii)&nbsp;identified and fully disclosed in <B><U>Schedule&nbsp;10.2.8</B></U>, (iv) under any documents relating to joint ventures of any Obligor to the extent that such joint ventures are not prohibited hereunder, (v) the foregoing shall not apply to any restrictions in existence prior to the time any such Person became a Subsidiary and not created in contemplation of any such acquisition, (vi) under any agreement relating to the Convertible Notes, Senior Notes, or any refinancing or replacement thereof, and (vii) under any agreement relating to Debt incurred under <B>Section 10.2.3(xvii)</B> to the extent not more restrictive than those existing on the date hereof.</P>
<P ALIGN="JUSTIFY">10.2.9.&nbsp;&nbsp;&nbsp;<U>Capital Expenditures</P>
</U><P ALIGN="JUSTIFY">.  Make Capital Expenditures (including expenditures by way of capitalized leases) which in the aggregate, as to all Borrowers and their Domestic Subsidiaries, exceed $60,000,000 (excluding any Capital Expenditures made with condemnation or insurance proceeds or Revolver Loan proceeds to the extent such condemnation or insurance proceeds are used to pay down the Revolver Loans)<B><I> </B></I>during the period from the date of this Agreement through December 31, 2006 or during any Fiscal Year thereafter; provided that if, for any Fiscal Year set forth above, the amount specified above for such Fiscal Year (as increased pursuant to this proviso) exceeds the aggregate amount of Capital Expenditures made by Borrowers and their Domestic Subsidiaries during such Fiscal Year (the amount of such excess being the "Excess Amount"), Borrowers shall be entitled to make additional Capital Expenditures in the immediately succeeding Fiscal Year in an amount (such amount being referred to herein as th
e "Carryover Amount") equal to the lesser of (i) the Excess Amount and (ii) 50% of the amount specified above for such immediately preceding Fiscal Year (as increased pursuant to this proviso).</P>
<P ALIGN="JUSTIFY">10.2.10.&nbsp;&nbsp;&nbsp;<U>Disposition of Assets</P>
</U><P ALIGN="JUSTIFY">.  Make any Asset Disposition other than a Permitted Asset Disposition.</P>
<P ALIGN="JUSTIFY">10.2.11.&nbsp;&nbsp;&nbsp;<U>Subsidiaries</P>
</U><P ALIGN="JUSTIFY">. <B><I> </B></I>Form or acquire any Domestic Subsidiary after the Closing Date, except  to the extent constituting a Permitted Subsidiary or except to the extent formed or acquired in connection with a Permitted Acquisition or a Permitted Investment or permit any existing Domestic Subsidiary to issue any additional Equity Interests except director's qualifying shares.</P>
<P ALIGN="JUSTIFY">10.2.12.&nbsp;&nbsp;&nbsp;<U>Restricted Investments</P>
</U><P ALIGN="JUSTIFY">.  Make or have any Restricted Investment.</P>
<P ALIGN="JUSTIFY">10.2.13.&nbsp;&nbsp;&nbsp;<U>Tax Consolidation</P>
</U><P ALIGN="JUSTIFY">.  File or consent to the filing of any consolidated income tax return with any Person other than a Subsidiary.</P>
<P ALIGN="JUSTIFY">10.2.14.&nbsp;&nbsp;&nbsp;<U>Accounting Changes; Change of Fiscal Year</P>
</U><P ALIGN="JUSTIFY">.  Make any significant change in accounting treatment or reporting practices, except as may be required by GAAP, or establish a fiscal year different from the Fiscal&nbsp;Year.</P>
<P ALIGN="JUSTIFY">10.2.15.&nbsp;&nbsp;&nbsp;<U>Organic Documents</P>
</U><P ALIGN="JUSTIFY">.  Amend, modify or otherwise change any of the terms or provisions in any of its Organic Documents, except for changes that do not affect (i) such Borrower's or any of its Domestic Subsidiaries' right and authority to enter into and perform the Loan&nbsp;Documents to which it is a party, (ii) the perfection of Agent's Liens in any Collateral, or (iii) the authority or obligation of an Obligor to pay or perform any of the Obligations for which it is liable pursuant to the Loan Documents.</P>
<P ALIGN="JUSTIFY">10.2.16.&nbsp;&nbsp;&nbsp;<U>Restrictive Agreements</P>
</U><P ALIGN="JUSTIFY">.  Permit any Domestic Subsidiary to enter into or become a party to any Restrictive Agreement, provided that the foregoing shall not apply to any agreement permitted under <B>Section 10.2.8</B>.</P>
<P ALIGN="JUSTIFY">10.2.17.&nbsp;&nbsp;&nbsp;<U>Hedging Agreements</P>
</U><P ALIGN="JUSTIFY">.  Enter into any Hedging Agreement, other than Hedging Agreements entered into in the Ordinary Course of Business to hedge or mitigate risks to which any Borrower or any Domestic Subsidiary is exposed in the conduct of its business or the management of its liabilities and not for any speculative purpose.</P>
<P ALIGN="JUSTIFY">10.2.18.&nbsp;&nbsp;&nbsp;<U>Compromise of Claims</P>
</U><P ALIGN="JUSTIFY">.  Discount, forgive, waive or otherwise compromise any claim or Debt owing to it (other than unsecured intercompany claims among the Consolidated Group in the Ordinary Course of Business), except for reasonable consideration negotiated on an arms-length basis and in the Ordinary Course of Business.</P>
<P ALIGN="JUSTIFY">10.2.19.&nbsp;&nbsp;&nbsp;<U>Anti-Terrorism Laws</U>.</P>
<P ALIGN="JUSTIFY">  Conduct any business or engage in any transaction or dealing with any Blocked Person, including the making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person; deal in, or otherwise engage in any transaction relating to, any Property or interests in Property blocked pursuant to Executive Order No.&nbsp;13224; or engage in on conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No.&nbsp;13224 or the USA Patriot Act.  Borrowers shall deliver to Agent and Lenders any certification or other evidence requested from time to time by Agent or any Lender, in its reasonable discretion, confirming each Borrower's and each of its Subsidiaries' compliance with this <B>Section&nbsp;10.2.19</B>.</P>
<P ALIGN="JUSTIFY">10.2.20.&nbsp;&nbsp;&nbsp;<U>Conduct of Business</P>
</U><P ALIGN="JUSTIFY">.  Engage in any business other than the business engaged in by it on the Closing Date and any business or activities which are substantially similar, related or incidental thereto.</P>
<P ALIGN="JUSTIFY">10.2.21.&nbsp;&nbsp;&nbsp;<U>Amendments to Indentures</P>
</U><P ALIGN="JUSTIFY">.  Amend, modify or supplement, or permit any Subsidiary to amend, modify or supplement (or consent to any amendment, modification or supplement of) any of the Convertible Note Documents or Senior Note Documents (or any replacements or substitutions or renewals thereof), or pursuant to which the Senior Notes or the Convertible Notes are issued or extended, except in connection with any refinancing thereof  permitted under <B>Section 10.2.3</B>, if such amendment, modification or supplement provides for any of the following or has any of the following effects:</P>
<P ALIGN="JUSTIFY">(i)&#9;increases the overall principal amount of any Debt evidenced by any of the Senior Notes or Convertible Notes;</P>
<P ALIGN="JUSTIFY">(ii)&#9;shortens the final maturity date of such Debt;</P>
<P ALIGN="JUSTIFY">(iii)&#9;amends, modifies  or adds any financial or negative covenants in a manner which when taken as a whole is more onerous or more restrictive in any material respect to Borrowers and their Domestic Subsidiaries taken as a whole or that is otherwise materially adverse to Borrowers and their Domestic Subsidiaries taken as a whole or Lenders; or</P>
<P ALIGN="JUSTIFY">(iv)&#9;results in any of the Loan Documents, or any of the credit facilities evidenced hereby, not constituting a permitted credit facility under the Senior Note Documents or Convertible Note Documents.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346572"><A NAME="_Toc99510232"><A NAME="_Toc102963372"><A NAME="_Toc105998343"><A NAME="_Toc105998753"><A NAME="_Toc105998885"><A NAME="_Toc117052398">10.3.&nbsp;&nbsp;&nbsp;<U>Financial Covenants</A></A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">.  For so long as there are any Commitments outstanding and thereafter until Full Payment of the Obligations, Borrowers covenant that they shall:</P>
<P ALIGN="JUSTIFY">10.3.1.&nbsp;&nbsp;&nbsp;<U>Fixed Charge Coverage Ratio</U>.</P>
<P ALIGN="JUSTIFY">  If a Restrictive Trigger Event occurs, then the Fixed Charge Coverage Ratio for the Consolidated Group shall not be less than 1.0 to 1.0 and shall be tested immediately as follows:</P>
<P ALIGN="JUSTIFY">(i)&nbsp;&nbsp;&nbsp;if the Restrictive Trigger Event occurs during the first full twelve Fiscal Months after the Closing Date, such calculation shall be made for the period beginning with the Fiscal Month of November 2005 through the Fiscal Month for which Borrowers have delivered financial statements to Agent under<B> Section 10.1.3</B> (whether such financial statements are delivered under <B>Section 10.1.3(i), (ii) or (iii)</B>), on a cumulative basis, and </P>
<P ALIGN="JUSTIFY">(ii)&nbsp;&nbsp;&nbsp;if the Restrictive Trigger Event occurs after the first full twelve Fiscal Months from the Closing Date, such calculation shall be based upon the immediately preceding twelve Fiscal Month period for which Borrowers have delivered financial statements to Agent under <B>Section 10.1.3</B> (whether such financial statements are delivered under <B>Section 10.1.3(i), (ii) or (iii)</B>), and thereafter, such calculation shall be based upon each Fiscal Month.</P>
<P ALIGN="JUSTIFY">Within five (5) Business Days after the occurrence of a Restrictive Trigger Event, Borrowers shall cause to be prepared and furnished to Agent a Compliance Certificate executed by the chief financial officer of Borrowers, which Compliance Certificate shall include the calculation of the Fixed Charge Coverage Ratio for the prior 12 month period based upon the most current financial statements received by Agent prior to such Restrictive Trigger Event.</P>
<P ALIGN="JUSTIFY">If after the occurrence of a Restrictive Trigger Event, Availability is at least $25,000,000 if the Term Loan is not outstanding (and $35,000,000 if the Term Loan is outstanding) for 60 consecutive days and no Event of Default exists, then on the 61<SUP>st</SUP> consecutive day (the "Covenant Spring-Back Date"), Agent thereafter will not require that Borrowers comply with the covenant referenced above unless another Restrictive Trigger Event occurs.  If a Restrictive Trigger Event has occurred as a result of an Event of Default and not as a result of the failure by Borrowers to meet the Availability or Average Availability requirements, and Agent (or to the extent required by this Agreement, all Lenders or Required Lenders) waive the Event of Default in writing, then the Covenant Spring-Back Date shall occur on the date of the waiver in writing of such Event of Default.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346573"><A NAME="_Toc102963373"><A NAME="_Toc105998344"><A NAME="_Toc105998754"><A NAME="_Toc105998886"><A NAME="_Toc117052399">SECTION 11.&nbsp;&nbsp;&nbsp;CONDITIONS PRECEDENT</A></A></A></A></A></A></P>
<P ALIGN="JUSTIFY"><A NAME="_Toc38346574"><A NAME="_Toc102963374"><A NAME="_Toc105998345"><A NAME="_Toc105998755"><A NAME="_Toc105998887"><A NAME="_Toc117052400">11.1&nbsp;&nbsp;&nbsp;<U>Conditions Precedent to Initial Credit Extensions</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Initial Lender shall not be required to fund any requested Loan, issue any Letter of Credit, or otherwise extend credit to Borrowers, unless, on or before October 26, 2005, each of the following conditions has been satisfied (unless otherwise waived or extended in writing by Agent in its sole discretion):</P>
<P ALIGN="JUSTIFY">11.1.1.&nbsp;&nbsp;&nbsp;<U>Loan Documents</P>
</U><P ALIGN="JUSTIFY">.  Each of the Loan Documents shall have been duly executed and delivered to Agent by each of the signatories thereto and accepted by Agent and each Borrower and each Consolidated Group Member shall be in&nbsp;compliance with all of the terms thereof.</P>
<P ALIGN="JUSTIFY">11.1.2.&nbsp;&nbsp;&nbsp;<U>Availability</P>
</U><P ALIGN="JUSTIFY">.  Agent shall have determined, and Initial Lender shall be satisfied, that, immediately after Initial Lender has made the initial Revolver Loans to be made on the Closing Date, Issuing Bank&nbsp;has issued the&nbsp;Letters of Credit to be issued on the Closing Date (if any), and Borrowers have paid (or made provision for payment of) all fees and closing costs incurred in connection with the Commitments and payable on the Closing Date, and after increasing the Availability Reserve in the amount of any payables of Borrowers that are stretched beyond Borrowers' customary payment practices, Availability is not less than $50,000,000.</P>
<P ALIGN="JUSTIFY">11.1.3.&nbsp;&nbsp;&nbsp;<U>Evidence of Perfection and Priority of Liens</P>
</U><P ALIGN="JUSTIFY">.  Agent shall have received copies of all filing receipts or acknowledgments issued by any Governmental Authority to evidence any&nbsp;filing or recordation necessary to perfect the Liens of Agent in the Collateral to the extent required by the Loan Documents and evidence in form satisfactory to Agent and Initial Lender that such Liens constitute valid and perfected Liens, and that there are no other Liens upon any Collateral except for Permitted Liens.</P>
<P ALIGN="JUSTIFY">11.1.4.&nbsp;&nbsp;&nbsp;<U>Organic Documents</P>
</U><P ALIGN="JUSTIFY">.  Agent shall have received copies of the Organic Documents of each Borrower and each Domestic Subsidiary, and all amendments thereto, certified by the Secretary of State or other appropriate officials of the jurisdiction of each Borrower's and each other Domestic Subsidiaries' states of organization.</P>
<P ALIGN="JUSTIFY">11.1.5.&nbsp;&nbsp;&nbsp;<U>Good Standing Certificates</P>
</U><P ALIGN="JUSTIFY">.  Agent shall have received good standing certificates for each Borrower and each Domestic Subsidiary, issued by the Secretary of State or other appropriate official of such Borrower's or such Domestic Subsidiary's jurisdiction of organization and each jurisdiction where the conduct of such Borrower's or such Domestic Subsidiary's business activities or ownership of its Property necessitates qualification except where failure to be so qualified would not have a Material Adverse Effect.</P>
<P ALIGN="JUSTIFY">11.1.6.&nbsp;&nbsp;&nbsp;<U>Opinion Letters</P>
</U><P ALIGN="JUSTIFY">.  Agent and Initial Lender shall have received a favorable, written opinion of Kirkland &amp; Ellis LLP and the respective local counsel to Borrowers and their Domestic Subsidiaries and Agent, covering, to Agent's reasonable satisfaction, the matters set forth on <B><U>Exhibit G</B></U> attached hereto.</P>
<P ALIGN="JUSTIFY">11.1.7.&nbsp;&nbsp;&nbsp;<U>Insurance</P>
</U><P ALIGN="JUSTIFY">.  Agent shall have received certified copies of the property and casualty insurance policies of Borrowers and their Domestic Subsidiaries with respect to the Collateral, or certificates of insurance with respect to such policies in form acceptable to Agent, and loss payable endorsements on Agent's standard form of loss payee endorsement naming Agent as lender's loss payee and mortgagee with respect to each such policy and certified copies of Borrowers' and their Domestic Subsidiaries liability insurance policies, including product liability policies, together with endorsements naming Agent as an additional insured, all as required by the Loan Documents.</P>
<P ALIGN="JUSTIFY">11.1.8.&nbsp;&nbsp;&nbsp;<U>Solvency Certificates</P>
</U><P ALIGN="JUSTIFY">.  Agent and Initial Lender shall have received certificates satisfactory to them from one or more knowledgeable Senior Officers of Borrowers that, after giving effect to the financing under this Agreement and the issuance of the Letters of Credit, the Consolidated Group, taken as a whole, is Solvent.</P>
<P ALIGN="JUSTIFY">11.1.9.&nbsp;&nbsp;&nbsp; <U>No Labor Disputes</P>
</U><P ALIGN="JUSTIFY">.  Agent shall have received assurances satisfactory to it that there are no threats of strikes or work stoppages by any employees, or organization of employees, of any Consolidated Group Member which could reasonably be expected to have a Material Adverse Effect.</P>
<P ALIGN="JUSTIFY">11.1.10.&nbsp;&nbsp;&nbsp;<U>Compliance with Laws and Other Agreements</P>
</U><P ALIGN="JUSTIFY">.  Agent shall have determined or received assurances satisfactory to it that none of the Loan Documents or any of the transactions contemplated thereby violate any Applicable Law, court order or agreement binding upon any Consolidated Group Member.</P>
<P ALIGN="JUSTIFY">11.1.11.&nbsp;&nbsp;&nbsp;<U>No Material Adverse Change</P>
</U><P ALIGN="JUSTIFY">.  No material adverse change in the financial condition of the Consolidated Group taken as a whole or in the quality, quantity or value of the Collateral (taken as a whole) shall have occurred since December 31, 2004.</P>
<P ALIGN="JUSTIFY">11.1.12.&nbsp;&nbsp;&nbsp;<U>Accounts Payable</P>
</U><P ALIGN="JUSTIFY">.  Agent shall have reviewed and found acceptable Borrowers' accounts payable practices and vendor arrangements.</P>
<P ALIGN="JUSTIFY">11.1.13.&nbsp;&nbsp;&nbsp;<U>Payment of Fees</P>
</U><P ALIGN="JUSTIFY">.  Borrowers shall have paid, or made provision for the&nbsp;payment on the Closing Date of, all fees and expenses to be paid hereunder to Agent on the Closing&nbsp;Date.</P>
<U><P ALIGN="JUSTIFY">11.1.14.&nbsp;&nbsp;&nbsp;Due Diligence</P>
</U><P ALIGN="JUSTIFY">.  Agent shall have completed its business and legal due diligence, including a roll forward of its previous Collateral audit, with results acceptable to Agent, and the receipt of Inventory, Equipment and Real Estate appraisals acceptable to Agent in all respects.</P>
<P ALIGN="JUSTIFY">11.1.15.&nbsp;&nbsp;&nbsp;<U>LC Conditions</P>
</U><P ALIGN="JUSTIFY">.  With respect to the issuance of any Letter of Credit on the&nbsp;Closing Date, each of the LC Conditions is satisfied.</P>
<P ALIGN="JUSTIFY">11.1.16.&nbsp;&nbsp;&nbsp;<U>Title Insurance Policies</P>
</U><P ALIGN="JUSTIFY">.  Agent shall have received, had at least 5 days to review and found acceptable fully paid mortgagee title insurance policies (or binding commitments to issue title insurance policies, marked to Agent's satisfaction to evidence the form of such policies to be delivered after the Closing Date), for each parcel of Real Estate listed on <B><U>Exhibit K</U> </B>attached hereto in standard ALTA form, issued by a title insurance company satisfactory to Agent, each in an amount equal to not less than the fair market value of such Real Estate or leasehold interest, as the case may be, subject to the Mortgages, insuring the Mortgages to create a valid Lien on such Real Estate or valid Liens on such leasehold interest described therein with no exceptions which Agent shall not have approved in writing, which policies (and commitments therefor) shall have acceptable zoning endorsements.</P>
<P ALIGN="JUSTIFY">11.1.17.&nbsp;&nbsp;&nbsp;<U>Surveys</P>
</U><P ALIGN="JUSTIFY">.  Agent shall have received, had at least 5 days to review and, found acceptable a current, as-built survey with respect to each parcel of the Real Estate listed on <B><U>Exhibit K</U> </B>attached hereto comprising a part of the Collateral, which survey shall indicate the following:  (i)&nbsp;an accurate metes and bounds or lot, block and parcel description of such Real Estate; (ii)&nbsp;the correct location of all buildings, structures and other&nbsp;improvements on such Real Estate, including all streets, easements, rights of way and utility lines; (iii)&nbsp;the location of ingress and egress from such Real Estate, and the location of any set-back or other building lines affecting such Real Estate; and (iv)&nbsp;a certification by a registered land surveyor in form and substance acceptable to Agent, certifying to the accuracy and completeness of such survey and to such other matters relating to such Real Estate and survey as Agent shall require.</P>
<P ALIGN="JUSTIFY">11.1.18.&nbsp;&nbsp;&nbsp;<U>Environmental Matters</P>
</U><P ALIGN="JUSTIFY">.  Agent shall have received, reviewed and found satisfactory the&nbsp;representations, warranties and disclosures in the Environmental Agreement and environmental audits of the Real Estate as requested by Agent and conducted by an environmental consulting firm reasonably acceptable to Agent.</P>
<P ALIGN="JUSTIFY">11.1.19.&nbsp;&nbsp;&nbsp;<U>Capital Structure.</U>  Agent shall have determined that the capital structure of each of (i) Parent (for Parent's consolidated domestic operations) and (ii) Parent and its Domestic Subsidiaries and Foreign Subsidiaries, including the terms of any additional debt capital that is to be arranged concurrently with or prior to the Closing Date and the legal documentation related thereto are reasonably satisfactory to Agent.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346575"><A NAME="_Toc102963375"><A NAME="_Toc105998346"><A NAME="_Toc105998756"><A NAME="_Toc105998888"><A NAME="_Toc117052401">11.2.&nbsp;&nbsp;&nbsp;<U>Conditions Precedent to All Credit Extensions</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  The obligations of the Lenders to fund any Loans or otherwise extend any credit to or for the benefit of Borrowers and of the Issuing Bank to issue each Letter of Credit is subject to the following conditions precedent:</P>
<P ALIGN="JUSTIFY">11.2.1.&nbsp;&nbsp;&nbsp;<U>No Defaults</P>
</U><P ALIGN="JUSTIFY">.  No Default or Event of Default exists at the time, or would result from the funding, of any Loan or other extension of credit hereunder.</P>
<P ALIGN="JUSTIFY">11.2.2.&nbsp;&nbsp;&nbsp;<U>Representations and Warranties</U>.  </P>
<P ALIGN="JUSTIFY">Each of the representations and warranties by an Obligor in any of the Loan Documents (including any representations and warranties in any certificate furnished at any time in connection herewith) are true and correct in all material respects on and as of the date of each extension of credit hereunder (except for those representations or warranties which expressly relate to an earlier date).</P>
<P ALIGN="JUSTIFY">11.2.3.&nbsp;&nbsp;&nbsp;<U>No Litigation</P>
</U><P ALIGN="JUSTIFY">.  No action, proceeding, investigation, regulation or legislation shall have been instituted, threatened or proposed before any court, governmental agency or legislative body to enjoin, restrain or prohibit, or to obtain damages in respect of, or which is related to or arises out of, this Agreement or any of the other Loan Documents or the consummation of the&nbsp;transactions contemplated hereby or thereby.</P>
<P ALIGN="JUSTIFY">11.2.4.&nbsp;&nbsp;&nbsp;<U>No Material Adverse Effect</P>
</U><P ALIGN="JUSTIFY">.  No event shall have occurred and no&nbsp;condition shall exist which has or could be reasonably expected to have a Material Adverse Effect since December 31, 2004.</P>
<P ALIGN="JUSTIFY">11.2.5.&nbsp;&nbsp;&nbsp;<U>Borrowing Base Certificate</P>
</U><P ALIGN="JUSTIFY">.  Agent shall have received the Borrowing Base Certificate then required to be delivered pursuant to <B>Section 8.6</B>, including, with respect to the initial Borrowing made on the Closing Date only, a Borrowing Base Certificate dated as of the most recent week-end preceding the Closing Date.</P>
<P ALIGN="JUSTIFY">11.2.6.&nbsp;&nbsp;&nbsp;<U>LC Conditions</P>
</U><P ALIGN="JUSTIFY">.  With respect to the issuance of any Letter of Credit after the&nbsp;Closing Date, each of the LC Conditions is satisfied.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346576"><A NAME="_Toc102963376"><A NAME="_Toc105998347"><A NAME="_Toc105998757"><A NAME="_Toc105998889"><A NAME="_Toc117052402">11.3&nbsp;&nbsp;&nbsp;<U>Inapplicability of Conditions</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  None of the conditions precedent set forth in <B>Sections&nbsp;11.1</B> or <B>11.2</B> shall be conditions to the obligation of (i)&nbsp;each Participating Lender to make payments to Issuing Bank pursuant to <B>Section&nbsp;2.3.2</B>, (ii)&nbsp;each Lender to deposit with Agent such Lender's Pro&nbsp;Rata share of a Borrowing in accordance with <B>Section&nbsp;4.1.2</B>, (iii)&nbsp;each Lender to fund its Pro Rata share of a Revolver Loan to repay outstanding Swingline Loans to BofA as provided in <B>Section&nbsp;4.1.3(ii)</B>, (iv)&nbsp;each Lender to&nbsp;pay any amount payable to Agent or any other Lender pursuant to this Agreement or (v)&nbsp;Agent to pay any amount payable to any Lender pursuant to this Agreement.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346577"><A NAME="_Toc102963377"><A NAME="_Toc105998348"><A NAME="_Toc105998758"><A NAME="_Toc105998890"><A NAME="_Toc117052403">11.4&nbsp;&nbsp;&nbsp;<U>Limited Waiver of Conditions Precedent</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  If Lenders shall make any Loan or otherwise extend any credit to Borrowers under this Agreement at a time when any of the foregoing conditions precedent are not satisfied (regardless of whether the failure of satisfaction of any&nbsp;such conditions precedent was known or unknown to Agent or Lenders) unless Agent, with the prior written consent of the Required Lenders, in writing waives the&nbsp;satisfaction of any condition precedent, in which event such waiver shall only be applicable for the&nbsp;specific instance given and only to the extent and for the period of time expressly stated in such written waiver, the funding of such Loan or other extension of credit shall not operate as a waiver of the right of Agent and Lenders to insist upon the satisfaction of all conditions precedent with respect to each subsequent Borrowing requested by Borrowers.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346578"><A NAME="_Toc102963378"><A NAME="_Toc105998349"><A NAME="_Toc105998759"><A NAME="_Toc105998891"><A NAME="_Toc117052404">section 12.&nbsp;&nbsp;&nbsp;EVENTS OF DEFAULT; REMEDIES ON DEFAULT</A></A></A></A></A></A></P>
<P ALIGN="JUSTIFY"><A NAME="_Toc38346579"><A NAME="_Toc102963379"><A NAME="_Toc105998350"><A NAME="_Toc105998760"><A NAME="_Toc105998892"><A NAME="_Toc117052405">12.1.&nbsp;&nbsp;&nbsp;<U>Events of Default</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  The occurrence or existence of any one or more of the following events or conditions shall constitute an "Event of Default" (each of which Events of Default shall be deemed to exist unless and until waived by Agent and Lenders in accordance with the provisions of <B>Section&nbsp;13.9</B>):</P>
<P ALIGN="JUSTIFY">12.1.1.&nbsp;&nbsp;&nbsp;<U>Payment of Obligations</P>
</U><P ALIGN="JUSTIFY">.  Borrowers shall (i) fail to pay any principal on any Loan or LC Obligation on the due date thereof (whether due at stated maturity, on demand, upon acceleration or otherwise), or (ii) fail to pay any interest on any Loan or LC Obligation within 3 Business Days after the due date thereof (whether due at stated maturity, on demand, upon acceleration or otherwise), or (iii) within 5 Business Days after the due date thereof (whether due at stated maturity, on demand, upon acceleration or otherwise), fail to pay any other Obligations.</P>
<P ALIGN="JUSTIFY">12.1.2.&nbsp;&nbsp;&nbsp;<U>Misrepresentations</P>
</U><P ALIGN="JUSTIFY">.  Any representation, warranty or other written statement to Agent or any Lender by or on behalf of any Obligor, whether made in or furnished in compliance with or in reference to any of the Loan Documents (including any representation made in any Borrowing Base Certificate), proves to have been incorrect in any material respect when made or furnished or when reaffirmed pursuant to <B>Section&nbsp;9.2</B>.</P>
<P ALIGN="JUSTIFY">12.1.3.&nbsp;&nbsp;&nbsp;<U>Breach of Specific Covenants</P>
</U><P ALIGN="JUSTIFY">.  Any Borrower shall fail or neglect to perform, keep or observe any covenant contained in (i) <B>Sections 7.6, 8.1.1, 8.1.2, 8.2.4, 8.2.5, 8.2.6, 10.1.1, 10.1.6, 10.1.11, 10.2 or 10.3</B> on the date that such Borrower is required to perform, keep or observe such&nbsp;covenant, or (ii) <B>Section 8.6 </B>with respect to Borrowers' obligation to deliver Borrowing Base Certificates under <B>Section 8.6</B> and <B>Sections 10.1.3(i) through (iv)</B> and <B>Section 10.1.5</B> with respect to Borrowers' obligation to deliver financial information under <B>Sections 10.1.3(i) through (iv)</B> and <B>Section 10.1.5</B>, and such failure under clause (ii) hereof shall remain unremedied (a) with respect to <B>Section 8.6</B> (during any period in which Borrowing Base Certificates are deliverable daily), 1 Business Day after Agent shall have given Borrower Representative notice thereof, on more than 3 occasions during any 30 day period and (b) with respect to <B>Section 8.6 </B>(during a period
 in which Borrowing Base Certificates are deliverable less frequently) and <B>Sections 10.1.3(i) through (iv)</B> and <B>Section 10.1.5</B>, 3 Business Days after Agent shall have given Borrower Representative notice thereof.</P>
<P ALIGN="JUSTIFY">12.1.4.&nbsp;&nbsp;&nbsp;<U>Breach of Other Covenants</P>
</U><P ALIGN="JUSTIFY">.  Any Borrower shall fail or neglect to perform, keep or observe any covenant contained in this Agreement or any other Loan Document (other than a covenant which is dealt with specifically elsewhere in <B>Section&nbsp;12.1</B>) and the breach of such other covenant is not cured to Agent's and the Required Lender's satisfaction within 30 days after Agent shall have given Borrower Representative notice thereof.</P>
<P ALIGN="JUSTIFY">12.1.5.&nbsp;&nbsp;&nbsp;<U>Other Defaults</P>
</U><P ALIGN="JUSTIFY">.  (i) There shall occur any default or event of default on the part of any Obligor under any agreement, document or instrument to which such Obligor is a party or by which such Obligor or any of its Properties is bound, creating or relating to any Debt (including the Convertible Notes but excluding the Obligations and the Senior Notes) in excess of $10,000,000 if (after giving effect to the expiration of any grace period set forth therein) the&nbsp;payment or maturity of such Debt may be accelerated in consequence of such default or event of default or demand for payment of such Debt may be made; or (ii) the Senior Notes shall not have been paid in full (but an Approved Escrow shall have been established) and any holder of the Senior Notes shall have commenced an enforcement action against any Consolidated Group Member; or (iii) the Senior Notes shall not have been paid in full (and no Approved Escrow shall have been established) and a default shall occur under the Senior Notes (after
 giving effect to the expiration of any grace period set forth therein).</P>
<P ALIGN="JUSTIFY">12.1.6.&nbsp;&nbsp;&nbsp;<U>Insolvency Proceeding</P>
</U><P ALIGN="JUSTIFY">.  Any Insolvency Proceeding shall be voluntarily commenced by any Obligor; in connection with any such Insolvency Proceeding an&nbsp;interim trustee is appointed to take possession all or a substantial portion of the Properties of such Obligor or to operate all or any substantial portion of the business of such Obligor or an order for relief shall have been issued or entered in connection with such Insolvency Proceeding; or any Obligor shall make a general assignment for the benefit of creditors.</P>
<P ALIGN="JUSTIFY">12.1.7.&nbsp;&nbsp;&nbsp;<U>Involuntary Insolvency Proceeding</P>
</U><P ALIGN="JUSTIFY">.  Any Insolvency Proceeding is commenced against any Obligor and any of the following events occur:  such Obligor takes corporate action to consent to the institution of the Insolvency Proceeding against it, the petition commencing the Insolvency Proceeding is not timely controverted by such Obligor, the petition commencing the Insolvency Proceeding is not dismissed within 60 days after the date of the filing thereof (provided that, in any event, during the pendency of any such period, Lenders shall be relieved from their obligation to make Loans or otherwise extend credit to or for the benefit of Borrowers hereunder).</P>
<P ALIGN="JUSTIFY">12.1.8.&nbsp;&nbsp;&nbsp;<U>Business Disruption; Condemnation</P>
</U><P ALIGN="JUSTIFY">.  There shall occur a cessation of a substantial part of the business of any one or more Obligors for a period which may be reasonably expected to have a Material Adverse Effect; or any substantial portion of the Collateral shall be taken through condemnation or the value of such Property shall be materially impaired through condemnation.</P>
<P ALIGN="JUSTIFY">12.1.9.&nbsp;&nbsp;&nbsp;<U>ERISA</P>
</U><P ALIGN="JUSTIFY">.  A Reportable Event shall occur which Agent, in its reasonable discretion, shall determine constitutes grounds for the termination by the Pension Benefit Guaranty Corporation of any Plan or for the appointment by the appropriate United States district court of a trustee for any Plan, or if any Plan shall be terminated or any such trustee shall be requested or appointed, or if&nbsp;any Borrower, any Subsidiary or any Obligor is in "default" (as defined in Section 4219(c)(5) of ERISA) with&nbsp;respect to payments to a Multiemployer Plan resulting from such Borrower's, such Subsidiary's or such&nbsp;Obligor's complete or partial withdrawal from such Multiemployer Plan, and, with respect to any of the events described above, in the reasonable judgment of Agent, has a Material Adverse Effect.</P>
<P ALIGN="JUSTIFY">12.1.10.&nbsp;&nbsp;&nbsp;<U>Challenge to or Insufficiency of Loan Documents</P>
</U><P ALIGN="JUSTIFY">.  (i) Any Obligor or any of its Affiliates shall challenge or contest (or support the challenge or contest of others) in any action, suit or proceeding the validity or enforceability of any of the Loan&nbsp;Documents, the legality or enforceability of any of the Obligations or the perfection or priority of any Lien granted to Agent, or (ii) any of the Loan Documents ceases to be in full force or effect for any reason other than releases by Agent of Liens in certain Collateral to the extent expressly authorized by this Agreement or a full or partial waiver or release by Agent and Lenders in accordance with the terms thereof.</P>
<P ALIGN="JUSTIFY">12.1.11.&nbsp;&nbsp;&nbsp;<U>Judgment</P>
</U><P ALIGN="JUSTIFY">.  One or more judgments or orders for the payment of money in an amount that exceeds, individually or in the aggregate, $5,000,000 shall be entered against any Borrower or any other Obligor and (i)&nbsp;enforcement proceedings shall have been commenced by any creditor upon such judgment or order, (ii)&nbsp;there shall be any period of 30 consecutive days during which a stay&nbsp;of enforcement of such judgment or order, by reason of a pending appeal or otherwise, shall not be in effect or (iii)&nbsp;results in the creation or imposition of a Lien upon any of the Collateral that is not a Permitted Lien.</P>
<P ALIGN="JUSTIFY">12.1.12.&nbsp;&nbsp;&nbsp;<U>Repudiation of or Default Under Guaranty</P>
</U><P ALIGN="JUSTIFY">.  Any Guarantor shall revoke or attempt to revoke the Guaranty signed by such Guarantor, or shall repudiate such Guarantor's liability thereunder.</P>
<P ALIGN="JUSTIFY">12.1.13.&nbsp;&nbsp;&nbsp;<U>Criminal Forfeiture</P>
</U><P ALIGN="JUSTIFY">.  Any Obligor (or any of its Senior Officers) is criminally indicted or convicted for (i) a felony committed in the conducted of the business of such Obligor or (ii) any state or federal law (including the Controlled Substances Act, the Money Laundering Control Act of 1986, and the Illegal Exportation of War Materials Act) that could lead to a forfeiture of any material (as determined by Agent in the exercise of its discretion) Collateral.</P>
<P ALIGN="JUSTIFY">12.1.14.&nbsp;&nbsp;&nbsp;<U>Change of Control</U>.</P>
<P ALIGN="JUSTIFY">  A Change of Control shall occur.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346580"><A NAME="_Toc102963380"><A NAME="_Toc105998351"><A NAME="_Toc105998761"><A NAME="_Toc105998893"><A NAME="_Toc117052406">12.2.&nbsp;&nbsp;&nbsp;<U>Acceleration of Obligations; Termination of Commitments</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Without in any way limiting the right of Agent to demand payment of any portion of the Obligations payable on demand in accordance with this Agreement upon or at any time after the occurrence of an Event of Default (other than pursuant to <B>Sections&nbsp;12.1.6</B> and <B>Section&nbsp;12.1.7</B>) and for so long as such Event of Default shall exist, Agent may with the consent of the Required Lenders or upon receipt of written instructions to do so from the Required Lenders, shall (a)&nbsp;declare the principal of and any accrued interest on the Loans and all other Obligations owing under any of the Loan&nbsp;Documents to be, whereupon the same shall become without further notice or demand (all of which notice and demand each Borrower expressly waives), forthwith due and payable and Borrowers shall forthwith pay to Agent the entire principal of and accrued and unpaid interest on the&nbsp;Loans and other Obligations plus reasonable attorneys' fees and court costs if such principa
l and interest are collected by or through an attorney-at-law and (b)&nbsp;terminate the Revolver Commitments; <U>provided</U>, <U>however</U>, that upon the occurrence of an Event of Default specified in <B>Section&nbsp;12.1.6</B>, all of the Obligations shall become automatically due and payable without declaration, notice or demand by Agent to or upon any Borrower or any other Obligor and the Revolver Commitments shall automatically terminate as if terminated by Agent pursuant to <B>Section&nbsp;6.2.1</B> and with the effects specified in <B>Section&nbsp;6.2.4</B>.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346581"><A NAME="_Toc102963381"><A NAME="_Toc105998352"><A NAME="_Toc105998762"><A NAME="_Toc105998894"><A NAME="_Toc117052407">12.3.&nbsp;&nbsp;&nbsp;<U>Other Remedies</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Upon and after the occurrence of an Event of Default and for so long as such Event of Default shall exist, Agent may in its discretion (and, upon receipt of written direction of the&nbsp;Required Lenders, shall) institute any Enforcement Action and exercise from time to time the following rights and remedies:</P>
<P ALIGN="JUSTIFY">12.3.1.&nbsp;&nbsp;&nbsp;All of the rights and remedies of a secured party under the UCC or under other Applicable Law, and all other legal and equitable rights to which Agent may be entitled under any&nbsp;of the Loan&nbsp;Documents, all of which rights and remedies shall be cumulative and shall be in addition to any other rights or remedies contained in this Agreement or any of the other Loan Documents, and none of which shall&nbsp;be&nbsp;exclusive.</P>
<P ALIGN="JUSTIFY">12.3.2.&nbsp;&nbsp;&nbsp;The right to collect all amounts at any time payable to a Borrower from any&nbsp;Account Debtor or other Person at any time indebted to such Borrower.</P>
<P ALIGN="JUSTIFY">12.3.3.&nbsp;&nbsp;&nbsp;The right to take immediate possession of any of the Collateral, and to&nbsp;(i)&nbsp;require Borrowers to assemble the Collateral, at Borrowers' expense, and make it available to Agent at a place designated by Agent which is reasonably convenient to both parties, and (ii) enter any premises where any of the Collateral shall be located and to keep and store the Collateral on said premises until sold (and if said premises be owned or leased by a Borrower, then such Borrower agrees not to charge Agent for storage of any Collateral therein).</P>
<P ALIGN="JUSTIFY">12.3.4.&nbsp;&nbsp;&nbsp;The right to sell or otherwise dispose of all or any Collateral in its then condition, or after any further manufacturing or processing thereof, at public or private sale or sales, with&nbsp;such notice as may be required by Applicable Law, in lots or in bulk, for cash or on credit, all as Agent, in its discretion, may deem advisable.  Each Borrower agrees that any requirement of notice to any Borrower or any other Obligor of any proposed public or private sale or other disposition of Collateral by Agent shall be deemed reasonable notice thereof if given at least 10&nbsp;days prior thereto, and such sale may&nbsp;be at such locations as Agent may designate in said notice.  Agent shall have the right to conduct such&nbsp;sales on any Borrower's or any&nbsp;other Obligor's premises, without charge therefor, and such sales may be adjourned from time to time in&nbsp;accordance with Applicable Law.  Agent shall have the right to sell, lease or otherwise dispose of the&n
bsp;Collateral, or any part thereof, for&nbsp;cash, credit or any combination thereof, and Agent may purchase all&nbsp;or any part of the Collateral at public or, if permitted by law, private sale and, in&nbsp;lieu of actual payment of such&nbsp;purchase price, may set off the&nbsp;amount of such price against the&nbsp;Obligations.  The proceeds realized from the sale or other disposition of any Collateral may be applied, after allowing 2&nbsp;Business Days for collection, first to any Extraordinary Expenses incurred by Agent and then to the remainder of the Obligations as specified in <B>Section</B> <B>5.6.1</B>.</P>
<P ALIGN="JUSTIFY">12.3.5.&nbsp;&nbsp;&nbsp;The right to obtain the appointment of a receiver, without notice of any kind whatsoever, to take possession of the Collateral and to exercise such rights and powers as the court appointing such receiver shall confer upon such receiver.</P>
<P ALIGN="JUSTIFY">12.3.6.&nbsp;&nbsp;&nbsp;The right to exercise all of Agent's remedies under the Mortgages with respect to any Real Estate.</P>
<P ALIGN="JUSTIFY">12.3.7.&nbsp;&nbsp;&nbsp;The right to require Borrowers to Cash Collateralize outstanding Letters of Credit, and, if Borrowers fail promptly to make such deposit, Lenders may (and shall upon the direction of the Required Lenders) advance such amount as a&nbsp;Revolver Loan (whether or not an Out-of-Formula Condition exists or is created thereby or the Commitments have been terminated).  Any such deposit or advance shall be held by Agent in the Cash Collateral Account to fund future payments on any Letter of Credit.  When all Letters of Credit have been drawn upon or expired, any amounts remaining in the Cash Collateral Account shall be applied against any outstanding Obligations, or, after Full Payment of  all Obligations, returned to Borrowers.</P>
<P ALIGN="JUSTIFY">12.3.8.&nbsp;&nbsp;&nbsp;Upon and after the occurrence of an Event of Default and for so long as such Event of Default shall exist, the right of Agent to exercise any option to purchase the building, improvements and Equipment that are leased by Parent from the Pleasants County Development Authority in Willow Island, West Virginia (to the extent that such Collateral is a component of the Borrowing Base).</P>
<P ALIGN="JUSTIFY">Agent is hereby granted a non-exclusive license or other right to use, license or sub-license (exercisable without payment of royalty or other compensation to any Obligor or any other Person) any&nbsp;or all of each Borrower's Intellectual Property and all of each Borrower's computer hardware and software trade secrets, brochures, customer lists, promotional and advertising materials, labels, and packaging materials, and any&nbsp;Property of a similar nature, in advertising for sale, marketing, selling and collecting and in completing the manufacturing of any Collateral, and each Borrower's rights under all licenses and all franchise agreements shall inure to Agent's benefit so long as such Event of Default shall exist.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346582"><A NAME="_Toc102963382"><A NAME="_Toc105998353"><A NAME="_Toc105998763"><A NAME="_Toc105998895"><A NAME="_Toc117052408">12.4&nbsp;&nbsp;&nbsp;<U>Setoff</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  In addition to any Liens granted under any of the Loan Documents and any rights now or hereafter available under Applicable Law, Agent and each Lender (and each of their respective Affiliates) is hereby authorized by Borrowers at any time that an Event of Default exists, without notice to Borrowers or any other Person (any such notice being hereby expressly waived), to set off and to appropriate and apply any and all deposits, general or special (including certificates of deposit whether matured or unmatured (but not including trust accounts)) and any other Debt at any time held or owing by such Lender or any of their Affiliates to or for the credit or the account of any Borrower against and on&nbsp;account of the Obligations of Borrowers arising under the Loan Documents to Agent, such Lender or any&nbsp;of their Affiliates, including all Loans and LC Obligations and all claims of any nature or description arising out of or in connection with this Agreement, irrespective of whet
her or not (i)&nbsp;Agent or such Lender shall have made any demand hereunder, (ii)&nbsp;Agent, at the request or with the consent of the Required Lenders, shall have declared the principal of and interest on the Loans and other amounts due hereunder to be due and payable as permitted by this Agreement and even though such Obligations may be contingent or unmatured or (iii)&nbsp;the Collateral for the Obligations is adequate.  Notwithstanding the foregoing, each of Agent and Lenders agree with each other that it shall not, without the express consent of the Required Lenders, and that it shall (to the&nbsp;extent that it is lawfully entitled to do so) upon the request of the Required Lenders, exercise its setoff rights hereunder against any accounts of any Borrower now or hereafter maintained with Agent, such Lender or any Affiliate of any of them, but no Borrower shall have any claim or cause of action against Agent or any Lender for any setoff made without the consent of the Required Lenders and the validit
y of any such setoff shall not be impaired by the absence of such consent.  If any party (or its Affiliate) exercises the right of setoff provided for hereunder, such party shall be obligated to share any such setoff in the manner and to the extent required by <B>Section&nbsp;13.5</B>.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346583"><A NAME="_Toc102963383"><A NAME="_Toc105998354"><A NAME="_Toc105998764"><A NAME="_Toc105998896"><A NAME="_Toc117052409">12.5&nbsp;&nbsp;&nbsp;<U>Remedies Cumulative; No Waiver.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">12.5.1.&nbsp;&nbsp;&nbsp;All covenants, conditions, provisions, warranties, guaranties, indemnities, and other undertakings of Borrowers contained in this Agreement, the other Loan Documents, or any other agreement between Agent or any Lender and any Obligor, heretofore, concurrently, or hereafter entered into, shall be deemed cumulative to and not in derogation or substitution of any of the terms, covenants, conditions, or agreements of Borrowers herein contained.  The rights and remedies of Agent and Lenders under this Agreement and the other Loan&nbsp;Documents shall be cumulative and not exclusive of any rights or remedies that Agent or any Lender would otherwise have.</P>
<P ALIGN="JUSTIFY">12.5.2.&nbsp;&nbsp;&nbsp;The failure or delay of Agent or any Lender to require strict performance by Borrowers of any provision of any of the Loan Documents or to exercise or enforce any rights, Liens, powers or remedies under any of the Loan Documents or with respect to any Collateral shall not operate as a waiver of such performance, Liens, rights, powers and remedies, but all such requirements, Liens, rights, powers, and remedies shall continue in full force and effect until all Loans and all other Obligations owing or to become owing from Borrowers to Agent and Lenders shall have been fully satisfied.  None of the undertakings, agreements, warranties, covenants and representations of Borrowers contained in this&nbsp;Agreement or any of the&nbsp;other Loan&nbsp;Documents and no Event of Default shall be deemed to have been suspended or waived by Agent or any Lender, unless such&nbsp;suspension or waiver is by an instrument in writing specifying such suspension or waiver and is signed b
y a duly authorized representative of Agent or such Lender and directed to Borrowers.</P>
<P ALIGN="JUSTIFY">12.5.3.&nbsp;&nbsp;&nbsp;If Agent or any Lender shall accept performance by a Borrower, in whole or in part, of any obligation that such Borrower is required by any of the Loan Documents to perform only when a Default or Event of Default exists, or if Agent or any Lender shall exercise any right or remedy under any of the&nbsp;Loan Documents that may not be exercised other than when a Default or Event of Default exists, Agent's or Lender's acceptance of such performance by a Borrower or Agent's or Lender's exercise of any&nbsp;such right or remedy shall not operate to waive any such Event of Default or to preclude the exercise by Agent or any Lender of any other right or remedy, unless otherwise expressly agreed in writing by Agent or such Lender, as the case may be.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346584"><A NAME="_Toc102963384"><A NAME="_Toc105998355"><A NAME="_Toc105998765"><A NAME="_Toc105998897"><A NAME="_Toc117052410">section 13&nbsp;&nbsp;&nbsp;AGENT</A></A></A></A></A></A></P>
<P ALIGN="JUSTIFY"><A NAME="_Toc38346585"><A NAME="_Toc102963385"><A NAME="_Toc105998356"><A NAME="_Toc105998766"><A NAME="_Toc105998898"><A NAME="_Toc117052411">13.1&nbsp;&nbsp;&nbsp;<U>Appointment, Authority and Duties of Agent.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">13.1.1.&nbsp;&nbsp;&nbsp;Each Lender hereby irrevocably appoints and designates BofA as Agent to act as herein specified.  Agent may, and each Lender by its acceptance of a Note and becoming a party to this Agreement shall be deemed irrevocably to have authorized Agent to, enter into all Loan Documents to which Agent is or is intended to be a party and all amendments hereto and all Security Documents at any time executed by any Obligor, for its benefit and the Pro&nbsp;Rata benefit of Lenders and, except as otherwise provided in this <B>Section 13</B>, to exercise such rights and powers under this Agreement and the other Loan Documents as are specifically delegated to Agent by the terms hereof and thereof, together with such other rights and powers as are reasonably incidental thereto.  Each&nbsp;Lender agrees that any action taken by Agent or the Required Lenders in&nbsp;accordance with the provisions of this Agreement or the other Loan Documents, and the exercise by Agent or the 
Required Lenders of any of the powers set forth herein or therein, together with such other powers as are reasonably incidental thereto, shall&nbsp;be authorized and binding upon all Lenders.  Without&nbsp;limiting the generality of the foregoing, Agent shall have the sole and exclusive right and authority to (a)&nbsp;act as the disbursing and collecting agent for Lenders with respect to all payments and collections arising in connection with this Agreement and the other Loan Documents; (b)&nbsp;execute and deliver as Agent each Loan Document<B><I> </B></I>and accept delivery of each such agreement by any Obligor or any other Person; (c) act as collateral agent for Secured Parties for purposes of the perfection of all security interests and Liens created by this Agreement or the Security Documents and, subject to the direction of the Required Lenders, for all other purposes stated therein, provided that Agent hereby appoints, authorizes and directs each Lender to act as a&nbsp;collateral sub-agent for Agent 
and the other Lenders for purposes of the perfection of all security interests and Liens with respect to a Borrower's Deposit Accounts maintained with, and all cash and Cash Equivalents held by, such Lender; (d)&nbsp;subject to the direction of the Required Lenders, manage, supervise or otherwise deal with the Collateral; and (e)&nbsp;except as may be otherwise specifically restricted by the terms of this Agreement and subject to the direction of the Required Lenders, exercise all remedies given to Agent with respect to any&nbsp;of the Collateral under the Loan Documents relating thereto and Applicable Law.  The duties of Agent shall be ministerial and administrative in nature, and Agent shall not have by reason of this&nbsp;Agreement or any other Loan Document a fiduciary relationship with any Lender (or any Lender's participants).  Unless and until its authority to do so is revoked in writing by Required Lenders, Agent alone shall be authorized to determine whether any Accounts or Inventory constitute Elig
ible&nbsp;Accounts or Eligible Inventory (basing such determination in each case upon the meanings given to such terms in <B>Section&nbsp;1</B>), or whether to impose or release any reserve, and to exercise its own credit judgment in&nbsp;connection therewith, which determinations and judgments, if exercised in good faith, shall exonerate Agent from any liability to Lenders or any other Person for any errors in judgment.</P>
<P ALIGN="JUSTIFY">13.1.2.&nbsp;&nbsp;&nbsp;Agent (which term, as used in this sentence, shall include reference to Agent's officers, directors, employees, attorneys, agents and Affiliates and to the officers, directors, employees, attorneys and agents of Agent's Affiliates) shall not:  (a)&nbsp;have any duties or responsibilities except those expressly set forth in this Agreement and the other Loan Documents or (b)&nbsp;be required to take, initiate or conduct any Enforcement Action (including any litigation, foreclosure or collection proceedings hereunder or under any of the other Loan Documents) except to the extent directed to do so by the Required Lenders during the continuance of any Event of Default.  The conferral upon Agent of any right hereunder shall not imply a duty on Agent's part to exercise any such right unless instructed to do so by the Required Lenders in accordance with this Agreement.</P>
<P ALIGN="JUSTIFY">13.1.3.&nbsp;&nbsp;&nbsp;Agent may perform any of its duties by or through its agents and employees and may employ one or more Agent Professionals and shall not be responsible for the negligence or misconduct of any such Agent Professionals selected by it with reasonable care.  Each Lender agrees promptly to pay to Agent, <B>on demand</B>, such Lender's Pro Rata share of any such reimbursement for expenses (including Extraordinary Expenses) that is not timely made by Borrowers to Agent.</P>
<P ALIGN="JUSTIFY">13.1.4.&nbsp;&nbsp;&nbsp;The rights, remedies, powers and privileges conferred upon Agent hereunder and under the other Loan Documents may be exercised by Agent without the necessity of the joinder of any other parties unless otherwise required by Applicable Law.  If Agent shall request instructions from the Required Lenders with respect to any act or action (including the failure to act) in connection with this Agreement or any of the other Loan Documents, Agent shall be entitled to refrain from such act or taking such action unless and until Agent shall have received instructions from the Required Lenders; and Agent shall not incur liability to any Person by reason of so refraining.  Without limiting the foregoing, no Lender shall have any right of action whatsoever against Agent as a result of Agent acting or refraining from acting hereunder or under any of the Loan Documents pursuant to or in accordance with the instructions of the Required Lenders except for Agent's own gross negligen
ce or willful misconduct in connection with any action taken by it.  Notwithstanding anything to the contrary contained in this Agreement, Agent shall not be required to take any action that is in its opinion contrary to Applicable Law or the terms of any of the Loan Documents or that would in its reasonable opinion subject it or any of its officers, employees or directors to personal liability.</P>
<P ALIGN="JUSTIFY">13.1.5.&nbsp;&nbsp;&nbsp;Agent shall promptly, upon receipt thereof, forward to each Lender (i)&nbsp;copies of any significant written notices, reports, certificates and other information received by Agent from any Obligor and (ii)&nbsp;copies of the results of any field audits or other examinations made or prepared by or on behalf of Agent in accordance with <B>Section 10.1.1</B> with&nbsp;respect to Borrowers or the Collateral (each, a "Report" and collectively, "Reports").</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346586"><A NAME="_Toc102963386"><A NAME="_Toc105998357"><A NAME="_Toc105998767"><A NAME="_Toc105998899"><A NAME="_Toc117052412">13.2&nbsp;&nbsp;&nbsp;<U>Agreements Regarding Collateral and Examination Reports.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">13.2.1.&nbsp;&nbsp;&nbsp;Lenders hereby irrevocably authorize Agent to release any Lien with respect to any Collateral (i)&nbsp;upon the termination of the Commitments and Full Payment of the Obligations, (ii)&nbsp;that is the subject of an Asset Disposition which Borrower Representative certifies in writing to Agent is a Permitted Asset Disposition (and Agent may rely conclusively on any such certificate without further inquiry), (iii) other releases of Collateral the fair market value of which does not exceed, as to all such Collateral, the lesser of $10,000,000 or ten percent of the aggregate Commitments on such date, in the aggregate during any Fiscal Year, and (iv)&nbsp;with the written consent of all Lenders.  Agent agrees to take action reasonably requested by Borrowers to evidence the release of its Lien on any assets sold or transferred pursuant to a Permitted Asset Disposition.  Agent shall have no obligation whatsoever to any of the Lenders to assure that any of the&nbsp
;Collateral exists or is owned by a Borrower or is cared for, protected or insured or has been encumbered, or that Agent's Liens have been properly, sufficiently or lawfully created, perfected, protected or enforced or are entitled to any particular priority or to exercise any duty of care with respect to any of the Collateral.</P>
<P ALIGN="JUSTIFY">13.2.2.&nbsp;&nbsp;&nbsp;Agent and Lenders each hereby appoints each other Lender as agent for the purpose of perfecting Liens (for the benefit of Secured Parties) in any Collateral that, in accordance with the UCC or any other Applicable Law, can be perfected only by possession.  Should any Lender obtain possession of any such Collateral, such Lender shall notify Agent thereof, and, promptly upon Agent's request therefor, shall deliver such Collateral to Agent or otherwise deal with such Collateral in accordance with Agent's instructions.</P>
<P ALIGN="JUSTIFY">13.2.3.&nbsp;&nbsp;&nbsp;Each Lender agrees that neither BofA nor Agent makes any representation or warranty as to the accuracy or completeness of any Report and shall not be liable for any information contained in or omitted from any such Report; agrees that the Reports are not intended to be comprehensive audits or examinations and that BofA or Agent or any other Person performing any audit or examination will inspect only specific information regarding Obligations or the Collateral and will rely significantly upon Borrowers' books and records as well as upon representations of Borrowers' officers and employees; agrees to keep all Reports confidential and strictly for its internal use and not to distribute the Reports (or the contents thereof) to any Person (except to its Participants, attorneys, accountants and other Persons with whom such Lender has a confidential relationship) or use any Report in any other manner; and, without limiting the generality of any other indemnification cont
ained herein, agrees to hold Agent and any other Person preparing a Report harmless from any action that the indemnifying Lender may take or conclusion the indemnifying Lender may reach or draw from any Report in connection with any Loans or other credit accommodations that the indemnifying&nbsp;Lender has made or may make to Borrowers, or the indemnifying Lender's participation in, or its purchase of, a loan or loans of any Obligor, and to pay and protect, and indemnify, defend and hold Agent and each other such Person preparing a Report harmless from and against all claims, actions, proceedings, damages, costs, expenses and other amounts (including attorneys' fees) incurred by Agent and any such other Person preparing a Report as the direct or indirect result of any third parties who might obtain all or any part of any Report through the indemnifying Lender.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346587"><A NAME="_Toc102963387"><A NAME="_Toc105998358"><A NAME="_Toc105998768"><A NAME="_Toc105998900"><A NAME="_Toc117052413">13.3.&nbsp;&nbsp;&nbsp;<U>Reliance By Agent</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Agent shall be entitled to rely, and shall be fully protected in so relying, upon any certification, notice or other communication (including any thereof by telephone, telex, telegram, telecopier message or cable) believed by it to be genuine and correct and to have been signed, sent or made by or on behalf of the proper Person or Persons, and upon advice and statements of Agent&nbsp;Professionals selected by Agent.  Without limiting the generality of the foregoing, Agent may rely upon any Notice of Borrowing,<B><I> </B></I>LC Request, Notice of Conversion/Continuation or any similar notice or request believed by Agent to be genuine. As to any matters not expressly provided for by this Agreement or any of the other Loan Documents, Agent shall in all cases be fully&nbsp;protected in acting or refraining from acting hereunder and thereunder in accordance with the&nbsp;instructions of the Required Lenders, and such&nbsp;instructions of the Required Lenders and any action taken or f
ailure to act pursuant thereto shall be binding upon Lenders.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346588"><A NAME="_Toc102963388"><A NAME="_Toc105998359"><A NAME="_Toc105998769"><A NAME="_Toc105998901"><A NAME="_Toc117052414">13.4.&nbsp;&nbsp;&nbsp;<U>Action Upon Default</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Agent shall not be deemed to have knowledge of the occurrence of a Default or an Event of Default unless it has received written notice from a Lender or any or all Borrowers specifying the occurrence and nature of such Default or Event of Default.  If Agent shall receive such a notice of a Default or an Event of Default or shall otherwise acquire actual knowledge of any Default or Event of Default, Agent shall promptly notify Lenders in writing and Agent shall take such action and assert such rights under this Agreement and the other Loan Documents, or shall refrain from taking such action and asserting such rights, as the Required Lenders shall direct from time to time.  If any Lender shall receive a notice of a Default or an Event of Default or shall otherwise acquire actual knowledge of any Default or Event of Default, such Lender shall promptly notify Agent and the other Lenders in writing.  As provided in <B>Section&nbsp;13.3</B>, Agent shall not be subject to any liability
 by reason of acting or refraining to act pursuant to any request of the Required Lenders except for its own willful misconduct or gross negligence in connection with any action taken by it.  Before directing Agent to take or refrain from taking any action or asserting any rights or remedies under this Agreement and the other Loan Documents on account of any Event of Default, the Required Lenders shall consult with and seek the advice of (but without having to obtain the consent of) each other Lender, and promptly after directing Agent to take or refrain from taking any such action or asserting any such rights, the Required Lenders will so advise each other Lender of the action taken or refrained from being taken and, upon request of any Lender, will supply information concerning actions taken or not taken.  In no event shall the Required Lenders, without the prior written consent of each Lender, direct Agent to accelerate and demand payment of the Loans held by one Lender without accelerating and demanding 
payment of all other Loans or to&nbsp;terminate the Commitments of one or more Lenders without terminating the Commitments of all Lenders.  Each Lender agrees that, except as otherwise provided in any of the Loan Documents or with the written consent of Agent and the Required Lenders, it will not take any legal action or institute any action or proceeding against any Obligor with respect to any of the Obligations or Collateral or accelerate or otherwise enforce its portion of the Obligations.  Without limiting the generality of the foregoing, none of Lenders may exercise any right that it might otherwise have under Applicable Law to credit bid at foreclosure sales, UCC sales or other similar sales or dispositions of any of the Collateral except as authorized by Agent and the Required Lenders.  Notwithstanding anything to the contrary set forth in this&nbsp;<B>Section&nbsp;13.4</B> or elsewhere in this Agreement, each Lender shall be authorized to take such action to preserve or enforce its rights against any
 Obligor where a deadline or limitation period is otherwise applicable and would, absent the taken of specified action, bar the enforcement of Obligations held by such Lender against such Obligor, including the filing of proofs of claim in any Insolvency Proceeding.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346589"><A NAME="_Toc102963389"><A NAME="_Toc105998360"><A NAME="_Toc105998770"><A NAME="_Toc105998902"><A NAME="_Toc117052415">13.5&nbsp;&nbsp;&nbsp;<U>Ratable Sharing</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  If any Lender shall obtain any payment or reduction (including any amounts received as adequate protection of a bank account deposit treated as cash collateral under the Bankruptcy Code) of any Obligation of Borrowers (whether voluntary, involuntary, through the exercise of any right of set-off or otherwise) in excess of its Pro Rata share of payments or reductions on account of such Obligations obtained by all of the Lenders, such Lender shall forthwith (i)&nbsp;notify the other Lenders and Agent of such receipt and (ii)&nbsp;purchase from the other Lenders such participations in the affected Obligations as shall&nbsp;be necessary to cause such purchasing Lender to share the excess payment or reduction, net of costs incurred in connection therewith, on a Pro Rata basis, <U>provided</U> that if all or any portion of such excess payment or reduction is thereafter recovered from such purchasing Lender or additional costs are incurred, the&nbsp;purchase shall be rescinded and the p
urchase price restored to the extent of such recovery or such&nbsp;additional costs, but without interest.  Each Borrower agrees that any Lender so purchasing a participation from another Lender pursuant to this <B>Section&nbsp;13.5</B> may, to the fullest extent permitted by Applicable Law, exercise all of its rights of payment (including the right of set-off) with respect to such participation as fully as if such Lender were the direct creditor of Borrowers in the amount of such participation.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346590"><A NAME="_Toc102963390"><A NAME="_Toc105998361"><A NAME="_Toc105998771"><A NAME="_Toc105998903"><A NAME="_Toc117052416">13.6.&nbsp;&nbsp;&nbsp;<U>Indemnification of Agent Indemnitees.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">13.6.1.&nbsp;&nbsp;&nbsp;Each Lender agrees to indemnify and defend the Agent Indemnitees (to the extent not reimbursed by Borrowers, but without limiting the indemnification obligations of Obligors under any of the Loan Documents), on a Pro Rata basis, and to hold each of the Agent Indemnitees harmless from and against, any and all Claims which may be imposed on, incurred by or asserted against any of the Agent Indemnitees in any way related to or arising out of any of the Loan&nbsp;Documents or referred to herein or therein or the&nbsp;transactions contemplated thereby (including the costs and expenses which Borrowers are obligated to pay under <B>Section&nbsp;15.2</B> or amounts Agent may be called upon to pay in connection with any lockbox or Dominion Account arrangement contemplated hereby or under any indemnity, guaranty or other assurance of payment or performance given by Agent pursuant to <B>Section&nbsp;3.4.2 </B>or the enforcement of any of the terms of any Loan Document
s.</P>
<P ALIGN="JUSTIFY">13.6.2.&nbsp;&nbsp;&nbsp;Without limiting the generality of the foregoing provisions of this <B>Section&nbsp;13.6</B>, if Agent should be sued by any receiver, trustee in bankruptcy, debtor-in-possession or other Person on account of any alleged preference or fraudulent transfer received or alleged to have been received from any Borrower or any&nbsp;other Obligor as the result of any transaction under the Loan Documents, then in such event any monies paid by Agent in settlement or satisfaction of such suit, together with all Extraordinary Expenses incurred by Agent in the defense of same, shall be promptly reimbursed to Agent by Lenders to the extent of each Lender's Pro Rata share.</P>
<P ALIGN="JUSTIFY">13.6.3.&nbsp;&nbsp;&nbsp;Without limiting the generality of the foregoing provisions of this <B>Section&nbsp;13.6</B>, if at any time (whether prior to or after the Commitment Termination Date) any action or proceeding shall be brought against any of the Agent Indemnitees by an Obligor or by any other Person claiming by, through or under an Obligor, to recover damages for any act taken or omitted by Agent under any of the Loan Documents or in the performance of any rights, powers or remedies of Agent against any Obligor, any Account Debtor, the Collateral or with respect to any Loans, or to obtain any other relief of any kind on account of any transaction involving any Agent Indemnitees under or in relation to any of the Loan Documents, each Lender agrees to indemnify, defend and hold the Agent Indemnitees harmless with respect thereto and to pay to the Agent Indemnitees such Lender's Pro Rata share of such amount as any of the Agent Indemnitees shall be required to pay by reason of a judg
ment, decree, or other order entered in such action or proceeding or by reason of any compromise or settlement agreed to by the Agent Indemnitees, including all interest and costs assessed against any of the Agent Indemnitees in defending or compromising such action, together with attorneys' fees and other legal expenses paid or incurred by the Agent Indemnitees in connection therewith; <U>provided</U>, <U>however</U>, that no Lender shall be liable to any Agent Indemnitee for any of the foregoing to the extent that they arise solely from the willful misconduct or gross negligence of such Agent Indemnitee.  In Agent's discretion, Agent may also reserve for or satisfy any such judgment, decree or order from proceeds of Collateral prior to any distributions therefrom to or for the account of Lenders.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346591"><A NAME="_Toc102963391"><A NAME="_Toc105998362"><A NAME="_Toc105998772"><A NAME="_Toc105998904"><A NAME="_Toc117052417">13.7&nbsp;&nbsp;&nbsp;<U>Limitation on Responsibilities of Agent</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B> Agent shall in all cases be fully justified in failing or refusing to act hereunder unless it shall have received further assurances to its satisfaction from Lenders of their indemnification obligations under <B>Section&nbsp;13.6</B> against any and all indemnified Claims which may be incurred by Agent by reason of taking or continuing to take any such action.  Agent shall not be liable to Lenders for any action taken or omitted to be taken under or in connection with this Agreement or the other Loan Documents except as a result and to the extent of losses caused by the Agent's actual gross negligence or willful&nbsp;misconduct.  Agent does not assume any responsibility for any failure or delay in performance or breach by any&nbsp;Obligor or any Lender of its obligations under this Agreement or any of the&nbsp;other Loan Documents.  Agent&nbsp;does not make to Lenders, and no Lender makes to Agent or the&nbsp;other&nbsp;Lenders, any express or implied warranty, representation or 
guarantee with respect to the Obligations, the&nbsp;Collateral, the Loan Documents or any&nbsp;Obligor.  Neither Agent nor any of its officers, directors, employees, attorneys or agents shall be responsible to Lenders, and no Lender nor any of its agents, attorneys or employees shall be responsible to Agent or the other Lenders, for:  (i)&nbsp;any recitals, statements, information, representations or warranties contained in any of the Loan Documents or in any certificate or other document furnished pursuant to the terms hereof; (ii)&nbsp;the execution, validity, genuineness, effectiveness or enforceability of any of the Loan Documents; (iii)&nbsp;the genuineness, enforceability, collectibility, value, sufficiency, location or existence of any Collateral, or the validity, extent, perfection or priority of any Lien therein; (iv) the validity, enforceability or collectibility of any the Obligations; or (v)&nbsp;the assets, liabilities, financial condition, results of operations, business, creditworthiness or le
gal status of any Obligor or any Account Debtor.  Neither Agent nor any of its officers, directors, employees, attorneys or agents shall have any obligation to any Lender to ascertain or inquire into the existence of any Default or Event of Default, the observance or performance by any&nbsp;Obligor of any of the duties or agreements of such Obligor under any of the Loan Documents or the satisfaction of any conditions precedent contained in any of the Loan Documents.  Agent may consult with and employ legal counsel, accountants and other experts and shall be entitled to act upon, and shall be fully protected in any action taken in good faith reliance upon, any advice given by such&nbsp;experts.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346592"><A NAME="_Toc102963392"><A NAME="_Toc105998363"><A NAME="_Toc105998773"><A NAME="_Toc105998905"><A NAME="_Toc117052418">13.8.&nbsp;&nbsp;&nbsp;<U>Successor Agent and Co-Agents.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">13.8.1.&nbsp;&nbsp;&nbsp;Subject to the appointment and acceptance of a successor Agent as provided below, Agent may resign at any time by giving at least 30 days written notice thereof to each Lender and Borrowers.  Upon receipt of any notice of such resignation, the Required Lenders, after prior consultation with (but without having to obtain consent of) each Lender, shall have the right to appoint a successor Agent which shall be (i)&nbsp;a Lender, (ii)&nbsp;a United States based Affiliate of a Lender, or (iii)&nbsp;a commercial bank that is organized under the laws of the United States or of any State thereof and has a combined capital surplus of at least $200,000,000 and, provided no Event of Default then exists, is reasonably acceptable to Borrowers (and for purposes hereof, any successor to BofA shall be deemed acceptable to Borrowers).  If no successor agent is appointed prior to the effective date of the resignation of Agent, then Agent may appoint, after consultation with
 Lenders and Borrower Representative, a successor agent from among Lenders.  Upon the acceptance by a successor Agent of an appointment to serve as&nbsp;Agent hereunder, such successor Agent shall thereupon succeed to and become vested with all the&nbsp;rights, powers, privileges and duties of the retiring Agent without further act, deed or conveyance, and the&nbsp;retiring Agent shall be discharged from its duties and obligations hereunder but shall continue to enjoy the benefits of the indemnification set forth in <B>Sections 13.6</B> and <B>15.2</B>.  After&nbsp;any retiring&nbsp;Agent's resignation hereunder as Agent, the provisions of this <B>Section&nbsp;13</B> (including the&nbsp;provisions of <B>Section&nbsp;13.6</B>) shall continue in effect for its benefit in respect of any actions taken or omitted to be taken by it while it was acting as Agent.  Notwithstanding anything to the contrary contained in this Agreement, any successor by merger or acquisition of the stock or assets of BofA shall continue
 to be Agent hereunder without further act on the part of the parties hereto unless such successor shall resign in accordance with the provisions hereof.</P>
<P ALIGN="JUSTIFY">13.8.2.&nbsp;&nbsp;&nbsp;It is the intent of the parties that there shall be no violation of any Applicable Law denying or restricting the right of financial institutions to transact business as agent or otherwise in any jurisdiction.  In case of litigation under any of the Loan Documents, or in case Agent deems that by reason of present or future laws of any jurisdiction Agent might be prohibited from exercising any of the powers, rights or remedies granted to Agent or Lenders hereunder or under any of the Loan Documents or from holding title to or a Lien upon any Collateral or from taking any other action which may be necessary hereunder or under any of the Loan Documents, Agent may appoint an additional Person as a separate collateral agent or co-collateral agent which is not so prohibited from taking any of such actions or exercising any of such powers, rights or remedies.  If Agent shall appoint an additional Person as a separate collateral agent or co-collateral agent as provided abo
ve, each and every remedy, power, right, claim, demand or cause of action intended by any of the Loan Documents to be exercised by or vested in or conveyed to Agent with respect thereto shall be exercisable by and vested in such separate collateral agent or co-collateral agent, but only to the extent necessary to enable such separate collateral agent or co-collateral agent to exercise such powers, rights and remedies, and every covenant and obligation necessary to the exercise thereof by such separate collateral agent or co-collateral agent shall run to and be enforceable by either of them.  Should any instrument from Lenders be required by the separate collateral agent or co-collateral agent so appointed by Agent in order more fully and certainly to vest in and confirm to him or it such rights, powers, duties and obligations, any and all of such instruments shall, on request, be executed, acknowledged and delivered by Lenders whether or not a Default or Event of Default then exists.  In case any separate co
llateral agent or co-collateral agent, or a successor to either, shall die, become incapable of acting, resign or be removed, all the estates, properties, rights, powers, duties and obligations of such separate collateral agent or co-collateral agent, so far as permitted by Applicable Law, shall vest in and be exercised by the Agent until the appointment of a new collateral agent or successor to such separate collateral agent or co-collateral agent.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346593"><A NAME="_Toc102963393"><A NAME="_Toc105998364"><A NAME="_Toc105998774"><A NAME="_Toc105998906"><A NAME="_Toc117052419">13.9.&nbsp;&nbsp;&nbsp;<U>Consents, Amendments and Waivers; Out-of-Formula Loans.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">13.9.1.&nbsp;&nbsp;&nbsp;No amendment or modification of any provision of this Agreement or any of the other Loan Documents, nor any waiver of any Default or Event of Default, shall be effective without the prior written agreement or consent of the Required Lenders; <U>provided</U>, <U>however</U>, that</P>
<P ALIGN="JUSTIFY">(i)&#9;without the prior written consent of Agent, no amendment or waiver shall be effective with respect to any provision in any of the Loan Documents (including <B>Section&nbsp;3.4</B> and this <B>Section&nbsp;13</B>) to the extent such provision relates to the rights, duties, immunities, exculpation, indemnification or discretion of  Agent;</P>
<P ALIGN="JUSTIFY">(ii)&#9;without the prior written consent of Issuing Bank, no amendment or waiver with respect to any of the LC&nbsp;Obligations or the provisions of <B>Sections&nbsp;2.3</B>, <B>4.1.3 </B>or <B>11.2.6 </B>shall&nbsp;be effective;</P>
<P ALIGN="JUSTIFY">(iii)&#9;without the prior written consent of all Lenders (except a defaulting Lender as provided in <B>Section 4.2</B>) no amendment or waiver shall be effective that would:</P>
<P ALIGN="JUSTIFY">(a)&#9;release Collateral not required or permitted by <B>Section 13.2.1</B> or any other Loan Document to be released;</P>
<P ALIGN="JUSTIFY">(b)&#9;extend the final maturity date of any Loan or the scheduled payment date of any installment of any Loan;</P>
<P ALIGN="JUSTIFY">(c)&#9;reduce the rate or extend the time of payment of interest thereon, or change the method of calculating interest thereon (other than any waiver of the Default Rate), or reduce or extend the time of payment of any fee payable to the Lenders hereunder;</P>
<P ALIGN="JUSTIFY">(d)&#9;reduce the principal amount of, or increase the amount of any Lender's Commitment;</P>
<P ALIGN="JUSTIFY">(e)&#9;amend, modify or waive any provision of this <B>Section&nbsp;13.9;</P>
</B><P ALIGN="JUSTIFY">(f)&#9;amend the Loan Agreement to increase the percentages set forth in the definition of "Borrowing Base" or change any of the definitions contained in the definition of "Borrowing Base";</P>
<P ALIGN="JUSTIFY">(g)&#9;(i) subordinate the payment or performance of the Loans to any other Debt or (ii) subordinate the Lien of Agent in the Collateral to any other Lien in favor of another Person (except for those Permitted Liens that have priority as a matter of law or are permitted under <B>Section 10.2.5(iv)</B>, <B>(vii)</B>, <B>(xiv)</B> or <B>(xvi)</B>); and</P>
<P ALIGN="JUSTIFY">(h)&#9;amend the definitions of "Pro Rata" or "Required Lenders."</P>
<P ALIGN="JUSTIFY">The making of any Loans hereunder by any Lender during the existence of a Default or Event of Default shall not be deemed to constitute a&nbsp;waiver of such Default or Event&nbsp;of Default.  Any&nbsp;waiver or consent granted by Lenders hereunder shall be effective only if in writing and then only in the specific instance and for the specific purpose for which it was given.</P>
<P ALIGN="JUSTIFY">13.9.2.&nbsp;&nbsp;&nbsp;No Borrower will, directly or indirectly, pay or cause to be paid any remuneration or other&nbsp;thing of value, whether by way of supplemental or additional interest, fee or otherwise, to any Lender (in its&nbsp;capacity as a&nbsp;Lender hereunder) as consideration for or as an inducement to the consent to or agreement by such Lender with any waiver or amendment of any of the terms and provisions of this Agreement or any of the other Loan Documents, unless such remuneration or thing of value is concurrently paid, on the same terms, on a Pro Rata or other mutually agreed upon basis to all Lenders; <U>provided</U>, <U>however</U>, that Borrowers may contract to pay a fee only to those Lenders who actually vote in writing to approve any waiver or amendment of the terms and provisions of this Agreement or any of the other Loan Documents to the extent that such waiver or amendment may be implemented by vote of the Required Lenders and such waiver or amendment is in fac
t approved.</P>
<P ALIGN="JUSTIFY">13.9.3.&nbsp;&nbsp;&nbsp;Any request, authority or consent of any Person who, at the time of making such request or giving such a authority or consent, is a Lender, shall be conclusive and binding upon any Transferee of such Lender.</P>
<P ALIGN="JUSTIFY">13.9.4.&nbsp;&nbsp;&nbsp;Unless otherwise directed in writing by the Required Lenders, Agent may require Lenders to honor requests by Borrowers for Out-of-Formula Loans (in which event, and notwithstanding anything to the contrary set forth in <B>Section 2.1.1</B> or elsewhere in this Agreement, Lenders shall continue to make Revolver Loans up to their Pro Rata share of the Commitments) and to&nbsp;forbear from requiring Borrowers to cure an Out-of-Formula Condition, (1) when no Event of Default exists (or if an Event of Default exists, when the existence of such Event of Default is not known by Agent), if and for so long as (i)&nbsp;such Out-of-Formula Condition does not continue for a period of more&nbsp;than 15<B><I> </B></I>consecutive days, following which no Out-of-Formula Condition exists for at least 15<B><I>&nbsp;</B></I>consecutive days before another Out-of-Formula Condition exists (provided, however, that there shall not be more than 4 of such 15-day Out-of-Formula Condition pe
riods during any single Loan Year), (ii) the amount of the Revolver Loans outstanding at any time does not exceed the aggregate of the Commitments at such time, and (iii)&nbsp;the Out-of-Formula Condition is not known by Agent at the time in question to exceed $10,000,000; and (2) regardless of whether or not an Event of Default exists, if Agent discovers the existence of an&nbsp;Out-of-Formula Condition not previously known by it to exist, but Lenders shall be obligated to&nbsp;continue making such Revolver Loans as directed by Agent only (A)&nbsp;if the amount of the Out-of-Formula Condition is not increased by more than $5,000,000 above the amount determined by Agent to exist on the date of discovery thereof and (B)&nbsp;for a period not to exceed 5&nbsp;Business Days.  In&nbsp;no event shall any Borrower or any other Obligor be deemed to be a beneficiary of this <B>Section&nbsp;13.9.4</B> or authorized to enforce any of the provisions of this <B>Section&nbsp;13.9.4</B>.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346594"><A NAME="_Toc102963394"><A NAME="_Toc105998365"><A NAME="_Toc105998775"><A NAME="_Toc105998907"><A NAME="_Toc117052420">13.10.&nbsp;&nbsp;&nbsp;<U>Due Diligence and Non-Reliance</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Each Lender hereby acknowledges and represents that it has, independently and without reliance upon Agent or the other Lenders, and based upon such documents, information and analyses as it has deemed appropriate, made its own credit analysis of each Obligor and its own decision to enter into this Agreement and to fund the Loans to be made by it hereunder, issue Letters of Credit and purchase participations in the LC Obligations pursuant to <B>Section 2.3.2</B>, and each&nbsp;Lender has made such inquiries concerning the Loan Documents, the Collateral and each Obligor as such Lender feels necessary and appropriate, and has taken such care on its own behalf as would have been the case had it entered into the other Loan Documents without the intervention or participation of the other&nbsp;Lenders or Agent.  Each Lender hereby further acknowledges and represents that the other Lenders and Agent have not made any representations or warranties to it concerning any Obligor, any of the
 Collateral or the legality, validity, sufficiency or enforceability of any of the  Loan Documents.  Each Lender also hereby acknowledges that it will, independently and without reliance upon the other Lenders or Agent, and based upon such financial statements, documents and information as it deems appropriate at the time, continue to make and rely upon its own credit decisions in making Loans and in taking or refraining to&nbsp;take any other action under this Agreement or any of the other Loan Documents.  Except for notices, reports and other information expressly required to be furnished to Lenders by Agent hereunder, Agent shall not have any duty or responsibility to provide any Lender with any notices, reports or certificates furnished to Agent by any Obligor or any credit or other information concerning the affairs, financial condition, business or Properties of any Obligor (or any of its Affiliates) which may come into possession of Agent or any of Agent's Affiliates.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346595"><A NAME="_Toc102963395"><A NAME="_Toc105998366"><A NAME="_Toc105998776"><A NAME="_Toc105998908"><A NAME="_Toc117052421">13.11&nbsp;&nbsp;&nbsp;<U>Representations and Warranties of Lenders</A></U>.</A></A></A></A></A></P>
</B><P ALIGN="JUSTIFY">Each&nbsp;Lender represents and warrants to each Borrower, Agent and the other Lenders that it has the power to enter into and perform its obligations under this Agreement and the other Loan Documents, and that it has taken all necessary and appropriate action to authorize its execution and performance of this&nbsp;Agreement and the other Loan Documents to which it is a party, each of which will be binding upon it and the obligations imposed upon it herein or therein will be enforceable against it in accordance with the respective terms of such&nbsp;documents; and none of the consideration used by it to make or fund its Loans or to participate in any other transactions under this Agreement constitutes for any purpose of ERISA or Section 4975 of the Internal Revenue Code assets of any "plan" as defined in Section&nbsp;3(3) of ERISA or Section 4975 of the Internal Revenue Code and the rights and interests of such Lender in and under the Loan Documents shall not constitute plan  assets un
der ERISA.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346596"><A NAME="_Toc102963396"><A NAME="_Toc105998367"><A NAME="_Toc105998777"><A NAME="_Toc105998909"><A NAME="_Toc117052422">13.12&nbsp;&nbsp;&nbsp;<U>The Required Lenders</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  As to any provisions of this Agreement or the other Loan Documents under which action may or is required to be taken upon direction or approval of the Required Lenders, the direction or approval of the Required  Lenders shall be binding upon each Lender to the same extent and with the same effect as if each Lender joined therein.  Notwithstanding anything to the contrary contained in this Agreement, Borrowers shall not be deemed to be a beneficiary of, or be entitled to enforce, sue upon or assert as a defense to any of the Obligations, any provisions of this Agreement that requires Agent or any Lender to act, or conditions their authority to act, upon the direction or consent of the Required Lenders; and any action taken by Agent or any Lender that requires the consent or direction of the Required Lenders as a condition to taking such action shall, insofar as Borrowers are concerned, be&nbsp;presumed to have been taken with the requisite consent or direction of the Required Len
ders.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346597"><A NAME="_Toc102963397"><A NAME="_Toc105998368"><A NAME="_Toc105998778"><A NAME="_Toc105998910"><A NAME="_Toc117052423">13.13.&nbsp;&nbsp;&nbsp;<U>Several Obligations</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  The obligations and Commitment of each Lender under this Agreement and the other Loan Documents are several and neither Agent nor any Lender shall be responsible for the performance by the other Lenders of its obligations or Commitment hereunder or thereunder.  Notwithstanding any liability of Lenders stated to be joint and several to third Persons under any of the Loan Documents, such liability shall be shared, as among Lenders, Pro Rata.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346598"><A NAME="_Toc102963398"><A NAME="_Toc105998369"><A NAME="_Toc105998779"><A NAME="_Toc105998911"><A NAME="_Toc117052424">13.14.&nbsp;&nbsp;&nbsp;<U>Agent in its Individual Capacity</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  With respect to its obligation to lend under this Agreement, the Loans made by it and each Note issued to it, Agent shall have the same rights and powers hereunder and under the other Loan Documents as any other Lender or holder of a Note and may exercise the same as though it were not performing the duties specified herein; and the terms "Lenders," "Required Lenders," or any similar term shall, unless the context clearly otherwise indicates, include Agent in its capacity as a Lender.  Agent and its Affiliates may each accept deposits from, maintain deposits or credit balances for, invest in, lend money to, act as trustee under indentures of, serve as financial advisor to, and generally engage in any kind of business with any Borrower or any other Obligor, or any Affiliate of any Borrower or any other Obligor, as if it were any other bank and without any duty to account therefor (or for any fees or other consideration received in connection therewith) to the other Lenders.  BofA
 or its&nbsp;Affiliates may receive information regarding any Borrower or any of such Borrower's Affiliates and Account Debtors (including information that may be subject to confidentiality obligations in favor of Borrowers or any of their Affiliates) and Lenders acknowledge that neither Agent nor BofA shall be under any obligation to provide such information to Lenders to the extent acquired by BofA in its individual capacity and not as Agent hereunder.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346599"><A NAME="_Toc102963399"><A NAME="_Toc105998370"><A NAME="_Toc105998780"><A NAME="_Toc105998912"><A NAME="_Toc117052425">13.15.&nbsp;&nbsp;&nbsp;<U>No Third Party Beneficiaries</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  This <B>Section 13</B> (except <B>Sections 13.2.1 and 13.9</B>) is not intended to confer any rights or benefits upon Borrowers or any other Person except Lenders and Agent, and no Person (including any Borrower) other than Lenders and Agent shall have any right to enforce any of the provisions of this&nbsp;<B>Section 13</B> (except <B>Sections 13.2.1 and 13.9</B>) except as expressly provided in <B>Section 13.17</B>.  As between Borrowers and Agent, any action that Agent may take or purport to take on behalf of Lenders under any of the Loan Documents shall be conclusively presumed to have been authorized and approved by Lenders as herein provided.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346600"><A NAME="_Toc102963400"><A NAME="_Toc105998371"><A NAME="_Toc105998781"><A NAME="_Toc105998913"><A NAME="_Toc117052426">13.16.&nbsp;&nbsp;&nbsp;<U>Notice of Transfer</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Agent may deem and treat a Lender party to this Agreement as the owner of such Lender's portion of the Revolver Loans for all purposes, unless and until a written notice of the assignment or transfer thereof executed by such Lender has been received by Agent.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346601"><A NAME="_Toc102963401"><A NAME="_Toc105998372"><A NAME="_Toc105998782"><A NAME="_Toc105998914"><A NAME="_Toc117052427">13.17.&nbsp;&nbsp;&nbsp;<U>Replacement of Certain Lenders</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  If a Lender ("Affected Lender") shall have (i)&nbsp;failed to fund its Pro Rata share of any Loan requested (or deemed requested) by Borrowers which such Lender is obligated to fund under the terms of this Agreement and which such failure has not been cured, (ii)&nbsp;requested compensation from Borrowers under <B>Section 3.7 </B>to recover increased costs incurred by such&nbsp;Lender (or its parent or holding company) which are not being incurred generally by the other Lenders (or their respective parents or holding companies), (iii)&nbsp;delivered a notice pursuant to <B>Section&nbsp;3.6</B> claiming that such Lender is unable to extend LIBOR Loans to Borrowers for reasons not generally applicable to the&nbsp;other Lenders, (iv) defaulted in paying or performing any of its obligations to Agent, or (v) failed or refused to give its consent to any amendment, waiver or action for which consent of all of the Lenders is required and in respect of which the Required Lenders have con
sented, then, in any such case and in addition to any other rights and remedies that Agent, any other Lender or any Borrower may have against such Affected Lender, any Borrower or Agent may make written demand on such Affected Lender (with&nbsp;a copy to Agent in the case of a demand by Borrowers and a copy to Borrowers in the case of a demand by Agent) for the Affected Lender to assign, and such Affected Lender shall assign pursuant to one or more duly executed Assignment and Acceptances within 5 Business Days after the date of such demand, to one or more Lenders willing to accept such assignment or assignments, or to one or more Eligible Assignees designated by Agent, all of such Affected Lender's rights and obligations under this Agreement (including its Commitment and all Loans owing to it) in accordance with <B>Section&nbsp;14</B>.  Agent is hereby irrevocably authorized to execute one or more Assignment and Acceptances as attorney-in-fact for any Affected Lender which fails or refuses to execute and de
liver the same within 5&nbsp;Business Days after the date of such demand.  The Affected Lender shall be entitled to receive, in cash and concurrently with execution and delivery of each such Assignment and Acceptance, all amounts owed to the Affected Lender hereunder or under any other Loan Document, including the aggregate outstanding principal amount of the Loans owed to such Lender, together with accrued interest thereon through the date of such assignment (but excluding any prepayment penalty or termination charge).  Upon the replacement of any Affected Lender pursuant&nbsp;to this <B>Section&nbsp;13.17</B>, such Affected Lender shall cease to have any&nbsp;participation in, entitlement to, or other&nbsp;right to share in the Liens of Agent in any Collateral and such&nbsp;Affected Lender shall have no further liability to Agent, any Lender or any other Person under any of the Loan Documents (except as provided in <B>Section&nbsp;13.6</B> as to events or transactions which occur prior to the replacement o
f such Affected Lender), including any commitment to make Loans or purchase participations in LC Obligations.  Agent shall have the right at any time, but shall not be obligated to, upon written notice to any Lender and with the consent of such Lender (which may be granted or withheld in such Lender's discretion), to purchase for Agent's own account all of such Lender's right, title and interest in and to this Agreement, the other Loan Documents and the Obligations (together with such Lender's interest in the Commitments), for the face amount of the Obligations owed to such Lender (or such greater or lesser amount as Agent and such Lender may mutually agree upon).</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346602"><A NAME="_Toc102963402"><A NAME="_Toc105998373"><A NAME="_Toc105998783"><A NAME="_Toc105998915"><A NAME="_Toc117052428">13.18.&nbsp;&nbsp;&nbsp;<U>Remittance of Payments and Collections.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">13.18.1.&nbsp;&nbsp;&nbsp;All payments by any Lender to Agent shall be made not later than the time set forth elsewhere in this Agreement on the Business Day such payment is due; <U>provided</U>, <U>however</U>, that if such payment is due <B>on demand</B> by Agent and such demand is made on the paying Lender after 11:00&nbsp;a.m. on such Business Day, then payment shall be made by 11:00 a.m. on the next Business Day.  Payment by Agent to any Lender shall be made by wire transfer, promptly following Agent's receipt of funds for the account of such Lender and in the type of funds received by Agent; <U>provided</U>, <U>however</U>, that if Agent receives such funds at or prior to 12:00 noon, Agent shall pay such funds to such Lender by 2:00&nbsp;p.m. on such Business Day, but if Agent receives such funds after 12:00 noon, Agent shall pay such&nbsp;funds to such&nbsp;Lender by 2:00 p.m. on the next Business Day.</P>
<P ALIGN="JUSTIFY">13.18.2.&nbsp;&nbsp;&nbsp;With respect to the payment of any funds from Agent to a Lender or from a Lender to Agent, the party failing to make full payment when due pursuant to the terms hereof shall, <B>on demand</B> by the other party, pay such amount together with interest thereon at the Federal Funds Rate.  In&nbsp;no event shall Borrowers be entitled to receive any credit for any interest paid by Agent to any Lender, or by any Lender to Agent, at the Federal Funds Rate as provided herein.</P>
<P ALIGN="JUSTIFY">13.18.3.&nbsp;&nbsp;&nbsp;If Agent pays any amount to a Lender in the belief or expectation that a related&nbsp;payment has been or will be received by Agent from an Obligor and such related payment is not received by Agent, then Agent shall be entitled to recover such amount from each Lender that receives such amount.  If&nbsp;Agent determines at any time that any amount received by it under this Agreement or any of the other&nbsp;Loan Documents must be returned to an Obligor or paid to any other Person pursuant to any Applicable Law, court order or otherwise, then, notwithstanding any other term or condition of this&nbsp;Agreement or any&nbsp;of the other Loan Documents, Agent shall not be required to distribute such amount to any Lender.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc117052429">13.19.&nbsp;&nbsp;&nbsp;<U>Hedging Arrangements</A></P>
</U><P ALIGN="JUSTIFY">.</B>  Each Lender shall notify Agent if such Lender or any of its Affiliates enters into a Hedging Agreement with any Borrower within 5 Business Days after consummation of such transaction, and at Agent's request from time to time, shall provide such information as Agent may request regarding such Hedging Agreement, including a mark to market value on each hedging arrangement.  If any Lender shall fail to notify Agent of its Hedging Agreement or if requested by Agent, its mark to market value on such hedging arrangement, then amounts owing to such Lender or its Affiliate under such Hedging Agreement shall be paid last in order under <B>Section 5.6.1</B>.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346604"><A NAME="_Toc102963403"><A NAME="_Toc105998375"><A NAME="_Toc105998785"><A NAME="_Toc105998917"><A NAME="_Toc117052430">SECTION 14.&nbsp;&nbsp;&nbsp;BENEFIT OF AGREEMENT; ASSIGNMENTS AND PARTICIPATIONS</A></A></A></A></A></A></P>
<P ALIGN="JUSTIFY"><A NAME="_Toc38346605"><A NAME="_Toc102963404"><A NAME="_Toc105998376"><A NAME="_Toc105998786"><A NAME="_Toc105998918"><A NAME="_Toc117052431">14.1.&nbsp;&nbsp;&nbsp;<U>Successors and Assigns</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  This Agreement shall be binding upon and inure to the benefit of Borrowers, Agent and Lenders and their respective successors and permitted assigns (which, in the case of Agent, shall include any successor Agent appointed pursuant to <B>Section&nbsp;13.8</B>), except that (i)&nbsp;no Borrower shall&nbsp; have the right to assign its rights or delegate performance of any of its obligations under any of the Loan Documents and (ii)&nbsp;any assignment by any Lender must be made in compliance with <B>Section&nbsp;14.3</B>.  Agent may treat the Person which made any Loan or holds any Note as the owner thereof for all purposes hereof unless and until such Person complies with<B> Section&nbsp;14.3</B> in the case of an assignment thereof or, in the case of any other transfer, a written notice of the transfer is filed with Agent.  Any assignee or transferee of any rights with respect to any Note or Loan agrees by acceptance thereof to be bound by all the terms and provisions of the Loan
 Documents.  Any request, authority or consent of any Person, who at the time of making such request or giving such authority or consent is the holder of a Note, shall be conclusive and binding on any subsequent holder, transferee or assignee of such Note or of any Note or Notes issued in exchange therefor.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346606"><A NAME="_Toc102963405"><A NAME="_Toc105998377"><A NAME="_Toc105998787"><A NAME="_Toc105998919"><A NAME="_Toc117052432">14.2.&nbsp;&nbsp;&nbsp;<U>Participations.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">14.2.1.&nbsp;&nbsp;&nbsp;<U>Permitted Participants; Effect</U>.  Any Lender may, in the ordinary course of its&nbsp;business and in accordance with Applicable Law, at any time sell to one or more banks or other financial institutions (each a "Participant") a participating interest in any of the Obligations owing to such&nbsp;Lender, any Commitment of such Lender or any other interest of such Lender under any of the Loan&nbsp;Documents.  In the event of any such&nbsp;sale by a Lender of participating interests to a Participant, such&nbsp;Lender's obligations under the Loan&nbsp;Documents shall remain unchanged, such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations, such Lender shall remain the holder of its Loans and Commitments for all purposes under the Loan Documents, all amounts payable by Borrowers under this Agreement and any of the Notes shall&nbsp;be determined as if such Lender had not sold such&nbsp;participating in
terests, and Borrowers and Agent shall&nbsp;continue to deal solely and directly with such Lender in connection with such Lender's rights and obligations under the&nbsp;Loan Documents.  If a Lender sells a&nbsp;participation to a Person other than an Affiliate of such Lender, then such&nbsp;Lender shall give prompt written notice thereof to Borrowers and Agent.  A Participant that would be a Foreign Lender if it were a Lender shall not be entitled to the benefits of <B>Section&nbsp;5.9</B> unless Borrowers consents to the participation sold to Participant and such Participant agrees, for the benefit of Borrowers, to comply with <B>Section&nbsp;5.10</B> as though such Participant were a Lender.</P>
<P ALIGN="JUSTIFY">14.2.2.&nbsp;&nbsp;&nbsp;<U>Voting Rights</P>
</U><P ALIGN="JUSTIFY">.  Each Lender shall retain the sole right to approve, without the consent of any Participant, any amendment, modification or waiver of any provision of the Loan Documents other than an amendment, modification or waiver with respect to any Loans or Commitment in which such Participant has an interest which forgives principal, interest or fees or reduces the stated interest rate or the stated rates at which fees are payable with respect to any such Loan or Commitment, postpones the Commitment Termination Date, or any date fixed for any regularly scheduled payment of interest or fees on such Loan or Commitment, or releases all or substantially all of the Collateral other than pursuant to a Permitted Asset Disposition or other transaction permitted under this Agreement.</P>
<P ALIGN="JUSTIFY">14.2.3.&nbsp;&nbsp;&nbsp;<U>Benefit of Set-Off</P>
</U><P ALIGN="JUSTIFY">.  Each Borrower agrees that each Participant shall be deemed to have the right of set-off provided in <B>Section&nbsp;12.4</B> in respect of its participating interest in amounts owing under the Loan Documents to the same extent and subject to the same requirements under this Agreement (including <B>Section&nbsp;13.5</B>) as if the amount of its participating interest were owing directly to it as a Lender under the Loan Documents, provided that each Lender shall retain the right of set-off provided in <B>Section&nbsp;12.4</B> with respect to the amount of participating interests sold to each Participant.  Lenders agree to share with each Participant, and each Participant by exercising the right of set-off provided in <B>Section&nbsp;12.4</B> agrees to share with each Lender, any amount received pursuant to the exercise of its right of set-off, such amounts to be shared in accordance with <B>Section&nbsp;13.5</B> as if each&nbsp;Participant were a Lender.</P>
<P ALIGN="JUSTIFY">14.2.4.&nbsp;&nbsp;&nbsp;<U>Notices</P>
</U><P ALIGN="JUSTIFY">.  Each Lender shall be solely responsible for notifying its Participants of any matters relating to the Loan Documents to the extent that any such notice may be required, and neither Agent nor any other Lender shall have any obligation, duty or liability to any Participant of any other Lender.  Without limiting the generality of the foregoing, neither Agent nor any Lender shall have any obligation to give notices or to provide documents or information to a Participant of another Lender.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346607"><A NAME="_Toc102963406"><A NAME="_Toc105998378"><A NAME="_Toc105998788"><A NAME="_Toc105998920"><A NAME="_Toc117052433">14.3.&nbsp;&nbsp;&nbsp;<U>Assignments.</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">14.3.1.&nbsp;&nbsp;&nbsp;<U>Permitted Assignments</P>
</U><P ALIGN="JUSTIFY">.  Subject to its compliance with <B>Section&nbsp;14.3.2</B>, a Lender may, in accordance with Applicable Law, at any time assign to any Eligible Assignee all or any part of its rights and obligations under the Loan Documents, so long as (i)&nbsp;each assignment is of a constant, and not a varying, ratable percentage of all of the transferor Lender's rights and obligations under the Loan Documents with respect to the Loans and the LC Obligations and, in&nbsp;the&nbsp;case of a partial&nbsp;assignment, is in a minimum principal amount of $5,000,000 (unless otherwise agreed by Agent in its discretion) and integral multiples of $1,000,000in excess of that amount; (ii)&nbsp;except in the case of an assignment in whole of a Lender's rights and obligations under the Loan Documents or an&nbsp;assignment by one original signatory to this Agreement to another such signatory, immediately after giving effect to any assignment, the aggregate amount of the Commitments retained by the transferor Len
der shall in no event be less than $5,000,000 (unless otherwise agreed by Agent in its discretion); and (iii)&nbsp;the parties to each such assignment shall execute and deliver to Agent, for its acceptance and recording, an Assignment and Acceptance.  Nothing contained herein shall limit in any way the right of a Lender to pledge or assign all or any portion of its rights under this Agreement or with respect to any of the Obligations to (x)&nbsp;any Federal Reserve Bank or the United States Treasury as collateral security pursuant to Regulation&nbsp;A of the Board of Governors and any Operating Circular issued by such Federal Reserve Bank, (y)&nbsp;direct or indirect contractual counterparties in swap agreements relating to the Loans, provided that any payment by Borrowers to the assigning Lender in respect of any assigned Obligations in accordance with the terms of this Agreement shall satisfy Borrowers' obligations hereunder in respect of such assigned Obligations to the extent of such payment, and no such
 assignment or pledge shall release the assigning Lender from its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party thereto.</P>
<P ALIGN="JUSTIFY">14.3.2.&nbsp;&nbsp;&nbsp;<U>Effect; Effective Date</U>.  Upon (i)&nbsp;delivery to Agent of a notice of assignment substantially in the form attached as <B><U>Exhibit&nbsp;I</B></U> hereto, together with any consents required by <B>Section&nbsp;14.3.1</B>, and (ii)&nbsp;payment of a $2,500 fee to the Agent for processing any assignment to an&nbsp;Eligible Assignee that is not an Affiliate of the transferor Lender, such assignment shall become effective on the&nbsp;effective date specified in such notice of assignment.  The Assignment and Acceptance shall contain a representation and warranty by the Eligible Assignee that the assignment evidenced thereby will not result in a non-exempt "prohibited transaction" under Section&nbsp;406 of ERISA.  On and after the effective date of such assignment, such Eligible Assignee shall for all purposes be a Lender party to this Agreement and the&nbsp;other Loan&nbsp;Document executed by the Lenders and shall have all the rights and obligations of a&nbsp
;Lender under the Loan Documents to the same extent as if it were an original party thereto, and no&nbsp;further consent or action by Borrowers, Lenders or Agent shall be required to release the transferor Lender with respect to the Commitment (or portion thereof) of such Lender and Obligations assigned to such Eligible Assignee.  Without limiting the generality of the foregoing, such Eligible Assignee shall be subject to and bound by all of the Loan Documents.  Upon the consummation of any assignment to an Eligible&nbsp;Assignee pursuant to this <B>Section&nbsp;14.3</B>, the transferor Lender, Agent and Borrowers shall make appropriate arrangements so that replacement Notes are issued to such transferor Lender and new Notes or, as appropriate, replacement Notes, are issued to such Eligible Assignee, in each case in principal amounts reflecting their respective Commitments, as adjusted pursuant to such assignment.  If the transferor Lender shall have assigned all&nbsp;of its interests, rights and obligations
 under this Agreement pursuant to <B>Section&nbsp;14.3.1</B>, then (i) such transferor Lender shall no longer have any obligation to indemnify Agent with&nbsp;respect to any&nbsp;transactions, events or occurrences that transpire after the effective date of such&nbsp;assignment, (ii)&nbsp;each Eligible Assignee to which such transferor Lender shall make an assignment shall be responsible to Agent to indemnify Agent in accordance with this Agreement with respect to transactions, events and occurrences transpiring on and after the effective date of such assignment to it, and (iii)&nbsp;the transferor Lender shall continue to be entitled to the benefits of those provisions of the Loan Documents (including indemnities from Obligors) that survive Full Payment of the Obligations.</P>
<P ALIGN="JUSTIFY">14.3.3.&nbsp;&nbsp;&nbsp;<U>Dissemination of Information</P>
</U><P ALIGN="JUSTIFY">.  Each Borrower authorizes each Lender and Agent to disclose to any Participant, any Eligible Assignee or any other Person acquiring an interest in the Loan&nbsp;Documents by operation of law (each a "Transferee"), and any prospective Transferee, any and all information in Agent's or such Lender's possession concerning each Borrower, the Subsidiaries of each Borrower or the Collateral, subject to appropriate confidentiality undertakings on the part of such Transferee.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346609"><A NAME="_Toc102963407"><A NAME="_Toc105998379"><A NAME="_Toc105998789"><A NAME="_Toc105998921"><A NAME="_Toc117052434">14.4.&nbsp;&nbsp;&nbsp;<U>Tax Treatment</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  If any interest in any Loan Document is transferred to any Transferee that is organized under the laws of any jurisdiction other than the United States or any State thereof, the&nbsp;transferor Lender shall cause such Transferee, concurrently with the effectiveness of such transfer, to&nbsp;comply with the provisions of <B>Section&nbsp;5.10</B>.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346610"><A NAME="_Toc102963408"><A NAME="_Toc105998380"><A NAME="_Toc105998790"><A NAME="_Toc105998922"><A NAME="_Toc117052435">SECTION 15.&nbsp;&nbsp;&nbsp;MISCELLANEOUS</A></A></A></A></A></A></P>
<P ALIGN="JUSTIFY"><A NAME="_Toc38346611"><A NAME="_Toc102963409"><A NAME="_Toc105998381"><A NAME="_Toc105998791"><A NAME="_Toc105998923"><A NAME="_Toc117052436">15.1.&nbsp;&nbsp;&nbsp;<U>Power of Attorney</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Each Borrower hereby irrevocably designates, makes, constitutes and appoints Agent (and all Persons designated by Agent) as such Borrower's true and lawful attorney (and agent-in-fact) and Agent, or Agent's designee, may, without notice to such Borrower and in either such Borrower's or Agent's name, but at the cost and expense of Borrowers:</P>
<P ALIGN="JUSTIFY">15.1.1.&nbsp;&nbsp;&nbsp;At such time or times as Agent or said designee, in its discretion, may determine, endorse such Borrower's name on any Payment Item or other proceeds of the Collateral (including proceeds of insurance) which come into the possession of Agent or under Agent's control.</P>
<P ALIGN="JUSTIFY">15.1.2.&nbsp;&nbsp;&nbsp;At any time that an Event of Default exists: (i)&nbsp;demand payment of the Accounts from the Account Debtors, enforce payment of the Accounts by legal proceedings or otherwise, and generally exercise all of such Borrower's rights and remedies with respect to the collection of the Accounts; (ii)&nbsp;settle, adjust, compromise, discharge or release any of the Accounts or other Collateral or any legal proceedings brought to collect any of the Accounts or other Collateral; (iii)&nbsp;sell or assign any of the Accounts and other Collateral upon such terms, for such amounts and at such time or times as Agent deems advisable; (iv)&nbsp;take control, in&nbsp;any manner, of any item of payment or proceeds relating to any Collateral; (v)&nbsp;prepare, file and sign such Borrower's name to a proof of claim in bankruptcy or similar document against any Account Debtor or to any&nbsp;notice of Lien, assignment or satisfaction of Lien or similar document in connection with any 
of the Collateral; (vi)&nbsp;receive, open and dispose of all mail addressed to such Borrower and to notify postal authorities to change the address for delivery thereof to such address as Agent may designate; (vii)&nbsp;endorse the name of such Borrower upon any Payment Item relating to any Collateral and deposit the same to the account of Agent for application to the Obligations; (viii)&nbsp;endorse the name of such Borrower upon any Chattel Paper, Document, Instrument, invoice, freight bill, bill of lading or similar document or agreement relating to any Accounts or Inventory of any Obligor and any other Collateral; (ix)&nbsp;use such Borrower's stationery and sign the name of such Borrower to verifications of the Accounts and notices thereof to Account Debtors; (x)&nbsp;use the information recorded on or contained in any data processing equipment and computer hardware and software relating to any Collateral; (xi)&nbsp;make and adjust claims under policies of insurance; (xii)&nbsp;sign the name of such Bo
rrower to and file any proof of claim in an Insolvency Proceeding of any Account Debtor and on notices of Liens, claims of mechanic's Liens or assignments or releases of mechanic's Liens securing any Accounts; (xiii)&nbsp;take all action as may be necessary to obtain the payment of any letter of credit or banker's acceptance of which such Borrower is a beneficiary; and (xiv)&nbsp;do all other acts and things necessary, in Agent's determination, to fulfill such Borrower's obligations under any of the Loan Documents.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346612"><A NAME="_Toc102963410"><A NAME="_Toc105998382"><A NAME="_Toc105998792"><A NAME="_Toc105998924"><A NAME="_Toc117052437">15.2.&nbsp;&nbsp;&nbsp;<U>General Indemnity</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Whether or not any of the transactions contemplated by any of the Loan Documents are consummated, each Borrower agrees to indemnify and defend the Indemnitees and hold the Indemnitees harmless from and against any Claims that may be instituted or asserted against or are incurred by any of the Indemnitees.  Without limiting the generality of the foregoing, this indemnity shall extend to any Claims instituted or asserted against or incurred by any of the Indemnitees (x) under any Environmental Laws or (y) under any Anti-Terrorism Laws, including any fines assessed against Agent or any Lender by any Governmental Authority as a result of conduct of an Obligor.  Additionally, if any intangibles tax, stamp tax or recording tax shall be payable by any party on account of the execution or delivery of this Agreement, or the execution, delivery, issuance or recording of any of the other Loan&nbsp;Documents, or the creation or repayment of any of the&nbsp;Obligations hereunder, by reason o
f any Applicable Law now or hereafter in effect, Borrowers shall pay (and&nbsp;shall promptly reimburse Agent and Lenders for their payment of) all such amounts, including any interest and penalties thereon, and will indemnify and hold Indemnitees harmless from and against all liability in connection therewith.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346613"><A NAME="_Toc102963411"><A NAME="_Toc105998383"><A NAME="_Toc105998793"><A NAME="_Toc105998925"><A NAME="_Toc117052438">15.3.&nbsp;&nbsp;&nbsp;<U>Survival of and Limitations Upon Indemnities</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Notwithstanding anything to the contrary in this Agreement or any of the other Loan Documents, the obligation of each Borrower and each Lender with respect to each indemnity given by it in this Agreement any shall survive the Full Payment of the Obligations, the termination of any of the Commitments and the resignation of Agent.  Notwithstanding anything to the contrary contained in this Agreement, no party shall have any obligation under this Agreement to indemnify an Indemnitee with respect to any Claim to the extent that it is determined in a final, non-appealable judgment by a court of competent jurisdiction that such Claim resulted from the gross negligence or willful misconduct of such Indemnitee or which constitute indirect, special, consequential or punitive damages.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346614"><A NAME="_Toc102963412"><A NAME="_Toc105998384"><A NAME="_Toc105998794"><A NAME="_Toc105998926"><A NAME="_Toc117052439">15.4.&nbsp;&nbsp;&nbsp;<U>Modification of Agreement</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  This Agreement may not be modified, altered or amended, except as provided in <B>Section&nbsp;13</B>; <U>provided</U>, <U>however</U>, that no consent, written or otherwise, of Borrowers shall be necessary or required in connection with any amendment of any of the provisions of <B>Sections 2.3.2, 4.1.3, 5.6,</B> or <B>13 </B>(other than <B>Sections&nbsp;13.2.1, 13.9 </B>and <B>13.17</B>), or any other provision of this Agreement that affects only the rights, duties and responsibilities of Lenders and Agent as among themselves so long as no such amendment imposes any&nbsp;additional obligations on Borrowers.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346615"><A NAME="_Toc102963413"><A NAME="_Toc105998385"><A NAME="_Toc105998795"><A NAME="_Toc105998927"><A NAME="_Toc117052440">15.5.&nbsp;&nbsp;&nbsp;<U>Severability</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Wherever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under Applicable Law, but if any provision of this Agreement shall be prohibited by or invalid under Applicable Law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346616"><A NAME="_Toc102963414"><A NAME="_Toc105998386"><A NAME="_Toc105998796"><A NAME="_Toc105998928"><A NAME="_Toc117052441">15.6.&nbsp;&nbsp;&nbsp;<U>Cumulative Effect; Conflict of Terms</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  The provisions of the Other Agreements and the Security Documents are hereby made cumulative with the provisions of this Agreement.  Without limiting the generality of the foregoing, the parties acknowledge that this Agreement and the other Loan Documents may use several different limitations, tests or measurements to regulate the same or similar matters and that such&nbsp;limitations, tests and measures are cumulative and each must be performed, except as may be expressly stated to the contrary in this Agreement.  Except as otherwise provided in any of the other Loan&nbsp;Documents by specific reference to the applicable provision of this Agreement, if any provision contained in this&nbsp;Agreement is in direct conflict with, or inconsistent with, any provision in any of the&nbsp;other Loan Documents, the provision contained in this Agreement shall govern and control.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346617"><A NAME="_Toc102963415"><A NAME="_Toc105998387"><A NAME="_Toc105998797"><A NAME="_Toc105998929"><A NAME="_Toc117052442">15.7.&nbsp;&nbsp;&nbsp;<U>Counterparts</A>; Facsimile Signatures</A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  This Agreement and any amendments hereto may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which counterparts taken together shall constitute but one and the same instrument.  Loan Documents may be executed by facsimile and the effectiveness of any such Loan Documents and signatures thereon shall, subject to Applicable Law, have the same force and effect as manually signed originals and shall be binding on all parties thereto.  Agent may require that any such documents and signatures be confirmed by a manually-signed original thereof, <U>provided</U> that the failure to request or deliver the same shall not limit the effectiveness of any facsimile signature.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346618"><A NAME="_Toc102963416"><A NAME="_Toc105998388"><A NAME="_Toc105998798"><A NAME="_Toc105998930"><A NAME="_Toc117052443">15.8.&nbsp;&nbsp;&nbsp;<U>Consent</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Whenever the consent of Agent or Lenders (or any combination of Lenders) is required to be obtained under this Agreement or any of the other Loan Documents as a condition to any action, inaction, condition or event, each party whose consent is required shall be authorized to give or withhold its consent in its discretion and to condition its consent upon the giving of additional collateral security for the&nbsp;Obligations, the payment of money or any other matter.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346619"><A NAME="_Toc74712042"><A NAME="_Toc102963417"><A NAME="_Toc105998389"><A NAME="_Toc105998799"><A NAME="_Toc105998931"><A NAME="_Toc117052444">15.9.&nbsp;&nbsp;&nbsp;<U>Notices</A></A> and Communications.</A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">15.9.1.&nbsp;&nbsp;&nbsp;Except as otherwise provided in <B>Section 4.1.5</B>, all notices, requests and other communications to or upon a party hereto shall be in writing (including facsimile transmission or similar writing) and shall be given to such party at the address or facsimile number for such party on the signature pages hereof (or, in the case of a Person who becomes a Lender after the date hereof, at the address shown on the applicable Assignment and Acceptance by which such Person became a Lender) or at such other address or facsimile number as such party may hereafter specify for the purpose by notice to Agent and Borrowers in accordance with the provisions of this <B>Section 15.9</B>.</P>
<P ALIGN="JUSTIFY">15.9.2.&nbsp;&nbsp;&nbsp;Except as otherwise provided in <B>Section 4.1.5</B>, each such notice, request or other communication shall be effective (i)&nbsp;if given by facsimile transmission, when transmitted to the facsimile number specified herein for the noticed party and confirmation of receipt is received, (ii)&nbsp;if given by mail, 3 Business Days after such communication is deposited in the U.S. Mail, with first-class postage pre-paid, addressed to the noticed party at the address specified herein, or (iii)&nbsp;if given by personal delivery, when duly delivered with receipt acknowledged in writing by the noticed party.  In no event shall a voicemail message be effective as a notice, communication or confirmation under any of the Loan Documents.  Notwithstanding the foregoing, no notice to or upon Agent, Issuing Bank or BofA pursuant to <B>Sections&nbsp;2.3, 3.1.2, 4.1 or 6.2.2</B> shall be effective until after actually received by the individual to&nbsp;whose attention at Agent s
uch notice is required to be sent.  Any written notice, request or demand that is not sent in conformity with the provisions hereof shall nevertheless be effective on the date that such&nbsp;notice, request or demand is actually received by the individual to whose attention at the&nbsp;noticed party such notice, request or demand is required to be sent.  Any notice received by Borrower Representative shall be deemed to have been received by all Borrowers.</P>
<P ALIGN="JUSTIFY">15.9.3.&nbsp;&nbsp;&nbsp;Electronic mail and (with the permission of the noticed party) intranet websites may be used only to distribute routine communications, such as financial statements, Borrowing Base Certificates and other information required by <B>Sections 10.1.2 </B>and<B> 10.1.3</B>, and to distribute Loan Documents for execution by the parties thereto, and may not be used for any other purpose as effective notice under this Agreement or any of the other Loan Documents.</P>
<P ALIGN="JUSTIFY">Agent and Lenders shall be authorized to rely and act upon any notices (including telephonic communications) purportedly given by or on behalf of any Borrower even if such notices were made in a manner other than as specified herein, were incomplete or were not preceded or followed by any other form of notice specified or required herein, or the terms thereof, as understood by the recipient, varied from any confirmation thereof.  Borrowers jointly and severally agree to indemnify and defend each Indemnitee from all losses, costs, expenses and liabilities resulting from the reliance by any such Indemnitee on each telephone communication purportedly given by or on behalf of any Borrower.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346620"><A NAME="_Toc102963418"><A NAME="_Toc105998390"><A NAME="_Toc105998800"><A NAME="_Toc105998932"><A NAME="_Toc117052445">15.10.&nbsp;&nbsp;&nbsp;<U>Performance of Borrowers' Obligations</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  If any Borrower shall fail to discharge any covenant, duty or obligation hereunder or under any of the other Loan Documents, Agent may, in its discretion at any time or from time to time, for such Borrower's account and at Borrowers' expense, pay&nbsp;any amount or do any act required of Borrowers hereunder or under any of the other Loan Documents or otherwise lawfully requested by Agent to (i)&nbsp;enforce any of the Loan Documents or collect any of the Obligations, (ii)&nbsp;preserve, protect, insure or maintain or realize upon any of the Collateral, or (iii)&nbsp;preserve, defend, protect or maintain the validity or priority of Agent's Liens in any of the Collateral, including the payment of any judgment against any Borrower, any insurance premium, any warehouse charge, any finishing or processing charge, any landlord claim, any other Lien upon or with respect to any of the Collateral (whether or not a Permitted Lien).  All payments that Agent may make under this Section and 
all out-of-pocket costs and expenses (including Extraordinary Expenses) that Agent pays or incurs in connection with any action taken by it hereunder shall be reimbursed to Agent by Borrowers, <B>on demand</B>, with interest from the date such payment is made or such costs or expenses are incurred to the date of payment thereof at the Default Rate applicable for Revolver Loans that are Base Rate Loans. Any&nbsp;payment made or other action taken by Agent under this Section shall be without prejudice to any right to assert, and without waiver of, an Event of Default hereunder and to without prejudice to Agent's right proceed thereafter as provided herein or in any of the other Loan Documents.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346621"><A NAME="_Toc102963419"><A NAME="_Toc105998391"><A NAME="_Toc105998801"><A NAME="_Toc105998933"><A NAME="_Toc117052446">15.11.&nbsp;&nbsp;&nbsp;<U>Credit Inquiries</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Each Borrower hereby authorizes and permits Agent and Lenders (but Agent and Lenders shall have no obligation) to respond to usual and customary credit inquiries from third parties concerning such Borrower or any of its Subsidiaries.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346622"><A NAME="_Toc102963420"><A NAME="_Toc105998392"><A NAME="_Toc105998802"><A NAME="_Toc105998934"><A NAME="_Toc117052447">15.12.&nbsp;&nbsp;&nbsp;<U>Time of Essence</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Time is of the essence of this Agreement, the Other Agreements and the Security Documents.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346623"><A NAME="_Toc102963421"><A NAME="_Toc105998393"><A NAME="_Toc105998803"><A NAME="_Toc105998935"><A NAME="_Toc117052448">15.13.&nbsp;&nbsp;&nbsp;<U>Indulgences Not Waivers</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  Agent's or any Lender's failure at any time or times hereafter, to require strict performance by Borrowers of any provision of this Agreement shall not waive, affect or diminish any right of Agent or any Lender thereafter to demand strict compliance and performance therewith.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346624"><A NAME="_Toc102963422"><A NAME="_Toc105998394"><A NAME="_Toc105998804"><A NAME="_Toc105998936"><A NAME="_Toc117052449">15.14.&nbsp;&nbsp;&nbsp;<U>Entire Agreement; Exhibits and Schedules</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  This Agreement and the other&nbsp;Loan Documents, together with all other instruments, agreements and certificates executed by the&nbsp;parties pursuant to any Loan Document, embody the entire understanding and agreement between the parties hereto and thereto with respect to the subject matter hereof and thereof and supersede all prior agreements, understandings and inducements, whether express or implied, oral or written, regarding the same subject matter.  Each of the Exhibits and each of the Schedules attached hereto are incorporated into this Agreement and by this reference made a part hereof.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346625"><A NAME="_Toc102963423"><A NAME="_Toc105998395"><A NAME="_Toc105998805"><A NAME="_Toc105998937"><A NAME="_Toc117052450">15.15.&nbsp;&nbsp;&nbsp;<U>Interpretation</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  No provision of this Agreement or any of the other Loan Documents shall be construed against or interpreted to the disadvantage of any party hereto by any court or other&nbsp;governmental or judicial authority by reason of such party having, or being deemed to have, structured, drafted or dictated such provision.  The paragraph and section headings are for convenience of reference only and shall not affect the substantive meaning of any provision of this Agreement.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346626"><A NAME="_Toc102963424"><A NAME="_Toc105998396"><A NAME="_Toc105998806"><A NAME="_Toc105998938"><A NAME="_Toc117052451">15.16.&nbsp;&nbsp;&nbsp;<U>Obligations of Lenders Several</A></A></A></A></A></A></P>
</U><P ALIGN="JUSTIFY">.</B>  The obligations of each Lender hereunder are several, and no Lender shall be responsible for the obligations or Commitment of any other Lender.  Nothing contained in this Agreement and no action taken by Lenders pursuant hereto shall be deemed to constitute Lenders to be a partnership, association, joint venture or any other kind of entity.  The amounts payable at any time hereunder to each Lender shall be a separate and independent debt, and each Lender shall be entitled, to the&nbsp;extent not otherwise restricted hereunder, to protect and enforce its rights arising out of this Agreement and any of the other Loan Documents and it shall not be necessary for Agent or any other Lender to be joined as an additional party in any proceeding for such purpose.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346628"><A NAME="_Toc102963425"><A NAME="_Toc105998397"><A NAME="_Toc105998807"><A NAME="_Toc105998939"><A NAME="_Toc117052452">15.17.&nbsp;&nbsp;&nbsp;<U>Confidentiality</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">.  Agent and Lenders each agrees to take normal and reasonable precautions to maintain the confidentiality of any information that is delivered or made available by Borrowers to it (including information made available to Agent or any Lender in connection with a visit or investigation by any Person contemplated in <B>Section&nbsp;10.1.1</B>), for a period of 24 months following the Commitment Termination Date, except that Agent and any Lender may disclose such information (i)&nbsp;to their respective&nbsp;Affiliates and individuals employed or retained by Agent or such Lender who are or are expected to become engaged in evaluating, approving, structuring, administering or otherwise giving professional advice with respect to any of the&nbsp;Loans or Collateral, including any of their respective legal counsel, auditors or other professional advisors; (ii)&nbsp;to any party to this&nbsp;Agreement from time to time or any Participant, (iii)&nbsp;pursuant the order of any court or admin
istrative agency, (iv)&nbsp;upon the request or demand of any&nbsp;regulatory agency or other Governmental Authority having jurisdiction over Agent or such Lender or in accordance with Agent's or Lender's regulatory compliance policies, (v)&nbsp;which has ceased to be confidential other than by an act or omission of Agent or any Lender except as permitted herein or which becomes available to Agent or any Lender on a nonconfidential basis from a source other than Obligors, (vi)&nbsp;to the extent reasonably required in connection with any litigation (with respect to any of the Loan&nbsp;Documents or any of the&nbsp;transactions contemplated thereby) to which Agent, any Lender or their&nbsp;respective Affiliates may be a party, (vii)&nbsp;to the extent reasonably required in connection with the&nbsp;exercise of any remedies hereunder, (viii)&nbsp;to any&nbsp;actual or proposed Participant, Assignee, counterparty or advisors to any swap or derivative transactions relating to Obligors and the Obligations, or any
 other Transferee of all or part of a&nbsp;Lender's rights hereunder so long as such Person has agreed in writing to be bound by the provisions of this Section, (ix)&nbsp;to the National Association of Insurance Commissioners or any similar organization or to any nationally recognized rating agency that requires access to information about a Lender's portfolio in connection with ratings issued with respect to such&nbsp;Lender, (x)&nbsp;to the extent required (on the advice of Agent's or such Lender's counsel) by Applicable Law, or (xi) with the consent of Borrowers.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc102963426"><A NAME="_Toc105998398"><A NAME="_Toc105998808"><A NAME="_Toc105998940"><A NAME="_Toc117052453">15.18.&nbsp;&nbsp;&nbsp;<U>Certifications Regarding Indentures.</A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">Each Borrower hereby certifies to Agent and Lenders that neither the execution or performance of this Agreement by Borrowers nor the incurrence of any Debt pursuant to the terms of this Agreement or any of the other Loan Documents violates any of the Senior Note Documents or Convertible Note Documents.  Each Borrower further certifies to Agent and Lenders that all Loans collectively constitute "Senior Indebtedness" under each of the Senior Note Documents and Convertible Note Documents.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc102963427"><A NAME="_Toc105998399"><A NAME="_Toc105998809"><A NAME="_Toc105998941"><A NAME="_Toc117052454">15.19.&nbsp;&nbsp;&nbsp;<U>Governing Law</U>.</A></A></A></A></A></P>
</B><P ALIGN="JUSTIFY">This Agreement has been negotiated, executed and delivered, and shall be deemed to have been made, in New York, New York and shall be governed by and construed in accordance with the internal laws (but without regard to conflict of law principles) of the State of New York, New York, but giving effect to federal laws relating to national banks.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc102963428"><A NAME="_Toc105998400"><A NAME="_Toc105998810"><A NAME="_Toc105998942"><A NAME="_Toc117052455">15.20.&nbsp;&nbsp;&nbsp;<U>Consent to Forum; Arbitration.</A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">Each Borrower hereby consents to the non-exclusive jurisdiction of any United States federal court sitting in or with direct or indirect jurisdiction over the Southern District of New York or in any New York state or superior court sitting in New York County, New York, in any action, suit or other proceeding arising out of or relating to this Agreement or any of the other Loan Documents and each Borrower irrevocably agrees that all claims and demands in respect of any such action, suit or proceeding may be heard and determined in any such court and irrevocably waives any objection it may now or hereafter have as to the venue of any such action, suit or proceeding brought in any such court or that such court is an inconvenient forum.  Nothing herein shall limit the right of Agent or any Lender to bring proceedings against any Borrower or with respect to any Collateral in the courts of any other jurisdiction.  Any judicial proceeding commenced by any Borrower against Agent, BofA, any
 Lender or any holder of any of the Obligations, or any Affiliate of Agent, BofA, any Lender or any holder of any Obligations, involving, directly or indirectly, any matter in any way arising out of, related to or connected with any Loan Document shall be brought only in a United States federal court sitting in or with direct jurisdiction over the Southern District of New York, or in any New York state or superior court sitting in New York County, New York.  Nothing in this Agreement shall be deemed to preclude the enforcement by Agent of any&nbsp;judgment or order obtained in such forum or the taking of any action under this Agreement to&nbsp;enforce same in any other appropriate forum or jurisdiction.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc117052456">15.21.&nbsp;&nbsp;&nbsp;<U>No Fiduciary Obligation</A></P>
</B></U><P ALIGN="JUSTIFY">.  Each Borrower acknowledges and agrees that in connection with all aspects of each transaction contemplated by this Agreement, Borrowers and BofA and any Affiliate through which BofA may be acting, including, Banc of America Securities LLC (each, a "Transaction Affiliate") have an arms-length business relationship that creates no fiduciary duty on the part of BofA or any Transaction Affiliate and each  Borrower expressly disclaims any fiduciary relationship.</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc117052457">15.22.&nbsp;&nbsp;&nbsp;<U>Quebec Collateral</A></P>
</B></U><P ALIGN="JUSTIFY">  For the purposes of creating a <I>solidarit&eacute; active</I> in accordance with Article 1541 of the Civil Code of Qu&eacute;bec between each Lender, taken individually, on the one hand, and the Agent, on the other hand, each Obligor granting a Lien (hypothec) to the Agent under the Civil Code of Quebec and each such Lender acknowledge and agree with the Agent that such Lender and the Agent are hereby conferred the legal status of solidary creditors of each such Obligor in respect of all indebtedness, liabilities and other obligations, present and future, owed by each such Obligor to the Agent and such Lender hereunder and under the other Loan Documents (collectively, the "<B>Solidary Claim</B>") and that, accordingly, but subject (for the avoidance of doubt) to Article 1542 of the Civil Code of Qu&eacute;bec, each such Obligor is irrevocably bound towards the Agent and each Lender in respect of the entire Solidary Claim of the Agent and such Lender.  As a result of the foregoin
g, the parties hereto acknowledge that the Agent and each Lender shall at all times have a valid and effective right of action for the entire Solidary Claim of the Agent and such Lender and the right to give full acquittance for it.  Accordingly, and without limiting the generality of the foregoing, the Agent, as solidary creditor with each Lender, shall at all times have a valid and effective right of action in respect of the Solidary Claim and the right to give a full acquittance for same.  By its execution of the Loan Documents to which it is a party, each such Obligor not a party hereto shall also be deemed to have accepted the stipulations hereinabove provided.  The parties further agree and acknowledge that such Liens (hypothecs) under the Loan Documents shall be granted to the Agent, for its own benefit and for the benefit of the Lenders, as solidary creditor as hereinabove set forth.</P>
<P ALIGN="JUSTIFY">For purposes of any Collateral located in Quebec or charged by any deed of hypothec, "personal property" shall be deemed to include "movable property", "security interest" shall be deemed to include a "hypothec" and "UCC" shall be deemed to include "the <I>Civil Code</I> of Quebec".</P>
<B><P ALIGN="JUSTIFY"><A NAME="_Toc38346631"><A NAME="_Toc102963429"><A NAME="_Toc105998401"><A NAME="_Toc105998811"><A NAME="_Toc105998943"><A NAME="_Toc117052458">15.23.&nbsp;&nbsp;&nbsp;<U>Waivers by Borrowers</A></A></A></A></A></A></P>
</B></U><P ALIGN="JUSTIFY">.<B>  To the fullest extent permitted by Applicable Law, each Borrower waives (i)&nbsp;the right to trial by jury (which Agent and each Lender hereby also waives) in&nbsp;any action, suit, proceeding or counterclaim of any kind arising out of or related to any of the&nbsp;Loan Documents, the Obligations or the Collateral; (ii)&nbsp;presentment, demand and protest and notice of presentment, protest, default, non payment, maturity, release, compromise, settlement, extension or renewal of any or all commercial paper, accounts, contract rights, documents, instruments, chattel paper and guaranties at any time held by Agent on which such Borrower may in any way be liable and hereby ratifies and confirms whatever Agent may do in this regard; (iii)</B>&nbsp;<B>notice prior to taking possession or control of the Collateral or any bond or security which might be required by any court prior to allowing Agent to exercise any of Agent's remedies; (iv)&nbsp;the&nbsp;benefit of all valuation, app
raisement and exemption laws; (v)&nbsp;any claim against Agent or any Lender, on any theory of liability, for special, indirect, consequential, exemplary or punitive damages (as&nbsp;opposed to direct or actual damages) in respect of any claim for breach of contract or any other theory of liability arising out of, or the taking of any Enforcement Action; or related to any of the Loan Documents, any transaction thereunder or the use of the proceeds of any Loans; and (vi)&nbsp;notice of acceptance hereof.  Each Borrower acknowledges that the foregoing waivers are a material inducement to Agent's and Lender's entering into this Agreement and that Agent and Lenders are relying upon the foregoing waivers in its future dealings with Borrowers.  Each&nbsp;Borrower warrants and represents that it has reviewed the foregoing waivers with its legal&nbsp;counsel and has knowingly and voluntarily waived its jury trial rights following consultation with legal  counsel.  In the  event of litigation, this Agreement may be f
iled as a written consent to a trial by the&nbsp;Court.</P>
</B><P ALIGN="CENTER">[Remainder of page intentionally left blank]</P>
<B><P>IN WITNESS  WHEREOF,</B>  this Agreement has been duly executed and delivered on the day and year specified at the beginning of this Agreement.</P>
</FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=638>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;</P>
<P>&nbsp;</P>
<P>ATTEST:</P>

<U><P>/s/ Robert F. Wrobel</U><BR>
Robert F. Wrobel<BR>
Secretary<BR>
</P>

<P>&nbsp;</FONT></TD>
<TD WIDTH="52%" VALIGN="TOP">
<B><FONT SIZE=3><P>BORROWERS</B>:</P>

<B><P>ALPHARMA INC.</P>

</B><P>By: &nbsp;&nbsp;&nbsp;<U>/s/ Matthew T. Farrell</U><BR>
Matthew T. Farrell<BR>
Title: Executive Vice President, Finance <BR>
&amp; Chief Financial Officer<BR>
Address: One Executive Drive<BR>
Fort Lee, NJ  07024<BR>
Attention: Chief Legal Officer&#9;&#9;<BR>
Telecopier No.:  (201) 592-1481&#9;&#9;<BR>
</P>
</FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;</P>
<P>ATTEST:</P>

<U><P>/s/ Robert F. Wrobel</U><BR>
Robert F. Wrobel<BR>
Secretary</P>
</FONT></TD>
<TD WIDTH="52%" VALIGN="TOP">
<B><FONT SIZE=3><P>ALPHARMA OPERATING CORPORATION</P>
</B>
<P>By: <U>/s/ Matthew T. Farrell</U><BR>
Matthew T. Farrell&#9;<BR>
Title: President&#9;&#9;&#9;&#9;<BR>
Address: One Executive Drive&#9;&#9;<BR>
Fort Lee, NJ  07024<BR>
Attention: Chief Legal Officer&#9;&#9;<BR>
Telecopier No.:  (201) 592-1481&#9;&#9;<BR>
</P>
</FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P>ATTEST:</P>
<P><BR>
<U>/s/ Robert F. Wrobel</U><BR>
Robert F. Wrobel<BR>
Secretary</P>
</FONT></TD>
<TD WIDTH="52%" VALIGN="TOP">
<B><FONT SIZE=3><P>ALPHARMA USPD INC.</P>
</B><P><BR>
By: /s/ Frederick J. Lynch&#9;<BR>
Frederick J. Lynch<BR>
Title: President &amp; Chief Executive Officer<BR>
Address: One Executive Drive&#9;&#9;<BR>
  Fort Lee, NJ  07024<BR>
Attention: Chief Legal Officer&#9;&#9;<BR>
Telecopier No.:  (201) 592-1481&#9;&#9;<BR>
</P>
</FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P>ATTEST:</P>

<P>/s/ Robert F. Wrobel<BR>
Robert F. Wrobel<BR>
Secretary</P>
</FONT></TD>
<TD WIDTH="52%" VALIGN="TOP">
<B><FONT FACE="Times New Roman Bold" SIZE=3><P>Alpharma U.S. Inc.</P>
</B>
</FONT><FONT SIZE=3><P>By: <U>/s/ Matthew T. Farrell<BR>
</U>Matthew T. Farrell<BR>
Title: President&#9;<BR>
Address: One Executive Drive&#9;&#9;<BR>
Fort Lee, NJ  07024<BR>
Attention: Chief Legal Officer&#9;&#9;<BR>
Telecopier No.:  (201) 592-1481&#9;&#9;</P>
<U>
<P>&nbsp;</U></FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P>ATTEST:</P>

<P>__/s/ Robert F. Wrobel _____________</P>
<P>Robert F. Wrobel</P>
<P>Secretary</P>
</FONT></TD>
<TD WIDTH="52%" VALIGN="TOP">
<B><FONT FACE="Times New Roman Bold" SIZE=3><P>G.F. Reilly Company</B> </P>
</FONT><FONT SIZE=3>
<P>By: <U>&#9;/s/ Matthew</U> T. Farrell&#9;&#9;<BR>
Matthew T. Farrell&#9;<BR>
Title: President &amp; Chief Executive Officer<BR>
Address: One Executive Drive&#9;&#9;<BR>
  Fort Lee, NJ  07024<BR>
Attention: Chief Legal Officer&#9;&#9;</P>
<P>Telecopier No.:  (201) 592-1481&#9;&#9;</P>

<P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P>ATTEST:</P>

<P>____/s/ Robert F. Wrobel ___________</P>
<P>Robert F. Wrobel</P>
<P>Secretary</P>
</FONT></TD>
<TD WIDTH="52%" VALIGN="TOP">
<B><FONT FACE="Times New Roman Bold" SIZE=3><P>Parmed Pharmaceuticals, Inc.</B> </P>
</FONT><FONT SIZE=3>
<P>By: <U>&#9;/s/ Frederick J. Lynch&#9;&#9;</P><DIR>
<DIR>
<DIR>
<DIR>

</U><P>Frederick J. Lynch&#9;&#9;</P></DIR>
</DIR>
</DIR>
</DIR>

<P>Title: <U>President &amp; Chief Executive Officer</P>
</U><P>Address: <U>One Executive Drive&#9;&#9;</P>
<P>&#9;  Fort Lee, NJ  07024</U>_________</P>
<P>Attention: <U>Chief Legal Officer&#9;&#9;</P>
</U><P>Telecopier No.: <U> (201) 592-1481&#9;&#9;</P>

<P>&nbsp;</U></FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P>ATTEST:</P>

<P>_/s/ Christopher J.N. Towner_________</P>
<P>Christopher J.N. Towner</P>
<P>Secretary</P>
</FONT></TD>
<TD WIDTH="52%" VALIGN="TOP">
<B><FONT FACE="Times New Roman Bold" SIZE=3><P>Alpharma Euro Holdings Inc.</B> </P>
</FONT><FONT SIZE=3><DIR>
<DIR>
<DIR>
<DIR>

<P>By: <U>&#9;/s/ Einar Thorstensen_________</P>
</U><P>Einar Thorstensen</P></DIR>
</DIR>
</DIR>
</DIR>

<P>Title: <U>President&#9;&#9;&#9;&#9;</P>
</U><P>Address: <U>One Executive Drive&#9;&#9;</P>
<P>&#9;</U>  <U>Fort Lee, NJ  07024</U>_________</P>
<P>Attention: <U>Chief Legal Officer&#9;&#9;</P>
</U><P>Telecopier No.: <U> (201) 592-1481&#9;&#9;</P>

<P>&nbsp;</U></FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P>ATTEST:</P>

<P>_/s/ Christopher J.N. Towner_________</P>
<P>Christopher J.N. Towner</P>
<P>Secretary</P>
</FONT></TD>
<TD WIDTH="52%" VALIGN="TOP">
<B><FONT FACE="Times New Roman Bold" SIZE=3><P>Alpharma (Bermuda) Inc.</B> </P>
</FONT><FONT SIZE=3><DIR>
<DIR>
<DIR>
<DIR>

<P>By: <U>&#9;/s/ Einar Thorstensen_________</P>
</U><P>Einar Thorstensen</P></DIR>
</DIR>
</DIR>
</DIR>

<P>Title: <U>President&#9;&#9;&#9;&#9;</P>
</U><P>Address: <U>One Executive Drive&#9;&#9;</P>
<P>&#9;  Fort Lee, NJ  07024</U>_________</P>
<P>Attention: <U>Chief Legal Officer&#9;&#9;</P>
</U><P>Telecopier No.: <U> (201) 592-1481&#9;&#9;</P>

</U><P>&nbsp;</FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P>&nbsp;</P>
<P>&nbsp;</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=638>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P>ATTEST:</P>

<P>_/s/ Christopher J.N. Towner_________</P>
<P>Christopher J.N. Towner</P>
<P>Secretary</P>
</FONT></TD>
<TD WIDTH="52%" VALIGN="TOP">
<B><FONT FACE="Times New Roman Bold" SIZE=3><P>Alpharma USHP Inc.</B> </P>
</FONT><FONT SIZE=3><DIR>
<DIR>
<DIR>
<DIR>

<P>By: By: <U>__/s/ Einar Thorstensen_______</P>
</U><P>Einar Thorstensen</P></DIR>
</DIR>
</DIR>
</DIR>

<P>Title: <U>President&#9;&#9;&#9;&#9;</P>
</U><P>Address: <U>One Executive Drive&#9;&#9;</P>
<P>&#9;  Fort Lee, NJ  07024</U>_________</P>
<P>Attention: <U>Chief Legal Officer&#9;&#9;</P>
</U><P>Telecopier No.: <U> (201) 592-1481&#9;&#9;</P>

<P>&nbsp;</U></FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;</P>
<P>ATTEST:</P>

<P>___/s/ Robert F. Wrobel _____________</P>
<P>Robert F. Wrobel</P>
<P>Secretary</P>
</FONT></TD>
<TD WIDTH="52%" VALIGN="TOP">
<B><FONT FACE="Times New Roman Bold" SIZE=3><P>Alpharma Animal Health Company</B> </P>
</FONT><FONT SIZE=3>
<P>By: <U>&#9;/s/ Carol Wrenn&#9;&#9;______</P><DIR>
<DIR>
<DIR>
<DIR>

</U><P>Carol Wrenn</P></DIR>
</DIR>
</DIR>
</DIR>

<P>Title: <U>President&#9;&#9;&#9;&#9;</P>
</U><P>Address: <U>One Executive Drive&#9;&#9;</P>
<P>&#9;  Fort Lee, NJ  07024</U>_________</P>
<P>Attention: <U>Chief Legal Officer&#9;&#9;</P>
</U><P>Telecopier No.: <U> (201) 592-1481&#9;&#9;</P>

</U><P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P>ATTEST:</P>

<P>__/s/ Robert F. Wrobel ______________</P>
<P>Robert F. Wrobel</P>
<P>Secretary</P>
</FONT></TD>
<TD WIDTH="52%" VALIGN="TOP">
<B><FONT FACE="Times New Roman Bold" SIZE=3><P>Mikjan Corporation</B> </P>
</FONT><FONT SIZE=3>
<P>By: <U>&#9;/s/ Matthew T. Farrell&#9;&#9;</P><DIR>
<DIR>
<DIR>
<DIR>

</U><P>Matthew T. Farrell&#9;</P></DIR>
</DIR>
</DIR>
</DIR>

<P>Title: <U>President &amp; Chief Executive Officer</P>
</U><P>Address: <U>One Executive Drive&#9;&#9;</P>
<P>&#9;  Fort Lee, NJ  07024</U>_________</P>
<P>Attention: <U>Chief Legal Officer&#9;&#9;</P>
</U><P>Telecopier No.: <U> (201) 592-1481&#9;&#9;</P>

<P>&nbsp;</U></FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P>&#9;ATTEST:</P>

<P>_/s/ Christopher J.N. Towner_________</P>
<P>Christopher J.N. Towner</P>
<P>Secretary</P>
</FONT></TD>
<TD WIDTH="52%" VALIGN="TOP">
<B><FONT FACE="Times New Roman Bold" SIZE=3><P>Alpharma Holdings Inc. </P>
</B></FONT><FONT SIZE=3><DIR>
<DIR>
<DIR>
<DIR>

<P>By: <U>&#9;/s/ Einar Thorstensen_________</P>
</U><P>Einar Thorstensen</P></DIR>
</DIR>
</DIR>
</DIR>

<P>Title: <U>President&#9;&#9;&#9;&#9;</P>
</U><P>Address: <U>One Executive Drive&#9;&#9;</P>
<P>&#9;  Fort Lee, NJ  07024</U>_________</P>
<P>Attention: <U>Chief Legal Officer&#9;&#9;</P>
</U><P>Telecopier No.: <U> (201) 592-1481&#9;&#9;</P>

<P>&nbsp;</U></FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P>&nbsp;</P>
<P>&nbsp;</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=638>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;</P>
<P>ATTEST:</P>

<P>_/s/ Christopher J.N. Towner_________<BR>
Christopher J.N. Towner<BR>
Secretary<BR>
</P>
</FONT></TD>
<TD WIDTH="52%" VALIGN="TOP">
<B><FONT FACE="Times New Roman Bold" SIZE=3><P>Alpharma Pharmaceuticals Inc.</B> </P>
</FONT><FONT SIZE=3><DIR>
<DIR>
<DIR>
<DIR>

<P>By: <U>&#9;/s/ Einar Thorstensen_________</P>
</U><P>Einar Thorstensen</P></DIR>
</DIR>
</DIR>
</DIR>

<P>Title: <U>President&#9;&#9;&#9;&#9;<BR>
</U>Address: <U>One Executive Drive&#9;&#9;<BR>
&#9;  Fort Lee, NJ  07024_________<BR>
</U>Attention: <U>Chief Legal Officer&#9;&#9;<BR>
</U>Telecopier No.: <U> (201) 592-1481&#9;&#9;<BR>
</P>
</U></FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;</P>
<P>ATTEST:</P>

<P>__/s/ Robert F. Wrobel ______________</P>
<P>Robert F. Wrobel</P>
<P>Secretary</P>
</FONT></TD>
<TD WIDTH="52%" VALIGN="TOP">
<B><FONT FACE="Times New Roman Bold" SIZE=3><P>Purepac Pharmaceutical Holdings, Inc.</B> </P>
</FONT><FONT SIZE=3>
<P>By: <U>___/s/ Frederick J. Lynch_________</P><DIR>
<DIR>
<DIR>
<DIR>

</U><P>Frederick J. Lynch</P></DIR>
</DIR>
</DIR>
</DIR>

<P>Title: <U>President &amp; Chief Executive Officer</P>
</U><P>Address: <U>One Executive Drive&#9;&#9;</P>
<P>&#9;Fort Lee, NJ  07024</U>_________</P>
<P>Attention: <U>Chief Legal Officer&#9;&#9;</P>
</U><P>Telecopier No.: <U> (201) 592-1481&#9;&#9;</P>

<P>&nbsp;</U></FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P>&nbsp;</P>
<P>ATTEST:</P>

<P>__/s/ Robert F. Wrobel ______________</P>
<P>Robert F. Wrobel</P>
<P>Secretary</P>
</FONT></TD>
<TD WIDTH="52%" VALIGN="TOP">
<B><FONT FACE="Times New Roman Bold" SIZE=3><P>Alpharma Branded Products Division Inc.</B> </P>
</FONT><FONT SIZE=3>
<P>By: <U>&#9;/s/ Ronald Warner&#9;&#9;</P><DIR>
<DIR>
<DIR>
<DIR>

</U><P>Ronald Warner</P></DIR>
</DIR>
</DIR>
</DIR>

<P>Title: <U>President &amp; Chief Executive Officer</P>
</U><P>Address: <U>One Executive Drive&#9;&#9;</P>
<P>&#9;  Fort Lee, NJ  07024</U>_________</P>
<P>Attention: <U>Chief Legal Officer&#9;&#9;</P>
</U><P>Telecopier No.: <U> (201) 592-1481&#9;&#9;</P>

<P>&nbsp;</U></FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P>ATTEST:</P>

<P>___/s/ Robert F. Wrobel _____________</P>
<P>Robert F. Wrobel</P>
<P>Secretary</P>
</FONT></TD>
<TD WIDTH="52%" VALIGN="TOP">
<B><FONT FACE="Times New Roman Bold" SIZE=3><P>Purepac Pharmaceutical Co.</B> </P>
</FONT><FONT SIZE=3>
<P>By: <U>&#9;/s/ Frederick J. Lynch&#9;&#9;</P><DIR>
<DIR>
<DIR>
<DIR>

</U><P>Frederick J. Lynch</P></DIR>
</DIR>
</DIR>
</DIR>

<P>Title: <U>President &amp; Chief Executive Officer</P>
</U><P>Address: <U>One Executive Drive&#9;&#9;</P>
<P>&#9;</U>  <U>Fort Lee, NJ  07024</U>_________</P>
<P>Attention: <U>Chief Legal Officer&#9;&#9;</P>
</U><P>Telecopier No.: <U> (201) 592-1481&#9;&#9;</P>

<P>&nbsp;</U></FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P>&nbsp;</P>
<P>&nbsp;</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=634>
<TR><TD WIDTH="48%" VALIGN="TOP">
<FONT SIZE=3><P>ATTEST:</P>

<P>_/s/ Robert F. Wrobel_______________</P>
<P>Robert F. Wrobel </P>
<P>Secretary</P>
</FONT></TD>
<TD WIDTH="52%" VALIGN="TOP">
<B><FONT FACE="Times New Roman Bold" SIZE=3><P>Alpharma Investment Inc.</P>
</B></FONT><FONT SIZE=3>
<P>By: <U>&#9;/s/ Matthew T. Farrell&#9;&#9;</P><DIR>
<DIR>
<DIR>
<DIR>

</U><P>Matthew T. Farrell&#9;</P></DIR>
</DIR>
</DIR>
</DIR>

<P>Title: <U>President &amp; Chief Executive Officer</P>
</U><P>Address: <U>One Executive Drive&#9;&#9;</P>
<P>&#9;  Fort Lee, NJ  07024</U>_________</P>
<P>Attention: <U>Chief Legal Officer&#9;&#9;</P>
</U><P>Telecopier No.: <U> (201) 592-1481&#9;&#9;</P>

<P>&nbsp;</U></FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P>&nbsp;</P>
<P>&nbsp;</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=638>
<TR><TD WIDTH="48%" VALIGN="TOP"><DIR>

<FONT SIZE=3><P>Revolver Commitment: $175,000,000.00</P>
<P>Term Loan Commitment: $35,000,000.00</P>
<B><I></DIR>
</B></I></FONT></TD>
<TD WIDTH="52%" VALIGN="TOP">
<B><FONT SIZE=3><P>LENDER</B>:</P>
<B><P>BANK OF AMERICA, N.A.</B>, as a Lender and Issuing Bank</P>
<P>By: <U>&#9;/s/ John M. Olsen&#9;&#9;</P>
</U><P>Title: <U>&#9;Vice President&#9;&#9;&#9;</P>
</U><P>LIBOR Lending Office:</P>
<P>Address:</P>
<P>Suite 800, 300 Galleria Parkway, N.W.</P>
<P>Atlanta, Georgia  30339</P>
<P>Attention:  Office Head</P>
<P>Telecopier No.:  (770) 859-2483</P>
</FONT></TD>
</TR>
<TR><TD WIDTH="48%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="52%" VALIGN="TOP">
<B><FONT SIZE=3><P>AGENT</B>:</P>
<B><P>BANK OF AMERICA, N.A.</B>,</P>
<P>As Agent</P>
<P>By: <U>&#9;/s/ John M. Olsen&#9;&#9;</P>
</U><P>Title: <U>&#9;Vice President&#9;&#9;&#9;</P>
</U><P>Address:</P>
<P>Suite 800, 300 Galleria Parkway, N.W.</P>
<P>Atlanta, Georgia  30339</P>
<P>Attention:  Office Head</P>
<P>Telecopier No.:  (770) 859-2483</P>
</FONT></TD>
</TR>
</TABLE>

<FONT SIZE=3><P ALIGN="CENTER">&nbsp;</P></FONT></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>exh10_4.htm
<DESCRIPTION>PROMISSORY NOTE
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>Promissory Note</TITLE>
<META NAME="subject" CONTENT="s t a n d a r d">
<META NAME="keywords" CONTENT="s t a n d a r d">
<META NAME="Template" CONTENT="P:\maler\juridisk\promnote.dot">
</HEAD>
<BODY>

<FONT FACE="Arial" SIZE=1><P><A NAME="promnote"></P>
</FONT><FONT FACE="Arial" SIZE=4><P>COPY</FONT><FONT FACE="Arial" SIZE=1>&#9;&#9;&#9;</P>
</FONT><FONT FACE="Arial" SIZE=2>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<B><P ALIGN="CENTER">P R O M I S S O R Y   N O T E</P>
</B>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>For value received we Alpharma AS of Harbitzall&eacute;en 3, 0212 Oslo, Norway promise to pay against this Promissory Note on 28 March 2006 to DnB NOR Bank ASA or order the sum of EUR&nbsp;30,000,000 plus interest at 1.00 % p.a. above EURIBOR for the period from 28 December 2005 until 28 March 2006. Effective payment to be made in EUR only, without deduction for and free of any tax, impost, levy or duty present or future of any nature under the laws of Norway.</P>

<P>This Promissory Note is payable at DnB NOR Bank ASA, Stranden 21, 0021 Oslo, Norway. </P>

<P>All requirements as to diligence, presentment, demand of payment, protest and notice of any kind with respect to this Promissory Note are hereby waived. We hereby accept enforcement of any outstanding amount under this Promissory Note, including interest and collection costs, without legal proceedings pursuant to Section 7-2 (a) of the Norwegian Enforcement Act.</P>

<P>This Promissory Note shall be governed by Norwegian law.</P>

<P>&nbsp;</P>
<P>&nbsp;</P>
<P>12/28/05</P>
<P>.................................................................................</P>
<P>Place, date</P>

<P>&nbsp;</P>
<P>ALPHARMA AS</P>

<P>/s/ Carl-Aake Carlsson</P>
<P>.................................................................................</P>

<P></A></P></FONT></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12A
<SEQUENCE>4
<FILENAME>exh10_12a.htm
<DESCRIPTION>RETENTION AGREEMENT
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>[FORM OF LETTER SUGGESTED FOR ALPHARMA EXECUTIVES SUPPORTING THE GX TRANSACTION]</TITLE>
<META NAME="DOCID" CONTENT="090305-0002-08620-NY02.2478921.7">
</HEAD>
<BODY LINK="#0000ff" VLINK="#800080">

<P ALIGN="RIGHT">December 5, 2005</P>

<P>&nbsp;</P>
<P>&nbsp;</P>
<P>Mr. Carl-Aake Carlsson<BR>
Batstojordet 93<BR>
N-1363 Hovik, Norway<BR>
</P>
<P>Dear Carl-Aake:</P>
<P>Alpharma AS, (the "Company") recognizes you as a valuable member of the team charged with responsibility for managing the API Business (which consists of the Active Pharmaceutical Ingredient business segment reported by Alpharma Inc. ("Alpharma") under the Securities Act of 1934, hereafter called "Active Pharmaceutical Ingredients Business").  As you know, Alpharma has announced that it is exploring its strategic alternatives.  In order to incentivize you to remain with the Company while this process occurs, and to protect you in the event your employment is terminated in connection with a transaction that results from this process, the Company is providing you with the retention and severance benefits set forth in this letter agreement (this "Agreement").</P>
<P>This Agreement will remain in effect until the third anniversary of the date hereof, and thereafter will remain in effect for a series of one-year periods unless either party shall give to the other written notice of expiration of this Agreement at least one year in advance of a subsequent renewal date.  In any event this Agreement, if it has not expired when a "Qualifying Transaction," as defined below, occurs, shall remain in effect for two years after a Qualifying Transaction.</P>
<B><P>Retention Benefits </P>
</B><P>&#9;<U>Retention Payment</U>.</P>
<P>The Company hereby grants you a series of "Retention Payments", payable in the following amounts and on the following dates:</P><DIR>
<DIR>

<P>&#9;1/3 of your Base Salary (as defined below) and target annual bonus opportunity as of the date of this Agreement (your "Annual Compensation"), payable on June 30, 2006</P></DIR>
</DIR>

<P>&#9;1/3 of your Annual Compensation on December&nbsp;29, 2006</P>
<P>&#9;1/3 of your Annual Compensation on June 29, 2007;</P>
<P>provided that you are an active employee of the Company on the applicable payment date.</P>
<P>However, all unpaid amounts under this paragraph will be accelerated and paid within ten (10) business days upon the first to occur of (x)&nbsp;your termination of employment as a result of death or termination by the Company for other than Cause (as defined below) or due to a disability that would qualify you for coverage under the applicable long-term disability plan that covers employees of the Company ("Disability"), (y)&nbsp;six months after a sale or other transfer of all or substantially all of the assets and business of Active Pharmaceutical Ingredients Business (a "Sale of Active Pharmaceutical Ingredients Business") that occurs while you are an active employee of the Company or (z)&nbsp;a "Change in Control" of Alpharma under Alpharma's Change in Control Plan that occurs while you are an active employee of the Company.  "Base Salary" shall mean your base salary at the applicable time (which shall include your executive allowance as indicated on the Company's payroll records).</P>
<P>&#9;<U>Performance Units</U>.</P>
<P>In the event of the sale or other transfer of all or substantially all of the assets and business of Global Generics to any person, entity or group unaffiliated with Alpharma on or before March 31, 2006 in a transaction that does not result in a "Change in Control" of Alpharma under Alpharma's Change in Control Plan (a "Sale of Global Generics"), the Performance Units that you have previously been granted under Alpharma's 2003 Omnibus Incentive Compensation Plan will be treated as follows:  each Performance Unit will be converted into the right to receive cash incentive payments from the Company if you are an active employee of the Company on both (x)&nbsp;the date of the Sale of Global Generics and (y)&nbsp;the scheduled vesting date for such cash incentive payments, as described below.  </P>
<P>Payment of this cash incentive payment will be made at the "target" level of $100.00 per Unit, but will be pro-rated based on the number of days you were employed by Alpharma and its affiliates prior to the applicable vesting date, but during the "Performance Period" applicable to such Unit compared to the total number of days in the Performance Period.  The vesting date will be the first to occur of (w)&nbsp;your employment being terminated as a result of death or Disability or by the Company for other than Cause, (x)&nbsp;a Sale of Active Pharmaceutical Ingredients Business while you are an active employee of the Company, (y) the end of the applicable Performance Period, provided you are then an active employee of the Company or (z)&nbsp;a "Change in Control" of Alpharma under Alpharma's Change in Control Plan while you are an active employee of the Company; provided that only a pro rata share of the full value of the Performance Units will be payable based on the number of days that have elapsed during
 the applicable Performance Periods as of the vesting date.  Payment of the cash incentive payment shall occur ten (10) business days after the vesting date.</P>
<B><P>Additional Benefits Upon a Sale of Active Pharmaceutical Ingredients Business or Change in Control</P>
</B><P>If either (x) a Sale of Active Pharmaceutical Ingredients Business or (y)&nbsp;a "Change in Control" of Alpharma under Alpharma's Change in Control Plan occurs while both you are an active employee of the Company and the Company is a subsidiary of Alpharma (a "Qualifying Transaction"), you will be entitled to the benefits described below in lieu of the benefits set forth in Alpharma's Severance or Change in Control Plans or any employment letter or agreement, or any other plan or arrangement, in existence prior to the date of this Agreement.</P>
<U><P>Treatment of Cash Bonuses and Equity Awards</U>.</P>
<OL TYPE="A">
<OL TYPE="A">

<U><LI>Annual Bonus</U>.</LI>
<P>If a Qualifying Transaction occurs while you are an active employee of the Company, your annual cash bonus for the calendar year of such Qualifying Transaction will be treated as follows:</P><OL TYPE="i">
<OL TYPE="A">

<OL>

<LI>if the Qualifying Transaction is either (x)&nbsp;a Sale of Active Pharmaceutical Ingredients Business that occurs on or prior to June 30 of any calendar year or (y)&nbsp;a "Change in Control" of Alpharma under Alpharma's Change in Control Plan, the Company will pay you a pro-rata bonus based on your target annual bonus opportunity, as in existence immediately prior to the Qualifying Transaction, under the Executive Bonus Plan based on the portion of such calendar year that occurred prior to the Qualifying Transaction, payable ten (10) business days after the applicable Qualifying Transaction; or</LI>
<LI>if the Qualifying Transaction is a Sale of Active Pharmaceutical Ingredients Business that occurs after June 30 of any calendar year, the Company will pay you a pro-rata bonus for that year based on actual performance in accordance with the terms of the Executive Bonus Plan based on the portion of such calendar year that occurred prior to the Qualifying Transaction, payable between January 1 and March&nbsp;15 of the following calendar year.</LI></OL>
</OL>
</OL>

<U><LI>Equity Awards</U>.</LI></OL>
</OL>

<P>In addition, if a Qualifying Transaction occurs while you are an active employee of the Company, then any Stock Options, Restricted Stock or Restricted Stock Units of Alpharma issued to you prior to the date of such Qualifying Transaction under either the 1997 Incentive Stock Option and Appreciation Rights Plan or the 2003 Omnibus Incentive Compensation Plan (or any successor plans) shall immediately vest (but otherwise be governed by the terms of such applicable grant document and Incentive Plan); provided that, if such Qualifying Transaction is a "Change in Control" of Alpharma under Alpharma's Change in Control Plan, then any such vesting with respect to Restricted Stock or Restricted Stock Units shall instead occur upon the earliest of (i) the vesting date set forth in the applicable grant document, (ii) the termination of your employment with the Company or the entity that acquires the Company (the "Acquiring Company") prior to the second anniversary of the Qualifying Transaction either by your emplo
yer without Cause or by you pursuant to a Constructive Termination of employment, as further described below, and (iii)&nbsp;the purchase or other acquisition by the Acquiring Company of all or substantially all of the issued and outstanding Class&nbsp;A and Class&nbsp;B common stock of Alpharma.  Notwithstanding the foregoing, no delivery with respect to Restricted Stock Units shall occur until the first day on which such delivery can occur without your incurring tax under Section 409A of the Internal Revenue Code of 1986, as amended (the "Code"). </P>
<U><P>Special Severance Arrangement</U>.</P>
<P>Should a Qualifying Transaction occur while you are an active employee of the Company and your employment with the Company or the Acquiring Company be terminated on or after the Qualifying Transaction, but on or prior to the second anniversary of the Qualifying Transaction (either by your employer without Cause or pursuant to a Constructive Termination of employment, as further described below), you shall receive from the Company the severance benefits and payments set forth in Appendix A of this Agreement.  </P>
<P>For purposes of this Agreement, a Constructive Termination means your voluntary termination following (i) any reduction in your Base Salary or in your target annual bonus opportunity, as in existence immediately prior to the Qualifying Transaction, (ii) your relocation to a base office or site that is more than 50 miles from the location of your present base office or site, (iii) any material reduction in your health, welfare and pension benefits in the aggregate or (iv) the assignment of duties substantially inconsistent with, or a substantial diminution of, the duties, responsibilities or status of your position with the Company immediately prior to the Qualifying Transaction; provided that, if you are eligible to voluntarily terminate employment pursuant to a Constructive Termination of employment within the first six months after the date of the Qualifying Transaction, the Company or the Acquiring Company may request that you continue as a full time employee to assist with transition and other activit
ies reasonably appropriate to your position, your background and history with the Company with no reduction in Base Salary, target annual bonus opportunity or benefits, and no relocation, as described above in the definition of "Constructive Termination" until six months after the Qualifying Transaction and any benefits and payments required under this paragraph (and, in the case of a Qualifying Transaction that is a Sale of Active Pharmaceutical Ingredients Business, any unpaid Retention Payments) shall be payable only upon your completion of such service, or your death or termination due to Disability.  In any of the foregoing events, in order to qualify as a Constructive Termination of employment, you must have provided written notice to your employer of the circumstances that entitle you to terminate due to a Constructive Termination, and the employer must be afforded 30 days in which to cure such circumstances before you can resign due to a Constructive Termination.  </P>
<P>For purposes of this Agreement, a termination for "Cause" shall mean your termination by the Company or the Acquiring Company due to (a) conviction of a felony, or (b) substantial and willful neglect of job duties or willful misconduct, in either case having a material and demonstrable effect on the Company or the Acquiring Company.</P>
<U><P>Gross-Up</U>.</P>
<P>You will be entitled to, and subject to, the "gross-up" provisions set forth in Appendix B of this Agreement. </P>
<U><P>Non-Competition and Non-Solicitation Obligations</U>.</P>
<P>The payments and benefits provided for hereunder are conditional on your agreement not to engage in competition with, or to solicit employees of, the Company and its affiliates, as further provided in Appendix B of this Agreement.   </P>
<U><P>No Mitigation</U>.</P>
<P>Unless expressly provided in this Agreement, the Company agrees that any income or other employment benefits received by you from any and all sources other than the Company, the Acquiring Company and their respective affiliates for any reason whatsoever shall in no way reduce or otherwise affect the Company's obligations to make payments and afford benefits under this Agreement.</P>
<U><P>Miscellaneous</U>.</P>
<P>This Agreement shall be governed by and construed in accordance with the laws of the State of New Jersey (regardless of the laws that might otherwise govern under applicable New Jersey principles of conflicts of law).</P>
<P>Except as specifically set forth in this Agreement, no other benefits shall be provided to you upon or after the occurrence of a Qualifying Transaction, including benefits set forth in Alpharma's Severance or Change in Control Plans or any employment letter or agreement, or other plan or arrangement, in existence prior to the date of this Agreement, and no amounts payable pursuant to this Agreement shall be taken into account for purposes of any benefit plan maintained by the Company or any affiliate of the Company.</P>
<P>Payments to you by the Company and its affiliates shall be subject to all applicable legal requirements with respect to withholding of taxes.</P>
<P>This Agreement shall be binding upon, and inure to the benefit of, the parties hereto, any successors to or assigns of the Company and your heirs and the personal representatives of your estate.  If the Company or the Acquiring Company consolidates with or merges into or sells all or substantially all of its assets to, another corporation, partnership or other entity or person, the Company (or the Acquiring Company, as the case may be) shall require such corporation, partnership or other entity or person to assume this Agreement, and upon such assumption, the successor corporation, partnership or other entity or person shall become obligated to perform all of the terms and conditions set forth herein.</P>
<P>This Agreement may not be modified, amended or waived in any manner except by an instrument in writing signed by the parties hereto.  The waiver by either party of compliance with any provision in this Agreement by the other party shall not operate or be construed to operate as a waiver of any provision of this Agreement, or any subsequent breach by such party of any provision of this Agreement.</P>
<P>This Agreement is not an offer or promise of continuing employment by the Company.  In addition, the Company shall have no responsibility or liability for your employment by an Acquiring Company other than with respect to payments due pursuant to the terms of this Agreement.</P>
<P>We ask that you acknowledge that, by countersigning this Agreement, you are agreeing to maintain a strict level of confidence regarding all information disclosed, developed or learned by you in the performance of your duties with the Company, including any facts, circumstances or discussions that could lead to a Qualifying Transaction ("Confidential Information").  By countersigning this Agreement, you agree that, unless you first secure the written consent of the Chief Executive Officer of Alpharma, you shall not disclose or use at any time, either during or after employment by the Company, any Confidential Information except to the extent that you are required to disclose or use such Confidential Information by law or in the performance of your assigned duties for the Company.  This obligation is in addition to the confidentiality agreement that you have previously executed as an employee of the Company, the general obligation of confidentiality existing under the law and the Non-Competition and Non-Sol
icitation obligations included herewith as Appendix B.</P>
<P>Notwithstanding anything in this Agreement to the contrary, any payments hereunder that would be subject to the additional income tax imposed by Section 409A of the Code shall be deferred until the earliest date that such payments may be made without the imposition of such tax, and any payments that would have been made to you but for this sentence shall be accumulated (without interest) and paid to you on such date.</P>
<P>We believe that the Incentive Payment and other potential payments and benefits set forth above clearly reflect your value to this organization and provide you with enhanced financial benefits in connection with the potential Qualifying Transaction.</P>
<P>Please indicate your acknowledgement of this Agreement, and your acceptance of its terms, by countersigning this Agreement where indicated below and returning one copy to the Company.</P>
<P>Sincerely,</P>
<P>ALPHARMA AS</P>

<P>By:<U>&#9;&#9;&#9;&#9;&#9;&#9;</P>
</U><B><P>I, acknowledge and agree to the terms and conditions of this Agreement, and I intend to be legally bound hereby.</P>
</B><P ALIGN="JUSTIFY">_________________________<BR>
</P>
<P>Dated: ______, 2005</P>
<P><BR>
<FONT FACE="Frutiger 45 Light" SIZE=3>Signature</FONT><BR>
</P>
<U><P ALIGN="CENTER">Appendix A</P>
<P>Special Severance Arrangement</P>
</U><P>The benefits and payments set forth in this Appendix A are as follows:</P>
<OL>

<OL>

<U><LI>Cash Severance</U> - Two (2) times the sum of (a) your Base Salary plus (b) your target annual bonus opportunity, in both cases as in effect immediately prior to a Qualifying Transaction; payable in equal installments over 24 months, on the first day of each calendar month, commencing on the first day of the calendar month after termination of employment, or, if later, the first day on which such payments can commence without your incurring tax under Section 409A of the Code, with a full catch-up of all amounts that, but for the delay due to application of the preceding clause relating to Section 409A of the Code, would have been paid to you under this paragraph prior to the first day of payment hereunder.</LI>
<U><LI>Medical, Dental and/or Life Insurance Coverage</U> - Continued coverage under the medical, dental, accidental death and dismemberment and life insurance benefits (including medical and dental coverage for your covered dependents, if any), as if you had remained an active employee of the Company, for a period of 24 months after termination of employment, at the same cost to you as is applicable to other active employees during such period.  In the event you are ineligible under the terms of one or more of such plans to continue to be so covered, the Company shall provide you with substantially equivalent coverage through other sources.</LI>
<U><LI>Outplacement</U> - Outplacement support in accordance with Alpharma's outplacement policies in effect on the date of this Agreement.</LI>
<U><LI>Employee Benefits</U> - Without duplication of the above, any benefits to which you are entitled under the terms of any Company pension or welfare benefit plan or program, other than any severance plan.</LI></OL>

<U><P ALIGN="CENTER">Appendix B</P>
</U><P>1.&#9;<U>Non-Competition; Non-Solicitation; Non-Interference</U><B> </P>
</B><P>For the benefit of Alpharma and the Company and their respective subsidiaries and affiliates (the "Protected Parties"), you hereby agree as follows: </P><OL TYPE="A">

<OL TYPE="i">

<U><LI>Non-Competition</U>.   During the 12-month period after the Qualifying Transaction, you will not, directly or indirectly:</LI>
<OL TYPE="A">

<LI>engage in any business that competes with any business that Alpharma or its affiliates or subsidiaries was conducting immediately prior to the date of the Qualifying Transaction (the "<U>Relevant Date</U>"), including, without limitation, Active Pharmaceutical Ingredients Business and any businesses that Alpharma or its affiliates or subsidiaries is actively considering conducting on the Relevant Date, so long as you know or reasonably should have known about such plan(s) in any geographical area that is within 100 miles of any geographical area where Alpharma or its affiliates or subsidiaries provides its products or services as of the Relevant Date (a "<U>Competitive Business</U>");</LI>
<LI>enter the employ of, or render any services to, any person or legal entity (or any division or controlled or controlling affiliate of any person or legal entity) who or which is a Competitive Business as of the date you enter such employment or render such services; or</LI>
<LI>acquire a financial interest in, or otherwise become actively involved with, any Competitive Business which is a Competitive Business as of the date of such acquisition or involvement, directly or indirectly, as an individual, partner, shareholder, officer, director, principal, agent, trustee or consultant.</LI></OL>

<P>The foregoing shall not prohibit you from (1) investing, as a passive investor, in any publicly held company provided that your beneficial ownership of any class of such publicly held company's securities does not exceed two percent (2%) of the outstanding securities of such class or (2) providing services to a subsidiary or affiliate of an entity that controls a separate subsidiary or affiliate that is a Competitive Business, so long as the subsidiary or affiliate for which you may be providing services is not itself a Competitive Business and you are not, as an employee of such subsidiary or affiliate, engaging in activities that would otherwise cause such subsidiary or affiliate to be deemed a Competitive Business.  </P>
<U><LI>Non-Interference with Business Relationships</U>.  During the 24-month period after the Qualifying Transaction (such period, the "<U>Restricted Period</U>"), you will not interfere with, or attempt to interfere with, business relationships (whether formed before, on or after the date of this Agreement) between any Protected Party and its customers, suppliers or partners, in any such case determined as of the Relevant Date.</LI>
<P>The provisions of subsections (i) and (ii) may be waived in writing in whole or in part by the Chief Executive Officer of Alpharma (after consulting with the Compensation Committee of Alpharma's Board of Directors).</P>
<U><LI>Non-Solicitation of Employees; Non-Solicitation of Consultants</U>.   During the Restricted Period, you will not, whether on your own behalf or on behalf of or in conjunction with any person or entity, directly or indirectly:</LI>
<OL TYPE="A">

<LI>solicit or encourage any employee of Alpharma or its affiliates or subsidiaries to leave the employment of Alpharma or its affiliates or subsidiaries; or</LI>
<LI>hire any such employee who was employed by Alpharma or its affiliates or subsidiaries as of the Relevant Date or who left the employment of Alpharma or its affiliates or subsidiaries coincident with, or within one year prior to or after, the Relevant Date; or</LI>
<LI>solicit or encourage to cease to work with Alpharma or its affiliates or subsidiaries any consultant that you know, or reasonably should have known, is then under contract with Alpharma or its affiliates or subsidiaries.</LI></OL>

<U><LI>Enforcement</U>.   It is expressly understood and agreed that although the Company, Alpharma and you consider the restrictions contained in this Appendix B to be reasonable, if a final judicial determination is made by a court of competent jurisdiction that the time or territory or any other restriction contained in this Appendix&nbsp;B is an unenforceable restriction against you, the provisions of this Appendix&nbsp;B shall not be rendered void but shall be deemed amended to apply as to such maximum time and territory and to such maximum extent as such court may judicially determine or indicate to be enforceable (provided that in no event shall any such amendment broaden the time period or scope of any restriction herein).  Alternatively, if any court of competent jurisdiction finds that any restriction contained in this Appendix&nbsp;B is unenforceable, and such restriction cannot be amended so as to make it enforceable, such finding shall not affect the enforceability of any of the other restrictio
ns contained herein.</LI></OL>
</OL>
</OL>

<P>2.&#9;<U>Parachute Tax Gross-Up</P>
</U><P>(i)&#9;If (a)&nbsp;it shall be determined that any payment, benefit or distribution (or combination thereof) by the Company, the Acquiring Company or any of their respective affiliates, or one or more trusts established by the Company for the benefit of its employees, to or for your benefit (whether paid or payable or distributed or distributable pursuant to the terms of this Agreement, or otherwise) (a "<U>Payment</U>") is subject to the excise tax imposed by Section 4999 of the Code or any interest or penalties are incurred by you with respect to such excise tax (such excise tax, together with any such interest and penalties, hereinafter collectively referred to as the "<U>Excise Tax</U>") and (b)&nbsp;such Excise Tax would be equal to $50,000 or less, then such Payments shall be reduced to the extent necessary so that the Payment is equal to 2.99 times your "base amount" (as defined in Section&nbsp;280G(b)(3) of the Code).  If (x)&nbsp;it shall be determined that any Payment is subject to Excise Ta
x and (y)&nbsp;such Excise Tax would be greater than $50,000, then you shall be entitled to receive from the Company an additional payment (a "<U>Gross-Up Payment</U>") in an amount such that after payment by you of all taxes (including any interest or penalties imposed with respect to such taxes), including, without limitation, any income taxes (and any interest and penalties imposed with respect thereto) and the Excise Tax imposed upon the Gross-Up Payment, you retain an amount of the Gross-Up Payment equal to the Excise Tax imposed upon the Payments.</P>
<P>(ii)&#9;All determinations required to be made under this Paragraph&nbsp;2, including whether and when a Gross-Up Payment is required and the amount of such Gross-Up Payment and the assumptions to be utilized in arriving at such determination, shall be made by BDO Seidman, LLP or such other nationally recognized certified public accounting firm as may be designated by the Company (the "<U>Accounting Firm</U>") which shall provide detailed supporting calculations both to the Company and you within ten business days of the receipt of notice from you that there has been a Payment, or such earlier time as is requested by the Company; <U>provided</U> that for purposes of determining the amount of any Gross-Up Payment, you shall be deemed to pay federal income tax at the highest marginal rates applicable to individuals in the calendar year in which any such Gross-Up Payment is to be made and deemed to pay state and local income taxes at the highest effective rates applicable to individuals in the state or local
ity of your residence or place of employment in the calendar year in which any such Gross-Up Payment is to be made, net of the maximum reduction in federal income taxes that can be obtained from deduction of such state and local taxes, taking into account limitations applicable to individuals subject to federal income tax at the highest marginal rates.  All fees and expenses of the Accounting Firm shall be borne solely by the Company.  Any Gross-Up Payment, as determined pursuant to this Paragraph&nbsp;2, shall be paid by the Company to you (or to the appropriate taxing authority on your behalf) when due.  If the Accounting Firm determines that no Excise Tax is payable by you, it shall so indicate to you in writing.  Any determination by the Accounting Firm shall be binding upon the Company and you.  As a result of the uncertainty in the application of Section&nbsp;4999 of the Code, it is possible that the amount of the Gross-Up Payment determined by the Accounting Firm to be due to (or on behalf of) you was
 lower than the amount actually due ("<U>Underpayment</U>").  In the event that the Company exhausts its remedies pursuant to Paragraph&nbsp;2(iii) and you thereafter are required to make a payment of any Excise Tax, the Accounting Firm shall determine the amount of the Underpayment that has occurred and any such Underpayment shall be promptly paid by the Company to or for the benefit of you.</P>
<P>(iii)&#9;You shall notify the Company in writing of any claim by the Internal Revenue Service that, if successful, would require the payment by the Company of any Gross-Up Payment.  Such notification shall be given as soon as practicable but no later than ten business days after you are is informed in writing of such claim and shall apprise the Company of the nature of such claim and the date on which such claim is requested to be paid.  You shall not pay such claim prior to the expiration of the thirty day period following the date on which you give such notice to the Company (or such shorter period ending on the date that any payment of taxes with respect to such claim is due).  If the Company notifies you in writing prior to the expiration of such period that it desires to contest such claim, you shall (i) give the Company any information reasonably requested by the Company relating to such claim, (ii) take such action in connection with contesting such claim as the Company shall reasonably request in 
writing from time to time, including, without limitation, accepting legal representation with respect to such claim by an attorney reasonably selected by the Company, (iii) cooperate with the Company in good faith in order to effectively contest such claim and (iv) permit the Company to participate in any proceedings relating to such claim; <U>provided</U>, <U>however</U>, that the Company shall bear and pay directly all costs and expenses (including additional interest and penalties) incurred in connection with such contest and shall indemnify and hold you harmless, on an after-tax basis, for any Excise Tax or income tax (including interest and penalties with respect thereto) imposed as a result of such representation and payment of costs and expenses.  Without limitation on the foregoing provisions of this Paragraph&nbsp;2(iii), the Company shall control all proceedings taken in connection with such contest and, at its sole option, may pursue or forego any and all administrative appeals, proceedings, heari
ngs and conferences with the taxing authority in respect of such claim and may, at its sole option, either direct you to pay the tax claimed and sue for a refund or contest the claim in any permissible manner, and you agrees to prosecute such contest to a determination before any administrative tribunal, in a court of initial jurisdiction and in one or more appellate courts, as the Company shall determine; <U>provided</U>, <U>further</U>, that if the Company directs you to pay such claim and sue for a refund, the Company shall advance the amount of such payment to you, on an interest-free basis, and shall indemnify and hold you harmless, on an after-tax basis, from any Excise Tax or income tax (including interest or penalties with respect thereto) imposed with respect to such advance or with respect to any imputed income with respect to such advance; <U>provided</U>, <U>further</U>, that if you are required to extend the statute of limitations to enable the Company to contest such claim, you may limit this e
xtension solely to such contested amount.  The Company's control of the contest shall be limited to issues with respect to which a Gross-Up Payment would be payable hereunder and you shall be entitled to settle or contest, as the case may be, any other issue raised by the Internal Revenue Service or any other taxing authority.</P>
<P>(iv)&#9;If, after the receipt by you of an amount paid or advanced by the Company pursuant to this Paragraph&nbsp;2, you become entitled to receive any refund with respect to a Gross-Up Payment, you shall (subject to the Company's complying with the requirements of Paragraph&nbsp;2(iii)) promptly pay to the Company the amount of such refund received (together with any interest paid or credited thereon after taxes applicable thereto).  If, after the receipt by you of an amount advanced by the Company pursuant to Paragraph&nbsp;2(iii), a determination is made that you shall not be entitled to any refund with respect to such claim and the Company does not notify you in writing of its intent to contest such denial of refund prior to the expiration of thirty days after such determination, then such advance shall be forgiven and shall not be required to be repaid and the amount of such advance shall offset, to the extent thereof, the amount of the Gross-Up Payment required to be paid.</P></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>5
<FILENAME>exh10_31.htm
<DESCRIPTION>TOLL MANUFACTURING AGREEMENT
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>Blank document-landscape</TITLE>
<META NAME="Cus_DocIDValue" CONTENT="K&amp;E 11025697.2">
<META NAME="Template" CONTENT="C:\PROGRAM FILES\MICROSOFT OFFICE\TEMPLATES\TLTEMPLATES\MAIN\Blank Portrait.dot">
</HEAD>
<BODY LINK="#0000ff" VLINK="#800080">

<B><P ALIGN="CENTER">TOLL MANUFACTURING AGREEMENT</P>
</B><P ALIGN="JUSTIFY">THIS TOLL MANUFACTURING AGREEMENT (the "<U>Agreement</U>") is made on 19<SUP>th</SUP> of December, 2005 ("<U>Effective Date</U>") between ALPHARMA BRANDED PRODUCTS DIVISION INC., a Delaware corporation ("<U>Alpharma</U>"), and PUREPAC PHARMACEUTICAL CO., a Delaware corporation ("<U>Purepac</U>").  Alpharma and Purepac are each individually a "<U>Party</U>" and are collectively the "<U>Parties</U>".</P>
<P ALIGN="JUSTIFY">WHEREAS, Alpharma will grant Purepac a non-exclusive, royalty free license to use Alpharma's Intellectual Property to allow Purepac to manufacture Kadian for Alpharma;</P>
<P ALIGN="JUSTIFY">WHEREAS, Purepac desires to manufacture and supply Alpharma with certain of Alpharma's requirements of such product; and</P>
<P ALIGN="JUSTIFY">WHEREAS, the Parties are willing to carry out the foregoing pursuant to the terms and conditions set forth in this Agreement.</P>
<P ALIGN="JUSTIFY">NOW, THEREFORE, in consideration of the mutual covenants herein contained, and the payments to be made by Alpharma to Purepac, all as hereinafter set forth, Alpharma and Purepac agree as follows:</P>
<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitions</P>
</B></FONT><P ALIGN="JUSTIFY">In this Agreement the following terms shall have the respective meanings set forth below:</P>
<P ALIGN="JUSTIFY">"<U>4 Wall Costs</U>" shall mean $**** per blended cost per one thousand (1000) capsules.</P>
<P ALIGN="JUSTIFY">"<U>Affiliate</U>" shall mean a legal entity controlling, controlled by or under common control with the Party in question.  "Control" means having the right to direct the operation of the business by equity participation and/or contract.</P>
<P ALIGN="JUSTIFY">"<U>API</U>" shall mean morphine sulphate meeting the requirements of the Specifications.</P>
<P ALIGN="JUSTIFY">"<U>Calendar Year</U>" shall mean one calendar year, starting January 1 of each year.</P>
<P ALIGN="JUSTIFY">"<U>Certificate of Conformity</U>" shall mean a document which confirms that the Product conforms with cGMP and other Regulatory Documents.</P>
<P ALIGN="JUSTIFY">"<U>cGMP</U>" shall mean the interpretations and industry practices used in connection with 21 CFR ICH Q7 A by the FDA from time to time.</P>
<P ALIGN="JUSTIFY">"<U>Confidential Information</U>" shall mean any information and data concerning the Product or any Derivative, including any technical or commercial information, which may come within the knowledge of either Party in connection with its performance under this Agreement, whether orally or in writing, whether learned prior to, on, or after the Effective Date, including, without limitation, any and all trade secrets, inventions, Know-how, designs, formulations, processes, specifications, data, manuals, supplier lists, customer lists, purchase and sales records, marketing information, in each case whether developed by either Party.</P>
<P ALIGN="JUSTIFY">"<U>DEA</U>" shall mean the United States Drug Enforcement Agency or any successor agency.</P>
<P ALIGN="JUSTIFY">"<U>Derivative</U>" shall mean, any morphine-based NDA product or Section 505(b)(2) product (exclusive of the Product) for which Alpharma may seek manufacture hereunder.</P>
<P ALIGN="JUSTIFY">"<U>DMF</U>" shall mean a Drug Master File, a confidential submission containing the information necessary to support use of Product in applications approved by the FDA or any other national, regional or local government or any subdivision or agency thereof.</P>
<P ALIGN="JUSTIFY">"<U>FDA</U>" shall mean the United States Food and Drug Administration or any successor agency.</P>
<P ALIGN="JUSTIFY">"<U>Governmental Agency</U>" shall mean the FDA, DEA or any state or local government or any subdivision or agency thereof within the Territory.</P>
<P ALIGN="JUSTIFY">"<U>Intellectual Property</U>" shall mean Trademarks, trade dress, copyrights, Know-How, Patents, Confidential Information and other intellectual property rights related to Kadian or any Derivative.</P>
<P ALIGN="JUSTIFY">"<U>Indemnitee</U>" shall mean the person or persons indemnified, or entitled, or claiming to be entitled to be indemnified, pursuant to Article 23.</P>
<P ALIGN="JUSTIFY">"<U>Indemnitor</U>" shall mean the person having the obligation to indemnify the Indemnitee pursuant to Article 23.</P>
<P ALIGN="JUSTIFY">"<U>Kadian</U>" means Kadian morphine sulfate extended release capsules.</P>
<P ALIGN="JUSTIFY">"<U>Know-how</U>" shall mean all proprietary information, data, processes (including the production process for morphine sulphate) and technology relating to the Product and Derivatives, including the manufacturing process, line extensions and additional dosage forms of the Product, the anti-abuse delivery system and alcohol resistant coating process, whether for use in connection with Kadian or any other pharmaceutical product and any alterations or improvements on such system or process; excluding sustained release technology and any general manufacturing processes presently utilized in the Manufacturing process for the Product (to the extent not covered by a Patent) which is used by Purepac on the date hereof for manufacture of pharmaceutical products other than the Product.</P>
<P ALIGN="JUSTIFY">"<U>Liabilities and Damages</U>" shall mean any and all claims, liabilities, actions, suits, proceedings, judgments, orders, fines, penalties, losses, injuries, damages (excluding consequential damages), costs and expenses (including, without limitation, costs of defense, settlements, and reasonable legal fees and expenses) of whatever kind or character, however occurring or arising and regardless of the basis of liability or legal principal involved (including, without limitation, contract, warranty, negligence, strict liability, other tort, violation of law or otherwise).</P>
<P ALIGN="JUSTIFY">"<U>Losses</U>" shall refer to "<U>Purepac Losses</U>" or "<U>Alpharma Losses</U>", as referred to in Article 23.</P>
<P ALIGN="JUSTIFY">"<U>Manufacture</U>" shall mean the production, packaging and labelling of the Products in a form ready for consumer use and marked with Alpharma's pertinent Trademark(s), such Trademark(s) being at all times the property of Alpharma.</P>
<P ALIGN="JUSTIFY">"<U>Patents</U>" means any patents or patent applications relating to any Product or a Derivative now or hereafter held by Alpharma, including without limitation patents as to which Alpharma is a licensee under that certain "Technology Transfer and License Agreement" between FH Faulding &amp; Co. Limited, as licensor and Faulding Pharmaceuticals Inc. (assigned to Alpharma; the "Faulding Patents"), and the patents and patent applications listed in <B>Appendix 3</B>.</P>
<P ALIGN="JUSTIFY">"<U>Product</U>" shall mean Kadian as presently manufactured pursuant to the current NDA and any related supplements to the NDA (whether currently effective or approved hereafter).</P>
<P ALIGN="JUSTIFY">"<U>Product Facility</U>" or the "<U>Site</U>" shall mean the plant and equipment located at Purepac's plant in Elizabeth, New Jersey which is registered with the FDA to the full extent required.</P>
<P ALIGN="JUSTIFY">"<U>Purchase Price</U>" shall have the meaning referred to in Article 16.</P>
<P ALIGN="JUSTIFY">"<U>Recall</U>" shall mean a withdrawal of the Product from the marketplace after it has left the possession of the Parties hereto pursuant to an order from the FDA or a reasonable decision by either of the Parties hereto that such recall is necessary to comply with the rules and regulations of the FDA.</P>
<P ALIGN="JUSTIFY">"<U>Regulatory Documents</U>" shall include the NDA and such other similar documents used to support the Manufacture, sale and use of Product in applications approved by Governmental Agencies and licenses, certificates or other written approvals issued by Governmental Agencies.</P>
<P ALIGN="JUSTIFY">"<U>Specifications</U>" shall mean the specifications for Kadian as are set forth in <B>Appendix 1</B>.  Appendix 1 may be amended or supplemented from time to time by Alpharma (including without limitation, amendments or supplements required in connection with any Product or any Derivative), or as required by the FDA, or other orders or regulations of a Government Agency; provided that any amendment in or supplement to the Specifications which is not required by a Government Agency shall be subject to Purepac's consent, which shall not be unreasonably withheld or delayed.</P>
<P ALIGN="JUSTIFY">"<U>Trademarks</U>" shall mean the trademarks relating to Kadian or a Derivative now or hereafter held by Alpharma, including without limitation the trademarks listed in <B>Appendix 2</B>.</P>
<P ALIGN="JUSTIFY">"<U>Term</U>" shall have the meaning provided in Section 19.1.</P>
<P ALIGN="JUSTIFY">"<U>Territory</U>" shall mean the United States and its territories, commonwealths and possessions.</P>
<P ALIGN="JUSTIFY">"<U>Test Protocols</U>" shall mean the test protocols set forth in Appendix 5.</P>
<P ALIGN="JUSTIFY">"Third Party", and collectively "<U>Third Parties</U>", shall mean any individual, corporation, partnership, joint venture, association, trust, unincorporated organization or Governmental Agency or other entity, other than Purepac and Alpharma and their respective Affiliates.</P>
<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Grant of License</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alpharma hereby grants to Purepac during the Term of this Agreement a non-exclusive, non-transferable, royalty free license (or, sublicense to the extent Alpharma holds such rights pursuant to the aforesaid Technology Transfer and License Agreement) to use the Intellectual Property for use in or in connection with the Manufacture of Products to be sold to Alpharma pursuant hereto and not for any product otherwise manufactured and/or sold by Purepac whether within or outside the Territory.</P>
<P ALIGN="JUSTIFY">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the extent Alpharma has not already done so, promptly after the date of this Agreement, Alpharma shall make available to Purepac the Intellectual Property not previously furnished to Purepac and which Alpharma determines is necessary for Purepac to perform its obligations hereunder or which Purepac reasonably requests for such purpose.  All Intellectual Property previously furnished to Purepac on the subject matter hereof shall be deemed to have been provided pursuant to the terms of this Agreement.</P>
<P ALIGN="JUSTIFY">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purepac recognizes that the Intellectual Property belongs to Alpharma and shall continue to solely belong to Alpharma during and after the Term of this Agreement.  Purepac agrees that it will not file for or use a trademark identical to or causing confusion with the Trademarks either within or outside the Territory.</P>
<P ALIGN="JUSTIFY">2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the extent any goodwill attached to the rights in and to the Trademarks are deemed to accrue to Purepac, Purepac hereby assigns any and all such rights at such time as they may be deemed to accrue to Alpharma and hereby agrees to execute any and all documents reasonably requested by Alpharma as necessary to accomplish such assignment.</P>
<P ALIGN="JUSTIFY">2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All labels, tags, packaging and printed matter bearing the Trademarks shall be timely approved by Alpharma and supplied by Purepac.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Supply and Sale of Product</P>
</B></FONT><P ALIGN="JUSTIFY">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manufacture.</P><DIR>
<DIR>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">3.1.1&nbsp;&nbsp;&nbsp;During the Term of this Agreement, Purepac agrees to Manufacture at the Product Facility and exclusively sell and deliver the Product to Alpharma for marketing and sale in the Territory in full compliance with the terms of this Agreement.</P>
<P ALIGN="JUSTIFY">3.1.2&nbsp;&nbsp;&nbsp;At Alpharma's option, Purepac will Manufacture and supply any Derivative pursuant to the terms hereof, and upon the exercise of such option any such Derivative shall be considered a Product hereunder, subject only to the Purchase Price for the Derivative being equal to ****.  The Parties agree that on January 1, 2009, the 4 Wall Costs shall be adjusted via a multiplier equal to the most recently published manufacturing index for the past calendar year published by the United States Government or such other index as to be agreed upon in good faith by the Parties for the pharmaceutical industry.</P>
<P ALIGN="JUSTIFY">3.1.3&nbsp;&nbsp;&nbsp;Upon Alpharma's prior written consent, not to be unreasonably withheld, Purepac shall have the right, at costs to be borne exclusively by Purepac, to transfer the Manufacture of the Products to an alternate facility ("New Facility").  Any such New Facility shall be subject to the same standards under this agreement as the Product Facility, and Purepac's responsibilities under this agreement shall not be altered due to the transfer.  Alpharma agrees that in the event Purepac elects to transfer Manufacture to a New Facility, it shall provide Purepac with all reasonable cooperation necessary (including, but not limited to the performance of bioequivalence studies and other testing, at Purepac's cost) to effectuate such a transfer.</P></DIR>
</DIR>
</DIR>
</DIR>

<P ALIGN="JUSTIFY">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alpharma reserves the right to manufacture or have manufactured by Third Parties the Product for sale in the Territory; provided only that Alpharma (i) first satisfy any purchase obligations set forth herein and (ii) give notice to Purepac at least **** prior to the first calendar quarter during which Alpharma intends to reduce its order for the Products by **** percent (****%) from the quantity of the Products Alpharma had ordered in the same calendar quarter in the prior year (the "<U>Reduction Amount</U>") in order for a Third Party to manufacture such Reduction Amount (or greater amount) of the Products for Alpharma.  Alpharma's obligations under this Section 3.2 shall be waived but only to the extent of any failure by Purepac to timely deliver Products in accordance with a purchase order issued pursuant to Section 7.2, any breach of this Agreement by Purepac, or any force majeure inability of Purepac to timely supply the Product in the quantities requi
red by this Agreement.</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alpharma shall market and sell the Product in full conformity with all Regulatory Documents.  All other terms and conditions of sale, including without limitation price, shall be at the full discretion of Alpharma.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory Documents</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Parties shall reasonably cooperate to submit, in satisfactory form and timely manner consistent with industry standards, such additional Regulatory Documents to the FDA and such other relevant Governmental Agencies as Alpharma finds appropriate.  The Regulatory Documents shall be submitted in the name of Alpharma, (or where required by law, in the name of Purepac), with Alpharma acting as exclusive agent.</P>
<P ALIGN="JUSTIFY">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alpharma shall (i) prepare any additional Regulatory Documents in Alpharma's layout, for filing with any Governmental Agency with the cooperation of Purepac (which shall include providing Alpharma access to relevant testing and manufacturing information required for inclusion in such Regulatory Documents), (ii) submit the Regulatory Documents to the relevant Governmental Agency in the Territory, (iii) be responsible for the review and acceptance process of the Regulatory Documents and conduct all correspondence with the Governmental Agency to this effect, (iv) maintain and update the Regulatory Documents when necessary or advisable after Governmental Agency acceptance of the Regulatory Documents is obtained and (v) provide a copy of any accepted Regulatory Documents submitted to the Governmental Agencies and any filed updates concerning changes to Purepac.</P>
<P ALIGN="JUSTIFY">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purepac shall cooperate at Alpharma's request and at Purepac's own expense, with Alpharma in all matters relating to the Regulatory Documents, including any reporting requested or required by any Governmental Agency.</P>
<P ALIGN="JUSTIFY">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All rights to the Regulatory Documents belong to Alpharma.  Purepac acknowledges and agrees that Alpharma's ownership of the NDA requires the following:</P>
<P ALIGN="JUSTIFY">4.4.1&nbsp;&nbsp;&nbsp;Only Alpharma shall submit documents to Governmental Agencies.</P>
<P ALIGN="JUSTIFY">4.4.2&nbsp;&nbsp;&nbsp;Only Alpharma shall submit any update, variation, supplement or annual update to the NDA to the relevant authorities.</P>
<P ALIGN="JUSTIFY">4.4.3&nbsp;&nbsp;&nbsp;Only Alpharma shall issue letters of authorization/access ("<U>LoA's</U>").</P>
<P ALIGN="JUSTIFY">4.4.5&nbsp;&nbsp;&nbsp;All questions from authorities and customers relating to the NDA shall be directed to Alpharma and Alpharma shall be responsible for any related communications to Purepac, authorities and/or customers.</P>
<P ALIGN="JUSTIFY">4.4.5&nbsp;&nbsp;&nbsp;Purepac shall not contact or respond directly or indirectly to any Governmental Agency with respect to Products and Derivatives unless legally required to do so, or if failure to do so would materially adversely affect Purepac.</P>
<P ALIGN="JUSTIFY">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alpharma hereby grants Purepac for the Term and solely for the purposes of supplying Product to Alpharma in the Territory under this Agreement a non-exclusive, non-transferable, royalty-free license to use all information contained within the Regulatory Documents as is reasonably required to enable Purepac to fulfill its obligations hereunder.</P>
<P ALIGN="JUSTIFY">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alpharma shall have the right, at its discretion during the Term, to identify and contract with additional manufacturers for the Product and to take all action necessary to qualify such additional suppliers with the FDA including without limitation the preparation and filing of all necessary Regulatory Documents.  Purepac shall, upon reasonable advance written notice by Alpharma, cooperate with Alpharma in all reasonable manners in connection with the qualification of such additional suppliers, including without limitation any reasonably necessary access to the Product Facility (and in any event only during business hours) and testing and manufacturing information.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Supply and Testing of Components</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alpharma shall be responsible for selecting the suppliers of all components (API, raw and packaging materials) necessary to produce the Product, consistent with the Specifications and the Regulatory Documents.  With respect to the API supplier, in addition to selecting that supplier, Alpharma shall manage the business relationship therewith.</P>
<P ALIGN="JUSTIFY">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purepac shall test all API to ensure that API meets Specifications prior to use for Manufacturing of the Product.  The results of such testing shall be available within thirty (30) days of receipt of API by Purepac.  Purepac shall promptly report any failure to meet Specifications to Alpharma.</P>
<P ALIGN="JUSTIFY">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purepac and Alpharma shall, from time to time, and in a timely manner, cooperate with each other in all reasonable efforts to obtain the required Regulatory Documents from the DEA to authorize the purchase of API in sufficient quantities to Manufacture at least ****-percent (****%) of the forecasts (both binding and non-binding) submitted by Alpharma pursuant to Section 7.1 for the period to be covered by the authorization being sought from the DEA.  Alpharma shall make (and Purepac shall facilitate and participate in) all necessary filings and undertake all discussions with the DEA reasonably necessary or appropriate to obtain the necessary Regulatory Documents.  Alpharma shall have the right to review all filings before submission to the DEA and to participate in any discussions with the DEA.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purepac's responsibilities</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purepac hereby warrants and undertakes to Alpharma that it shall adhere to the Specifications for the Manufacture, packaging and labeling of the Product and shall comply in all respects with the applicable laws and regulations and the requirements of any Governmental Agency having jurisdiction over such Manufacture, packaging and labeling.</P>
<P ALIGN="JUSTIFY">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purepac hereby warrants and undertakes to Alpharma that, in no event later than one hundred and twenty (120) days following the Closing (as such term is defined in the Stock and Asset Purchase Agreement signed by the Parties of even date herewith), it shall maintain all registrations, permits, licenses, consents and/or approvals from all Governmental Agencies of the Territory in place as of the Closing which are necessary for Purepac to carry out the Manufacture and other obligations of Purepac hereunder with respect to the Product, and shall obtain (with cooperation from Alpharma where reasonably necessary) all such registrations, permits, licenses, consents and/or approvals which shall become necessary during the Term.</P>
<P ALIGN="JUSTIFY">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purepac further warrants and undertakes to Alpharma that it shall, upon request by Alpharma, promptly deliver all documents evidencing the effecting of any of the documentation requirements, registrations, recordals and/or filings stated in Section 6.2 to Alpharma for its inspection and/or retention.</P>
<P ALIGN="JUSTIFY">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purepac at its own cost shall maintain the Product Facility and promptly repair or replace the equipment used to Manufacture the Product as necessary to perform its obligations hereunder in accordance with Purepac's past practice.  Purepac is also responsible for all Product Facility costs related to the Manufacture of the Product, including all capital investments required to implement Alpharma's manufacturing process except any future capital investment for equipment that will be dedicated solely to the Manufacture of the Product which, subject to Alpharma's prior written approval, shall be purchased by Purepac but paid for and owned by Alpharma; provided that Alpharma shall not be required to pay for any such dedicated equipment unless (i) such equipment becomes necessary as a result of increased quantities of Products ordered hereunder by Alpharma and then (ii) only if such additional equipment would be necessary if the equipment then at the Product Fac
ility continues to be utilized to Manufacture the Products in the same manner, and for the same periods of time, as it was used immediately prior to the request by Purepac for the purchase of dedicated equipment or (Hi) if such equipment is requested by Alpharma.</P>
<P ALIGN="JUSTIFY">6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the fulfillment of its supply obligations hereunder, nothing in this Agreement shall limit Purepac from using the Product Facility and the equipment therein to manufacture products other than the Products.</P>
<P ALIGN="JUSTIFY">6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purepac warrants that it will Manufacture the Product in accordance with cGMP, the Specifications, and all applicable laws in order to enable Alpharma to sell the Product in the Territory.  Alpharma shall make any final determination with respect to Product disposition.  Purepac agrees that if Alpharma requests a change in the Specifications, Purepac will use its reasonably commercial efforts to deliver the Products in conformance with the changed Specifications.  If Purepac is unable to deliver the Products in conformance with the changed Specifications Alpharma may terminate this Agreement with six (6) months written notice.  In addition Purepac undertakes and warrants that it will, at costs to be borne by Alpharma, alter the Specifications and/or the testing required by this Agreement if such alterations are required by the FDA, or other orders or regulations of any other Government Agency (including pharmacopendial requirements).  Purepac shall implemen
t such alterations in time to allow Alpharma to sell the Product on the date that the altered Specifications or testing requirements are to take effect.  Alpharma will provide reasonable technical consultation to implement any changes requested or required by this Section.</P>
<P ALIGN="JUSTIFY">6.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purepac will be responsible for creating and retaining manufacturing, analytical and distribution records, testing materials, undertaking production and quality controls, and analyses relating to the Product and the raw materials (including the API) contained in the Product in accordance with cGMP and shall provide Alpharma access to this information upon reasonable notice to Purepac.</P>
<P ALIGN="JUSTIFY">6.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purepac will conduct relevant stability studies on Product in accordance with cGMP and the NDA to assure validity of such Product for its shelf-life.</P>
<P ALIGN="JUSTIFY">6.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purepac will promptly inform Alpharma in writing of any noted incidents occurring or abnormal results found at any time during the Manufacture or testing of the Product or its raw materials (including API) and refrain from any activity that will adversely affect the quality of the Product.</P>
<P ALIGN="JUSTIFY">6.10&nbsp;&nbsp;&nbsp;&nbsp;From and after the receipt of each Annual Forecast Quantity, Purepac shall take all action reasonably necessary to assure that the Product Facility has and will maintain available capacity and ability to timely deliver Products in accordance with the Annual Forecast Quantity.  Purepac shall timely deliver Products as required by the Quarterly Delivery Forecast provided for in this Agreement as defined in Article 7.  Product shall be shipped to Alpharma (or to a third party facility at Alpharma's direction) no later than **** from the release date for Product on the Certificate of Conformity.  All Products so delivered shall be salable in the marketplace pursuant to the Specifications and relevant Regulatory Documents for at least **** after the date of delivery of the Product to Alpharma hereunder.  Purepac acknowledges that time is of the essence with respect to Purepac's obligations hereunder and that prompt and timely performance of all such obligations is st
rictly required for Alpharma in light of its commitments to Third Parties.  In the event that Purepac is unable to meet its obligations hereunder, Purepac shall be liable to Alpharma for all reasonable costs of cover incurred by Alpharma.  If Alpharma is not able to obtain cover due to the fact that no Third Party is then currently able or authorized to Manufacture the Product, Purepac shall then be liable for Liabilities and Damages actually suffered or incurred by Alpharma.</P>
<P ALIGN="JUSTIFY">6.11&nbsp;&nbsp;&nbsp;&nbsp;Packaging design and the contents of product inserts and labels shall be provided by Alpharma in a timely manner to permit Purepac to meet the delivery requirements set forth in Section 7.  Purepac shall package the Product in accordance with the Specifications and all applicable laws.  Alpharma may request that certain Product be delivered in bulk without packaging and in the event that Alpharma so requests all packaging costs shall be deducted from the Purchase Price for all Product subject to such request.  Materials and products procured by Purepac and used in the Product (excluding materials and products supplied by Alpharma or its designee) shall be suitable for their intended purpose and meet applicable Specifications and quality standards.</P>
<P ALIGN="JUSTIFY">6.12&nbsp;&nbsp;&nbsp;Upon reasonable written notice (in no event less than seven (7) days) of Manufacture of the Product or quality control related to the Product by Purepac to Alpharma, a designated employee of Alpharma shall remain on-site at the Product Facility (or New Facility) as Alpharma's manufacturing coordinator during the course of said manufacturing or quality control ("<U>Alpharma Coordinator</U>").  Purepac shall provide such individual with a reasonably suitable and adequate work environment (commensurate with office and work environment of a Purepac employee at a similar level and pay grade), including reasonable office space and reasonable access to and use of Purepac's facilities.  The parties agree that any Alpharma Coordinator shall be required to sign a Confidentiality Agreement (to be negotiated between the parties in good faith) before having access to the Product Facility (or New Facility) as contemplated by this Section 6.12.</P>
<P ALIGN="JUSTIFY">6.13&nbsp;&nbsp;&nbsp;&nbsp;The parties have entered into a Technical (GMP) Agreement in the form as set forth in <B>Appendix 4</B>.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forecasts and Orders</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On or before **** of each year (except as otherwise mutually agreed), Alpharma shall submit to Purepac in writing Alpharma's non-binding estimate of its desired quantity of production of morphine coated pellets for use in the Products for the next Calendar Year (the "<U>Annual Forecast Quantity</U>").</P>
<P ALIGN="JUSTIFY">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the Effective Date and thereafter at least **** prior to the beginning of each calendar quarter, Alpharma shall submit to Purepac in writing:</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">7.2.1&nbsp;&nbsp;&nbsp;Alpharma's firm and binding forecast, specifying the quantity (by individual SKU) of Product Alpharma wishes to be available for delivery during the upcoming quarter, together with any instructions for special packaging (the "<U>Quarterly Delivery Forecast</U>") Alpharma's firm and binding Quarterly Delivery Forecast for the upcoming quarter shall represent the minimum quantity that Alpharma agrees to purchase during that quarter.  At least **** prior to the beginning of a calendar quarter, Alpharma may, at its option, increase its Quarterly Delivery Forecast for said quarter by placing a written purchase order for an increased amount; provided however that, while Purepac shall use its reasonable efforts to fulfill any such increased order it shall not be obligated to supply an increased order to the extent it exceeds an additional **** percent (****%) of the original Quarterly Delivery Forecast.</P>
<P ALIGN="JUSTIFY">7.2.2&nbsp;&nbsp;&nbsp;Forecasts for each of the **** calendar quarters immediately following the quarter for which a purchase order must be submitted (by SKU) concurrent with the delivery of said Quarterly Delivery Forecast.  It is understood that such forecasts constitute an estimate of the future requirements of Alpharma and do not comprise a binding commitment of Alpharma.  Alpharma shall use its reasonable commercial endeavors to provide Purepac with accurate forecasts.</P>
<P ALIGN="JUSTIFY">7.2.3&nbsp;&nbsp;&nbsp;All Products shall be purchased by way of submission of purchase orders by Alpharma.  Alpharma shall submit a binding purchase order for Products conforming with the Quarterly Delivery Forecast, and setting forth requested delivery dates (which shall not require that any more than **** percent (****%) of the Quarterly Delivery Forecast, adjusted as permitted herein, be delivered in any single month) at least **** prior to the commencement of said calendar quarter.  A purchase order will represent a firm commitment by Alpharma to purchase the Products included thereon.  Purepac shall accept any purchase order which is ****-percent (****%) or less of Alpharma's Quarterly Delivery Forecast.  Within **** of receipt of a purchase order, Purepac shall advise Alpharma whether it is able to fulfill the order and the date of shipment; provided that it shall have no right to object to the quantity or delivery dates requested by Alpharma to the extent such request is within the
 scope permitted by this Section 7.2.  In case Purepac has not replied within the stated time limit, Purepac shall be deemed to have accepted the order as placed.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purepac shall advise Alpharma promptly of any event or circumstance that may make Purepac unable to deliver the Product as contemplated by this Agreement.  A failure by Alpharma to purchase the Product provided for in any purchase order which Purepac is unable to deliver shall not constitute a breach by Alpharma of any term of this Agreement.</P>
<P ALIGN="JUSTIFY">7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase orders shall be placed at least **** in advance of the requested delivery date.</P>
<P ALIGN="JUSTIFY">7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The terms and conditions of this Agreement shall prevail if the terms and conditions stated in Alpharma's purchase order or in Purepac's purchase order confirmations or in any other communication of the Parties relating to any purchase order are inconsistent with these terms and conditions.</P>
<P ALIGN="JUSTIFY">7.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If a shipment from Purepac is delayed more than **** for any reason and the delay causes any shortage of supply to Alpharma's customers, then, without prejudice to Alpharma's other rights and remedies with respect to such failure under this Agreement, and/or at law or in equity, Purepac shall air freight, at its own cost, Product directly to any and all such customers.</P>
<P ALIGN="JUSTIFY">7.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If either Party determines that any of the various time frame requirements found within Sections 7.1 through 7.6 herein materially affect their abilities to perform their respective obligations pursuant to this Agreement, the Parties agree to enter into good faith negotiations with the intent to alter such timing requirements in the best interests of the Parties.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Minimum Purchase Requirements</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During each calendar year, Alpharma shall be required to purchase Products utilizing a minimum quantity of **** percent (****%) of the morphine coated pellets contained in Alpharma's Annual Forecast Quantity applicable to such calendar year.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;****</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the notice requirements of Article 7, the minimum quantity of morphine coated pellets required to be purchased by Alpharma in 2006 shall be **** bottles of 100 capsules each, subject to Alpharma's ability to obtain DEA approval for the required amount of morphine.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manufacturing Samples and Records.</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly upon the completion of the Manufacture and testing by Purepac of each batch of Product, Purepac shall notify and shall provide Alpharma with a written certificate of analysis (the "<U>Certificate of Analysis</U>") setting forth Purepac's results of testing in accordance with the Test Protocols set forth in <B>Appendix 5</B> and providing Alpharma with a Certificate of Conformity.  If requested by Alpharma, Purepac shall provide Alpharma at a location designated by Alpharma with a representative sample of such batch for analysis.</P>
<P ALIGN="JUSTIFY">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purepac shall release the Products on behalf of Alpharma, unless Alpharma, upon prior written notice to Purepac, elects to release the Products itself or via a Third Party.  Alpharma will on a regular basis verify the analysis and testing conducted by Purepac in relation to releasing the Products for sale.  Purepac will in this connection provide Alpharma with the necessary reports and certificates.</P>
<P ALIGN="JUSTIFY">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alpharma shall have the right to reject the Products, or any part thereof, within thirty (30) days after receipt of shipment of Product (i) if Purepac deviated from cGMP in the manufacturing process for such Product or (ii) where the test results provided in Sections 9.1 and 9.2 demonstrate that the Product is in material non-compliance with the Specifications.  Alpharma shall also have the right to reject Products, or any part thereof within thirty (30) working days after Alpharma has actual knowledge of a latent defect, latent deficiency or latent non-conformity.  Alpharma shall notify Purepac in writing and the Parties shall endeavor to determine if the delivery in question meets Specifications and if not (a) the cause of the Specification failure and (b) which out of specification action ("<U>OOS-Action</U>") to take.  Purepac shall be entitled at all reasonable times to inspect and/or analyze the Product in question.  The Parties shall use their best e
ndeavors to resolve any dispute that may arise.  If the Parties fail to agree as to whether Product meets Specification or the reason for a failure 'to meet Specifications, the dispute shall be determined by an independent laboratory approved by Alpharma and Purepac using the Test Protocols and the decision of the independent laboratory shall be final and binding on the Parties.  Such laboratory's fees shall be borne by the Party against whom the independent laboratory's decision is given.  If Purepac agrees or the independent laboratory finds that any delivery of the Product has not complied with the relevant Specifications, Purepac shall replace such delivery with a Product that complies with the Specifications at its sole cost and expense (unless noncompliance is due the API supplied to Purepac by Alpharma's designated API supplier ("<U>Alpharma API Designee</U>"); in such instance all costs and expenses shall be borne by Alpharma).</P>
<P ALIGN="JUSTIFY">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With respect to a Product that meets the Specifications, but which otherwise is held by a Governmental Agency to be contaminated or adulterated (through an act or omission of Purepac or while under Purepac's control), Purepac shall make arrangements for the disposal of, or dispose of, such Product in a legal and environmentally safe manner and shall maintain appropriate and required records concerning any such disposal and shall refund in full to Alpharma any purchase price paid by Alpharma for such Product (unless such defect is due to the API supplied to Purepac by the Alpharma API Designee).</P>
<P ALIGN="JUSTIFY">9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With respect to batches which do not meet the Specifications but which can be brought within the Specifications by reprocessing in accordance with cGMP guidelines and the NDA, Purepac shall replace, or reprocess such batch at its sole cost and expense (unless such defect is due to the API supplied to Purepac by the Alpharma API Designee; in such instance all costs and expenses shall be borne by Alpharma).</P>
<P ALIGN="JUSTIFY">9.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With respect to batches which do not meet the Specifications and which cannot be brought within the Specifications by reprocessing in accordance with cGMP guidelines and the NDA, Purepac shall make alternate arrangements for or dispose of such batches in a legal and environmentally safe manner and shall maintain appropriate and required records concerning any such disposal.  The cost and expense of this disposal shall be paid by Purepac (unless such defect is due to the API supplied to Purepac by the Alpharma API Designee; in such instance all costs and expenses shall be borne by Alpharma).</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Invention and Discoveries</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">10.1&nbsp;&nbsp;&nbsp;&nbsp;Any and all inventions and discoveries, whether or not patentable, arising out of Purepac's activities related to the Product or a Derivative, or process technology related to the manufacture of the Product or a Derivative at any time during the Term of the Agreement, shall belong solely to Alpharma.  Purepac shall perform such acts, execute and deliver such instruments and documents, and do such other things as may be reasonably necessary to effect Alpharma's ownership interest in and to any such inventions and discoveries.  Alpharma shall grant a non-exclusive, irrevocable, royalty-free license to Purepac for the period of this Agreement for the use of any such invention or discovery to fulfill its obligations hereunder.</P>
<P ALIGN="JUSTIFY">10.2&nbsp;&nbsp;&nbsp;Alpharma shall have the right, but not the obligation, to prepare, file, and prosecute any patent applications and maintain patents with respect to any such inventions or discoveries referred to in Section 10.1.  The cost of preparing, filing, and prosecuting any such patent applications and maintaining such patents shall be borne and paid for by Alpharma itself; provided, however, that nothing in this Agreement shall obligate Alpharma to obtain or maintain any such patents.  Purepac, if reasonably requested to do so by Alpharma, shall afford all reasonable assistance to Alpharma in the preparation and prosecution of patent applications pursuant to this Article and the reasonable costs of such assistance shall be borne and paid for by Alpharma.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">11.&nbsp;&nbsp;&nbsp;&nbsp;The Intellectual Property</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">11.1&nbsp;&nbsp;&nbsp;&nbsp;Purepac shall observe and comply with all reasonable requirements, procedures and directions prescribed by Alpharma with respect to the use and safeguarding of the Intellectual Property.  Purepac agrees that unless authorized or required by Alpharma, it will not make or authorize to be made, any use, directly or indirectly, of the Intellectual Property in connection with any articles of any description other than the Products, or in any manner other than as provided for herein.</P>
<P ALIGN="JUSTIFY">11.2&nbsp;&nbsp;&nbsp;&nbsp;Purepac shall in no way represent that it has any ownership in the Intellectual Property and specifically acknowledges that any use of said Intellectual Property during the term of this Agreement has not created and will not hereafter create any right, title or interest therein or thereto other than as provided for in this Agreement.  Purepac agrees that it shall at no time during the Term adopt, use, register, purchase or otherwise acquire, without Alpharma's prior written consent, any word, trademark or commercial name which is the same as or confusingly similar to the Trademarks owned or used by Alpharma and that it shall not use any of the Trademarks as a corporate name.  For the avoidance of doubt, the previous sentence shall not apply where Purepac's use of a trademark, commercial name or corporate name occurs prior to the use by Alpharma of a Trademark with respect to a Derivative.</P>
<P ALIGN="JUSTIFY">11.3&nbsp;&nbsp;&nbsp;&nbsp;If Purepac becomes aware of (i) the fraudulent imitation of any Product or the infringement or potential infringement or violation of the Intellectual Property; or (ii) any claim that the Manufacture, use or sale of any Product infringes or violates any trademark, the patent or know-how rights of any third party, Purepac shall immediately notify Alpharma and shall assist Alpharma or its authorized representative with respect thereto at the cost of Alpharma.  Purepac shall take no steps nor initiate any action to suppress any infringement or violation of the Intellectual Property without Alpharma's prior written authorization.  Purepac shall be guided in its actions with respect thereto by the instructions issued by Alpharma.  Participation in an action by Purepac at Alpharma's request shall be at Alpharma's sole expense unless the infringement is found to be the fault of Purepac in which case Purepac shall bear the associated expenses.</P>
<P ALIGN="JUSTIFY">11.4&nbsp;&nbsp;&nbsp;&nbsp;Alpharma shall pay the fees necessary to maintain in force the Patents and Trademarks and shall pay the legal fees and incidental expenses arising from the defense or enforcement of the Intellectual Property.  Purepac and Alpharma shall co-operate in any such defense or enforcement of the Intellectual Property but shall be controlled by Alpharma.  Any amounts payable to Alpharma and/or to Purepac as a result of a settlement, judgment or other resolution of a defense or enforcement action or claim with respect to the Intellectual Property shall be for the sole benefit of Alpharma.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">12.&nbsp;&nbsp;&nbsp;&nbsp;Confidentiality and Non-Compete</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">12.1&nbsp;&nbsp;&nbsp;&nbsp;Purepac shall maintain in confidence and shall not disclose to any Third Party or use for any purpose other than under this Agreement, any Confidential Information or Know-how received pursuant to this Agreement for the Term of this Agreement and thereafter for the later of (a) 10 (ten) years or (b) the period of validity of any relevant patents, without the prior written consent of Alpharma provided, however, that such undertakings shall not apply to information which the receiving Party ("<U>Recipient</U>") can demonstrate (w) was in, or enters, the public domain without a breach of this Agreement, (x) was received from a Third Party under no secrecy obligation to the other Party hereto, (y) pertains to general information about chemical manufacturing or processing which is not specific and/or material to the Product or a Derivative (z) it is obligated by law to disclose.  Purepac shall utilize Confidential Information and Know-how only in connectio
n with the performance of obligations and enjoyment of rights pursuant to this Agreement and shall take all steps to protect the Confidential Information and Know-how with the same degree of care taken to protect their own confidential or proprietary information, but in no event shall Purepac use less than a reasonable standard of care.</P>
<P ALIGN="JUSTIFY">12.2&nbsp;&nbsp;&nbsp;&nbsp;Purepac may disclose Confidential Information and/or Know-how only to its directors, officers, employees and agents (collectively, the "<U>Agents</U>") who have a reasonable need to know such information for the purpose of the implementation of this Agreement; provided that Alpharma is notified of such disclosures (and the reasons therefore) before such disclosure is made and Purepac will require all such Agents to sign a confidentially agreement acknowledging the obligations created by this Agreement and provide a copy thereof to Alpharma.  Purepac agrees to advise all Agents of the obligations arising under this Agreement concerning the treatment of Confidential Information and Know-how and shall be responsible for enforcing the obligations set forth herein both during their employment or agency and after the termination of such employment or agency.  Purepac shall keep a list of all Agents who have received Confidential Information and Know-how.  Such list sh
all be sent immediately to the Alpharma upon its request.</P>
<P ALIGN="JUSTIFY">12.3&nbsp;&nbsp;&nbsp;&nbsp;During the Term of this Agreement, Purepac shall not develop, manufacture, market or sell any Product (including without limitation a generic version of the Product other than as may be agreed between the Parties pursuant to Section 24.1) or any product competitive with the Product which would require an NDA or 505(b)(2) filing for marketing nor shall it offer any assistance, or permit any of its employees to offer any assistance to any Third Party (including for this purpose any Affiliate of Purepac) to take any action which Purepac would be prohibited from engaging in pursuant to this Section 12.3.  For the purpose of clarification, the prohibitions in this Section 12.3 apply only to Purepac and not to any Affiliate of Purepac.</P>
<P ALIGN="JUSTIFY">12.4&nbsp;&nbsp;&nbsp;&nbsp;During the Term of this Agreement, Purepac agrees that it will not take any action, nor assist any Third Party in taking any action, to invalidate or otherwise restrict or limit the claims of the Patents.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">13.&nbsp;&nbsp;&nbsp;&nbsp;Interruptions</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">13.1&nbsp;&nbsp;&nbsp;&nbsp;If Purepac's Manufacturing or supply of the Product may become subject to interruption, for any reason whatsoever, Purepac shall provide Alpharma with immediate written notice of each such anticipated interruption.</P>
<P ALIGN="JUSTIFY">13.2&nbsp;&nbsp;&nbsp;&nbsp;If Purepac's Manufacturing or supply of the Product is actually interrupted, for any reason whatsoever, Purepac shall provide Alpharma with immediate written notice of each such interruption and within three (3) days give Alpharma written notice stating when Purepac shall be able to remedy such interruption.  With the regard to the interruption of supply of the Product from Purepac, if such interruption continues for more than twenty (20) consecutive days, Alpharma shall have the option, in its sole discretion, to terminate this Agreement immediately upon written notice, unless such interruption is due to API supplied to Purepac by the Alpharma API Designee (without prejudice to Alpharma's other rights and remedies with respect to such failure under this Agreement, and/or at law or in equity).</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">14.&nbsp;&nbsp;&nbsp;&nbsp;Process Modifications</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">14.1&nbsp;&nbsp;&nbsp;&nbsp;Purepac shall not make any modifications to any of its manufacturing operations relating to the Product or to raw material sources that would require a modification to any Regulatory Document without the prior written consent of Alpharma which shall not be unreasonably withheld.  Once a Regulatory Document has been filed with a Governmental Agency, Purepac agrees to take no action that would invalidate or otherwise jeopardize the information included in such Regulatory Document.</P>
<P ALIGN="JUSTIFY">14.2&nbsp;&nbsp;&nbsp;&nbsp;The Parties have agreed to a document (attached hereto as <B>Appendix 6</B>) which describes the necessary change control procedure and change control specifications to be followed, which cannot be changed unless both parties agree in writing.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">15.&nbsp;&nbsp;&nbsp;&nbsp;Inspections</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">15.1&nbsp;&nbsp;&nbsp;&nbsp;Purepac shall upon reasonable prior notice, but in no event more than three (3) times every twelve (12) months, permit Alpharma's designated directors, officers, employees, consultants and agents with full access to all portions of the Product Facility used or related to the Manufacture and testing of the Product and Alpharma shall be permitted to inspect such portions of the Product Facility and records related to the testing of the Product during regular business hours and observe its operation, including all aspects of production and quality control.  In addition, Purepac shall permit Alpharma (or its reasonable designated third party auditor that has entered into a confidentiality agreement with Purepac that is reasonably satisfactory to Purepac), upon reasonable prior written notice, to audit Purepac's facilities and records in connection with Alpharma's programs to monitor Alpharma's compliance with Laws (e.g., Sarbanes-Oxley).</P>
<P ALIGN="JUSTIFY">15.2&nbsp;&nbsp;&nbsp;&nbsp;Alpharma shall have the right to inspect and make copies of Purepac's books and records concerning the processing and cost of raw materials for, and the production, testing and quality control of, the Product.  Purepac agrees to submit to Alpharma or its designee, at no charge, upon request by Alpharma, a sufficient quantity of free samples of the Product and their raw materials and intermediates, including packaging, labels and other material utilized therewith, to enable Alpharma to perform quality control checks to ensure Purepac's compliance with Alpharma's instructions, standards and specifications.</P>
<P ALIGN="JUSTIFY">15.3&nbsp;&nbsp;&nbsp;&nbsp;Promptly after Alpharma or Purepac receives notice of an inspection of the Product Facility or Product by any Governmental Agency, the relevant party shall give the other Party notice of such inspection(s) and within twenty-four (24) hours after receipt send a copy of any notices or correspondence it receives from any other Governmental Agency relating thereto.  To the extent relating to or affecting the Manufacture of the Product, Purepac shall provide Alpharma with a daily summary of inspectional activities and shall forward to Alpharma its proposed reply to the Governmental Agency for prior written approval by Alpharma.  Purepac shall not submit a response to a Governmental Agency without Alpharma's prior written approval.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">16.&nbsp;&nbsp;&nbsp;&nbsp;Price</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">16.1&nbsp;&nbsp;&nbsp;The "<U>Purchase Price</U>" for the Product shall be equal to ****.  The Parties agree that on January 1, 2009, the 4 Wall Costs shall be adjusted via a multiplier equal to the most recently published manufacturing index published by the United States Government or such other index as to be agreed upon in good faith by the Parties for the pharmaceutical industry.</P>
<P ALIGN="JUSTIFY">16.2&nbsp;&nbsp;&nbsp;Raw material costs shall be based upon the amount of raw materials actually contained in the Product delivered to Alpharma at the average net cost paid by Purepac for such materials during the **** calendar quarters immediately preceding the calendar quarter during which the Product is delivered to Alpharma, multiplied by **** to take into consideration normal yield loss in Manufacturing.  4 Wall Costs shall remain constant until December 31, 2008.  Alpharma shall have reasonable access to the financial records of Purepac during normal business hours to confirm the propriety of the raw material costs being utilized in the calculation of Purchase Price.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">17.&nbsp;&nbsp;&nbsp;Payment</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">17.1&nbsp;&nbsp;&nbsp;Upon delivery of the Product to Alpharma, Purepac shall invoice Alpharma for the Purchase Price.</P>
<P ALIGN="JUSTIFY">17.2&nbsp;&nbsp;&nbsp;If Alpharma fails to pay an invoice price within **** after receipt (or upon satisfaction of any bona fide claim or inquiry with respect to such invoice), Purepac shall be entitled to an additional payment of interest on the outstanding amount owed at the rate of the lesser of one-half of one percent (0.5%) per month or the maximum amount provided by applicable law.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">18.&nbsp;&nbsp;&nbsp;Force Majeure</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">18.1&nbsp;&nbsp;&nbsp;Subject to Section 18.4 below, neither Party shall be liable for any failure or delay in the performance of its obligations under this Agreement to the extent such failure or delay both: (i) is caused by any of the following: acts of war, terrorism, civil riots or rebellions; quarantines, embargoes and other similar unusual governmental action; extraordinary elements of nature or acts of God or other event or condition outside the reasonable control of the Party subject to such failure or delay; and (ii) could not have been prevented by the non-performing Party's reasonable precautions or commercially accepted processes.  An event meeting both of the criteria set forth in (i) and (ii) is referred to as a "<U>Force Majeure Event</U>".  The Parties expressly acknowledge that Force Majeure Events do not include the regulatory acts of governmental agencies in the ordinary course or the non-performance of subcontractors or third party suppliers of the non-perfor
ming Party, unless such failure or non-performance by a subcontractor or third party suppliers is itself caused by a Force Majeure Event.  Upon the occurrence of a Force Majeure Event, the non-performing Party shall be excused from any further performance or observance of the affected obligation(s) for as long as such circumstances prevail, and such Party continues to attempt to recommence performance or observance to the greatest extent possible without delay.</P>
<P ALIGN="JUSTIFY">18.2&nbsp;&nbsp;&nbsp;Upon the occurrence of a Force Majeure Event or such other interruption as set forth in Article 13, the Parties agree to discuss the matter within forty-eight (48) hours and if, and the extent to which, performance by the affected Party may be resumed.</P>
<P ALIGN="JUSTIFY">18.3&nbsp;&nbsp;&nbsp;Alpharma shall be relieved from any obligations hereunder, including any minimum purchase requirements, during the existence of any Force Majeure Event or other interruption of supply as set forth in Article 13 and during such further period of time and for such amounts of Product as Alpharma, using commercially reasonable purchasing practices, issued orders for the Products to a Third Party.</P>
<P ALIGN="JUSTIFY">18,4&nbsp;&nbsp;&nbsp;Notwithstanding any other provision of this Agreement, a Force Majeure Event shall obligate and require Purepac to perform its obligations under the Disaster Recovery Plan (as defined in Section 18.5) within the time period described therein.</P>
<P ALIGN="JUSTIFY">18.5&nbsp;&nbsp;&nbsp;Purepac shall apply Purepac's business continuity and disaster recovery plans to its obligations to Manufacture and deliver the Product hereunder.  An outline and executive summary of Purepac's business continuity and disaster recovery plan is attached hereto as Appendix 7 (such outline and summary, along with any modifications or additions mutually agreed to by the Parties, plus all of Purepac's supporting detailed documentation and plans as contemplated by the provisions of this Section 18.5, the "Disaster Recovery Plan").  The Disaster Recovery Plan shall: (i) be designed to resume as soon as practicable all Purepac's critical business operations notwithstanding the occurrence of a crisis; (ii) specify procedures and frequency of testing; and (iii) shall be, and shall be maintained, consistent with then-current generally accepted industry standards.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">19.&nbsp;&nbsp;&nbsp;Term and Termination</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">19.1&nbsp;&nbsp;&nbsp;This Agreement shall remain in effect until December 31, **** ("<U>Term</U>").  This Agreement may be terminated, without recourse to any court:</P>
<P ALIGN="JUSTIFY">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By either Party upon notice to the other Party, with immediate effect, in the event of:</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">(i)&nbsp;&nbsp;&nbsp;an assignment by the other Party for the benefit of creditors;</P>
<P ALIGN="JUSTIFY">(ii)&nbsp;&nbsp;&nbsp;the admitted insolvency of the other Party;</P>
<P ALIGN="JUSTIFY">(iii)&nbsp;&nbsp;&nbsp;the institution of voluntary or involuntary proceedings by or against the other Party in bankruptcy, insolvency, moratorium or for a receivership, or for a winding-up or for the dissolution or reorganization of the other Party (other than a solvent reorganization); or</P>
<P ALIGN="JUSTIFY">(iv)&nbsp;&nbsp;&nbsp;the taking of any action by the other Party under an act for relief from creditors.</P>
<P ALIGN="JUSTIFY">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By Alpharma, in the event an FDA inspection of the Product Facility results in an inability to deliver Products as required by this Agreement or an inability to obtain approvals for Derivatives and Purepac is unable to thereafter deliver the Product or obtain the relevant approvals within ****.</P>
<P ALIGN="JUSTIFY">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By Alpharma, immediately upon written notice, if it, in good faith, determines that it would be unreasonable to sell Products Manufactured at the Product Facility as a result of Purepac's noncompliance with cGMP or other requirements of law.</P>
<P ALIGN="JUSTIFY">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By Alpharma with **** written notice if it has reasonably determined that it is no longer commercially viable to sell the Product.</P>
<P ALIGN="JUSTIFY">e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Agreement may be terminated upon **** written notice to the other Party in case of a material breach (such notice specifying the material breach), unless such breach is curable and is cured or the Parties have reached agreement on a plan to achieve a cure of such breach prior to the end of such **** notice period, provided however, that in the event that either Party disputes whether the material breach is subject to cure during such **** period, the Agreement shall not be terminated and the Parties shall follow the dispute resolution provisions set forth in Article 24.</P></DIR>
</DIR>
</DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect of Termination</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">20.1&nbsp;&nbsp;&nbsp;Upon the expiration or termination of this Agreement, Purepac shall promptly return to Alpharma all Regulatory Documentation and other Confidential Information including all copies and shall immediately discontinue any further use thereof as well as the use of Alpharma's name and Intellectual Property.</P>
<P ALIGN="JUSTIFY">20.2&nbsp;&nbsp;&nbsp;Except to the extent any Section expressly survives termination or as stated below in Section 20.4, upon termination of this Agreement for any reason, and subject to any rights or obligations that have accrued prior to termination, neither Party shall have any further obligation to purchase or supply the Product under this Agreement.</P>
<P ALIGN="JUSTIFY">20.3&nbsp;&nbsp;&nbsp;Upon expiration or termination of this Agreement by Alpharma or Purepac for whatever reason, Alpharma shall have the option to purchase any stores of materials used in the Manufacture of the Product and/or Product that meets the Specifications held by Purepac at the time of such expiration or termination of this Agreement, and the price shall be Purepac's net asset value of such materials and the Purchase Price for the Product; provided that Alpharma shall have the obligation to purchase all stores of materials (except materials which can reasonably be used for other products in the normal course of the operations of Purepac) and Products if this Agreement is validly terminated (i) by Purepac under Section 19.1(a), (ii) upon an Alpharma breach under Section 19.2(b), or (iii) under Section 19.1 (d).</P>
<P ALIGN="JUSTIFY">20.4&nbsp;&nbsp;&nbsp;The following Articles shall survive termination: 10 (Inventions and Discoveries), 11 (The Intellectual Property), 12 (Confidentiality), 20 (Effect of Termination), 22 (Warranties), 23 (Liability), 24 (Governing Law) and 27 (Miscellaneous).</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">21.&nbsp;&nbsp;&nbsp;Title and Risk of Loss</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">21.1&nbsp;&nbsp;&nbsp;Purepac shall transfer to Alpharma good and marketable title to the Product and its packaging, free and clear of all liens and encumbrances.  Title and risk of loss in and to any Product and its packaging shall pass to Alpharma at the time of delivery to Alpharma at the location designated by Alpharma.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">22.&nbsp;&nbsp;&nbsp;Warranties and Recall</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">22.1&nbsp;&nbsp;&nbsp;Purepac warrants that (i) the Product will be Manufactured in accordance with cGMP and any applicable regulatory requirements, and, will comply in all respects with all applicable laws with respect to the manufacture and the sale of the Product as contemplated in this Agreement; and (ii) at the time of delivery of the Product, the Product will comply with the Specifications.  Purepac shall deliver the Product FOB to locations designated by Alpharma, but in no event to locations outside the United States or its territories.</P>
<P ALIGN="JUSTIFY">22.2&nbsp;&nbsp;&nbsp;In the event a Product is scrapped during the Manufacturing process or is otherwise not able to be sold to Third Parties or is recalled as a result of a breach of Purepac's warranty contained in Section 22.1 (a) (unless such breach is caused by ****), Alpharma shall not pay for such Product, or if such payment has already been made pursuant to Article 17, such payment shall be refunded by Purepac and (b) Purepac shall pay for the reasonable costs of any Recall.</P>
<P ALIGN="JUSTIFY">22.3&nbsp;&nbsp;&nbsp;Purepac and Alpharma each warrant to the other that it has all rights and authority necessary to perform its respective obligations under this Agreement.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">23.&nbsp;&nbsp;&nbsp;Liability</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">23.1&nbsp;&nbsp;&nbsp;Alpharma shall indemnify and hold harmless Purepac and its officers, directors, employees, agents, successors and assigns from any and all Liabilities and Damages actually suffered or incurred by any of them (hereinafter "<U>Purepac Losses</U>") in connection with Third Party claims arising out of or resulting from Alpharma's performance of, or failure to perform, its obligations under this Agreement, the inherent nature of the Product, the infringement of any third party patent by Manufacture or sale of the Product, or Alpharma's negligence, willful misconduct, or breach of any term of this Agreement, other than those Purepac Losses arising out of or resulting from Purepac's negligence, willful misconduct, or breach of any term of this Agreement.</P>
<P ALIGN="JUSTIFY">23.2&nbsp;&nbsp;&nbsp;Purepac shall indemnify and hold harmless Alpharma and its officers, directors, employees, agents, successors and assigns from any and all Liabilities and Damages actually suffered or incurred by any of them (hereinafter "<U>Alpharma Losses</U>") in connection with third party claims arising out of or resulting from Purepac's performance of, or failure to perform, its obligations under this Agreement, or Purepac's negligence, willful misconduct, or breach of any term of this Agreement, other than those Alpharma Losses arising out of or resulting from Alpharma's negligence, willful misconduct, or breach of any term of this Agreement.</P>
<P ALIGN="JUSTIFY">23.3&nbsp;&nbsp;&nbsp;An Indemnitee shall promptly give the Indemnitor notice of any matter ("<U>Third Party Claims</U>") which an Indemnitee has determined has given or could give rise to a right of indemnification under this Agreement, stating the amount of the Losses, if known, the method of computation thereof, and the basis for the claim, all with reasonable particularity.</P>
<P ALIGN="JUSTIFY">23.4&nbsp;&nbsp;&nbsp;The obligations and liabilities of an Indemnitor under this Article 23 are contingent upon the following additional terms and conditions:</P>
<P ALIGN="JUSTIFY">If an Indemnitee receives notice of any Third Party Claim, the Indemnitee shall give the Indemnitor prompt notice of such claim and shall permit the Indemnitor, at its option, to assume and control the defense of such Third Party Claim at the Indemnitor's expense and through counsel of its choice (which counsel shall be reasonably satisfactory to Indemnitee) if it gives prompt notice of its intention to do so to the Indemnitee.  The failure of the Indemnitee to give notice as provided herein shall not relieve the Indemnitor of its obligations under this Agreement, except to the extent that such failure results in a lack of actual notice to the Indemnitor and such Indemnitor is prejudiced as a result of such failure to give notice.</P>
<P ALIGN="JUSTIFY">If the Indemnitor exercises its right to undertake the defense against such Third Party Claim as provided above, the Indemnitee shall reasonably cooperate with the Indemnitor and make available to the Indemnitor all witnesses, pertinent records, materials and information in its possession or under its control relating thereto as is reasonably required by the Indemnitor.  Similarly, in the event the Indemnitor does not exercise its right to undertake the defense of any Third Party Claim and the Indemnitee is, directly or indirectly, conducting the defense against such Third Party Claim, at the Indemnitor's expense, the Indemnitor shall reasonably cooperate with the Indemnitee in such defense and make available the same kind of information as is reasonably required by the Indemnitee.  If the Indemnitor exercises its right to undertake the defense against such Third Party Claim, and the Indemnitee in good faith determines that the Indemnitee has available to it one or more defenses or counter
claims that are inconsistent with one or more of those that may be available to the Indemnitor in respect of such claim or litigation relating thereto, the Indemnitee shall have the right at all times to take over and assume control over the defense, settlement, negotiation, or litigation relating to any such claim at the sole expense of the Indemnitor.</P>
<P ALIGN="JUSTIFY">23.5&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary in this Agreement, no Third Party Claim may be settled by the Indemnitee without the prior written consent of the Indemnitor.</P>
<P ALIGN="JUSTIFY">23.6&nbsp;&nbsp;&nbsp;Each Party to this agreement will obtain, at their own cost and expense, obtain and maintain in full force and effect the following insurance commencing on the date hereof and continuing for a period of **** following termination of this Agreement for any reason ("Insurance Term"): (1) Commercial general liability insurance with per-occurrence and general aggregate limits of not less than $**** ("Commercial Liability Insurance"); (2) Products and completed operations liability insurance with per occurrence and general aggregate limits of not less than $**** ("Product Insurance"); (3) Statutory Workers' Compensation and Employer's Liability Insurance with an amount not less than $**** including excess liability coverage; (4) Professional Services Errors &amp; Omissions Liability Insurance with per claim and aggregate limits of not less than $**** covering sums that Purepac becomes legally obligated to pay as damages resulting from claims made by Alpharma for errors or 
omissions committed in the conduct of the services outlined in the Agreement.  With respect to the Commercial Liability Insurance and Product Insurance, Purepac shall amend its policy(ies) to name Alpharma as an additional named insured, commencing on the date hereof and continuing for the Insurance Term.  Purepac shall provide to Alpharma at least thirty (30) days prior written notice of any cancellation, termination or relevant material change in such insurance coverage.  In the event that any of the required policies of insurance are written on a claims made basis, then such policies shall be maintained during the entire Term and for a period of not less than **** following the termination or expiration of this Agreement.  In lieu of insurance, either Party may substitute a self insurance program ("<U>Self Insurance</U>") upon written notice to the other Party together with information demonstrating the adequacy of such program.  Such Self Insurance must be acceptable to the other Party as evidenced by a 
written affirmation to that effect.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">24.&nbsp;&nbsp;&nbsp;Authorized Generics</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">24,1&nbsp;&nbsp;&nbsp;Upon the request of Purepac, the parties will, commencing at least **** prior to such time as **** will be available for generic manufacture and sale under the FDA Act (as such term is defined in the Stock and Asset Purchase Agreement signed by the Parties of even date herewith), or earlier, upon the filing by a third party of an abbreviated new drug application to the FDA (as such term is defined in the Stock and Asset Purchase Agreement signed by the Parties of even date herewith) for approval of the manufacture and/or sale of **** under Section 505(j)(A)(vii)(IV) of the FDA Act, enter into good faith negotiations for the license by Alpharma to Purepac of such rights as would be necessary for Purepac to be the exclusive authorized generic manufacturer and seller of ****.</P>
<P ALIGN="JUSTIFY">24.2&nbsp;&nbsp;&nbsp;Alpharma shall use commercially reasonable efforts to **** the **** to Purepac solely for use in the manufacture and sale of an AB rated generic version of ****.  In the event that Alpharma is unable to obtain such right, Alpharma agrees to negotiate in good faith with Purepac the terms and conditions of an agreement whereby the related ANDA (as such term is defined in the Stock and Asset Purchase Agreement signed by the Parties of even date herewith) would be transferred to Alpharma and Purepac would become the exclusive toll manufacturer and distributor of the generic version of **** for Alpharma on economic terms and conditions satisfactory to Purepac.  The Parties agree that, in the event such an agreement is entered into between the Parties, the costs of any litigation and resulting judgments related to such generic version of ****, including any costs related to **** litigation, shall be borne by Purepac.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">25.&nbsp;&nbsp;&nbsp;Governing Law and Arbitration</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">25.1&nbsp;&nbsp;&nbsp;This Agreement shall be construed and interpreted in accordance with, and its performance shall be governed by, the substantive laws of New Jersey irrespective of its choice of law rules.</P>
<P ALIGN="JUSTIFY">25.2&nbsp;&nbsp;&nbsp;The Parties shall attempt to resolve any dispute arising out of, including its existence, validation and termination or relating to the implementation of this Agreement through friendly consultation.  Such consultation shall begin immediately after one Party has delivered to the other Party written notice of a request for such consultation.  On proposal of a Party and consent of the other Party, the dispute may also be mediated by a Third Party designated by the Parties.</P>
<P ALIGN="JUSTIFY">25.3&nbsp;&nbsp;&nbsp;If a dispute not involving Intellectual Property (which term, for the purpose of this Section 25.3 only, shall have the meaning provided in the Stock and Asset Purchase Agreement signed by the Parties of even date herewith) still cannot be resolved within thirty (30) days following the date on which the notice provided for in Section 24.2 is given, either Party shall have the right to refer the dispute to, and be finally resolved by, arbitration in New Jersey in accordance with the Arbitration Rules of the American Arbitration Association for the time being in force, which rules are deemed to be incorporated by reference in this clause.  The decision or award of the Tribunal shall be final and binding upon both Parties, shall not be appealable, and shall be enforceable in any court of competent jurisdiction.</P>
<P ALIGN="JUSTIFY">25.4&nbsp;&nbsp;&nbsp;Sections 24.3 and 24.4 above do not hinder either party from seeking injunctive or similar equitable actions against the other party in a court of competent jurisdiction in case of a breach of this Agreement when appropriate.</P>
<P ALIGN="JUSTIFY">24.5&nbsp;&nbsp;&nbsp;During the period in which a dispute is being resolved, except for the matter in dispute, the Parties shall in all respects continue their implementation of, and adherence to, this Agreement.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">26.&nbsp;&nbsp;&nbsp;Cooperation and Assignment</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">26.1&nbsp;&nbsp;&nbsp;Each Party will reasonably cooperate with the other in the performance of their respective obligations hereunder, including but not limited to the collection and supply of data and in taking other actions reasonably necessary to obtain and maintain all permits and permissions necessary to the performance of this Agreement.</P>
<P ALIGN="JUSTIFY">26.2&nbsp;&nbsp;&nbsp;Purepac shall not assign, charge, sub-contract or otherwise deal in any or all of its rights and/or obligations hereunder (herein collectively called "<U>Assignment</U>") without the prior written consent of Alpharma, except Purepac shall have the right to assign to Affiliates or in connection with the sale of all or substantially all of the assets of the business.  In the event of any Assignment by Purepac, unless expressly agreed otherwise between the Parties, Purepac shall remain primarily liable for performance of this Agreement.  Alpharma may assign any part of or the entire Agreement to Alpharma Inc. or any of its Affiliates or any other party which purchases all or substantially all of the business or assets of Alpharma without the consent of Purepac.</P>
<P ALIGN="JUSTIFY">26.3&nbsp;&nbsp;&nbsp;Notwithstanding anything in this Agreement to the contrary, Alpharma has the right to cause one or more of its Affiliates, including without limitation Alpharma Inc., to order and sell the Product, provided that such action shall not limit or diminish Alpharma's duties pursuant to this Agreement.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">27.&nbsp;&nbsp;&nbsp;Notices</P><DIR>
<DIR>

</B></FONT><P ALIGN="JUSTIFY">27.1&nbsp;&nbsp;&nbsp;Any notice required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been sufficiently given when hand-delivered by one Party to an officer (or his designee) of the other Party, or upon delivery when sent by overnight express mail (e.g., Fed Ex) for next business day delivery to the address noted below, or on the third business day after mailing when mailed, postage prepaid, by certified mail, return receipt requested, addressed as follows:</P>
<P>If to Purepac, addressed to:<BR>
<BR>
Purepac Pharmaceutical Co.<BR>
14 Commerce Drive<BR>
Cranford NJ 07016<BR>
Attention: President US Generics</P>
<I><P>with a copy to</I>:<BR>
<BR>
Purepac Pharmaceutical Co. <BR>
14 Commerce Drive<BR>
Cranford NJ 07016<BR>
Attention: US General Counsel</P>
<P>If to Alpharma, addressed to:<BR>
<BR>
Alpharma Branded Products Division Inc. <BR>
One New England Avenue<BR>
Piscataway, NJ 08854<BR>
Attention: President</P>
<I><P>with a copy to</I>:<BR>
<BR>
Alpharma Inc.<BR>
One Executive Drive<BR>
Ft. Lee, NJ<BR>
Attention: Chief Legal Officer</P>
<P ALIGN="JUSTIFY">or to such other address or addresses as may be specified from time to time in a written notice given by such Party.  The Parties shall acknowledge in writing the receipt of any such notice delivered in person.  Notwithstanding the foregoing, routine instructions, requests, directions and notices dealing with day to day operations under this Agreement may be given in such manner to such persons as may be agreed by the Parties is reasonable and practicable.</P></DIR>
</DIR>

<B><FONT FACE="Times New Roman Bold"><P ALIGN="JUSTIFY">28.&nbsp;&nbsp;&nbsp;Miscellaneous</P><DIR>
<DIR>

</FONT><P ALIGN="JUSTIFY">28.1&nbsp;&nbsp;&nbsp;Entire Agreement</B>.  This Agreement, of which the Appendices are a part, constitutes, with respect to the matters set forth herein, the full understanding of the Parties, a complete allocation of risks between them, and a complete and exclusive statement of the terms and conditions of their agreement and supersedes all prior agreements between the Parties, whether written or oral, relating to the same or similar subject matter.  No conditions, usage of trade, course of dealing or performance, or understanding or agreement purporting to modify, vary, explain, or supplement the terms or conditions of this Agreement shall be binding unless hereafter made in writing and signed by the Party to be bound; and no modification shall be deemed to have been made by the acknowledgment or acceptance of any purchase order, acknowledgement, or other form containing terms or conditions at variance with, or in addition to, those set forth in this Agreement.</P>
<B><P ALIGN="JUSTIFY">28.2&nbsp;&nbsp;&nbsp;Binding Effect</B>.  The covenants, agreements, terms, and conditions contained in this Agreement shall apply to, inure to the benefit of, and be binding upon, the Parties hereto and upon their respective Affiliates, subsidiaries, heirs, executors, administrators, assigns, and successors in interest.</P>
<B><P ALIGN="JUSTIFY">28.3&nbsp;&nbsp;&nbsp;No Waiver</B>.  No waiver by either Party with respect to any breach or default, and no waiver of enforcement of any right or remedy, and no course of dealing shall be deemed to constitute (i) a waiver of a subsequent breach or default of the same or a different provision; (ii) a waiver of subsequent enforcement of any right or remedy, or (iii) a continuing waiver of any kind, unless such waiver is expressed in writing and signed by the Party to be bound.</P>
<B><P ALIGN="JUSTIFY">28.4&nbsp;&nbsp;&nbsp;Severability</B>.  In case any provision or part thereof not material to this Agreement shall be declared invalid, illegal, or unenforceable, the validity, legality, and enforceability of the remaining provisions and parts of this Agreement shall not in any way be affected or impaired thereby.</P>
<B><P ALIGN="JUSTIFY">28.5&nbsp;&nbsp;&nbsp;Counterparts</B>.  This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which shall constitute one and the same agreement.</P>
<B><P ALIGN="JUSTIFY">28.6&nbsp;&nbsp;&nbsp;Interpretation</B>.  The word "including" shall not limit a more general preceding phrase and the word "hereof' shall refer to this Agreement as a whole.</P>
<B><P ALIGN="JUSTIFY">28.7&nbsp;&nbsp;&nbsp;Customer Contact</B>.  Purepac shall not have direct contact with Alpharma's customers unless authorized by Alpharma.</P>
<B><P ALIGN="JUSTIFY">28.8&nbsp;&nbsp;&nbsp;Relationship between the Parties</B>.  Nothing in this Agreement shall create, or be deemed to create, a partnership or the relationship of principal and agent between Alpharma and Purepac or their respective Affiliates; nor shall the Parties be deemed joint ventures for any purpose whatsoever.  The Parties agree that the relationship created by this Agreement is that of independent contractors.</P>
<B><P ALIGN="JUSTIFY">28.9&nbsp;&nbsp;&nbsp;Headings</B>.  Headings of particular Articles and Articles in this Agreement are inserted only for convenience and are in no way to be construed as part of this Agreement or a limitation of the scope of the particular Articles or Articles to which they refer.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">IN WITNESS WHEREOF, Purepac and Alpharma have caused this Agreement to be duly signed in duplicate originals by their duly authorized representatives as of the day and year first above written.</P>
<B><P ALIGN="JUSTIFY">Purepac Pharmaceutical Co</P>
</B><P>By: <U>/s/ John W. LaRocca&#9;<BR>
</U>Name:  John W. LaRocca<BR>
Title:  Secretary</P>
<B><P ALIGN="JUSTIFY">Alpharma Branded Products Division Inc.</P>
</B><P>By: <U>/s/ Robert F. Wrobel&#9;<BR>
</U>Name:  Robert F. Wrobel<BR>
Title:  Secretary</P></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33A
<SEQUENCE>6
<FILENAME>exh10_33a.htm
<DESCRIPTION>AMENDENT TO ALPHARMA INC. EXECUTIVE BONUS PLAN
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>STATEMENT OF UNANIMOUS WRITTEN CONSENT</TITLE>
</HEAD>
<BODY>

<P ALIGN="CENTER">AMENDMENT TO THE ALPHARMA INC. <BR>
EXECUTIVE BONUS PLAN</P>
<B><FONT SIZE=3><P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P>
</B><P>&#9;</P>
</FONT><P ALIGN="JUSTIFY">The Alpharma Inc. Executive Bonus Plan (the "Plan") is hereby amended effective as of August 15, 2005, as follows:</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">1.&#9;Section 11 is hereby amended replacing Section 11 in its entirety as set forth below:</P>
<P ALIGN="JUSTIFY"></P>
<B><P>11. &#9;<U>Partial Year Employees.</P>
</B></U>
<P>&#9;If any employee of the Company or an SBU meets all of the conditions set forth within the definition of "Eligible Employee" (i) as of the last day of an Incentive Year except the requirement that he or she have been employed by the Company or an SBU for the entire Incentive Year or (ii) his or her employment was terminated, or interrupted, during the Incentive Year by death, disability, a leave of absence of 3 months or more, Retirement or, at the discretion of the Committee, upon the sale of an SBU, such employee shall be eligible for a Bonus Award computed (based upon the previously approved performance criteria and subject to the adoption of other rules or procedures deemed equitable in the circumstances by the Committee,) as if he or she had been an Eligible Employee for the entire Incentive Year but then reduced pro rata for the portion of the Incentive Year during which he or she was not an employee of the Company or an SBU.   If an employee transfers from one SBU to another (or between the Comp
any and an SBU) during the Incentive Year his or her Bonus Award shall be prorated based upon the portion of the Incentive Year in each unit.  The Company Target Bonus Pool, and the relevant SBU Target Bonus Pool, shall be increased by an amount equal to the sum of any Bonus Awards payable under this Section 10.</P>

<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>7
<FILENAME>exh10_35.htm
<DESCRIPTION>ALPHARMA INC. EMPLOYEE STOCK PURCHASE PLAN
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>_ALPHARMA INC</TITLE>
<META NAME="DOCID" CONTENT="A">
</HEAD>
<BODY>

<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<B><P ALIGN="CENTER">ALPHARMA INC.<BR>
EMPLOYEE STOCK PURCHASE PLAN<BR>
<BR>
(As Amended and Restated<BR>
Effective as of January 1, 2005)<BR>
</P>
</B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<B><P ALIGN="CENTER">ALPHARMA INC.<BR>
<U>EMPLOYEE STOCK PURCHASE PLAN<BR>
</U><BR>
<U>Table of Contents</P>
</B></U><P ALIGN="JUSTIFY"></P>
<FONT SIZE=2><P ALIGN="JUSTIFY"><DIR>
<DIR>

</FONT><P ALIGN="JUSTIFY">1.&#9;History of The Plan&#9;1</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">2.&#9;Purpose&#9;1</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">3.&#9;Effective Date&#9;1</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">4.&#9;Plan Administration&#9;1</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">5.&#9;Eligibility&#9;2</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">6.&#9;Participation&#9;2</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">7.&#9;Payroll Deductions and Other Contributions&#9;2</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">8.&#9;Contributions by the Company&#9;3</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">9.&#9;The Plan Year&#9;3</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">10.&#9;Plan Quarters&#9;4</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">11.&#9;Allocation of Participant and Company Contributions&#9;4</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">12.&#9;Share Purchases&#9;4</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">13.&#9;Allocation of Shares&#9;5</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">14.&#9;Issuance, Transfer or Sale of Share Certificates&#9;6</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">15.&#9;Expenses&#9;7</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">16.&#9;Cash Dividends and Share Distributions&#9;7</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">a.&#9;Cash Dividends&#9;7</P>
<P ALIGN="JUSTIFY">b.&#9;Share Distributions and Share Splits&#9;7</P>
<P ALIGN="JUSTIFY">c.&#9;Share Rights and Warrants&#9;8</P>
<P ALIGN="JUSTIFY">d.&#9;Changes in Common Stock&#9;8</P>
<P ALIGN="JUSTIFY"></P></DIR>
</DIR>

<P ALIGN="JUSTIFY">17.&#9;Voting Rights&#9;8</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">18.&#9;Records and Reports to Participants.&#9;8</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">19.&#9;Termination of Employment&#9;9</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">20.&#9;Amendment and Termination of the Plan&#9;10</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">21.&#9;Limitation on Sale of Shares&#9;10</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></P></DIR>
</DIR>
</P>
</FONT><P ALIGN="JUSTIFY">22.&#9;Amendments to Effect Registration&#9;10</P>
<P ALIGN="JUSTIFY">&#9;<B>ALPHARMA INC.</P>
<P ALIGN="JUSTIFY">&#9;<U>EMPLOYEE STOCK PURCHASE PLAN</P>
</B></U><P ALIGN="JUSTIFY"></P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>1.&#9;<U>History of The Plan</U>.  This plan was originally adopted by A.L. Laboratories, Inc. on September 7, 1990 as the A.L. Laboratories, Inc. Employee Stock Purchase Plan with an effective date of October&nbsp;1, 1990.  The Plan was subsequently amended from time to time and amended and restated in its entirety, effective as of October 1, 2002 as the Alpharma Inc. Employee Stock Purchase Plan (the "Plan").  The Plan is being amended and restated in its entirety effective as of January 1, 2005. </P>
<P ALIGN="JUSTIFY">The Plan is maintained by Alpharma Inc. (the "Company") and any of its domestic or international subsidiaries that may adopt the Plan from time to time (each such adopting subsidiary referred to herein as a "Covered Entity") with the Company's consent.</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>2.&#9;<U>Purpose</U>.  The purpose of the Plan is to give employees wishing to do so a convenient means of purchasing shares of Alpharma Inc. Class A Common Stock (the "Shares") through after-tax payroll deductions, supplemented by contributions made by the Company or a Covered Entity.  The Company believes that ownership of Shares by employees will foster greater employee interest in the Company's growth and development.</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>3.&#9;<U>Effective Date</U>.  The "effective date" of this amendment and restatement of the Plan is January 1, 2005.</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>4.&#9;<U>Plan Administration</U>.  The Plan shall be administered by a committee appointed for such purpose by the Company's Board of Directors (the "Benefit Plans Administrative Committee").  As Plan administrator, the Benefit Plans Administrative Committee shall have complete control of the administration of the Plan, which includes the determination of employees' eligibility for participation in accordance with the standards set forth in Section 5 hereof, the interpretation of provisions of the Plan, the adoption of any rules or regulations which may be necessary, advisable or desirable in the operation of the Plan, including restrictions on the sale by employees of Shares purchased under the Plan, and the delegation of certain of the duties of the Benefit Plans Administrative Committee to an agent to facilitate the purchase and transfer of Shares and to otherwise assist in the administration of the Plan.  The Benefit Plans Administrative Committee shall control the 
general administration of the Plan with all powers necessary to enable it to carry out its duties in that respect, except that, if for any reason a Benefit Plans Administrative Committee shall not have been appointed or shall cease to exist or function, all authority and duties of the Benefit Plans Administrative Committee under this Plan shall be vested in and exercised by the Board of Directors of the Company.</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>5.&#9;<U>Eligibility</U>.  Any employee of the Company or a Covered Entity shall be eligible to participate in the Plan on the January&nbsp;1, April 1, July&nbsp;1 or October 1 (or at special entry dates approved by the Benefit Plans Administrative Committee) coinciding with or next following the completion of three months of employment (the "Plan Entry Date") provided such employee (i)&nbsp;regularly works at least 9 months during the calendar year (or the Company anticipates as of the Plan Entry Date that the employee shall work at least 9 months during the calendar year), (ii) has an average work week of 20 hours or more during the period worked, (iii) has attained age 18, (iv)&nbsp;does not, and shall not by reason of participating in the Plan, own stock in the Company possessing 5% or more of the total combined voting power or the value of all classes of stock of the Company or its subsidiary corporations, and (v) is not an employee of a domestic or international s
ubsidiary of the Company which is (a) prohibited by law from participating in the Plan, or (b) in the discretion of the Benefit Plans Administrative Committee, precluded from participating in the Plan by government regulation or other action ("Eligible Employees").  The Benefit Plans Administrative Committee shall determine which employees are eligible to participate in the Plan in accordance with the standards set forth in this Section.</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>6.&#9;<U>Participation</U>.  Participation in the Plan is entirely voluntary.  An Eligible Employee may become a participant at a Plan Entry Date by submitting an election to participate on a form supplied by the Company and submitting such form to the Company at least 30 days prior to the Plan Entry Date (or otherwise in accordance with administrative procedures approved by the Benefit Plans Administrative Committee) on which that Eligible Employee would like to begin participation. </P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>7.&#9;<U>Payroll Deductions and Other Contributions</U>.  A participant may authorize payroll deductions under the Plan, in an amount equal to one to four percent (in whole percentages) of a participant's compensation paid by the Company or other Covered Entity during the Plan Quarter.  For this purpose, "compensation" means the basic earnings paid to the participant excluding overtime pay, bonuses and commissions and any other incentive pay.  For purposes of the preceding sentence, a participant's compensation paid by the Company or Covered Entities shall include any salary reduction amounts elected by the participant and credited to a qualified or nonqualified deferred compensation program during the Plan Year notwithstanding the fact that amounts deferred under such programs are not reflected on the participant's federal withholding tax statement, Form W-2 (or other comparable wage statement designated by the Company).</P>
<P ALIGN="JUSTIFY">Payroll deductions can be changed as of the beginning of any calendar quarter only by giving written notice to the Company adequately in advance of the beginning of such calendar quarter.  Reductions in payroll deductions to zero may be changed effective as of the next payroll date,  by giving written notice to the Company adequately in advance of such payroll date.  The Benefit Plans Administrative Committee may prospectively impose restrictions on participants who reduce their payroll deductions to zero.</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>8.&#9;<U>Contributions by the Company</U>.  The Company or the Covered Entity by whom a participant is employed on the last day of a calendar quarter will make contributions to the Plan in an amount equal to 50% of the total amount of participant contributions paid to the Plan during such quarter.  Such contributions, whether made by the Company or a Covered Entity, as appropriate, are sometimes referred to herein as "Company Contributions." Neither the Company nor the Covered Entity shall be required to make any contributions for a participant for the Plan Quarter in which such participant's employment terminates.  The Company or the Covered Entity may elect to make such additional contributions into the Plan in excess of the 50% contribution as it, in the exercise of its sole discretion, deems appropriate.  These additional contributions to the Plan by the Company or the Covered Entity in excess of 50% ("Company Voluntary Contributions"), if any, shall be made on an a
d hoc basis and may vary based upon the discretion of the management of the employing entity with the consent of the Benefit Plans Administrative Committee.  The Benefit Plans Administrative Committee shall distribute Company Voluntary Contributions among participants in any manner the Company desires, and the Company or Covered Entity may direct that such Company Voluntary Contributions be distributed in a manner other than in proportion to the participants' own contributions to the Plan.</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>9.&#9;<U>The Plan Year</U>.  The Plan shall operate on a fiscal year beginning on the first day of January in each year and ending on the 31st day of December.  This fiscal year is referred to herein as the "Plan Year."</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>10.&#9;<U>Plan Quarters</U>.  The Plan Year shall be divided into four Plan quarters ending March 31, June 30, September 30 and December 31.  Each such quarter is referred to herein as a "Plan Quarter."  Notwithstanding the foregoing, with respect to participants whose employment is transferred from the controlled group that includes the Company to the controlled group that includes Actavis Group hf. on December 16, 2005, the last day of the Plan Quarter shall mean December 16, 2005 rather than December 31, 2005.</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>11.&#9;<U>Allocation of Participant and Company Contributions</U>.  The Benefit Plans Administrative Committee will establish a "cash account" and a "Share account" for each participant under the Plan for bookkeeping purposes.  As soon as practicable on or after the last day of each Plan Quarter, but in no case later than the fifteenth day of the month immediately following the end of the Plan Quarter, the Benefit Plans Administrative Committee will credit each participant's cash account with such participant's payroll deductions during the Plan Quarter ("Credited Payroll Deductions"), and will pay and allocate the Company Contributions applicable to such participant.  The date of crediting of such Credited Payroll Deductions and Company Contributions is referred to herein as the "Deduction Crediting Date".</P>
<P ALIGN="JUSTIFY">The Benefit Plans Administrative Committee will allocate Company Contributions to each participant's cash account in an amount equal to 50% of each participant's Credited Payroll Deductions; provided, however, that Company Voluntary Contributions may be allocated among participants' accounts in any manner the Company may choose.  The Company shall not be required to pay or accrue interest on payroll deductions, the cash balances in participants' cash accounts or on the value of participants' Share accounts.</P>
<P ALIGN="JUSTIFY">Benefits or rights which any person may expect to receive (contingently or otherwise) under the Plan may not be assigned or pledged.</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>12.&#9;<U>Share Purchases</U>.  The Benefit Plans Administrative Committee shall determine before the end of each Plan Quarter the number of Shares to be purchased for the benefit of participants, and whether such Shares shall be purchased on the open market, by private purchase or from the Company.  The Benefit Plans Administrative Committee shall then promptly notify its agent, if any, of this determination.  The Benefit Plans Administrative Committee will use the entire balance of funds in participants' cash accounts to purchase the Shares to be allocated to participants' accounts within the first 15 working days following the end of each Plan Quarter.  Shares to be purchased from the Company pursuant to the Plan shall be made available from currently or subsequently authorized and unissued Shares or Shares authorized, issued and owned now or hereafter by the Company.  In the event of a purchase by the Benefit Plans Administrative Committee (or its agent) on the open
 market, the cost per Share to participants will be determined by the actual average price per Share paid for the Shares by the Benefit Plans Administrative Committee (or its agent).  In the event of a private purchase or purchases by the Benefit Plans Administrative Committee (or its agent), the cost per Share to participants shall be equal to the average closing market price on the New York Stock Exchange per Share on the dates such Shares were actually purchased.  In the event of a purchase from the Company by the Benefit Plans Administrative Committee (or its agent), the cost per Share to participants shall be equal to the average closing market price on the New York Stock Exchange per Share during such Plan Quarter.</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>13.&#9;<U>Allocation of Shares</U>.  As soon as practicable after all necessary Shares have been purchased by the Benefit Plans Administrative Committee (or its agent) for the benefit of participants, the Benefit Plans Administrative Committee will allocate such Shares to participants' Share accounts (the date of such allocation to be referred to as the "Share Allocation Date") in the following manner:</P><DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">(a)&#9;The Company will determine the average cost per Share to participants of all Shares purchased;</P>
<P ALIGN="JUSTIFY">(b)&#9;The Company will then allocate whole Shares and fractional Shares to the Share accounts of the individual participants to the extent of the balances in their respective cash accounts.  The cash accounts will be charged with the cost to participants of all Shares so allocated.  No cash balances will remain in the participants' cash accounts immediately after each Share Allocation Date;</P>
<P ALIGN="JUSTIFY">(c)&#9;Until certificates are issued, no person shall have any right to sell, assign, mortgage, pledge, hypothecate or otherwise encumber any of the Shares allocated to a participant's Share account, except as permitted under Section 14 by satisfying the specific administrative procedures directing the Share Administrative Agent to sell Shares directly from the participant's Share account.</P>
<P ALIGN="JUSTIFY"></P></DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>

<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>14.&#9;<U>Issuance, Transfer or Sale of Share Certificates</U>.  Share certificates for the number of whole Shares in each participant's Share account may be issued to such participant or his brokerage account in paper form or electronically.  Share certificates shall be issued only upon receipt by the Share Administrative Agent, (who shall be selected from time to time in the discretion of the Benefit Plans Administrative Committee), of a participant's request indicating the number of Shares (up to a maximum of the number of whole Shares in the participant's Share account) for which the participant wishes to receive certificates.  Such request shall be made on a form or in such other manner as prescribed by the Benefit Plans Administrative Committee.  Share certificates shall be issued to the participant or his brokerage account as soon as practicable after such request is properly made.  If a participant requests the withdrawal of all whole Shares in his account, the 
whole number of Shares will be distributed to him in the form of Share certificates and, if requested, the remaining fractional Shares will be distributed to him in cash.</P>
<P ALIGN="JUSTIFY">A participant may sell any or all of his Shares by providing a request (made in accordance with administrative procedures adopted by the Benefit Plans Administrative Committee) to the Share Administrative Agent.  The participant's Shares will be sold as soon as administratively practicable after such request is received by the Share Administrative Agent and the participant will receive the net proceeds of the sale of the Shares in the form of a local currency check (currently for a fee of US $15.00) or a wire transfer (for non-US participants only and currently for a fee of US $25.00) shortly thereafter.  As of October&nbsp;1, 2002, net proceeds equals the gross proceeds from the actual sale of Shares less a processing fee of US $17.00 and a commission of 12 cents ($0.12) per Share sold -- the term "net proceeds" is subject to modification by the Benefit Plans Administrative Committee, in its sole discretion.</P>
<P ALIGN="JUSTIFY">The Benefit Plans Administrative Committee, in its discretion, may impose additional restrictions on the issuance, transfer or sale of Shares, provided that (i)&nbsp;participants are provided with notice in advance of the effective date of any such restrictions, (ii)&nbsp;such restrictions would only apply to Shares which participants purchase after the effective date of such restrictions and (iii)&nbsp;such restrictions are administered in a nondiscriminatory and uniform manner.</P>
<P ALIGN="JUSTIFY">A participant may elect in writing or in such other manner as prescribed by the Benefit Plans Administrative Committee on a form prescribed by and filed with the Benefit Plans Administrative Committee (or its agent) to have such Share certificates issued to both such participant and a designated individual, in joint tenancy with right of survivorship or in tenancy in common.  A joint ownership election will be effective with respect to the date that such Share certificates are issued.  Such joint ownership election will remain in effect for Share certificates issued to such participant on or before the earlier to occur of (i) the participant's death or (ii) the date which is 31 days after the participant files a proper written revocation of such election with the Benefit Plans Administrative Committee (or its agent).  A participant who revokes a joint ownership election may not make another joint ownership election during the 12 month period following the date the written revocation was re
ceived by the Benefit Plans Administrative Committee (or its agent).</P>
<P ALIGN="JUSTIFY">Notwithstanding the foregoing provisions of this Section or any other provisions contained in this Plan, no Share certificates will be issued, transferred or sold on behalf of any participant who is an "Officer" of the Company, as such term is defined in Rule 16a-l(f) promulgated under the Securities Exchange Act of 1934, as amended, until six months after such Shares have been purchased for the account of the participant.</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>15.&#9;<U>Expenses</U>.  The Company or the Covered Entity will bear the costs associated with administering the Plan and purchasing Shares, including any brokers' fees, commissions, postage or transfer taxes.  No expenses attributable to a participant's sale or transfer of Shares, however, will be borne by the Company or the Covered Entity.</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>16.&#9;<U>Cash Dividends and Share Distributions</U>.</P><DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>a.&#9;<U>Cash Dividends</U>.  Cash dividends attributable to Shares allocated to participants' Share accounts as of the record date for which such cash dividends are declared will be credited to participants' Share accounts as of the dividend payment date and applied to Share purchases and allocations on such date in accordance with the methods set forth in Sections 12 and 13 hereof. </P>
<P ALIGN="JUSTIFY"></P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>b.&#9;<U>Share Distributions and Share Splits</U>.  Share distributions and Share splits attributable to Shares allocated to participants' Share accounts as of the Share distribution record date or the Share split effective date will be credited directly to participants' Share accounts as of the record date and the effective date, respectively, of such Share distributions and such Share splits.</P>
<P ALIGN="JUSTIFY"></P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>c.&#9;<U>Share Rights and Warrants</U>.  The Company may, from time to time, in the exercise of its sole discretion, declare Share rights or warrants with respect to Shares.  Following and as of the record date for determining those shareholders of record entitled to receive Share rights or warrants with respect to their Shares, the Company shall issue, and the Benefit Plans Administrative Committee shall allocate, such Share rights and/or warrants directly to the appropriate participants as though the Shares allocated to the account of each such participant were held of record by such participant.  Certificates representing such Share rights or warrants, if any such certificates have been authorized by the Board of Directors of the Company, may be issued to participants pursuant to the procedures set forth in Section 14 of this Plan.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">d.&#9;<U>Changes in Common Stock</U>.  In the event of a reorganization, recapitalization, stock split, merger, consolidation or other event causing an increase or change in the Shares, the Benefit Plans Administrative Committee shall take appropriate changes in the number and type of Shares that at the time of such event remain available for purchase under the Plan.</P>
<P ALIGN="JUSTIFY"></P></DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>

<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>17.&#9;<U>Voting Rights</U>.  Holders of Shares have the right to vote on matters affecting the Company.  If one of these matters is submitted to the stockholders for a vote, then following the record date for any stockholder meeting at which such vote is to occur, the Benefit Plans Administrative Committee shall advise the Company of the number of participants for whom Shares are held in Share accounts on such record date, and the Company shall furnish the Benefit Plans Administrative Committee (or its agent) with sufficient sets of its proxy soliciting materials to deliver one set to each such participant.  The Benefit Plans Administrative Committee shall thereupon forward one set to each participant for whom allocated Shares are being held and request voting instructions.  Upon receipt of voting instructions, the Benefit Plans Administrative Committee shall vote the Shares as instructed.  The Benefit Plans Administrative Committee shall not vote any Share allocated t
o a participant's Share account unless voting instructions have been received from the participant.</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>18.&#9;<U>Records and Reports to Participants</U>.  The Benefit Plans Administrative Committee shall cause to be maintained true and accurate books of account, and a record of all transactions under the Plan, and such accounts, books and records relating thereto shall be open to inspection and audit by such person or persons designated by the Company.  At least annually, but in all cases on or before March 31 of each year, the Benefit Plans Administrative Committee shall file with the Treasurer of the Company a written report setting forth all receipts and disbursements and other transactions effected on behalf of the Plan during the last preceding Plan Year, including a description of all Shares purchased together with the cost of all such Shares.  Such report shall also disclose any liabilities of the Plan and shall show, as of the close of the Plan Year, the value of each active cash account and Share account of each participant together with the record of Share cert
ificates delivered to each of the participants during such Plan Year.  The Benefit Plans Administrative Committee shall have the right to maintain one or more bank accounts for funds contributed to the Plan, and to make deposits in and withdrawals therefrom in connection with its administration of the Plan.</P>
<P ALIGN="JUSTIFY">An annual report shall be rendered to each participant in the Plan annually within 90 days after the close of the Plan Year, showing for the Plan Year just ended:</P><DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>a.&#9;the amounts of employee payroll deductions made for such participant;</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>b.&#9;the amounts of Company Contributions made for such participant;</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>c.&#9;the amounts of any Company Voluntary Contributions allocated to such participant's account;</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>d.&#9;the amounts of cash dividends credited to such participant's cash account;</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>e.&#9;the number of Shares acquired for such participant's Share account (including the amounts of Share distributions or Share splits so allocated or credited);</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>f.&#9;the cost to the participant per Share of Shares purchased for such participant;</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>g.&#9;the number of Shares, if any, for which certificates were delivered to such participant; and</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>h.&#9;the beginning and ending balances in the participant's Share and cash accounts.</P>
<P ALIGN="JUSTIFY"></P></DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>

<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>19.&#9;<U>Termination of Employment</U>.  Settlement of the accounts of participants whose employment has terminated shall be made as soon as possible following the date on which termination of employment occurred.  As promptly as practicable after the date on which termination of employment occurred, the Benefit Plans Administrative Committee will deliver to such former participant (or such former participant's brokerage account, if elected by such participant on a timely basis) a certificate for the number of whole Shares allocated to such participant's Share account and not previously distributed, together with a check for (i) any remaining cash balance and (ii) the value of any fractional Shares allocated to such participant's Share account.  Alternatively, the terminated participant may elect on a timely basis to have the Share Administrative Agent sell the Shares in order to receive the net proceeds in lieu of the Shares.</P>
<P ALIGN="JUSTIFY">In the event of a participant's death, settlement will be made to the participant's designated beneficiary, if any.  If no beneficiary has been designated, or if such beneficiary does not survive the participant, settlement will be made to the participant's duly appointed legal representative after the satisfaction of any applicable legal requirements.  If a participant has been married for at least one year at the time of his death, his spouse must consent (or have consented) in writing for any nonspousal beneficiary designation to be effective.</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>20.&#9;<U>Amendment and Termination of the Plan</U>.  The Company reserves the right to amend this Plan at any time and to terminate this Plan at the end of any Plan Quarter.  Any amendments, however, will not affect any participant's right to the benefit of contributions made by such participant and by the Company prior to the date of the amendment.</P>
<P ALIGN="JUSTIFY">In the event of termination of the Plan, the Benefit Plans Administrative Committee will make an allocation of Shares to the Share accounts of the participants in the usual manner.  As soon as practicable, the Benefit Plans Administrative Committee will distribute to or on behalf of each participant the number of whole Shares held in such participant's Share account plus an amount of cash equal to the balance in such participant's cash account and the value of any fractional Shares allocated to such participant's Share account.</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>21.&#9;<U>Limitation on Sale of Shares</U>.  No Shares will be sold under the Plan to any employee residing or employed in any jurisdiction where the sale of such Shares is not permitted under the applicable laws.</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></FONT>22.&#9;<U>Amendments to Effect Registration</U>.  The Benefit Plans Administrative Committee is authorized upon advice of counsel to make such amendments to the Plan as may be necessary or desirable to facilitate obtaining an effective registration statement with the Securities and Exchange Commission under the Securities Act of 1933 and covering Shares issued pursuant hereto.</P>
<FONT SIZE=2><P ALIGN="JUSTIFY"></P></FONT></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37A
<SEQUENCE>8
<FILENAME>exh10_37a.htm
<DESCRIPTION>AMENDMENT NO. 1 TO ALPHARMA INC. 2005 SUPPLEMENTAL SAVINGS PLAN
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>AMENDMENT NO</TITLE>
</HEAD>
<BODY>

<B><P ALIGN="CENTER">AMENDMENT NO.  1 TO THE</P>
<P ALIGN="CENTER">ALPHARMA INC. 2005 SUPPLEMENTAL SAVINGS PLAN</P>
<P ALIGN="CENTER"></P>
</B><P>&nbsp;</P>
<P ALIGN="JUSTIFY">&#9;&#9;The Alpharma Inc. 2005 Supplemental Savings Plan (the "Plan") is hereby amended effective as of the dates indicated below, as follows:</P>
<P ALIGN="JUSTIFY"></P>
<OL>
<DIR>
<DIR>

<OL>

<P ALIGN="JUSTIFY"><LI>Effective January 1, 2006, the Introduction to the Plan is hereby amended by adding the following to the end thereof: </LI></P>
<P ALIGN="JUSTIFY">"No employee shall become a Participant in the Plan after December 31, 2005.  Participants are no longer permitted to elect to defer Compensation effective as of the first payroll period ending in 2006."</P>
<P ALIGN="JUSTIFY"><BR>
</P>
<P ALIGN="JUSTIFY"><LI>Effective January 1, 2006, Section 2.1 of the Plan is hereby amended by adding the following to the end thereof: </LI></P>
<P ALIGN="JUSTIFY">"No employee shall become a Participant in the Plan after December 31, 2005."</P>
<P ALIGN="JUSTIFY"><BR>
</P>
<P ALIGN="JUSTIFY"><LI>Effective January 1, 2006, Section 3.1(c) of the Plan is hereby amended by adding the following to the end thereof: </LI></P>
<P ALIGN="JUSTIFY">"All Compensation Deferral Elections made prior to December 31, 2005 shall be revoked with respect to compensation paid after the last payroll period ending in 2005."</P>
<P ALIGN="JUSTIFY"><BR>
</P>
<P ALIGN="JUSTIFY"><LI>Effective January 1, 2006, Section 3.1(d) of the Plan is hereby amended by adding the following to the end thereof: </LI></P>
<P ALIGN="JUSTIFY">"All Payment Elections made prior to December 31, 2005 shall be revoked."</P>
<P ALIGN="JUSTIFY"><BR>
</P>
<P ALIGN="JUSTIFY"><LI>Effective January 1, 2005, Section 3.2 of the Plan is hereby amended by deleting the phrase "under the Savings Plan". </LI></P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"><LI>Effective January 1, 2006, Section 3.3 of the Plan is hereby amended by adding the following to the end thereof: </LI></P>
<P ALIGN="JUSTIFY">"No Company Matching Contributions shall be made to the Plan with respect to compensation paid after the last payroll period ending in 2005."</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY"><LI>Effective October 17, 2005, Article V of the Plan is hereby amended by adding the following to the end thereof:</LI></P></OL>
</DIR>
</DIR>
</OL>
<DIR>
<DIR>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">"Notwithstanding the foregoing, Participants (i) whose employment is transferred from the controlled group that includes the Company to the controlled group that includes Actavis Group hf. on or about December 16, 2005, or (ii) who are employees involuntarily terminated as a result of the sale of the Company's generics business, shall become one-hundred (100%) vested in their Company Matching Contribution Accounts." </P>
</DIR>
</DIR>
</DIR>
</DIR>

<P ALIGN="CENTER">- END -</P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.42
<SEQUENCE>9
<FILENAME>exh10_42.htm
<DESCRIPTION>ALPHARMA INC. SEVERANCE PLAN
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>ALPHARMA SEVERANCE AND CHANGE OF CONTROL PLAN</TITLE>
</HEAD>
<BODY>

<B><P ALIGN="CENTER">ALPHARMA INC. SEVERANCE PLAN <BR>
Amended and Restated Effective January 1, 2005 </P>
</B><P ALIGN="CENTER">&nbsp;</P>
<B><U><P>Purpose of the Plan</P>
</B></U><P ALIGN="JUSTIFY">The purpose of the Alpharma Inc. Severance Plan (the "Plan"), is to provide permanent Employees (as defined below) with uniform severance benefits that will financially assist them with their transition following an involuntary termination of employment, other than for cause.  The Plan was initially effective March 11, 2002, and was amended and restated effective February 19, 2004.  The Plan is being amended and restated in its entirety effective January 1, 2005.</P>
<P ALIGN="JUSTIFY">This Plan represents an amendment and restatement of all prior severance plans, practices or policies in effect at Alpharma or any of its Subsidiaries as of the effective date hereof, and supersedes any and all such prior severance plans, practices and policies to the extent permitted by law.  Except as otherwise specified in the Plan all such prior severance plans, practices and policies are hereby discontinued and terminated.</P>
<P ALIGN="JUSTIFY">Wherever any words are used herein in the masculine gender they shall be construed as though they were also used in the feminine gender in all cases where they would so apply, and wherever any words are used herein in the singular form they shall be construed as though they were also used in the plural form in all cases where they would so apply. </P>
<B><U><P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">SECTION I - DEFINITIONS</P>
</B></U><P ALIGN="JUSTIFY">The following definitions shall apply for purposes of this Plan:</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">1.1&#9;"Alpharma" - Alpharma Inc., a Delaware company.</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">1,2&#9;"Benefit Continuation Period" - In the case of a Participant who receives a Severance Benefit, his Benefit Continuation Period will be determined based on the number of weeks or months, as the case may be, used in Section 4.2 to compute the Participant's Severance Benefit.  </P>
<P ALIGN="JUSTIFY">1.3&#9;"Board" - The Board of Directors of Alpharma.</P>
<P ALIGN="JUSTIFY">1.4&#9;"Change in Control Plans" - The Change in Control Plan, as may be approved by the Board or the Board's Compensation Committee.</P>
<P ALIGN="JUSTIFY">1.5&#9;"Chief Executive Officer" - Chief Executive Officer of Alpharma Inc.</P>
<P ALIGN="JUSTIFY">1.6&#9;"Committee" - The Benefits Committee appointed by the Chief Executive Officer to administer the Plan which shall consist of three (3) employees: the Executive Vice President, Human Resources, the Chief Financial Officer, and the Chief Legal Officer.</P>
<P ALIGN="JUSTIFY">1.7&#9;"Company" - Alpharma Inc., its US Subsidiaries and any non-US Subsidiary, whose Board of Directors (or similar governing body) has adopted this Plan, or any successor by merger, consolidation or sale of assets.</P>
<P ALIGN="JUSTIFY">1.8&#9;"Employee" - A full-time permanent salaried or hourly employee of the Company as determined by the Committee. An Employee shall not include any individual classified by the Company as either a temporary employee, a leased employee or an independent contractor (regardless of whether such individual is classified or retroactively reclassified as an employee of the Company by any person, entity or agency).</P>
<P ALIGN="JUSTIFY">1.9&#9;"Executive" - An Employee who is providing services to the Company in one of the following capacities: the Chief Executive Officer, a member of the Leadership Team, or an Employee holding the title of Vice President or Director (not to be confused with a member of the Board) of the Company or its Operating Divisions or any other individual deemed by the Committee to be an Executive.</P>
<P ALIGN="JUSTIFY">1.10&#9;"Involuntary Termination of Employment" - A Termination of Employment, which was initiated by the Company other than a Termination for Cause.  The Committee shall have complete discretion to determine whether an Involuntary Termination of Employment has occurred. </P>
<P ALIGN="JUSTIFY">1.11&#9;Leadership Team" - The Chief Executive Officer and those officers of the Company that report directly to the Chief Executive Officer and such other Employees who the Chief Executive Officer, in his sole discretion, determines is eligible to be classified as a member of the Leadership Team for purposes of this Plan. </P>
<P ALIGN="JUSTIFY">1.12&#9;"Non Qualifying Sale" - A sale of (i) the stock or assets of a Subsidiary or the assets of an Operating Division of the Company or (ii) assets of the Company.</P>
<P ALIGN="JUSTIFY">1.13&#9;Operating Division" - The Company's operating divisions, which for management or financial purposes are reported as individual business segments.</P>
<P ALIGN="JUSTIFY">1.14&#9;"Participant" - An Employee or an Executive who the Committee determines is eligible to receive Severance Benefits pursuant to Article II.</P>
<P ALIGN="JUSTIFY">1.15&#9;"Plan" - The Alpharma Inc. Severance Plan.</P>
<P ALIGN="JUSTIFY">1.16&#9;"Salary" - (a) A Participant's annual base salary immediately preceding his Termination Date.  In the United States, Salary shall include amounts contributed on behalf of the Employee to a cafeteria plan or a cash or deferred arrangement and not includable in compensation under Section 125 or 402(e)(3) of the Internal Revenue Code.  Salary shall also include cash amounts paid to an Executive in lieu of fringe benefits.  Salary shall exclude the following:  commissions; incentive compensation; bonuses; overtime; extended workweek premiums; cost-of-living allowances; shift premiums; other premiums; deferred compensation; payments under consulting agreements; payments under advisory agreements; any other special payments, fees, or allowances. </P>
<P ALIGN="JUSTIFY"> (b) For purposes of this Plan, weekly Salary shall be equal to a Participant's annual Salary divided by 52.</P>
<P ALIGN="JUSTIFY">1.17&#9;"Severance Benefits" - Has the meaning provided in Section 4.2.</P>
<P ALIGN="JUSTIFY">1.18&#9;"Subsidiary" - Any corporation in which Alpharma owns either directly or indirectly, more than 50% of the voting stock.</P>
<P ALIGN="JUSTIFY">1.19&#9;"Termination Date" - The date a Participant's active employment with the Company terminates as a result of an Involuntary Termination of Employment.</P>
<P ALIGN="JUSTIFY">1.20&#9;"Termination for Cause" - A Termination of Employment for reasons such as a conviction of a felony, habitual excessive use of drugs or alcohol, unsatisfactory attendance, substantial and willful neglect of job duties, failure or inability to adequately perform job duties, disclosure of confidential information regarding the Company or its operations, or the aiding or assisting of any person or entity which is competitive with the Company or its successors.  The determination of whether an Employee is terminated for cause or not for cause (as it relates to eligibility to receive benefits under the Plan) shall be made by the Committee in its sole discretion and shall be final and conclusive.</P>
<P ALIGN="JUSTIFY">1.21&#9;"Termination of Employment" - A termination of employment with the Company for any reason other than by reason of retirement, death or disability.</P>
<P ALIGN="JUSTIFY">1.22&#9;"US Subsidiary" - Any Subsidiary incorporated in the United States.</P>
<P ALIGN="JUSTIFY">1.23&#9;"US Employee" - An Employee whose primary place of employment is in the United States.</P>
<P ALIGN="JUSTIFY">1.24&#9;"Waiver and Release" - A form of waiver and release provided by the Company which has the effect of releasing the Company, its affiliates, officers, directors on the Board and employees from any and all claims, demands, causes of action, damages, expenses and liabilities, whether known or unknown, which the Participant has or may later have against the Company which relate in any way to his employment by the Company, or his separation from employment with the Company, or any other matter at the time of Termination of Employment.  </P>
<P ALIGN="JUSTIFY">1.25&#9;"Years of Service" - Each complete twelve (12) months of uninterrupted employment with the Company as an Employee. Only the last period of continuous employment as an Employee with the Company shall be considered in the determination of a Participant's number of Years of Service with the Company.</P>
<B><U><P ALIGN="CENTER">&nbsp;</P></DIR>
</DIR>

<P ALIGN="CENTER">ARTICLE II - ELIGIBILITY</P>
</B></U><P>2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Eligibility for Severance Benefits</U>.<U>  </P><DIR>
<DIR>
<DIR>
<DIR>

</U><P ALIGN="JUSTIFY">(a)&nbsp;&nbsp;Subject to Section 3.1, an Employee shall be eligible to receive Severance Benefits specified under Article IV in the event that he has an Involuntary Termination of Employment. </P>
<P ALIGN="JUSTIFY">(b)&nbsp;&nbsp;An Employee shall not be eligible for Severance Benefits if (i) he is eligible to receive Change in Control Benefits as defined under any Change in Control Plan or (ii) he is subject to a collective bargaining agreement or comparable labor agreement or is otherwise not permitted to participate pursuant to the laws of the jurisdiction where he is employed or (iii) to the extent he is an Employee other than an Executive, he is eligible to receive different severance benefits pursuant to the laws of the jurisdiction in which he is employed. </P>
<P ALIGN="JUSTIFY">(c)&#9;An Employee shall not be entitled to Severance Benefits upon a Non-Qualifying Sale unless the Committee, in its discretion, adopts rules extending Severance Benefits to such Non-Qualifying Sale.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">2.2&#9;<U>Committee Discretion</U>.  The Committee shall have full discretion to determine eligibility to receive benefits under this Plan.  Such discretion shall be exercised in accordance with the provisions set forth herein and in a uniform and non-discriminatory fashion.</P>
<P>&nbsp;</P>
<B><U><P ALIGN="CENTER">ARTICLE III - CONDITIONS</P>
</B></U><P ALIGN="JUSTIFY">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severance Benefits Conditions</U>.  The following are conditions to a Participant receiving Severance Benefits: </P><DIR>
<DIR>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">(a)&#9;Termination Date on or after March 11, 2002;</P>
<P ALIGN="JUSTIFY">(b)&#9;Termination Date does not immediately follow a period during which the Participant has not been actively at work due to leave of absence, layoff or salary continuance, unless the Committee specifically designates the condition as not applicable to the Participant; and</P>
<P ALIGN="JUSTIFY">(c)&#9;Participant executes a Waiver and Release and does not revoke it within seven (7) days after the execution thereof.  </P>
<P ALIGN="JUSTIFY">(d)&#9;To the extent the duration of the Severance Benefits is longer than any notice period required under the laws of the jurisdiction in which participant is employed, then such severance benefits shall be in lieu of such notice period.</P></DIR>
</DIR>
</DIR>
</DIR>

<B><U><P ALIGN="CENTER">ARTICLE IV - SEVERANCE BENEFITS</P></DIR>
</DIR>

</B></U><P ALIGN="JUSTIFY">4.1&#9;<U>General</U>.  </P>
<P ALIGN="JUSTIFY">Subject to Section 6.1, a Participant who is eligible under Section 2.1 to receive Severance Benefits and who satisfies the conditions in Section 3.1 shall receive the amount of Severance Benefits specified under Section 4.2 payable in accordance with Article VII and those other benefits as specified in Article V.</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">4.2&#9;<U>Amount of Severance Benefits</U>.  The amount of severance benefits ("Severance Benefits") shall be as follows:</P></DIR>
</DIR>

<OL TYPE="a">

<OL TYPE="a">

<P ALIGN="JUSTIFY"><LI>The Severance Benefit payable to a Participant who is not an Executive shall be an amount equal to two (2) weeks' Salary for each Year of Service.  In no event shall the Severance Benefit determined under the prior sentence be less than four (4) weeks' Salary or greater than fifty-two (52) weeks' salary.  </LI></P>
<P ALIGN="JUSTIFY"><LI>The Severance Benefit payable to an Executive shall be an amount determined as follows:</LI></P></OL>
</OL>

<OL TYPE="i">
<DIR>
<DIR>

<OL TYPE="i">

<P ALIGN="JUSTIFY"><LI>In the case of Chief Executive Officer, Salary during each of the 24 months following the Termination Date.  Additionally, he shall receive his bonus or other cash incentive award (as in effect immediately preceding the date of the Change in Control event), at 100% of his annual target rate, with an assumed 100% funding of any applicable bonus pool, for such 24 month period;</LI></P>
<P ALIGN="JUSTIFY"><LI>In the case of a member of the Leadership Team, Salary during each of the 18 months following the Termination Date.  Additionally, he shall receive his bonus or other cash incentive award (as in effect immediately preceding the date of the Change in Control event), at 100% of his annual target rate, with an assumed 100% funding of any applicable bonus pool, for such 18 month period;</LI></P>
<P ALIGN="JUSTIFY"><LI>In the case of a Vice President, Salary during each of the 12 months following the Termination Date; and</LI></P>
<P ALIGN="JUSTIFY"><LI>In the case of a Director (employee title, not member of the Board), the greater of (i) Salary during each of the 6 months following the Termination date or (ii) Salary during the period determined under paragraph (a).</LI></P></OL>
</DIR>
</DIR>
</OL>

<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">4.3&#9;<U>Bonus and Incentive Awards</U>.</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">&#9;Notwithstanding anything herein to the contrary, an Executive's target bonus or incentive award may not reduced upon his or her becoming eligible to receive Severance Benefits.</P>
<P>&nbsp;</P>
<B><U><P ALIGN="CENTER">ARTICLE V - OTHER BENEFIT PROVISIONS</P></DIR>
</DIR>

</B></U><P ALIGN="JUSTIFY">5.1&#9;<U>Medical, Dental and/or Life Insurance Coverage</U>.</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">A Participant shall be entitled to continued coverage under the medical, dental, accidental death and dismemberment and/or life insurance benefits plan sponsored by the Company under which Participant is covered and as in effect on the Participant's Termination Date (including medical and dental coverage for the participant's covered dependents, if any) for the duration of the applicable Benefit Continuation Period whether or not the Participant receives the benefit payments in a lump sum or in monthly payments.  Such coverage shall be equal to the coverage offered to the Employees of the Company during such Benefit Continuation Period and shall be at the same cost to the Participant as applicable to such Employees during the Benefit Continuation Period.   In no event shall a Participant who is a US Employee be entitled to add dependents to his medical or dental coverage after his Termination Date except as would otherwise be allowed by the Consolidated Omnibus Budget Reconciliation Act of
 1985 ("COBRA").</P>
<P ALIGN="JUSTIFY"> At the end of the Benefit Continuation Period, a Participant who is a US Employee may elect to continue medical and dental benefits according to the continuation coverage requirements of group health plans in COBRA, and all of the health insurance continuation provisions under COBRA shall regulate a Participant's election to continue medical and dental benefits at the end of the period during which he is covered under the terms of this Plan.  The period for which such Participant is eligible for COBRA shall be reduced by the number of weeks during which he received medical and/or dental coverage as a result of his participation in the Plan.  </P>
<P ALIGN="JUSTIFY">At the end of the Benefit Continuation Period, accidental death and dismemberment and life insurance benefits shall cease.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">5.2&#9;<U>Retiree Medical Benefits</U>.</P>
<OL>

<OL>

<P ALIGN="JUSTIFY"><LI>A Participant who is eligible to retire and who is eligible for retiree medical insurance as of his Termination Date shall be provided retiree welfare benefits in accordance with the provisions of the applicable plans rather than the benefits described in this Article V.</LI></P></OL>
</OL>
<DIR>
<DIR>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">(2)&#9;A Participant who is eligible to retire and who is not eligible for retiree medical insurance as of his Termination Date shall be eligible for Medical/Dental benefits for the Benefit Continuation Period, in accordance with the provisions of this Article V. </P></DIR>
</DIR>

<P ALIGN="JUSTIFY">5.3&#9;<U>Retirement Plans</U>.</P>
<P ALIGN="JUSTIFY">In the event a Participant becomes eligible to receive Severance Benefits, the benefit payments under this Plan shall not be considered for purposes of computing benefits under the Alpharma Inc. Pension Plan and the A.L. Pharma Inc. Supplemental Pension Plan or any similar pension or retirement plan.  A Participant shall not be eligible to actively participate under such Plans after his Termination Date.</P>
<P ALIGN="JUSTIFY">5.4&#9;<U>Savings Plan and Stock Purchase Plan</U>.</P>
<P ALIGN="JUSTIFY">In the event a Participant becomes eligible to receive Severance Benefits, the benefit payments under this Plan shall not be considered for purposes of computing benefits under any defined contribution plan or stock purchase plan sponsored by the Company including the Employee Stock Purchase Plan, the Alpharma Inc. Savings Plan and the Alpharma Inc. Supplemental Savings Plan.  A Participant shall not be eligible to actively participate under any of these Plans after his Termination Date.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">5.5&#9;<U>Stock Options</U>.</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">In the event that a Participant is eligible to receive Severance Benefits and the Participant has any (a) outstanding Options or Units (as such terms are defined in the 1997 Incentive Stock Option and Appreciation Right Plan, as amended, ("Stock Option Plan")) or (b)&nbsp;outstanding NQSOs and/or ISOs (as such terms are defined in the 2003 Omnibus Incentive Compensation Plan (the "Omnibus Plan")), as of his or her Termination Date then:</P><DIR>
<DIR>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">(i)&#9;any unvested Options, Units, NQSOs and ISOs shall be forfeited unless another plan or agreement specifically provides for the vesting of such options or Units, and</P>
<P ALIGN="JUSTIFY">(ii)&#9;any nonforfeitable Options, Units, NQSOs and ISOs shall become exercisable for the period permitted under the Stock Option Plan and/or the Omnibus Plan, as applicable.  </P></DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>

<P ALIGN="JUSTIFY">5.6&#9;<U>Other Plans</U>.</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">A Participant's participation in all other employee benefit plans sponsored by the Company or the Company shall cease being effective as of the Participant's Termination Date.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">5.7&#9;<U>Terms of Other Plans</U>.</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">Continued participation during the Benefit Continuation Period in any of the plans noted above shall be subject to the terms of said plans; as in the past, the Company continues to retain the right to amend or terminate such plans at any time.</P>
<P>&nbsp;</P>
<B><U><P ALIGN="CENTER">ARTICLE VI - EMPLOYMENT AGREEMENTS</P></DIR>
</DIR>

</B></U><P>6.1&#9;<U>Employment Agreements</U>.</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">Notwithstanding anything to the contrary herein, to the extent that an Employee is party to an employment agreement with the Company or any of its Subsidiaries, to the extent an Employee satisfies the conditions in Sections 2.1 and 3.1, the Employee shall be entitled to receive severance benefits (taken individually) equal to the greater of (i) the severance benefits available under the Plan or (ii) benefits available under such employment agreement under laws of jurisdiction. </P>
<P ALIGN="JUSTIFY">6.2&#9;<U>Local Laws</U>.</P>
<P ALIGN="JUSTIFY">&#9;Notwithstanding anything to the contrary herein, to the extent that an Employee satisfies the conditions in Sections 2.1 and 3.1 and such Employee is entitled to benefits at the time of a Termination of Employment under applicable local laws which are more favorable than the Severance Benefits available under the Plan, then Employee shall<U> </U>receive only those benefits available under local law.</P>
<P> </P>
<B><U><P ALIGN="CENTER">ARTICLE VII - PAYMENT</P>
</B></U><P>7.1&#9;<U>Method of Payment</U>.</P></DIR>
</DIR>

<OL TYPE="a">

<OL TYPE="a">

<P ALIGN="JUSTIFY"><LI>Severance Benefits under Section 4.2 shall be paid to a Participant in installments in accordance with the Company's standard payroll cycles beginning with the first payroll period immediately after his Termination Date and continuing for the applicable Benefit Continuation Period.  Notwithstanding the foregoing, effective January 1, 2005, Severance Benefits to a Participant who is a key employee within the meaning of Proposed Treasury Regulation Section 1.409A-1(i)(1)  shall begin no earlier than six months after his Termination Date if necessary to comply with Section 409A of the Code and the regulations issued thereunder.</LI></P></OL>
</OL>
<DIR>
<DIR>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">(b)&#9;If a Participant dies after his Involuntary Termination of Employment but before receiving the total amount of his Severance Benefit such benefit will instead be paid in a lump sum to the Participant's surviving spouse, if any, and otherwise to the Participant's estate commencing as soon as administratively feasible after the date of death.</P>
<P>&nbsp;</P></DIR>
</DIR>
</DIR>
</DIR>

<B><U><P ALIGN="CENTER">ARTICLE VIII - ADMINISTRATION</P>
</B></U><P ALIGN="JUSTIFY">8.1&#9;<U>The Committee</U>.</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">The Committee shall have the complete authority to: (a) determine eligibility for benefits in accordance with the provisions of the Plan; (b) construe the terms of the Plan; and (c) control and manage the operation of the Plan.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">8.2&#9;<U>Administrative Rules</U>.</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">Subject to the limitations of the Plan, the Committee from time to time shall establish rules for the administration and interpretation of the Plan and the transaction of its business.  The determination of the Committee as to any disputed question shall be conclusive.  All actions, decisions and interpretations of the Committee in administering the Plan shall be conclusive.  All actions, decisions and interpretations of the Committee in administering the Plan shall be performed in a uniform and non-discriminatory manner.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">8.3&#9;<U>Delegation</U>.</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">The Committee may, in its sole discretion, delegate some or all of its functions to third parties and employ counsel and other agents and may procure such clerical, actuarial accounting and other services as the Committee may require in carrying out the provisions of the Plan.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">8.4.&#9;<U>Indemnification</U>.</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">The Company shall indemnify and hold harmless each member of the Committee against all expenses and liabilities arising out of the Committee member's service as such, excepting only expenses and liabilities arising from the member's own gross negligence or willful misconduct.</P>
<P ALIGN="JUSTIFY">8.5&#9;<U>Claim Procedure</U>.</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">(a)&#9;The Company will notify an Employee at the time of Termination of Employment what benefits, if any, he will receive under the Plan.  If an Employee believes that he is entitled to receive additional benefits under the Plan he must submit a claim for benefits in writing to the Committee.  Any claim for benefits must be received by the Committee within 60 days after the date of the Employee's Terminated Employment.  If a claim for benefits under the Plan is denied in whole or in part, the claimant will receive written notice of the denial within 90 days after the filing of the claim.  The notice will state the specific reason for the denial of benefits.</P>
<P ALIGN="JUSTIFY">(b)&#9;Any claimant whose claim for benefits is denied may request a review of the decision denying his claim.  The claimant or his duly authorized representative must submit a written request for review to the Committee within 60 days after receiving the notice of denial.  When making a request for review, a claimant should state the reasons why he believes the claim was improperly denied and should submit any documents or information relevant to the claim.</P>
<P ALIGN="JUSTIFY">(c)&#9;The decision on review will be completed and furnished to the claimant in writing within 60 days after receipt of the request for review.  All decisions of the Committee are final and binding.  In unusual circumstances the Committee may require an extension of time for deciding on a claim for benefits or a request for review.  Whenever there is a need for an extension of time, the Committee will notify the claimant of the extension.  In no event will such an extension exceed a period of 90 days in the case of the initial claim or 60 days in the case of the decision on review.</P>
<P ALIGN="JUSTIFY">(d)&#9;If the Committee fails to take any action required by it within the time limits specified above, the claim shall be deemed denied as of the latest date by which such action should have been completed.</P>
<P ALIGN="JUSTIFY">&nbsp;</P></DIR>
</DIR>
</DIR>
</DIR>

<B><U><P ALIGN="CENTER">ARTICLE IX - MISCELLANEOUS</P>
</B></U><P ALIGN="JUSTIFY">9.1&#9;<U>Amendment and Termination</U>.</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">The Company reserves the right to amend or modify the Plan, to terminate the Plan in its entirety, or to terminate the participation in the Plan of any Subsidiary, provided that (i) any such amendment, modification or termination shall be approved by the Compensation Committee of the Board of Directors, and (ii) any such amendment, modification or termination shall not be applicable to a Participant who has already been notified of a Termination of Employment.  </P></DIR>
</DIR>

<P ALIGN="JUSTIFY">9.2&#9;<U>Parachute Payments</U>.</P><DIR>
<DIR>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">(a)&#9;Notwithstanding anything in this Agreement to the contrary, to the extent that any payment or benefit received or to be received by an Employee in connection with the termination of such Employee's employment (whether pursuant to the terms of this Agreement ("Contract Payments") or pursuant to any other plan, arrangement or agreement with the Company or its affiliates (collectively with the Contract Payments, the "Total Payments")) would, as determined by tax counsel selected by the Company, result in "Excess Parachute Payments" (as defined below) subject to the tax ("Excise Tax") imposed by Section 4999 of the Internal Revenue Code (or any similar tax that may hereafter be imposed), then such Total Payments shall be reduced to the extent necessary so that no portion thereof shall be subject to the Excise Tax, but only if, by reason of such reduction, the Employee's "net after-tax benefit" (defined below) shall exceed what the net after-tax benefit would have been if such reduction 
were not made and the Employee paid such Excise Tax.</P>
<P ALIGN="JUSTIFY">(b)&#9;"Net after-tax benefit" shall mean (1) the sum of all payments and benefits which the Employee receives or is then entitled to receive from the Company and any of its Subsidiaries that would constitute a "parachute payment" within the meaning of Section 280G of the Code, less (2) the amount of federal income taxes payable with respect to the payments and benefits described in (1) above calculated at the maximum marginal income tax rate for each year in which such payments and benefits shall be paid to the Employee (based upon the rate in effect for such year as set forth in the Code at the time of the first payment of the foregoing), less (3) the amount of Excise Taxes imposed with respect to the payments and benefits described in (1) above by Section 4999 of the Code.</P>
<P ALIGN="JUSTIFY">(c)&#9;"Excess Parachute Payments" shall mean "parachute payments" as defined in Section 280G of the Code other than (1) health and life insurance benefits and (2)&nbsp;payments attributable to any award, benefit or other compensation plan or program based upon the number of full or fractional months of any restricted period (relating thereto) which has elapsed prior to the Termination Date.  The terms of any new or revised tax regulations relating to Excess Parachute Payments shall be incorporated by reference herein.  </P></DIR>
</DIR>
</DIR>
</DIR>

<P ALIGN="JUSTIFY">9.3&#9;<U>Withholding</U>.</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">The Company shall withhold all required local, state and federal income taxes from any benefits payable under this Plan.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">9.4&#9;<U>Binding on Successors</U>.</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">The obligations of the Company under the Plan shall be binding upon any organization which shall succeed to all or substantially all of the assets of the Company, and the term "Company," whenever used in the Plan, shall mean and include any such organization after the succession.</P>
<P ALIGN="JUSTIFY">9.5&#9;<U>Applicable Law</U>.  </P>
<P ALIGN="JUSTIFY">&#9;The Plan shall be governed by and construed in accordance with the laws of the State of New Jersey (regardless of the laws that might otherwise govern under applicable New Jersey principles of conflicts of law).</P>
<P ALIGN="JUSTIFY">9.6&#9;<U>Contract Right of Participants.</U>  </P>
<P ALIGN="JUSTIFY">&#9;Subject to Section 9.1 above, the Board of Directors of the Company intends this Plan to constitute an enforceable contract between the Company and each Participant and intends this Plan to vest rights in such Participants as third party beneficiaries. </P>
<P ALIGN="JUSTIFY">9.7&#9;<U>Compensation.</U>  <BR>
For all purposes hereof, the determination of a Participant's bonus or incentive award amount, compensation, rate of base earnings, job grade or band, target award and similar amounts or status shall be made based upon the highest such amount that was in effect at the time of the termination of the Participant's employment. </P></DIR>
</DIR>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.43
<SEQUENCE>10
<FILENAME>exh10_43.htm
<DESCRIPTION>ALPHARMA INC. CHANGE IN CONTROL PLAN
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>ALPHARMA SEVERANCE AND CHANGE OF CONTROL PLAN</TITLE>
</HEAD>
<BODY>

<B><P ALIGN="CENTER">ALPHARMA INC. CHANGE IN CONTROL PLAN<BR>
Amended and Restated Effective January 1, 2005 </P>
<U><P>&nbsp;</P>
<P>Purpose of the Plan</P>
</B></U><P ALIGN="JUSTIFY">The purpose of the Alpharma Inc. Change in Control PlanFebruary 19, 2004 (the "Plan") is to provide certain executive Employees with benefits that will assist them with their transition following a Change in Control.  The Plan was initially effective March 11, 2002, and was amended and restated effective April 5, 2004.  The Plan is being amended and restated in its entirety effective January&nbsp;1, 2005.</P>
<P ALIGN="JUSTIFY">This Plan represents an amendment and restatement of all prior change in control plans, practices or policies in effect at Alpharma or any of its Subsidiaries as of the effective date hereof, and supersedes any and all such prior change in control plans, practices and policies.  Except as otherwise specified in the Plan all such prior change in control plans, practices and policies are hereby discontinued and terminated, to the extent permitted by law.</P>
<P ALIGN="JUSTIFY">Wherever any words are used herein in the masculine gender they shall be construed as though they were also used in the feminine gender in all cases where they would so apply, and wherever any words are used herein in the singular form they shall be construed as though they were also used in the plural form in all cases where they would so apply. </P>
<B><U><P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">SECTION I - DEFINITIONS</P>
</B></U><P ALIGN="JUSTIFY">The following definitions shall apply for purposes of this Plan:</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">1.1&#9;"Acquiring Company" - Has the meaning provided in the definition of Change in Control.</P>
<P ALIGN="JUSTIFY">1.2&#9;"Alpharma" - Alpharma Inc., a Delaware Company.</P>
<P ALIGN="JUSTIFY">1.3&#9;"Benefit Continuation Period" -In the case of an Executive who receives a Change in Control Benefit, his Benefit Continuation Period will be determined based on the number of months used in Section 4.2 to compute the Executive's Change in Control Benefit.</P>
<P ALIGN="JUSTIFY">1.4&#9;"Board" - The Board of Directors of Alpharma.</P>
<P ALIGN="JUSTIFY">1.5&#9;"Change in Control" -  (i) The acquisition by any person, entity or "group" (Acquiring Company") within the meaning of Section 13(d) (3) or 14(d) (2) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (excluding, for this purpose, Alpharma or its Subsidiaries, or any employee benefit plan of Alpharma or its Subsidiaries which acquires beneficial ownership of voting securities of Alpharma) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of shares of Common Stock of Alpharma sufficient to elect a majority of directors to the Board; (ii) persons who, as of the date of this Plan, constitute the Board  (the "Incumbent Board") cease for any reason to constitute at least a majority of the Board, provided that any person becoming a director on the Board subsequent to the date hereof whose election, or nomination for election by Alpharma's stockholders, was approved by a vote of at least a majority of the directors on the Boa
rd then comprising the Incumbent Board shall be considered as though such person were a member of the Incumbent Board; (iii) approval by the stockholders of Alpharma or a reorganization, merger or consolidation, in each case, with respect to which persons who were the stockholders of Alpharma immediately prior to such reorganization, merger or consolidation do not, immediately thereafter, beneficially own shares sufficient to elect a majority of directors in the election of directors of the reorganized, merged or consolidated company; or (iv) a liquidation or dissolution of Alpharma (other than pursuant to the United States Bankruptcy Code) or the conveyance, transfer or leasing of all or substantially all of the assets of Alpharma to any person; provided, <U>however</U>, that for the purposes of clauses (i) - (iv) above, the terms "person", "entity" and "group" shall not include (x) A.L. Industrier ASA ("Industrier"), (y) the stockholders of Industrier in the case of a distribution of shares of capital stoc
k of Alpharma beneficially owned by Industrier to the shareholders of Industrier, unless a Change in Control of Industrier has occurred or occurs concurrently with such a distribution, or in series of related transaction of which such distribution is part, (determined without regard to this clause (y) of this proviso) or (z) E.W. Sissener, his spouse, any heir or descendant of Mr. Sissener or the spouse of any such heir or descendant of the estate of Mr. Sissener (each, an "EWS Party"), or any trust or other similar arrangement for the benefit of any EWS Party or any corporation or other person or entity controlled by one or more EWS Party or any group of which any EWS Party is a member. For purposes of the preceding sentence, a "liquidation" or "dissolution" shall not be deemed to include any transfer of Alpharma property solely to any persons identified in clauses (x), (y) and (z) of the proviso of such sentence.  Notwithstanding anything to the contrary in the foregoing, effective September 8, 2005, no tr
ansaction or series of transactions shall constitute a 'Change in Control' unless the Committee affirmatively concludes that such transaction or series of transactions constitutes a 'Change of Control'.</P>
<P ALIGN="JUSTIFY">1.6&#9;"Change in Control Benefits" - Has the meaning provided in Section 4.2.</P>
<P ALIGN="JUSTIFY">1.7 &#9;"Chief Executive Officer" - Chief Executive Office of Alpharma </P>
<P ALIGN="JUSTIFY">1.8&#9;"Committee" - The Benefits Committee appointed by the Chief Executive Officer to administer the Plan which shall consist of at least three (3) employees: the Executive Vice President, Human Resources, the Chief Financial Officer, and the Chief Legal Officer.  Effective September 8, 2005, 'Committee' shall mean the Compensation Committee of the Board. </P>
<P ALIGN="JUSTIFY">1.9&#9;"Company" - Alpharma Inc. and its US Subsidiaries and any non-US Subsidiary whose Board of Directors (or similar governing body) has adopted this plan, or any successor by merger, consolidation or sale of assets.</P>
<P ALIGN="JUSTIFY">1.10&#9;"Constructive Termination" - A voluntary resignation following a Change in Control and following an action initiated by Alpharma, a Subsidiary or an Acquiring Company which results in (i) a reduction in the Executive's compensation or a reduction in the basis upon which such Executive's bonus or commission is determined, (ii) the Executive's relocation to a base office or site which is more than 50 miles from the location of the Executive's office or site prior to the Change in Control, (iii) the assignment of duties substantially inconsistent with, or a substantial diminution of, the duties, responsibilities or status of the position that the Executive held prior to the Change in Control, (iv) a reduction in benefits, or (v) a change in reporting relationship which is detrimental to the Executive (including, without limitation, a detrimental change in the position to which the Executive reports and not including, without limitation, the termination or change in the person who held
 the position to whom the Executive reported prior to the Change in Control). </P>
<P ALIGN="JUSTIFY">1.11&#9;"Employee" - A full-time permanent salaried or hourly employee of the Company, as determined by the Committee.  An Employee shall not include any individual classified by the Company as either a temporary employee, a leased employee or an independent contractor (regardless of whether such individual is classified or retroactively reclassified as an employee of the Company by any person, entity or agency).</P>
<P ALIGN="JUSTIFY">1.12&#9;"Executive" - An Employee who is providing services to the Company in one of the following capacities: the Chief Executive Officer, a member of the Leadership Team, an Employee holding the title of Vice President or Director (not to be confused with a member of the Board) of the Company or its Operating Divisions, or any other individual deemed by the Committee to be an Executive.</P>
<P ALIGN="JUSTIFY">1.13&#9; "Involuntary Termination of Employment" - A Termination of Employment which was initiated by the Company other than a Termination for Cause.  The Committee shall have complete discretion to determine whether an Involuntary Termination of Employment has occurred. </P>
<P ALIGN="JUSTIFY">1.14&#9;"Leadership Team" - Those officers of the Company that report directly to the Chief Executive Officer and such other employees who the Chief Executive Officer, in his sole discretion, determines is eligible to be classified as a member of the Leadership Team for purposes of this Plan. </P>
<P ALIGN="JUSTIFY">1.15&#9;"Non Qualifying Sale" - A sale of (i) the stock or assets of a Subsidiary or the assets of an Operating Division or (ii) assets (other than substantially all the assets of the Company).</P>
<P ALIGN="JUSTIFY">1.16&#9;Operating Division" - The Company's operating divisions, which for management or financial purposes are reported as individual business segments.</P>
<P ALIGN="JUSTIFY">1.17&#9;"Plan" - The Alpharma Inc. Change in Control Plan.</P>
<P ALIGN="JUSTIFY">1.18&#9;"Salary" - An Executive's annual base salary immediately preceding his Termination Date.  In the United States, Salary shall include amounts contributed on behalf of the Executive to a cafeteria plan or a cash or deferred arrangement and not includable in compensation under Section 125 or 402(e)(3) of the Internal Revenue Code.  Salary shall also include cash amounts paid to an Executive in lieu of fringe benefits.  Salary shall exclude the following: commissions; incentive compensation; bonuses; overtime; extended workweek premiums; cost-of-living allowances; shift premiums; other premiums; deferred compensation; payments under consulting agreements; payments under advisory agreements; any other special payments, fees, or allowances. </P>
<P ALIGN="JUSTIFY">1.19&#9;"Subsidiary" - Any corporation in which Alpharma owns either directly or indirectly, more than 50% of the voting stock.</P>
<P ALIGN="JUSTIFY">1.20&#9;"Termination Date" - The date an Executive's active employment with the Company terminates as a result of an Involuntary Termination of Employment or a Constructive Termination.</P>
<P ALIGN="JUSTIFY">1.21&#9;"Termination for Cause" - A Termination of Employment for reasons such as a conviction of a felony, habitual excessive use of drugs or alcohol, unsatisfactory attendance, substantial and willful neglect of job duties, failure or inability to adequately perform job duties, disclosure of confidential information regarding the Company or its operations, or the aiding or assisting of any person or entity which is competitive with the Company or its successors.  The determination of whether an Executive is terminated for cause or not for cause shall be made by the Committee in its sole discretion and shall be final and conclusive.</P>
<P ALIGN="JUSTIFY">1.22&#9;"Termination of Employment" - A termination of employment with the Company for any reason other than by reason of retirement, death or disability provided that a transfer of employment to the Acquiring Company or any of its affiliates shall not be a Termination of Employment unless it constitutes a Constructive Termination.</P>
<P ALIGN="JUSTIFY">1.23&#9;"US Employee" - An Employee whose primary place of employment is in the United States.</P>
<P ALIGN="JUSTIFY">1.24&#9;"US Subsidiary" - Any Subsidiary incorporated in the United States.</P>
<P ALIGN="JUSTIFY">1.25&#9;"Waiver and Release" - A form of waiver and release provided by the Company which has the effect of releasing the Company, its affiliates, officers, directors on the Board and employees from any and all claims, demands, causes of action, damages, expenses and liabilities, whether known or unknown, which the Executive has or may later have against the Company which relate in any way to his employment by the Company, or his separation from employment with the Company, or any other matter at the time of Termination of Employment.  </P>
<B><U><P ALIGN="CENTER">&nbsp;</P></DIR>
</DIR>

<P ALIGN="CENTER">ARTICLE II - ELIGIBILITY</P><DIR>
<DIR>

</B></U><P ALIGN="JUSTIFY">2.1&#9;<U>Eligibility for Change in Control Benefits.</P></DIR>
</DIR>

<OL TYPE="a">

<OL TYPE="a">

</U><P ALIGN="JUSTIFY"><LI>Subject to Section 3.1, an Executive shall be eligible to receive Change in Control Benefits specified under Article IV if concurrently with or within the 24-month period following the Change in Control he has either (i) an Involuntary Termination of Employment or (ii) a Constructive Termination.</LI></P>
<P ALIGN="JUSTIFY"><LI>An Executive shall not be eligible for Change in Control Benefits if he is subject to a collective bargaining agreement or comparable labor agreement or is otherwise not permitted to participate pursuant to the laws of the jurisdiction where he is employed.</LI></P>
<P ALIGN="JUSTIFY"><LI>A Non Qualifying Sale shall not be deemed a Change in Control and an Executive shall not be eligible to receive Change in Control Benefits upon a Non Qualifying Sale.  </LI></P></OL>
</OL>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">2.2&#9;<U>Committee Discretion</U>.  The Committee shall have full discretion to determine eligibility to receive benefits under this Plan.  Such discretion shall be exercised in accordance with the provisions set forth herein and in a uniform and non-discriminatory fashion.</P>
<P>&nbsp;</P>
<B><U><P ALIGN="CENTER">ARTICLE III - CONDITIONS</P>
</B></U><P ALIGN="JUSTIFY">3.1&#9;<U>Change in Control Benefits Conditions</U>. The following are conditions to an Executive receiving Change in Control Benefits: </P></DIR>
</DIR>

<OL TYPE="a">
<DIR>
<DIR>

<OL TYPE="a">

<P ALIGN="JUSTIFY"><LI>Termination Date on or after March 11, 2002;</LI></P>
<P ALIGN="JUSTIFY"><LI>Termination Date does not immediately follow a period during which the Executive has not been actively at work due to leave of absence, layoff or salary continuance, unless the Committee specifically designates the condition as not applicable to the Executive; </LI></P>
<P ALIGN="JUSTIFY"><LI>To the extent that an Executive claims that Constructive Termination has occurred, such claim shall be made in writing to the Committee within 90 days following the Constructive Termination event;</LI></P>
<P ALIGN="JUSTIFY"><LI>If requested by the Company or Acquiring Company, the Executive shall remain employed with the Company or the Acquiring Company for up to six months following the Change in Control; and </LI></P>
<P ALIGN="JUSTIFY"><LI> Executive executes a Waiver and Release and does not revoke it within seven (7) days after the execution thereof.    </LI></P></OL>
</DIR>
</DIR>
</OL>
<DIR>
<DIR>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">To the extent the duration of the Change in Control Benefits is longer than any notice period required under the laws of the jurisdiction in which an Executive is employed, then such Change in Control Benefits shall be in lieu of such notice period.</P></DIR>
</DIR>

<B><U><P ALIGN="CENTER">ARTICLE IV - CHANGE IN CONTROL BENEFITS</P>
</B></U><P ALIGN="JUSTIFY">4.1&#9;<U>General.</P>
</U><P ALIGN="JUSTIFY"> Subject to Section 6.1, an Executive who is eligible under Section 2.1 to receive Change in Control Benefits and who satisfies the conditions in Section 3.1 shall receive the amount of Change in Control Benefits specified under Section 4.2 payable in accordance with Article VII and those other benefits as specified in Article V.</P>
<P ALIGN="JUSTIFY">4.2&#9;<U>Amount of Change in Control Benefits</U>.</P>
<P ALIGN="JUSTIFY">&#9;An Executive who satisfies the eligibility requirements under Section 2.1 shall be entitled to receive Change in Control benefits ("Change in Control Benefits") equal to the following:</P></DIR>
</DIR>

<OL TYPE="i">
<DIR>
<DIR>

<OL TYPE="i">

<P ALIGN="JUSTIFY"><LI>In the case of the Chief Executive Officer, Salary during each of the 36 months following the Termination Date.  Additionally, he shall receive his bonus or other cash incentive award (as in effect immediately preceding the date of the Change in Control event), at 100% of his annual target rate, with an assumed 100% funding of any applicable bonus pool, for such 36 month period;</LI></P>
<P ALIGN="JUSTIFY"><LI>In the case of a member of the Leadership Team, Salary during each of the 30 months following the Termination Date.  Additionally, he shall receive his bonus or other cash incentive award (as in effect immediately preceding the date of the Change in Control event), at 100% of his annual target rate, with an assumed 100% funding of any applicable bonus pool, for such 30 month period;</LI></P>
<P ALIGN="JUSTIFY"><LI>In the case of a Vice President, Salary during each of the 18 months following the Termination Date; and</LI></P></OL>
</DIR>
</DIR>
</OL>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">(iv)&#9;In the case of a Director (employee title, not member of the Board), Salary during each of the 12 months following the Termination Date.</P></DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>

<P ALIGN="JUSTIFY">4.3&#9;<U>Bonus and Incentive Awards</U>.</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">Any bonus or incentive award payable under the terms of this Plan shall be in addition to any bonus or incentive award otherwise payable under any then-existing bonus or incentive award plans during the year in which the Change in Control event occurs.  Notwithstanding anything herein to the contrary, upon a Change in Control event, an Executive's target annual bonus or incentive award amounts or rates may not be reduced.</P>
<B><U><P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER">ARTICLE V - OTHER BENEFIT PROVISIONS<BR>
</P></DIR>
</DIR>

</B></U><P ALIGN="JUSTIFY">5.1&#9;<U>Medical, Dental and/or Life Insurance Coverage</P><DIR>
<DIR>

</U><P ALIGN="JUSTIFY">An Executive shall be entitled to continued coverage under the medical, dental, accidental death and dismemberment and/or life insurance benefits plan sponsored by the Company under which the Executive is covered and as in effect on the Executive's Termination Date (including medical and dental coverage for the Executive's covered dependents, if any) for the duration of the applicable Benefit Continuation Period whether or not the Executive receives the benefit payments in a lump sum or in monthly payments.  Such coverage shall be equal to the coverage offered to the Employees of the Company or Acquiring Company, as the case may be, during such Benefit Continuation Period and shall be at the same cost to the Executive as is applicable to such Employees during the Benefit Continuation Period.  In no event shall an Executive be entitled to add dependents to his medical or dental coverage after his Termination Date except for US Employees as would otherwise be allowed by the Consolidated 
Omnibus Budget Reconciliation Act of 1985 ("COBRA").</P>
<P ALIGN="JUSTIFY">At the end of the Benefit Continuation Period, an Executive which is a US Employee may elect to continue medical and dental benefits according to the continuation coverage requirements of group health plans in COBRA, and all of the health insurance continuation provisions under COBRA shall regulate an Executive's election to continue medical and dental benefits at the end of the period during which he is covered under the terms of this Plan.  The period for which such Executive is eligible for COBRA shall be reduced by the number of weeks during which he received medical and/or dental coverage as a result of his participation in the Plan.  At the end of the Benefit Continuation Period, accidental death and dismemberment and life insurance benefits shall cease.</P>
<P ALIGN="JUSTIFY">5.2&#9;<U>Retiree Medical Benefits.</P></DIR>
</DIR>

<OL>

<OL>

</U><P ALIGN="JUSTIFY"><LI>An Executive who is eligible to retire and who is eligible for retiree medical insurance as of his Termination Date shall be provided retiree welfare benefits in accordance with the provisions of the applicable plans rather than the benefits described in this Article V.</LI></P>
<P ALIGN="JUSTIFY"><LI>An Executive who is eligible to retire and who is not eligible for retiree medical insurance as of his Termination Date shall be eligible for Medical/Dental benefits for the Benefit Period, in accordance with the provisions of this Article V. </LI></P></OL>
</OL>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">5.3&#9;<U>Retirement Plans.</P>
</U><P ALIGN="JUSTIFY">In the event an Executive becomes eligible to receive Change in Control Benefits, the benefit payments under this Plan shall not be considered for purposes of computing benefits under the Alpharma Inc. Pension Plan and the Alpharma Inc. Supplemental Pension Plan or any similar pension or retirement plan.  An Executive shall not be eligible to actively participate under any such Plans after his Termination Date. </P>
<P ALIGN="JUSTIFY">5.4&#9;<U>Savings Plan and Stock Purchase Plan</P>
</U><P ALIGN="JUSTIFY">In the event an Executive becomes eligible to receive Change in Control Benefits, the benefit payments under this Plan shall not be considered for purposes of computing benefits under any defined contribution plan or stock purchase plan sponsored by the Company including the Employee Stock Purchase Plan, the Alpharma Inc. Savings Plan and the Alpharma Inc. Supplemental Savings Plan. An Executive shall not be eligible to actively participate under any of these Plans after his Termination Date.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">5.5&#9;<U>Long Term Incentive Awards</U>. <U>Stock Options.</P>
<OL>

<OL>

</U><P ALIGN="JUSTIFY"><LI>As permitted under Section 8 of the Alpharma Inc. 1997 Incentive Stock Option and Appreciation Rights Plan, as amended ("Stock Option Plan"), upon the occurrence of a Change in Control, all Options and Units (as defined under the Stock Option Plan) held by an Executive shall become immediately exercisable by the optionee and grantee, respectively, and shall remain exercisable for the lesser of (i) the length of time during which the Option or Unit, as the case may be, may be exercised or (ii) the maximum period permitted under the Stock Option Plan.</LI></P></OL>
</OL>

<OL>

<OL>

<P ALIGN="JUSTIFY"><LI>(2)  As permitted under Article 16 of the Alpharma Inc. 2003 Omnibus Incentive Compensation Plan ("Omnibus Plan"), upon the occurrence of a Change in Control, all NQSOs and ISOs (both as defined under the Omnibus Plan) held by an Executive shall become immediately exercisable by the optionee and shall remain exercisable for the lesser of (i)&nbsp;the length of time during which the NQSO or ISO may be exercised and (ii) the maximum period permitted under the Omnibus Plan.</LI></P>
<P ALIGN="JUSTIFY"><LI>As permitted under Article 16 of the Omnibus Plan, upon the occurrence of a Change in Control followed by either (i) an Involuntary Termination of Employment or a Constructive Termination within twenty-four (24) months after the date of said Change in Control or (ii) the purchase or other acquisition by the entity effecting such Change in Control (either as part of the transaction giving rise to the Change in Control or in a separate transaction or transactions or in a combination of such transactions ) of all or substantially all of the issued and outstanding Class A and Class B common stock, (x) all Restricted Stock (as defined under the Omnibus Plan) held by an Executive in the employ of the Company as of the day immediately prior to the date upon which condition (i) or (ii) is first satisfied shall immediately vest and become the property of said Executive and (y) all Performance Shares and Performance Units (as defined under the Omnibus Plan) held by an Executive in the employ of 
the Company as of the day immediately prior to the date upon which condition (i) or (ii) is first satisfied shall have a final value computed on a date as close as practicable to the date upon which condition (i) or (ii) is first satisfied and such sum shall thereupon be paid to the Executive.  </LI></P></OL>
</OL>
<DIR>
<DIR>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">(43)&#9;Notwithstanding anything herein to the contrary,upon a Change in Control, this Plan shall only accelerate exercisability of Options, Units, NQSOs and ISOs as set forth in this Section 5.5. the a  Additional changes and modifications to benefits granted under the Omnibus Plan not inconsistent with the treatment of such benefits as set forth in this Section 5.5 may be made upon a Change in Control pursuant to Section 4.2 of the Omnibus Plan.</P></DIR>
</DIR>
</DIR>
</DIR>

<P ALIGN="JUSTIFY">5.6&#9;<U>Other Plans.</P><DIR>
<DIR>

</U><P ALIGN="JUSTIFY">An Executive's participation in all other employee benefit plans sponsored by the Company shall cease being effective as of the Executive's Termination Date.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">5.7&#9;<U>Terms of Other Plans.</P><DIR>
<DIR>

</U><P ALIGN="JUSTIFY">Continued participation in any of the plans noted above shall be subject to the terms of said plans; as in the past, the Company continues to retain the right to amend or terminate such plans at any time.</P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<B><P ALIGN="CENTER">ARTICLE VI - OTHER AGREEMENTS AND LAWS</P>
</B><P ALIGN="JUSTIFY">6.1&#9;<U>General.</P>
</U><P ALIGN="JUSTIFY">Notwithstanding anything to the contrary herein, to the extent that an Executive is party to an employment agreement with the Company, the Executive shall be entitled to receive benefits (taken individually) equal to the greater of (i) the benefits available under the Plan or (ii) the benefits available under such employment agreement.</P>
<P ALIGN="JUSTIFY">6.2&#9;<U>Local Laws</P>
</U><P ALIGN="JUSTIFY">Notwithstanding anything to the contrary herein, to the extent that an Employee satisfies the conditions in Sections 2.1 and 3.1, and any such Employee is entitled to benefits at the time of a Termination of Employment under applicable local law, which are more favorable than the Severance Benefits available under the Plan, the Employee shall receive only those benefits available under local law.</P>
<P ALIGN="JUSTIFY">&nbsp;</P></DIR>
</DIR>

<B><U><P ALIGN="CENTER">ARTICLE VII - PAYMENT</P><DIR>
<DIR>

</B></U><P ALIGN="JUSTIFY">7.1&#9;<U>Method of Payment.</P></DIR>
</DIR>

<OL TYPE="a">

<OL TYPE="a">

</U><P ALIGN="JUSTIFY"><LI>Change in Control Benefits under Section 4.2 shall be paid to an Executive in installments in accordance with the Company's standard payroll cycles beginning with the first payroll period immediately after his Termination Date and continuing for the applicable Benefit Continuation Period.  Notwithstanding the foregoing, effective January 1, 2005, Change in Control Benefits to an Executive who is a key employee within the meaning of Proposed Treasury Regulation Section 1.409A-1(i)(1) shall begin no earlier than six months after his Termination Date if necessary to comply with Section 409A of the Code and the regulations issued thereunder. </LI></P></OL>
</OL>

<OL START=2 TYPE="a">

<OL TYPE="a">

<P ALIGN="JUSTIFY"><LI>If an Executive dies after his Involuntary Termination of Employment or Constructive Termination but before receiving the total amount of his Change in Control Benefit, such benefit will instead be paid in a lump sum to the Executive's surviving spouse, if any, and otherwise to the Executive's estate commencing as soon as administratively feasible after the date of death.</LI></P></OL>
</OL>

<P>&nbsp;</P>
<B><U><P ALIGN="CENTER">SECTION VIII - ADMINISTRATION</P>
</B></U><P ALIGN="JUSTIFY">8.1&#9;<U>The Committee</U>.</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">The Committee shall have the complete authority to: (a) determine eligibility for benefits in accordance with the provisions of the Plan; (b) construe the terms of the Plan; and (c) control and manage the operation of the Plan.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">8.2&#9;<U>Administrative Rules.</P><DIR>
<DIR>

</U><P ALIGN="JUSTIFY">Subject to the limitations of the Plan, the Committee from time to time shall establish rules for the administration and interpretation of the Plan and the transaction of its business.  The determination of the Committee as to any disputed question shall be conclusive.  All actions, decisions and interpretations of the Committee in administering the Plan shall be conclusive.  All actions, decisions and interpretations of the Committee in administering the Plan shall be performed in a uniform and non-discriminatory manner.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">8.3&#9;<U>Delegation.</P><DIR>
<DIR>

</U><P ALIGN="JUSTIFY">The Committee may, in its sole discretion, delegate some or all of its functions to third parties and employ counsel and other agents and may procure such clerical, actuarial accounting and other services as the Committee may require in carrying out the provisions of the Plan.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">8.4.&#9;<U>Indemnification.</P><DIR>
<DIR>

</U><P ALIGN="JUSTIFY">The Company shall indemnify and hold harmless each member of the Committee against all expenses and liabilities arising out of the Committee member's service as such, excepting only expenses and liabilities arising from the member's own gross negligence or willful misconduct.</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">8.5&#9;<U>Arbitration.</U>  </P><DIR>
<DIR>

<P ALIGN="JUSTIFY">All disputes regarding the application of the definition of Constructive Termination shall be submitted to an Arbitration Panel whose findings shall be binding on the Company and the Executive.  For purposes of this Plan, the term "Arbitration Panel" shall mean three (3) independent arbitrators, one of whom shall be selected by the Company, one by the Executive and the third shall be selected by the two other arbitrators. In the event that agreement cannot be reached on the selection of the third arbitrator, such arbitrator shall be selected by the American Arbitration Association. All arbitrators shall be selected from a list provided by the American Arbitration Association. All matters presented to the Arbitration Panel shall be decided by majority vote. All costs of the arbitration, including the Executive's attorneys' fees, if any, shall be paid by the Company.</P>
<P ALIGN="JUSTIFY">8.6&#9;<U>Claim Procedure.</P><DIR>
<DIR>

</U><P ALIGN="JUSTIFY">(a)&#9;The Company will notify an Executive at the time of Termination of Employment what benefits, if any, he will receive under the Plan.  If an Executive believes that he is entitled to receive additional benefits under the Plan he must submit a claim for benefits in writing to the Committee.  Any claim for benefits must be received by the Committee within 60 days after the date of the Executive's Terminated Employment.  If a claim for benefits under the Plan is denied in whole or in part, the claimant will receive written notice of the denial within 90 days after the filing of the claim.  The notice will state the specific reason for the denial of benefits.</P>
<P ALIGN="JUSTIFY">(b)&#9;Any claimant whose claim for benefits is denied may request a review of the decision denying his claim.  The claimant or his duly authorized representative must submit a written request for review to the Committee within 60 days after receiving the notice of denial.  When making a request for review, a claimant should state the reasons why he believes the claim was improperly denied and should submit any documents or information relevant to the claim.</P>
<P ALIGN="JUSTIFY">(c)&#9;The decision on review will be completed and furnished to the claimant in writing within 60 days after receipt of the request for review.  All decisions of the Committee are final and binding.  In unusual circumstances the Committee may require an extension of time for deciding on a claim for benefits or a request for review.  Whenever there is a need for an extension of time, the Committee will notify the claimant of the extension.  In no event will such an extension exceed a period of 90 days in the case of the initial claim or 60 days in the case of the decision on review.</P>
<P ALIGN="JUSTIFY">(d)&#9;If the Committee fails to take any action required by it within the time limits specified above, the claim shall be deemed denied as of the latest date by which such action should have been completed.</P>
<P ALIGN="JUSTIFY">&nbsp;</P></DIR>
</DIR>
</DIR>
</DIR>

<B><P ALIGN="CENTER">ARTICLE IX - MISCELLANEOUS</P><DIR>
<DIR>

</B><P ALIGN="JUSTIFY">9.1&#9;<U>Amendment and Termination</U>.</P>
<P ALIGN="JUSTIFY">The Company reserves the right to amend or modify the Plan, to terminate the Plan in its entirety, or to terminate the participation in the Plan of any Subsidiary, provided that (i) any such amendment, modification or termination shall be approved by the Compensation Committee of the Board, (ii) any such amendment, modification or termination shall not be applicable to an Executive who has already been notified of a Termination of Employment, and (iii) the Plan shall not be amended, modified or terminated after the earlier of (a) the Board's initial consideration of a transaction which would be a Change in Control or (b) the execution of a contract which results in a Change in Control.  </P>
<P ALIGN="JUSTIFY">Notwithstanding the foregoing, effective September 8, 2005, the Company reserves the right to amend or modify the Plan, to terminate the Plan in its entirety, or to terminate the participation in the Plan of any Subsidiary, provided that (i) any such amendment, modification or termination shall be approved by the Compensation Committee of the Board, (ii) any such amendment, modification or termination shall not be applicable to an Executive who has already been notified of a Termination of Employment, and (iii)&nbsp;the Plan shall not be amended, modified or terminated after the date on which a Change of Control shall have occurred.</P>
<P ALIGN="JUSTIFY">9.2&#9;<U>Parachute Payments.</P><DIR>
<DIR>

</U><P ALIGN="JUSTIFY">(a)&#9;Notwithstanding anything in this Agreement to the contrary, to the extent that any payment or benefit received or to be received by an Executive in connection with a Change in Control (whether pursuant to the terms of this Agreement ("Contract Payments") or pursuant to any other plan, arrangement or agreement with (1) the Company, (2) any person whose actions result in a Change in Control or (3) any person affiliated with the Company or such person (collectively with the Contract Payments, "Total Payments")) would, as determined by tax counsel selected by the Company, result in "Excess Parachute Payments" (as defined below) subject to the tax ("Excise Tax") imposed by Section 4999 of the Internal Revenue Code (or any similar tax that may hereafter be imposed), then such Total Payments shall be reduced to the extent necessary so that no portion thereof shall be subject to the Excise Tax, but only if, by reason of such reduction, the Executive's "net after-tax benefit" (defined be
low) shall exceed what the net after-tax benefit would have been if such reduction were not made and the Executive paid such Excise Tax.</P>
<P ALIGN="JUSTIFY">(b)&#9;"Net after-tax benefit" shall mean (1) the sum of all payments and benefits which the Executive receives or is then entitled to receive from the Company and any of its Subsidiaries that would constitute a "parachute payment" within the meaning of Section 280G of the Code, less (2) the amount of federal income taxes payable with respect to the payments and benefits described in (1) above calculated at the maximum marginal income tax rate for each year in which such payments and benefits shall be paid to the Executive (based upon the rate in effect for such year as set forth in the Code at the time of the first payment of the foregoing), less (3)&nbsp;the amount of Excise Taxes imposed with respect to the payments and benefits described in (1) above by Section 4999 of the Code.</P>
<P ALIGN="JUSTIFY">(c)&#9;"Excess Parachute Payments" shall mean "parachute payments" as defined in Section 280G of the Code other than (1) health and life insurance benefits and (2)&nbsp;payments attributable to any award, benefit or other compensation plan or program based upon the number of full or fractional months of any restricted period (relating thereto) which has elapsed prior to the date of the Change in Control.  The terms of any new or revised tax regulations relating to Excess Parachute Payments shall be incorporated by reference herein.  </P></DIR>
</DIR>

<P ALIGN="JUSTIFY">9.3&#9;<U>Withholding</U>.</P>
<P ALIGN="JUSTIFY">The Company shall withhold all required local, state and federal income taxes from any benefits payable under this Plan.</P>
<P ALIGN="JUSTIFY">9.4&#9;<U>Binding on Successors</U>.</P>
<P ALIGN="JUSTIFY">The obligations of the Company under the Plan shall be binding upon any organization which shall succeed to all or substantially all of the assets of the Company, and the term "Company," whenever used in the Plan, shall mean and include any such organization after the succession.</P>
<P ALIGN="JUSTIFY">9.5&#9;<U>Applicable Law</U>.</P>
<P ALIGN="JUSTIFY">&#9;The Plan shall be governed by and construed in accordance with the laws of the State of New Jersey (regardless of the laws that might otherwise govern under applicable New Jersey principles of conflicts of law.</P>
<P ALIGN="JUSTIFY">9.6&#9;<U>Contract Right of Executives.</P>
</U><P ALIGN="JUSTIFY">&#9;Subject to Section 9.1 above, the Board intends this Plan to constitute an enforceable contract between the Company and each Executive and intends this Plan to vest rights in such Executives as third party beneficiaries. </P>
<P ALIGN="JUSTIFY">9.7&#9;<U>Compensation.</U><BR>
For all purposes hereof, the determination of an Executive's bonus or incentive award amount, compensation, rate of base earnings, job grade or band, target award and similar amounts or status shall be made based upon the highest such amount that was in effect at the time of the occurrence of a Change in Control. </P></DIR>
</DIR>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.46
<SEQUENCE>11
<FILENAME>exh10_46.htm
<DESCRIPTION>ALPHARMA INC. AMENDED AND RESTATED DEFERRED COMPENSATION PLAN
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>ALPHARMA INC</TITLE>
</HEAD>
<BODY>

<P ALIGN="CENTER"></P>
<P ALIGN="CENTER">ALPHARMA INC.<BR>
AMENDED AND RESTATED<BR>
DEFERRED COMPENSATION PLAN<BR>
EFFECTIVE JULY 1, 1984<BR>
AMENDED OCTOBER 14, 1994</P>
<B><P ALIGN="CENTER"></P>
<P>&nbsp;</P><DIR>
<DIR>

<U><P ALIGN="JUSTIFY">PREAMBLE</P>
</B></U><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">This Plan is an unfunded, unqualified deferred compensation arrangement for a select group, of directors and highly compensated personnel ("Participants") and all rights of any Participant hereunder shall be governed and construed strictly in accordance with the terms of the Plan, as from tine to time amended.</P>
<P ALIGN="JUSTIFY"></P>
<B><U><P ALIGN="JUSTIFY">TERMS AND CONDITIONS</P>
</B></U><P ALIGN="JUSTIFY"></P>
<B><P>I.&#9;<U>Administration</P>
</B></U>
<P ALIGN="JUSTIFY">Full power and authority to construe, interpret and administer the Deferred Compensation Plan of ALPHARMA INC. (the "Plan") shall be vested in a committee (the "Committee") consisting of the Vice President - Finance, Vice President - Human Resources, Secretary and Treasurer of ALPHARMA INC. (the "Employer") and/or such other officer(s) of the Employer as the President may appoint The Committee's interpretations and construction of the Plan, and its actions thereunder, shall be binding and conclusive on all persons for all purposes. In particular, the Committee shall make each determination provided for in the Plan and may promulgate such rules and regulations as the Committee considers necessary or appropriate for the implementation or management of the Plan Any determination so made shall be conclusive, including the determination of a Participant's account balance, the amount of charges or credits thereto and the effectiveness and interpretation of any Deferral Notice. The Committee may 
act at a meeting of two or more members or by the written consent of a majority of its members, which shall for all purposes constitute a valid and effective act of the Committee whether or not all members of a Committee were notified of or approved such act</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Committee members may be Participants in the Plan, but no member of the Committee may participate in any decision directly affecting the computation of his/her benefits under the Plan or the approval of any emergency payments requested by him/her in accordance with the Plan.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">No member of the Committee shall be liable to any person for any action taken or omitted in connection with the interpretation, construction and administration of this Plan unless attributable to his/her own willful misconduct or lack of good faith.</P>
<P ALIGN="JUSTIFY"></P></DIR>

<B><P ALIGN="JUSTIFY">II.&#9;<U>Eligibility</P>
</B></U><P ALIGN="JUSTIFY"></P><DIR>

<P ALIGN="JUSTIFY">Participants eligible to participate in the Plan shall include those individuals designated by the Chief Executive Officer who are in a select group of management or arc highly compensated.</P>
<P ALIGN="JUSTIFY"></P></DIR>

<B><P ALIGN="JUSTIFY">Ill&#9;<U>Deferred Amounts</P>
</B></U><P ALIGN="JUSTIFY"></P><DIR>

<B><P ALIGN="JUSTIFY">A.&#9;<U>Salary, Fees and Commissions,</P>
</B></U><P ALIGN="JUSTIFY">Each Participant electing to defer salary, fee or commission compensation shall designate in writing, the amount (expressed in terms of dollars or a percentage) of such compensation to be deferred in each succeeding calendar quarter under the Plan Such notice ("the Deferral Notice") shall be delivered to a member of  the Committee at least thirty (30) days prior to the beginning to the first calendar quarter with respect to which compensation is to be deferred.  A Deferral Notice may subsequently be modified or terminated at any time by a Participant upon thirty (30) days' prior written notice to the Committee but such modification or termination shall be effective only with respect to calendar quarters beginning after modifying or terminations of such notice is received by a member of the Committee. A deferral as to any calendar quarter shall be effective only as to the compensation earned  (including directors lees) with respect to the subject calendar quarter, and for this purpo
se salaries or fees stated on an annual basis shall be deemed to be earned in equal proportions during each quarter of the year, and commissions shall be deemed earned in the calendar quarter in which such commissions are earned for payment purposes under the Employer's then prevailing policy.</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">B.&#9;<U>Bonuses</P>
</B></U><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Each Participant electing to defer bonus compensation shall designate by a Deferral Notice the amount (in terms of dollars or a percentage or a combination thereof i.e., 50%<I> </I>of any amount in excess of $5,000) of bonus compensation to be deferred annually under the Plan. Such Deferral Notice shall be delivered to a member of the Committee at least thirty (30) days prior to the end of the calendar year with respect to which the bonus is awarded. A Deferral Notice relating to bonus compensation may be modified or terminated at any time by a Participant upon thirty (30) days' written notice to the Committee but such modification or termination shall be effective only with respect to calendar years which have at least thirty (30) days remaining after such modifying or terminating notice is received by a member tithe Committee.</P>
<B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">C. &#9;<U>Crediting </P>
</B><P ALIGN="JUSTIFY"></P>
</U><P ALIGN="JUSTIFY">The amounts of compensation designated to be deferred shall be credited, as of the first day of <U>calendar</U> quarter following the period as to which such compensation was deferred, to a deferred compensation account (the "Account") established by the Employer for each Participant. The Participant shall at all times have a fully vested and nonforf&eacute;itable interest in his/her Account The Employer may establish subaccounts for deferred amounts which are payable at different times or on different tams.</P>
<P ALIGN="JUSTIFY"></P></DIR>

<B><P ALIGN="JUSTIFY">IV.&#9;<U>Account</P>
</B></U><P ALIGN="JUSTIFY"></P><DIR>

<P ALIGN="JUSTIFY">Each calendar quarter interest on the balance of a Account as of the last day of such quarter shall be credited to each Account (which term includes all subaccounts) at the rate of two percentage points below the prime rate as published in the Wall Street Journal on the last day of such quarter, provided, that in no event shall the rate at which interest is credited to Accounts exceed 12% or be less than 4%. The amount of the Account, upon which interest shall be calculated, shall include amounts of interest previously credited td the Account.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Title to and beneficial ownership of any assets, whether cash or investments which the Employer may earmark to pay the deferred compensation hereunder, shall at all times remain in the Employer. Any such investment (which shall not be required) shall be solely for the Employer's own account, and the Participant shall have no right, title or interest in any such investments. Employer makes no representation that any investment it chooses to make will be used solely to provide benefits under this Plan.  Each Participant is solely an unsecured creditor of the Employer with respect to any benefit payable to a Participant hereunder.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Nothing contained in this Plan and no action taken pursuant to the provisions of this Plan shall be create or be construed to create a trust of any kind, segregation of assets by the Employer, or a fiduciary relationship between the Employer and the Participant, his/her designated beneficiary or any other person.</P>
<P ALIGN="JUSTIFY"></P></DIR>

<B><P ALIGN="JUSTIFY">V.&#9;Payment of Funds</P>
<P ALIGN="JUSTIFY"></P><DIR>

<P ALIGN="JUSTIFY">A.&#9;<U>Payment Pursuant to Designation</P>
</B></U><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Each Participant may designate in any Deferral Notice the date on which the amounts deferred pursuant to such Deferral Notice shall become payable, and if such amounts are to become payable in more than one installment, the number and timing (not more frequent than quarterly) of such installments; and the Account or subaccount relating to compensation deferred pursuant to such Deferral Notice shall be paid by the Employer to the Participant in accordance with such designation.  The Committee shall have the authority to reject any designation in any Deferral Notice by giving the Participant notice of such rejection and the reasons therefor within sixty (60) days after such Deferral Notice is received by the Committee. The Committee may from time to time establish such limitations as the Committee deems advisable with respect to the payment terms which Participants may designate.  Except as set forth in Section D of this Article V, the designation of payment terms for compensation previously
 credited to a Participants Account may not be modified.</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">B.&#9;<U>Termination of Reasons Other Than Death</P>
</B></U><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">If no designation of payment terms pursuant to Section A of this Article V is in effect with respect to any Account or subaccount, each Participant shall upon the termination of employment by Employer or any subsidiary of Employer for any reason other than death be entitled to payment of such Account or subaccount balance pursuant to the following schedule;</P>
<P ALIGN="JUSTIFY"></P><DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">(a)&#9;&#9;As of the first day of the calendar year coincident with or next following the date the Participant's employment terminates, one-sixth of the balance in such Account or subaccount as of that date (after crediting any interest to be credited as of that date) shall be paid to the Participant; and</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">(b)&#9;&#9;On each anniversary of the date mentioned in (a) above as of which payments commence, there shall be paid to the Participant an amount  equal to the net balance in the Account or suhaccount as of such anniversary date (after crediting interest as of that date) multiplied by a fraction, the numerator of which is one and the denominator of which is six (6) minus the number of payments previously made under this subsection.  Accordingly, the final payment shall be the sixth payment which shall be made as of the fifth anniversary of the date the first payment is made, and the Account or subaccount shall be reduced to zero as of such date and thereafter.</P>
<P ALIGN="JUSTIFY"></P></DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>

<B><P ALIGN="JUSTIFY">C.&#9;<U>Payments Upon Death</P>
</B></U><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">If a Participant dies before any Account or subaccount balance has been paid pursuant to Section A or B of this Article V. the balance thereof shall be paid to the person or persons (including trustee or trustees) named in the last written instrument signed by the Participant and received by the Committee prior to his/her death (the "Beneficiary'), and unless there is a contrary designation under Section A specifically referring to payments upon death, all Account or subaccount balances shall he paid to the Beneficiary within 120 days following the date of death Such written instrument may be in a form prescribed by the Committee.  To the extent, if any, that the Participant fails effectively to designate a Beneficiary, or the Beneficiary designated dies before the date of the Participant's death or before complete payment of any Account or subaccount, payments shall be made to the legal representative or representatives of the estate of the last to die of a Participant and his/her Benefic
iary. The Employer and the members of the Committee shall be fully protected in making any payment due hereunder in accordance with what the Employer believes to such last written instrument received by it, or the absence of such written instrument</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">D.&#9;Payment Designation Change</P>
</B>
<P ALIGN="JUSTIFY">A Participant may, from the to time, make a written election designating the number, timing, and/or amount of payments relating to amounts theretofore credited to his/her Account or any subaccount, provided that (i) no such election shall accelerate into the calendar year in which such election is made any payment that otherwise would be made in a later calendar year and (ii) no such election shall defer into a later calendar year a payment that otherwise would be made in the calendar year in which such election is made. Each such election shall revoke all prior payment designations made with respect to such Account or subaccount, whether in the Participant's Deferral Notice or through a prior election tinder this Section D of Article V.</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">E.&#9;<U>Emergency Payments</P>
</B></U>
<P ALIGN="JUSTIFY">Upon written application of a Participant, or if the Participant is physically or mentally unable to make application him/herself upon written application of one responsible for his/her care, or upon written application by the Participants beneficiary, setting forth the circumstances and financial need, the Committee may permit such recipient to receive an emergency distribution in an amount no greater than the lesser of: (a) the amount needed to meet or satisfy expenses resulting from the emergency, or (b) the entire amount of Participant's Account.   Any such distribution shall be for the sole purpose of enabling the Participant or his/her beneficiary to meet or satisfy expenses arising as a result of personal injury, sickness, disability, substantial damage or real or personal property or other unforeseen or unanticipated emergency oft Participant (or a member of his/her family) or the beneficiary (or a member of his/her family) which would otherwise cause great financial hardship Norma
l expenses for education, purchase of a home or home improvements are specifically excluded as events deemed to constitute an emergency. Such  distribution shall reduce the amount of any installments remaining to be paid thereunder and/or the number of such installments, in the Committee's sole direction.</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">F.&#9;Payment to Incapacitated Person</P>
</B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Payments may be made to a person who is, in the opinion of Committee, incapacitated in any way so as to be unable to manage his/her financial affairs, in such of the following ways as the Committee shall determine:</P>
<P ALIGN="JUSTIFY"></P><DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">(a)&#9;Directly to such person;</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">(b)&#9;To the legal representative of such person; or</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">(c)&#9;To some relative or friend of such person to be used for the latter's  benefit.</P></DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>

<B><P ALIGN="JUSTIFY">G.&#9;Payment Procedure</P>
</B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">The Committee may withhold from any payment any amounts required for federal and/or state income and employment tax withholding purposes, or for purposes of paying any estate, inheritance or other tax attributable to any amounts payable hereunder. All payments hereunder shall be made in person or upon the recipient's personal receipt or endorsement I</P>
<P ALIGN="JUSTIFY"></P>
<B><P>VI.&#9;<U>Non-assignability of Benefits</P>
</B></U>
<P ALIGN="JUSTIFY">The right of any Participant. Beneficiary, or any other person to the payment of deferred compensation or other benefits under this Plan shall not be assigned, transferred, alienated or encumbered, voluntarily or involuntarily, except by will or by the laws of the descent and distribution.</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">VII.&#9;<U>Miscellaneous </P>
</B></U><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">The Plan shall be binding upon and will inure to the benefit of the Employer, its successors and assigns, and the Participant and his/her heirs, assigns and legal representatives.</P>
<P ALIGN="JUSTIFY"></P>
<B><P ALIGN="JUSTIFY">VIII.&#9;Termination or Amendment</P>
</B><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">The Committee may in its discretion terminate the Plan or amend it from time to time. No such termination or amendment shall after a Participants or his/her Beneficiary right to receive payments front amounts previously credited to such Participant's Account or reduce the rate of interest as to then existing Account balances, provided, however; that if the Employer is liquidated or merged or consolidated with another corporation the Employer's Board of Directors shall have the exclusive right to determine that any unpaid Account or subaccount balances shall be paid in any manner which the Board determines to be just and equitable.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P></DIR>
</DIR>

<P ALIGN="CENTER">&#9;****************</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P><DIR>
<DIR>

<P ALIGN="JUSTIFY">Pursuant to resolution of the Board of Directors of ALPHARMA INC., adopted May 23, l~84, this Plan became effective as of July 1, 1984, upon the approval of the President and Secretary.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">Pursuant to a meeting of the Committee on October 14, 1994, this Plan was amended restated effective October 14, 1994.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P></DIR>
</DIR>

<P ALIGN="JUSTIFY">&#9;&#9;&#9;&#9;&#9;&#9;&#9;      ____________________________________&#9;</P><DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">Beth P. Hecht, Secretary</P>

<P>&nbsp;</P></DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.46A
<SEQUENCE>12
<FILENAME>exh10_46a.htm
<DESCRIPTION>AMENDMENT NO. 1 TO THE ALPHARMA INC. AMENDED AND RESTATED DEFERRED COMPENSATION PLAN
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>AMENDMENT NO</TITLE>
</HEAD>
<BODY>

<B><P ALIGN="CENTER">AMENDMENT NO. 1 TO THE ALPHARMA INC. <BR>
AMENDED AND RESTATED DEFERRED COMPENSATION PLAN</P>
<P ALIGN="CENTER"></P>
</B><P>&nbsp;</P>
<P ALIGN="JUSTIFY">The Alpharma Inc. Amended and Restated Deferred Compensation Plan (the "Plan") is hereby amended effective as of the date indicated below, as follows:</P>
<P ALIGN="JUSTIFY"></P>
<OL>
<DIR>
<DIR>

<OL>

<P ALIGN="JUSTIFY"><LI>Effective January 1, 2006, Section II. of the Plan is hereby amended by adding the following to the end thereof: </LI></P>
<P ALIGN="JUSTIFY">"No employee shall become a participant in the Plan after December 31, 2005."</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY"><LI>Effective with the first payroll period ending in 2006, Section III. A of the Plan is hereby amended by adding the following to the end thereof: </LI></P>
<P ALIGN="JUSTIFY">"Effective January 1, 2006, no employee shall be permitted to defer salary, fee or commission compensation to the Plan."</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY"><LI>Effective with the first payroll period ending in 2006, Section III. B. of the Plan is hereby amended by adding the following to the end thereof: </LI></P></OL>
</DIR>
</DIR>
</OL>
<DIR>
<DIR>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">"Effective January 1, 2006, no employee shall be permitted to defer bonus compensation to the Plan."</P>
<P ALIGN="JUSTIFY"></P></DIR>
</DIR>
</DIR>
</DIR>

<P ALIGN="CENTER">- END -</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY">&nbsp;</P></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.47
<SEQUENCE>13
<FILENAME>exh10_47.htm
<DESCRIPTION>A.L. PHARMA INC. SUPPLEMENTAL PENSION PLAN
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>Draft</TITLE>
</HEAD>
<BODY>

<FONT FACE="Courier New" SIZE=3>
<U><P ALIGN="CENTER">A. L. PHARMA INC.</U><BR>
</P>
<U><P ALIGN="CENTER">SUPPLEMENTAL PENSION PLAN</U><BR>
</P>
<U><P ALIGN="CENTER">SECTION 1</U><BR>
</P>
<U><P ALIGN="CENTER">Introduction</P>
</U>
<P>1.1&#9;<U>The Plan and Its Effective Date</U>. The A. L. Pharma Inc. Supplemental Pension Plan (the "Plan") has been established by</P>
<P>A.&#9;L. Pharma Inc., a Delaware corporation (the "Company"), effective as of July 1, 1994 (the "effective date")</P>

<P>1.2&#9;<U>Purpose</U>. The Company maintains the A. L. Pharma Inc. Pension Plan (the "pension plan") which is intended to meet the requirements of a "qualified plan" under the Internal Revenue Code of 1986, as amended (the "Code") </FONT><FONT FACE="Arial" SIZE=1>. </FONT><FONT FACE="Courier New" SIZE=3>While the Code places limitations on the maximum amount of an employee's compensation that may be taken into account for determining benefits payable under a qualified plan, the Employee Retirement Income Security Act of 1974, as amended ("ERISA"), permits the payment under an "unfunded plan" of the benefits which may not be paid under a qualified plan because of such limitation. The purpose of this Plan is to provide a certain level of additional benefits which may not be provided under the pension plan because of the maximum compensation limitation of the Code.</P>

<U><P ALIGN="CENTER">SECTION 2</P>
</U>
<P>2.1&#9;<U>Eligibility</U>. Only those highly compensated or key</P>
<P>management employees of the Company or its affiliates, who</P>
<P>participate in the pension plan and who were employed on June 30,</P>
<P>1994, shall participate in the Plan (the "participants"), subject</P>
<P>to the conditions and limitations of the Plan.</P>

<P>2.2&#9;<U>Amount of Benefits</U>. With respect to a participant who becomes entitled to a pension benefit under the pension plan, and such benefit has been limited as a result of the maximum compensation limitation imposed by Section 401(a) (17) of the Code (as such maximum compensation limitation is incorporated in the pension plan and as it may be changed from time to time), he or she shall be entitled to receive under this Plan the portion of the participant's pension benefit under the pension plan which exceeds the benefit payable to the participant under the pension</P>
<P>plan after applying the legal maximum compensation limitation. Such estimated limitation shall be determined by the Committee (as defined in section 3.1) </FONT><FONT FACE="Arial" SIZE=1>. </FONT><FONT FACE="Courier New" SIZE=3>A participant's benefit under this Plan shall be referred to hereinafter as a participant's "supplemental pension benefit."</P>

<P>&nbsp;</P>
<P>&nbsp;</P>
<P>2.3&#9;<U>Payment of Benefits</U>. A participant's supplemental pension benefit under this Plan shall be paid to the participant in the form of monthly annuity installments over the life of the participant or, if the participant is married at the time of his or her retirement and has not elected another form of distribution, monthly annuity installments over the joint lives of the participant and his or her spouse. At the election of the participant, in the alternative, benefits can be paid in the form of a period certain and life monthly annuity, a 50% or 100% joint and survivor monthly annuity, or a lump sum. In the case of the death of the participant prior to commencement of benefits hereunder, if the participant is married at the time of his or her death, 50% of his or her Plan benefit shall be paid as a monthly annuity installment for the life of his or her spouse beginning as of the later of the participant's death or the date the participant would have attained age 55.</P>

<P>2.4&#9;<U>Funding</U>. Benefits payable under this Plan to a participant or his beneficiary shall be paid directly by the Company. The Company shall not be required to segregate on its books or otherwise any amount to be used for payment of supplemental pension benefits under this Plan. This Plan shall constitute an unfunded arrangement and any amounts actually set aside by the Company shall remain as Company assets, subject to the general creditors of the Company.</P>

<U><P ALIGN="CENTER">SECTION 3</P>
</U>
<U><P ALIGN="CENTER">General Provisions</P>
</U>
<P>3.1&#9;<U>Committee</U>. This Plan shall be administered by the pension plan administrative committee (the "Committee") </FONT><FONT FACE="Arial" SIZE=1>. </FONT><FONT FACE="Courier New" SIZE=3>The Committee shall have, to the extent appropriate, the same powers, rights, duties and obligations with respect to this Plan as it has with respect to the pension plan. Each determination provided for in this Plan shall be made by the Committee under such procedure as may from time to time be prescribed by the Committee and shall be made in the absolute discretion of the Committee. Any determination so made shall be conclusive on all parties.</P>

<P>3.2&#9;<U>Beneficiary</U>. A participant's "beneficiary" under this Plan means (i) any person who becomes entitled to benefits under the pension plan because of the participant's death, or (ii) if the</P>
</FONT><FONT SIZE=2>
</FONT><FONT FACE="Courier New" SIZE=3><P>participant has no designated beneficiary for purposes of the pension plan as set forth in (i) above, or if his or her beneficiary designated for purposes of the pension plan as set forth in (i) above dies before the date of the participant's death, any one or more of the participant's estate and his or her relatives by blood or marriage, in such proportions as the Committee determines.</P>

<P>&nbsp;</P>
<P>3.3&#9;<U>Employment Rights</U>. Establishment of the Plan shall not be construed to give any participant the right to be retained in the Company's service or to any benefits not specifically provided by the Plan.</P>

<P>3.4&#9;<U>Withholding</U>. The Committee shall deduct from all payments under the Plan any taxes required to be withheld under the laws of the United States or any state, including but not limited to Federal and/or state income and employment taxes.</P>

<P>3.5&#9;<U>Interests </FONT><FONT FACE="Courier New" SIZE=2>Not Transferable</U>. Except as to withholding of </FONT><FONT FACE="Courier New" SIZE=3>any tax under the laws of the United States or any state, the interests of the participants and their beneficiaries under the Plan are not subject to the claims of their creditors and may not be voluntarily or involuntarily transferred, assigned, alienated or encumbered. No participant shall have any right to any benefit payments hereunder prior to the participant's termination of employment with the Company and all other companies which are part of the controlled group of companies which includes the Company.</P>

<P>3.6&#9;<U>Payment with Respect to Incapacitated Participants or </FONT><FONT FACE="Courier New" SIZE=2>Beneficiaries</U>. If any person entitled to benefits under the Plan </FONT><FONT FACE="Courier New" SIZE=3>is under a legal disability or in the Committee's opinion is incapacitated in any way so as to be unable to manage his or her financial affairs, the Committee may direct the payment of such benefit to such person's legal representative or to a relative or friend of such person for such person's benefit, or the Committee may direct the application of such benefits for the benefit of such person in any manner which the Committee may select that is consistent with the Plan. Any payments made in accordance with the foregoing provisions of this section shall be a full and complete discharge of any liability for such payments. The Committee shall deduct from all payments any taxes required to be withheld under the laws of the United States or any state, including but not limited to Federal and/or state i
ncome and employment taxes.</P>

<P>3.7&#9;<U>Limitation of Liability</U>. To the extent permitted by law, no person (including the Company, the Board of Directors of the Company, the Committee, any present or former member of the</P>

<P>Board, or the Committee, and any present or former officer of the Company) shall be personally liable for any act done or omitted to be done in good faith in the administration of the Plan.</P>

<P>3.8&#9;<U>Controlling Law</U>. To the extent not superseded by federal law, the laws of New Jersey shall be controlling in all matters relating to the Plan.</P>

<P>3.9&#9;<U>Gender and Number</U>. Where the context admits, words in the masculine gender shall include the feminine and neuter genders, the plural shall include the singular and the singular shall include the plural.]</P>

<P>3.10&#9;<U>Action by the Company</U>. Any action required of or permitted by the Company under the Plan shall be by resolution of the Board of Directors of the Company or any person or persons </FONT><FONT FACE="Courier New" SIZE=2>authorized by resolution of such Board.</P>

</FONT><FONT FACE="Courier New" SIZE=3><P>3.11&#9;<U>Successor to the Company</U>. The term "Company" as used in the Plan shall include any successor to the Company by reason of merger, consolidation, the purchase of all or substantially all of the Company's assets or otherwise.</P>

<P>3.12&#9;<U>Miscellaneous</U>. The Plan shall be binding upon and inure to the benefit of the parties, their legal representatives, successors and assigns, and all persons entitled to benefits hereunder. Any notice given in connection with the Plan shall be in writing and shall be delivered in person or by registered mail, return receipt requested. Any notice given by registered mail shall be deemed to have been given upon the date of delivery indicated on the registered mail return receipt, if correctly </FONT><FONT FACE="Courier New" SIZE=2>addressed.</P>

</FONT><U><FONT FACE="Courier New" SIZE=3><P ALIGN="CENTER">SECTION 4</P>
</U>
<U><P ALIGN="CENTER">Amendment and Termination</P>
</U>
<P>While the Company expects to continue the Plan, it must necessarily reserve and hereby does reserve the right to amend the Plan from time to time or to terminate the Plan at any time; provided that no amendment of the Plan nor the termination of the Plan may cause the reduction or cessation of any benefits that were accrued as of the date of such amendment or termination and otherwise would be payable under this Plan, but for such amendment or termination.</P>

<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>IN WITNESS WHEREOF, this Plan has been executed on behalf of the Company by its duly authorized officer.</P>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

<P>&#9;&#9;A.L. PHARMA INC.</P></DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>

<P>Date </FONT><FONT FACE="Arial" SIZE=1>___________________&#9;&#9;&#9;&#9;&#9;</FONT><FONT FACE="Courier New" SIZE=3>By________________</P>

<P ALIGN="CENTER">&#9;Its________________</P>
</FONT></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.47A
<SEQUENCE>14
<FILENAME>exh10_47a.htm
<DESCRIPTION>FIRST AMENDMENT TO ALPHARMA INC. SUPPLEMENTAL PENSION PLAN
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>FIRST AMENDMENT</TITLE>
</HEAD>
<BODY>

<P ALIGN="CENTER">FIRST AMENDMENT</P>
<P ALIGN="CENTER">OF THE</P>
<U><P ALIGN="CENTER">A.L. Pharma Inc. Supplemental Pension Plan</P>
<P ALIGN="CENTER"></P>
</U><P>&#9;&#9;WHEREAS, Alpharma Inc. (the "Company") (formerly known as A.L. Pharma Inc.) maintains the A.L. Pharma Inc. Supplemental Pension Plan (the "Plan"); and</P>

<P>&#9;&#9;WHEREAS, the Company desires to change the name of the Plan to be consistent with the name of the Company; and</P>

<P>&#9;&#9;WHEREAS, the Company desires to decrease the vesting requirement under the Plan from ten years to five years; and</P>

<P>&#9;&#9;WHEREAS, the Plan has been amended and further amendment of the Plan is now considered necessary and desirable to reflect the aforementioned changes;</P>

<P>&#9;&#9;NOW, THEREFORE, IT IS RESOLVED that, in accordance with the power reserved to the Company by section 4 of the Plan, and pursuant to resolutions adopted by the Compensation Committee of the Company on May 7, 1998, the Plan, as previously amended, be and it hereby is further amended, effective as of July 1, 1998, as follows:</P>

<P>&#9;&#9;&#9;The following shall be substituted as Section 2.3 of the Plan:</P>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

<P>2.3&#9;<U>Vesting.</U>&#9;If a participant resigns or is dismissed from the employ of the Company and all of its controlled group members prior to completing at least five years of employment service with the Company or any of its controlled group, the participant shall not be entitled to any benefit under the Plan.</P>

<P>&nbsp;</P></DIR>
</DIR>

<P>&#9;&#9;&#9;*&#9;*&#9;*</P>
</DIR>
</DIR>
</DIR>
</DIR>

<P>&#9;IN WITNESS WHEREOF, the Company has caused this First Amendment of the A.L. Pharma Inc. Supplemental Pension Plan to be executed on its behalf on the ___ day of _______________, 1998.</P>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>
<DIR>

<P>Alpharma Inc.</P>

<P>By:______________________________</P>
<P>Its:______________________________</P>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>
</DIR>

<P>ATTEST:</P>

<P>By:______________________________</P>
<P>Its:______________________________</P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.47B
<SEQUENCE>15
<FILENAME>exh10_47b.htm
<DESCRIPTION>SECOND AMENDMENT TO ALPHARMA INC. SUPPLEMENTAL PENSION PLAN
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>SECOND AMENDMENT </TITLE>
</HEAD>
<BODY>

<B><P ALIGN="CENTER">SECOND <FONT SIZE=3>AMENDMENT</FONT> OF THE <BR>
ALPHARMA INC. SUPPLEMENTAL PENSION PLAN</P>
<P ALIGN="CENTER"></P>
<P ALIGN="CENTER">&nbsp;</P>
</B><P ALIGN="JUSTIFY">&#9;&#9;The Alpharma Inc. Supplemental Pension Plan (the "Plan") is hereby amended effective as of the dates indicated below, as follows:</P>
<B>
<OL>
<DIR>
<DIR>

<OL>

</B><P ALIGN="JUSTIFY"><LI>Effective January 1, 2006, Section 1.2 of the Plan is hereby amended by adding the following to the end thereof:</LI></P>
<P ALIGN="JUSTIFY">"Effective January 1, 2006, the Plan is frozen."</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY"><LI>Effective January 1, 2006, Section 2.2 of the Plan is hereby amended by adding the following to the end thereof:</LI></P>
<P ALIGN="JUSTIFY">"With respect to determining a participant's supplemental pension benefit, service after December 31, 2005 and compensation paid after the last payroll period ending in 2005, shall not be taken into account."</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY"> </P>
<P ALIGN="JUSTIFY"><LI>"Effective October 17, 2005, Section 2.3 of the Plan is hereby amended by adding the following to the end thereof:</LI></P>
<P ALIGN="JUSTIFY">"Notwithstanding the foregoing, participants (i) whose employment is transferred from the controlled group that includes the Company to the controlled group that includes Actavis Group hf. on or about December 16, 2005, or (ii) who are employees involuntarily terminated as a result of the sale of the Company's generics business, shall be entitled to a benefit under the Plan based on their service through termination date, regardless of whether such participants have completed at least five years of employment service."</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P ALIGN="JUSTIFY"><LI>Effective January 1, 2006, Section 2.4 of the Plan is hereby amended by adding the following to the end thereof:</LI></P></OL>
</DIR>
</DIR>
</OL>
<DIR>
<DIR>
<DIR>
<DIR>

<P ALIGN="JUSTIFY">"Notwithstanding the foregoing, effective January 1, 2006, upon a participant's termination from employment, a participant's supplemental pension benefit under the Plan shall be paid to the participant, or in the event of his or her death, the participant's beneficiary, in a lump sum on or as soon as administratively practicable following the date that is six months after such Participant's termination from employment.  The lump sum payment shall be determined using the actuarial assumptions used to determine lump sum payments under the Alpharma Inc. Pension Plan as of the date of distribution."</P>
</DIR>
</DIR>
</DIR>
</DIR>

<P ALIGN="CENTER">- END -</P></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>16
<FILENAME>exh21.htm
<DESCRIPTION>LIST OF SUBSIDIARIES OF REGISTRANT
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>EX-21 17 ex21</TITLE>
</HEAD>
<BODY>

<P>LIST OF SUBSIDIARIES </P>
<FONT FACE="Frutiger 45 Light"><P ALIGN="RIGHT">EXHIBIT 21</P>
<P ALIGN="CENTER">ALPHARMA INC.<BR>
Subsidiaries of the Registrant</P></FONT>
<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=590>
<TR><TD WIDTH="63%" VALIGN="TOP">
<U><FONT FACE="Frutiger 45 Light"><P>Name</U></FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">
<U><FONT FACE="Frutiger 45 Light"><P>Jurisdiction which Organized</U></FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">
<U><FONT FACE="Frutiger 45 Light"><P>United States</U>:</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Alpharma U.S. Inc.</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Delaware</FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>ParMed Pharmaceuticals, Inc.</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Delaware</FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Alpharma Operating Corporation</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Delaware</FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>&nbsp;Purepac Pharmaceutical Holdings Inc.</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Delaware</FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">&nbsp;</TD>
<TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">
<U><FONT FACE="Frutiger 45 Light"><P>Foreign</U>:</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">&nbsp;</TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Alpharma ApS</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Denmark</FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Alpharma AS</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Norway</FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Allabinc de Mexico, S.A. de C.V.</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Mexico</FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Empresa Laboratories de Mexico S.A. de C.V.</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Mexico</FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Alpharma do Brazil Ltda</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Brazil</FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Alpharma SARL</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>France</FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Alpharma Fine Chemicals, Kft.</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Hungary</FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Alpharma Animal Health Pty Ltd.</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Australia</FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Alpharma (Belgium) B.V.B.A.</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Belgium</FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Alpharma (Luxembourg) Sarl</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Luxembourg</FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Alpharma Bermuda G.P.</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Bermuda</FONT></TD>
</TR>
<TR><TD WIDTH="63%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Alpharma International AS</FONT></TD>
<TD WIDTH="37%" VALIGN="TOP">
<FONT FACE="Frutiger 45 Light"><P>Norway</FONT></TD>
</TR>
</TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>17
<FILENAME>exh23_1.htm
<DESCRIPTION>CONSENT
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</TITLE>
</HEAD>
<BODY>

<B><P ALIGN="CENTER">Consent of Independent Registered Public Accounting Firm</P>
</B><P>We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (File Nos. 33-60495, 333-107873, 333-104253 and 333-104252) and Form S-3 (File Nos. 333-39554, 333-57501, 333-70229, 333-86037 and 333-86153) of Alpharma, Inc. of our report dated March 31, 2005, except for the restatement discussed in Note 2b (not presented herein) to the consolidated financial statements appearing under Item 15 of the Company's 2004 annual report on Form 10-K/A, as to which the date is May 5, 2005 and for the effects of discontinued operations discussed in Note 3 to the consolidated financial statements, as to which the date is March 16, 2006, relating to the consolidated financial statements which appears in this Form 10-K.</P><DIR>
<DIR>

<P>&nbsp;</P>
<P>&nbsp;</P></DIR>
</DIR>

<P>/s/ PricewaterhouseCoopers LLP<BR>
Florham Park, NJ<BR>
March 16, 2006</P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>18
<FILENAME>exh23_2.htm
<DESCRIPTION>CONSENT
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</TITLE>
<META NAME="_ReviewCycleID" CONTENT="-155146701">
</HEAD>
<BODY>

<U><P ALIGN="CENTER">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</P>
<P ALIGN="CENTER"></P>
</U><P>&nbsp;</P>
<P>We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (File Nos. 33-60495, 333-107873, 333-104253 and 333-104252) and Form S-3 (File Nos. 333-39554, 333-57501, 333-70229, 333-86037 and 333-86153) of Alpharma, Inc. of our reports dated March 15, 2006 relating to the consolidated financial statements, and effectiveness of Alpharma, Inc.'s internal control over financial reporting which appears in this Form 10-K.</P>

<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<P>&nbsp;</P>
<FONT SIZE=3><P>/s/ BDO Seidman, LLP<BR>
</FONT>New York, New York<BR>
March 16, 2006</P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>19
<FILENAME>alo302ceo.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>SAMPLE CERTIFICATION FOR FORM 10-Q</TITLE>
</HEAD>
<BODY>

<B><U><FONT SIZE=2><P ALIGN="CENTER">SARBANES-OXLEY ACT OF 2002<BR>
SECTION 302 CERTIFICATION</P>
</B></U><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;I, <B>Ingrid Wiik, Chief Executive Officer</B> of Alpharma Inc., certify that:</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;1.&#9;I have reviewed this annual report on Form 10-K of Alpharma Inc.;</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;2.&#9;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;3.&#9;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;4.&#9;The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;&#9;(a)&#9;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;&#9;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;&#9;(c)&#9;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;&#9;(d)&#9;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;5.&#9;The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;&#9;(a)&#9;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;&#9;(b)&#9;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</P>
<P ALIGN="JUSTIFY"></P>
<P>Date: March 16, 2006</P>
<P ALIGN="JUSTIFY"></P>
<P>/s/ Ingrid Wiik<BR>
Ingrid Wiik<BR>
Chief Executive Officer</P>
<P ALIGN="JUSTIFY"></P></FONT></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>20
<FILENAME>alo302cfo.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>SAMPLE CERTIFICATION FOR FORM 10-Q</TITLE>
</HEAD>
<BODY>

<B><U><FONT SIZE=2><P ALIGN="CENTER">SARBANES-OXLEY ACT OF 2002<BR>
SECTION 302 CERTIFICATION</P>
</B></U><P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;I, <B>Matthew Farrell</B>, Chief Financial Officer of Alpharma Inc., certify that:</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;1.&#9;I have reviewed this annual report on Form 10-K of Alpharma Inc.;</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;2.&#9;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;3.&#9;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;4.&#9;The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;&#9;(a)&#9;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;&#9;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;&#9;(c)&#9;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;&#9;(d)&#9;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and </P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;5.&#9;The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;&#9;(a)&#9;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;&#9;(b)&#9;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P>
<P>Date: March 16, 2006<BR>
</P>
<U><P ALIGN="JUSTIFY">/s/ Matthew Farrell</U>________________</P>
<P>Matthew Farrell <BR>
Executive Vice President and Chief Financial Officer</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&nbsp;</P></FONT></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>21
<FILENAME>alo906.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND THE PRINCIPAL FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>

<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>Exhibit 99</TITLE>
</HEAD>
<BODY>

<B><FONT FACE="Frutiger 45 Light" SIZE=3><P ALIGN="RIGHT"></P>
</B><P>&nbsp;</P>
<P ALIGN="CENTER">CERTIFICATION PURSUANT TO <BR>
</P>
<P ALIGN="CENTER">18 U.S.C. SECTION 1350,<BR>
</P>
<P ALIGN="CENTER">AS ADOPTED PURSUANT TO<BR>
</P>
<P ALIGN="CENTER">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002<BR>
</P>
<P ALIGN="JUSTIFY"><BR>
<BR>
<BR>
In connection with the Annual Report of Alpharma Inc. (the "Company") on Form 10-K for the period ended December 31, 2005 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies, pursuant to 18 U.S.C. 1350, as adopted pursuant to 906 of the Sarbanes-Oxley Act of 2002, that:</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;(1)&#9;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>
<P ALIGN="JUSTIFY"></P>
<P ALIGN="JUSTIFY">&#9;(2)&#9;The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</P>
<P ALIGN="JUSTIFY"></P>
<P>Dated:   March 16, 2006<BR>
</P>
<U><P>/s/ Ingrid Wiik</U><BR>
Ingrid Wiik<BR>
Chief Executive Officer<BR>
</P>

<P>Dated:  March 16, 2006<BR>
<BR>
<U>/s/ Matthew T. Farrell</U><BR>
Matthew T. Farrell <BR>
Chief Financial Officer</P>

</FONT><FONT FACE="Frutiger 45 Light" SIZE=1><P>&nbsp;</P></FONT></BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
